<SEC-DOCUMENT>0001558370-23-003929.txt : 20230315
<SEC-HEADER>0001558370-23-003929.hdr.sgml : 20230315
<ACCEPTANCE-DATETIME>20230315172505
ACCESSION NUMBER:		0001558370-23-003929
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		73
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230315
DATE AS OF CHANGE:		20230315

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Acurx Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001736243
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40536
		FILM NUMBER:		23736268

	BUSINESS ADDRESS:	
		STREET 1:		259 LIBERTY AVENUE
		CITY:			STATEN ISLAND
		STATE:			NY
		ZIP:			10305
		BUSINESS PHONE:		917-533-1469

	MAIL ADDRESS:	
		STREET 1:		259 LIBERTY AVENUE
		CITY:			STATEN ISLAND
		STATE:			NY
		ZIP:			10305

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Acurx Pharmaceuticals, LLC
		DATE OF NAME CHANGE:	20180402
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>acxp-20221231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.2.0.4 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/15/2023 9:18:52 PM -->
      <!-- iXBRL Library version: 1.0.8405.27969 -->
      <!-- iXBRL Service Job ID: daa58ed1-4fc8-4381-a17a-501b8714c178 -->

  <html xmlns:acxp="http://www.acurxpharma.com/20221231" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" xs:nil="true" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" name="us-gaap:CommitmentsAndContingencies" id="Hidden_0To5aG5ayEeWsfoYnrjh9Q"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" xs:nil="true" contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw" name="us-gaap:CommitmentsAndContingencies" id="Hidden_qMXX6Qpp-kG_R1RF2J6ZpQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" xs:nil="true" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_FhifAapFH0uKzJs-MjO_1g" name="us-gaap:MembersCapital" id="Hidden_CjhtDG9o-0eHLcphgHG_2Q"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" xs:nil="true" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_svnDIsmsoEWsEvfBIapN1g" name="us-gaap:MembersCapital" id="Hidden_z-cA2B_zx0afjyItvPH4_Q"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" xs:nil="true" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember__wGs7OIFT0CPK-kkN4m2Tg" name="us-gaap:MembersCapital" id="Hidden_1vP5TIDe006NnCGIW5-y5Q"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" xs:nil="true" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_TKQ1abvx9UijoSdLGqZqww" name="us-gaap:MembersCapital" id="Hidden_clbq5dV84UWgpftBSE5TLw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_7GDmEFwfuUmQonB5fSquiQ">11627609</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:EntityCentralIndexKey" id="Tc_kldvYc0vIEOE4zQkO47BrQ_2_1">0001736243</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:CurrentFiscalYearEndDate" id="Tc_KlsDt4Op7U-g671RsWGygw_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:DocumentFiscalYearFocus" id="Tc_SWKvYl5oUUuif026bGP6qQ_4_1">2022</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:DocumentFiscalPeriodFocus" id="Tc_P9aZrxWbuUygEOfkkSfCNA_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:AmendmentFlag" id="Tc_1VWpinzz8EyW7JA6HZ9xNg_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q" contextRef="Duration_7_1_2021_To_7_31_2021_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_8YmAD-SQN0Gy2_-YJBttqQ" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_EzWf9zq7yU2COrvaqFHBLw">0.25</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" sign="-" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="2" name="us-gaap:EarningsPerShareBasic" id="Tc_wPXw0E442UG5-WFLunMfqw_4_3">1.12</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" sign="-" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="2" name="us-gaap:EarningsPerShareBasic" id="Tc_9GKmzq3TF0eyMwIQXoFW1g_4_6">1.49</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Tc_uzdYWJ9yIEaikKMAvF16OA_5_3">10816412</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Tc_GflXhuF6m0iVMW-L9rqovw_5_6">8535873</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" sign="-" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Tc_lRZ12Qay6EOceUx3t_RE_A_6_3">1.12</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" sign="-" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Tc_oFmrqxhv8Eakqm6xQzfRNA_6_6">1.49</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Tc_PsnNGrFzPE-DAFx-f8ov6A_7_3">10816412</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Tc_FLTpBblsfk2jyRBqdq8fOg_7_6">8535873</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q" contextRef="Duration_4_1_2022_To_4_30_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateApril2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_qohyZAg_4kexsYHlr-DRIg" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden__yx0SlixZk2t446zKw_EWA">0.25</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q" contextRef="Duration_1_1_2022_To_1_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Py4eXl-AxUWLsBuY7wnXUg" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_GOeJkjeOiU-aNE91SNMVSA">0.25</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_Y_m6Q1ZS4FGUy3pAlacn4HHg" contextRef="As_Of_6_29_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_SubsidiarySaleOfStockAxis_acxp_UnderwriterMember_72h-4I7Sxki4jJ07k-e5bQ" decimals="1" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" id="Hidden_RMD-11b8a0WEvsJ9XyenQg">4.5</ix:nonFraction><ix:nonNumeric contextRef="Duration_9_1_2022_To_9_30_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateSeptember2022Member_8MlpVu0cokmsSI5c6YJyTg" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Hidden_pe6sq_5jwkGHEr32NVYkWA">P6M</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member_90xI89oKiEeLdXH5k-9FsA" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Hidden_xpnuvER5pkCZfclL6LaL-Q">P6M</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_hn7L1KzQWEKv4ikJD9PDqA">10215792</ix:nonFraction><ix:nonNumeric contextRef="As_Of_5_31_2020_us-gaap_ShortTermDebtTypeAxis_acxp_PaycheckProtectionProgramLoanMember_sS6eiAQzIkmyBpb68LMOBA" name="us-gaap:LongTermDebtTerm" id="Hidden_nx3AzEkhbUS8BxsxeUh0lg">P2Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="acxp-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="As_Of_7_25_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_SubsidiarySaleOfStockAxis_acxp_PlacementAgentsMember_DLWS4dqct0WPZhuICr1W5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acxp:PlacementAgentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_25_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_acxp_PlacementAgentsMember_24jUSFL8IkuQJWmQuEKwcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acxp:PlacementAgentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_25_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_SubsidiarySaleOfStockAxis_acxp_PlacementAgentsMember_3LCeKF0DIEaVdX-Uh1jhPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acxp:PlacementAgentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_25_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_SubsidiarySaleOfStockAxis_acxp_PlacementAgentsMember_BIzTc_rBT0-1HSfagb5b0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acxp:PlacementAgentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_29_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_SubsidiarySaleOfStockAxis_acxp_UnderwriterMember_v5jYpz8bRUyI--9gq4owJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acxp:UnderwriterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_29_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_acxp_UnderwriterMember_u8q_TpmED0-Ky05QbeiMpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acxp:UnderwriterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_29_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_SubsidiarySaleOfStockAxis_acxp_UnderwriterMember_sGehJTCm7kCXCyDe_BzraA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acxp:UnderwriterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_29_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_SubsidiarySaleOfStockAxis_acxp_UnderwriterMember_72h-4I7Sxki4jJ07k-e5bQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acxp:UnderwriterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2018_To_2_28_2018_srt_ProductOrServiceAxis_acxp_AcxThreeSixtyTwoEMember_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_J2BW4s8qOUKn-acaK_Oxcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acxp:AcxThreeSixtyTwoEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassBMemberSCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_1_31_2021_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_JtClA5RErEGfEeffjvyvtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassBMemberSCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantedInThirdQuarter2021Member_I8bs4d9ViU-viuLd-_7bTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantedInThirdQuarter2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_MYOlceR8bEyBXaE8PmDn2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDatePreIpoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassMemberSCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_10_31_2019_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_Gf1McXFwrk6xhgFzNeubnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateOctober2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassMemberSCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_23_2021_To_6_23_2021_TsxTykL9E0-yFWUKq9d3cQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-23</xbrli:startDate><xbrli:endDate>2021-06-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_uxop3ZMQk0-ZXskL-V_mVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OYU0ijkQlkuzhtPcTOLIow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_GWozgFjldEK0a6rNLQuu1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XcVxdLM7g0aTslPVvSHW0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_XyHsu6ymoke-MXFBVwUwUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_25_2022_srt_TitleOfIndividualAxis_acxp_AffiliateInvestorsMember_0RaPP3HInkGg-_0ekTA3OQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">acxp:AffiliateInvestorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_Ol44zQexSUa7wj9xwWiDsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassMemberSCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_boZANUamJEaYYgHn5Q9v8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassBMemberSCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member_7kblQvMdtEmqcKGRTUh1qw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member_YIfVK7k8V069cOaEAb-EWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateSeptember2022Member_lQ0vComUSUesFn-c_7_IYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateSeptember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateMarch2022Member_XlEHT5yyoES9L354AxvHSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateMarch2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member_mxmMtGXpS0GIYfMeHwojow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2019_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_619kTaw0GEyZLXk7eliAdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateOctober2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassMemberSCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_4_30_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateApril2022Member_Jnl-Bb2R2EiM_K13OPkf4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateApril2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member_BaBBng1QkES6yfdBQj_5SA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateJanuary2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_7_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_D82Hstg3QkSYlPP9MHSV6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateJuly2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJune2021Member_iWpvZWkOx02nS35b2LJKJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateJune2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2021_To_6_30_2021_aPFoy3uQQkGd9asBZ1avUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_g7TcRnVZ-EeKEa9jZmWMBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateJuly2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_1_31_2021_srt_TitleOfIndividualAxis_acxp_NonEmployeeMember_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_UquoWzH2YUOrWpEKLgXNoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">acxp:NonEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassBMemberSCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_acxp_EquityIncentivePlan2021Member_W5IQ42UzGEy4rC9lIUrHjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">acxp:EquityIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_acxp_EquityIncentivePlan2021Member_TIyqWUA_-EClFlY5kpwukQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">acxp:EquityIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member_90xI89oKiEeLdXH5k-9FsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2022_To_9_30_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateSeptember2022Member_8MlpVu0cokmsSI5c6YJyTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateSeptember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member_wrQ7Eh3v4EOO3IZeFBTejw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member_F_YLDKPV7UizWtFPSMLXBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_F5y4v9FsWES_CUZktDE-_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassMemberSCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_PvS7_eCOf02Kg60XmKqo1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassMemberSCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_4_30_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateApril2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_qohyZAg_4kexsYHlr-DRIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateApril2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Py4eXl-AxUWLsBuY7wnXUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateJanuary2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_7_31_2021_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_8YmAD-SQN0Gy2_-YJBttqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateJuly2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJune2021Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_xCQTnSxqU0yUl6NgiOZEdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateJune2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_4_30_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateApril2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_yPD_ZJI8H06PJt30JeyqDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateApril2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_4BRIuZGIFUyVO7Kq0DGlew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateJanuary2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_7_31_2021_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_owyoKTuxS0ybPw8J5ZH77A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateJuly2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_7_31_2021_srt_TitleOfIndividualAxis_acxp_IndependentDirectorsConsultantMember_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_Cgh2BZaRvECW2Z1yqwQ8tA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">acxp:IndependentDirectorsConsultantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateJuly2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJune2021Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_p0UPlSeFgEOxcBPz5o_OfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateJune2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_3_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateMarch2022Member_-nNTg44K_E6nnbx1CwtZmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateMarch2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member_w1T2TY_SNkCVkeO9pZPLhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2018_srt_ProductOrServiceAxis_acxp_AcxThreeSixtyTwoEMember_b8X5m76NYkaaQE7rN9N3KQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acxp:AcxThreeSixtyTwoEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Go-pCQ7LGkWyi1cgoF9ZQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__BvIcav9hkGe2hyzvEmB2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_FhifAapFH0uKzJs-MjO_1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassMemberSCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember__wGs7OIFT0CPK-kkN4m2Tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassBMemberSCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_svnDIsmsoEWsEvfBIapN1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassMemberSCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_TKQ1abvx9UijoSdLGqZqww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassBMemberSCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2020_us-gaap_ShortTermDebtTypeAxis_acxp_PaycheckProtectionProgramLoanMember_sS6eiAQzIkmyBpb68LMOBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">acxp:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ShortTermDebtTypeAxis_acxp_PaycheckProtectionProgramLoanMember_ITpBNU5NNkaQ1aNsqLkRmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">acxp:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2020_To_5_31_2020_us-gaap_ShortTermDebtTypeAxis_acxp_PaycheckProtectionProgramLoanMember_6co5NWgV9EOO1mbFZkcoFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">acxp:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_29_2021_To_6_29_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassAndClassBMemberSCapitalMember_sGnNM7X_Y0a52s50X0s31g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassAndClassBMemberSCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-29</xbrli:startDate><xbrli:endDate>2021-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_23_2021_To_6_23_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassAndClassBMemberSCapitalMember_9R3-6dGcWEaNHCoKMihkrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassAndClassBMemberSCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-23</xbrli:startDate><xbrli:endDate>2021-06-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_LiabilitiesTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_acxp_VendorOneMember_r8R9a4Obr0Ot0gf8VEQ9Gw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">acxp:VendorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_acxp_VendorTwoMember_yFuWsT6s0UCyH_YTEghzqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">acxp:VendorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_acxp_VendorOneMember_4oZxhIVJI0KIX3uwgXpLww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">acxp:VendorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_LiabilitiesTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_acxp_VendorOneMember_FamfXN_U9ECbf8TAjQXRNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">acxp:VendorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_acxp_VendorTwoMember__H92yBaZYkKfxsX2SKyheA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">acxp:VendorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_acxp_VendorOneMember_8CM4InADYkOReoekH1g7Zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">acxp:VendorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_27b4PKohgEW2UtRdiEuquw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassMemberSCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_vRcsmNgV3Eq09f5ms-XUQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassBMemberSCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2gVXSaZ170Wf8nqxjc_rMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_scb5hQt9d0-OCtp3xVkWXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_25_2022_YegiBECCekyLQBPmihkK7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2021_us-gaap_AwardTypeAxis_acxp_EquityIncentivePlan2021Member_HrihoDSDdE2dXqf1m4_VhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">acxp:EquityIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member_UmPpwgUbXEq7CaPHpNFPOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_27_2022_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Igcj6YgXu0uL014Kv8JyFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acxp:SeriesWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_27_2022_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_BaulSGACgEqCM8yVww4XkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acxp:SeriesBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_25_2022_srt_TitleOfIndividualAxis_us-gaap_InvestorMember_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesWarrantsMember_NWDnHTpMZUCylxU3oQXj-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acxp:SeriesWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_25_2022_srt_TitleOfIndividualAxis_acxp_AffiliateInvestorsMember_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesBWarrantsMember_0trLt8KDDU2-A92s7AKaAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">acxp:AffiliateInvestorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acxp:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_25_2022_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesWarrantsMember_HHLsVDf1Skma7FwgAwWjhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acxp:SeriesWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_25_2022_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesBWarrantsMember_WAQhRe6t0EmrCSaWui2e9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acxp:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_WeightedAverageMember__LDIrfLVM0-4X8uUinUNww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_25_2022_srt_TitleOfIndividualAxis_us-gaap_InvestorMember_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesBWarrantsMember_EZQw2mZf6Euo9EwTGvaY4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acxp:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_25_2022_srt_TitleOfIndividualAxis_acxp_AffiliateInvestorsMember_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesWarrantsMember_6hXj30MhOU2VHM0OprvNzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">acxp:AffiliateInvestorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acxp:SeriesWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_25_2022_srt_TitleOfIndividualAxis_us-gaap_InvestorMember_Ri0JCPeSzE6DD189Cr4yVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_25_2022_us-gaap_SubsidiarySaleOfStockAxis_acxp_PlacementAgentsMember_xZ4u8T8GOEmEbz0QrR2l2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acxp:PlacementAgentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RangeAxis_srt_WeightedAverageMember_e70u-YktPE-UR-XzQ15xzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_acxp_UnderwriterMember_UBZF9KBTGk6x1d7NF_WJMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acxp:UnderwriterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_29_2021_jxXdY4PAdk6_gydSF_zR1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2018_srt_ProductOrServiceAxis_acxp_AcxThreeSixtyTwoEMember_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_gOS8l29JHkSEb-8_CljtJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acxp:AcxThreeSixtyTwoEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassBMemberSCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_GjIfeLZ3Ck689XNTpPYicQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_HEBRdNbrGUqT6x6-UyBm6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_m6mpGMbdVU2n0bKhzjnGLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJune2021Member_QNhUB26_yk2TvwRPRCTv5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateJune2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_dQo-EEliWUuFEj9-VZ9N3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateJuly2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member_eIYvcQou2k6kRaWtqOy8qQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateJanuary2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateApril2022Member_vR_7z-bGCUubmqFX9FxQYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateApril2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJune2021Member_vb95mGglMUy4oh0WaAepFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateJune2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_qx3OtHXhPUaPRIR812d3Ww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateJuly2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_arPPEgMHzESpDcWdrf7Z0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_15_2023_EMUzP5iUwESxrsXBZFLNEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_25_2022_To_7_25_2022_srt_TitleOfIndividualAxis_acxp_AffiliateInvestorsMember_p7F3gkO8pE2NTMNCZ9i1nQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">acxp:AffiliateInvestorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-25</xbrli:startDate><xbrli:endDate>2022-07-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_27_2022_To_7_27_2022_us-gaap_SubsidiarySaleOfStockAxis_acxp_RegisteredDirectOfferingMember_95IFFOAcVEe4mj_2dDLvKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acxp:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-27</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_25_2022_To_7_25_2022_sWcLqEbyWkeHbC8OdzC6_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-25</xbrli:startDate><xbrli:endDate>2022-07-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_29_2021_To_6_29_2021_ZftWEESwJUi8qhJm8t8FPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-29</xbrli:startDate><xbrli:endDate>2021-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bAx1kdchGkS4wq4G6E6-eA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_NHdyZ3imJk-CuOuyJfGKCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassMemberSCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_po048zYXXkK5B_bKRi3sOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_1_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_8oqL0Hgh60e7ICqaSonkbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassMemberSCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jVrdnRA-J0qI3Y9UjDQQ5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zlsc7iOms0m26BVpMKK4ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member_dxrWwDmqfUKvdyQbLpmhnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateSeptember2022Member_FgQUZhXKi0mL6FXLRm0gIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateSeptember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember_EdWadodcnUyBlBRFeYfBqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDatePreIpoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateOctober2021Member_WyWUGX-ss020568gQjYm8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateOctober2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member_glK66UkK8kaOPtF_EMotIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateOctober2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateMarch2022Member_laHCYr4uL0S16Yf2nc-A4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateMarch2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_10_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateOctober2021Member_6LGtqepcjEOliJ4jOXHUIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateOctober2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_m2h7V2EdPEine3-RW3GKcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDatePreIpoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_At7Vvf6ODEu2VV8vZNhcWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDatePreIpoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantedInThirdQuarter2021Member_Tlp76MoUFEqKyMnI6aK_eQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantedInThirdQuarter2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateOctober2021Member_5i2X2rTyx0SYX8Xybc8Psw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateOctober2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member_TsKzRMZrzEyys7D-3GS8aw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateOctober2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_25_2022_To_7_25_2022_us-gaap_SubsidiarySaleOfStockAxis_acxp_PlacementAgentsMember_E-IOxhM4rk2gkD8cStTzjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acxp:PlacementAgentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-25</xbrli:startDate><xbrli:endDate>2022-07-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2018_To_2_28_2018_srt_ProductOrServiceAxis_acxp_AcxThreeSixtyTwoEMember_Ney4atHhPEWi0zip1SpT4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acxp:AcxThreeSixtyTwoEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_25_2022_To_7_25_2022_srt_TitleOfIndividualAxis_us-gaap_InvestorMember__XKurX6OPUKTdaHa_IwqkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-25</xbrli:startDate><xbrli:endDate>2022-07-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_WeightedAverageMember_XhK5Z9PZ80SoOyza28-Ohw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_29_2021_To_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_acxp_UnderwriterMember_-kSXTBxSPkq5OVNeYmsV1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acxp:UnderwriterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-29</xbrli:startDate><xbrli:endDate>2021-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_YaTMIktqsk6w51g7L20gNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassBMemberSCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001736243</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Y_m6Q1ZS4FGUy3pAlacn4HHg"><xbrli:measure>acxp:Y</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:9.2pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_8d692549_b43a_43a4_b734_87e54b5c12be"></a><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">_____________________</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:DocumentType" id="Narr_0eWHmz9UQk213bwRlX2Xig"><b style="font-size:8pt;font-weight:bold;">10-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">_____________________</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:17.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:DocumentAnnualReport" id="Narr_-u4OKbxiHkSlwQaoOudcGw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:8pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><b style="font-size:8pt;font-weight:bold;">For the fiscal&#160;year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:DocumentPeriodEndDate" id="Narr_fEIwqM72LU6UbBl6K16k9Q"><b style="font-size:8pt;font-weight:bold;">December&#160;31, 2022</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">OR</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:17.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:DocumentTransitionReport" id="Narr_VbxtM2UHxkG3nkBA4UK07A"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;"><b style="font-size:8pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">FOR THE TRANSITION PERIOD FROM TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><b style="font-size:8pt;font-weight:bold;">Commission File Number </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:EntityFileNumber" id="Narr_9np30a0ZYEuVZeiuaGhj_Q"><b style="font-size:8pt;font-weight:bold;">001-40536</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:EntityRegistrantName" id="Narr_vpDq0cSp4UqEAt_KYPHpuA"><b style="font-size:8pt;font-weight:bold;">Acurx Pharmaceuticals,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Exact name of Registrant as specified in its Charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:83.87%;"><tr><td style="vertical-align:top;width:49.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:EntityIncorporationStateCountryCode" id="Narr_LPTf94vezE-Us40hmVmxRA"><b style="font-size:8pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">incorporation or organization)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:EntityAddressAddressLine1" id="Narr_pPf78jDtzEGSJYATv4ssEg"><b style="font-size:8pt;font-weight:bold;">259 Liberty Ave.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:EntityAddressCityOrTown" id="Narr_7loCAQU7WkiO6AnJW6sVQg"><b style="font-size:8pt;font-weight:bold;">Staten Island</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:EntityAddressStateOrProvince" id="Narr_j39j5HnWLUmN0wezIkiQ-g"><b style="font-size:8pt;font-weight:bold;">NY</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.01%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:EntityTaxIdentificationNumber" id="Narr_fBNA0NIHB0ezEHebFNkpaw"><b style="font-size:8pt;font-weight:bold;">82-3733567</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Identification No.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:EntityAddressPostalZipCode" id="Narr_TjxX2nqpFE6lJbAvcM2RBQ"><b style="font-size:8pt;font-weight:bold;">10305</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr><tr><td style="vertical-align:top;width:49.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.01%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><b style="font-size:8pt;font-weight:bold;">Registrant&#8217;s telephone number, including area code: (</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:CityAreaCode" id="Narr_88K_QOKa70ewqo17aMQQpw"><b style="font-size:8pt;font-weight:bold;">917</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:LocalPhoneNumber" id="Narr_vSif5ez_J0y0YPTtyEzUFQ"><b style="font-size:8pt;font-weight:bold;">533-1469</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_e308b77f_be88_408e_8a4b_5b340115a2a2"></a><a id="Tc_ghAYx9JPzkSuBBNLI_2EIA_0_0"></a><a id="Tc_85yNeODlK0eM2J8hHmXZDQ_0_2"></a><a id="Tc_XfgqK3dKBEmSWGt3pQEX9A_0_4"></a><a id="Tc_SXMfpievlEO9XiEset0vxA_1_4"></a><a id="Tc_N_sdrXXavEmSh8dG0qu-Gw_3_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:37.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:14.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading </b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Symbol(s)</b></p></td><td style="vertical-align:top;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:43.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:Security12bTitle" id="Tc_FxjgwsKAoEi92VCYW6RJ2A_1_0"><span style="font-size:8pt;">Common Stock, $0.001 par value per share</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.67%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:TradingSymbol" id="Tc_cELoj8nc1EiTUfh68spBQw_1_2"><span style="font-size:8pt;">ACXP</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">The </span><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:SecurityExchangeName" id="Narr_ZSV2V4SbSkGg0GdfnJGWnw"><span style="font-size:8pt;">Nasdaq</span></ix:nonNumeric><span style="font-size:8pt;"> Capital Market</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="5" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">registered pursuant to Section 12(g)</b><b style="font-weight:bold;"> of the Act: None</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. Yes </span><span style="font-size:8pt;">&#9744;</span><span style="font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_FOod1RMQlk6E_JLNtG88HA"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d)&#160;of the Act. Yes </span><span style="font-size:8pt;">&#9744;</span><span style="font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:EntityVoluntaryFilers" id="Narr_b_NYlwUpXkOUZdVTIIJ--Q"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:EntityCurrentReportingStatus" id="Narr_d2PWDfAr3UKBk9kM4Hot8A"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-size:8pt;">&#9746;</span><span style="font-size:8pt;"> No </span><span style="font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the Registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:EntityInteractiveDataCurrent" id="Narr_GbOdqsYvWUSFOBFqv3Y9Cw"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-size:8pt;">&#9746;</span><span style="font-size:8pt;"> No </span><span style="font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_ba15f688_23e7_4f40_a949_929be3391ee1"></a><a id="Tc_8q2o5JS2Z0mNa0mESg3iSg_1_0"></a><a id="Tc_Jk8Vl3nYxEOghAA6DPlF9A_1_2"></a><a id="Tc_F4rTaIJZjkWMn9v56Np2ZQ_1_4"></a><a id="Tc_9lnAAFzjQEW4DLxzkWIvtw_1_6"></a><a id="Tc_z1XbKMB0eECnaZ3ljD1lXA_3_2"></a><a id="Tc_2Wj_qRo1uEK5zg244fLwWA_3_4"></a><a id="Tc_i9rWkPEHwkejxk5ipIh3mA_5_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.64%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:3.14%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:16.87%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:3.25%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:25.04%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:21%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:3.04%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.64%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Large accelerated filer</p></td><td style="vertical-align:bottom;width:3.14%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:16.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">&#9744;</p></td><td style="vertical-align:bottom;width:3.25%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:25.04%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Accelerated filer</p></td><td style="vertical-align:bottom;width:21%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:3.04%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">&#9744;</p></td></tr><tr style="height:1pt;"><td style="vertical-align:middle;width:27.64%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:3.14%;margin:0pt;padding:0.25pt;"></td><td colspan="3" style="vertical-align:middle;width:45.17%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:24.04%;margin:0pt;padding:0.25pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.64%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:EntityFilerCategory" id="Tc_uC96wqgKkEKZFGBB52lr7g_3_0"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:3.14%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:16.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">&#9746;</p></td><td style="vertical-align:bottom;width:3.25%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:25.04%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:bottom;width:21%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:3.04%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:EntitySmallBusiness" id="Tc_SEanpHGeFEKDtqGLeK7pxA_3_6"><span style="font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr style="height:1pt;"><td style="vertical-align:middle;width:27.64%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:3.14%;margin:0pt;padding:0.25pt;"></td><td colspan="3" style="vertical-align:middle;width:45.17%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:24.04%;margin:0pt;padding:0.25pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.64%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:bottom;width:3.14%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:16.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:EntityEmergingGrowthCompany" id="Tc_FuRFhv4FwEuUlaV-xBBlIg_5_2"><span style="font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:3.25%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:25.04%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:21%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:3.04%;margin:0pt;padding:0.25pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:EntityExTransitionPeriod" id="Narr_HKZ_VKWUfEOAMl2hK6K_Yg"><span style="font-family:'MS Gothic';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section&#160;404(b)&#160;of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:IcfrAuditorAttestationFlag" id="Narr_ASQMpyv4nkyylnB3-8pkvQ"><span style="font-family:'MS Gothic';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><span style="white-space:pre-wrap;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.  &#61551;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><span style="white-space:pre-wrap;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).  &#61551;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:EntityShellCompany" id="Narr_1lYe_JrvFE-bJQGEm2I_LA"><span style="font-family:'MS Gothic';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> No </span><span style="font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt 0pt 3pt 0pt;">The aggregate market value of the registrant&#8217;s common stock, $0.001 per value per share, held by non-affiliates of the registrant on June&#160;30, 2022, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" format="ixt:numdotdecimal" scale="6" contextRef="As_Of_6_30_2022_arPPEgMHzESpDcWdrf7Z0Q" decimals="-5" name="dei:EntityPublicFloat" id="Narr_K2R2_7yAmE6rqi10wUYp9w">29.8</ix:nonFraction> million (based on the closing sales price of the registrant&#8217;s common stock on that date). This calculation does not reflect a determination that certain persons are affiliates of the registrant for any other purpose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt 0pt 3pt 0pt;">The number of shares of Registrant&#8217;s Common Stock outstanding as of March&#160;15, 2023 was <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_3_15_2023_EMUzP5iUwESxrsXBZFLNEA" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_qZJzBoLOIUqOVO2HtdaSsQ">11,635,795</ix:nonFraction>.</p><div style="margin-left:-0.25pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr><td style="vertical-align:middle;width:33.31%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Auditor Name: </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:AuditorName" id="Narr_BUaWsW5urEaJGKLzKyMy9g"><span style="font-size:8pt;">CohnReznick LLP</span></ix:nonNumeric></p></td><td style="vertical-align:middle;width:33.34%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Auditor Location: </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:AuditorLocation" id="Narr_EzlDQ8ovhUO9dQAOOF4LvQ"><span style="font-size:8pt;">Parsippany, NJ</span></ix:nonNumeric></p></td><td style="vertical-align:middle;width:33.34%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Auditor Firm ID: </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="dei:AuditorFirmId" id="Narr_mZNmeUMECkGb41wxQMl0cQ"><span style="font-size:8pt;">596</span></ix:nonNumeric></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-indent:0pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_7c25099a_037a_4128_8e74_367b5f61107e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">DOCUMENTS INCORPORATED BY REFERENCE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The following documents (or parts thereof) are incorporated by reference into the following parts of this Form&#160;10-K: Certain information required in Part&#160;III of this Annual Report on Form&#160;10-K is incorporated from the registrant&#8217;s definitive proxy statement for the 2023 annual meeting of stockholders (the &#8220;2023 Proxy Statement&#8221;) to be filed pursuant to Regulation 14A with the Securities and Exchange Commission within 120&#160;days of the registrant&#8217;s fiscal&#160;year ended December&#160;31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e81c4ac2_8f42_4812_94ed_a84e280ef0fe"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">TABLE OF CONTENTS</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:88.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTI_978573"><span style="font-style:normal;font-weight:normal;">PART&#160;I</span></a></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:88.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><a href="#Item1Business_391704"><span style="font-style:normal;font-weight:normal;">Item&#160;1. Business. </span></a> </p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:88.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><a href="#Item1ARiskFactors_544059"><span style="font-style:normal;font-weight:normal;">Item&#160;1A. Risk Factors. </span></a> </p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:88.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><a href="#Item1BUnresolvedStaffComments_555882"><span style="font-style:normal;font-weight:normal;">Item&#160;1B. Unresolved Staff Comments. </span></a> </p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">56</p></td></tr><tr><td style="vertical-align:top;width:88.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><a href="#Item2Properties_350715"><span style="font-style:normal;font-weight:normal;">Item&#160;2. Properties. </span></a> </p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">56</p></td></tr><tr><td style="vertical-align:top;width:88.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><a href="#Item3LegalProceedings_79427"><span style="font-style:normal;font-weight:normal;">Item&#160;3. Legal Proceedings. </span></a> </p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">56</p></td></tr><tr><td style="vertical-align:top;width:88.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><a href="#Item4MineSafetyDisclosures_704844"><span style="font-style:normal;font-weight:normal;">Item&#160;4. Mine Safety Disclosures. </span></a> </p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">56</p></td></tr><tr><td style="vertical-align:top;width:88.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTII_739086"><span style="font-style:normal;font-weight:normal;">PART&#160;II</span></a></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">57</p></td></tr><tr><td style="vertical-align:top;width:88.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. </span></a> </p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">57</p></td></tr><tr><td style="vertical-align:top;width:88.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><a href="#Item6SelectedFinancialData_535789"><span style="font-style:normal;font-weight:normal;">Item&#160;6. Selected Financial Data. </span></a> </p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">57</p></td></tr><tr><td style="vertical-align:top;width:88.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. </span></a> </p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">58</p></td></tr><tr><td style="vertical-align:top;width:88.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk. </span></a> </p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">67</p></td></tr><tr><td style="vertical-align:top;width:88.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Item&#160;8. Financial Statements and Supplementary Data. </span></a> </p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">67</p></td></tr><tr><td style="vertical-align:top;width:88.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure. </span></a> </p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">68</p></td></tr><tr><td style="vertical-align:top;width:88.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><a href="#Item9AControlsandProcedures_695557"><span style="font-style:normal;font-weight:normal;">Item&#160;9A. Controls and Procedures. </span></a> </p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">68</p></td></tr><tr><td style="vertical-align:top;width:88.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><a href="#Item9BOtherInformation_911217"><span style="font-style:normal;font-weight:normal;">Item&#160;9B. Other Information. </span></a> </p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">69</p></td></tr><tr><td style="vertical-align:top;width:88.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><a href="#Item9CDisclosureRegardingForeignJurisdic"><span style="font-style:normal;font-weight:normal;">Item&#160;9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. </span></a> </p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">69</p></td></tr><tr><td style="vertical-align:top;width:88.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIII_167870"><span style="font-style:normal;font-weight:normal;">PART&#160;III</span></a></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">70</p></td></tr><tr><td style="vertical-align:top;width:88.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><a href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Item&#160;10. Directors, Executive Officers and Corporate Governance. </span></a> </p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">70</p></td></tr><tr><td style="vertical-align:top;width:88.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><a href="#Item11ExecutiveCompensation_91664"><span style="font-style:normal;font-weight:normal;">Item&#160;11. Executive Compensation. </span></a> </p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">73</p></td></tr><tr><td style="vertical-align:top;width:88.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. </span></a> </p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">73</p></td></tr><tr><td style="vertical-align:top;width:88.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence. </span></a> </p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">73</p></td></tr><tr><td style="vertical-align:top;width:88.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><a href="#Item14PrincipalAccountingFeesandServices"><span style="font-style:normal;font-weight:normal;">Item&#160;14. Principal Accounting Fees and Services. </span></a> </p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">73</p></td></tr><tr><td style="vertical-align:top;width:88.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIV_144597"><span style="font-style:normal;font-weight:normal;">PART&#160;IV</span></a></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">74</p></td></tr><tr><td style="vertical-align:top;width:88.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><a href="#Item15ExhibitsFinancialStatementSchedule"><span style="font-style:normal;font-weight:normal;">Item&#160;15. Exhibits, Financial Statement Schedules. </span></a> </p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">74</p></td></tr><tr><td style="vertical-align:top;width:88.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><a href="#Item16Form10KSummary_406457"><span style="font-style:normal;font-weight:normal;">Item&#160;16. Form&#160;10-K Summary. </span></a> </p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">76</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">i</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_1b76e085_1627_4367_9741_b12ff6edf9cb"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SPECIAL NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This Annual Report on Form&#160;10-K (this &#8220;Form&#160;10-K&#8221;) contains forward-looking statements that involve risks and uncertainties. All statements other than statements of historical facts contained in this Form&#160;10-K are forward-looking statements. In some cases, you can identify forward-looking statements by words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or the negative of these words or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain and maintain regulatory approval of ibezapolstat and/or our other product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to successfully commercialize and market ibezapolstat and/or our other product candidates, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to contract with third-party suppliers, manufacturers and other service providers and their ability to perform adequately;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential market size, opportunity and growth potential for ibezapolstat and/or our other product candidates, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to build our own sales and marketing capabilities, or seek collaborative partners, to commercialize ibezapolstat and/or our other product candidates, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain funding for our operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of anticipated regulatory filings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of availability of data from our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of the ongoing COVID-19 pandemic and our response to it;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the accuracy of our estimates regarding expenses, capital requirements and needs for additional financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to advance product candidates into, and successfully complete, clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to recruit and enroll suitable patients in our clinical trials and the timing of enrollment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing or likelihood of the accomplishment of various scientific, clinical, regulatory and other product development objectives;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the pricing and reimbursement of our product candidates, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the rate and degree of market acceptance of our product candidates, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the implementation of our business model and strategic plans for our business, product candidates and technology;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments relating to our competitors and our industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the development of major public health concerns, including the novel coronavirus outbreak or other pandemics arising globally, and the future impact of it and COVID-19 on our clinical trials, business operations and funding requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effects of the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide from the conflict between Russia and Ukraine; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the volatility of the price of our common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our financial performance; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other risks and uncertainties, including those listed in &#8220;Risk Factors.&#8221;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in the &#8220;Risk Factors&#8221; section and elsewhere in this Form&#160;10-K. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Form&#160;10-K may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable as of the date of this Form&#160;10-K, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Form&#160;10-K to conform these statements to new information, actual results or to changes in our expectations, except as required by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">You should read this Form&#160;10-K and the documents that we reference in this Form&#160;10-K and have filed with the Securities and Exchange Commission, or SEC, as exhibits to this Form&#160;10-K with the understanding that our actual future results, levels of activity, performance, and events and circumstances may be materially different from what we expect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This Form&#160;10-K includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Such data involves a number of assumptions and limitations and contains projections and estimates of the future performance of the markets in which we operate and intend to operate that are subject to a high degree of uncertainty. We caution you not to give undue weight to such projections, assumptions and estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This Form&#160;10-K contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Form&#160;10-K, including logos, artwork and other visual displays, may appear without the &#174; or TM symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_30952e94_9b35_43a8_a853_4414876b7533"></a><a id="PARTI_978573"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;I</p><a id="Item1Business_391704"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1. Business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization (&#8220;WHO&#8221;), the U.S. Centers for Disease Control and Prevention (&#8220;CDC&#8221;) and the U.S. Food and Drug Administration (&#8220;FDA&#8221;). Priority pathogens are those which require new antibiotics to address the worldwide crisis of antimicrobial resistance (&#8220;AMR&#8221;) as identified by the WHO, CDC and FDA. The CDC estimates that, in the U.S., antibiotic-resistant pathogens infect one individual every 11 seconds and result in one death every 15 minutes. The WHO recently stated that growing antimicrobial resistance is equally as dangerous as the ongoing COVID-19 pandemic, threatens to unwind a century of medical progress and may leave us defenseless against infections that today can be treated easily. According to the WHO, the current clinical development pipeline remains insufficient to tackle the challenge of the increasing emergence and spread of antimicrobial resistance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our approach is to develop a new class of antibiotic candidates that block the DNA polymerase IIIC enzyme (&#8220;Pol IIIC&#8221;). We believe we are developing the first Pol IIIC inhibitor to enter clinical trials and have clinically validated the efficacy of our lead Pol IIIC antibiotic candidate in a Phase 2a clinical trial. Pol IIIC is the primary catalyst for DNA replication of several Gram-positive bacterial cells. Our research and development pipeline includes clinical stage and early stage antibiotic candidates that target Gram-positive bacteria for oral and/or parenteral treatment of infections caused by Clostridium difficile (&#8220;C. difficile&#8221;), Enterococcus (including vancomycin-resistant strains (&#8220;VRE&#8221;)), Staphylococcus (including methicillin-resistant strains (&#8220;MRSA&#8221;)), and Streptococcus (including antibiotic resistant strains).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pol IIIC is required for the replication of DNA in certain Gram-positive bacterial species. By blocking this enzyme, our antibiotic candidates are believed to be bactericidal and inhibit proliferation of several common Gram-positive bacterial pathogens, including both sensitive and resistant C. difficile, MRSA, vancomycin-resistant Enterococcus, penicillin-resistant Streptococcus pneumonia (&#8220;PRSP&#8221;) and other resistant bacteria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We intend to &#8220;de-risk&#8221; this new class of antibiotics through our drug development activities and potentially partner with a fully-integrated pharmaceutical company for late-stage clinical trials and commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our lead antibiotic candidate, ibezapolstat (formerly named ACX-362E), has a novel mechanism of action that targets the Pol IIIC enzyme, a previously unexploited scientific target. Phase 2a clinical data validate the efficacy of our lead antibiotic candidate as well as Pol IIIC as an appropriate bacterial target. On December 3, 2021, we commenced enrollment in a Phase 2b 64-patient, randomized (1-to1), non-inferiority, double-blind trial of oral ibezapolstat compared to oral vancomycin, a standard of care to treat C. difficile infections (&#8220;CDI&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to that, we completed our Phase&#160;2a clinical trial of ibezapolstat to treat patients with CDI and reported the top-line data in November&#160;2020. The Phase&#160;2a clinical trial was terminated early based upon the recommendation of our Scientific Advisory Board (the &#8220;SAB&#8221;). The SAB reviewed the study data presented by management, including adverse events and efficacy outcomes, and discussed its clinical impressions. The SAB unanimously supported the early termination of the Phase&#160;2a trial after 10 patients were enrolled in the trial instead of 20 patients as originally planned. The early termination was further based on the evidence of meeting the treatment goals of eliminating the infection with an acceptable adverse event profile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The SAB noted that 10 out of 10 patients enrolled in the Phase&#160;2a trial reached the Clinical Cure endpoint, defined in the study protocol as the resolution of diarrhea in the 24-hour period immediately before the end-of-treatment that is maintained for 48 hours after end of treatment. Such cure was sustained, meaning that the patients showed no sign of infection recurrence, for 30&#160;days thereafter. This constitutes a 100% response rate for the primary and secondary endpoints of the trial. All 10 patients enrolled in the Phase 2a trial met the study&#8217;s primary and secondary efficacy endpoints, namely, Clinical Cure at end of treatment and Sustained Clinical Cure of no recurrence of CDI at the 28-day </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:148.52pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">follow-up visit. No treatment-related serious adverse events (&#8220;SAEs&#8221;) were reported by the investigators who enrolled patients in the trial. We believe these results represent the first-ever clinical data showing Pol IIIC has potential as a therapeutically-relevant antibacterial target. Our Phase 2b clinical trial commenced enrollment on December&#160;3, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The SAB is comprised of seven scientists and clinicians who have significant expertise in the scientific disciplines required for the research and development of antibiotics. The members of the SAB serve at the pleasure of management, are paid in cash on an hourly basis for their services and do not receive equity compensation. Generally, the SAB is consulted by management during the process of designing our preclinical and clinical trials as well as in the process of analyzing data generated from these trials, although the SAB&#8217;s services are not limited to such activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Currently available antibiotics used to treat CDI infections utilize other mechanisms of action. We believe ibezapolstat is the first antibiotic candidate to work by blocking the DNA Pol IIIC enzyme in <i style="font-style:italic;">C. difficile</i>. This enzyme is necessary for replication of the DNA of certain Gram-positive bacteria, like <i style="font-style:italic;">C. difficile</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We also have an early-stage pipeline of antibiotic product candidates with the same previously unexploited mechanism of action which has established proof of concept in animal studies. This pipeline includes ACX-375C, a potential oral and parenteral treatment targeting Gram-positive bacteria, including MRSA, VRE and PRSP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Technology</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The results of our Phase 2a clinical trial also represent the first-ever clinical validation of DNA polymerase IIIC as a therapeutically relevant antibacterial target. Ibezapolstat was very well tolerated with no treatment-related SAEs noted in the Phase&#160;2a trial. Additionally, data obtained to date demonstrate that ibezapolstat enhances actinobacteria in the microbiome and suppresses regrowth of proteobacteria; potentially lessening the likelihood of CDI recurrence or new infection by MDR Gram-negative bacteria. Additionally, the unexpected finding from further analysis of the Phase 2a study is that the beneficial Firmicutes were shown to regrow while patients were receiving ibezapolstat therapy. Several follow-up experiments have demonstrated that many of these beneficial Firmicutes have heterogeneous susceptibility to ibezapolstat allowing them to continue to perform their beneficial biologic functions even while a patient is receiving ibezapolstat for their C. difficile infection. (Garey, Oral Presentation, IDSA, IDWeek 2022 Conference, Oct 19-23, 2022). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="acxp-20221231x10k002.jpg" alt="Graphic" style="display:inline-block;height:148.22pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:332.23pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Prior to conducting the Phase&#160;2a clinical trial, we successfully completed a Phase&#160;1 clinical trial of ibezapolstat for the oral treatment of CDI (the &#8220;Phase&#160;1 Trial&#8221;). The Phase&#160;1 Trial, conducted in the U.S., was a double-blind, placebo- controlled study to determine safety, tolerability, pharmacokinetics (&#8220;PK&#8221;) and fecal concentrations of ibezapolstat in 62 healthy volunteers. It was conducted in two parts; first, single ascending doses were administered to four cohorts of eight subjects each, and second, multiple ascending doses were administered that simulate the anticipated clinical treatment regimen. Safety information was analyzed through assessment of adverse events and other standard safety measures, while concentrations of ibezapolstat were determined in both blood and the feces, the latter being the critical site of drug delivery for treating CDI. In addition, the laboratory of Dr.&#160;Kevin Garey at the University of Houston performed state-</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">of-the-art microbiomic testing of gastrointestinal flora in trial subjects as compared with vancomycin, the standard of care for the treatment of patients with CDI, which testing was the first of its kind in Phase&#160;1 clinical trials for CDI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Data from the case report forms completed by the principal investigators of the Phase&#160;I Trial showed that single and multiple ascending doses of ibezapolstat demonstrated a safety signal similar to placebo according to the principal investigators as evidenced by the case report forms. There were no safety signals reported on the case report forms related to physical examination or vital signs (blood pressure, pulse or oral temperature) in any part of the study. No significant abnormalities developed in the 12-lead electrocardiogram traces for any subject at any dose given according to the data reported by the principal investigators in the case report forms. No changes were observed in serum biochemistry or hematological blood evaluations. No dose-dependent increase in adverse events, (each, an &#8220;AE&#8221;) was reported, and no serious AEs were observed. The proportion of ibezapolstat-dosed subjects with an AE was similar to placebo at each dosing level. All AEs were considered mild or moderate and none required a change in therapy or intervention.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Systemic exposure following oral dosing was very low and no accumulation occurred after ten&#160;days of repeated dosing. In addition, oral dosing of ibezapolstat resulted in rapid and sustained fecal concentrations that are approximately 2,500 times the minimum inhibitory concentration of ibezapolstat required to kill the CDI bacteria in the colon at the site of the infection. Comparative microbiome analysis versus vancomycin demonstrated a two to three log favorable difference in the reduction of the predominantly healthy bacteria in the gut microbiome. Free concentrations of ibezapolstat were found to be high enough to kill <i style="font-style:italic;">C. difficile</i> but too low to kill healthy bacteria like Bacteroides&#160;&amp; Firmicutes which constitute approximately 90% of healthy microbiome in the judgment of our scientific advisors. Upon review of the final Phase&#160;1 Trial data, our medical and scientific advisors suggested these data supported advancing ibezapolstat into a Phase&#160;2 clinical trial at doses up to 450 mg, twice daily, for 10&#160;days of treatment, as described above. We believe that ibezapolstat is the only clinical-stage compound currently known to target <i style="font-style:italic;">C. difficile</i> by acting specifically on Pol IIIC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have worked closely with the FDA to obtain our investigational new drug application (&#8220;IND&#8221;), and to obtain FDA fast track designation as well as designation of ibezapolstat as a qualified infectious disease product (&#8220;QIDP&#8221;), which provides incentives through the Generating Antibiotic Incentives Now Act (the &#8220;GAIN Act&#8221;) including FDA priority review for the first application submitted for the QIDP, fast track designation eligibility and extension of statutory exclusivity periods in the U.S. for an additional 5&#160;years upon FDA marketing approval of the product to treat patients with CDI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ibezapolstat originally was sponsored by GLSynthesis&#160;Inc., which completed several pre-clinical studies, developed the current manufacturing process and filed for several of the patents that have been granted to date. We acquired worldwide rights to manufacture, develop and commercialize ibezapolstat from GLSynthesis&#160;Inc. on February&#160;5, 2018, pursuant to an asset purchase agreement executed by the parties on that date. At closing, we paid GLSynthesis $110,174 in cash and 100,000 Class&#160;B Membership Interests. We are also required to pay up to $700,000 in success-based clinical milestone payments to GLSynthesis, including a payment of $500,000 upon the successful completion of two phase 3 clinical trials and a royalty of 4% on net sales of ibezapolstat throughout the duration of the patent period, which currently extends to September&#160;2030.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of the date of this Form&#160;10-K, of the $700,000 of potential milestone payments, we have paid to GLSynthesis a total of $50,000, including $25,000 paid upon receipt of a &#8220;safe to proceed&#8221; notification from FDA relating to the commencement of clinical trials (December&#160;2018) and $25,000 paid upon the successful completion of clinical trial drug supply suitable to support our Phase 1 clinical trial (December&#160;2018). The patent jurisdictions of the acquired patents include the U.S., European Union, Japan and Canada.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">About QIDP and Fast Track Designations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The GAIN Act, which was enacted as part of the Food and Drug Administration Safety and Innovation Act (&#8220;FDASIA&#8221;) in 2012, created incentives for the development of novel antibiotic and antifungal products intended to treat serious and life-threatening infections. The GAIN Act amended the federal Food, Drug, and Cosmetic Act to add a designation for QIDPs. A QIDP is defined as &#8220;an antibacterial or antifungal drug for human use intended to treat serious </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">or life-threatening infections, including those caused by (1)&#160;an antibacterial or antifungal resistant pathogen, including novel or infectious pathogens, or (2)&#160;qualifying pathogens listed under&#8221; 21 C.F.R. &#167;&#160;317.2. The primary incentive for developing a QIDP is a five-year exclusivity extension for the relevant antibiotic or antifungal indications of the QIDP, but the designation also offers FDA priority review for the first application submitted for the QIDP and eligibility for fast track designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">FDA&#8217;s fast track designation is a process designed to facilitate the development and expedite the regulatory pathway of new drugs to treat serious or life-threatening conditions and that fill a high unmet medical need. To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need by providing a therapy where none exists or a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. Fast track designation provides opportunities for more frequent interactions with the FDA review team to expedite development and review of the product. The FDA may also review sections of the new drug application (&#8220;NDA&#8221;) for a fast track product on a rolling basis before the complete application is submitted, if the sponsor and the FDA agree on a schedule for the submission of the application sections and the sponsor pays any required user fees upon submission of the first section of the NDA. In addition, fast track designation may be withdrawn by the sponsor or rescinded by the FDA if the designation is no longer supported by data emerging from the clinical trial process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based upon advice from our scientific advisors, we believe ACX-375C, our second antibiotic candidate currently in pre-clinical development, will also be eligible for FDA&#8217;s QIDP and fast track designations. This advice is supported by the &#8220;qualifying&#8221; criteria for a QIDP listed in GAIN Act legislation of 2012 enacted as part of the FDASIA. A QIDP is defined as &#8220;an antibacterial or antifungal drug for human use intended to treat serious or life-threatening infections, including those caused by qualifying pathogens listed under 21 C.F.R. &#167; 317.2 which include bacterial pathogens against which ACX-375C has demonstrated microbiological activity namely, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus. These bacteria are generally causative of serious or life-threatening infections, including, but not limited to, acute bacterial skin and skin structure infections, community acquired pneumonia, blood stream infections, hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia, which are planned to be studied in future clinical trials at the appropriate time in product development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Mechanism of Action</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">DNA Pol IIIC has proved essential for replicative DNA synthesis in aerobic, low G-C Gram-positive bacteria, i.e. those with a low guanine-cytosine (G-C) ratio relative to their adenine-thymine (A-T) ratio. Pol IIIC-specific genes of several such Gram-positive bacteria have been cloned and expressed, and the DNA Pol IIIC enzymes appear to share a unique capacity to be inhibited by 6-anilinouracils (AU), 2-phenylguanines (PG) and related compounds which are analogs of 2 &#8216;-deoxyguanosine 5&#8217;&#160;-triphosphate (dGTP).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The hypothesis supporting further development of ibezapolstat is that dGTP analog compounds bind to Pol IIIC via a &#8220;base-pairing domain&#8221; and an enzyme-specific &#8220;aryl domain&#8221; (<b style="font-weight:bold;">Figure 1</b>). Through its base-pairing domain, which mimics that of guanine, the dGTP analog base pairs with an un-apposed template cytosine just distal to the DNA primer terminus. Simultaneously, the aryl domain binds an aryl-specific &#8220;receptor&#8221; near the POL IIIC enzyme&#8217;s dNTP binding site, causing the formation of an inactive ternary complex of inhibitor (dGTP analog), DNA and Pol IIIC (<b style="font-weight:bold;">Figure 2</b>).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:273pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="acxp-20221231x10k003.jpg" alt="Graphic" style="display:inline-block;height:273pt;width:448.5pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the ternary binding hypothesis described above, Torti et al. (2011) reported that ibezapolstat&#160;(362E) inhibited purified Pol IIIC derived from C. <i style="font-style:italic;">difficile</i> (Ki 0.325 &#181;M) and from Bacillus subtilis (Ki 0.34 &#181;M) in <i style="font-style:italic;">in vitro</i> resting. <i style="font-style:italic;">C. difficile</i> has a single circular chromosome and one origin of replication (<i style="font-style:italic;">oriC</i>) from which DNA replication begins in a bi-directional fashion (<b style="font-weight:bold;">Figure 3A</b>). Using marker frequency analysis, the abundance of the <i style="font-style:italic;">oriC</i> proximal genes relative to the terminus (<i style="font-style:italic;">terC</i>) proximal genes can be determined. <i style="font-style:italic;">C. difficile</i> treated with 4 &#181;g/mL of ibezapolstat (362E) demonstrated an 8-16-fold increased oriC:terC ratio, which would be expected for inhibition of DNA replication (<b style="font-weight:bold;">Figure 3B</b>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 3. (A)&#160;Bi-directional replication of prokaryotes. (B)&#160;Marker Frequency Analysis of subinhibitory effects of PolC inhibitor ibezapolstat (362E) compared to the antibiotic Chloramphenicol (Cm).</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="acxp-20221231x10k004.jpg" alt="Graphic" style="display:inline-block;height:156pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:381.75pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Leiden University Medical Center/Health Holland Research Project</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In August&#160;2021, Health Holland awarded a grant of approximately $500,000 USD to Leiden University Medical Center (&#8220;LUMC&#8221;) to further study the mechanism of action of pol IIIC inhibitors in a consortium partnership with our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Company (the &#8220;Health Holland Research Project&#8221;). This innovative research project entitled &#8220;Bad bugs, new drugs: Elucidation of the Structure of DNA Polymerase C (PolC) of Multidrug Resistant Bacteria in Complex with Novel Classes of Antimicrobials (POLSTOP2)&#8221; will study 3-dimensional structures of DNA polymerases and their binding interactions with our inhibitors. The antibacterial molecular target of our pipeline of novel DNA pol IIIC inhibitors has been clinically validated by ibezapolstat&#8217;s recent completion of a Phase 2a trial in patients with CDI. The Health Holland Research Project is intended to accelerate lead product candidate selection for our ACX-375 program for systemic treatment against multidrug resistant bacteria such as methicillin resistant <i style="font-style:italic;">Staphylococcus aureus</i> (MRSA), vancomycin resistant <i style="font-style:italic;">Enterococci</i> (VRE) and Drug-Resistant Streptococcus Pneumoniae (DRSP) and for other WHO, CDC and FDA high-priority, drug-resistant Gram-positive pathogens where new classes of antibiotics are needed. This project was initiated by LUMC in September&#160;2021 and emerging data are expected to contribute to the ACX-375C program development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Pre-Clinical Studies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All IND-enabling preclinical studies for ibezapolstat have been completed, including FDA-required toxicology, pharmacokinetics and <i style="font-style:italic;">in vitro</i> microbiology studies and <i style="font-style:italic;">in vivo</i> animal models. Highlights from these studies are included below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Toxicology</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Genetic Toxicology Studies:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Ames test: Negative</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Mouse Lymphoma Assay: Negative</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Micronucleus assay: Negative</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Cardiovascular Safety:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hERG Assay: The IC50 observed represents an adequate safety margin</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Cardiovascular safety studies in telemetered dogs showed no significant CV risk</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">14-day Toxicology Studies:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Rat: No effect on clinical observations, body weight, ophthalmology, hematology, clinical chemistry, urinalysis, micronucleus, gross necropsy, and microscopic endpoints; the no observed adverse effect level (&#8220;NOAEL&#8221;), is considered to be approximately 1000 mg/kg via oral administration</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dog: Emesis and diarrhea were observed in the high dose groups, which are considered test article-related; No drug-related effects were observed for body weights, food consumption, ophthalmology, clinical pathology, organ weight, gross necropsy and microscopic evaluations; the NOAEL is approximately 200 mg/kg/day following 14&#160;days oral administration</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pharmacokinetics</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Administration in male rats of a 5 mg/kg IV bolus dose of a salt form of GLS362E showed rapid systemic clearance and a short terminal half-life (0.34 hours). Plasma concentrations were BQL (&lt;0.5ng/mL) at three to four hours post-dose. All oral dosing of GLS362E, now known as ibezapolstat, did not use the salt form, only the parent molecule since the salt form is not necessary for oral dosing. Administration in male rats of a single 50mg/kg oral dose of ibezapolstat in a suspension formulation, Cmax was 119ng/mL and was observed at 15 minutes post-dose. Plasma levels declined with an apparent terminal half&#8201;&#8212;&#8201;life of 3.82&#160;hours and were still quantifiable at 24 hours post-dose. Oral bioavailability in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">male rats was 8.6%. Ibezapolstat excretion in feces was much greater than urinary excretion, consistent with incomplete oral bioavailability. After administration in male rats of a single 50 mg/kg oral dose of ibezapolstat in a suspension formulation, concentrations in the GI mucosa of all regions of the gastrointestinal tract were &gt;10&#181;g/mL at four hours post-dose, and &gt;10 &#181;g/mL at ten hours post-dose for ileum, cecum, colon and rectum. Fecal concentrations after oral dosing were approximately 100 to 200 mcg/mL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In vitro Microbiology</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Several <i style="font-style:italic;">in vitro</i> susceptibility tests have been completed. Below is a summary data table showing MIC values for 22 <i style="font-style:italic;">C. difficile</i> strains, conducted in triplicate, with the testing conducted by the R.M. Alden Laboratory in California and the isolates obtained from the same. The table below shows that the activity of GLS362E was similar to that of vancomycin and metronidazole.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 18pt;">22 <span style="font-style:italic;">C. difficile</span> isolate MIC testing (&#181; g/mL), Median values Testing Conducted at R.M. Alden Labs in California</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Drug</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">MIC&#160;range</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">MIC50</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">MIC90</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ibezapolstat</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1&#8201;&#8211;&#8201;4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 4</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vancomycin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1&#8201;&#8211;&#8201;8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 4</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Metronidazole</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0.25&#8201;&#8211;&#8201;4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 4</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Data in the table below show that ibezapolstat was not active against two <i style="font-style:italic;">Bifidobacterium</i> species or <i style="font-style:italic;">Eubacterium lentum</i> at 32 &#181;g/mL, the highest concentration tested. Activity was observed for lactobacilli and <i style="font-style:italic;">Clostridium perfringens</i>. Most importantly, ibezapolstat was active against ten clinical isolates of <i style="font-style:italic;">C.&#160;difficile</i> with an MIC range of 0.5&#8201;&#8211;&#8201;4 &#181;g/mL, MIC50 of 2 &#181;g/mL, and an MIC90 of 4 &#181;g/mL. Since the Pol&#160;IIIC target enzyme is present in only a narrow spectrum of Gram-positive organisms, minimal disruption of gut flora is anticipated. This is supported by the data in the table below, which shows that representative specimens of other gut bacteria&#8201;&#8212;&#8201;lactobacillus, bifidobacterium, and eubacterium&#8201;&#8212;&#8201;are not susceptible to ibezapolstat.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Study Report GLS001: Agar Dilution MIC (&#181; g/mL) Testing Conducted at Micromyx, 2010.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Organism</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Micromyx&#160;Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">362E</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Metronidazole</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Bifidobacterium brevi</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3967 (ATCC(1) 15698)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&gt;32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Bifidobacterium longum</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:15.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3968 (ATCC 15707)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&gt;32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Lactobacillus casei</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1722 (ATCC 393)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 16</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&gt;32</p></td></tr><tr><td style="vertical-align:bottom;width:55.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Lactobacillus acidophilus</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0681</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&gt;32</p></td></tr><tr><td style="vertical-align:bottom;width:55.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Eubacterium lentum</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1274 (ATCC 43055)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&gt;32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.25</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Clostridium perfringens</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3414</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 16</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Clostridium difficile</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3579</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.25</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3580</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.25</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3581</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.5</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3582</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.5</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3584</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.25</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3585</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.25</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3587</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.5</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Study Report GLS001: Agar Dilution MIC (&#181; g/mL) Testing Conducted at Micromyx, 2010.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Organism</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Micromyx&#160;Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">362E</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Metronidazole</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3588</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.25</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3589</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quality Control Strains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Clostridium difficile</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:13.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">4381 (ATCC 700057)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">0.25  (0.12&#8201;&#8211;&#8201;0.5)(2)</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Bacteroides fragilis</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0123 (ATCC 25285)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&gt;32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">0.25  (0.25&#8201;&#8211;&#8201;1)</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">American Type Culture Collection</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Quality control range</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additional testing has shown that ibezapolstat is highly potent against 98 strains of recent clinical isolates of <i style="font-style:italic;">C. difficile</i> in the U.S.<i style="font-style:italic;">,</i> with an MIC50 of 2 &#181;g/mL and an MIC90 of 4 &#181;g/mL, as shown in the table below. Similar recent testing of 364 European isolates showed identical MIC values.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">362E</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">MTZ</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">VAN</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FDX</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">MIC range:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.5&#8201;&#8211;&#8201;8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.25&#8201;&#8211;&#8201;&gt;32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.5&#8201;&#8211;&#8201;16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.03 &#8201;&#8211;&#8201;&gt; 8</p></td></tr><tr><td style="vertical-align:bottom;width:55.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">MIC50:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.5</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">MIC90:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Abbreviations: MTZ=metronidazole; VAN=vancomyein; FDX=fidaxomicin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The in vitro activity of ibezapolstat was tested in June&#160;2019 by conducting minimum inhibitory concentration (MIC) testing against 104 <i style="font-style:italic;">C. difficile</i> clinical isolates, including those with important ribotypes. Fidaxomicin, vancomycin, and metronidazole were used as comparators. When ibezapolstat achieved the &#8805;99.9% bacterial kill (i.e., 3-log reduction in bacterial numbers), it met the Clinical Laboratory Standards Institute (&#8220;CLSI&#8221;) criteria for bactericidal activity which is accepted by FDA. This represents a laboratory measure of antibacterial potency but does not translate directly into human efficacy which can only be established in clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Results indicated that the activity of ibezapolstat was similar to that of the comparators evaluated, with a narrow MIC range against 104 <i style="font-style:italic;">C. difficile</i> clinical isolates, of which ~30% were of different ribotypes and another 30% were toxigenic. In addition, 4 isolates of the epidemic strain ribotypes 027 and 078 demonstrated ACX-362E sensitivities similar to those of other ribotypes. In Vitro Activity (in &#956;g/mL) of ACX-362E (ibezapolstat) and Comparators against 104 C. difficile Clinical Isolates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">In Vitro Activity (in &#181;g/mL) of ACX-362E (ibezapolstat) and Comparators against 104 C. difficile Clinical Isolates</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ACX-362E&#160;</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(ibezapolstat)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">MTZ</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">VAN</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FDX</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">MIC range:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1&#8201;&#8211;&#8201;8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.25&#8201;&#8211;&#8201;16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.5&#8201;&#8211;&#8201;4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.015&#8201;&#8211;&#8201;1</p></td></tr><tr><td style="vertical-align:bottom;width:54.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">MIC50:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.12</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">MIC90:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.25</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:2pt;margin:0pt 0pt 12pt 18pt;">Abbreviations: FDX=fidaxomicin; MIC=minimum inhibitory concentration; MTZ=metronidazole; VAN=vancomycin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Overall, the results of this study indicated that the activity of ibezapolstat was similar to that of the comparators evaluated in this study. With a narrow MIC range against 104 <i style="font-style:italic;">C. difficile</i> clinical isolates, approximately 30% were of different ribotypes and another 30% were toxigenic.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July&#160;2019 the bactericidal activity of ibezapolstat was evaluated by first determining the MIC and then the minimum bactericidal concentration (MBC) against 3 <i style="font-style:italic;">C. difficile</i> isolates; vancomycin and metronidazole were used as comparators in these assays. In a second measure of bactericidal activity, the time-kill kinetics of ibezapolstat was assessed in comparison to vancomycin and metronidazole against the same 3 <i style="font-style:italic;">C. difficile</i> isolates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Against two of the three isolates, ibezapolstat had MBC:MIC ratios of 1 to 4 across replicates indicating bactericidal activity. For the remaining isolate, MBC:MIC ratios of 2 to &gt;8 were observed although in instances where the ratio was &gt;8, counts indicated &gt;2-log10 killing at or near the MIC. When the time-kill kinetics (or the result of a microbiological laboratory study of antimicrobial activity of a compound over time) of ibezapolstat were evaluated against <i style="font-style:italic;">C. difficile</i> MMX 5680 and BAA-1382, bactericidal activity was observed at the two later time points and at all three evaluated doses (MMX 5680) or the two highest doses (BAA-1382). Against <i style="font-style:italic;">C. difficile</i> isolate BAA-1875, ibezapolstat did not demonstrate the &#8805;3 log10 CFU/mL killing required for bactericidal activity, but bacterial levels were reduced by &gt;2 log10 CFU at the 24- and 48-hour time points at 16X and 32X the MIC. In the case of metronidazole and vancomycin, the highest MIC value recorded from the triplicate testing was used to calculate 8X, 16X, and 32X the MIC for the time kill study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Activity of ibezapolstat and Comparators against C. difficile Isolates</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:15.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:15.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ACX-362E&#160;</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:15.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(ibezapolstat)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Metronidazole</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Vancomycin</b></p></td></tr><tr><td style="vertical-align:bottom;width:15.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Organism</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Isolate&#160;No.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Replicate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">MIC</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">MBC</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">MIC</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">MBC</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">MIC</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">MBC</b></p></td></tr><tr><td style="vertical-align:bottom;width:15.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">C. difficile</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">MMX 5680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Ribotype 027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.5</span></p></td></tr><tr><td style="vertical-align:bottom;width:15.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.5</span></p></td></tr><tr><td style="vertical-align:bottom;width:15.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">C</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.25</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.25</span></p></td></tr><tr><td style="vertical-align:bottom;width:15.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">BAA- 1382</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Ribotype 012</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td></tr><tr><td style="vertical-align:bottom;width:15.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td></tr><tr><td style="vertical-align:bottom;width:15.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">C</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td></tr><tr><td style="vertical-align:bottom;width:15.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">BAA- 1875</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Ribotype 078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&gt;8*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.25</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.5</span></p></td></tr><tr><td style="vertical-align:bottom;width:15.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.5</span></p></td></tr><tr><td style="vertical-align:bottom;width:15.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">C</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&gt;8*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.5</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 18pt;">Abbreviations: MIC=minimum inhibitory concentration; MBC=minimum bactericidal concentration.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Counts only slightly exceeded the rejection values for 3-log killing (indicating that 3-log killing was nearly achieved).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Nonclinical data indicate that ibezapolstat demonstrates reproducible and consistent <i style="font-style:italic;">in vitro</i> potency against C. <i style="font-style:italic;">difficile</i> and is comparable to vancomycin in the standard and predictive Syrian Golden Hamster model of CDI. The nonclinical data also indicate that ibezapolstat may be active against <i style="font-style:italic;">C. difficile</i> in the human colon, and in fact, ibezapolstat concentrations reached approximately 2,500-fold greater than the MIC needed to kill the <i style="font-style:italic;">C. difficile</i> in this Phase 1 first-in-man clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">In vivo Efficacy Animal Models</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GLS-362E (and GLS-359E) were studied <i style="font-style:italic;">in vivo</i> in the golden Syrian hamster model of <i style="font-style:italic;">C. difficile</i>-induced colitis. Both compounds had low GI absorption (&lt;5% of an oral dose of 75 mg/kg was absorbed) and low toxicity (up to 1,000 mg/kg in hamsters). In the <i style="font-style:italic;">in vivo</i> model, hamsters are first treated subcutaneously with clindamycin, followed 24 h later with ~107 CFU of <i style="font-style:italic;">C. difficile</i> spores administered orally; therapy was initiated ~17 hours post-infection. Initial experiments evaluated the efficacy of the two compounds in this model (Dvoskin, et al, 2012, AAC) with studies designed to optimize the dose and length of therapy. In experiment 1 (shown in Table 2, below), treatment was given twice daily for three&#160;days with either vancomycin (50 mg/kg),</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:174pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="acxp-20221231x10k006.jpg" alt="Graphic" style="display:inline-block;height:173.95pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:239.61pt;" /></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="acxp-20221231x10k007.jpg" alt="Graphic" style="display:inline-block;height:135.73pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:209.97pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="acxp-20221231x10k008.jpg" alt="Graphic" style="display:inline-block;height:38.24pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:203.97pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">GLS-359E or GLS-362E (GLS-359E and GLS-362E dosed at 50, 25, 12.5, or 6.25 mg/kg), with survivorship followed through 120 hours. 362E was found to be more efficacious at lower doses than GLS-359E: 6.25 mg/kg of 362E was superior to an equivalent dose of GLS-359E (P&lt;0.001). For this reason, GLS-362E was profiled further.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subsequent experiments extended the length of therapy for GLS-362E to 7 or 14&#160;days because in the experiment shown in Table 2 it was observed that survival was not maintained beyond five&#160;days after the end of treatment in any group; studies were then designed to evaluate recurrence rates. Table 2 displays (below, from Dvoskin, et. al, 2012, AAC) twice-daily treatment for three&#160;days with either GLS-362E (50 mg/kg) or vancomycin (50 mg/kg), 67% of treated animals died. When treatment with GLS-362E is extended to 7 or 14&#160;days, survival increased to 60 and 100%, respectively. Upon necropsy, the intestinal contents of surviving hamsters were negative for toxin A and/or B whereas those for animals that had died were positive. The results for the 3-day dosing shown in Table 2 above were from additional studies. Other studies conducted by Dvoskin et al. evaluated GLS-362E efficacy/recurrence rates in the hamster model at lower doses: after 14&#160;days of dosing (100% survival for all groups at 25, 12.5 and 6.25 mg/kg out to 36&#160;days; negative for A/B toxins): after 10&#160;days of dosing at 10 mg/kg, GLS-362E treatment resulted in 86% survival on Day 36 post-infection, compared to vancomycin treatment&#8217;s 43% survival at the same dose (see graph and table below) and animals that died with <i style="font-style:italic;">C. difficile</i> disease symptoms tested positive for A/B toxin, whereas the surviving animals did not.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:247.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="acxp-20221231x10k009.jpg" alt="Graphic" style="display:inline-block;height:246.75pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:319.5pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Hamster Efficacy vs C. difficile infection**</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:56.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Survivors&#160;acute</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Survivors&#160;with&#160;no&#160;recurrent</p></td></tr><tr><td style="vertical-align:bottom;width:56.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Drug</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">infection/total&#160;animals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">infection&#160;/total&#160;animals</p></td></tr><tr><td style="vertical-align:bottom;width:56.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">GLS362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">7/7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6/7</p></td></tr><tr><td style="vertical-align:bottom;width:56.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(ibezapolstat)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">vancomycin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">7/7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3/7</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">**</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Animals were infected and treated orally with 2x10mg/kg/day of the indicated drug for 10&#160;days; acute responses were determined during the treatment and recurrent infections after 36&#160;days.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">C. difficile Infection Overview</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">Clostridioides difficile</i> infection (&#8220;CDI&#8221;) is a bacterial infection of the colon that produces toxins causing inflammation of the colon and severe diarrhea. CDI can also result in more serious disease complications, including pseudomembranous colitis, bowel perforation, toxic megacolon and sepsis. CDI represents a serious healthcare issue in hospitals, long-term care homes and, increasingly, in the wider community. We estimate that there are over one million cases of CDI each&#160;year in the U.S. and Europe, based on an epidemiology report on CDI that was published in 2015 by Decision Resources, a healthcare research and consulting company. In addition, CDI is responsible for approximately 29,000 deaths per&#160;year in the U.S., according to a study published in the <i style="font-style:italic;">New England Journal of Medicine</i> in 2015. A separate study published in 2018 in <i style="font-style:italic;">Clinical Microbiology and Infection</i>, a peer reviewed journal published by the European Society of Clinical Microbiology and Infectious Diseases, indicated that CDI may be underdiagnosed in approximately 25% of cases. A study published in <i style="font-style:italic;">The Journal of Hospital Infection</i>, a peer reviewed journal published by the Healthcare Infection Society, reported that CDI is two to four times more common than hospital associated infections caused by methicillin-resistant <i style="font-style:italic;">Staphylococcus aureus</i>, a bacterium frequently associated with such infections. The Healthcare Cost and Utilization Project, a family of databases developed through a federal-state-industry partnership sponsored by the Agency for Healthcare Research and Quality of the U.S. Department of Health and Human Services, reported an approximate three and one-half-fold increase in hospital stays associated with CDI between 2000 and 2008. The economic impact of CDI is significant. A study published in 2012 in <i style="font-style:italic;">Clinical Infectious Diseases</i> estimated that acute care costs for CDI total $4.8&#160;billion per&#160;year in the U.S. alone. According to the 2017 Update (published February&#160;2018) of the <i style="font-style:italic;">Clinical Practice Guidelines for C. difficile Infection by the Infectious Diseases Society of America (IDSA) and Society or Healthcare Epidemiology of America (SHEA),</i> CDI remains a significant medical </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">problem in hospitals, in long-term care facilities and in the community. <i style="font-style:italic;">C. difficile</i> is one of the most common causes of health care-associated infections in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. <i style="font-style:italic;">difficile</i> approaches 500,000 infections annually in the U.S. and is associated with approximately 20,000 deaths annually. (Guh, 2020, New England Journal of Medicine). Based on internal estimates, the recurrence rate of two of the three antibiotics currently used to treat CDI is between 20% and 40% among approximately 150,000 patients treated. We believe the annual incidence of CDI in the U.S. approaches 600,000 infections and a mortality rate of approximately 9.3%. There are an additional six million patients in the U.S. per&#160;year with other Gram+ infections, such as <i style="font-style:italic;">Staphylococcus</i>, <i style="font-style:italic;">Streptococcus</i> or <i style="font-style:italic;">Enterococcal</i>, with approximately 300,000 patients treated for such infections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CDI originates from a bacterium known as <i style="font-style:italic;">Clostridium difficile, or Clostridioides difficile</i>, or <i style="font-style:italic;">C. difficile</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">C. difficile</i> can be a harmless resident of the gastrointestinal tract. The complex community of microorganisms that make up the natural gut flora usually moderates levels and pathogenicity of <i style="font-style:italic;">C. difficile</i>. The natural gut flora is an essential part of the normal function of the gastrointestinal tract and also has wide implications to human health, such as the proper function of the immune system. CDI typically develops following the use of broad-spectrum antibiotic agents that can cause widespread damage to the natural gut flora and allow overgrowth of <i style="font-style:italic;">C. difficile</i>. Hypervirulent <i style="font-style:italic;">C. difficile</i> strains have also emerged and are frequently associated with more severe disease. In the U.S., the hypervirulent strain, ribotype 027, accounts for approximately one-third of all CDI cases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An important clinical issue with CDI is disease recurrence. This is in contrast to other bacterial threats for which drug resistance is the principal concern. According to an article published in 2012 in the peer reviewed journal <i style="font-style:italic;">Clinical Microbiology and Infection</i>, 20% to 40% of patients with CDI suffer a second episode of the infection. The risk of further recurrence rises to 65% after a patient suffers a third episode of CDI. In addition, each episode of recurrent disease is associated with greater disease severity and higher mortality rates. Recurrent disease is associated with an increased burden on the healthcare system.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2013, and again in a 2019 Update, the CDC highlighted <i style="font-style:italic;">C. difficile</i> as one of five pathogens that pose an immediate public health threat and require urgent and aggressive action. In 2012, the GAIN Act provisions became law along with the rest of FDASIA. The goal of the GAIN Act is to encourage the development of new antibiotics that treat specific pathogens, including <i style="font-style:italic;">C. difficile</i>, which cause serious and life-threatening infections. Since the GAIN Act was adopted, there have been two antibiotic candidates developed for CDI that have been granted QIDP status under the GAIN Act, one of which was approved by the FDA in 2011. See &#8220;<i style="font-style:italic;">Current CDI Antibiotic Treatments</i>&#8221; below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Current CDI Antibiotic Treatments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Current treatment options for CDI are limited. The current standard-of-care for CDI is treatment with vancomycin or off label use of metronidazole, both of which are broad-spectrum antibiotics. Although these antibiotics reduce levels of <i style="font-style:italic;">C. difficile</i>, both also cause significant collateral damage to the gut flora as a result of their broad spectrum of activity. This collateral damage to the gut flora leaves patients vulnerable to recurrent CDI. A review published in 2012 in the peer reviewed journal <i style="font-style:italic;">International Journal of Antimicrobial Agents</i> reported recurrence rates of 24.0% for vancomycin and 27.1% for metronidazole. Metronidazole is frequently used in mild or moderate cases of CDI and has been associated with a number of side effects. The 2017 Update (published February&#160;2018) of the <i style="font-style:italic;">Clinical Practice Guidelines for C. difficile Infection by the Infectious Diseases Society of America (IDSA) and Society of Healthcare Epidemiology of America (SHEA)</i> provides a recommendation for clinicians to prescribe either vancomycin or fidaxomicin over metronidazole for an initial episode of CDI and metronidazole is no longer recommended for treatment of patients with CDI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Fidaxomicin (Dificid<sup style="font-size:9pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>) is an antibiotic approved to treat patients with CDI in the U.S. and the European Union, but it has not been shown to be superior to vancomycin in the treatment of patients with the hypervirulent strain ribotype 027. Fidaxomicin (Dificid<sup style="font-size:9pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>) was approved by FDA in 2011. In July&#160;2013, Optimer Pharmaceuticals,&#160;Inc., the sponsor of the fidaxomicin program, was sold to Cubist Pharmaceuticals for $535&#160;million plus up to $266&#160;million in contingent value right (&#8220;CVR&#8221;) payments post-closing. Fidaxomicin was the first antibacterial drug the FDA approved in more than 30&#160;years to treat CDI. Cubist Pharmaceuticals was acquired by Merck in 2015 for approximately $8.4 billion. Merck </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:207.72pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">continues to market fidaxomicin (Dificid<sup style="font-size:9pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>) and is expected to continue through the patent life which is expected to expire in mid-2027.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Summit Therapeutics had a clinical stage antibiotic, ridinilazole, and in January&#160;2019 had opened enrollment of two Phase&#160;3 clinical trials to treat patients with CDI. In December&#160;2021, Summit Therapeutics announced that ridinilazole had failed to achieve the primary endpoint in the Phase 3 clinical trials and has since announced a plan to partner ridinalazole and has moved strategically into oncology drug development. The ridinilazole Phase&#160;3 program included two randomized trials testing efficacy in CDI versus oral vancomycin, the standard of care, as the positive control. The trials appeared to be identical in design and planned to enroll 680 patients each. Prior to failing to achieve the primary endpoint in its Phase 3 clinical trials, in the fourth quarter of 2021, Summit Therapeutics announced that the FDA had rejected Summit&#8217;s request to change the endpoint in the then ongoing Phase 3 clinical trials. Ridinilazole is an orally administered small molecule antibiotic designed to selectively target <i style="font-style:italic;">C. difficile</i> bacteria without causing collateral damage to the gut flora and thereby reduce CDI recurrence rates. Prior to failing in its Phase 3 clinical trial, ridinilazole completed two Phase&#160;2 clinical trials successfully meeting or exceeding its primary efficacy endpoints.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Despite the approval of fidaxomicin to treat CDI, the CDC continues to cite C. <i style="font-style:italic;">difficile</i> bacteria as an urgent need for new antibiotics to treat CDI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Clinical Strategy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on advice from our medical and scientific consultants and advisors, we believe we will need to conduct one Phase&#160;2 clinical trial prior to conducting one or two large Phase&#160;3 clinical trials in order to file a new drug application with the FDA for the oral use of ibezapolstat to treat patients with CDI. The trial design and anticipated size of the required clinical trials is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="acxp-20221231x10k011.jpg" alt="Graphic" style="display:inline-block;height:207.72pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:305.96pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Phase&#160;1 Clinical Trial: Data reported in August&#160;2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Phase&#160;1 clinical trial design was a randomized, double-blind, placebo-controlled, single and multiple ascending dose trial to determine the safety, pharmacokinetics and fecal microbiological effects of ibezapolstat administered orally to 62 healthy adults 18&#160;years of age or older. For the single-dose ascending portion of the trial, the objectives were to evaluate the safety and determine the pharmacokinetics and systemic exposure of single doses as well as the effects of food on PK. The multiple ascending dose portion of the trial evaluated the safety, PK and fecal concentrations of repeated doses as well as evaluate the effects of ibezapolstat on characteristics of the gut microbiome in comparison to the current standard of care treatment antibiotic, oral vancomycin. We successfully completed the Phase&#160;1 clinical trial in August&#160;2019 and the data supported advancing to Phase&#160;2 according to our medical and scientific advisors. Blood levels </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">of ibezapolstat show low systemic exposure, as predicted by previously conducted animal studies and are desirable in treating CDI, and fecal concentrations of ibezapolstat were 2 to 3 orders of magnitude above the level required to kill CDI bacteria at the site of the infection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Phase&#160;2 Clinical Trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Phase&#160;2 clinical trial design is structured as a randomized, controlled Phase&#160;2 trial of the efficacy and safety of ibezapolstat compared to vancomycin in the treatment of CDI in a total of up to 84 evaluable patients (Phase&#160;2a; up to 20 patients; Phase&#160;2b; 64 patients). Phase&#160;2a was designed to enroll up to 20 patients with a data review planned by a Trial Oversight Committee after 10 patients completed the trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based upon the recommendation of the SAB, in August&#160;2020, we terminated enrollment in Phase 2a early and advanced to Phase 2b in December&#160;<span style="white-space:pre-wrap;">2021.  The SAB unanimously supported the early termination of the Phase&#160;2a trial after 10 patients were enrolled in the trial instead of 20 patients as originally planned. The early termination was further based on the evidence of meeting the treatment goals of eliminating the infection with an acceptable adverse event profile.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The SAB noted that 10 out of 10 patients enrolled in the Phase 2a trial reached the Clinical Cure endpoint, defined in the study protocol as the resolution of diarrhea in the 24-hour period immediately before the end-of-treatment that is maintained for 48 hours after end of treatment. Such cure was sustained, meaning that the patients showed no sign of infection recurrence, for 30&#160;days thereafter. This constitutes a 100% response rate for the primary and secondary endpoints of the trial. All 10 patients enrolled in the Phase&#160;2a trial met the study&#8217;s primary and secondary efficacy endpoints, namely, Clinical Cure at end of treatment and Sustained Clinical Cure of no recurrence of CDI at the 28-day follow-up visit. No treatment-related serious adverse events were reported by the investigators who enrolled patients in the trial. We believe these results represent the first-ever clinical data showing Pol&#160;IIIC has potential as a therapeutically-relevant antibacterial target. The Phase&#160;2b portion of the Phase&#160;2 clinical trial is designed as a 64-patient vancomycin- controlled, non-inferiority designed efficacy study. 32 of the patients will receive 450mg of ibezapolstat twice per day, and 32 of the patients will receive 125mg of vancomycin four times per day. Both groups of patients will receive this treatment for 10&#160;days. Phase&#160;2b began enrollment on December&#160;3, 2021. In the event non-inferiority of ibezapolstat to vancomycin is demonstrated, further analysis will be conducted to test for superiority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The SAB is comprised of seven scientists and clinicians who have significant expertise in the scientific disciplines required for the research and development of antibiotics. The members of the SAB serve at the pleasure of management, are paid in cash on an hourly basis for their services and do not receive equity compensation. Generally, the SAB is consulted by management during the process of designing our preclinical and clinical trials as well as in the process of analyzing data generated from these trials, although the SAB&#8217;s services are not limited to such activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Phase&#160;3 Clinical Trial(s).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We intend to meet with the FDA after completing the Phase&#160;2b clinical trial to finalize the size and scope of the Phase&#160;3 clinical trial program. Regulatory precedent indicates that two Phase&#160;3 trials of approximately 400 patients each would need to be conducted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Regulatory Status</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The regulatory timeline for a newly proposed product can take eight to ten&#160;years from pre-clinical studies through marketing approval. However, we inherited the manufacturing and pre-clinical data generated by the prior sponsor of our lead product candidate which we believe will reduce the timeline for regulatory approval by two to three&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have worked closely with the FDA to obtain our IND, and to obtain FDA fast track designation as well as designation of ibezapolstat as a QIDP, which provides incentives through the GAIN Act including FDA priority review for the first application submitted for the QIDP, fast-track designation eligibility and extension of statutory exclusivity periods in the U.S. for an additional five&#160;years upon FDA approval of the product for the treatment of CDI.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Government Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing, among other things, of drug products are extensively regulated by governmental authorities in the U.S. and other countries. The processes for obtaining regulatory approvals in the U.S. and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory requirements, require the expenditure of substantial time and financial resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">U.S. Government regulation of drug products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the U.S., the FDA regulates human drugs under the FDCA, and its implementing regulations. Failure to comply with the applicable U.S. requirements may subject an applicant to administrative or judicial sanctions, such as FDA refusal to approve pending NDAs, or the agency&#8217;s issuance of warning letters, or the imposition of fines, civil penalties, product recalls, product seizures, total or partial suspension of production or distribution, injunctions and/or criminal prosecution brought by the FDA and the U.S. Department of Justice or other governmental entities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The process required by the FDA before a drug may be marketed in the United States generally involves the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of preclinical laboratory tests, animal studies and formulation studies according to Good Laboratory Practices (&#8220;GLP&#8221;), regulations or other applicable regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an IND, which must become effective before human clinical trials may begin;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval by an independent institutional review board (&#8220;IRB&#8221;), or ethics committee at each clinical trial site before each clinical trial may be initiated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, good clinical practice regulations and standards (&#8220;GCP&#8221;), and other clinical-trial related regulations to evaluate the safety and efficacy of the investigational product for each proposed indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an NDA for marketing approval, including payment of application user fees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current good manufacturing practice regulations (&#8220;cGMP&#8221;), to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality and purity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential FDA audit of the clinical trial sites to assure compliance with GCP and the integrity of the clinical data submitted in support of the NDA; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA review and approval of the NDA, including satisfactory completion of an FDA advisory committee review of the product candidate, where appropriate or if applicable, prior to any commercial marketing or sale of the product in the United States.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Before testing any drug product candidate in humans, the product candidate must undergo rigorous preclinical testing. The preclinical developmental stage generally involves laboratory evaluations of drug chemistry, formulation and stability, as well as studies to evaluate toxicity in animals, which support subsequent clinical testing. The sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational product to humans, and must become effective before human clinical trials may begin.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Preclinical studies include laboratory evaluation of product chemistry and formulation, as well as <i style="font-style:italic;">in vitro</i> and animal studies, to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety and toxicology studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All clinical trials must be conducted under the supervision of qualified investigators and in accordance with protocols detailing the objectives of the study, the parameters to be used in monitoring the safety and effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND and each study subject must sign an informed consent form before participating in a clinical trial. An IND automatically becomes effective 30&#160;days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Clinical holds may be imposed by the FDA at any time before or during studies due to safety concerns or non-compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, an IRB representing each institution that is participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must thereafter conduct a continuing review and reapprove the trial at least annually.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Phase&#160;1:</i>&#160;&#160;&#160;The product candidate is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some products for severe or life-threatening diseases, such as cancer, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Phase&#160;2:</i>&#160;&#160;&#160;This phase involves studies in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Phase&#160;3:</i>&#160;&#160;&#160;Clinical trials are undertaken with an expanded patient population to further evaluate dosage, clinical efficacy and safety in an expanded patient population, often at geographically dispersed clinical study sites. These studies are intended to establish the overall risk-benefit ratio of the product candidate and provide, if appropriate, an adequate basis for product labeling. These trials may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Post-approval trials, sometimes referred to as Phase&#160;4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase&#160;4 clinical trials as a condition of approval of an NDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events (&#8220;SAEs&#8221;) occur. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the clinical protocol, GCP, or other IRB requirements or if the drug has been associated with unexpected serious harm to patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Assuming successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, along with information relating to the product&#8217;s chemistry, manufacturing, and controls and proposed labeling, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. Under federal law, the fee for the submission of an NDA for which clinical data is substantial (for example, for fiscal&#160;year 2021 this application fee exceeds $2.8&#160;million), and the sponsor of an approved NDA is also subject to an annual program fee, currently more than $300,000 per program. These fees are typically adjusted annually, but exemptions and waivers may be available under certain circumstances.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;), for original NDAs, the FDA has ten&#160;months from the filing date in which to complete its initial review of a standard application and respond to the applicant, and six&#160;months from the filing date for an application with priority review. For an all new molecular entity (&#8220;NME&#8221;), NDAs, the ten and six-month time periods run from the filing date; for all other original applications, the ten and six-month time periods run from the submission date. Despite these review goals, it is not uncommon for FDA review of an NDA to extend beyond the goal date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Before approving an NDA, the FDA will typically conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether the manufacturing processes and facilities comply with cGMP. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The FDA also may inspect the sponsor and one or more clinical trial sites to assure compliance with GCP requirements and the integrity of the clinical data submitted to the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product&#8217;s identity, strength, quality and purity. On the basis of the FDA&#8217;s evaluation of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue either an approval letter or a Complete Response Letter (&#8220;CRL&#8221;). An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A CRL indicates that the review cycle of the application is complete and the application will not be approved in its present form and outlines the deficiencies in the submission that must be addressed for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following approval of a new product, the manufacturer and the approved product are subject to pervasive and continuing regulation by the FDA, including, among other things, monitoring and recordkeeping activities, reporting of adverse experiences with the product, product sampling and distribution restrictions, complying with promotion and advertising requirements, which include restrictions on promoting drugs for unapproved uses or patient populations (i.e., &#8220;off-label use&#8221;) and limitations on industry-sponsored scientific and educational activities. Once a drug is granted approval, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market or clinical trials to assess new safety risks; or imposition of distribution or other restrictions. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning letters or other enforcement-related letters or clinical holds on post-approval clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal to permit the import or export of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consent decrees, corporate integrity agreements, debarment, or exclusion from federal health care programs; or mandated modification of promotional materials and labeling and the issuance of corrective information.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Manufacturing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Overall, management believes the manufacturing process established by the prior sponsor of our ibezapolstat development program is efficient with cost of goods sold expected to be less than 5% of a preliminary range of proposed sales price estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Thus far, ibezapolstat drug substance (DS) has been manufactured successfully in both 1 kg and 9 kg batches, with 9 kg batches considered to be a commercial scale. We anticipate that the commercial batch size upon completion of the clinical development program and submission of a New Drug Application (NDA) will be 10 kg to 15 kg which in our estimation will further reduce our cost of goods sold. The 9 kg batch was sufficient to support the Phase 1 and Phase 2 clinical trial needs (Phase 2a and Phase 2b). No material issues were noted in the manufacture of either the 1 kg or 9 kg batches of ibezapolstat to date with 36-month stability very good and well within acceptable FDA standards. Additionally, we can extrapolate to 48-months stability per FDA Manufacturing Guidance in advance of a 48-month pull point to occur in the first half of 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ibezapolstat drug product (DP), 150mg capsules, have been manufactured and used in the Phase 1 and Phase 2a clinical trial and are being used in the Phase 2b clinical trial. Thirty-six&#160;months stability data on capsules show no significant changes in the key quality attributes and no discernable data trends at any of the storage conditions. A minimum of 24-months shelf-life is anticipated. Through our outside manufacturing vendors, we will continue to monitor the stability of DS and DP on an ongoing basis as we continue to advance the clinical development program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Market Opportunity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the 2017 Update (published February&#160;2018) of the <i style="font-style:italic;">Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children by the Infectious Diseases Society of America (IDSA) and Society of Healthcare Epidemiology of America (SHEA),</i> CDI remains a significant medical problem in hospitals, in long-term care facilities and in the community. <i style="font-style:italic;">Clostridioides (formerly Clostridium) difficile</i>, also known as <i style="font-style:italic;">C. difficile</i> or <i style="font-style:italic;">C. diff,</i> is one of the most common causes of health care-associated infections in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest <i style="font-style:italic;">C. difficile</i> approaches 500,000 infections annually in the U.S. and is associated with approximately 20,000 deaths. (Guh, 2020, New England Journal of Medicine). Based on internal estimates including a recurrence rate of between 20% and 40% among approximately 150,000 patients treated, we believe that the annual incidence in the U.S. approaches 600,000 infections and a mortality rate of approximately 9.3%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Antibiotics are the gold standard to treat CDI. However, while currently marketed antibiotics achieve a relatively high initial cure rate, they can fail to eliminate <i style="font-style:italic;">C. difficile</i>, especially drug-resistant strains, in the gut, allowing the continued growth of the bacteria. This, together with a pronounced detrimental effect on the gut microbiome, leads to recurrence in over 25% of CDI patients after therapy is stopped. A significant unmet need remains for antibiotics that can meaningfully reduce recurrence. According to our recent clinical data, we believe ibezapolstat has the potential to continue to provide a bactericidal effect combined with a low incidence of recurrence when used to treat CDI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Antibiotics provide advantages over the use of antibodies, microbiologics, and vaccines. Antibodies are generally only administered in combination with an antibiotic. Due to high costs and the inability to use antibodies as a first-line treatment, antibodies have gained limited commercial traction and there has only been one antibody treatment for CDI approved to date. As of the date of this Form&#160;10-K, there are currently two microbiologics in late-stage development with clinical data forthcoming. Safety is a concern with microbiologics, and this course of treatment is only recommended for patients with multiple recurrences of CDI who have failed appropriate antibiotic treatments. There are also several vaccines against <i style="font-style:italic;">C. difficile</i> in late-stage development, but none are currently approved. A vaccine is only likely to be commercially viable as a prevention of recurrent CDI in high-risk patients, if such patients can be identified. Additionally, large numbers of patients are required for clinical trials of vaccines, which could significantly delay the clinical development process for and eventual release of any CDI vaccine products currently in development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">C. difficile</i> has surpassed MRSA, as the leading cause of death among hospitalized patients. CDI is a serious illness resulting from infection of the inner lining of the colon by <i style="font-style:italic;">C. difficile</i> bacteria that produce toxins causing inflammation of the colon, severe diarrhea and, in the most serious cases, death. Patients typically develop CDI from the use of broad-</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:180.45pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, thus allowing <i style="font-style:italic;">C. difficile</i> bacteria to flourish and produce toxins. <i style="font-style:italic;">C. difficile</i> is a spore forming bacterium, creating spores excreted in the environment of the patients that can survive for&#160;months on dry surfaces in hospital rooms such as beds and doors, and can contaminate other patients by fecal-oral transmission through the hands of healthcare workers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We estimate that, if approved with clinical data consistent with current data generated to date, ibezapolstat could capture over 40% of the CDI market in peak&#160;year sales based on the incidence rates noted above. At a preliminary price estimate of $3,000 to $3,500 per full course of treatment, this projects out to estimated peak&#160;year sales of over $1 billion per year in the U.S. alone. The peak market penetration of 40% assumes that there will be at least two treatment options available to treat CDI in addition to ibezapolstat even though only two antibiotics are currently recommended for the treatment of CDI and oral vancomycin has vulnerabilities with its 20%-40% reinfection rate and poor impact on patients&#8217; microbiome. The selling price estimate of $3,000 to $3,500 is considered by management to be conservative as it is well below the price point of fidaxomicin, the most- recent approval in treating CDI which we believe is between $4,500 and $5,000 for a full course of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management believes that this market opportunity is substantial and provides significant upside potential for those investing at this early stage of development. We believe the size of the market and relatively few treatment options available will drive our market capitalization and availability of financing alternatives as it completes Phase&#160;2 clinical trials successfully.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, we believe ibezapolstat&#8217;s profile provides an opportunity to develop significant market penetration of patients with recurrent infection following use of one of the initial-episode treatment options because of its unique mechanism of action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="acxp-20221231x10k012.jpg" alt="Graphic" style="display:inline-block;height:180.45pt;width:468pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Competition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe that our technologies, knowledge, experience and scientific resources provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biopharmaceutical companies, academic institutions, government agencies and private and public research institutions. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Many of our competitors may have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific advisors and consultants as well as management personnel and establishing clinical trial sites and patient registration for </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Other small or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain marketing approvals for their products more rapidly than we obtain approval for ours. In addition, our ability to compete in the marketplace may be affected because in some cases insurers or other third-party payors seek to encourage the use of generic products. This may have the effect of making branded products less attractive, from a cost perspective, to buyers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The key competitive factors affecting the success of our product candidate and other potential product candidates in the future are likely to be their efficacy, safety, convenience, price and the availability of coverage and reimbursement from government and other third-party payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The competition for ibezapolstat include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Several pharmaceutical companies have established themselves in the market for the treatment of CDI and several other companies are developing investigational antibiotics for the treatment of CDI. We expect these products, if approved, will compete with ibezapolstat;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">Current antibiotic treatments used for patients with CDI include broad spectrum antibiotics like vancomycin and metronidazole, both of which are available in generic form in the U.S. Generic antibiotics typically are sold at lower prices than branded and currently marketed antibiotics and generally are preferred by managed care providers of health services although we believe we price competitively compared to any currently marketed branded or generic antibiotic to treat patients with CDI based on low cost of goods to manufacture ibezapolstat.  Further pricing strategy will follow completion of our clinical development program;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Fidaxomicin (Dificid&#174; in the U.S., Dificlir&#8482; in Europe) is approved for the treatment of CDI in the U.S. and Europe. Fidaxomicin was originally developed by Optimer Pharmaceuticals,&#160;Inc., which was later acquired by Cubist Pharmaceuticals,&#160;Inc. (&#8220;Cubist&#8221;). Cubist was then acquired by Merck&#160;&amp; Co.,&#160;Inc. (&#8220;Merck&#8221;) in 2015;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A number of other approaches for the treatment of CDI are in development or have been approved as follows:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Merck developed a monoclonal antibody, bezlotoxumab, and obtained FDA approval for it in 2016 and EMA approval in 2016. This antibody neutralizes certain toxins that are produced by </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">C.&#160;Difficile</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> bacteria and would be an adjunctive therapy to antibiotics.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Fecal biotherapy aims to recolonize the bacteria that comprise the natural gut flora and, according to the 2017 IDSA Guidelines would be used for patients with multiple recurrences of CDI who have failed to resolve their infection despite treatment attempts with antibiotic agents targeting CDI. Finch Therapeutics recently failed with CP101, its lead therapeutic targeting patients with multiple recurrences of CDI using donor derived stool samples in an oral formulation, to our understanding, and in January 2023 discontinued its Ph3 clinical trial in this area.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Fecal biotherapy approaches in development include SER-109, being developed by Seres Therapeutics,&#160;Inc., which is an investigational oral microbiome therapeutic for the prevention of recurrent </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">C. difficile</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> infection in adults with multiply recurrent CDI. The FDA has granted SER-109 both Breakthrough Therapy and Orphan Drug designations and has recently initiated a Phase&#160;3 clinical trial.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Rebiota&#8482;(fecal microbiota, live-jslm) was recently approved by FDA as a fecal microbiota product which is prepared from stool donated by qualified individuals and delivered via enema for the prevention of recurrent Clostridioides difficile infection (CDI) in adults.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:260pt;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">CRS3123 (Crestone Inc) is a novel small molecule that selectively inhibits methionyl-tRNA synthetase of </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">C. difficile</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and is reported on clinicaltrials.gov as recruiting in a Phase&#160;2 clinical trial with a primary completion date that was targeted for December&#160;2021 but is listed as currently ongoing on the Crestone website.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">MGB-BP-3 (MGB Biopharma) is a novel synthetic polyamide active against Gram- positive pathogens and binds to the minor groove of DNA. MGB announced that it has completed a dose-ranging Phase&#160;2 clinical trial in 2020 but there are no indications publicly that MGB BioPharma has commenced Ph3.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">No new antibiotics in clinical development have shown improvement in either initial clinical cure (&#8220;ICR&#8221;) or sustained clinical response (&#8220;SCR&#8221;) in comparison to currently marketed antibiotics. The data in the chart below constitute comparisons of data from prior clinical trials published in scientific journals for each listed antibiotic or antibiotic candidate and does not incorporate data, if any, from any control arm(s)&#160;that may be or may have been required to seek and obtain FDA approval. The data listed for ibezapolstat are from the Phase 2a clinical trial where no comparator agent was used. The only comparative data for ibezapolstat in clinical trials currently relate only to comparisons of the impact on the microbiome for ibezapolstat and vancomycin but do not compare clinical cure rates. All data presented is based on identical clinical endpoints used for ICR and SCR.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="acxp-20221231x10k013.jpg" alt="Graphic" style="display:inline-block;height:260pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:442.2pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Competitive Strengths</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We attribute our success to the following competitive strengths:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:22.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have a novel mechanism of action which we believe will be highly advantageous given the continuing rate of recurrent CDI with currently available treatment options and the rising prevalence of antimicrobial resistance;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:22.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Since ibezapolstat&#8217;s molecular structure and mechanism of action are unrelated to any other antimicrobial chemical class, its use is not expected to foster the emergence of bacteria that are resistant to other classes of antibiotics;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:22.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Phase&#160;1 Trial showed highly selective activity against </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">C. difficile</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> bacteria with minimal disruption to the gut flora as it is poorly soluble which has been corroborated by the data from the microbiome analysis;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:22.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(iv)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Phase 2a clinical trial data demonstrated a 100% cure rate at end of treatment and 100% sustained clinical response, in each case, in the ten patients who were enrolled and was terminated early based on the recommendation of our SAB based on the efficacy data and safety and tolerability profile;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:22.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(v)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Microbiome data from Phase 2a trial patients demonstrated complete eradication of colonic C. difficile by day three of treatment with ibezapolstat as well as the observed overgrowth of healthy gut microbiota, Actinobacteria and Firmicute phyla species, both during and after treatment. Significantly, emerging data show an increased concentration of secondary bile acids which is known to correlate with a low risk of reinfection. Moreover, a decrease in primary bile acids and the favorable increase in the ratio of secondary-to-primary bile acids provides more scientific evidence suggesting recurrences may be very low in future trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:22.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(vi)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To date, ibezapolstat has shown an excellent human safety profile;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:22.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(vii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our designation by the FDA of Qualified Infectious Disease (QIDP) status and Fast Track designation provides significant benefits to our development of ibezapolstat. We have significant existing patent coverage in the world&#8217;s largest pharmaceutical markets (U.S., Europe, Japan and Canada) extending to September&#160;2030 in the United States and September&#160;2030 in foreign markets. There is also the possibility to extend those patents thereafter;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:22.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(viii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have a simple and low-cost process of manufacturing which is expected to yield cost of goods of less than 5% of the anticipated retail price; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:22.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(ix)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We believe that there is a high probability that the Phase&#160;2b trial will be successful. If the vancomycin cure rate in our Phase 2b trial is 26/32 (81%); then ibezapolstat needs to achieve a cure rate of 24/32 (75%) in the Phase 2b clinical trial to be considered non-inferior (&#8220;NI&#8221;), to vancomycin based on a &#8220;p-value&#8221; of .0344. A &#8220;p value&#8221; is a statistical probability value used by FDA and drug developers to evaluate the efficacy, in this case, of development stage antibiotic candidates and their comparability to one or more approved products. A &#8220;p value&#8221; of .0344 is within FDA standards used by drug development companies to compare an experimental product candidate, like ibezapolstat, against an existing standard-of-care.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual Property and Market Exclusivity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have two U.S. patents (U.S. Patent Numbers 6,926,763 and 8,796,292), with claims that cover ibezapolstat that expire in May&#160;2023 and September&#160;2030, respectively. The most important U.S. patent in management&#8217;s view, is the composition-of-matter patent (8,796,292) which expires in September&#160;2030. Patent Number 6,926,763 includes claims that cover disubstituted purine compounds, compositions, surface coatings, and methods of treating bacterial infection or inhibiting bacterial growth, and these claims cover ibezapolstat. Patent Number 8,796,292 includes other claims that cover other disubstituted purine compounds, compositions, and methods of inhibiting bacterial growth and these claims cover ibezapolstat. Either patent may be subject to extension subject to certain circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For ibezapolstat, we also have one composition-of-matter patent in each of Europe, Japan and Canada. All of these non-U.S. patents expire in September&#160;2030, subject to extension under certain circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, we have filed three provisional patent applications in 2021 covering methods of treating <i style="font-style:italic;">C. difficile</i><span style="white-space:pre-wrap;"> infection and preventing recurrence as well as simultaneous promotion of microbiome health.  We filed a non-</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">provisional patent application and an international patent application in 2022 covering methods of treating C. difficile infection and preventing recurrence while simultaneously promoting microbiome health.  We also filed a new provisional patent application in 2022 covering compositions and methods to promote gut microbiome health.   </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe the commercial opportunity for ibezapolstat is best protected by regulatory exclusivity in the U.S. that has been made available for new chemical entities (five&#160;years) and QIDP designated products (five&#160;years).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA has granted QIDP status for the oral use of ibezapolstat to treat CDI. QIDP status is provided by the FDA under the GAIN Act and provides incentives for us as the sponsor of the ibezapolstat development program, including FDA priority review for the first application submitted for the QIDP, eligibility for &#8220;fast track&#8221; status and extension of statutory exclusivity periods in the U.S. for an additional five&#160;years upon FDA approval of ibezapolstat for the treatment of CDI. In January&#160;2019, the FDA approved &#8220;fast track&#8221; designation for ibezapolstat for the oral treatment of CDI. Accordingly, we will have 10&#160;years of regulatory exclusivity on the oral use of ibezapolstat to treat CDI from the date of FDA marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe the patent and regulatory coverage already in place provides strong protection for the commercialization of ibezapolstat and we will continue to consider additional patent submissions as we review available pre-clinical and clinical data as it becomes available throughout the development program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We have obtained three U.S. patents and one Israeli patent on ACX-375C, our second antibiotic program, and has a fourth U.S. patent application and multiple foreign applications pending for ACX-375C.  Our three U.S. patents and Israeli patent on ACX-375C include composition-of-matter, surface coating, and method of use claims.  Absent any patent extensions, these patents will expire in December 2039.  We anticipate that the patent protection will be further supported by regulatory exclusivity available to new classes of antibiotics treating life-threatening infections (QIDP Designation by FDA &#8211; 5 years) and New Chemical Entity Designation (5 years).  We anticipate filing for and receiving QIDP Designation as well as &#8220;Fast Track&#8221; with FDA in the next 24 months for ACX-375C, both of which designations have been granted by FDA for ibezapolstat, our lead antibiotic program.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">GAIN Exclusivity for Antibiotics</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our regulatory strategy includes targeting QIDP designation by the FDA under the GAIN Act. Congress passed the GAIN Act as part of FDASIA in 2012 to encourage the development of antibacterial and antifungal drug products that treat pathogens that cause serious and life-threatening infections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Potential External Positive Drivers for Sector</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Future external funding opportunities change over time but include the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">PASTEUR Act</span>. &#160;The PASTEUR Act is legislation currently in the U.S. congress which, if approved, would provide &#8220;pull&#8221; incentives in the U.S. for developers of new classes of antibiotics that target a critical need. According to the Pasteur Act, the US Department of Health and Human Services would pay a subscription payment for eligible products of $750&#160;million to $3&#160;billion over a ten-year period and patients would receive the drug at no cost. In addition, HHS would provide transitional support to fund Phase&#160;3 clinical trials and manufacturing requirements for certain innovative antimicrobial drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">AMR Action Fund</span>. &#160;The AMR Action Fund was created by the Antimicrobial Resistance Congress to generate interest to develop new classes of antibiotics to treat priority pathogens on the WHO and CDC priority pathogens list. The AMR Action Fund is funded by over 20 fully integrated worldwide pharmaceutical companies which have pledged over $1&#160;billion to fund clinical activities of up to 15 sponsors of new classes of antibiotics to treat priority pathogens.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">DISARM Act</span>. &#160;The DISARM Act is legislation currently in the U.S. Congress which would remove the financial disincentives now in place for prescribers of antibiotics to use novel agents possibly more efficacious than older, less effective antibiotics that are prescribed at a lower cost. Accordingly, treating physicians would have the opportunity to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:181.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">treat patients with infectious disease with the most effective agents thereby enhancing patient outcomes as well as reducing the cost burden on public health.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">EU Pull Incentives</span>. &#160;Given the adoption of pull incentives for certain critical antibiotics adopted in the U.K. and under consideration in the U.S., the European Union currently is considering adopting certain pull incentives specifically to incentivize sponsors of key antibiotic development programs in the European Union. The European Union also is considering the creation and funding of a new regulatory organization similar to the Biomedical Advanced Research and Development Authority (&#8220;BARDA&#8221;), which is a division of the HHS which, among other things, is responsible to protect the U.S. against pandemic threats.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Pipeline Products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A series of novel antibacterial molecules derived from ACX-375C appear to share the same mechanism of action with ibezapolstat, i.e. they inhibit the Pol IIIC enzyme in certain Gram-positive bacterial cells including both sensitive and resistant <i style="font-style:italic;">Clostridium difficile (C. difficile),</i> MRSA, vancomycin resistant Enterococcus, PRSP and other resistant bacteria. Further characterization and testing of these molecules is ongoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="acxp-20221231x10k014.jpg" alt="Graphic" style="display:inline-block;height:180.75pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:288.75pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This diverse series of new agents which are believed to bind Pol IIIC and thereby prevent it from synthesizing new DNA, as shown below, where the gray area is the Pol IIIC enzyme and the therapeutic molecule occupies the critical binding pocket.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Compounds in this series have demonstrated potent activity against clinically important pathogens including minimum inhibitory concentration values (&#8220;MIC values&#8221;) against MRSA, VRE and PRSP of 1&#8201;&#8211;&#8201;4 &#181;g/mL. Further characterization and testing in animal models are ongoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Acurx has pioneered the clinical development of a pol IIIC inhibitor as a clinically valid bacterial target. Ibezapolstat cured 10 of 10 (100%) patients after 10-days treatment with no recurrences during the 30-day follow up period in a Phase 2a trial for C. difficile infection (CDI). Gut microbiome analyses further showed that potentially beneficial bacterial species are selectively preserved in CDI patients during treatment with ibezapolstat; the pol IIIC Mechanism-of-Action (MOA) suggests that this is a class effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Acurx is also developing a systemic pol IIIC Gram-positive selective spectrum (GPSS&#61652;) oral and IV antibiotic. The initial hit ACX 375C is pan-active against wild-type and drug-resistant Gram-positive bacteria (e.g., MRSA, VRE </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">and PRSP).  Acurx has synthesized and tested &gt;600 novel analogs targeting pol IIIC. To date, 20 novel compounds with MIC values &#8804;1 &#956;g/mL for both MRSA and VRE have been identified (see Table below).</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:49.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">MIC Range</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">MRSA</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:14.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">VRE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:14.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">MRSA&#160;and&#160;VRE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.5%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&lt;</span> 1 &#181;g/mL</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.49%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20 compounds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.51%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">65 compounds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.78%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20 compounds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">&gt;1 to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&lt;</span>2 &#181;g/mL</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">74 compounds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">111 compounds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">74 compounds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">&gt;2 to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&lt; </span>4 &#181;g/mL</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">82 compounds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">92 compounds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">82 compounds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Hit-to-Lead program produced improvements in solubility, cytotoxicity, and protein binding with a comprehensive SAR understanding. Pol IIIC inhibitors have a novel MOA and activity of ACX-375 against MRSA and VRE bacteria was not impacted by vancomycin-, daptomycin-, or linezolid-resistance. Pol IIIC is absent in Gram-negative bacteria and mammalian cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">New analogs show improved characteristics directly related to clinical therapeutic utility: improved solubility for IV formulation, improved safety vs. HepG2, as an initial predictor of pharmacologic safety, and decreased plasma protein binding, to further improve in vivo efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">These analogs have maintained potent MICs against MRSA, MSSA, PRSP, E.  faecalis and VRE.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In vivo pharmacology studies have been encouraging but are not yet determinative. PK studies in mice demonstrate oral and IV exposures sufficient for efficacy testing in infection models. Oral bioavailability of 31-59% was demonstrated by 10 different analogs when administered as a simple liquid formulation. Oral bioavailability will improve further through formulation optimization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The solubility of pol IIIC inhibitors has been improved by prodrug efforts, which support the viability of an IV formulation. Phosphate prodrugs for two compounds showed rapid conversion from inactive prodrug to active parent drug with good exposures following IV and PO dosing in mice. Solubility was improved to the range of 1 mg/mL, which is viable for IV formulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Efficacy has been demonstrated in 4 different mouse models involving different body sites including the critically important lung and thigh. The models were: MRSA peritonitis (3 analogs &gt;60% protection, median survival &gt;7 days); MRSA thigh (neutropenic; 1 analog 1.28 log10 CFU reduction); VRE thigh (neutropenic; 4 analogs 1.21-1.94 log10 CFU reduction); and PRSP lung (neutropenic; 5 analogs 1.03-1.69 log10 CFU reduction). Oral efficacy was demonstrated in 3 models. Lead optimization will seek to further improve efficacy, especially in the thigh model which is a simulation of the initial clinical indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">One analog tested in a battery of safety screens (Eurofins 44 panel, CiPA panel, and CYP inhibition assays) showed no liabilities. As a pilot study, two analogs were tested in 5-day repeat dose studies in mice at 50 mg/kg TID (150 mg/day). One analog showed no HepG2 cytotoxicity (IC50 &gt;128 &#181;g/mL) in vitro, while the 2nd showed effects (IC50 30 &#181;g/mL). There were no adverse effects observed in life, no changes in body weight, and no significant gross necropsy findings for either compound. Serum chemistry showed no effects (treated vs. control; n=5/group) for the 1st compound (IC50 &gt;128 &#181;g/mL) while the 2nd (IC50 30 &#181;g/mL) showed elevated liver enzymes for one analog in several mice dosed IV and PO. These results were encouraging since the HepG2 in vitro assay is used as a marker for potential in vivo toxicity. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Spontaneous resistance frequency is low (&lt;3.17x10-9 and &lt;1.30x10-9 for MRSA and VRE, respectively, at 4xMIC), and there is no cross-resistance with other antibiotics. Acurx is studying potential MOR (Mechanism of Resistance) to pol IIIC inhibitors using whole genome sequencing. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In collaboration with two laboratories at Leiden University Medical Center under a Dutch government grant, the 3-D structure of pol IIIC from MRSA, VRE and PRSP alone and bound to Acurx inhibitors will be studied using cryo-EM/X-ray crystallography. Using this, novel analogs with improved binding will be tested.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Acurx Lead Optimization program is modifying existing leads to develop compounds with improved potency, less plasma protein binding, and increased exposures. The Lead Optimization Program includes developing an improved rapid assay of pol IIIC inhibitor activity (Ki) for MRSA, VRE, and PRSP; determining the 3 D structure of Acurx compounds bound to pol IIIC enzymes for improved SAR; developing/testing novel oral formulations to improve bioavailability; and testing prodrug compounds in animal infection/safety models. Oral and IV candidates from Lead Optimization will then advance to preclinical testing and Phase 1 SAD (Single Ascending Dose) / MAD (Multiple Ascending Dose) trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The initial clinical indication is targeting gram-positive acute bacterial skin and skin structure infections (ABSSSI); subsequent trials may target confirmed Gram-positive infections for hospital-acquired bacterial pneumonia (HABP), bloodstream infections/endocarditis, diabetic foot infections, and/or osteomyelitis. ABSSSI is an ideal clinical indication for a pan active gram-positive drug since the clinical end points, comparators, and execution are well established.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These bacterial targets (MRSA, VRE and PRSP) involve an incidence of approximately six million patients per&#160;year in the U.S. alone. Based on a review of other antibiotics currently marketed to treat these bacterial infections, our early estimate of peak&#160;year sales potential is 4% to 5% of this annual incidence and a peak&#160;year sales potential of approximately $1&#160;billion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employees and Human Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March&#160;15, 2023, we had four full-time employees. Of these employees, one was engaged in research and development activities for a portion of his time. Substantially all of our employees are based in Staten Island, New York. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Corporate Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We were organized as a limited liability company in the State of Delaware in July&#160;2017 and we commenced operations in February&#160;2018 upon acquiring the rights to our lead antibiotic product candidate from GLSynthesis,&#160;Inc. Our principal executive offices are located at 259 Liberty Avenue, Staten Island, NY 10305 and our telephone number is (917) 533-1469. Our website address is www.acurxpharma.com. The information contained on, or that can be accessed through, our website is not, and shall not be deemed to be part of, this Form&#160;10-K. On June&#160;23, 2021, Acurx Pharmaceuticals, LLC converted from a Delaware limited liability company into a Delaware corporation pursuant to a statutory conversion, and changed its name to Acurx Pharmaceuticals,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Available Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We file annual, quarterly, and current reports, proxy statements, and other documents with the Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934 (Exchange Act). The SEC maintains a website at www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers, including us, that file electronically with the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We also make available free of charge on our Internet website at www.acurxpharma.com our annual reports on Form&#160;10-K, quarterly reports on Form&#160;10-Q, current reports on Form&#160;8-K, and, if applicable, amendments to those reports filed or furnished pursuant to Section&#160;13(a)&#160;or 15(d)&#160;of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. These reports are available through the &#8220;Investors&#8212;SEC Filings&#8221; section of our website. Our code of ethics is available through our Internet website at www.acurxpharma.com.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_dba4b143_5616_4bf4_86d9_189c8a87b09e"></a><a id="Item1ARiskFactors_544059"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1A. Risk Factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, the section of this Annual Report Form&#160;10-K entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation&#8221; and our financial statements and related notes, before investing in our common stock. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. If any of the following risks occur, our business, operating results and prospects could be materially harmed. In that event, the price of our common stock could decline, and you could lose part or all of your investment.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our business is subject to a number of risks of which you should be aware before making an investment decision. These risks include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are a clinical-stage company and have a limited operating history, which may make it difficult to evaluate our current business and predict our future performance.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have incurred significant net losses in each period since our inception and anticipate that we will continue to incur net losses in for the foreseeable future and may never achieve or maintain profitability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are reliant on the success of our lead product candidate, ibezapolstat, which we are developing for the treatment of CDI. If we are unable to commercialize ibezapolstat, or experience significant delays in doing so, our business will be materially harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If serious adverse or inappropriate side effects are identified during the development of ibezapolstat or any other product candidate, we may need to abandon or limit our development of that product candidate.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Ibezapolstat or our other product candidates may never achieve sufficient market acceptance even if we obtain regulatory approval.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are exposed to product liability, and non-clinical and clinical liability risks which could place a substantial financial burden upon us, should lawsuits be filed against us.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our current and future operations substantially depend on our management team and our ability to hire other key personnel, the loss of any of whom could disrupt our business operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our failure to complete or meet key milestones relating to the development of our technologies and proposed products and formulations would significantly impair our financial condition.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will compete with larger and better capitalized companies, and competitors in the drug development or pharmaceutical industries may develop competing products which outperform or supplant our proposed products.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The outbreak of the novel coronavirus disease, COVID-19, could adversely impact our business, including our preclinical studies and clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Because results of preclinical studies and early clinical trials are not necessarily predictive of future results, any product candidate we advance may not have favorable results in later clinical trials or receive regulatory approval. Moreover, interim, &#8220;top-line,&#8221; and preliminary data from our clinical trials that we announce or publish may change, or the perceived product profile may be negatively impacted, as more patient data or additional endpoints (including efficacy and safety) are analyzed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If clinical trials of our lead product candidate fail to demonstrate safety and efficacy to the satisfaction of the FDA, or the EMA, or do not otherwise produce favorable results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of ibezapolstat or any other product candidate.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we experience any of a number of possible unforeseen events in connection with our clinical trials, potential marketing approval or commercialization of our product candidates could be delayed or prevented.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our failure to obtain costly government approvals, including required FDA approvals, or to comply with ongoing governmental regulations relating to our proposed products and formulations could delay or limit introduction of our proposed formulations and products and result in failure to achieve revenues or maintain our ongoing business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our results of operations may be adversely affected by current and potential future healthcare legislative and regulatory actions.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be successful in commercializing ibezapolstat or any other product candidate if and when such product candidates are approved.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We contract with third parties for the manufacture of our product candidates for preclinical studies and our ongoing clinical trials, and expect to continue to do so for additional clinical trials and ultimately for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or drugs or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If ultimate users of our product candidates are unable to obtain adequate reimbursement from third- party payers, or if new restrictive legislation is adopted, market acceptance of our proposed products may be limited and we may not achieve material revenues.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may be involved in lawsuits to protect or enforce our patents.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The price of our stock may be volatile, and you could lose all or part of your investment.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our largest stockholders will exercise significant influence over our company for the foreseeable future, including the outcome of matters requiring stockholder approval.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Cyber incidents or attacks directed at us could result in information theft, data corruption, operational disruption and/or financial loss.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">There may be limitations on the effectiveness of our internal controls, and a failure of our control systems to prevent error or fraud may materially harm us.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Relating to Our Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage company and have a limited operating history, which may make it difficult to evaluate our current business and predict our future performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage biopharmaceutical company that was formed in July&#160;2017. We acquired the rights to our lead product candidate, ibezapolstat, in February&#160;2018 and we have a limited operating history. Our operations to date have been limited to securing our initial product candidate, generating a second product candidate in-house, conducting clinical and regulatory development for our lead program and raising capital. We have no products approved for commercial sale and have not generated any revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Investing in an early-stage company with limited history, financial or otherwise, includes a high degree of risk. As an early-stage company, our prospects must be considered in light of the uncertainties, risks, expenses, and difficulties frequently encountered by companies in their early stages of operations. We have generated losses since inception and we expect to continue to run at a loss for several&#160;years until our initial program, or one of our pipeline products, is approved by the FDA or another worldwide regulatory body. We expect to incur substantial operating expenses over the next several&#160;years as our product development activities and related costs increase. No assurance can be given that we will be able to successfully implement any or all of our business plan, or if implemented, that we will accomplish the desired objectives, including achieving profitability. Our short history as an operating company makes any assessment of our future success or viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by early-stage companies in rapidly evolving fields. If we do not address these risks successfully, our business will suffer.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have incurred significant net losses in each period since our inception and anticipate that we will continue to incur net losses in for the foreseeable future and may never achieve or maintain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are not profitable and have incurred significant losses in each period since our inception, including net losses of $12.1&#160;million for the&#160;year ended December&#160;31, 2022, and $12.7&#160;million for the&#160;year ended December&#160;31, 2021. We have not commercialized any products and have never generated any revenue from product sales. We expect these losses to increase as we continue to incur significant research and development and other expenses related to our ongoing operations, seek regulatory approvals for our product candidates,&#160;scale-up&#160;manufacturing capabilities and hire additional personnel to support the development of our product candidates and to enhance our operational, financial and information management systems.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A critical aspect of our strategy is to invest significantly in our clinical and regulatory development for our lead program. To become and remain profitable, we must develop and eventually commercialize products with significant market potential, which we may never achieve. Even if we succeed in commercializing one or more of these product candidates, we will continue to incur losses for the foreseeable future relating to our substantial research and development expenditures to develop our product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital. Further, the net losses we incur may fluctuate significantly from quarter-to-quarter and&#160;year-to-year, such that a period to period comparison of our results of operations may not be a good indication of our future performance. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of the company and could impair our ability to raise capital, maintain our discovery and preclinical development efforts, expand our business or continue our operations and may require us to raise additional capital that may dilute your ownership interest. A decline in the value of our company could also cause you to lose all or part of your investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our independent registered public accounting firm noted in its report accompanying our financial statements for the fiscal year ended December 31, 2022 that we had suffered significant accumulated deficit and had negative operating cash flows and that the development and commercialization of our product candidates are expected to require substantial expenditures. We have not yet generated any material revenues from our operations to fund our activities, and are therefore dependent upon external sources for financing our operations. There can be no assurance that we will succeed in obtaining the necessary financing to continue our operations. As a result, our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. If we cannot successfully continue as a going concern, our stockholders may lose their entire investment in our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect our expenses to increase in connection with our ongoing activities, particularly as we continue research and development and initiate additional clinical trials of our product candidates and seek regulatory approval for these and potentially other product candidates. In addition, if we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. In particular, the costs that may be required for the manufacture of any product candidate that receives marketing approval may be substantial. Accordingly, we may need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022 we had approximately $9.1 million in cash. In June&#160;2021, we completed the IPO for net cash proceeds of $14.8&#160;million after deducting underwriting discounts and commissions and offering expenses. In July 2022, we completed a registered direct offering and concurrent private placement for net cash proceeds of $3.7 million after deducting placement agent fees and offering expenses. We believe that, based upon our current operating plan, our existing capital resources, will not be sufficient to fund our anticipated operations for at least 12&#160;months from the issuance of our financial statements for the&#160;year ended December&#160;31, 2022. Our future capital requirements and the period for which we expect our existing resources to support our operations may vary significantly from what we expect. Our&#160;monthly spending levels vary based on new and ongoing research and development and other corporate activities. Because the length of time and activities associated with successful research and development of our product candidates is highly uncertain, we are unable to estimate the actual funds we will require for development and any approved marketing and commercialization activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our future capital requirements will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, progress, and results of our ongoing and planned clinical trials of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to manufacture sufficient clinical supply of our products candidates and the costs thereof;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">discussions with regulatory agencies regarding the design and conduct of our clinical trials and the costs, timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of any other product candidates or technologies we pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and maintain strategic partnerships, licensing or other arrangements and the financial terms of such agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the revenue, if any, received from commercial sales of any product candidates for which we receive marketing approval; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We cannot be certain that additional funding will be available on acceptable terms, or at all. Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. Our ability to raise additional funding will depend on financial, economic and market conditions and other factors, over which we may have no or limited control, including the conflict between Russia and Ukraine. In addition, our ability to obtain future funding when needed through equity financings, debt financings or strategic collaborations may be particularly challenging in light of the uncertainties and circumstances regarding the&#160;COVID-19&#160;pandemic. We have no committed source of additional capital and if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives. We could be required to seek collaborators for our product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available or relinquish or license on unfavorable terms our rights to our product candidates in markets where we otherwise would seek to pursue development or commercialization ourselves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Until such time as we can generate substantial revenue from product sales, if ever, we expect to finance our cash needs through a combination of public and private equity offerings, debt financings, strategic partnerships, and alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to us. If we are unable to raise additional capital through equity or debt financings when needed (including if we are unable to do so as a result of the&#160;COVID-19&#160;pandemic), we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise develop and market ourselves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are reliant on the success of our lead product candidate, ibezapolstat, which we are developing for the treatment of CDI. If we are unable to commercialize ibezapolstat, or experience significant delays in doing so, our business will be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our ability to generate product revenues, which may not occur for several&#160;years, if ever, currently depends heavily on the successful development and commercialization of ibezapolstat. The success of ibezapolstat will depend on a number of factors, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful completion of clinical development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receipt of marketing approvals from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing commercial manufacturing arrangements with third-party manufacturers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">protecting our rights in our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing sales, marketing and distribution capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">launching commercial sales of ibezapolstat, if and when approved, whether alone or in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of ibezapolstat, if and when approved, by patients, the medical community and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectively competing with other CDI therapies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining a continued acceptable safety profile of ibezapolstat following approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize ibezapolstat, which would materially harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If serious adverse or inappropriate side effects are identified during the development of ibezapolstat or any other product candidate, we may need to abandon or limit our development of that product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our product candidates are in clinical development and its risk of failure is high. It is impossible to predict when our product candidates will prove effective or safe in humans or will receive marketing approval. If our product candidates are associated with undesirable side effects or have characteristics that are unexpected, we may need to abandon their development or limit development to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Many compounds that initially show promise in clinical or earlier stage testing have later been found to cause side effects or other safety issues that prevented further development. If we elect or are forced to suspend or terminate any clinical trial of our product candidates, the commercial prospects of such product candidate will be harmed and our ability to generate product revenues from such product candidate will be delayed or eliminated. Any of these occurrences could materially harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Ibezapolstat or our other product candidates may never achieve sufficient market acceptance even if we obtain regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If ibezapolstat or any of our other future product candidates receive marketing approval, such products may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenues or revenue from collaboration agreements or any profits from operations. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efficacy and potential advantages compared to alternative treatments or competitive products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to offer our product candidates for sale at competitive prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">convenience and ease of administration compared to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining regulatory clearance of marketing claims for the uses that we are developing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to timely and effectively manufacture, market and distribute our products, either on our own or through third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pricing and reimbursement policies of government and third-party payers such as insurance companies, health maintenance organizations and other health plan administrators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of any such marketing approval in relation to other product approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">support from patient advocacy groups;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to attract corporate partners, including pharmaceutical companies, to assist in commercializing our proposed formulations or products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any restrictions on concomitant use of other medications.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If our products do not achieve an adequate level of acceptance by the relevant constituencies, or adequate pricing, we may not generate significant product revenue and may not become profitable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are exposed to product liability, and non-clinical and clinical liability risks which could place a substantial financial burden upon us, should lawsuits be filed against us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our business exposes us to potential product liability and other liability risks that are inherent in the testing, manufacturing and marketing of pharmaceutical formulations and products. We expect that such claims are likely to be asserted against us at some point, although we do carry product liability and clinical trial insurance to mitigate this risk. In addition, the use in our clinical trials of pharmaceutical formulations and products and the subsequent sale of these formulations or products by us or our potential collaborators may cause us to bear a portion of or all product liability risks. A successful liability claim or series of claims brought against us could have a material adverse effect on our business, financial condition and results of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our current and future operations substantially depend on our management team and our ability to hire other key personnel, the loss of any of whom could disrupt our business operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our business does and will depend in substantial part on the continued services of David P. Luci, Robert J. DeLuccia and Robert G. Shawah. The loss of the services of any of these individuals would significantly impede implementation and execution of our business strategy and result in the failure to reach our goals. We do not carry key person life insurance on any member of our management, which would leave us uncompensated for the loss of any member of our management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our future financial condition and ability to achieve profitability will also depend on our ability to attract, retain and motivate highly qualified personnel in the diverse areas required for continuing our operations. There is a risk that we will be unable to attract, retain and motivate qualified personnel, both near term or in the future, and our failure to do so may severely damage our prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our failure to complete or meet key milestones relating to the development of our technologies and proposed products and formulations would significantly impair our financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to be commercially viable, we must research, develop and obtain regulatory approval to manufacture, introduce, market and distribute formulations or products incorporating our technologies. For each drug that we formulate, we must meet a number of critical developmental milestones, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">demonstration of the benefit of each specific drug through our drug delivery technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">demonstration, through non-clinical and clinical trials, that our drug delivery technologies are safe and effective; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment of a viable current good manufacturing process (&#8220;cGMP&#8221;) capable of potential scale-up.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The estimated required capital and time-frames necessary to achieve these developmental milestones is subject to inherent risks, many of which are beyond our control. As such, we may not be able to achieve these or similar milestones for any of our proposed product candidates or other product candidates in the future. Our failure to meet these or other critical milestones would adversely affect our financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Conducting and completing the clinical trials necessary for FDA approval is costly and subject to intense regulatory scrutiny as well as the risk of failing to meet the primary endpoint of such trials. We will not be able to commercialize and sell our proposed products and formulations without completing such trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to conduct clinical trials that are necessary to obtain approval by the FDA to market a formulation or product, it is necessary to receive clearance from the FDA to conduct such clinical trials. The FDA can halt clinical trials at any time for safety reasons or because we or our clinical investigators did not follow the FDA&#8217;s requirements for conducting clinical trials. If we are unable to receive clearance to conduct clinical trials or the trials are permanently halted by the FDA, we would not be able to achieve any revenue from such product as it is illegal to sell any drug or medical device for human consumption or use without FDA approval. Moreover, there is a risk that our clinical trials will fail to meet their primary endpoints, which would make them unacceptable in having the subject product approved by the FDA. If this were to occur, such event would materially and adversely affect our business, results of operations and financial condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We will compete with larger and better capitalized companies, and competitors in the drug development or pharmaceutical industries may develop competing products which outperform or supplant our proposed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Drug companies and/or other technology companies have developed (and are currently marketing in competition with us), have sought to develop and may in the future seek to develop and market similar product candidates and drug delivery technologies which may become more accepted by the marketplace or which may supplant our technology entirely. In addition, many of our current competitors are, and future competitors may be, significantly larger and better financed than we are, thus giving them a significant advantage over us. Our competitors may also have significantly greater expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific advisors and consultants as well as management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Other small or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. We may be unable to respond to competitive forces presently in the marketplace which would severely impact our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not be able to effectively manage our growth and expansion or implement our business strategies, in which case our business and results of operations may be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The expected growth of our business, if it occurs, will place increased demands on our management, operational and administrative resources. These increased demands and operating complexities could cause us to operate our business less effectively which, in turn, could cause a deterioration in our financial performance and negatively impact our growth. Any planned growth will also require that we continually monitor and upgrade our management information and other systems, as well as our infrastructure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There can be no assurance that we will be able to grow our business and achieve our goals. Even if we succeed in establishing new strategic partnerships, we cannot assure that we will achieve planned revenue or profitability levels in the time periods estimated by us, or at all. If any of these initiatives fails to achieve or is unable to sustain acceptable revenue and profitability levels, we may incur significant costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The outbreak of the novel coronavirus disease, COVID-19, could adversely impact our business, including our preclinical studies and clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2020, the World Health Organization characterized COVID-19&#160;as a pandemic, and the President of the United States declared the COVID-19&#160;<span style="white-space:pre-wrap;">outbreak a national emergency. Authorities throughout the world have implemented measures to contain or mitigate the spread of the virus, including at various times physical distancing, travel bans and restrictions, closure of non-essential businesses, quarantines, work-from-home directives, mask requirements, shelter-in-place orders and vaccination programs. Despite these efforts, COVID-19 has persisted, has mutated into new variants, and is expected to become endemic. Additionally, new waves of COVID-19 or its variants could cause the reinstatement of such restrictions and limitations. The impact of COVID-19 and its variants, including direct and indirect economic effects as a result of inflation, supply chain disruptions and labor shortages, have been and remain unpredictable.  We are unable to fully evaluate the ever-changing impact of the coronavirus outbreak on our business, but coronavirus may continue to affect our ability to complete enrollment for our clinical trials and may slow our ability to conduct our clinical trials in a timely manner or to conduct research and development of our complement programs in our planned time frame. The extent to which the coronavirus impacts our operations will continue to evolve and depends on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration and severity of the outbreak, and the actions that may be required to contain the coronavirus or treat its impact. In particular, as a result of the COVID-19 pandemic, we may continue to experience supply-chain disruptions and enrollment challenges that could negatively impact our business, preclinical studies, drug manufacturing and clinical trials including:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or difficulties in enrolling potential trial participants in our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diversion of healthcare resources away from the conduct of clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures, which may impact the integrity of subject data and clinical study endpoints;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption or delays in the operations of the Food and Drug Administration, European Medicines Agency or other regulatory authorities, which may impact review and approval timelines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages&#160;and disruptions in delivery systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruptions in preclinical studies due to restricted or limited operations at laboratory facilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension or termination of our clinical trials for various reasons, such as a finding that the participants are being exposed to infectious diseases like COVID-19 or the participants involved in our clinical trials have become infected with COVID-19;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations on employee resources that would otherwise be focused on the conduct of our preclinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">material delays and complications with respect to our research and development programs.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, a recession or market correction resulting from the spread of COVID-19 could materially affect our operations and the value of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Disruption in our global supply chain could negatively impact our businesses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The materials we need for our research and development activities and the drug supply we use for our clinical trials, in each case, are sourced from a wide variety of domestic and international vendors, and any future disruption in our supply chain or inability to find qualified vendors and access products and/or supplies that meet requisite quality and safety standards in a timely and efficient manner could adversely impact our businesses. The loss or disruption of such supply arrangements for any reason, including for issues such as COVID-19 or other health epidemics or pandemics, labor disputes, loss or impairment of key manufacturing sites, inability to procure sufficient raw materials, quality control issues, ethical sourcing issues, a supplier&#8217;s financial distress, natural disasters, looting, vandalism or acts of war or terrorism, trade sanctions or other external factors over which we have no control, could interrupt product supply and, if not effectively managed and remedied, have a material adverse impact on our business operations, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for new or current products could limit our ability to market those products and decrease our ability to generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford expensive treatments. Sales of our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. Moreover, increasing efforts by governmental and third-party payors, in the U.S. and abroad, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">healthcare costs in general has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Because results of preclinical studies and early clinical trials are not necessarily predictive of future results, any product candidate we advance may not have favorable results in later clinical trials or receive regulatory approval. Moreover, interim, &#8220;top-line,&#8221; and preliminary data from our clinical trials that we announce or publish may change, or the perceived product profile may be negatively impacted, as more patient data or additional endpoints (including efficacy and safety) are analyzed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pharmaceutical development has inherent risks. The outcome of preclinical development testing and early clinical trials may not be predictive of the outcome of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates. Once a product candidate has displayed sufficient preclinical data to warrant clinical investigation, we will be required to demonstrate through adequate and well-controlled clinical trials that our product candidates are effective with a favorable benefit-risk profile for use in populations for their target indications before we can seek regulatory approvals for their commercial sale. Many drug candidates fail in the early stages of clinical development for safety and tolerability issues or for insufficient clinical activity, despite promising pre-clinical results. Accordingly, no assurance can be made that a safe and efficacious dose can be found for these compounds or that they will ever enter into advanced clinical trials alone or in combination with other product candidates. Moreover, success in early clinical trials does not mean that later clinical trials will be successful because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety or efficacy despite having progressed through initial clinical testing. Companies frequently experience significant setbacks in advanced clinical trials, even after earlier clinical trials have shown promising results. There is an extremely high rate of failure of pharmaceutical candidates proceeding through clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Individually reported outcomes of patients treated in clinical trials may not be representative of the entire population of treated patients in such studies. In addition, larger scale Phase&#160;3 studies, which are often conducted internationally, are inherently subject to increased operational risks compared to earlier stage studies, including the risk that the results could vary on a region to region or country to country basis, which could materially adversely affect the outcome of the study or the opinion of the validity of the study results by applicable regulatory agencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may publicly disclose top-line or preliminary data from our clinical trials, which is based on a preliminary analysis of then available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of such data, and we may not have received or had the opportunity to fully and carefully evaluate all data from the particular study or trial, including all endpoints and safety data. As a result, top-line or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the topline, interim, or preliminary data we previously published. When providing top-line results, we may disclose the primary endpoint of a study before all secondary endpoints have been fully analyzed. A positive primary endpoint does not translate to all, or any, secondary endpoints being met. As a result, top-line and preliminary data should be viewed with caution until the final data are available, including data from the full safety analysis and the final analysis of all endpoints.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Further, from time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. For example, time-to-event based endpoints such as duration of response and progression free survival have the potential to change, sometimes drastically, with longer follow-up. In addition, as patients continue on therapy, there can be no assurance given that the final safety data from studies, once fully analyzed, will be consistent with prior safety data presented, will be differentiated from other similar agents in the same class, will support continued development, or will be favorable enough to support regulatory approvals for the indications studied. Further, others, including regulatory agencies, may </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. The information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and regulators or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the interim, top-line or preliminary data that we report differ from final results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, or successfully commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We previously identified a material weakness in our internal control over financial reporting, and if we are unable to achieve and maintain effective internal control over financial reporting, the accuracy and timing of our financial reporting may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to our IPO in June&#160;2021, we were a private company with limited accounting and finance personnel, adequate review processes and other resources with which to address our internal controls and procedures. Based on the evaluation of our internal controls, we concluded that our disclosure controls and procedures were not effective as of December&#160;31, 2021 as a result of a material weakness in our internal control over financial reporting due to inadequate segregation of duties resulting from the size of our Company and our limited personnel. A &#8220;material weakness&#8221; is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">To remediate the material weakness due to the inadequate segregation of duties, our management (i) engaged a third-party specialist to review our current internal controls and to recommend design improvements given the limited number of employees and (ii) hired a controller to remediate the segregation of duties issue, who commenced employment in April 2022 and (iii) implemented a quarterly financial statement close process that includes formal reviews of financial statement account balances and journal entries.  Accordingly, management believes it has remediated the material weakness related to inadequate segregation of duties.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We can give no assurance that additional material weaknesses in our internal control over financial reporting will not be identified in the future. Our failure to implement and maintain effective internal control over financial reporting could result in errors in our financial statements that could result in a restatement of our financial statements and cause us to fail to meet our reporting obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Regulatory Approval</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If clinical trials of our lead product candidate fail to demonstrate safety and efficacy to the satisfaction of the FDA, or the EMA, or do not otherwise produce favorable results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of ibezapolstat or any other product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many&#160;years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials, particularly with a small number of patients, may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. The design of a clinical trial can determine whether its results will support approval of a product, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced or completed. We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that believe their product candidates performed satisfactorily in preclinical studies and clinical trials have failed to obtain marketing approval of their products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we experience any of a number of possible unforeseen events in connection with our clinical trials, potential marketing approval or commercialization of our product candidates could be delayed or prevented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to enroll a sufficient number of patients in our clinical trials to ensure adequate statistical power to detect any statistically significant treatment effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulators, institutional review boards or independent ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the participants are being exposed to unacceptable health risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulators, institutional review boards or independent ethics committees may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trials are costly and the cost of clinical trials of our product candidates may be greater than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators, institutional review boards or independent ethics committees to suspend or terminate the clinical trials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our product development costs will increase if we experience delays in testing or marketing approvals. We do not know whether any preclinical tests or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant preclinical or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we experience delays or difficulties in the enrollment of patients in our clinical trials, our receipt of necessary marketing approvals could be delayed or prevented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We may not be able to initiate or continue clinical trials for our product candidates, including our planned clinical trials of ibezapolstat, if we are unable to locate and enroll a sufficient number of eligible patients to participate in these clinical trials. CDI is an acute infection that requires rapid diagnosis. For our clinical trials of ibezapolstat, we need to identify potential patients, test them for CDI and enroll them in the clinical trial within a 24-hour period. In addition, our competitors have ongoing clinical trials for product candidates that could be competitive with our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">competitors&#8217; product candidates. For our clinical trials of ibezapolstat, we need to identify potential patients and enroll them in the clinical trial based on a history of diarrhea within 24 hours of a positive stool test for&#160;<i style="font-style:italic;">C. difficile</i>&#160;toxin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of our common stock to decline and limit our ability to obtain additional financing. Our inability to enroll a sufficient number of patients in our planned clinical trials of ibezapolstat would result in significant delays or may require us to abandon one or more clinical trials altogether.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our failure to obtain costly government approvals, including required FDA approvals, or to comply with ongoing governmental regulations relating to our proposed products and formulations could delay or limit introduction of our proposed formulations and products and result in failure to achieve revenues or maintain our ongoing business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our research and development activities and the manufacture and marketing of our product candidates are subject to extensive regulation for safety, efficacy and quality by numerous government authorities in the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">U.S. and abroad. Before receiving FDA or foreign regulatory clearance to market our proposed formulations and products, we will have to demonstrate that our products are safe and effective in the patient population and for the diseases that are to be treated. Clinical trials, manufacturing and marketing of drugs are subject to the rigorous testing and approval process of the FDA and equivalent foreign regulatory authorities. The Federal Food, Drug and Cosmetic Act and other federal, state and foreign statutes and regulations govern and influence the testing, manufacture, labeling, advertising, distribution and promotion of drugs and medical devices. As a result, regulatory approvals can take&#160;years to obtain and require the expenditure of substantial financial, managerial and other resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, we may not receive regulatory approval of any of our proposed products. We may be unable to obtain all required regulatory approvals, and our failure to do so would materially and adversely affect our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our results of operations may be adversely affected by current and potential future healthcare legislative and regulatory actions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Legislative and regulatory actions affecting government prescription drug procurement and reimbursement programs occur relatively frequently. In the U.S., the Patient Protection and Affordable Care Act (the &#8220;ACA&#8221;) was enacted in 2010 to expand healthcare coverage. Since then, numerous efforts have been made to repeal, amend or administratively limit the ACA in whole or in part. For example, the Tax Cuts and Jobs Act (&#8220;TCJA&#8221;), signed into law by President Trump in 2017, repealed the individual health insurance mandate, which is considered a key component of the ACA. In December&#160;2018, a U.S. District Court Judge in the Northern District of Texas ruled that the individual mandate was a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the TCJA, the remaining provisions of the ACA were invalid and the law in its entirety was unconstitutional. In December&#160;2019, the U.S. Court of Appeals for the Fifth Circuit upheld the District Court ruling that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether other reforms enacted as part of the ACA but not specifically related to the individual mandate or health insurance could be severed from the rest of the ACA so as not to be declared invalid as well. On March&#160;2, 2020, the United States Supreme Court granted the petitions for writs of certiorari to review this case and allocated one hour for oral arguments, which occurred on November&#160;10, 2020. It is unclear how this litigation and other efforts to repeal and replace the ACA will impact the implementation of the ACA, the pharmaceutical industry more generally, and our business. Complying with any new legislation or reversing changes implemented under the ACA could be time-intensive and expensive, resulting in a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Efforts to control prescription drug prices could also have a material adverse effect on our business. For example, in 2018, President Trump and the Secretary of the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) released the &#8220;American Patients First Blueprint&#8221; and have begun implementing certain portions. The initiative includes proposals to increase generic drug and biosimilar competition, enable the Medicare program to negotiate drug prices more directly and improve transparency regarding drug prices and ways to lower consumers&#8217; out-of-pocket costs. The Trump administration also proposed to establish an &#8220;international pricing index&#8221; that would be used as a benchmark to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">determine the costs and potentially limit the reimbursement of drugs under Medicare Part&#160;B. Among other pharmaceutical manufacturer industry-related proposals, Congress has proposed bills to change the Medicare Part&#160;D benefit to impose an inflation-based rebate in Medicare Part&#160;D and to alter the benefit structure to increase manufacturer contributions in the catastrophic phase. The volume of drug pricing-related bills has dramatically increased under the current Congress, and the resulting impact on our business is uncertain and could be material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, many states have proposed or enacted legislation that seeks to indirectly or directly regulate pharmaceutical drug pricing, such as by requiring biopharmaceutical manufacturers to publicly report proprietary pricing information or to place a maximum price ceiling on pharmaceutical products purchased by state agencies. For example, in 2017, California&#8217;s governor signed a prescription drug price transparency state bill into law, requiring prescription drug manufacturers to provide advance notice and explanation for price increases of certain drugs that exceed a specified threshold. Both Congress and state legislatures are considering various bills that would reform drug purchasing and price negotiations, allow greater use of utilization management tools to limit Medicare Part&#160;D coverage, facilitate the import of lower-priced drugs from outside the U.S. and encourage the use of generic drugs. Such initiatives and legislation may cause added pricing pressures on our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Changes to the Medicaid program at the federal or state level could also have a material adverse effect on our business. Proposals that could impact coverage and reimbursement of our products, including giving states more flexibility to manage drugs covered under the Medicaid program and permitting the re-importation of prescription medications from Canada or other countries, could have a material adverse effect by limiting our products&#8217; use and coverage. Furthermore, state Medicaid programs could request additional supplemental rebates on our products as a result of an increase in the federal base Medicaid rebate. To the extent that private insurers or managed care programs follow Medicaid coverage and payment developments, they could use the enactment of these increased rebates to exert pricing pressure on our products, and the adverse effects may be magnified by their adoption of lower payment schedules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other proposed regulatory actions affecting manufacturers could have a material adverse effect on our business. It is difficult to predict the impact, if any, of any such proposed legislative and regulatory actions or resulting state actions on the use and reimbursement of our products in the U.S., but our results of operations may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Dependence on Third Parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be successful in commercializing ibezapolstat or any other product candidate if and when such product candidates are approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We do not have a sales or marketing infrastructure and have no experience in the sale or marketing of pharmaceutical products. To achieve commercial success for any approved product, we must either develop a sales and marketing organization or outsource these functions to third parties. If ibezapolstat receives marketing approval, we intend to commercialize it in the U.S. with our own focused, specialized sales force. We plan to evaluate the potential for utilizing additional collaboration, distribution and marketing arrangements with third parties to commercialize ibezapolstat in other jurisdictions where we retain commercialization rights. There are risks involved with establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Factors that may inhibit our efforts to commercialize our products on our own include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability of sales personnel to obtain access to or persuade adequate numbers of physicians to prescribe any future products;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to competitors with more extensive product lines; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we enter into arrangements with third parties to perform sales and marketing services, our product revenues or the profitability of these product revenues will likely be lower than if we were to market and sell any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so on terms that are acceptable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We contract with third parties for the manufacture of our product candidates for preclinical studies and our ongoing clinical trials, and expect to continue to do so for additional clinical trials and ultimately for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or drugs or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We do not currently have the infrastructure or internal capability to manufacture supplies of our product candidates for use in development and commercialization. We rely, and expect to continue to rely, on third-party manufacturers for the production of our product candidates for preclinical studies and clinical trials under the guidance of members of our organization. We do not have long-term supply agreements. Furthermore, the raw materials for our product candidates are sourced, in some cases, from a single-source supplier although other sources are available. For example, drug substance and drug product are sourced from our principal supplier, Piramal Pharma Solutions, in Ennore, India and Ahmedabad, India, respectively. Chemical raw materials used for drug substance manufacture are sourced locally in India and are generally available. Accordingly, we do not anticipate difficulties sourcing drug substance for our clinical trials or, if FDA approved, for our marketing period, but we have not yet sourced a backup supplier because we currently have sufficient supply to complete our Phase 2b clinical trial. We are considering U.S. sources of drug substance for the commercial period if ibezapolstat is FDA approved and we anticipate several manufacturing options will be available. If we were to experience an unexpected loss of supply of any of our product candidates or any of our future product candidates for any reason, whether as a result of manufacturing, supply or storage issues or otherwise, we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials. For example, the extent to which the COVID-19 pandemic impacts our ability to procure sufficient supplies for the development of our products and product candidates will depend on the severity and duration of the spread of the virus, and the actions undertaken to contain COVID-19 or treat its effects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect to continue to rely on third-party manufacturers for the commercial supply of any of our product candidates for which we obtain marketing approval. We may be unable to maintain or establish required agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the failure of the third party to manufacture our product candidates according to our schedule, or at all, including if our third-party contractors give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the reduction or termination of production or deliveries by suppliers, or the raising of prices or renegotiation of terms;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the termination or nonrenewal of arrangements or agreements by our third-party contractors at a time that is costly or inconvenient for us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the breach by the third-party contractors of our agreements with them;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the failure of third-party contractors to comply with applicable regulatory requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the failure of the third party to manufacture our product candidates according to our specifications;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug or placebo not being properly identified;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the misappropriation of our proprietary information, including our trade secrets and know-how.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We do not have complete control over all aspects of the manufacturing process of, and are dependent on, our contract manufacturing partners for compliance with cGMP regulations for manufacturing both active drug substances and finished drug products. Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the U.S. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, EMA or others, they will not be able to secure and/or maintain marketing approval for their manufacturing facilities. In addition, we do not have control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA, EMA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain marketing approval for or market our product candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could subject us and our third-party manufacturers to warning letters or other enforcement-related letters, holds on clinical trials or could result in further sanctions being imposed on us or our third-party manufacturers, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or drugs and harm our business and results of operations. Our current and anticipated future dependence upon others for the manufacture of our product candidates or drugs may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We rely on third party clinical investigators, contract research organizations (&#8220;CROs&#8221;), clinical data management organizations and consultants to design, conduct, supervise and monitor preclinical studies and clinical trials of our product candidates. Because we rely on third parties and do not have the ability to conduct preclinical studies or clinical trials independently, we have less control over the timing, quality and other aspects of preclinical studies and clinical trials than we would if we conducted them on our own. These investigators, CROs and consultants are not our employees and we have limited control over the amount of time and resources that they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our programs. Further, these third parties may not be diligent, careful or timely in conducting our preclinical studies or clinical trials, resulting in the preclinical studies or clinical trials being delayed or unsuccessful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines, our preclinical and clinical development programs could be delayed and otherwise adversely affected. In all events, we are responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. The FDA and other health authorities require preclinical studies to be conducted in accordance with GLP and clinical trials to be conducted in accordance with GCP, including conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. If we or our CROs fail to comply with these requirements, the data generated in our clinical trials may be deemed unreliable or uninterpretable and the FDA may require us to perform additional preclinical studies or clinical trials. Our reliance on third parties that we do not control does not relieve us of these responsibilities and requirements. Any such event could adversely affect our business, financial condition, results of operations and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If ultimate users of our product candidates are unable to obtain adequate reimbursement from third- party payers, or if new restrictive legislation is adopted, market acceptance of our proposed products may be limited and we may not achieve material revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The continuing efforts of government and insurance companies, health maintenance organizations and other payers of healthcare costs to contain or reduce costs of healthcare may affect our future revenues and profitability, and the future revenues and profitability of our potential customers, suppliers and collaborative partners and the availability of capital. For example, in the U.S., given recent federal and state government initiatives directed at lowering the total cost of healthcare, the U.S. Congress and state legislatures will likely continue to focus on healthcare reform, the cost of prescription pharmaceuticals and on the reform of the Medicare and Medicaid systems. While we cannot predict whether any such legislative or regulatory proposals will be adopted, the announcement or adoption of such proposals and related laws, rules&#160;and regulations could materially harm our business, financial condition, results of operations or stock price. Moreover, the passage of the ACA in 2010, and efforts to amend or repeal such law, has created significant uncertainty relating to the scope of government regulation of healthcare and related legal and regulatory requirements, which could have an adverse impact on sales of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, our ability to commercialize our product candidates will depend in part on the extent to which appropriate reimbursement levels for the cost of such products and related treatments are obtained by governmental authorities, private health insurers and other organizations, such as HMOs. Consumers and third-party payers are increasingly challenging the prices charged for medical drugs and services. Also, the trend toward managed healthcare in the U.S. and the concurrent growth of organizations such as HMOs, which could control or significantly influence the purchase of healthcare services and drugs, as well as legislative proposals to reform healthcare or reduce government insurance programs, may all result in lower prices for or rejection of our proposed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our relationships with future customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we would market, sell and distribute our products. As a pharmaceutical company, even though we do not and may not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#8217; rights are and will be applicable to our business. These regulations include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Federal Healthcare Anti-Kickback Statute that prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid, and which will constrain our marketing practices and the marketing practices of our licensees, educational programs, pricing policies, and relationships with healthcare providers or other entities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal physician self-referral prohibition, commonly known as the Stark Law, which prohibits physicians from referring Medicare or Medicaid patients to providers of &#8220;designated health services&#8221; with whom the physician or a member of the physician&#8217;s immediate family has an ownership interest or compensation arrangement, unless a statutory or regulatory exception applies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal false claims laws that prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other government reimbursement programs that are false or fraudulent, and which may expose entities that provide coding and billing advice to customers to potential criminal and civil penalties, including through civil whistleblower or qui tam actions, and including as a result of claims presented in violation of the Federal Healthcare Anti-Kickback Statute, the Stark Law or other healthcare-related laws, including laws enforced by the FDA;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Health Insurance Portability and Accountability Act of 1996, (&#8220;HIPAA&#8221;), which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program and also created federal criminal laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services that, as amended by the Health Information Technology for Economic and Clinical Health Act, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal physician sunshine requirements under the ACA, which requires manufacturers of approved drugs, devices, biologics and medical supplies to report annually to the HHS, information related to payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Federal Food, Drug, and Cosmetic Act, which, among other things, strictly regulates drug product marketing, prohibits manufacturers from marketing drug products for off-label use and regulates the distribution of drug samples; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, state laws requiring pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and which may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, and state and foreign laws governing the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and often are not preempted by federal laws such as HIPAA, thus complicating compliance efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any physicians or other healthcare providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be involved in lawsuits to protect or enforce our patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Competitors may infringe our patents. To counter infringement or unauthorized use, we or our collaborators may be required to file infringement lawsuits that can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one of our patents is not valid, is unenforceable and/or is not infringed, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put any pending applications at risk of being interpreted narrowly and not issuing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Interference proceedings or derivation proceedings may be filed to determine the priority of inventions with respect to our patents or patent applications or those of our licensors (if any). An unfavorable outcome could require us to cease using the related technology or to attempt to license rights from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. We may not be able to prevent, alone or with our licensors (if any), misappropriation of our intellectual property rights, both in the U.S. and in countries where the laws may not protect those rights as fully as in the U.S. Other proceedings, such as proceedings before the U.S. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Patent and Trademark Office Patent Trial and Appeal Board, filed by a third party may result in the invalidation of one or more of our patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims, regardless of their merit, would cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, in addition to paying royalties, redesign infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. A court may also issue an injunction against us preventing us from manufacturing and bringing our products to market. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A third party may hold intellectual property, including patent rights, that is important or necessary to the development or commercialization of our products. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially. Such licenses may not be available which could prevent us from commercializing our products. Further, if we are alleged to infringe third party intellectual property rights, we could face costly litigation, the outcome of which could negatively affect or prevent us from commercializing or developing our products. In the event of an adverse decision against us in a litigation, we could be required to: pay substantial damages and license fees, or even be prevented from using or commercializing our technologies and methods; and also be prevented from further research and development efforts. In such case, we may be unable to develop alternative non-infringing products or methods and unable to obtain one or more licenses from third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to adequately protect or enforce our rights to intellectual property or secure rights to third-party patents, we may lose valuable rights, experience reduced market share, assuming any, or incur costly litigation to enforce, maintain or protect such rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our ability to license, obtain, enforce and maintain patents, maintain trade secret protection and operate without infringing the proprietary rights of others is important to the commercialization of any formulations or products under development. The patent positions of biotechnology and pharmaceutical companies, including ours, are frequently uncertain and involve complex legal and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued. Consequently, our patents, patent applications and other intellectual property rights may not provide protection against competitive technologies or products or may be held invalid if challenged or could be circumvented. Our competitors may also independently develop products similar to ours or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">design around or otherwise circumvent patents issued to, or licensed by, us. In addition, the laws of some foreign countries may not protect our proprietary rights to the same extent as U.S. law. Any of these occurrences would have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development, sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Accordingly, costs and lost management time, as well as uncertainties resulting from the initiation and continuation of patent litigation or other proceedings, could have a material adverse effect on our ability to compete in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to seeking patents for some of our technology and products, we will also rely on trade secrets, including unpatented know-how, technology and other proprietary and confidential information, to maintain our competitive position. We will seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. However, we cannot guarantee that we will have executed these agreements with each party that may have or have had access to our trade secrets or that the agreements we do execute will provide adequate protection. Any party with whom we have executed such an agreement could breach that agreement and disclose our proprietary or confidential information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the U.S. are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets, particularly unpatented know-how, were to be obtained or independently developed by a competitor, our competitive position would be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have never paid or declared any cash dividends on our common stock. We currently intend to retain earnings, if any, to finance the growth and development of our business and we do not anticipate paying any cash dividends in the foreseeable future. As a result, only appreciation of the price of our common stock will provide a return to our members.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">These provisions might discourage, delay or prevent a change in control of our company or a change in our management. The existence of these provisions could adversely affect the voting power of holders of common stock and limit the price that investors might be willing to pay in the future for shares of our common stock. Furthermore, we have the authority to issue shares of our preferred stock without further stockholder approval, the rights of which will be determined at the discretion of the board of directors and that, if issued, could operate as a &#8220;poison pill&#8221; to dilute the stock ownership of a potential hostile acquirer to prevent an acquisition that our board of directors does not approve. In </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">addition, our certificate of incorporation and bylaws contain provisions that may make the acquisition of our company more difficult, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our authorized but unissued and unreserved common stock and preferred stock could make more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our board of directors is classified into three classes of directors with staggered three-year terms and directors are only able to be removed from office for cause;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our stockholders will only be able to take action at a meeting of stockholders and will not be able to take action by written consent for any matter, except in certain circumstances;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a special meeting of our stockholders may only be called by the chairperson of our board of directors or a majority of our board of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">advance notice procedures apply for stockholders to nominate candidates for election as directors or to bring matters before an annual meeting of stockholders; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">certain amendments to our certificate of incorporation and any amendments to our bylaws by our stockholders will require the approval of at least two-thirds of our then-outstanding voting power entitled to vote generally in an election of directors, voting together as a single class.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are an &#8220;emerging growth company,&#8221; and a &#8220;smaller reporting company&#8221; and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make our common stock less attractive to investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we intend to take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">being permitted to provide only two&#160;years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure in this Form&#160;10-K;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exemptions from the requirements of holding nonbinding advisory stockholder votes on executive compensation and stockholder approval of any golden parachute payments not previously approved.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We will remain an emerging growth company until the earlier of (1)&#160;the last day of the fiscal&#160;year (a)&#160;following the fifth anniversary of the completion of our initial public offering, (b)&#160;in which we have total annual gross revenue of at least $1.07&#160;billion (as adjusted for inflation pursuant to SEC rules&#160;from time to time), or (c)&#160;in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700&#160;million as of the prior June&#160;30th, and (2)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt securities during the prior three-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We intend to take advantage of the extended transition period for adopting new or revised accounting standards under the JOBS Act as an emerging growth company. As a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are also a smaller reporting company, and we will remain a smaller reporting company until the fiscal&#160;year following the determination that our voting and non-voting shares of common stock held by non-affiliates is more than $250&#160;million measured on the last business day of our second fiscal quarter, or our annual revenues are less than $100&#160;million during the most recently completed fiscal&#160;year and our voting and non-voting shares of common stock held by non-affiliates is more than $700&#160;million measured on the last business day of our second fiscal quarter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations, such as an exemption from providing selected financial data and an ability to provide simplified executive compensation information and only two&#160;years of audited financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The price of our stock may be volatile, and you could lose all or part of your investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The market price of shares of our common stock could be subject to wide fluctuations in response to many risk factors listed in this section and many others beyond our control. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this Form&#160;10-K,&#160;these factors include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the commencement, enrollment, completion or results of our current Phase 2b clinical trial of ibezapolstat;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any delay in our regulatory filings for ibezapolstat or our future product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse results or delays, suspensions or terminations in future preclinical studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse regulatory decisions, including failure to receive regulatory approval of ibezapolstat or any other product candidate or the failure of a regulatory authority to accept data from preclinical studies or clinical trials conducted in other countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in laws or regulations applicable to ibezapolstat or any other product candidate, including but not limited to clinical trial requirements for approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse developments concerning our manufacturers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to establish collaborations, if needed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our failure to commercialize our product candidates, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additions or departures of key scientific or management personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unanticipated serious safety concerns related to the use of ibezapolstat or any other product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">introduction of new products or services offered by us or our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to effectively manage our growth;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated variations in quarterly operating results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our cash position;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">publication of research reports about us or our industry, or product candidates in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the market valuations of similar companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the structure of the healthcare payment systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">overall performance of the equity markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of our common stock by us or our stockholders in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trading volume of our common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in accounting practices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ineffectiveness of our internal controls;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant lawsuits, including patent or stockholder litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general political and economic conditions, many of which are beyond our control, such as military conflict between Russia and Ukraine, and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other events or factors, many of which are beyond our control.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the stock market has experienced significant volatility, particularly with respect to pharmaceutical, biotechnology and other life sciences company stocks. The volatility of pharmaceutical, biotechnology and other life sciences company stocks often does not relate to the operating performance of the companies represented by the stock. If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the past, securities class action litigation has often been initiated against companies following periods of volatility in their stock price. This type of litigation could result in substantial costs and divert our management&#8217;s attention and resources, and could also require us to make substantial payments to satisfy judgments or to settle litigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our largest stockholders will exercise significant influence over our company for the foreseeable future, including the outcome of matters requiring stockholder approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our officers, directors and their affiliates currently collectively own 4,057,210 shares of our common stock (on an as-converted basis) or approximately 31% of our outstanding shares of common stock (on an as-converted basis) as of December 31, 2022. Accordingly, if these stockholders were to choose to act together, they could have a significant influence over all matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions, such as a merger or other sale of our company or all or a significant&#160;percentage of our assets. This concentration of ownership could limit your ability to influence corporate matters and may have the effect of delaying or preventing a third party from acquiring control over us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We cannot assure you that the interests of our officers, directors and affiliated persons will coincide with the interests of the investors. So long as our officers, directors and affiliated persons collectively controls a significant portion of our common stock, these individuals and/or entities controlled by them, will continue to collectively be able to strongly influence or effectively control our decisions. Therefore, you should not invest in reliance on your ability to have any control over our company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Nasdaq may delist our securities from trading on its exchange, which could limit investors&#8217; ability to make transactions in our securities and subject us to additional trading restrictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Should we fail to satisfy the Nasdaq&#8217;s continued listing requirements, such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock, and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting, we would take actions to restore our compliance with Nasdaq&#8217;s listing requirements, but we can provide no assurance that any such action taken by us would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below Nasdaq&#8217;s minimum bid price requirement or prevent future non-compliance with the Nasdaq&#8217;s listing requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Nasdaq does not maintain the listing of our securities for trading on its exchange, we could face significant material adverse consequences, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a limited availability of market quotations for our common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduced liquidity for our common stock;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a determination that our common stock is a &#8220;penny stock&#8221; which will require brokers trading in our common stock to adhere to more stringent rules&#160;and possibly result in a reduced level of trading activity in the secondary trading market for our securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a limited amount of news and analyst coverage; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a decreased ability to issue additional common stock or obtain additional financing in the future.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a public company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. We will be subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which will require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules&#160;subsequently adopted by the SEC and The Nasdaq Capital Market to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial reporting controls and changes in corporate governance practices. Further, in July&#160;2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules&#160;and regulations in these areas such as &#8220;say on pay&#8221; and proxy access. Recent legislation permits EGCs to implement many of these requirements over a longer period and up to five&#160;years from the pricing of our IPO. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect the rules&#160;and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have an adverse effect on our business. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, we expect these rules&#160;and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Effective internal control over financial reporting is necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section&#160;404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We are required to disclose changes made in our internal controls and procedures on a quarterly basis and our management is required to assess the effectiveness of these controls annually. However, for as long as we are an EGC, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section&#160;404. We could be an EGC for up to five&#160;years. An independent assessment of the effectiveness of our internal control over financial reporting could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal control over financial reporting could lead to restatements of our financial statements and require us to incur the expense of remediation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cyber incidents or attacks directed at us could result in information theft, data corruption, operational disruption and/or financial loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We depend on digital technologies, including information systems, infrastructure and cloud applications and services, including those of third parties with which we may deal. Sophisticated and deliberate attacks on, or security breaches in, our systems or infrastructure, or the systems or infrastructure of third parties or the cloud, could lead to corruption or misappropriation of our assets, proprietary information and sensitive or confidential data. As an early-stage company without significant investments in data security protection, we may not be sufficiently protected against such occurrences. We may not have sufficient resources to adequately protect against, or to investigate and remediate any vulnerability to, cyber incidents. It is possible that any of these occurrences, or a combination of them, could have adverse consequences on our business and lead to financial loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our issuance of additional capital stock in connection with potential future financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect to issue additional capital stock in the future that will result in dilution to all other stockholders. We expect to grant equity awards to employees, directors and consultants under our stock incentive plans. We may also raise capital through equity financings in the future. As part of our business strategy, we may acquire or make investments in complementary companies, products or technologies and issue equity securities to pay for any such acquisition or investment. Any such issuances of additional capital stock may cause stockholders to experience significant dilution of their ownership interests and the per share value of our common stock to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and collaborators. Misconduct by these parties could include intentional failures to comply with the regulations of the FDA and non-U.S. regulators, to provide accurate information to the FDA and non-U.S. regulators, to comply with healthcare fraud and abuse laws and regulations in the U.S. and abroad, to report financial information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained during clinical studies that could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">There may be limitations on the effectiveness of our internal controls, and a failure of our control systems to prevent error or fraud may materially harm us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Proper systems of internal control over financial accounting and disclosure are critical to the operation of a public company. We may be unable to effectively establish such systems, especially in light of the fact that we expect to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">operate as a publicly reporting company. This would leave us without the ability to reliably assimilate and compile financial information about us and significantly impair our ability to prevent error and detect fraud, all of which would have a negative impact on us from many perspectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, we do not expect that disclosure controls or internal control over financial reporting, even if established, will prevent all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. Failure of our control systems to prevent error or fraud could materially adversely impact us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The estimates and judgments we make, or the assumptions on which we rely, in preparing our financial statements could prove inaccurate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our financial statements have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of our assets, liabilities, revenues and expenses, the amounts of charges accrued by us and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. We cannot assure, however, that our estimates, or the assumptions underlying them, will not change over time or otherwise prove inaccurate. Any potential litigation related to the estimates and judgments we make, or the assumptions on which we rely, in preparing our financial statements could have a material adverse effect on our financial results, harm our business, and cause our share price to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Failure to comply with the United States Foreign Corrupt Practices Act could subject us to penalties and other adverse consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a Delaware corporation, we are subject to the United States Foreign Corrupt Practices Act, which generally prohibits U.S. companies from engaging in bribery or other prohibited payments to foreign officials for the purpose of obtaining or retaining business. Some foreign companies, including some that may compete with us, may not be subject to these prohibitions. Corruption, extortion, bribery, pay-offs, theft and other fraudulent practices may occur from time-to-time in countries in which we conduct our business. However, our employees or other agents may engage in conduct for which we might be held responsible. If our employees or other agents are found to have engaged in such practices, we could suffer severe penalties and other consequences that may have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Litigation may adversely affect our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time in the normal course of our business operations, we may become subject to litigation that may result in liability material to our financial statements as a whole or may negatively affect our operating results if changes to our business operation are required. The cost to defend such litigation may be significant and may require a diversion of our resources. There also may be adverse publicity associated with litigation that could negatively affect customer perception of our business, regardless of whether the allegations are valid or whether we are ultimately found liable. As a result, litigation may adversely affect our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, but this insurance may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, we may incur substantial costs to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts that could adversely affect our business, financial condition, results of operations or prospects. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If securities or industry analysts do not publish research or reports about our business, or they publish negative reports about our business, our share price and trading volume could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business, our market and our competitors. We do not have any control over these analysts. If one or more of the analysts who cover us downgrade our shares or change their opinion of our shares, our share price would likely decline. If one or more of these analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Delaware law contains anti-takeover provisions that could deter takeover attempts that could be beneficial to our stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Provisions of Delaware law could make it more difficult for a third party to acquire us, even if doing so would be beneficial to our stockholders. Section&#160;203 of the Delaware General Corporation Law may make the acquisition of our company and the removal of incumbent officers and directors more difficult by prohibiting stockholders holding 15% or more of our outstanding voting stock from acquiring us, without the consent of our board of directors, for at least three&#160;years from the date they first hold 15% or more of the voting stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our certificate of incorporation and our bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our certificate of incorporation and our bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our certificate of incorporation or our bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. Notwithstanding the foregoing, the exclusive forum provision does not apply to suits brought to enforce any liability or duty created by the Exchange Act, the Securities Act or any other claim for which the federal courts have exclusive jurisdiction. Unless we consent in writing to the selection of an alternative forum, the federal district courts of the U.S. of America shall, to the fullest extent permitted by applicable law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. The choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. Alternatively, if a court were to find the choice of forum provision contained in our certificate of incorporation and our bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could materially and adversely affect our business, financial condition, and results of operation.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_15ab4438_9a14_49d4_9804_1a9af6ee0aa5"></a><a id="Item1BUnresolvedStaffComments_555882"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1B. Unresolved Staff Comments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_c1e882f9_5730_40fc_8332_a42d6a0423f3"></a><a id="Item2Properties_350715"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;2. Properties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our headquarters is located in Staten Island, New York, where we lease a total of approximately 150 square feet of office.</p><a id="_2cad1293_d2ac_4794_afc5_7075d3b98eb7"></a><a id="Item3LegalProceedings_79427"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;3. Legal Proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</p><a id="_061f3440_a414_452d_85a3_eb301dd6f069"></a><a id="Item4MineSafetyDisclosures_704844"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;4. Mine Safety Disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTII_739086"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;II</p><a id="_4dc80da8_d2be_446d_992b_adaaa44fa3ad"></a><a id="Item5MarketforRegistrantsCommonEquityRel"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Market Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June&#160;25, 2021, our common stock began trading on The Nasdaq Capital Market under the symbol &#8220;ACXP&#8221;. Prior to that time, there was no public market for our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Holders of Our Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March&#160;15, 2023, there were approximately 358 holders of record of shares of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Dividends</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and future earnings, if any, for use in the operation of our business and do not anticipate paying any cash dividends on our common stock in the foreseeable future. Any future determination to declare and pay dividends will be made at the discretion of our board of directors and will depend on various factors, including applicable laws, our results of operations, our financial condition, our capital requirements, general business conditions, our future prospects and other factors that our board of directors may deem relevant. Our ability to pay cash dividends on our capital stock in the future may also be limited by the terms of any preferred securities we may issue or agreements governing any additional indebtedness we may incur. Investors should not purchase our common stock with the expectation of receiving cash dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Sales of Unregistered Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We did not sell any of our unregistered securities during the&#160;year-ended December&#160;31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Proceeds from Initial Public Offering</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our initial public offering of common stock, or the IPO, was effected through a Registration Statement on Form&#160;S-1 (File No.&#160;333-256516) that was declared effective by the SEC on June&#160;24, 2021. We issued and sold in aggregate 2,875,000 shares of common stock, which included 375,000 shares of our common stock issued pursuant to the underwriters&#8217; option to purchase additional shares, at a public offering price of $6.00 per share, for net cash proceeds of $14.8 million after deducting underwriting discounts and commissions and other offering costs. None of the underwriting discounts and commissions or offering expenses were incurred or paid to directors or officers of ours or their associates or to persons owning 10% or more of our common stock or to any of our affiliates. We have invested the net proceeds from the IPO in a money market fund. There has been no material change in our planned use of the net proceeds from the IPO as described in our final prospectus filed pursuant to Rule&#160;424(b)(4)&#160;under the Securities Act with the SEC on June&#160;28, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Issuer Purchases of Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable</p><a id="_d9046666_c100_481e_87bf_9c45d331efd8"></a><a id="Item6SelectedFinancialData_535789"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;6. Selected Financial Data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9676566c_e3f5_4fc7_b57b_312b87135209"></a><a id="Item7ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes appearing elsewhere in this Form&#160;10-K and our final prospectus for our initial public offering filed pursuant to Rule&#160;424(b)(4)&#160;under the Securities Act of 1933, as amended, or the Securities Act, on June&#160;28, 2021, or the Prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this Form&#160;10-K, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this Form&#160;10-K, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Investors and others should note that we routinely use the Investor Relations section of our website to announce material information to investors and the marketplace. While not all of the information that we post on the Investor Relations section of our website is of a material nature, some information could be deemed to be material. Accordingly, we encourage investors, the media, and others interested in us to review the information that it shares on the Investors section of our website, www.acurxpharma.com.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Acurx Pharmaceuticals, Inc., (the &#8220;Company&#8221;), a Delaware corporation, formerly Acurx Pharmaceuticals, LLC (the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization (&#8220;WHO&#8221;), the U.S. Centers for Disease Control and Prevention (&#8220;CDC&#8221;) and the U.S. Food and Drug Administration (&#8220;FDA&#8221;). Priority pathogens are those which require new antibiotics to address the worldwide crisis of antimicrobial resistance (&#8220;AMR&#8221;) as identified by the WHO, CDC and FDA. The CDC estimates that, in the U.S., antibiotic-resistant pathogens infect one individual every 11 seconds and result in one death every 15 minutes. The WHO recently stated that growing antimicrobial resistance is equally as dangerous as the ongoing COVID-19 pandemic, threatens to unwind a century of medical progress and may leave us defenseless against infections that today can be treated easily. According to the WHO, the current clinical development pipeline remains insufficient to tackle the challenge of the increasing emergence and spread of antimicrobial resistance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our approach is to develop a new class of antibiotic candidates that block the DNA polymerase IIIC (&#8220;Pol IIIC&#8221;). We believe we are developing the first Pol IIIC inhibitor to enter clinical trials and have clinically validated the bacterial target by demonstrating the efficacy of our lead antibiotic candidate in a Phase 2a clinical trial. Pol IIIC is the primary catalyst for DNA replication of several Gram-positive bacterial cells. Our research and development pipeline includes clinical stage and early stage antibiotic candidates that target Gram-positive bacteria for oral and/or parenteral treatment of infections caused by Clostridium difficile (&#8220;C. difficile&#8221;), Enterococcus (including vancomycin-resistant strains (&#8220;VRE&#8221;)), Staphylococcus (including methicillin-resistant strains), and Streptococcus (including antibiotic resistant strains).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pol IIIC is required for the replication of DNA in certain Gram-positive bacterial species. By blocking this enzyme, our antibiotic candidates are believed to be bactericidal and inhibit proliferation of several common Gram-positive bacterial pathogens, including both sensitive and resistant C. difficile, methicillin-resistant Staphylococcus aureus (&#8220;MRSA&#8221;), vancomycin-resistant Enterococcus, penicillin-resistant Streptococcus pneumonia (&#8220;PRSP&#8221;) and other resistant bacteria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We intend to &#8220;de-risk&#8221; this new class of antibiotics through our drug development activities and potentially partner with a fully-integrated pharmaceutical company for late-stage clinical trials and commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our lead antibiotic candidate, ibezapolstat (formerly named ACX-<span style="white-space:pre-wrap;">362E), has a novel mechanism of action that targets the Pol IIIC enzyme, a previously unexploited scientific target. Phase 2a clinical efficacy of our lead antibiotic validate the Pol IIIC bacterial target.  On December&#160;3, 2021, we commenced enrollment in a Phase 2b 64-patient, </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">randomized (1-to-1), non-inferiority, double-blind, trial of oral ibezapolstat compared to oral vancomycin, a standard of care to treat C. difficile infections (&#8220;CDI&#8221;).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to that, we completed our Phase 2a clinical trial of ibezapolstat to treat patients with CDI and reported the top-line data in November&#160;2020. The Phase 2a clinical trial was terminated early based upon the recommendation of our Scientific Advisory Board (the &#8220;SAB&#8221;). The SAB reviewed the study data presented by management, including adverse events and efficacy outcomes, and discussed its clinical impressions. The SAB unanimously supported the early termination of the Phase 2a trial after 10 patients were enrolled in the trial instead of 20 patients as originally planned. The early termination was further based on the evidence of meeting the treatment goals of eliminating the infection with an acceptable adverse event profile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The SAB noted that 10 out of 10 patients enrolled in the Phase 2a trial reached the Clinical Cure endpoint, defined in the study protocol as the resolution of diarrhea in the 24-hour period immediately before the end of treatment that is maintained for 48 hours after end of treatment. Such cure was sustained, meaning that the patients showed no sign of infection recurrence, for 30&#160;days thereafter. This constitutes a 100% response rate for the primary and secondary endpoints of the trial. All 10 patients enrolled in the Phase 2a trial met the study&#8217;s primary and secondary efficacy endpoints, namely, Clinical Cure at end of treatment and Sustained Clinical Cure of no recurrence of CDI at the 28-day follow-up visit. No treatment-related serious adverse events (&#8220;SAEs&#8221;) were reported by the investigators who enrolled patients in the trial. We believe these results represent the first-ever clinical data showing Pol IIIC has potential as a therapeutically relevant antibacterial target. Our Phase 2b clinical trial commenced enrollment on December&#160;3, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Currently available antibiotics used to treat CDI infections utilize other mechanisms of action. We believe ibezapolstat is the first antibiotic candidate to work by blocking the DNA Pol IIIC enzyme in <i style="font-style:italic;">C. difficile</i>. This enzyme is necessary for replication of the DNA of certain Gram-positive bacteria, like <i style="font-style:italic;">C. difficile</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We also have an early stage pipeline of antibiotic product candidates with the same previously unexploited mechanism of action which has established proof of concept in animal studies. This pipeline includes ACX-375C, a potential oral and parenteral treatment targeting Gram-positive bacteria, including MRSA, VRE and PRSP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, we had cash of approximately $9.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Developments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Based on the blinded observed data from the ongoing Phase 2b clinical trial to date, in January 2023, the Company filed a protocol amendment to its Investigational New Drug Application (IND) with FDA to allow for an Independent Data Monitoring Committee (IDMC) to review interim clinical data.  If acceptable to FDA, the IDMC will review the clinical data upon enrollment of 36 patients in the Phase 2b clinical trial. The Company currently has enrolled 25 patients in the Phase 2b clinical trial.  The IDMC will determine and recommend to the Company whether the most appropriate course of action forward is to early terminate the Phase 2b clinical trial (as the Company had done with the Phase 2a clinical trial) or to continue patient enrollment.  The Company intends to report available data promptly after the IDMC conducts this interim review.  The Company assembled its IDMC in the first quarter of 2023 for this purpose.   </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Referring Physician Program and Trial Site Expansion</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July 2022, we launched an innovative patient enrollment acceleration program (&#8220;Referring Physician Program&#8221;) to optimize patient enrollment in our ongoing Phase 2b clinical trial of ibezapolstat in patients with CDI. Our newly instituted Referring Physician Program involves principal investigators and study coordinators of our clinical trial sites reaching out to potential Referring Physicians (&#8220;RPs&#8221;) within an approximately twenty-five mile radius of our clinical trial sites. In each case, our scientific team has identified all of these potential RPs as high-prescribing physicians of the most commonly used antibiotics for treatment of CDI over a recent twelve-month period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">According to the physician prescribing data available to us from an industry-standard source, identified RPs in the aggregate of just fourteen of our currently activated clinical trial sites treated a total of over 30,000 patients in a recent one-year period, suggesting that a substantial number of subjects could potentially be available for referral to one of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">these fourteen clinical trial sites if the patients qualify. The first tranche of this program has been activated with seventeen of our clinical trial sites and any further increases, if any, will follow after the review by IDMC of interim data from the Phase 2b clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe the Referring Physician Program, which has a number of other supportive elements, will enhance the rate of enrollment potentially mitigating or partially mitigating the countervailing enrollment disruption caused by the COVID-19 pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, in July 2022, we increased the number of clinical trial sites participating in our Phase 2b clinical trial from the original twelve clinical trial sites to twenty eight. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Registered Direct Offering</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On July 25, 2022, we entered into securities purchase agreements (the &#8220;Purchase Agreements&#8221;) with David P. Luci, our President and Chief Executive Officer, Robert J. DeLuccia, our Executive Chairman, Carl V. Sailer, a member of our board of directors (collectively, the &#8220;Affiliate Investors&#8221;), and a single U.S. institutional investor (the &#8220;Investor&#8221;) pursuant to which we issued and sold in a registered direct offering an aggregate of 1,159,211 shares of our common stock, par value $0.001 per share and pre-funded warrants to purchase an aggregate of 130,769 shares of our common stock. The Affiliate Investors purchased an aggregate of 59,211 shares of common stock at a purchase price of $3.80 per share. The Investor purchased an aggregate of 1,100,000 shares of common stock at a purchase price of $3.25 per share and an aggregate of 130,769 pre-funded warrants at a purchase price of $3.2499 per pre-funded warrant. The pre-funded warrants sold to the Investor have an exercise price of $0.0001, were immediately exercisable and may be exercised at any time until fully exercised.  As of December 31, 2022, all of the pre-funded warrants were exercised.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The gross proceeds to us from the registered direct offering were $4.2 million and net proceeds after deducting the placement agents&#8217; fees and other offering expenses payable by us were approximately $3.7 million. The securities were offered by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-265956) previously filed with the SEC on July 1, 2022, and which was declared effective by the SEC on July 11, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In a concurrent private placement, we issued to the Affiliate Investors and the Investor, series A warrants to purchase 1,289,980 shares of our common stock and series B warrants to purchase 1,289,980 shares of our common stock, all of which are deemed equity classified. We issued an aggregate of 59,211 series A warrants and an aggregate of 59,211 series B warrants to the Affiliate Investors with an exercise price per share of $3.55. Additionally, we issued an aggregate of 1,230,769 series A warrants and an aggregate of 1,230,769 series B warrants to the Investor with an exercise price per share of $3.25. The series A warrants are exercisable commencing on January 27, 2023 and will expire on January 27, 2028. The series B warrants are exercisable commencing on January 27, 2023 and will expire on January 27, 2024. The registered direct offering and concurrent private placement closed on July 27, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 25, 2022, we entered into a co-placement agent agreement (the &#8220;Placement Agent Agreement&#8221;), with A.G.P./Alliance Global Partners (&#8220;AGP&#8221;) and Maxim Group LLC (&#8220;Maxim&#8221;, and together with AGP, the &#8220;Placement Agents&#8221;) in connection with the registered direct offering pursuant to which we paid the Placement Agents a cash fee of $287,874 and issued to the Placement Agents an aggregate of 63,018 warrants to purchase shares of common stock (which is 5% of the aggregate number of shares of common stock and pre-funded warrants sold in the registered direct offering to the Investor and 2.5% of the aggregate number of shares of common stock sold to the Affiliate Investors). The warrants will have an exercise price of $3.60 per share (representing 110% of the weighted average public offering price of the aggregate number of shares of common stock sold in the registered direct offering to the Investor and Affiliate Investors), are exercisable beginning January 27, 2023, and will expire on July 27, 2027.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Initial Public Offering</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On June&#160;29, 2021, we completed our IPO, in which we issued and sold 2,875,000 shares of our common stock, including the full exercise by the underwriters of their option to purchase 375,000 additional shares of our common stock, at a public offering price of $6.00 per share, which resulted in net cash proceeds of $14.8 million after deducting underwriting discounts and commissions and offering expenses. The proceeds from the IPO are being used (i)&#160;to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">complete the Phase 2b clinical trial of ibezapolstat in patients with CDI, (ii)&#160;to complete pre-clinical development of ACX-375C and (iii)&#160;for general corporate purposes, which may include, without limitation, expenditures relating to research, development and clinical trials other than those specified above, manufacturing, capital expenditures, hiring additional personnel, acquisitions of new technologies or products, the payment, repayment, refinancing, redemption or repurchase of existing or future indebtedness, obligations or capital stock, and working capital. Prior to the IPO, we converted from a Delaware limited liability company into a Delaware corporation, and our previously outstanding Class&#160;A membership interests and Class&#160;B membership interests were converted to shares of common stock pursuant to a conversion ratio of one-half of one share of common stock for each Class&#160;A membership interest or Class&#160;B membership interest&#160;outstanding, resulting in the conversion of 14,082,318 Class&#160;A membership interests and Class&#160;B membership interests into 7,041,208 shares of common stock. Our common stock began trading on the Nasdaq Capital Market on June&#160;25, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Effects of Coronavirus (COVID-19) on Our Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The World Health Organization (&#8220;WHO&#8221;) recognized COVID-19 as a public health emergency of international concern on January&#160;30, 2020 and as a global pandemic on March&#160;11, 2020. The global pandemic and actions taken to contain COVID-19 have adversely affected the global economy and financial markets. Vaccines for COVID-19 continue to be administered in the United States and other countries around the world, but the extent and rate of vaccine adoption, the long-term efficacy of these vaccines and other factors remain uncertain. Authorities throughout the world have implemented measures to contain or mitigate the spread of the virus, including at various times physical distancing, travel bans and restrictions, closure of non-essential businesses, quarantines, work-from-home directives, mask requirements, shelter-in-place orders and vaccination programs. Despite these efforts, COVID-19 has persisted, has mutated into new variants, and is expected to become endemic. Additionally, new waves of COVID-19 or its variants could cause the reinstatement of such limitations. The impact of COVID-19 and its variants, including direct and indirect economic effects as a result of inflation, supply chain disruptions and labor shortages, have been and remain unpredictable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since the start of the COVID-19 pandemic, we continued to enroll patients in our Phase 2a and Phase 2b clinical trial of our lead antibiotic candidate, ibezapolstat, although enrollment rates decreased significantly compared to expectations at certain of our clinical trial sites. Other areas of our business experienced no change, including our research and development activities with key vendors. We believe that the COVID-19 pandemic has highlighted the importance of antibiotic development in responding to global health issues particularly because many hospitalized COVID-19 patients were also prescribed antibiotics which only accelerates the current antimicrobial resistance crisis described by several regulatory bodies worldwide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The extent to which the COVID-19 pandemic will ultimately impact our business, results of operations, financial condition and cash flows depends on future developments that are highly uncertain, rapidly evolving and difficult to predict at this time. While we are not experiencing material adverse impacts at this time, given the global economic slowdown, the overall disruption of global supply chains and distribution systems and the other risks and uncertainties associated with the COVID-19 pandemic, our business, financial condition, results of operations and growth prospects could be materially and adversely affected. While we believe that we are well positioned for the future as we navigate the crisis and prepare for an eventual return to a more normal operating environment, we continue to closely monitor the COVID-19 pandemic as we evolve our business continuity plans and response strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2020, we received a Paycheck Protection Program loan (&#8220;PPP Loan&#8221;) under the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES ACT&#8221;), as administered by the U.S. Small Business Administration (&#8220;SBA&#8221;) in the amount of $66,503. The PPP Loan carried an annual interest rate of 0.98% and matures two (2)&#160;years from issuance. On April&#160;13, 2021, the SBA authorized the full forgiveness of the PPP Loan. Upon forgiveness of the PPP Loan, we reduced the liability and recorded a gain on the forgiveness of the PPP Loan in our statement of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Components of our Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have not generated any revenue since our inception and do not expect to generate any revenue from the sale of products in the near future, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To date, our research and development expenses have related primarily to development of ibezapolstat, preclinical studies and other preclinical activities related to our portfolio. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">external research and development expenses incurred under agreements with contract research organizations, or CROs, and consultants to conduct our preclinical, toxicology and other preclinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">laboratory supplies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs related to manufacturing product candidates, including fees paid to third-party manufacturers and raw material suppliers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">license fees and research funding; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent, maintenance of facilities, insurance, equipment and other supplies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. We outsource a substantial portion of our clinical trial activities, utilizing external entities such as CROs, independent clinical investigators and other third-party service providers to assist us with the execution of our clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We plan to substantially increase our research and development expenses for the foreseeable future as we continue the development of our product candidates and seek to discover and develop new product candidates. Due to the inherently unpredictable nature of preclinical and clinical development, we cannot determine with certainty the timing of the initiation, duration or costs of future clinical trials and preclinical studies of product candidates. Clinical and preclinical development timelines, the probability of success and the amount of development costs can differ materially from expectations. We anticipate that we will make determinations as to which product candidates and development programs to pursue and how much funding to direct to each product candidate or program on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments and our ongoing assessments as to each product candidate&#8217;s commercial potential. In addition, we cannot forecast which product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our future clinical development costs may vary significantly based on factors such as:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">per-patient trial costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of trials required for regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of sites included in the trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the countries in which the trials are conducted;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the length of time required to enroll eligible patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of patients that participate in the trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of doses that patients receive;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the drop-out or discontinuation rates of patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential additional safety monitoring requested by regulatory agencies;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the duration of patient participation in the trials and follow-up;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the phase of development of the product candidate; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efficacy and safety profile of the product candidate.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of salaries and employee-related costs, including stock-based compensation, for personnel in our executive, finance and other administrative functions. Other significant costs include facility-related costs, legal fees relating to intellectual property and corporate matters, professional fees for accounting and consulting services and insurance costs. We anticipate that our general and administrative expenses will increase in the future to support our continued research and development activities, pre-commercialization and, if any product candidates receive marketing approval, commercialization activities. We also anticipate increased expenses related to audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums and investor relations costs associated with operating as a public company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Years Ended December&#160;31, 2022 and 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our results of operations for the&#160;years ended December&#160;31, 2022 and 2021:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percentage</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:65.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">OPERATING EXPENSES:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Research and Development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,754</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,030</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 134</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">General and Administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,340</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,784</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (32)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">TOTAL OPERATING EXPENSES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,094</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,814</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (6)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gain on forgiveness of Paycheck Protection Program Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 67</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (100)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (12,094)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (12,747)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (5)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Expenses. </i>Research and development expenses were $4.8&#160;million for the&#160;year ended December&#160;31, 2022, and $2.0&#160;million for the&#160;year ended December&#160;31, 2021, an increase of $2.8 million primarily due to increase in consulting related costs for the Phase 2b clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">General and Administrative Expenses. </i>General and administrative expenses were $7.3&#160;million for the&#160;year ended December&#160;31, 2022, and $10.8&#160;million for the&#160;year ended December&#160;31, 2021. General and administrative expenses decreased by approximately $3.5 million primarily due to $1.3 million decrease in professional fees, $2.3 million decrease in share-based compensation costs, offset by $0.1 million increase in insurance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net Loss. </i>Net loss was $12.1&#160;million for the&#160;year ended December&#160;31, 2022, compared to $12.7&#160;million for the&#160;year ended December&#160;31, 2021, a decrease of $0.6&#160;million, primarily due to the reasons stated above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Since inception, we have generated no revenue from operations and we have incurred cumulative losses of approximately $38.6 million as of December 31, 2022. We have funded our operations primarily from equity issuances. We received net cash proceeds of approximately $12.9 million from equity financings closed between March 2018 and October 2020. On June 29, 2021, we completed our IPO resulting in net proceeds of approximately $14.8 million after deducting underwriter discounts of $1.4 million and offering costs of approximately $1.1 million.  On July 27, 2022, we completed a registered direct offering and concurrent private placement resulting in net proceeds of approximately $3.7 million after deducting placement agents commission of $0.3 million and offering costs of $0.2 million.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based upon our lack of revenue expected for the foreseeable future, and because of numerous risks and uncertainties associated with the research, development and future commercialization of our product candidates, we are unable to estimate with certainty the amounts of increased capital outlays and operating expenditures associated with our anticipated clinical trials and development activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, we had working capital of $7.3 million, consisting primarily of $9.1 million of cash and $0.3 million of prepaid expenses, offset by $2.1 million of accounts payable and accrued expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Sources of Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To date, we have financed our operations principally through private placements of equity issuances, the IPO, and a registered direct offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Class&#160;A Membership Financings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have funded our operations primarily from equity issuances. We received net cash proceeds of approximately $12.9 million from equity financings closed between March&#160;2018 and October&#160;2020 starting with investments from the co-founders. All of our equity financings were consummated at a price ranging from $1.00 per Class&#160;A Membership Interest (March&#160;2018) to $3.25 per Class&#160;A Membership Interest (July&#160;2020 and October&#160;2020). Warrant coverage was provided in all but our most-recent financing and the warrant coverage in our early-stage financings ranged from 25% warrant coverage to 50% warrant coverage, in each case, with a conversion price equal to the issue price in each offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Paycheck Protection Program Loan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2020, we received a PPP Loan under the CARES ACT, as administered by the SBA in the amount of $66,503. We did not provide any collateral or guarantees in connection with the PPP Loan, nor did we pay any facility charge to obtain the PPP Loan. The PPP Loan carried an annual interest rate of 0.98% and was scheduled to mature two (2)&#160;years from issuance. On April&#160;13, 2021, the SBA authorized the full forgiveness of the PPP Loan. Upon forgiveness of the PPP Loan, we reduced the liability and recorded a gain on the forgiveness of the PPP Loan in the statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Initial Public Offering</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2021, we completed the IPO and issued and sold an aggregate 2,875,000 shares of common stock, which included 375,000 shares of our common stock issued pursuant to the underwriters&#8217; option to purchase additional shares, at a public offering price of $6.00 per share, for net cash proceeds of $14.8 million after deducting underwriting discounts and commissions and other offering costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Registered Direct Offering</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In July 2022, we completed a registered direct offering and a concurrent private placement, issuing 1,159,211 shares of common stock and 130,769 pre-funded warrants and series A warrants to purchase 1,289,980 shares of common stock and series B warrants to purchase 1,289,980 shares of common stock for gross proceeds of approximately $4.2 million.  </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth a summary of the net cash flow activity for the&#160;years ended December&#160;31, 2022 and 2021:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash (used in) provided by:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (7,542)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (5,013)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,695</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14,797</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net (decrease) / increase in cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (3,847)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,784</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operating Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities was $7.5 million for the year ended December 31, 2022, primarily attributable to the net loss of $12.1 million, offset by share-based compensation of $2.9 million, share-based payments to vendors of $0.4 million and an increase of $1.3 million in accounts payable and accrued expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities was $5.0 million for the&#160;year ended December&#160;31, 2021, primarily attributable to the net loss of $12.7 million, offset by share-based compensation of $5.2 million, share-based payments to vendors of $1.6 million and $0.9 million of share-based executive compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Investing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by investing activities were none&#160;for the&#160;years ended December&#160;31, 2022 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities was $3.7 million for the year ended December 31, 2022, which was attributable to the net proceeds from the registered direct offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities was $14.8 million for the&#160;year ended December&#160;31, 2021, primarily due to the net proceeds from our IPO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Funding Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that our existing cash will not be sufficient to meet our anticipated cash requirements for at least 12&#160;months from the issuance of our financial statements for the&#160;year ended December&#160;31, 2022. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially, including with regard to the impact of COVID-19 on our clinical trial enrollment. We have based this estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our future capital requirements will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, progress, and results of our ongoing and planned clinical trials of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to manufacture sufficient clinical supply of our product candidates and the costs thereof;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">discussions with regulatory agencies regarding the design and conduct of our clinical trials and the costs, timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of any other product candidates or technologies we pursue;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and maintain strategic partnerships, licensing or other arrangements and the financial terms of such agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the revenue, if any, received from commercial sales of any product candidates for which we receive marketing approval; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Until such time, if ever, as we can generate substantial product revenues to support our capital requirements, we expect to finance our cash needs through a combination of public or private equity offerings, debt financings, collaborations and licensing arrangements or other capital sources. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, or other similar arrangements with third parties, we may need to relinquish valuable rights to our product candidates, future revenue streams or research programs or may have to grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings as and when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and market such product candidates ourselves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Financial Accounting Standards Board has issued certain accounting pronouncements as of December&#160;31, 2022 that will become effective in subsequent periods; however, we do not believe that any of those pronouncements would have significantly affected our financial accounting measurements or disclosures had they been in effect during 2022, or that they will have a significant impact on us at the time they become effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Policies and Significant Judgments and Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company expenses research and development costs when incurred. At times, the Company may make cash advances for future research and development services. These amounts are deferred and expensed in the period the service is provided. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Costs for certain research and development activities, such as the provision of services for clinical trial activity, are estimated based on an evaluation of the progress to completion of specific tasks which may use data such as subject enrollment, clinical site activations or information provided to the Company by its vendors with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development expense, as the case may be. The estimates are adjusted to reflect the best information available at the time of the financial statement issuance. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#39;s estimate of the status and timing of services performed relative to the actual status and timing of services performed may vary. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Share-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for the cost of services performed by employees, officers and directors received in exchange for an award of Company membership interests, common stock or stock options, based on the grant-date fair value of the award. The Company recognizes compensation expense based on the requisite service period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Compensation expense associated with stock option awards is recognized over the requisite service period based on the fair value of the option at the grant date determined based on the Black-Scholes option pricing model. Option valuation models require the input of highly subjective assumptions including the expected price volatility. The Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair value computation using the Black-Scholes option pricing model. Because there is no public market for the Company&#8217;s stock options and very little historical experience with the Company&#8217;s stock, similar public companies were used for the comparison of volatility and the dividend yield. The risk-free rate of return was derived from U.S. Treasury notes with comparable maturities. We will continue to analyze the expected stock price volatility and will adjust our Black-Scholes option pricing assumptions as appropriate.  Any changes in the foregoing Black-Scholes assumptions, or if we were to elect to utilize an alternative method for valuing stock options granted to employees, officers and directors, could potentially impact our stock-based compensation expense and our results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Share-Based Payments to Vendors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company accounts for the cost of services performed by vendors in exchange for an award of Company membership interests, common stock, or stock options, based on the grant-date fair value of the award or the fair value of the services rendered; whichever is more readily determinable. We also use Black-Scholes option pricing model for the purpose of estimating the fair value of options and warrants.  Changes in our Black-Scholes assumptions, or if we were to utilize an alternative method for valuing options or warrants issued to our vendors, could impact our expense and our results of operations</span></p><a id="_2b54c7f1_8150_465f_9b28_a7d2c92dc881"></a><a id="Item7AQuantitativeandQualitativeDisclosu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate risks, foreign currency exchange rate risks and inflation risks. Periodically, we maintain deposits in accredited financial institutions in excess of federally insured limits. We deposit our cash in financial institutions that we believe have high credit quality and have not experienced any significant losses on such accounts and do not believe we are exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Foreign Currency Exchange Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All of our employees and our operations are currently located in the United States. We have, from time-to-time, engaged in contracts with contractors or other vendors in a currency other than the U.S. dollar. To date, we have had minimal exposure to fluctuations in foreign currency exchange rates as the time period between the date that transactions are initiated and the date of payment or receipt of payment is generally of short duration. Accordingly, we believe we do not have a material exposure to foreign currency risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Effects of Inflation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Inflation generally affects us by increasing our cost of labor and research and development contract costs. We do not believe inflation has had a material effect on our results of operations during the periods presented.</p><a id="_8db9a19d_7e0e_4e80_881c_db908b98dcd9"></a><a id="Item8FinancialStatementsandSupplementary"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;8. Financial Statements and Supplementary Data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The financial statements and related financial statement schedules required to be filed are listed in the Index to Financial Statements and are incorporated in Item&#160;15 of Part&#160;IV of this Form&#160;10-K.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a79e0bb3_8cbd_48d0_8599_16373808bc30"></a><a id="Item9ChangesinandDisagreementswithAccoun"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_eba13fc7_9a7b_4237_b29f_4aed1c02e203"></a><a id="Item9AControlsandProcedures_695557"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9A. Controls and Procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We maintain &#8220;disclosure controls and procedures,&#8221; as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules&#160;and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As required by Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;of the Exchange Act, our management, including our principal executive officer and our principal financial officer, conducted an evaluation as of the end of the period covered by this Form 10-K of the effectiveness of the design and operation of our disclosure controls and procedures. In designing and evaluating our disclosure controls and procedures, our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of the end of the period covered by this Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We can give no assurance that material weaknesses in our internal control over financial reporting will not be identified in the future. Our failure to implement and maintain effective internal control over financial reporting could result in errors in our financial statements that could result in a restatement of our financial statements and cause us to fail to meet our reporting obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our management is responsible for establishing and maintaining adequate internal control over our financial reporting, as such term is defined in Rule&#160;13a-15(f)&#160;and 15d-15(f) under the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our management conducted an assessment of the evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2022 based on the criteria set forth in &#8220;Internal Control &#8211; Integrated Framework (2013)&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on this assessment, our management concluded that our internal control over financial reporting was effective as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Attestation Report of the Registered Public Accounting Firm</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">This Annual Report on Form&#160;10-K does not include an attestation report of our registered public accounting firm due to an exemption established by the JOBS Act for &#8220;emerging growth companies&#8221;. Additionally, our independent </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">registered public accounting firm will not be required to opine on our internal control over financial reporting until we are no longer an emerging growth company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in Internal Control Over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">As previously reported, management recognized that the Company had material weaknesses in its internal control over financial reporting as of December 31, 2021.  We identified a material weakness as it relates to a lack of adequate segregation of accounting functions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">To remediate the inadequate segregation of duties, our management (i) engaged a third-party specialist to review our current internal controls and to recommend design improvements given the limited number of employees, (ii) hired a controller to remediate the segregation of duties issue, who commenced employment in April 2022 and (iii) implemented a quarterly financial statement close process that includes formal reviews of financial statement account balances and journal entries.  Accordingly, management believes it has remediated the material weakness related to inadequate segregation of duties. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except as noted above, there were no additional changes in our internal control over financial reporting (as defined in Rule&#160;13a-15(f)&#160;of the Exchange Act) identified in connection with the evaluation of such internal control that occurred during the fourth quarter of our last fiscal year that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p><a id="_d3ae7d8a_399f_4e43_b302_403412d191d3"></a><a id="Item9BOtherInformation_911217"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9B. Other Information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_8311c5df_42f9_4fce_bca6_31c28fe771b5"></a><a id="Item9CDisclosureRegardingForeignJurisdic"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3cc7131a_4a19_43f1_9f1a_3f8af5a8ee8b"></a><a id="PARTIII_167870"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;III</p><a id="Item10DirectorsExecutiveOfficersandCorpo"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;10. Directors, Executive Officers and Corporate Governance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Set forth below are the names of our directors and officers and each of their principal occupations and employers, as applicable. Additional information required by this Item will be included in the 2023 Proxy Statement and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">David P. Luci &#8212; President and Chief Executive Officer, Director</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Mr. Luci is our co-founder, President and Chief Executive officer and has served as Director since February 2018.  Mr. Luci previously served as our Managing Director from February 2018 until June 2021. Previously, Mr. Luci was the President and Chief Executive Officer of Dipexium Pharmaceuticals (Nasdaq: DPRX), a pharmaceutical company focused on antibiotic drug development, from February 2010 until its sale to PLx Pharma Inc. (Nasdaq: PLXP) in a merger valued at $69.0 million in April 2017. From February 2009 to January 2010, Mr. Luci served as a member of the board of directors of Access, where he also served as Chairman of the Audit Committee and Chairman of the Compensation Committee as well as serving in a consulting capacity following the acquisition of MacroChem. From December 2007 through February 2009, Mr. Luci served as a member of the board of directors and President of MacroChem. Prior to that, Mr. Luci served as Executive Vice President, Chief Financial Officer, General Counsel and Corporate Secretary of Bioenvision, Inc. (or Bioenvision), an international biopharmaceutical company focused upon the development, marketing and commercialization of oncology products and product candidates. Mr. Luci began his career with Ernst &amp; Whinney LLP (now Ernst &amp;Young LLP) in New York as a certified public accountant working in the Healthcare Practice Group. He later practiced corporate law at Paul Hastings LLP in New York, where his practice encompassed all aspects of public and private mergers and acquisitions, corporate finance, restructurings and private equity transactions, with a core focus in the healthcare industry. Mr. Luci graduated from Bucknell University with a degree as a Bachelor of Science in Business Administration with a concentration in Accounting and graduated from Albany Law School of Union University where he served as Managing Editor of the Journal of Science &amp; Technology. Mr. Luci became a certified public accountant in the State of Pennsylvania in 1990 (inactive) and is a member of the New York State Bar Association. Mr. Luci was selected to serve on our board of directors because of his extensive experience in the pharmaceutical industry.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Robert J. DeLuccia &#8212; Executive Chairman</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Mr. DeLuccia is our co-founder and Executive Chairman and has served as Director since February 2018.  Mr. DeLuccia previously served as our Managing Partner from February 2018 until June 2021.  February 2018. Previously, Mr. DeLuccia was the Executive Chairman of Dipexium Pharmaceuticals (Nasdaq: DPRX), a pharmaceutical company focused on antibiotic drug development, from February 2010 until its sale to PLx Pharma Inc. (Nasdaq: PLXP) in a merger valued at $69 million in April 2017. Previously, from 2004 to 2009, Mr. DeLuccia served in several capacities at MacroChem, a development-stage, publicly traded pharmaceutical company using topical drug delivery technology for products in dermatology, podiatry, urology and cancer, including as Chairman of the board of directors, President and Chief Executive Officer. Prior to joining MacroChem, Mr. DeLuccia served as President and Chief Executive Officer of Immunomedics, Inc., a publicly-traded biopharmaceutical company focused on antibody-based therapeutic products and diagnostic imaging for cancer and infectious diseases. Mr. DeLuccia also served as President of Sterling Winthrop, Inc. (or Sterling Winthrop) (as an independent corporation and then as subsidiary of Eastman Kodak), and subsequently, upon acquisition, the U.S. subsidiary of  Sanofi-Aventis (or Sanofi)  and currently serves as a member of the board of directors of IBEX Technologies Inc., which manufactures and markets proprietary enzymes (heparinases and chondroitinases) for use in pharmaceutical research and Heparinase I, used in many leading hemostasis monitoring devices. Mr. DeLuccia began his career as a pharmaceutical sales representative for Pfizer, Inc. (or Pfizer) and progressed to Director of Marketing, Pfizer Laboratories Division, and to Vice President Marketing and Sales Operations for Pfizer&#8217;s Roerig Division. Mr. DeLuccia received a Bachelor of Business Administration with a concentration in Marketing and a Master&#8217;s Degree in Business Administration from Iona College. Mr. DeLuccia was selected to serve as Chairman of our board of directors because of his extensive executive leadership and experience in the pharmaceutical industry.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Carl V. Sailer &#8212; Director</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Mr. Sailer has served as our director since October 2018. Since May 2019, Mr. Sailer has served as VP, Global Account Lead for Syneos Health (Nasdaq: SYNH). Previously, Mr. Sailer served as VP, Sales and Marketing for Emisphere Technologies from October 2012 until March 2019, Vice President of Commercial Operations at New American Therapeutics from August 2010 to September 2012, and VP, Commercial Operations Akrimax Pharmaceuticals from May 2008 to July 2010. Mr. Sailer started his career in various sales, marketing and sales management roles in the pharmaceutical and consumer products divisions of Bristol-Myers Squibb and Bayer Healthcare. Mr. Sailer has over 25 years of experience as a commercial leader in the biopharmaceutical industry. Mr. Sailer earned a Master of Business Administration from Hofstra University and a Bachelor of Science in Marketing from Seton Hall University, where he currently serves on the Advisory Board of the Market Research Center at the Stillman School of Business. Mr. Sailer was selected to serve on our board of directors because of his extensive experience in the pharmaceutical and consumer goods industries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Thomas Harrison &#8212; Director</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Mr. Harrison has served as our director since July 2021. Since June 2016, Mr. Harrison has served as Chairman Emeritus of the Diversified Agency Services (&#8220;DAS&#8221;) division of Omnicom Group Inc. (NYSE: OMC), the world&#8217;s largest group of marketing services companies, having previously served as its President, then Chairman and CEO. DAS provides an unparalleled range of marketing communications services including public relations, crisis management, branding, sales promotion, customer relationship management and specialty communications including health care advertising. With over 5000 worldwide clients, the DAS division under Mr. Harrison had annual revenues of over $6.0 billion and became the largest business unit within Omnicom Group. Under Mr. Harrison&#8217;s leadership, the DAS division grew from Omnicom&#8217;s smallest to its largest division and accounted for over 50% of Omnicom&#8217;s total revenues. He acquired and led a group of companies which became the most influential in their respective disciplines and built the largest, most innovative, diverse and relevant group of specialized agencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Mr. Harrison&#8217;s multi-faceted career brought him to Omnicom in 1992 when Omnicom acquired the firm he co-founded, Harrison &amp; Star Business Group, which was the most successful and rapidly growing agency group in the healthcare industry. Mr. Harrison served as Chairman of the Harrison &amp; Star Group and Chairman of Diversified Healthcare Communications, a group of eight healthcare agencies within Omnicom, until his appointment as President of DAS in 1997. He was named Chairman and Chief Executive of DAS in 1998 and remained in this role until being named Chairman Emeritus in 2013.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">With an advanced degree in cell biology and physiology, Mr. Harrison began his business career at Pfizer Laboratories as a pharmaceutical sales representative His agency, Harrison &amp; Star, was an entrepreneurial agency that fused high science with high creativity. The agency became uniquely positioned in the market due to its understanding of the clinical and scientific underpinnings of prescription product promotion and its ability to communicate with practicing physicians using the language of science not sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Mr. Harrison brought his scientific acumen and career experience in healthcare, wellness, branding and communication to the evolving cannabis marketplace in 2015 when he joined the Board of Directors of Zynerba Pharmaceuticals, a leader in pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare psychiatric disorders. Mr. Harrison joined Merida Capital Partners in 2019 as Senior Operating Partner. At Merida, he serves as a strategic and operational advisor across the firm&#8217;s portfolio companies. Mr. Harrison is focused on contributing his expertise to this dynamic industry as it continues to unfold.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Mr. Harrison is a member of the Executive Committee of the Montefiore Health System and currently sits on the board of Fifth Street Asset Management (2014 &#8211; Present) where he serves as Lead Independent Director and Chairman of the Audit Committee. He also serves on the board of Madison Logic, a digital business to business agency (2017 &#8211; Present). Most recently, Mr. Harrison was appointed to the board of MainStem, a cannabis-related supply company and also ACTV8me, a digital advertising attribution company.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Mr. Harrison is a past board member at ePocrates, a publicly traded healthcare information company, where he served from 2006 until its acquisition in 2013 and he has also served as a board member for The Morgans Hotel Group (2006 &#8211; 2013). Mr. Harrison joined the board of Dipexium Pharmaceuticals in 2011 and served until its acquisition in 2017. He was a board member of rVue, a digital out-of-home media company from 2013 until 2016 and sat on the board of Social Growth Technologies from 2014 until its acquisition in 2016. Mr. Harrison was appointed to the board of directors of Zynerba Pharmaceuticals in 2015 serving as Chair of the Nominations and Corporate Governance Committee and as a member of the Compensation Committee until 2019 when he joined Merida Capital Partners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Mr. Harrison earned an LH.D and Masters of Science in cell biology from West Virginia University, and a Bachelor of Science in cell biology and physiology from Shepherdstown University. Mr. Harrison was selected to serve on our board of directors because of his extensive public company experience and his knowledge of the pharmaceutical industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Joseph C. Scodari &#8212; Director</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Mr. Scodari has served as our director since July 2021. Since October 2017, Mr. Scodari has served as Chairman of the Board of Directors of Optinose (Nasdaq: OPTN), a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (&#8220;ENT&#8221;) and allergy specialists. Mr. Scodari was previously Worldwide Chairman, Pharmaceuticals Group, of Johnson &amp; Johnson, and a member of Johnson &amp; Johnson&#8217;s Executive Committee from March 2005 until his retirement in March 2008. From  2003 to March 2005, Mr. Scodari was Company Group Chairman of Johnson &amp; Johnson&#8217;s Biopharmaceutical Business. Mr. Scodari joined Centocor in 1996 as President, Pharmaceutical Division and was named President and COO in 1998, a position that he served in until Conocor Inc.&#8217;s acquisition by Johnson &amp; Johnson in 1999.  Mr. Scodari began his career in 1974 in sales for Winthrop Laboratories, Division of Sterling Drug. He progressed through various management positions, eventually leading the Diagnostic Imaging Division for Winthrop and later Strategic Marketing at the corporate level for the Imaging business.  Mr. Scodari joined Rorer Pharmaceuticals (shortly thereafter, Rh&#244;ne-Poulenc Rorer) in 1989 as Vice President of Marketing and Business Development. He later served as Vice President and General Manager for the United States, and subsequently, North America, and finally as Senior Vice President and General Manager for the Americas. Mr. Scodari previously served as a director of Actelion Pharmaceuticals, Ltd., Endo Health Solutions, Inc. and Covance, Inc. Mr. Scodari has served on various non-profit boards, including the University of the Health Sciences in Philadelphia, the Board of Overseers for the Robert Wood Johnson School of Medicine, and on the Board of Trustees for Gwynedd Mercy College. He has also served on various industry association boards, including the NWDA Associate Member Board, the National Pharmaceutical Council, as Vice Chairman of the Biotechnology Industry Organization (&#8220;BIO&#8221;), and Chairman of PA BIO. Mr. Scodari received a B.A. from Youngstown State University. Mr. Scodari was selected to serve on our board of directors because of his extensive experience in the pharmaceutical industry.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jack H. Dean, Ph.D., Sc.D. (Hon.), DABT, Fellow ATS &#8212; Director</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Dr. Dean has served as our director since July 2021. He previously served as a director of our predecessor, Dipexium Pharmaceuticals (Nasdaq: DPRX), a pharmaceutical company focused on antibiotic drug development from October 2010 until its sale to PLx Pharma Inc. (Nasdaq: PLXP) in a merger valued at $69.0 million in April 2017. Since 2006, Dr. Dean has served as an advisor to the Executive Vice President of Drug Development for Sanofi, consulting on drug development strategy, drug safety issues and immunotoxicology through his company Drug Development Advisors, LLC where he serves as President. Dr. Dean is also a research professor in the departments of Medical Pharmacology and Pharmacology/ Toxicology, Colleges of Medicine and Pharmacy, at University of Arizona in Tucson. Prior to January 2006, Dr. Dean served as the President, U.S. Science and Medical Affairs (R&amp;D), Sanofi in Malvern, Pennsylvania and the Global Director of Preclinical Development for Sanofi. Dr. Dean joined Sterling Winthrop in 1988, as Director of the Department of Toxicology and was appointed Vice President, Drug Safety worldwide in 1989. In addition, Dr. Dean served as Director of the Sterling Winthrop Research Center in Alnwick, England from 1990 to 1992. Dr. Dean was appointed Executive Vice President, Drug Development, in 1992 where he managed Non-Clinical and Clinical Development, and Regulatory Affairs. Before joining Sterling Winthrop, Dr. Dean headed the Department of Cellular and Molecular Toxicology, Chemical Industry Institute of Toxicology, Research Triangle Park, NC from 1982 to 1988. Prior to 1982, he headed the Immunotoxicology Section, National Institute of Environmental Health Services and National Toxicology Program, NIH in Research Triangle Park. From 1972 to 1979, Dr. Dean was in the Department </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">of Immunology at Litton Bionetics (Department Director from 1975 to 1979) conducting research in tumor immunology. Dr. Dean holds a Bachelor of Science in microbiology and a Master of Science in medical microbiology from California State University at Long Beach. He earned a Ph.D. in molecular biology and minor in biochemistry in 1972 from the College of Medicine, University of Arizona. Dr. Dean held adjunct professorships at the University of North Carolina, Chapel Hill and Duke University from 1981 to 1988. Dr. Dean was selected to serve on our board of directors because of his extensive experience in the pharmaceutical industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">James Donohue &#8212; Director</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Mr. Donohue has served as our director since July 2021. Mr. Donohue has been a Vice President with Charles River Associates (Nasdaq: CRAI), a leading global consulting firm specializing in economic, financial, and management consulting services, since April 2004. Mr. Donohue has nearly 30 years of experience in valuation, damages, and forensic accounting. Mr. Donohue is a Certified Public Accountant (CPA) in Maryland and has a Bachelor of Science degree in Accountancy from Villanova University. He is also a Certified Valuation Analyst (CVA) and is Accredited in Business Valuation (ABV). Mr. Donohue was selected to serve on our board of directors because of his expertise in financial accounting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Robert Shawah &#8212; Chief Financial Officer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Mr. Shawah has served as our Chief Financial Officer since June 2021. Mr. Shawah previously served as our Chief Accounting Officer and Vice President of Finance from February 2018 to June 2021. Previously, Mr. Shawah served as Chief Accounting Officer of Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX) from 2014 until when Dipexium Pharmaceuticals was sold to PLX Pharma (Nasdaq: PLXP) in a merger valued at $69.0 million in April 2017. Further, Mr. Shawah has served as Vice President of Baldwin Pearson &amp; Co, Inc., a commercial real estate firm. From August 2018 to December 2018, Mr. Shawah served as a director for Ameri100, a software integration company. Mr. Shawah graduated from Bucknell University with a degree as a Bachelor of Science in Business Administration with a concentration in Accounting.</p><a id="_c659d856_4ae4_4a34_93db_284dee20e7a9"></a><a id="Item11ExecutiveCompensation_91664"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;11. Executive Compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The information required by this Item&#160;will be included in the 2023 Proxy Statement and is incorporated herein by reference.</p><a id="_d5f22649_1c21_4ee9_a8bf_18a64b896ce2"></a><a id="Item12SecurityOwnershipofCertainBenefici"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The information required by this Item&#160;will be included in the 2023 Proxy Statement and is incorporated herein by reference.</p><a id="_71feec5a_72ce_408b_8332_3669e935dc41"></a><a id="Item13CertainRelationshipsandRelatedTran"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The information required by this Item&#160;will be included in the 2023 Proxy Statement and is incorporated herein by reference.</p><a id="Item14PrincipalAccountingFeesandServices"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;14. Principal Accounting Fees and Services.</p><a id="_0ba57d81_d6eb_4f82_8a78_f28f44466bbd"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The information required by this Item&#160;will be included in the 2023 Proxy Statement and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d56eaa8c_98cc_4339_9253_81056aecf8ec"></a><a id="PARTIV_144597"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;IV</p><a id="Item15ExhibitsFinancialStatementSchedule"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;15. Exhibits, Financial Statement Schedules.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The financial statements filed as part of this Form&#160;10-K are listed in the Index to Financial Statements. Certain schedules are omitted because they are not applicable, or not required, or because the required information is included in the financial statements or notes thereto. The Exhibits are listed in Item&#160;15(b)&#160;below.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Exhibit&#160;Index.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:101.07%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:32.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed</b><br /><b style="font-weight:bold;">Herewith</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.4%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">by</b><br /><b style="font-weight:bold;">Reference</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">herein</b><br /><b style="font-weight:bold;">from Form&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">or</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Schedule</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.43%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing</b><br /><b style="font-weight:bold;">Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SEC File/</b><br /><b style="font-weight:bold;">Registration</b><br /><b style="font-weight:bold;">Number</b></p></th></tr><tr><td style="vertical-align:top;width:9.17%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1736243/000110465921072553/tm2111636d3_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Incorporation of Acurx Pharmaceuticals,&#160;Inc.</span></a></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/27/21</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-256516</p></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1736243/000110465921072553/tm2111636d3_ex3-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Bylaws of Acurx Pharmaceuticals,&#160;Inc.</span></a></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/27/21</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-256516</p></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1736243/000110465921072553/tm2111636d6_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Common Stock Certificate.</span></a></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/27/21</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-256516</p></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1736243/000110465922082266/tm2221625d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Series A Warrant</span></a></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/25/22</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-40536</p></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.3</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1736243/000110465922082266/tm2221625d1_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Series B Warrant</span></a></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/25/22</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-40536</p></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.4</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1736243/000110465922082266/tm2221625d1_ex4-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Pre-Funded Warrant.</span></a></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/25/22</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-40536</p></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.5</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1736243/000110465922082266/tm2221625d1_ex4-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Placement Agent Warrant.</span></a></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/25/22</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-40536</p></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.6</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="acxp-20221231xex4d6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Securities.</span></a></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1736243/000110465921072553/tm2111636d3_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Indemnification Agreement.</span></a></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/27/21</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-256516</p></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1736243/000110465921072553/tm2111636d3_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Warrant.</span></a></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/27/21</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-256516</p></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1736243/000110465921072553/tm2111636d6_ex10-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Common Stock Purchase Warrant.</span></a></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/27/21</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-256516</p></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.4</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1736243/000110465922082266/tm2221625d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Securities Purchase Agreement.</span></a></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/25/22</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-40536</p></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.5</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1736243/000110465921072553/tm2111636d3_ex10-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Investor Rights Agreement, by and between the Registrant and certain purchasers.</span></a></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/27/21</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-256516</p></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.5.1+</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1736243/000110465921072553/tm2111636d6_ex10-9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Acurx Pharmaceuticals,&#160;Inc. 2021 Equity Incentive Plan</span></a></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/27/21</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-256516</p></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.5.2+</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1736243/000110465921093551/tm2122419d1_ex99-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Stock Option Agreement under the 2021 Equity Incentive Plan.</span></a></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-8</p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/21</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-258026</p></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.5.3+</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1736243/000110465921093551/tm2122419d1_ex99-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Restricted Stock Agreement under the 2021 Equity Incentive Plan.</span></a></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-8</p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/21</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-258026</p></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.5.4+</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1736243/000110465921093551/tm2122419d1_ex99-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Recapitalization Exchange Option Agreement.</span></a></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-8</p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">07/19/21</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-258026</p></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.6+</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1736243/000110465921072553/tm2111636d6_ex10-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Employment Agreement, by and between Acurx Pharmaceuticals,&#160;Inc. and Robert J. DeLuccia, dated May&#160;25, 2021.</span></a></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/27/21</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-256516</p></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.7+</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1736243/000110465921072553/tm2111636d6_ex10-7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Employment Agreement, by and between Acurx Pharmaceuticals,&#160;Inc. and David P. Luci, dated May&#160;25, 2021.</span></a></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/27/21</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-256516</p></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.8+</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1736243/000110465921072553/tm2111636d6_ex10-8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Employment Agreement, by and between Acurx </span></a></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/27/21</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-256516</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;table-layout:auto;width:101.07%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:32.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed</b><br /><b style="font-weight:bold;">Herewith</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.4%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">by</b><br /><b style="font-weight:bold;">Reference</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">herein</b><br /><b style="font-weight:bold;">from Form&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">or</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Schedule</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.43%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing</b><br /><b style="font-weight:bold;">Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SEC File/</b><br /><b style="font-weight:bold;">Registration</b><br /><b style="font-weight:bold;">Number</b></p></th></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1736243/000110465921072553/tm2111636d6_ex10-8.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pharmaceuticals,&#160;Inc. and Robert Shawah, dated May&#160;25, 2021.</span></a></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.9</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1736243/000110465921072553/tm2111636d3_ex10-10.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Master Clinical Services Agreement, dated October&#160;11, 2019, by and between Acurx Pharmaceuticals,&#160;Inc. and Syneos Health,&#160;LLC.</span></a></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/27/21</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-256516</p></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.10#</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1736243/000110465921072553/tm2111636d6_ex10-11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Asset Purchase Agreement, dated February&#160;5, 2018, by and between Acurx Pharmaceuticals,&#160;Inc. and GLSynthesis&#160;Inc.</span></a></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/27/21</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-256516</p></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">21.1</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="acxp-20221231xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Subsidiaries</span></a></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">23.1</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="acxp-20221231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of CohnReznick&#160;LLP.</span></a></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31.1</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="acxp-20221231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of the Principal Executive Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31.2</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="acxp-20221231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of the Principal Financial Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32.1</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="acxp-20221231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section&#160;1350, as Adopted Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32.2</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="acxp-20221231xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section&#160;1350, as Adopted Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.INS</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">Inline XBRL Instance Document&#160;- the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.SCH</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Schema Document</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.CAL</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.DEF</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.LAB</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.PRE</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.17%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">Cover Page&#160;Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit)</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:top;width:2.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.1%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.43%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.92%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">#</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Certain confidential portions of this Exhibit&#160;were omitted by means of marking such portions with brackets (&#8220;[***]&#8221;) because the identified confidential portions (i)&#160;are not material and (ii)&#160;would be competitively harmful if publicly disclosed.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:0.5pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:26.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">+</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Denotes management compensation plan or contract.</p></td></tr></table><a id="_a3c776fb_3ed0_45cd_afa4_264b75f5bb31"></a><a id="Item16Form10KSummary_406457"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;16. Form&#160;10-K Summary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_8b35f26f_3337_4c9a_9fd3_7c552a575a33"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized<b style="font-weight:bold;">.</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">ACURX PHARMACEUTICALS, INC.</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Date: March 15, 2023</p></td><td style="vertical-align:top;width:5.7%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:44.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">/s/ David P. Luci</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.7%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:44.29%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">David P. Luci</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.7%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">President and Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.53%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:bottom;width:2.16%;border-bottom:1px solid transparent;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.58%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:bottom;width:2.16%;border-bottom:1px solid transparent;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.55%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.53%;border-top:1px solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.58%;border-top:1px solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.55%;border-top:1px solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:34.53%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ David P. Luci</p></td><td style="vertical-align:bottom;width:2.16%;border-bottom:1px solid transparent;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.58%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">President, Chief Executive Officer and Director</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.55%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;15, 2023</p></td></tr><tr><td style="vertical-align:top;width:34.53%;border-top:1px solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">David P. Luci</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:44.58%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(Principal Executive Officer)</i></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;white-space:nowrap;width:16.55%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:34.53%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.58%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.55%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:34.53%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Robert G. Shawah</p></td><td style="vertical-align:bottom;width:2.16%;border-bottom:1px solid transparent;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.58%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chief Financial Officer</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.55%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;15, 2023</p></td></tr><tr><td style="vertical-align:top;width:34.53%;border-top:1px solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Robert G. Shawah</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:44.58%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(<i style="font-style:italic;">Principal Accounting Officer and Principal Financial Officer</i>)</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;white-space:nowrap;width:16.55%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:34.53%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.58%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.55%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:34.53%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Robert J. DeLuccia</p></td><td style="vertical-align:bottom;width:2.16%;border-bottom:1px solid transparent;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.58%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Executive Chairman </p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.55%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;15, 2023</p></td></tr><tr><td style="vertical-align:top;width:34.53%;border-top:1px solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Robert J. DeLuccia</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:44.58%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.55%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:34.53%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.58%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.55%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:34.53%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Carl V. Sailer</p></td><td style="vertical-align:bottom;width:2.16%;border-bottom:1px solid transparent;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.58%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.55%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;15, 2023</p></td></tr><tr><td style="vertical-align:top;width:34.53%;border-top:1px solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Carl V. Sailer</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:44.58%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.55%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:34.53%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.58%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.55%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:34.53%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Joseph C. Scodari</p></td><td style="vertical-align:bottom;width:2.16%;border-bottom:1px solid transparent;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.58%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.55%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;15, 2023</p></td></tr><tr><td style="vertical-align:top;width:34.53%;border-top:1px solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Joseph C. Scodari</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:44.58%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.55%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:34.53%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.58%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.55%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:34.53%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Thomas Harrison</p></td><td style="vertical-align:bottom;width:2.16%;border-bottom:1px solid transparent;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.58%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.55%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;15, 2023</p></td></tr><tr><td style="vertical-align:top;width:34.53%;border-top:1px solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thomas Harrison</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:44.58%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.55%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:34.53%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.58%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.55%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:34.53%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jack H. Dean</p></td><td style="vertical-align:bottom;width:2.16%;border-bottom:1px solid transparent;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.58%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.55%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;15, 2023</p></td></tr><tr><td style="vertical-align:top;width:34.53%;border-top:1px solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jack H. Dean</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:44.58%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.55%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:34.53%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.58%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.55%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:34.53%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ James Donohue</p></td><td style="vertical-align:bottom;width:2.16%;border-bottom:1px solid transparent;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.58%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.55%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;15, 2023</p></td></tr><tr><td style="vertical-align:top;width:34.53%;border-top:1px solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">James Donohue</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:44.58%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.55%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_84e9a8d2_221c_437b_b873_b3d6f266cb94"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">INDEX TO FINANCIAL STATEMENTS</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:bottom;width:88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 1pt;"><b style="font-weight:bold;">Years Ended December 31, 2022 and 2021</b></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:bottom;width:88%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><a href="#REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (PCAOB ID: 596)</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.71%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-2</p></td></tr><tr><td style="vertical-align:bottom;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><a href="#BALANCESHEETS_523353"><span style="font-style:normal;font-weight:normal;">Balance Sheets</span></a></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-3</p></td></tr><tr><td style="vertical-align:bottom;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><a href="#STATEMENTSOFOPERATIONS_417592"><span style="font-style:normal;font-weight:normal;">Statements of Operations</span></a></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-4</p></td></tr><tr><td style="vertical-align:bottom;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><a href="#STATEMENTSOFCHANGESINMEMBERSANDSHAREHOLD"><span style="font-style:normal;font-weight:normal;">Statements of Changes in Members&#8217; and Shareholders&#8217; Equity</span></a></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-5</p></td></tr><tr><td style="vertical-align:bottom;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><a href="#STATEMENTSOFCASHFLOWS_204474"><span style="font-style:normal;font-weight:normal;">Statements of Cash Flows</span></a></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-6</p></td></tr><tr><td style="vertical-align:bottom;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><a href="#NOTESTOTHEFINANCIALSTATEMENTS_553029"><span style="font-style:normal;font-weight:normal;">Notes to the Financial Statements</span></a></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-7</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8d63edcf_d409_4c9a_8899_3f6fe480e6d9"></a><a id="REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">To the Board of Directors and Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Acurx Pharmaceuticals, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Opinion on the Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:6pt 0pt 0pt 0pt;">We have audited the accompanying balance sheets of Acurx Pharmaceuticals, Inc. (the &#8220;Company&#8221;) as of December 31, 2022 and 2021, and the related statements of operations, changes in members&#8217; and shareholders&#8217; equity and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021 and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">The Company&#39;s Ability to Continue as a Going Concern</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:6pt 0pt 0pt 0pt;"><span style="white-space:pre-wrap;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern.  As discussed in Note 1 to the financial statements, the Company has incurred recurring losses from operations since inception and has stated that substantial doubt exists about the Company&#39;s ability to continue as a going concern.  Management&#39;s evaluation of the events and conditions and management&#39;s plans regarding these matters are also described in Note 1.  The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Basis for Opinion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:6pt 0pt 0pt 0pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:6pt 0pt 0pt 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:6pt 0pt 0pt 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:6pt 0pt 0pt 0pt;">We have served as the Company&#8217;s auditor since 2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:6pt 0pt 0pt 0pt;">/s/ CohnReznick LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Parsippany, New Jersey</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">March 15, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_769dc9e5_8890_411f_ad2c_1a0875e0c622"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">ACURX PHARMACEUTICALS, INC.</p><a id="BALANCESHEETS_523353"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">AS OF DECEMBER 31, 2022 and 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_f8c113a8_d7c1_4557_8382_163be8c217e6"></a><a id="Tc_7EA_7hO55kKPk2kvNyYyfw_1_2"></a><a id="Tc_mK1tYSB2KkGCERiDzVBaiQ_1_5"></a><a id="Tc_hS-TYFx6jke8hmNWR9W4ew_2_2"></a><a id="Tc_D1Vc-CLb1kWuM7jPhcIjog_2_5"></a><a id="Tc_OqnuVaSqxkCBAhNPYU1ESA_4_0"></a><a id="Tc_rSd3WiWy0UWH97VILCgfnQ_6_0"></a><a id="Tc_1a9ULt-hHE-3R6WsrqSgNw_7_0"></a><a id="Tc_jMwwUPgRzUGFNWwb49eU2g_7_2"></a><a id="Tc_oqZCRTQo7E2pElWgMDJ2yA_7_5"></a><a id="Tc_fImBJJARkU-wgioWrEc9MA_8_0"></a><a id="Tc_z36ZvZ-tUUuvmKVIS8RGvQ_9_0"></a><a id="Tc_xHgbArDJfE6B79StHvOuoQ_9_2"></a><a id="Tc_Pm8ROjUAE0G7YX1CbAujOQ_9_5"></a><a id="Tc_ZkrgSpApRkaL6-sVGeXiKQ_11_0"></a><a id="Tc_Xq2GSN5wO06UvoFRCXOgGg_13_0"></a><a id="Tc_-s-4R4m7BEGLfiqjwd5a6w_14_0"></a><a id="Tc_APmWlRe5j0qPFgeJuqoeuQ_14_2"></a><a id="Tc_mwMVOAgZ9U-g00wUSGNHuw_14_5"></a><a id="Tc_1GfjEUIDjkiRWaaJETVdkA_15_0"></a><a id="Tc_pSIGZfLxh0qAk0RC5MjXHw_17_0"></a><a id="Tc_ZutqXHrJjUKCvkCmfxRShA_19_0"></a><a id="Tc_gyoMhIRRpUOvjUpIBSDBSQ_21_0"></a><a id="Tc_HI_e8zEEkE6TIkQbqUcCvA_22_0"></a><a id="Tc_Rb86W04AvEWoN9HPnVtRsA_23_0"></a><a id="Tc_l9HGeyAxRkGxW-ouXynEoQ_24_0"></a><a id="Tc_OLPrfMl310-7ivs3Pm4QKQ_25_0"></a><a id="Tc_O6m1Q2i7JEiYQwVjAzuBhQ_26_0"></a><a id="Tc_27uh8-JsgE22NThVx95rdg_28_0"></a><a id="Tc_aM997U1ZC0yUzFaL4d6XPQ_30_0"></a><a id="Tc_LokXEWxEqk-euM1r5i7Uhg_30_2"></a><a id="Tc_2AcH5IAb60GNqIW9mzzQ9w_30_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ASSETS</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CURRENT ASSETS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="0" id="Tc_BB-AxLiX3UGFMk3oi7heUw_7_3">9,111,751</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="0" id="Tc_iNX1tgjQvkyjRYrGfYTaJA_7_6">12,958,846</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Prepaid Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" id="Tc_RatL04oMgUq3Uorcwa1UGg_8_3">264,955</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" id="Tc_qvJhMPbDS0G9rAnv5D7y9g_8_6">295,304</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">TOTAL ASSETS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_Fy2UC94FzU6mOVlAro9ZLw_9_3">9,376,706</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_d705WBIW5U2OlPmO84SU7Q_9_6">13,254,150</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">LIABILITIES AND MEMBERS&#39; AND SHAREHOLDERS&#8217; EQUITY</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CURRENT LIABILITIES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts Payable and Accrued Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="Tc_Cac6AhHj5UqYB5qW7b7Rfg_14_3">2,061,685</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="Tc_31v1ostg2kakB5CDlpNiTA_14_6">843,909</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">TOTAL CURRENT LIABILITIES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_9F1-2VCpu0Son5Oyn6DSdg_15_3">2,061,685</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_4-Ik8Fjmf06AUEZYuZsj1w_15_6">843,909</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">TOTAL LIABILITIES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_fH7ZbJ0mCEWMtNu3KFLZPQ_17_3">2,061,685</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_bNK6xiwPXEGqBezEg5K37A_17_6">843,909</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COMMITMENTS AND CONTINGENCIES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">MEMBERS&#39; AND SHAREHOLDERS&#39; EQUITY</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Members&#8217; Equity, Class A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_CjhtDG9o-0eHLcphgHG_2Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_z-cA2B_zx0afjyItvPH4_Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Members&#8217; Equity, Class B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_1vP5TIDe006NnCGIW5-y5Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_clbq5dV84UWgpftBSE5TLw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common Stock; $<ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_Lbar9G-8OUeEkkO7ooRzig"><ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_DHKGlpxTwEWv_VDKTPvsAQ">.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_9FoVDLHZu0KkBv6lGujtwQ"><ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_CcDq2ynyMk2Srd5qOXgh-w">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_VkWQZ7Z5kkOhDKErdCwcBg">11,627,609</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_KCbMvC9HoUa-fFFGh_aaGA">10,215,792</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_7GDmEFwfuUmQonB5fSquiQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_hn7L1KzQWEKv4ikJD9PDqA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> at December&#160;31,&#160;2022 and 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_IMJ4_tzQLUS1HlLCnsrNyQ_24_3">11,628</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_9Dk58kYJ4UeiP11bhfiCKg_24_6">10,216</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additional Paid-In Capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_CMGooX_pbEanj-QcHFNhvA_25_3">45,944,478</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_v3HzWjxLZUy5h7UiqJNB-w_25_6">38,948,334</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated Deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_JUoBhOQ1V0iQC9EQLNqcZw_26_3">38,641,085</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_upPBgoH-NEm7t6XmLm71mQ_26_6">26,548,309</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">TOTAL MEMBERS&#39; AND SHAREHOLDERS&#8217; EQUITY</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_uZZ2jFZM406kMO4sJnEdEA_28_3">7,315,021</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_YI03XrFWlUKYo7iCUbk3Zg_28_6">12,410,241</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TOTAL LIABILITIES AND MEMBERS&#39; AND SHAREHOLDERS&#8217; EQUITY</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_t4VXjwdHzEilbXAnd03UyQ_30_3">9,376,706</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_vCfb6syQ9EW8g7yGQnPEVw_30_6">13,254,150</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">See accompanying notes to the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f1e88a91_892f_4c70_af53_e4bdd812ca7d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">ACURX PHARMACEUTICALS, INC.</p><a id="STATEMENTSOFOPERATIONS_417592"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">STATEMENTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">YEARS ENDED DECEMBER 31, 2022 AND 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_d5df1c87_3e9b_4d55_bf70_e93e938d9939"></a><a id="Tc_BESvftjVCUKWP10kJhWMQQ_3_2"></a><a id="Tc_j8JR9rfN-0C9e0e_cuFodA_3_5"></a><a id="Tc_P965T6rP0kyICszHAtkG2g_5_0"></a><a id="Tc_WdggDuMlMkSBRBE_md3bzA_6_0"></a><a id="Tc_LM8blW2XtkydUE9bAEfI_A_6_2"></a><a id="Tc_O4bJFe2Uyk2HunXbxIGGQg_6_5"></a><a id="Tc_lPTG9Hs9-EeCwWzEWuIZrg_7_0"></a><a id="Tc_yvB2Tt3Z60-wLj6NOH-NKQ_9_0"></a><a id="Tc_zp2Y4G8QD0izfijOxL1yzw_11_0"></a><a id="Tc_kfSkkmYwskCKex9tNG0y6w_11_3"></a><a id="Tc_6SDQX50Q50mJzPeUlTXkVA_13_0"></a><a id="Tc_DKV72Es7Jk6wjjs-RkFDmw_13_2"></a><a id="Tc_Ez6ZBjhFaUCk_C5I1Sf9qg_13_5"></a><a id="Tc_VGsJXkkHRk-3ZpkOJTwpPg_15_0"></a><a id="Tc_ZpGJFgu7xkaxm0xW4NJJDg_16_0"></a><a id="Tc_ApSLlVuwu06DxXntKn4PTA_16_2"></a><a id="Tc_ie-UKa3dwES2mz91R7E_Dw_16_5"></a><a id="Tc_IUGdXUy1qUKBvzr0kkw6mA_18_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2021</p></td></tr><tr><td style="vertical-align:bottom;width:72.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">OPERATING EXPENSES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and Development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_lv6uEQlXBkmPy39ISUAEhg_6_3">4,754,271</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_x_0jrJhPfkOvIMz_wtwqog_6_6">2,030,177</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and Administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_rVV5Kx1tPEmIkIcdqz1ebg_7_3">7,338,505</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_LYcX-h6FvEiCQ5CQ7DyeLA_7_6">10,784,023</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">TOTAL OPERATING EXPENSES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_LHG8VslPjEaSrVr3jTuBRA_9_3">12,092,776</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_fhmxJk3OKEaoCu1Jo1-mXQ_9_6">12,814,200</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gain on Forgiveness of Paycheck Protection Program Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="Tc_q1Gz_IIEZUuQmyJHwt3ixQ_11_6">66,503</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">NET LOSS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_SfbKLyKDo0uDa8m1Q8wrvA_13_3">12,092,776</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_ADgPtfHI1U6Q8IP4fNTCDw_13_6">12,747,697</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">LOSS PER SHARE</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_PG7F54kU10yovPamns1wnw_16_3">1.12</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_D38B5ESFNEGXh7dm8wTgCw_16_6">1.49</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average common shares outstanding basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_E9Rkq9WeSEa4GPoqyPvQ0Q_18_3">10,816,412</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc__HFK1niRfUu0Ta8xQws2hg_18_6">8,535,873</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">See accompanying notes to the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_759280da_63bb_4cfb_b10e_3844d0074500"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">ACURX PHARMACEUTICALS, INC.</p><a id="STATEMENTSOFCHANGESINMEMBERSANDSHAREHOLD"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">STATEMENTS OF CHANGES IN MEMBERS&#8217; AND SHAREHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">YEARS ENDED DECEMBER 31, 2022 AND 20201</p><a id="_6f8d39c8_fcb9_4d57_9b45_c6d7bc4caaf6"></a><a id="Tc_v_MPSaSLoUuBAJfGd7ke4Q_1_2"></a><a id="Tc_d0zGPaQ6L0eAKQyctiuWmA_1_7"></a><a id="Tc_VnLn6HvO9EyiH9eamSVuZQ_2_2"></a><a id="Tc_LKu0IG4yzk-myMaj1tjfgw_2_7"></a><a id="Tc_QB-dXzD900Wx9tega-fGxw_2_12"></a><a id="Tc_BLiy--Ximk6ANWpPSuoVvg_2_24"></a><a id="Tc_tGUHI7KLq0uhqhmPtt7pwA_3_18"></a><a id="Tc_bW715Lzbf0i6PszWhWzGvw_3_24"></a><a id="Tc_B5PHBtkCeEaO8kd08IX4WA_4_2"></a><a id="Tc_AjcUkccTsUaUaKb0aEfPMw_4_7"></a><a id="Tc_DfsX7t3DTESyd5dYSVB_rQ_4_18"></a><a id="Tc_iNuwFmiiJUmMusZr1MbPFQ_4_21"></a><a id="Tc_-xuwpxKpr0CiqxFBRRW-FQ_4_24"></a><a id="Tc_1QhPhbEtW0iqITb7JpywdA_5_2"></a><a id="Tc_FIL-vrwFp0u7DwP76Pzukw_5_4"></a><a id="Tc_JLZYVPFV2kKYSBQ735BIqQ_5_7"></a><a id="Tc_uimnfs3VJEaHeEYxzCRcgQ_5_9"></a><a id="Tc_mmQQKJgzvUi14Jsxvlti0g_5_12"></a><a id="Tc_xbmQDkr9OEax6-t_1IM8ZQ_5_15"></a><a id="Tc_E_ASeJuFOUuFyjZ5BDIaxg_5_18"></a><a id="Tc_XlAABjXPt0-ryyplf3d9hw_5_21"></a><a id="Tc_7lZSYA0730u5WdIXmlBTyw_5_24"></a><a id="Tc_DqRe4sp7ckKmuJ4s1Wnxeg_6_0"></a><a id="Tc_zSBJe25fVEOCq2ugGpPEcw_6_4"></a><a id="Tc_jEdsFhzSfkqZowu0TqbLmw_6_9"></a><a id="Tc_uHJKXz90R0y-P6ibqMSTUg_6_12"></a><a id="Tc_MvX-4T_I_0-Qwj3OHLVuVg_6_14"></a><a id="Tc_rgCRrM-OsUascqOUBmOSFg_6_15"></a><a id="Tc_MMGgAFpE90-SH9AEyEv5GQ_6_17"></a><a id="Tc_ijo1aZBsoE2Sz9LV89f94Q_6_18"></a><a id="Tc_SyCOwrEFSk6VDTxdFBzbBw_6_20"></a><a id="Tc_-BhzzHQ-T0qc2zMUtz6_-Q_6_23"></a><a id="Tc_EZZCziDJ8EOwoguUGNCs5A_7_0"></a><a id="Tc_Ol2U4Bp2EkGJvM6Mcg0fgQ_7_12"></a><a id="Tc_019u1Z8L_EybJJMwApB0ZA_7_15"></a><a id="Tc_ON4tiNRlJ0OsqH8LEsPjAA_7_18"></a><a id="Tc_22LABRelbk6_NmEo3eM5Fw_7_21"></a><a id="Tc_iJ03uQkFXkKspQVMytpfXw_8_0"></a><a id="Tc_YNiEZOM_LE2g0T38Zam1UA_8_2"></a><a id="Tc_SUTjioo_2E-PfDt-rahqmQ_8_5"></a><a id="Tc_y6Nt8uRVREKuq8tnOaMLQg_8_10"></a><a id="Tc_kQO30pZBN060ziH-sBhwuw_8_12"></a><a id="Tc_IUz4frCaw0KSku_oh_f48A_8_15"></a><a id="Tc_R09cpdStjU6npJvy0tXpnw_8_18"></a><a id="Tc_Y6EISBQLE0mYTrTas_7w_Q_8_21"></a><a id="Tc_zRmrLxqcR0--fKcysFyseA_8_24"></a><a id="Tc_FZ3ruOELI06oMyDcn0i3_g_9_0"></a><a id="Tc_rb0bUDQRY0qHk2u9x8BQnA_9_7"></a><a id="Tc_1nKP9f5qCki4X7mwoB6-ng_9_10"></a><a id="Tc_Vwk_6qtcPEyY0ySYkHXpuw_9_12"></a><a id="Tc_4mQn4pStx02foapbC1PvDA_9_15"></a><a id="Tc_CvHST8kDUk6K9HQw8TNGDQ_9_21"></a><a id="Tc_OYi8PAxxeEunWS_L1HKGlw_10_0"></a><a id="Tc_-p2rCT5Zq0iWdwEsHpBccw_10_7"></a><a id="Tc_30U5gyHYs0iqP5ZZNDwQ5A_10_10"></a><a id="Tc_9IH_oi0SY0uk-NWKW-YNjg_10_21"></a><a id="Tc_beVAVSpiGUigzeY57pILPA_11_0"></a><a id="Tc_RgyVnh43mkmHdXJ5w8oIIw_11_21"></a><a id="Tc_GjV-gbSkvkCbOAQXkgMTDw_11_24"></a><a id="Tc_Aj8sveCLeU-5WQpnZ1XvdA_12_0"></a><a id="Tc_6feyqjjjMkqLV4L3wf7wOA_12_2"></a><a id="Tc_o3xXqVCipEm4JOgyk2L18Q_12_5"></a><a id="Tc_ybF4adcPHUGFBkNJcCGy-A_12_7"></a><a id="Tc_z2WgEC82KkWwbsX1iU1Naw_12_10"></a><a id="Tc_aUHb-HKQwUC6RFwlRv0k9A_12_21"></a><a id="Tc_va10CirUKU-jbjbwrCNsrg_13_0"></a><a id="Tc_XYJAFVtypE2MZlPZ9pSGPA_13_2"></a><a id="Tc_Pv7eR0U6HUeY2YO59tbnVA_13_5"></a><a id="Tc_Jh_XRQ-6y0uRypeuO67JpA_13_7"></a><a id="Tc_Dz-qX3j2oE2X7DtKoEiuiA_13_10"></a><a id="Tc_rx1aqnn910yjg8RgFHlt7Q_13_12"></a><a id="Tc_ilnzL7esrU-aVuho5-7qog_13_15"></a><a id="Tc_izF9-E2EBUK0WXfbXEMdzA_13_18"></a><a id="Tc_sZvmKHRl-0OIKug6mPHTrg_14_0"></a><a id="Tc_GWqW1rCLrUi0l9_ICF3Grw_14_2"></a><a id="Tc_KA3qhJyJIkGUeMKh0cCNXQ_14_5"></a><a id="Tc_7FlL_Pm7mECdvIS3dBWoIA_14_7"></a><a id="Tc_LBrJkm4Ff0Kf0B4DjjZOXA_14_10"></a><a id="Tc_3XZONxyAR0O3te5j-sRw6A_15_0"></a><a id="Tc_nF-wGU0mgUyJotXCp_Gq1Q_15_2"></a><a id="Tc__1IrdknLBkS1ZJgzJAlXDw_15_5"></a><a id="Tc_GFVdZnFJrk2QbRuKjQq_Gg_15_7"></a><a id="Tc_68BNQJUJBEWcA7Xyy1DN9A_15_10"></a><a id="Tc_IM-x5-NCckOgVdq4KRfzUQ_15_12"></a><a id="Tc_VwgMz5ECekKbos1BnroW7w_15_15"></a><a id="Tc_WHJ91T0xy02baFXdK3-Bjw_15_21"></a><a id="Tc_7keaskzEpUCu73hk5z2j3w_16_0"></a><a id="Tc_6QDhk69Jh06XzrOMRuJFKw_16_2"></a><a id="Tc_8E0RpSB2UU-jtA4ijSfBAA_16_5"></a><a id="Tc_75e__vYvN0u6c_zLQKxHjg_16_7"></a><a id="Tc_OsrBCTeIF0m84QEAb3wJiw_16_10"></a><a id="Tc_d9u7bUIdzkqUDNA07stmmw_16_21"></a><a id="Tc_IeLVr5H5Skq80sgLoHNpAg_17_0"></a><a id="Tc_-WsPQkSyQU2RUQ2D8P_cGw_17_2"></a><a id="Tc_ZCJgWTQF2kSfIweOv_lpPg_17_5"></a><a id="Tc_fHh2xsexpEqMKfTzUHbj2Q_17_7"></a><a id="Tc_iwkWjPpxdkuNSh7LRO0oMw_17_10"></a><a id="Tc_x5Bo28glWkW7BQzSf5M7_g_17_21"></a><a id="Tc_h4KlwMtuUEGIu-1wgYzUYg_18_0"></a><a id="Tc_kEvUlbxd60qTVVX7OJjLkA_18_2"></a><a id="Tc_-zR2FiGgRkqAx-YALaIHJg_18_5"></a><a id="Tc_V8ZODXpAuEmiB8D1EKvtvg_18_7"></a><a id="Tc_uy1PxWrIYkGortp1a7o2AQ_18_10"></a><a id="Tc_2KcNgRraiEaIUmfNxghsbg_18_21"></a><a id="Tc_WgQcD7GUnUC2Kk-bJbL87g_18_24"></a><a id="Tc_f7K8tJGTlEWuZTdXBUxP7g_19_0"></a><a id="Tc_mVMhdw7TuE6L-HuVikQAiA_19_2"></a><a id="Tc_QtbC1HowEEm_x1QbUJowbw_19_5"></a><a id="Tc_Kseq1TSu1kGOAsKG0tlrGA_19_7"></a><a id="Tc_Ivi_YIl3oUOa_7biDHMbbA_19_10"></a><a id="Tc_m7s_VewOh0qPJjjgfIIhNw_19_21"></a><a id="Tc_U8szZXfBykKFKU1Kt6Pe_g_20_0"></a><a id="Tc_nY0ytbEFSUi0WQiVUQK7zw_20_2"></a><a id="Tc_unX23isg50CYI-Pt6qzpLg_20_5"></a><a id="Tc_TRWNSzo2zEmW_HxnIjI8dA_20_7"></a><a id="Tc_zgFxseISwEmNh7EBnKbA5A_20_10"></a><a id="Tc_b85VLck7kUKhyvdqjhL0Pw_20_12"></a><a id="Tc_CKcQj03Xy0udCrV3YLYKqQ_20_15"></a><a id="Tc_MynRfqI4IE-EPG-ITXFJ2g_20_18"></a><a id="Tc_lf_ItArkMEuQJNgTtnWSIw_21_0"></a><a id="Tc_ZVl-UhotqEmF1Qscxar5cQ_21_2"></a><a id="Tc_KFPCH03r402pWpx_7-0fiw_21_4"></a><a id="Tc_M0xLvo9zbk2TCbnrCKaaZQ_21_5"></a><a id="Tc_FX4fkXQBH0qSau5EdTYvdw_21_7"></a><a id="Tc_Z3qXRpJhHk63pzgWwki4rA_21_9"></a><a id="Tc_7jWINvLYk0yqewXeJbAo-g_21_10"></a><a id="Tc_qpKiVH33HU-FzyA9fkothw_21_14"></a><a id="Tc_Ss4UzbgUF0KyExTyngb99w_21_17"></a><a id="Tc_NnB4n_7IfU6jBQGopY-5ow_21_20"></a><a id="Tc_X0XHEDsle0OOaChX5wKIHA_21_23"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:25.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Class&#160;A&#160;Membership&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Class&#160;B&#160;Membership&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">    <span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Interests</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Interests</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:13.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">Total</p></td></tr><tr><td style="vertical-align:bottom;width:25.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">Additional</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">Members&#8217;</p></td></tr><tr><td style="vertical-align:bottom;width:25.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 48pt;"><span style="font-size:6pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">Number of</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">Number&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">Paid-In</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">Accumulated</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">&#160;and&#160;Shareholders&#8217;</p></td></tr><tr><td style="vertical-align:bottom;width:25.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:6pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"> Units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">Amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">of&#160;Units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">Amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">Amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">&#160;Capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">Deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">&#160;Equity</p></td></tr><tr><td style="vertical-align:bottom;width:25.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Balance at January 1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_27b4PKohgEW2UtRdiEuquw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonUnitOutstanding" scale="0" id="Tc_9NORdN3MTk26klxefcrxWQ_6_2">13,493,807</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_27b4PKohgEW2UtRdiEuquw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_uENOgUswtEaNLyTtbnFILg_6_5">16,402,198</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_vRcsmNgV3Eq09f5ms-XUQQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonUnitOutstanding" scale="0" id="Tc_s0ffuAGVDEyk5xqZ6Uxv2A_6_7">100,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_vRcsmNgV3Eq09f5ms-XUQQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_Xa3WsUseqEC6VqNfb5S6NA_6_10">100,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_XyHsu6ymoke-MXFBVwUwUQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_NVLDynPPvE2Uzx0Jl-pJ-g_6_21">13,800,612</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2020_GjIfeLZ3Ck689XNTpPYicQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_x5nM851HGEKNwmbqAEFkig_6_24">2,701,586</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;">Executive Compensation Settled with Membership Interests</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_NHdyZ3imJk-CuOuyJfGKCQ" decimals="INF" format="ixt:numdotdecimal" name="acxp:StockUnitsIssuedDuringPeriodSharesExecutiveCompensationSettled" scale="0" id="Tc_Qj9kun2T4UezZ3wGzwwBdA_7_2">57,430</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_NHdyZ3imJk-CuOuyJfGKCQ" decimals="0" format="ixt:numdotdecimal" name="acxp:StockUnitsIssuedDuringPeriodValueExecutiveCompensationSettled" scale="0" id="Tc_MUSdJNdQGUuMi5aEvMjvdA_7_5">186,650</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_YaTMIktqsk6w51g7L20gNQ" decimals="INF" format="ixt:numdotdecimal" name="acxp:StockUnitsIssuedDuringPeriodSharesExecutiveCompensationSettled" scale="0" id="Tc_I0BaRZHZ1UKgUAdFyFvoAQ_7_7">471,042</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_YaTMIktqsk6w51g7L20gNQ" decimals="0" format="ixt:numdotdecimal" name="acxp:StockUnitsIssuedDuringPeriodValueExecutiveCompensationSettled" scale="0" id="Tc_LjfGSfxy_0i0fEq9aCZuWQ_7_10">730,115</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="0" format="ixt:numdotdecimal" name="acxp:StockUnitsIssuedDuringPeriodValueExecutiveCompensationSettled" scale="0" id="Tc_Tp4VT1Lc-0GqqE1rWyid6A_7_24">916,765</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;">Cancellation of Class B Issuance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_YaTMIktqsk6w51g7L20gNQ" decimals="INF" format="ixt:numdotdecimal" name="acxp:CancellationOfStockUnitsShares" scale="0" id="Tc_Tb40Krhi1EerIOBJjGnCLw_8_7">471,042</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:25.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;">Share-Based Compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_NHdyZ3imJk-CuOuyJfGKCQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="Tc_B-eSILxrwk2w1Ec5dFYhfQ_9_2">400,936</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_NHdyZ3imJk-CuOuyJfGKCQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="0" id="Tc_Jx-NAzkC4kubiczxMtT9xA_9_5">755,556</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bAx1kdchGkS4wq4G6E6-eA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="0" id="Tc_4mjRzJbXXUGEExwCJ41-VA_9_18">4,399,158</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="0" id="Tc_30OubhT270OwKxHPRqmvnQ_9_24">5,154,714</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;">Share-Based Payments to Vendors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_NHdyZ3imJk-CuOuyJfGKCQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="Tc_WprY4jdsl06SgWZMa2ilTw_10_2">30,145</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_NHdyZ3imJk-CuOuyJfGKCQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_56f-bi4A_0Gx2JjtOeCtyg_10_5">172,971</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_po048zYXXkK5B_bKRi3sOQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="Tc_0iJBznJCakOn_VTpK2loKA_10_12">299,584</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_po048zYXXkK5B_bKRi3sOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_7noU_ySMO06-3HWzhWDhbQ_10_15">300</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bAx1kdchGkS4wq4G6E6-eA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_NcIeBl0i-UW1roEcFo968Q_10_18">1,414,470</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_X0H2kdDJAE-zQe_jv0cZzA_10_24">1,587,741</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;">Corporate Conversion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_NHdyZ3imJk-CuOuyJfGKCQ" decimals="INF" format="ixt:numdotdecimal" name="acxp:StockIssuedDuringPeriodSharesCorporateConversionOfUnits" scale="0" id="Tc_EPfJgw76qEK8NF8gsYZ_qA_11_2">13,982,318</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_NHdyZ3imJk-CuOuyJfGKCQ" decimals="0" format="ixt:numdotdecimal" name="acxp:StockIssuedDuringPeriodValueCorporateConversionOfUnits" scale="0" id="Tc_yQbwaG7yTUqUiEL3ZQe1Xw_11_5">17,517,375</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_YaTMIktqsk6w51g7L20gNQ" decimals="INF" format="ixt:numdotdecimal" name="acxp:StockIssuedDuringPeriodSharesCorporateConversionOfUnits" scale="0" id="Tc_5XMCypNU4kK7812ItZ3xGw_11_7">100,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_YaTMIktqsk6w51g7L20gNQ" decimals="0" format="ixt:numdotdecimal" name="acxp:StockIssuedDuringPeriodValueCorporateConversionOfUnits" scale="0" id="Tc_R5uFpR6btkixBnloQuSeKg_11_10">830,115</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_po048zYXXkK5B_bKRi3sOQ" decimals="INF" format="ixt:numdotdecimal" name="acxp:StockIssuedDuringPeriodSharesCorporateConversionOfUnits" sign="-" scale="0" id="Tc_P23a0S_oxkGxB75y2nUw6w_11_12">7,041,208</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_po048zYXXkK5B_bKRi3sOQ" decimals="0" format="ixt:numdotdecimal" name="acxp:StockIssuedDuringPeriodValueCorporateConversionOfUnits" sign="-" scale="0" id="Tc_RPgUujhNEU-8DRLqrboEYA_11_15">7,041</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bAx1kdchGkS4wq4G6E6-eA" decimals="0" format="ixt:numdotdecimal" name="acxp:StockIssuedDuringPeriodValueCorporateConversionOfUnits" sign="-" scale="0" id="Tc_2Xi2JYuKIEeHbu_7Fq8rwA_11_18">18,340,449</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:25.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;">Initial Public Offering and underwriter warrants, net of $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Narr_RcqqmYHA802oLgTmUHZSvA">2,452,868</ix:nonFraction> cash issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_po048zYXXkK5B_bKRi3sOQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_uInYiQ9_UUWjCovGxBWfLA_12_12">2,875,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_po048zYXXkK5B_bKRi3sOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_zf-g3i4WWUK4KqYw_l3-wg_12_15">2,875</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bAx1kdchGkS4wq4G6E6-eA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_bG26gHP8E0qiyKNJe9i9nw_12_18">14,794,257</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_tdSo8AyHIUWEzWnDwI5_IA_12_24">14,797,132</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;">Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__BvIcav9hkGe2hyzvEmB2Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_FahQ9Eigwk6vYF6SkTt-xQ_13_21">12,747,697</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_8LW4rR2W9UanRhqqtgvGSw_13_24">12,747,697</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:25.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Balance at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_scb5hQt9d0-OCtp3xVkWXA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_JJUASPVojku_hxoDMYW0Tg_14_12">10,215,792</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_scb5hQt9d0-OCtp3xVkWXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_W4lGOSH1MUOkEvBf40N4kg_14_15">10,216</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XcVxdLM7g0aTslPVvSHW0A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_yIXw5FoB00mzdrkT7nsrQA_14_18">38,948,334</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_GWozgFjldEK0a6rNLQuu1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_KZDRuPzhY0O7beWT7Fzdjw_14_21">26,548,309</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_HWBxvqgdh0KbVsyu7bnFnA_14_24">12,410,241</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:25.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;">Share-Based Compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zlsc7iOms0m26BVpMKK4ag" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="0" id="Tc_CqjCfLvA50mytZ27C9fvTA_15_18">2,871,681</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="0" id="Tc_5ddCgEWxdkeFf4KWrEWXcQ_15_24">2,871,681</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:25.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;">Share-Based Payments to Vendors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jVrdnRA-J0qI3Y9UjDQQ5w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="Tc_69QpntfeNE-eL5_AxYluWQ_16_12">114,889</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jVrdnRA-J0qI3Y9UjDQQ5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_GVzjxGnu7EakYgsPFngWhQ_16_15">115</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zlsc7iOms0m26BVpMKK4ag" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_eSx2z5zEBUKmtFJITulM7g_16_18">430,565</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_DgSaLHVhFEiss5yNKgBzcA_16_24">430,680</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;">Issuance of shares of common stock and pre-funded warrants in registered direct offering, net of $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Narr_OlD0KfZIwE63c44Pvngbdw">529,805</ix:nonFraction> cash issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jVrdnRA-J0qI3Y9UjDQQ5w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_ukUb81aKVkOSV8MBeQGf2A_17_12">1,159,211</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jVrdnRA-J0qI3Y9UjDQQ5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_nJyvY3gwQkeDcUSLZGOhdQ_17_15">1,159</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zlsc7iOms0m26BVpMKK4ag" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_xYCXKJcDvkijwTDeJ52yRA_17_18">3,694,023</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_c6yTxgvBF0uCc2dZEeC1Og_17_24">3,695,182</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:25.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;">Cashless Warrant Exercise</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jVrdnRA-J0qI3Y9UjDQQ5w" decimals="INF" format="ixt:numdotdecimal" name="acxp:StockIssuedDuringPeriodSharesPeriodIncreaseDecreaseThroughCashlessWarrantExercise" scale="0" id="Tc_rViCsKrNPEueyb4sVWhbgg_18_12">6,948</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jVrdnRA-J0qI3Y9UjDQQ5w" decimals="0" format="ixt:numdotdecimal" name="acxp:StockholdersEquityPeriodIncreaseDecreaseThroughCashlessWarrantExercise" scale="0" id="Tc_mVLN4C07AEuNXH1K17qALw_18_15">7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zlsc7iOms0m26BVpMKK4ag" decimals="0" format="ixt:numdotdecimal" name="acxp:StockholdersEquityPeriodIncreaseDecreaseThroughCashlessWarrantExercise" sign="-" scale="0" id="Tc_a28poIEfwkCV1nPUZNeyIA_18_18">7</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:25.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;">Pre-funded Warrant Exercise</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jVrdnRA-J0qI3Y9UjDQQ5w" decimals="INF" format="ixt:numdotdecimal" name="acxp:WarrantExercisePreFundedShares" scale="0" id="Tc_v3jcy3Yve06gRn_aGnd5lg_19_12">130,769</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jVrdnRA-J0qI3Y9UjDQQ5w" decimals="0" format="ixt:numdotdecimal" name="acxp:WarrantExercisePreFunded" scale="0" id="Tc_E3mKIQlMckahnBKxAoxuOw_19_15">131</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zlsc7iOms0m26BVpMKK4ag" decimals="0" format="ixt:numdotdecimal" name="acxp:WarrantExercisePreFunded" sign="-" scale="0" id="Tc_osK9cxORBEupwZSgfmREYQ_19_18">118</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="0" format="ixt:numdotdecimal" name="acxp:WarrantExercisePreFunded" scale="0" id="Tc_wziH2OnPxkWmlJqeJ4GYag_19_24">13</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;">Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Go-pCQ7LGkWyi1cgoF9ZQw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_pDtQD7mIv0aQsECQxPae8Q_20_21">12,092,776</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_4OGuDyw8fUqfkmTLUEbXTA_20_24">12,092,776</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:25.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Balance at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2gVXSaZ170Wf8nqxjc_rMg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_lrdfo9-qBkOl3earhFxvBg_21_12">11,627,609</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2gVXSaZ170Wf8nqxjc_rMg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_GGIzovSkBUiXFavSU3-85A_21_15">11,628</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OYU0ijkQlkuzhtPcTOLIow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_-DzhqsKt4E6k1bSnOCx-OA_21_18">45,944,478</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_uxop3ZMQk0-ZXskL-V_mVw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_hUMQXte0bUiGPxBTOPqu6Q_21_21">38,641,085</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_NnPeug4Y4kKxyeDiK95FBQ_21_24">7,315,021</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">See accompanying notes to the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_45489bce_b889_4014_bb61_0df100f0af25"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">ACURX PHARMACEUTICALS, INC.</p><a id="STATEMENTSOFCASHFLOWS_204474"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">YEARS ENDED DECEMBER 31, 2022 AND 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_8727a9a5_f775_46aa_b13d_0ec18625aba0"></a><a id="Tc_xT6d47USW0aMg-aCZRE-dw_1_2"></a><a id="Tc_GN4RPVcazEqS9QVN8kZF7w_2_2"></a><a id="Tc_3rkTvhmEVUeNYrAQYf-_Aw_3_2"></a><a id="Tc_2igRlhraiEK1egBVJcDcDg_3_5"></a><a id="Tc_JrhLz7wT6Uu6DLEe_zE9Sg_5_0"></a><a id="Tc_CvWsQiQ1ika3zI0LRe7NxA_6_0"></a><a id="Tc_ggjpg6_UOUy-cxFvq17jkA_6_2"></a><a id="Tc_gL5C0X-kAUydZ_AdtbPtWw_6_5"></a><a id="Tc_PRByHj05QEqKUHM7fEdP-A_7_0"></a><a id="Tc_cYXHYaBwfUi6sGItT6obag_8_0"></a><a id="Tc_dqoQ-vvM40ujV_ThVr4Kcg_9_0"></a><a id="Tc_1DWpAYz7dEiCESeYcOS3Gw_10_0"></a><a id="Tc_NTU5lLtp20iTjLVhkf4aWA_10_3"></a><a id="Tc_otgNw_DbBEOywD8QvG4pcQ_11_0"></a><a id="Tc_ihIRRKmmykKQJc0dn8PhVQ_11_3"></a><a id="Tc_CGtHFSFzpUy7vt6MaSri4g_12_0"></a><a id="Tc_rsJGskd0UkKIHE1-ZmsZ0w_13_0"></a><a id="Tc_OxS77wDEnU-CVpP8bJqvTg_14_0"></a><a id="Tc_qNET3oSe90W89Yp_grEF0w_15_0"></a><a id="Tc_H_8A133sTEipIGBl1VZwPg_17_0"></a><a id="Tc_b3MW-Ic4OEeCZJHvESmTGQ_18_0"></a><a id="Tc_YV-HlVRaxEiihcmcaVryvg_18_3"></a><a id="Tc_83LA1zj2uUGXoIsLja262w_19_0"></a><a id="Tc_m3SqlW0gzkaU5R8UtJ9h0Q_19_6"></a><a id="Tc_kz0PrV_7YUyLciP-XP6Pyg_20_0"></a><a id="Tc_yeaK-Ir-y02-lr-cQabS7A_20_6"></a><a id="Tc_5LJsQcwANUWQBESXK0-zdA_21_0"></a><a id="Tc_5pAVHGLKp0qa-Q-Y4ln5eQ_22_0"></a><a id="Tc_g4RmwnKcnUqSZqky81JDLg_23_0"></a><a id="Tc_q_S24vIqQUuQgw3MXm48Ow_24_0"></a><a id="Tc_SeXPSwXCFEKWV5rb_HLENw_24_2"></a><a id="Tc_yEB9YZoSEk6jHr-oce4ZdA_24_5"></a><a id="Tc_JQCckA6Lj0-BB2vvu1EWHw_25_0"></a><a id="Tc_a_1gLGUGyEO_U4KN8ZjYnA_26_0"></a><a id="Tc_l8tmtNu6hUy9f9CNbg7qHQ_26_2"></a><a id="Tc_6lQvG_c_YEaBkkYIOk5lsg_26_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash Flow from Operating Activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_9rf1BzhKB0qFTluH1OFGRw_6_3">12,092,776</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_5Z07wuO2PEC2EJQNr8kUaQ_6_6">12,747,697</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Share-Based Compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_fIehG5k7HkusCenzac4tVA_8_3">2,871,681</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_JxHZU1z9rUWhCyBZGqnhEA_8_6">5,154,714</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Share-Based Payments to Vendors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="0" format="ixt:numdotdecimal" name="acxp:ShareBasedPaymentToVendors" scale="0" id="Tc_K9BoXO6kEEaLBeXMazlb_A_9_3">430,680</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="0" format="ixt:numdotdecimal" name="acxp:ShareBasedPaymentToVendors" scale="0" id="Tc_v2C2jNgD4Uae_ojnsbz5rw_9_6">1,587,741</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Executive Compensation Settled with Membership Interests</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="0" id="Tc_sSqU4WY5lE2A5fvnDo2bbg_10_6">916,765</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Gain on Forgiveness of Paycheck Protection Program Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="Tc_r5SKqYlQP0SLMNFHOIZTpA_11_6">66,503</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">(Increase) / Decrease in:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Prepaid Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" sign="-" scale="0" id="Tc_HPlVF-o9PkeuLDako4pU2w_13_3">30,349</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" id="Tc_Mzhp957UbUK6duYSS0Xv6A_13_6">246,695</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Accounts Payable and Accrued Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="Tc_R-_lGN2kCkOmeZ_ufeSObg_14_3">1,217,776</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="Tc_Txh7q3wRFE2uJLwHYTYtzw_14_6">387,978</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net Cash Used in Operating Activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_vKzZ1A2LOEyEYN9XaZvoLw_15_3">7,542,290</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_mIoZ1djtjEuF6TEwS2NOyw_15_6">5,013,697</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash Flow from Financing Activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Proceeds from Initial Public Offering, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="0" id="Tc_4zUtID1sQU-9gKjJsVH4eA_18_6">14,797,132</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Proceeds from Registered Direct Offering, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Tc_rqId2cdBrkqaQak7Xwhcyw_19_3">3,695,182</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Pre-funded Warrant Exercise</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="0" id="Tc_ZJJTUTStSUyM2uKGG0Y2rA_20_3">13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net Cash Provided by Financing Activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_17n4_8RfPUKYEJnkbDX5_w_21_3">3,695,195</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_I9BNdBr9MUiNZD-qK0e4fg_21_6">14,797,132</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net (Decrease) Increase in Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="0" id="Tc_67QXhmETK0CHV9wyJf5IsQ_22_3">3,847,095</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="Tc_3DC5rkd0G0-bC4lOqIOeYA_22_6">9,783,435</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash at Beginning of Year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_dy3CxiV6OEm8nfyXezTlxQ_23_3">12,958,846</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2020_GjIfeLZ3Ck689XNTpPYicQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_VCkNTtfsaUCRgh8lNnBqcA_23_6">3,175,411</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash at End of Year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_G5XQo-B9aUalAUItpyxdZg_24_3">9,111,751</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_rWAqqqlSaky2j8vRToOE1w_24_6">12,958,846</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING ACTIVITIES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Warrants issued in connection with offerings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="0" format="ixt:numdotdecimal" name="acxp:NonCashFinancingActivitiesOfWarrantsIssuedInConnectionWithOfferings" scale="0" id="Tc_HKSFB5gLcEy1B2wtpVe4iQ_26_3">171,409</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="0" format="ixt:numdotdecimal" name="acxp:NonCashFinancingActivitiesOfWarrantsIssuedInConnectionWithOfferings" scale="0" id="Tc_ZhkclRfj_EaOAALu7HMT3g_26_6">618,000</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">See accompanying notes to the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f4c37bcd_7abb_40ee_b46f_532925ae7e72"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">ACURX PHARMACEUTICALS,&#160;INC.</p><a id="NOTESTOTHEFINANCIALSTATEMENTS_553029"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO THE FINANCIAL STATEMENTS</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="us-gaap:NatureOfOperations" id="Tb_nnSLHEIprki9xdHgMVXqiw" continuedAt="Tb_nnSLHEIprki9xdHgMVXqiw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NOTE&#160;1&#160;&#8211; NATURE OF OPERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Business:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Acurx Pharmaceuticals,&#160;Inc., a Delaware corporation, formerly Acurx Pharmaceuticals, LLC (the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company formed in July&#160;2017, with operations commencing in February&#160;2018. The Company is focused on developing a novel class of antibiotics that address serious or life threatening bacterial infections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2020, the World Health Organization declared the outbreak of COVID-19, a novel strain of coronavirus, a global pandemic. This outbreak caused major disruptions to businesses and markets worldwide as the virus continued to spread. The COVID-19 pandemic has disrupted, and the Company expects it will continue to disrupt, its operations. The extent of the effect on the Company&#8217;s operational and financial performance will depend on future developments, including the duration, spread and intensity of the pandemic, and governmental, regulatory and private sector responses, direct and indirect economic effects as a result of inflation, supply chain disruptions and labor shortages all of which are uncertain and difficult to predict. Although the Company is unable to estimate the financial effect of the pandemic, at this time, if the pandemic continues over a long period of time, it could have a material adverse effect on the Company&#8217;s business, results of operations, financial condition, and cash flows. The financial statements do not reflect any adjustments as a result of the pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2018, the Company purchased the active pharmaceutical ingredient, the intellectual property and other rights to an antibiotic product candidate known as GLS362E (renamed ACX-362E and now approved for non-proprietary name, ibezapolstat) (the &#8220;Asset&#8221;) from GLSynthesis,&#160;Inc. The Company paid $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_2_1_2018_To_2_28_2018_srt_ProductOrServiceAxis_acxp_AcxThreeSixtyTwoEMember_Ney4atHhPEWi0zip1SpT4Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForOperatingActivities" scale="0" id="Narr_pH4O5_HNp06BuVlggbimdQ">110,174</ix:nonFraction> in cash, along with granting <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_2_1_2018_To_2_28_2018_srt_ProductOrServiceAxis_acxp_AcxThreeSixtyTwoEMember_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_J2BW4s8qOUKn-acaK_Oxcg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" scale="0" id="Narr_lhTw_SMa10-vIknrb3Em9g">100,000</ix:nonFraction> Class&#160;B Membership Interests, profits interests as defined in the operating agreement, with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="As_Of_2_28_2018_srt_ProductOrServiceAxis_acxp_AcxThreeSixtyTwoEMember_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_gOS8l29JHkSEb-8_CljtJw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_6NMEccEozkCeYvUrt8vaMg">0.10</ix:nonFraction> per share. The Company was also required to make certain milestone payments totaling $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_2_28_2018_srt_ProductOrServiceAxis_acxp_AcxThreeSixtyTwoEMember_b8X5m76NYkaaQE7rN9N3KQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherCommitment" scale="0" id="Narr_wlWOQ7uA8ECgmwhwqZJkxw">700,000</ix:nonFraction> in aggregate if certain milestones are achieved, $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_2_1_2018_To_2_28_2018_srt_ProductOrServiceAxis_acxp_AcxThreeSixtyTwoEMember_Ney4atHhPEWi0zip1SpT4Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="0" id="Narr_B5uDqXeZNEOhi08eDaVwMQ">50,000</ix:nonFraction> of which has already been paid by the Company and royalty payments equal to <ix:nonFraction unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q" contextRef="Duration_2_1_2018_To_2_28_2018_srt_ProductOrServiceAxis_acxp_AcxThreeSixtyTwoEMember_Ney4atHhPEWi0zip1SpT4Q" decimals="2" format="ixt:numdotdecimal" name="acxp:PercentageOfRoyaltyPaymentsOnNetSales" scale="-2" id="Narr_yPEfpvA5bU6v633v7OQueQ">4</ix:nonFraction>% of net sales for a period of time equal to the last to expire of any applicable patents, as defined in the asset purchase agreement. The purchase of the Asset has resulted in our lead antibiotic product candidate, ibezapolstat, which targets the treatment of C. difficile infections (&#8220;CDI&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s primary activities since inception aside from organizational activities have included performing research and development activities relating to the development of its two antibiotic candidates and raising funds through equity offerings including its initial public offering (&#8220;IPO&#8221;) consummated in June&#160;2021. The Company has not generated any revenues since inception.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. The Company has needed to raise capital from sales of its securities to sustain operations. On June&#160;29, 2021, the Company completed the IPO, issuing <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_6_29_2021_To_6_29_2021_ZftWEESwJUi8qhJm8t8FPQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_prJ-kPpSHUmHsz_f8--H-Q">2,875,000</ix:nonFraction> shares of common stock at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="As_Of_6_29_2021_jxXdY4PAdk6_gydSF_zR1g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_QytYRAzjSEK_kZK6UoP7Lg">6.00</ix:nonFraction> per share, with gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_6_29_2021_To_6_29_2021_ZftWEESwJUi8qhJm8t8FPQ" decimals="-5" format="ixt:numdotdecimal" name="acxp:StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts" scale="6" id="Narr_OPkOVSEC8ESJwCzuL7LxaA">17.3</ix:nonFraction> million. On July 27, 2022, the Company completed a registered direct offering and a concurrent private placement, issuing <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_7_27_2022_To_7_27_2022_us-gaap_SubsidiarySaleOfStockAxis_acxp_RegisteredDirectOfferingMember_95IFFOAcVEe4mj_2dDLvKQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_uDrpny78CU2uvJEI5PifRg">1,159,211</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_7_27_2022_To_7_27_2022_us-gaap_SubsidiarySaleOfStockAxis_acxp_RegisteredDirectOfferingMember_95IFFOAcVEe4mj_2dDLvKQ" decimals="INF" format="ixt:numdotdecimal" name="acxp:WarrantExercisePreFundedShares" scale="0" id="Narr_oLzNYzVMOEW8dheq4EWGGw">130,769</ix:nonFraction> pre-funded warrants and series A warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="As_Of_7_27_2022_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Igcj6YgXu0uL014Kv8JyFA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_N0a65ViJ3EuIfz_n-Xw-lQ">1,289,980</ix:nonFraction> shares of common stock and series B warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="As_Of_7_27_2022_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_BaulSGACgEqCM8yVww4XkA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_uDF-7XKbUUuhJJXHXD_A0g">1,289,980</ix:nonFraction> shares of common stock for gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_7_27_2022_To_7_27_2022_us-gaap_SubsidiarySaleOfStockAxis_acxp_RegisteredDirectOfferingMember_95IFFOAcVEe4mj_2dDLvKQ" decimals="-5" format="ixt:numdotdecimal" name="acxp:StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts" scale="6" id="Narr_bE0G22TkKEOVIE2uyfvDCA">4.2</ix:nonFraction><span style="white-space:pre-wrap;"> million.  As of December&#160;31, 2022, the Company had a cash balance of approximately </span>$<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="6" id="Narr_0x0xgIgyVU-ui5xdJ5iVaA">9.1</ix:nonFraction> million, which based on current estimates will not be sufficient to meet our anticipated cash requirements for at least 12&#160;months from the issuance of the financial statements for the&#160;year ended December&#160;<span style="white-space:pre-wrap;">31, 2022. Management believes that the Company will continue to incur losses for the foreseeable future and will need additional resources to sustain its operations until it can achieve profitability and positive cash flows, if ever. Management plans to seek additional equity financing and grant funding, but cannot assure that such financing and funding will be available at acceptable terms, or at all. These matters raise substantial doubt about the Company&#8217;s ability to continue as a going concern.  The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty. There can be no assurance that the Company&#8217;s research and development will be successfully completed or that any Company product candidate will be approved by </span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_nnSLHEIprki9xdHgMVXqiw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">the Food and Drug Administration (&#8220;FDA&#8221;) or any other worldwide regulatory authority or become commercially viable. The Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with FDA and other governmental regulations and approval requirements</span>.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_VZl6lUJN4kq0YsmTWs9bgw" continuedAt="Tb_VZl6lUJN4kq0YsmTWs9bgw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NOTE&#160;2&#160;&#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="us-gaap:UseOfEstimates" id="Tb_qLxEFSOFZU2dWK0adujUeg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;text-decoration-line:none;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results </span><span style="font-weight:normal;text-decoration-line:none;">could differ from those estimates.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_fqxuU3WMQUCKiuDfnLB3WA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company estimates an annual effective tax rate of <ix:nonFraction unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr_Ei66PiOkaE-ml1Wc9FWI9w">0</ix:nonFraction>% as the Company incurred net losses for the&#160;year ended December&#160;31, 2022 resulting in an estimated net loss for both financial statement and tax purposes. Therefore, <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" scale="0" id="Narr_5TQ1x2iUwEqNxOS2WpfKIg">no</ix:nonFraction> current federal or state income tax expense has been recorded in the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Based on the Company&#8217;s history of generating operating losses and its anticipation of operating losses for the foreseeable future, the Company has determined that it is more likely than not that the tax benefits from those net operating losses would not be realized and a full valuation allowance against all deferred tax assets has been recorded. Should the Company&#8217;s assessment change, tax benefits associated with the historic net operating loss carryforwards could be limited due to future ownership changes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Prior to the Company&#8217;s corporate conversion in June&#160;2021, the Company was organized as a limited liability company. As such, the Company was not a tax paying entity for federal income tax purposes and, therefore, <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Narr_kcsEUeXlQEKmy7IfJLvSug">no</ix:nonFraction> income tax expense has been recorded in the financial statements. Income or losses of the Company was passed through to the members for inclusion in their respective income tax returns.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_IhFkXCtPDEmSLf6cRtV6Dg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Concentration of Credit Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company maintains its cash balance in one financial institution. The balance is insured up to the maximum allowable by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company has not experienced any losses in such accounts and does not believe it is exposed to any significant risk of loss on cash. At times, the cash balance may exceed the maximum insured limit of the FDIC. As of December&#160;31, 2022, the Company had cash of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="6" id="Narr_NVJeOp1odUKVAfssY2aItA">9.1</ix:nonFraction> million in U.S. bank accounts which was not fully insured by the FDIC.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies" id="Tb_I2sQOofwPEWWgXK-XE7lgw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Guaranteed Payments to Members</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Prior to the corporate conversion, guaranteed payments to members of the Company that were designated to represent reasonable compensation for services rendered were accounted for as Company expenses rather than an allocation of the Company&#8217;s net income.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_QMBzVb4h9EuqVENkEL8i9A" continuedAt="Tb_QMBzVb4h9EuqVENkEL8i9A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Research and Development</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company expenses research and development costs when incurred. At times, the Company may make cash advances for future research and development services. These amounts are deferred and expensed in the period the service is provided. The Company incurred research and development expenses in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Narr_CKF-frw0tEGy7sYflBoozQ">4,754,271</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Narr_KCnFwwT9skKJoE1uss6-eA">2,030,177</ix:nonFraction> for the&#160;years ended December&#160;31, 2022 and 2021, respectively.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_VZl6lUJN4kq0YsmTWs9bgw_cont1"><ix:continuation id="Tb_QMBzVb4h9EuqVENkEL8i9A_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Costs for certain research and development activities, such as the provision of services for clinical trial activity, are estimated based on an evaluation of the progress to completion of specific tasks which may use data such as subject enrollment, clinical site activations or information provided to the Company by its vendors with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development expense, as the case may be. The estimates are adjusted to reflect the best information available at the time of the financial statement issuance. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#39;s estimate of the status and timing of services performed relative to the actual status and timing of services performed may vary. </p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_SuRhtDQE3UaT-c2RmLE9ug" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Share-Based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for the cost of services performed by officers and directors received in exchange for an award of Company membership interests, common stock or stock options, based on the grant-date fair value of the award. The Company recognizes compensation expense based on the requisite service period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Compensation expense associated with stock option awards is recognized over the requisite service period based on the fair value of the option at the grant date determined based on the Black-Scholes option pricing model. Option valuation models require the input of highly subjective assumptions including the expected price volatility. The Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair value computation using the Black-Scholes option pricing model. Because there is no public market for the Company&#8217;s stock options and very little historical experience with the Company&#8217;s stock, similar public companies were used for the comparison of volatility and the dividend yield. The risk-free rate of return was derived from U.S. Treasury notes with comparable maturities.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="acxp:ShareBasedPaymentsToVendorsPolicyTextBlock" id="Tb_KGSGebMGEESMzzf2_7qKwQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Share-Based Payments to Vendors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for the cost of services performed by vendors in exchange for an award of Company membership interests, common stock, or stock options, based on the grant-date fair value of the award or the fair value of the services rendered; whichever is more readily determinable. The Company recognizes the expense in the same period and in the same manner as if the Company had paid cash for the services.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_QElX4vnjkEGb8fFZMjf9OQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Major Vendor</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company had a major vendor that accounted for approximately <ix:nonFraction unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_acxp_VendorOneMember_4oZxhIVJI0KIX3uwgXpLww" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_55yiZv9kDkO8ccvAlOBLkg">55</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_acxp_VendorOneMember_8CM4InADYkOReoekH1g7Zg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_sG1ugIlmPEeG2U8LynEDbw">42</ix:nonFraction>% of the research and development expenditures for the&#160;years ended December&#160;31, 2022 and 2021, respectively. The same vendor also accounted for approximately <ix:nonFraction unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_LiabilitiesTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_acxp_VendorOneMember_r8R9a4Obr0Ot0gf8VEQ9Gw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_d207u5vZ8ESCHw5-PPLy2w">56</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_LiabilitiesTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_acxp_VendorOneMember_FamfXN_U9ECbf8TAjQXRNg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_JWJ2GshvXE6PgMA0ziYQWQ">5</ix:nonFraction>% of the total accounts payable and accrued expenses as of December&#160;31, 2022 and 2021, respectively. The Company continues to maintain this vendor relationship and anticipates incurring significant expenses with this vendor over the next 12&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company had an additional major vendor that accounted for approximately <ix:nonFraction unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_acxp_VendorTwoMember_yFuWsT6s0UCyH_YTEghzqA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_VL374KonTU6ND-guUv4DwQ">4</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_acxp_VendorTwoMember__H92yBaZYkKfxsX2SKyheA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_L-ugyJaYXUeIgM1O4rWk-w">15</ix:nonFraction>% of the research and development expenditures for the&#160;years ended December&#160;31, 2022 and 2021. The same vendor did not account for any material portion of the total accounts payable and accrued expenses. The Company will continue to maintain this vendor relationship over the next 12&#160;months.</p></ix:nonNumeric></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_YVCN2V8LFEemjsrJ64spNQ" continuedAt="Tb_YVCN2V8LFEemjsrJ64spNQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NOTE&#160;3&#160;- ACCOUNTS PAYABLE AND ACCRUED EXPENSES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Accounts payable and accrued expenses as of December&#160;31, 2022 and 2021 were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_G-4w8GXIzE-XplryH1XPvg" continuedAt="Tb_G-4w8GXIzE-XplryH1XPvg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_L6AzB1hYpES-R37Qjbb4gg_1_2"></a><a id="Tc_AZiJFaiYM0W7teU10nCT5A_1_5"></a><a id="Tc_kzZ2oM901EWZyQdMwdwhfA_2_0"></a><a id="Tc_LtXT6U1i2EizXMJc8PWK2w_2_2"></a><a id="Tc_YrA2hdN5lU-AJzZfPUZV_A_2_5"></a><a id="Tc_BGubteYuREma7qmbX-Eh5A_3_0"></a><a id="Tc_to_uoZ4ovE-GaBMTm4Z3-A_4_0"></a><a id="Tc_k-oDqbJhq0a8rALUIOeNnw_5_0"></a><a id="Tc_Jqh3bqCyJk2CIEp-0oX_TQ_6_0"></a><a id="Tc_5cEW__R0cki7JxK_Z06ijg_6_2"></a><a id="Tc_AuoqGnwJykaO9G_eURg6Bw_6_5"></a><ix:continuation id="Tb_YVCN2V8LFEemjsrJ64spNQ_cont1"><ix:continuation id="Tb_G-4w8GXIzE-XplryH1XPvg_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_JzpOAwDvH0Kd2_E40vcYsQ_2_3">542,895</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_b_qMHHBFp06ob3xZwpisDg_2_6">508,343</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="0" format="ixt:numdotdecimal" name="acxp:AccruedResearchAndDevelopmentCurrent" scale="0" id="Tc_k3Kwp_pGn0WCADfhmcH7Rg_3_3">1,405,536</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw" decimals="0" format="ixt:numdotdecimal" name="acxp:AccruedResearchAndDevelopmentCurrent" scale="0" id="Tc_MKvC-lOSV02gniVihdHu2A_3_6">229,090</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_u2C6_POBUEO2uEBI6U40xQ_4_3">83,715</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_VxJiQWfceUipMEa9I3u5Vg_4_6">43,102</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" id="Tc_aNcnNK-8A0SRz5OIBPkMOQ_5_3">29,539</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" id="Tc_5RBQTPuVGEO1N5V7Hmj3mA_5_6">63,374</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="Tc_B6JrSmNcj020zSteUwwsKQ_6_3">2,061,685</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="Tc_Xun4CoBDykeRrlalUMEzSA_6_6">843,909</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="acxp:PaycheckProtectionProgramLoanDisclosureTextBlock" id="Tb_Hxl_2VREOEadXP0F6zFFTw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NOTE&#160;4&#160;&#8211; PAYCHECK PROTECTION PROGRAM LOAN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2020, the Company received a Paycheck Protection Program loan (&#8220;PPP Loan&#8221;) under the CARES Act, as administered by the U.S. Small Business Administration (&#8221;SBA&#8221;) in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_5_1_2020_To_5_31_2020_us-gaap_ShortTermDebtTypeAxis_acxp_PaycheckProtectionProgramLoanMember_6co5NWgV9EOO1mbFZkcoFA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="0" id="Narr_Ddgc-knUWUyy9vjuY4eVQQ">66,503</ix:nonFraction>. <span style="color:#252525;">&#160;The Company did not provide any collateral or guarantees in connection with the PPP loan, nor did the Company pay any facility charge to obtain the&#160;PPP Loan. The note and agreement provided for customary events of default, including those relating to failure to make payment, bankruptcy, breaches of representations and material adverse effects. The Company was permitted to prepay the principal of the&#160;PPP Loan&#160;at any time without incurring any prepayment charges. </span>The PPP Loan carried an annual interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q" contextRef="Duration_5_1_2020_To_5_31_2020_us-gaap_ShortTermDebtTypeAxis_acxp_PaycheckProtectionProgramLoanMember_6co5NWgV9EOO1mbFZkcoFA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="Narr_fT7pTVsfBUit_cVp4WOsnw">0.98</ix:nonFraction>% and a maturity date <span style="-sec-ix-hidden:Hidden_nx3AzEkhbUS8BxsxeUh0lg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> (2)&#160;years from issuance. The Company was not obligated to make any payments of principal or interest before the date on which the SBA remits the loan forgiveness amount to the lender or notifies the lender that no loan forgiveness is allowed. On April&#160;13, 2021, the SBA authorized the full forgiveness of the PPP Loan. Accordingly, the Company reduced the full amount of the liability and recorded a gain in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShortTermDebtTypeAxis_acxp_PaycheckProtectionProgramLoanMember_ITpBNU5NNkaQ1aNsqLkRmg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="Narr_9eDEDcgh60CCTAsfcvGThw">66,503</ix:nonFraction> on the forgiveness of the PPP loan in the statements of operations for the&#160;year ended December&#160;31, 2021.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="us-gaap:CompensationRelatedCostsGeneralTextBlock" id="Tb_4DQe3rLfMUG0ibFKmlWl-A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NOTE&#160;5&#160;&#8211; EXECUTIVE COMPENSATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2021, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_8oqL0Hgh60e7ICqaSonkbQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" id="Narr_rlxgW674P0KGGc3zWDu2lw">57,430</ix:nonFraction> Class&#160;A Membership Interests at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="As_Of_1_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_Ol44zQexSUa7wj9xwWiDsQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_Hh6-XgJzekejawdjLD3l5Q">3.25</ix:nonFraction> per unit, equal to the value of the most recent private placement, to two of its executives to settle unpaid&#160;year-end bonus award and deferred compensation, which was approved by the board of directors. The&#160;year-end bonus component was equal to <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_8oqL0Hgh60e7ICqaSonkbQ" decimals="INF" format="ixt:numdotdecimal" name="acxp:StockIssuedDuringPeriodSharesBonus" scale="0" id="Narr_jq5DMKQzTkSMOtgwZl5YVg">38,353</ix:nonFraction> Class&#160;A Membership Interests, which was included as accrued compensation. In January&#160;2021, the Company also amended the employment agreements for the three executives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The board of directors also approved certain grants to members of management as a component of&#160;their 2020&#160;year-end compensation, authorizing the issuance of <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_1_1_2021_To_1_31_2021_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_JtClA5RErEGfEeffjvyvtg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" id="Narr_wDh9Ia6dWU6k3i4ty9Obfw">1,540,000</ix:nonFraction> Class&#160;B Membership Interests to its three executives, as well as <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_1_1_2021_To_1_31_2021_srt_TitleOfIndividualAxis_acxp_NonEmployeeMember_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_UquoWzH2YUOrWpEKLgXNoA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_ffYGDTj5N0amJn0I8Ms8Xg">75,000</ix:nonFraction> Class&#160;B Membership Interests which were granted to non-employee management team members. The Class&#160;B Membership Interests are profits interests with a defined exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="As_Of_1_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_boZANUamJEaYYgHn5Q9v8g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_O7NRB83-n0eIY7xax--_Gg">3.25</ix:nonFraction> per interest, the Company&#8217;s most recent financing offering price. In March&#160;2021, the Company along with its three executives and non-employee management team agreed voluntarily to cancel the aforementioned equity grants. The Company granted options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_6_1_2021_To_6_30_2021_aPFoy3uQQkGd9asBZ1avUg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_Tte_DVmJ8ketLPB-zi8iKw">770,000</ix:nonFraction> shares of the Company&#8217;s common stock in June&#160;2021 to the three-member management team in replacement of the cancelled&#160;year-end grants described above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company is currently managed by three executives, in each case pursuant to new employment agreements effective June&#160;29, 2021 and a controller hired in April 2022.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb__aSFRGZej06UQah44a0NcQ" continuedAt="Tb__aSFRGZej06UQah44a0NcQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NOTE&#160;6&#160;&#8211; ISSUANCE OF EQUITY INTERESTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On June&#160;23, 2021, Acurx Pharmaceuticals, LLC was converted into a corporation and renamed Acurx Pharmaceuticals,&#160;Inc. The Company&#8217;s certificate of incorporation authorizes <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_ccPjeDPXiE20L5XP6nulGA">200,000,000</ix:nonFraction> shares of common stock of which <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_DjNmT8p6hE2nhm9i2NmCzg">11,627,609</ix:nonFraction> were outstanding as of December&#160;31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">On June&#160;29, 2021, the Company completed an IPO issuing <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_6_29_2021_To_6_29_2021_ZftWEESwJUi8qhJm8t8FPQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_YCojkCXLAEmiscJQp4cYbA">2,875,000</ix:nonFraction> shares of common stock at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="As_Of_6_29_2021_jxXdY4PAdk6_gydSF_zR1g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_I4Rz196mOEmcXG8_M2JuZA">6.00</ix:nonFraction> per share, resulting in net cash proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_6_29_2021_To_6_29_2021_ZftWEESwJUi8qhJm8t8FPQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" id="Narr_evKRhJAiEUqldZ5g161f8w">14.8</ix:nonFraction> million, with cash issuance costs of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_6_29_2021_To_6_29_2021_ZftWEESwJUi8qhJm8t8FPQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_dJGbpgwQAk6-LUnKcsvi-A">2.4</ix:nonFraction> million. The outstanding Class&#160;A and Class&#160;B Membership Interests were converted to shares of common stock pursuant to a conversion ratio of one-for-two of the Membership Interests outstanding, resulting in the conversion of <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_6_29_2021_To_6_29_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassAndClassBMemberSCapitalMember_sGnNM7X_Y0a52s50X0s31g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_7AsQ3rJQWES7BzZJvLJc8w">14,082,318</ix:nonFraction> Class&#160;A and Class&#160;B Membership Interests into <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_6_29_2021_To_6_29_2021_ZftWEESwJUi8qhJm8t8FPQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" id="Narr_D4pLN02qbUGhYdRGjfoeCw">7,041,208</ix:nonFraction> shares of common stock. Warrants to purchase Class&#160;A </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_Zrpjogyqt0iwhzBCIaeK_g_1_5"></a><a id="Tc_WnB6JyUKOEmp1HJyQ1OGCQ_2_3"></a><a id="Tc_k05HlepcQUeYzbr9c8yJpg_2_5"></a><a id="Tc_7MCKfzGigkqaYeyI5YsKyA_3_0"></a><a id="Tc_yrkA5kNrnEWNjFTAgdb08Q_3_5"></a><a id="Tc_pUbOy8gYAUqcnyaligruvg_4_0"></a><a id="Tc_htpSPNF6nUC2zcyaYBudAw_5_0"></a><a id="Tc_9DF5S8k2wEismmYXEq2h7g_6_0"></a><a id="Tc_Cm2bxov0rk20-BtnqD4a5g_6_5"></a><ix:continuation id="Tb__aSFRGZej06UQah44a0NcQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Membership Interests were converted to warrants to purchase common stock at the same one-for two conversion ratio, resulting in <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="As_Of_6_29_2021_jxXdY4PAdk6_gydSF_zR1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_5Z64-H5WXkOuXJYmW7xrIg">1,437,577</ix:nonFraction> warrants to purchase common stock with a weighted average exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="As_Of_6_29_2021_jxXdY4PAdk6_gydSF_zR1g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_GSHa1kaCqEGCOAQ4A_ka5A">2.88</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In connection with the IPO, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="As_Of_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_acxp_UnderwriterMember_UBZF9KBTGk6x1d7NF_WJMw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_HyWA3-clSUi1-DjN99dWew">150,000</ix:nonFraction> warrants to the underwriter. Each warrant is exercisable for <ix:nonNumeric contextRef="Duration_6_29_2021_To_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_acxp_UnderwriterMember_-kSXTBxSPkq5OVNeYmsV1w" format="ixt-sec:duryear" name="acxp:ClassOfWarrantOrRightExercisableTerm" id="Narr_Lyc7B_Ao-k659mm9SrRseg">4.5</ix:nonNumeric> years from December&#160;21, 2021 at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="As_Of_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_acxp_UnderwriterMember_UBZF9KBTGk6x1d7NF_WJMw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_vxaEIxfTjE-f1G_5rQjm6w">7.50</ix:nonFraction> per share. The Company used the Black-Scholes model to calculate the value of the warrants with an estimated fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_acxp_UnderwriterMember_UBZF9KBTGk6x1d7NF_WJMw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="0" id="Narr_sO7NlsbNZkm540Y99trG0Q">618,000</ix:nonFraction>. The inputs utilized in the calculation were as follows: <span style="-sec-ix-hidden:Hidden_RMD-11b8a0WEvsJ9XyenQg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four</span></span> and a half-year term, <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_6_29_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_acxp_UnderwriterMember_u8q_TpmED0-Ky05QbeiMpw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_Isrhz25eREiIulKMV7qZ6A">0.79</ix:nonFraction>% risk-free rate, stock price at grant date of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="As_Of_6_29_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_SubsidiarySaleOfStockAxis_acxp_UnderwriterMember_v5jYpz8bRUyI--9gq4owJw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_oi7znlsjxESatoUS4FCbSw">6.26</ix:nonFraction>, and a <ix:nonFraction unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q" contextRef="As_Of_6_29_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_SubsidiarySaleOfStockAxis_acxp_UnderwriterMember_sGehJTCm7kCXCyDe_BzraA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_1bCmI0pqoUCioXEK0kBsUw">94</ix:nonFraction>% volatility utilizing comparable companies. This amount was recorded as both an increase to additional paid-in capital and as a non-cash issuance cost of the offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On July 25, 2022, the Company entered into securities purchase agreements (the &#8220;Purchase Agreements&#8221;) with two of the Company&#8217;s executives and a member of the Company&#8217;s board of directors (collectively, the &#8220;Affiliate Investors&#8221;), and a single U.S. institutional investor (the &#8220;Investor&#8221;) pursuant to which the Company issued and sold in a registered direct offering an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_7_25_2022_To_7_25_2022_sWcLqEbyWkeHbC8OdzC6_A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_e8fbb_VDwU2R_d92v6pikA">1,159,211</ix:nonFraction> shares of common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="As_Of_7_25_2022_YegiBECCekyLQBPmihkK7Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_secrVBmJ8kWU8-AaaqvvKA">0.001</ix:nonFraction> per share and pre-funded warrants to purchase an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_7_25_2022_To_7_25_2022_srt_TitleOfIndividualAxis_acxp_AffiliateInvestorsMember_p7F3gkO8pE2NTMNCZ9i1nQ" decimals="INF" format="ixt:numdotdecimal" name="acxp:WarrantExercisePreFundedShares" scale="0" id="Narr_R9WpSmedpUexT0Y9z8sNZg">130,769</ix:nonFraction> shares of common stock. The Affiliate Investors purchased an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_7_25_2022_To_7_25_2022_srt_TitleOfIndividualAxis_acxp_AffiliateInvestorsMember_p7F3gkO8pE2NTMNCZ9i1nQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_wiYwzFPgd0KNtqswsKVxeQ">59,211</ix:nonFraction> shares of common stock at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="As_Of_7_25_2022_srt_TitleOfIndividualAxis_acxp_AffiliateInvestorsMember_0RaPP3HInkGg-_0ekTA3OQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_LujeHguQPE-hSbflk_rZbg">3.80</ix:nonFraction> per share. The Investor purchased an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_7_25_2022_To_7_25_2022_srt_TitleOfIndividualAxis_us-gaap_InvestorMember__XKurX6OPUKTdaHa_IwqkA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_35xhorLLaES2FaeZZm-mbg">1,100,000</ix:nonFraction> shares of common stock at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="As_Of_7_25_2022_srt_TitleOfIndividualAxis_us-gaap_InvestorMember_Ri0JCPeSzE6DD189Cr4yVQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_nTeRY4U9C06NGgGo3LDmYw">3.25</ix:nonFraction> per share and an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_7_25_2022_To_7_25_2022_srt_TitleOfIndividualAxis_us-gaap_InvestorMember__XKurX6OPUKTdaHa_IwqkA" decimals="INF" format="ixt:numdotdecimal" name="acxp:WarrantExercisePreFundedShares" scale="0" id="Narr_zacjdO0ZO0idS9u3t0z0pA">130,769</ix:nonFraction> pre-funded warrants at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="Duration_7_25_2022_To_7_25_2022_srt_TitleOfIndividualAxis_us-gaap_InvestorMember__XKurX6OPUKTdaHa_IwqkA" decimals="4" format="ixt:numdotdecimal" name="acxp:ClassOfWarrantOrRightPurchasePrice" scale="0" id="Narr_KgYXMvIbmE-i3N38dWa9Jw">3.2499</ix:nonFraction> per pre-funded warrant. The pre-funded warrants sold to the Investor have an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="As_Of_7_25_2022_srt_TitleOfIndividualAxis_us-gaap_InvestorMember_Ri0JCPeSzE6DD189Cr4yVQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_h1Cf2CzL5UOG1Vw8vxusOA">0.0001</ix:nonFraction><span style="white-space:pre-wrap;">, were immediately exercisable.  As of December 31, 2022, all of the pre-funded warrants were exercised.  The Company also issued to the Affiliate Investors and the Investor, series A warrants to purchase </span><ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="As_Of_7_25_2022_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesWarrantsMember_HHLsVDf1Skma7FwgAwWjhA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_Qa3YnWPPrUWITTeUfLaT1A">1,289,980</ix:nonFraction> shares of common stock and series B warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="As_Of_7_25_2022_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesBWarrantsMember_WAQhRe6t0EmrCSaWui2e9A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_HTxJJeNBmECZKfCva8aElA">1,289,980</ix:nonFraction> shares of common stock, all of which are deemed equity classified. These warrants included <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="As_Of_7_25_2022_srt_TitleOfIndividualAxis_acxp_AffiliateInvestorsMember_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesWarrantsMember_6hXj30MhOU2VHM0OprvNzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_-grvrhBhK0WdsC4pb3rQpA">59,211</ix:nonFraction> series A warrants and an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="As_Of_7_25_2022_srt_TitleOfIndividualAxis_acxp_AffiliateInvestorsMember_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesBWarrantsMember_0trLt8KDDU2-A92s7AKaAg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_rsu5JiNP00qe3sXO6O-Vog">59,211</ix:nonFraction> series B warrants to the Affiliate Investors with an exercise price per share of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="As_Of_7_25_2022_srt_TitleOfIndividualAxis_acxp_AffiliateInvestorsMember_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesWarrantsMember_6hXj30MhOU2VHM0OprvNzQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_F4hwmusrR0a_Vspymoj2jA">3.55</ix:nonFraction> and an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="As_Of_7_25_2022_srt_TitleOfIndividualAxis_us-gaap_InvestorMember_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesWarrantsMember_NWDnHTpMZUCylxU3oQXj-Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_cjVEJb6N0E6qw6go3emz-w">1,230,769</ix:nonFraction> series A warrants and an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="As_Of_7_25_2022_srt_TitleOfIndividualAxis_us-gaap_InvestorMember_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesBWarrantsMember_EZQw2mZf6Euo9EwTGvaY4g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_eOCCYBTF_U2jbgb5U37Nww">1,230,769</ix:nonFraction> series B warrants to the Investor with an exercise price per share of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="As_Of_7_25_2022_srt_TitleOfIndividualAxis_us-gaap_InvestorMember_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesBWarrantsMember_EZQw2mZf6Euo9EwTGvaY4g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_uhWSwVkrhEWUlP-xULU94g">3.25</ix:nonFraction>. The series A warrants will be exercisable commencing on January 27, 2023 and will expire on January 27, 2028. The series B warrants will be exercisable commencing on January 27, 2023 and will expire on January 27, 2024. The registered direct offering closed on July 27, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The gross proceeds to the Company from the registered direct offering were $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_7_25_2022_To_7_25_2022_sWcLqEbyWkeHbC8OdzC6_A" decimals="-5" format="ixt:numdotdecimal" name="acxp:StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts" scale="6" id="Narr_oDwPZEgd00Sr1FZAnkD-MA">4.2</ix:nonFraction> million and net proceeds after deducting the placement agents&#8217; fees and other offering expenses payable by the Company were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_7_25_2022_To_7_25_2022_sWcLqEbyWkeHbC8OdzC6_A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_1o4oVSOO80Gj_aFnl_PF1g">3.7</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On July 25, 2022, the Company entered into a co-placement agent agreement (the &#8220;Placement Agent Agreement&#8221;), with two placement agents in connection with the registered direct offering pursuant to which the Company paid the Placement Agents a cash fee of $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_7_25_2022_To_7_25_2022_us-gaap_SubsidiarySaleOfStockAxis_acxp_PlacementAgentsMember_E-IOxhM4rk2gkD8cStTzjA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Narr_gPLZWWlBwECF-VMJleqk_A">287,874</ix:nonFraction> and issued to the Placement Agents an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="As_Of_7_25_2022_us-gaap_SubsidiarySaleOfStockAxis_acxp_PlacementAgentsMember_xZ4u8T8GOEmEbz0QrR2l2w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_8E4cALhA_UumkUG5sr3lfg">63,018</ix:nonFraction><span style="white-space:pre-wrap;"> warrants to purchase shares of common stock.  The warrants have an exercise price of </span>$<ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="As_Of_7_25_2022_us-gaap_SubsidiarySaleOfStockAxis_acxp_PlacementAgentsMember_xZ4u8T8GOEmEbz0QrR2l2w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_lcWq8bcdw0yxjXIh4yM7bQ">3.60</ix:nonFraction> per share (representing <ix:nonFraction unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q" contextRef="Duration_7_25_2022_To_7_25_2022_us-gaap_SubsidiarySaleOfStockAxis_acxp_PlacementAgentsMember_E-IOxhM4rk2gkD8cStTzjA" decimals="2" format="ixt:numdotdecimal" name="acxp:PercentageOfWeightedAveragePublicOfferingPriceOfAggregateNumberOfSharesOfCommonStockSold" scale="-2" id="Narr_W-xEbZ4zPkuVAxqe_dmJeA">110</ix:nonFraction>%<span style="white-space:pre-wrap;"> of the weighted average public offering price of the aggregate number of shares of common stock sold in the registered direct offering to the Investor and Affiliate Investors) and expire on July 27, 2027.  The Company used the Black-Scholes model to calculate the value of the warrants with an estimated fair value of </span>$<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_7_25_2022_us-gaap_SubsidiarySaleOfStockAxis_acxp_PlacementAgentsMember_xZ4u8T8GOEmEbz0QrR2l2w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="0" id="Narr_BaIAMzl_eUO_pxsnewY5bg">171,409</ix:nonFraction><span style="white-space:pre-wrap;">.  The inputs utilized in the calculation were as follows: </span><ix:nonFraction unitRef="Unit_Standard_Y_m6Q1ZS4FGUy3pAlacn4HHg" contextRef="As_Of_7_25_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_SubsidiarySaleOfStockAxis_acxp_PlacementAgentsMember_BIzTc_rBT0-1HSfagb5b0g" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_zohC2CNbM0iZDgw59QiIxQ">five</ix:nonFraction> year term, <ix:nonFraction unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q" contextRef="As_Of_7_25_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_acxp_PlacementAgentsMember_24jUSFL8IkuQJWmQuEKwcA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_yLnrLfSr_06DZbfdKZgAeA">2.82</ix:nonFraction>% risk free rate, stock price at grant date of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="As_Of_7_25_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_SubsidiarySaleOfStockAxis_acxp_PlacementAgentsMember_DLWS4dqct0WPZhuICr1W5Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_7ZzqtuTifU6G2NTh717WHA">3.70</ix:nonFraction> and a <ix:nonFraction unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q" contextRef="As_Of_7_25_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_SubsidiarySaleOfStockAxis_acxp_PlacementAgentsMember_3LCeKF0DIEaVdX-Uh1jhPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_i6yAkiw5f0yYVHa6UYNx7w">95</ix:nonFraction>%<span style="white-space:pre-wrap;"> volatility utilizing comparable companies.  This amount was recorded as both an increase to additional paid-in capital and as a non-cash issuance cost of the offering.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at December 31, 2022:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="Tb_No94wPldJUiiK2iIX7jGOg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_oyEGPQE0802Nzzjw5qiZDQ_3_3">1,588,477</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_WeightedAverageMember_e70u-YktPE-UR-XzQ15xzQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_dOuOjsPmDUGFT29awMEF_A_3_6">3.32</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">   Issued</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="INF" format="ixt:numdotdecimal" name="acxp:ClassOfWarrantOrRightIssued" scale="0" id="Tc_t7XKoKBKgUyKFdgkfJSNSw_4_3">2,776,476</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_WeightedAverageMember_XhK5Z9PZ80SoOyza28-Ohw" decimals="2" format="ixt:numdotdecimal" name="acxp:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued" scale="0" id="Tc_pZe3zY5ELUqa1YZRPSgA_Q_4_6">3.12</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">   Exercised</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="INF" format="ixt:numdotdecimal" name="acxp:ClassOfWarrantOrRightExercised" sign="-" scale="0" id="Tc_5pFAeU1EjUGHXtDvHpmaag_5_3">147,144</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_WeightedAverageMember_XhK5Z9PZ80SoOyza28-Ohw" decimals="2" format="ixt:numdotdecimal" name="acxp:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" scale="0" id="Tc_TzIwOwFZbEezhtH5VRRH8Q_5_6">0.27</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_o96rWBJKakWVLgOPYfN_aA_6_3">4,217,809</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_WeightedAverageMember__LDIrfLVM0-4X8uUinUNww" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_WPmaeoxGYEOSXgO1__cavw_6_6">3.29</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_nsczCzXLjk66U5T5f_9GPA_1_2"></a><a id="Tc_mJnUAee1nkeyqe7QgGq7yQ_2_2"></a><a id="Tc_IW8vZrJ-7UKygL7gOj8wng_3_2"></a><a id="Tc_sILAewvgV0-Cg8gxN17IdA_5_0"></a><a id="Tc_CwEHKkw1E0ytKAlDWZJp1w_6_0"></a><a id="Tc_Ac6Dd2RCYkSENAD4eqOeqA_7_0"></a><a id="Tc_hSYeRYWosE6ITDfu04F-7w_7_2"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_KAl1sVPhSkm75fQV9SKf9A" continuedAt="Tb_KAl1sVPhSkm75fQV9SKf9A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;7&#160;&#8211; SHARE-BASED COMPENSATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">While the Company was a limited liability company in its pre-IPO phase of corporate development, the Company granted performance-based awards of restricted Class&#160;A Membership Interests to board members and corporate advisory council members in exchange for services. All of these awards of membership interests became fully vested upon consummation of the Company&#8217;s corporate conversion from Delaware limited liability company to a Delaware corporation immediately prior to the Company&#8217;s IPO, with the Company recognizing all previously unrecognized compensation expense. The fair value of the membership interests granted during 2020 and 2019 was equal to the per-membership interest value of the most recent private placement with a weighted average of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember_EdWadodcnUyBlBRFeYfBqg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_TwfHtwJtRUCI6kgLbzSGVA">2.14</ix:nonFraction> per membership interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Total share-based compensation associated with these awards has been recorded as general and administrative expenses in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_fOm5Yu9uyEi4lsBq5eB1Xg">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_LTu4SGsc0U2gtD32yot-xg">755,556</ix:nonFraction> for the&#160;years ended December&#160;31, 2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the unvested Class&#160;A Membership Interests converted to common stock pursuant to a conversion ratio of one-for-two, and associated activity for the 12&#160;months ended December&#160;31, 2021:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" id="Tb_8SXmwpUFY02Ss1Hc8lpNJg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:39.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Class A</p></td></tr><tr><td style="vertical-align:bottom;width:57.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Membership Interests</p></td></tr><tr><td style="vertical-align:bottom;width:57.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Converted to common stock at one-for-two ratio</p></td></tr><tr><td style="vertical-align:bottom;width:57.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_PvS7_eCOf02Kg60XmKqo1Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc__Dxa_G-PH0m1OFr2e_u2EQ_5_2">200,463</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_F5y4v9FsWES_CUZktDE-_A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_McXaynkWpUyvXdjgLT2PrQ_6_2">200,463</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2021, the board of directors approved the creation of the 2021 Equity Incentive Plan (the &#8220;Plan&#8221;). The Plan became effective as of the completion of the corporate conversion. The Plan originally reserved an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="As_Of_4_30_2021_us-gaap_AwardTypeAxis_acxp_EquityIncentivePlan2021Member_HrihoDSDdE2dXqf1m4_VhQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_83QvOJ326kWdHv_8tPdjUQ">2,000,000</ix:nonFraction> shares of common stock, subject to annual adjustments as provided in the Plan, which was <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_acxp_EquityIncentivePlan2021Member_TIyqWUA_-EClFlY5kpwukQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_Zibw4BWffEeB-wFAWJ_ipg">408,632</ix:nonFraction> shares for 2022, of which <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="As_Of_4_30_2021_us-gaap_AwardTypeAxis_acxp_EquityIncentivePlan2021Member_HrihoDSDdE2dXqf1m4_VhQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_z14BdFycrkmHPyemfV0WUA"><ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_acxp_EquityIncentivePlan2021Member_W5IQ42UzGEy4rC9lIUrHjA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_1caikmbvYUeRXLpu8Fg-8g">537,937</ix:nonFraction></ix:nonFraction> shares are currently still available for issuance as of December 31, 2022. The purpose of the Plan is to attract, retain and incentivize directors, officers, employees, and consultants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2021, the Company granted stock options to purchase a total of <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJune2021Member_iWpvZWkOx02nS35b2LJKJg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_Mp8bx6frH0-UC_Bu6ib8TQ">807,500</ix:nonFraction> shares of common stock to its three executives and three non-employee management team members to replace the Class&#160;B Membership Interests that were cancelled in March&#160;2021. The options were issued at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJune2021Member_iWpvZWkOx02nS35b2LJKJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_Sw5oThlBcEWABwapRirCEA">6.26</ix:nonFraction>, with the employee options vesting <ix:nonFraction unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q" contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJune2021Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_xCQTnSxqU0yUl6NgiOZEdg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_zpcpxRdrgUeBIHDMh58TLw">40</ix:nonFraction>% upon issuance and the balance over <ix:nonNumeric contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJune2021Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_p0UPlSeFgEOxcBPz5o_OfQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_18ytK9Aipke4iiSA0Xl37w">36 months</ix:nonNumeric>, and the non-employee options vesting at grant date. The Company recorded general and administrative expense of $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJune2021Member_QNhUB26_yk2TvwRPRCTv5Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_ExRgtshJnUaokdC9I9MTkg">726,880</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJune2021Member_vb95mGglMUy4oh0WaAepFQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_1OKeUnLYlEOLBhsgYT3y-w">2,019,325</ix:nonFraction> for the&#160;years ended December&#160;31, 2022 and 2021, respectively, related to compensation expense for these options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In July&#160;2021, the Company granted stock options to purchase a total of <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_7_1_2021_To_7_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_D82Hstg3QkSYlPP9MHSV6Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_pi499Hp30EWGztdAxnY4HQ">1,550,000</ix:nonFraction> shares of common stock to its three executives pursuant to their respective employment agreements, the independent directors, and one consultant, pursuant to the Plan. The options were issued at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="Duration_7_1_2021_To_7_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_D82Hstg3QkSYlPP9MHSV6Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_S2dy3DITDUulCcSb2z1beQ">6.18</ix:nonFraction>, the grant date fair value, with <span style="-sec-ix-hidden:Hidden_EzWf9zq7yU2COrvaqFHBLw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-quarter of the executive&#8217;s options vesting upon issuance and the balance over <ix:nonNumeric contextRef="Duration_7_1_2021_To_7_31_2021_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_owyoKTuxS0ybPw8J5ZH77A" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_fGfkw6aVVEC47ZPXu_HZLQ">36 months</ix:nonNumeric>, and the options granted to the directors and consultants vesting over <ix:nonNumeric contextRef="Duration_7_1_2021_To_7_31_2021_srt_TitleOfIndividualAxis_acxp_IndependentDirectorsConsultantMember_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_Cgh2BZaRvECW2Z1yqwQ8tA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr__RLxQlpS1EejvCtfIpQGvA">36 months</ix:nonNumeric>. The Company recorded general and administrative expenses of $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_dQo-EEliWUuFEj9-VZ9N3g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_4jvNcZ2FDkGU8yRdXtFqfg">1,963,667</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_qx3OtHXhPUaPRIR812d3Ww" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_ir-iWhy5mkWb5uj6K-Lssw">2,379,833</ix:nonFraction> for the&#160;years ended December&#160;31, 2022 and 2021, respectively, related to compensation expense for these options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In January 2022, the Company granted stock options to purchase a total of <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_1_1_2022_To_1_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member_BaBBng1QkES6yfdBQj_5SA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_RxGPKUzSPkW0jfsp4MeFmw">80,000</ix:nonFraction> shares of common stock to seven consultants pursuant to the Plan. The options were issued at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="Duration_1_1_2022_To_1_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member_BaBBng1QkES6yfdBQj_5SA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_ARe_7KHztkqArYWd9xcqOg">4.44</ix:nonFraction>, the grant date fair value, with <span style="-sec-ix-hidden:Hidden_GOeJkjeOiU-aNE91SNMVSA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-quarter of the options vesting upon issuance and the balance over <ix:nonNumeric contextRef="Duration_1_1_2022_To_1_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_4BRIuZGIFUyVO7Kq0DGlew" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_vHfauoGEjkSFunVnvIX5WA">36 months</ix:nonNumeric>. The Company recorded general and administrative expenses of $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member_eIYvcQou2k6kRaWtqOy8qQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_dNoIvAEZ4UaY7XUq7QuZew">145,283</ix:nonFraction> for the year ended December 31, 2022 related to compensation expense for these options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">In April 2022, the Company granted stock options to purchase a total of <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_4_1_2022_To_4_30_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateApril2022Member_Jnl-Bb2R2EiM_K13OPkf4Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_ytKUc3KMNU-dRjV4UiDjjA">30,000</ix:nonFraction> shares of common stock to a new employee pursuant to the Plan. The options were issued at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="Duration_4_1_2022_To_4_30_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateApril2022Member_Jnl-Bb2R2EiM_K13OPkf4Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_wJjwDQ3OHEGlpZ0NodlHmw">3.79</ix:nonFraction>, the grant date fair value, with <span style="-sec-ix-hidden:Hidden__yx0SlixZk2t446zKw_EWA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_nxGVHgqPWEqJCWUAysfqPQ_1_2"></a><a id="Tc_vQ0vkrb8-EamZTPnY3cXzw_2_2"></a><a id="Tc_2WLYrrqlV0q7EC_ixGdtag_3_0"></a><a id="Tc_KpOBuAqMyUigeQBQLRjcTA_3_4"></a><a id="Tc_U1xg7mwlokOOc36RaE0wOw_4_0"></a><a id="Tc_CpSD-pKKn0SgfTBk_JXlTA_4_4"></a><a id="Tc_90Gp5SFzpUm23zcf2aTzHA_5_0"></a><a id="Tc_nfcdxTVzN0W2pBe90FysEw_5_3"></a><a id="Tc_kUBl9Ifbi0uZurEhZGBE3g_5_4"></a><a id="Tc_z7C0qxpk2UqSxP5WRdggmw_6_0"></a><a id="Tc_QNGQvkmLzU269SiVIwqcbw_6_4"></a><a id="Tc_Dzw4UPZmsU2XJH50tR_cEg_7_0"></a><a id="Tc_dmJ2uJKnYke30fTVVPU5sA_7_2"></a><a id="Tc_3oyEH25hr0Gzyo6T6JM--w_1_2"></a><a id="Tc_C3gseE4l3EGrUFdC82NYlQ_1_4"></a><a id="Tc_Pm6PmPAj1EOU8My5gxEVmA_2_2"></a><a id="Tc_ouXr5QE7rUiZAmcwtPjreA_2_4"></a><a id="Tc_H47B_Htiz0StpWCU-K31Dw_3_0"></a><a id="Tc_tfK4nptmK0aaB4eH4OqR-A_3_4"></a><a id="Tc_PwnC-ztQzUuq19_JAW9IjQ_4_0"></a><a id="Tc_Dwkljtm-lUiOKzvu1o5e6Q_4_4"></a><a id="Tc_Ar0rT23oQE6O2iEZQsdwsg_5_0"></a><a id="Tc_ptSsRtePfEe2N3irGA8tbg_5_2"></a><a id="Tc_s7d8Vra2c0WUARkIa8y7LQ_5_5"></a><a id="Tc_IZM3hRgsu0-FamP9Rj8eXg_6_0"></a><a id="Tc_m9HdpsGaskaD1wgTEQ-2LA_6_2"></a><a id="Tc_Nnui2Zh3EE6DoIZEeZfxSw_6_5"></a><a id="Tc_7759LbZOgkCr84wsHE9vYg_7_0"></a><a id="Tc_EmkhAToI8keU6wJhZSAOYw_7_4"></a><a id="Tc_F5iTOXy3H0CAsJ26OVDKGQ_8_0"></a><a id="Tc_i4rAVFbnmUy5kpkDfdDTkQ_8_4"></a><ix:continuation id="Tb_KAl1sVPhSkm75fQV9SKf9A_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">quarter of the options vesting upon issuance and the balance over <ix:nonNumeric contextRef="Duration_4_1_2022_To_4_30_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateApril2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_yPD_ZJI8H06PJt30JeyqDw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_OZTyuHkGi0yOYZP1fZldTQ">36 months</ix:nonNumeric>. The Company recorded general and administrative expenses of $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateApril2022Member_vR_7z-bGCUubmqFX9FxQYw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_X3WGKkZAfkimQX_eJquqVA">35,850</ix:nonFraction> for the year ended December 31, 2022 related to compensation expense for these options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Compensation expense associated with these awards is recognized over the vesting period based on the fair value of the option at the grant date determined based on the Black-Scholes option pricing model. Option valuation models require the input of highly subjective assumptions including the expected price volatility. The Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair value computation using the Black-Scholes option pricing model. Because there is no public market for the Company&#8217;s stock options and very little historical experience with the Company&#8217;s stock, similar public companies were used for the comparison of volatility and the dividend yield. The risk-free rate of return was derived from U.S. Treasury notes with comparable maturities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company determined the fair value of the option awards using the Black-Scholes option pricing model using the following weighted average assumptions:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_mB96oKJ6H0On2LZZn37JPg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Year Ended </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_whipuyNts06X85_eUQTrFg_3_3"> 9</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_2UeuKEl9kUirhHZoL1bMhw_4_3">90</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_19NBSmomSkuWJKRA90C1kw_6_3">2.01</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average grant date fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_ELIKiQA-eUaDFvsflNrdXQ_7_3">3.54</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">A summary of the Company&#8217;s stock option activity is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_9Ssx-cDm00aYMCFJfKutBA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Year Ended </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Weighted&#160;Average</p></td></tr><tr><td style="vertical-align:bottom;width:55.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Exercise&#160;Price</p></td></tr><tr><td style="vertical-align:bottom;width:55.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at the beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_22xARAZ8J0yW9Y5eMwOkHQ_3_2">2,357,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_ZUDI2GxGF0SJ8R3i_PaTWg_3_5">6.21</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_tCGLWipbNEmpOPh88OpKCg_4_2">110,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_k4kwJmoezEC8ptKCOnekLA_4_5">4.26</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:55.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:55.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at the end of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_SvX9vRiIbE-2lmIJe1C-UA_7_2">2,467,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_RbZPZlJ5y02y6Bpl4b7xLw_7_5">6.12</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_UwpnhEdBQ0u87OerPfn9Sg_8_2">1,552,333</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_PgoMw-4vUUuOcUufyo2R3g_8_5">6.15</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The total compensation expense not yet recognized as of December&#160;31, 2022 was $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" id="Narr_ZFSqaN5WA0iwHLE7nsisGw">4,243,927</ix:nonFraction>. The weighted average vesting period for the unvested options is <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_yACK6Z0UQU2hN9UsU9RGwg">1.54</ix:nonNumeric> years. The intrinsic value of the stock options as of December&#160;31, 2022 was $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Narr_-J6AKAvIPEiqPhiXlbD0OA">5,700</ix:nonFraction>, with a remaining weighted average contractual life of <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Narr_q2lrwi_5W0iDponQ7Iz-Nw">8.53</ix:nonNumeric> years. The weighted average grant date fair value of all options granted is $<ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="Narr_VA94clAlIEWWNDgrRZOSLg">4.67</ix:nonFraction> as of December&#160;31, 2022. The Company records the impact of any forfeitures of options as they occur.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="acxp:ShareBasedPaymentsToVendorsDisclosureTextBlock" id="Tb_HyXS-TPqwEuXJ6UvE6ypuw" continuedAt="Tb_HyXS-TPqwEuXJ6UvE6ypuw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NOTE&#160;8&#160;&#8211; SHARE-BASED PAYMENTS TO VENDORS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">While the Company was a limited liability company in its pre-IPO phase of corporate development, the Company granted Class&#160;A Membership Interests to certain vendors in the ordinary course of business in exchange for consulting services relating to research and development activities and investor relations. The Company granted <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_MYOlceR8bEyBXaE8PmDn2g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="Narr_8jd9D4xdDUyWlAM2B7T3gw">30,145</ix:nonFraction> Class&#160;A Membership Interests for the&#160;year ended December&#160;31, 2021. The fair value of the Class&#160;A Membership Interests granted was equal to the value of the most recent private placement. The Company recognized the expense in the same period and in the same manner as if the Company had paid cash for the services. The Company recorded general and administrative expenses and research and development expenses for vendor equity grants in the amounts of $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember_EdWadodcnUyBlBRFeYfBqg" decimals="0" format="ixt:numdotdecimal" name="acxp:ShareBasedPaymentToVendors" scale="0" id="Narr_zIPLWyJmjEK3Obw0vrwAPQ">0</ix:nonFraction> for the year ended December 31, 2022 and $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_At7Vvf6ODEu2VV8vZNhcWQ" decimals="0" format="ixt:numdotdecimal" name="acxp:ShareBasedPaymentToVendors" scale="0" id="Narr_4uwicf0r7kiLmSq4WJS72Q">201,375</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_m2h7V2EdPEine3-RW3GKcg" decimals="0" format="ixt:numdotdecimal" name="acxp:ShareBasedPaymentToVendors" scale="0" id="Narr_ezxfJ67vuE63njPgRZZC5g">21,596</ix:nonFraction> for the&#160;year ended December&#160;31, 2021, respectively.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_HyXS-TPqwEuXJ6UvE6ypuw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2019, the Company granted a total of <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_Gf1McXFwrk6xhgFzNeubnw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="Narr_RF90H45TJUyYyYbqzupRrw">150,000</ix:nonFraction> restricted Class&#160;A Membership Interests to three consultants for investor relations consulting services performed in 2019 through October&#160;2021. These Class&#160;A Membership Interests vested on the second anniversary of the grant date, and were subject to accelerated vesting provisions upon a change of control of the Company. The fair value of the Class&#160;A Membership Interests granted was equal to the value of the most recent private placement, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="As_Of_10_31_2019_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_619kTaw0GEyZLXk7eliAdQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_HdFtSLq260K2psD0cq_hcg">2.00</ix:nonFraction> per Class&#160;A Membership Interest. The Company recognized the expense on a straight-line basis over the vesting period. The Company recorded general and administrative expenses of $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member_glK66UkK8kaOPtF_EMotIg" decimals="0" format="ixt:numdotdecimal" name="acxp:ShareBasedPaymentToVendors" scale="0" id="Narr_Y4IZxP4-902ut8ix_aF54g">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member_TsKzRMZrzEyys7D-3GS8aw" decimals="0" format="ixt:numdotdecimal" name="acxp:ShareBasedPaymentToVendors" scale="0" id="Narr_CeEuvLSoo0iAo-HBBJKEWg">125,000</ix:nonFraction> for the&#160;years ended December&#160;31, 2022 and 2021, respectively. The conversion adjusted shares of common stock were issued in October&#160;2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In the second quarter of 2021, the Company entered into a number of agreements with vendors pursuant to which the Company made grants of a total of <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member_w1T2TY_SNkCVkeO9pZPLhA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="Narr_cjNzVSC8KUWROyhE6621PQ">175,000</ix:nonFraction> shares of common stock with a grant date fair value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="As_Of_6_30_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member_mxmMtGXpS0GIYfMeHwojow" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_s2B43oT9pUy_Ep4GfjCnrg">6.26</ix:nonFraction>, cash payments in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member_w1T2TY_SNkCVkeO9pZPLhA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToSuppliers" scale="0" id="Narr_my8DozThaU6QQ6_igzG2nw">343,500</ix:nonFraction>, and <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_g7TcRnVZ-EeKEa9jZmWMBw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_M_Lndmh2IUeCkgKR-KfA-Q">100,000</ix:nonFraction> options which were included as a part of the July&#160;2021 grant. These contracts have terms which range from <ix:nonNumeric contextRef="Duration_4_1_2021_To_6_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member_wrQ7Eh3v4EOO3IZeFBTejw" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_F3KarQywwkeXl4bTA4L0yA">six months</ix:nonNumeric> to <ix:nonNumeric contextRef="Duration_4_1_2021_To_6_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member_F_YLDKPV7UizWtFPSMLXBw" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr__w8xjg0sykq42t0uomWRFw">three years</ix:nonNumeric>. The common stock was valued based on the grant date fair value and the options valued utilizing Black-Scholes option pricing model. The cash payments were expensed over the service period and the equity component expensed consistent with the contractual vesting. These shares and options were granted in the third quarter of 2021 pursuant to the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In the third quarter of 2021, the Company granted vendors a total of <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantedInThirdQuarter2021Member_I8bs4d9ViU-viuLd-_7bTQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="Narr_3KOgGrEya0m8Gc7JuBWFgw">35,695</ix:nonFraction> shares of common stock, which fully vested in 2021, pursuant to the Plan. The Company recorded general and administrative expense of $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantedInThirdQuarter2021Member_Tlp76MoUFEqKyMnI6aK_eQ" decimals="0" format="ixt:numdotdecimal" name="acxp:ShareBasedPaymentToVendors" scale="0" id="Narr_5qEXVxl9EkuMSJbADTTeIg">208,270</ix:nonFraction>, based on the respective grant date fair values, for the&#160;year ended December&#160;31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2021, the Company entered into an agreement with a consultant to provide financial advisory services for a <ix:nonNumeric contextRef="Duration_10_1_2021_To_10_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateOctober2021Member_6LGtqepcjEOliJ4jOXHUIA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_SoDJEbMebkqNIWsB2vIX_g">six-month</ix:nonNumeric> term. Pursuant to the agreement, the Company granted $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_10_1_2021_To_10_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateOctober2021Member_6LGtqepcjEOliJ4jOXHUIA" decimals="0" format="ixt:numdotdecimal" name="acxp:ShareBasedPaymentToVendors" scale="0" id="Narr_Xcly0RZrxkydyMuUE0yL4g">150,000</ix:nonFraction> of common stock over the term of service. The Company granted total of <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_10_1_2021_To_10_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateOctober2021Member_6LGtqepcjEOliJ4jOXHUIA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="Narr_EDKL85QzfkyPxIujxgRINw">27,778</ix:nonFraction> shares of common stock at grant date fair value and recorded general and administrative expenses of $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateOctober2021Member_5i2X2rTyx0SYX8Xybc8Psw" decimals="0" format="ixt:numdotdecimal" name="acxp:ShareBasedPaymentToVendors" scale="0" id="Narr_vQSClH2f2UuLsJdn1NxRvg"><ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateOctober2021Member_WyWUGX-ss020568gQjYm8g" decimals="0" format="ixt:numdotdecimal" name="acxp:ShareBasedPaymentToVendors" scale="0" id="Narr_748ZcNeJPEKvWtRcCY_CPA">75,000</ix:nonFraction></ix:nonFraction> for each of the&#160;years ended December&#160;31, 2022, and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In March 2022, the Company entered into an agreement with a consultant to provide investor relation services for a <ix:nonNumeric contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateMarch2022Member_-nNTg44K_E6nnbx1CwtZmQ" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_SvvdNK_ilEKEkiKG5yvkGA">six-month</ix:nonNumeric> term. Pursuant to the agreement, the Company granted <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateMarch2022Member_-nNTg44K_E6nnbx1CwtZmQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="Narr_SqUd0tSvX0Cd_Ci4_x_0rA">30,000</ix:nonFraction> shares of common stock with a grant date fair value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="As_Of_3_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateMarch2022Member_XlEHT5yyoES9L354AxvHSw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_5kFzUrTBO0GCiGBKADbEjw">3.77</ix:nonFraction> and paid $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateMarch2022Member_-nNTg44K_E6nnbx1CwtZmQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToSuppliers" scale="0" id="Narr_V09Ufb5Tg0amKOnRN7Fcig">25,000</ix:nonFraction> of cash compensation The cash component was expensed over the service period and the equity component was expensed consistent with the contractual vesting. The Company recorded general and administrative expenses of $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateMarch2022Member_laHCYr4uL0S16Yf2nc-A4A" decimals="0" format="ixt:numdotdecimal" name="acxp:ShareBasedPaymentToVendors" scale="0" id="Narr_QHwyyo7FKUmCOTL0UEXQNw">113,100</ix:nonFraction> for the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In September 2022, the Company entered into an agreement with a company to provide consulting services for a <span style="-sec-ix-hidden:Hidden_pe6sq_5jwkGHEr32NVYkWA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">six-month</span></span><span style="white-space:pre-wrap;"> term.  Pursuant to the agreement, the Company granted </span><ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_9_1_2022_To_9_30_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateSeptember2022Member_8MlpVu0cokmsSI5c6YJyTg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="Narr_Miw8gIrQfUacUT7EiMcB4g">36,000</ix:nonFraction> shares of common stock with a grant date fair value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="As_Of_9_30_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateSeptember2022Member_lQ0vComUSUesFn-c_7_IYg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_GJsWzWAQVUWqvrwomu0h3A">3.53</ix:nonFraction><span style="white-space:pre-wrap;">, which was expensed consistent with the contractual vesting.  The Company recorded general and administrative expenses of </span>$<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateSeptember2022Member_FgQUZhXKi0mL6FXLRm0gIQ" decimals="0" format="ixt:numdotdecimal" name="acxp:ShareBasedPaymentToVendors" scale="0" id="Narr_DJhcDkm1hE2PdoQbROcpLw">127,080</ix:nonFraction><span style="white-space:pre-wrap;"> for the year ended December 31, 2022.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In the fourth quarter of 2022, the Company entered into a number of agreements with vendors pursuant to which the Company will make grants of a total of <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_10_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member_90xI89oKiEeLdXH5k-9FsA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="Narr_ZUDCIKCF80qE8eRF3dMyQQ">43,186</ix:nonFraction> share of common stock with a grant date fair values ranging from $<ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member_7kblQvMdtEmqcKGRTUh1qw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_PDIx5PA9YEinBnPyJAN_IA">3.30</ix:nonFraction> to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng" contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member_YIfVK7k8V069cOaEAb-EWA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_LfXzLV_XcU2RSwUzJ4putA">3.67</ix:nonFraction>, up to <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="As_Of_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member_UmPpwgUbXEq7CaPHpNFPOg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_vEjU-cha60eYBPxxscAuhQ">10,096</ix:nonFraction><span style="white-space:pre-wrap;"> of warrants, and cash payments.  These contracts have </span><span style="-sec-ix-hidden:Hidden_xpnuvER5pkCZfclL6LaL-Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">six-months</span></span><span style="white-space:pre-wrap;"> terms with various contractual vesting periods.  The cash payments will be expensed over the service period and the equity component will be expensed consistent with the various contractual vesting periods.  The Company recorded general and administrative expenses of </span>$<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member_dxrWwDmqfUKvdyQbLpmhnA" decimals="0" format="ixt:numdotdecimal" name="acxp:ShareBasedPaymentToVendors" scale="0" id="Narr_icmzTVpj9kai_BI4GjBUCA">115,500</ix:nonFraction> for the year ended December 31, 2022.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_k3ELON3oh02k_nxMhqx_5g" continuedAt="Tb_k3ELON3oh02k_nxMhqx_5g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NOTE&#160;9&#160;&#8211; INCOME TAXES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company has $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_RhsfWXp1O0eZpgL50bp_dw">10.7</ix:nonFraction> million of net operating loss carryforwards and $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_JhOvv4-Snk2R560WdGXkrQ">0.1</ix:nonFraction> million of research tax credit carryforwards as of December&#160;31, 2022. The net operating loss carryforwards are indefinite lived and research tax credit carryforwards will expire in 2042. Net operating loss and tax credit carryforwards may become subject to annual limitations in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined by Sections 382 and 383 of the Internal Revenue Code as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The components of the net deferred income tax asset at December&#160;31, 2022 and 2021 are as follows:</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_LGkL8VmXxE-wlcMZBIO30A_1_2"></a><a id="Tc_h1zFi-9cWki1FLhRSfPoAA_1_5"></a><a id="Tc_GQfeVZdg9UC4Ne0KdCuuLQ_2_0"></a><a id="Tc_qKZBU1OYEEaCkuCvYsev3w_3_0"></a><a id="Tc_19kaZI7bGUejlnGkaaSPtg_3_2"></a><a id="Tc_QmSXK3L3BEeUsaXwG2--RA_3_5"></a><a id="Tc_00jSC0MyOEiz3W8JANleSA_4_0"></a><a id="Tc_1NR_B_64s02UB97Lh8UPxg_5_0"></a><a id="Tc_f5YubLECsEegdE61L9xV2w_6_0"></a><a id="Tc_HXVq407TcE-Ovsj9NJcuTQ_6_6"></a><a id="Tc_kuiBKrJn2UqLFhTuWN0fIw_7_0"></a><a id="Tc_7EYuZe0_P0-xA26dc2ee-g_8_0"></a><a id="Tc_G8w73pu6wEGzmguZeBMk6g_9_0"></a><a id="Tc_Ysx2Hg_t80-PQe76Z00pdg_9_2"></a><a id="Tc_81XXCjoWr0G_yG1LZKENQA_9_3"></a><a id="Tc_EJEI6YuG80OtYZYBLg00AQ_9_5"></a><a id="Tc_ygebbiLMVEKi1SCInoh_1w_9_6"></a><a id="Tc_1pzfD9fEi02IX50Yd6TZgw_1_1"></a><a id="Tc_db7PVBfqVkKw5ZiWY36DoQ_1_4"></a><a id="Tc_T3g87YfyAUmZaF_b3VlTTg_2_0"></a><a id="Tc_SAZqQKnmHEiGUcEKgrz5HA_2_2"></a><a id="Tc_68KNUvbaLE2mBYCLkod3qQ_2_5"></a><a id="Tc_VSVE8qgfEU-jLVJMBGpxqg_3_0"></a><a id="Tc_QesqPmAglEOfyGSps9Qm-g_4_0"></a><a id="Tc_dBkZIh9opkChmn8mJWD6ng_4_4"></a><a id="Tc_JQIWeW1SdUGKmdWVPJ04RA_5_0"></a><a id="Tc_Y8i5ixLf70OBgy0HH6kCwQ_6_0"></a><a id="Tc_v_Cg3rIQQUegM87Gfgp0_Q_7_0"></a><a id="Tc_vkTqh7FKvEapve4Ym9pyrQ_7_1"></a><a id="Tc_ikz5tcZFKkeyYLRnbZcAQQ_7_2"></a><a id="Tc_Erazd0E98UWXXyX0GiF-1Q_7_4"></a><a id="Tc_amOXizt_DkqAfTw_-naAUw_7_5"></a><ix:continuation id="Tb_k3ELON3oh02k_nxMhqx_5g_cont1"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_vEW6edb1O0ibfvaDgKeEeg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Net operating loss carry forwards</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_e-w-RJ4ViECjmRS4_kGcRg_3_3">3,359,183</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_VnW-BUeaskatMKM9FAu1Fg_3_6">1,594,650</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Share-based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" id="Tc_TMr7T_eQlkyUhzT5Ztwzaw_4_3">2,262,381</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" id="Tc_Q3AhFMZIH0WrIlOxzdzz-g_4_6">1,149,720</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Research and development credit carryforwards</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" id="Tc_vJjB2CjL1UGClyiiUxJoPQ_5_3">141,671</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" id="Tc_lsTYdC86zEy8CxMAv8f_Ow_5_6">105,881</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Capitalized research and development </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="0" id="Tc_zPuJizMTAEi2EDEtcQ2mPw_6_3">1,347,028</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Gross deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_uiviOngoWkGfgWJ7htH7wQ_7_3">7,110,263</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_-ZjacOLyi0ewUprjMdn0kw_7_6">2,850,251</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_zi9XNSdG8UOixp972tt5FA_8_3">7,110,263</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_Bg22lZQpokCyMemWdegZaA_8_6">2,850,251</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">    Net deferred tax asset</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Tax Cuts and Jobs Act of 2017 (TCJA) amended IRC Section 174 to require capitalization of all research and developmental (R&amp;D) costs incurred in tax years beginning after December 31, 2021. These costs are required to be amortized over five years if the R&amp;D activities are performed in the U.S., or over 15 years if the activities were performed outside the U.S. The Company capitalized approximately $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired" scale="6" id="Narr_Q2tg3l4r0Uuw5K2jFttucg">4.3</ix:nonFraction> million of R&amp;D expenses incurred as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In assessing the realizability of deferred tax assets, the Company considers whether it is more-likely-than-not that some portion or all the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the temporary differences representing net future deductible amounts become deductible. After consideration of all the evidence, both positive and negative, the Company has recorded a full valuation allowance against their net deferred tax assets at December&#160;31, 2022 because the Company has concluded that it is more-likely-than-not that these assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">A reconciliation of income tax expense (benefit) at the statutory Federal income tax rate and income taxes as reflected in the financial statements for both&#160;years ended December&#160;31, 2022 and 2021 is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_V-Mz0xg_Q0-xS7XTH_Siig" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:49.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:81.59%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:16.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:17.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Federal income tax expense at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_huLn2AfGpEaUipyFeXvg1Q_2_1">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_xBCgzGu63kiszIwvAXjE-A_2_4">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State income tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_id0cXTHYUUKl1yGcyrJ0UA_3_1">14.4</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_5-6EvSL9dE-vdFVAJEMeBQ_3_4">5.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" sign="-" scale="-2" id="Tc_n-XvKW6mZ0mpFcef08oGbQ_4_1">0.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development tax credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" id="Tc_5fMXiAbxa0irRyfPflh4VA_5_1">0.3</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" id="Tc_qu0Qo0uJiEmtsjhnRI9-Dw_5_4">1.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q" contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_Iln44orXs0acuIuorPe-xA_6_1">35.2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q" contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_KJemDoaeJki7isOLpGWJKg_6_4">27.1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company files income tax returns in the U.S. and the State of New York. The tax&#160;years 2022 and 2021 are open and potentially subject to examination by the federal and state taxing authorities. The Company is currently not under examination by the Internal Revenue Service (&#8220;IRS&#8221;) or any other jurisdictions for any tax&#160;years and has no knowledge of any pending examinations by the IRS or any other jurisdictions. To the extent the Company utilizes any tax attributes from a tax period that may otherwise be closed due to statute expiration, the IRS, state tax authorities, or other governing parties may still adjust the tax attributes upon their examination of the future period in which the attribute was utilized. There are <ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Narr_r-zZ8cyhsEuNoebgw9uYQg">no</ix:nonFraction> uncertain tax positions recorded for any federal or state positions. The Company&#8217;s policy is to record interest and penalties related to tax matters in income tax expense.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="us-gaap:EarningsPerShareTextBlock" id="Tb_-OrNgNCjEESdrFC4hKrcLw" continuedAt="Tb_-OrNgNCjEESdrFC4hKrcLw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NOTE&#160;10&#160;&#8211; NET LOSS PER SHARE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On June&#160;23, 2021, the Company completed a corporate conversion from a limited liability company to a corporation. Accordingly, the outstanding Class&#160;A and Class&#160;B Membership Interests were converted to shares of common stock using a conversion ratio of one-half of one share of common stock for each Class&#160;A membership interest or Class&#160;B membership interest, resulting in the conversion of <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_6_23_2021_To_6_23_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassAndClassBMemberSCapitalMember_9R3-6dGcWEaNHCoKMihkrA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_6e_PeRloPEuHfm4ML_uooQ">14,082,318</ix:nonFraction> Class&#160;A and Class&#160;B Membership Interests into <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_6_23_2021_To_6_23_2021_TsxTykL9E0-yFWUKq9d3cQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" id="Narr_fbc3b-o1KkayBfqoqB8wPA">7,041,208</ix:nonFraction> shares of common stock.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_-OrNgNCjEESdrFC4hKrcLw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Basic and diluted net loss per share of common stock for the year ended December&#160;31, 2022 was determined by dividing net loss by the weighted average shares of common stock outstanding during the period. The Company&#8217;s potentially dilutive shares, consisting of <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_HEBRdNbrGUqT6x6-UyBm6w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_NucdiJBPNEG7ScwsEXhctg">4,217,809</ix:nonFraction> warrants, and <ix:nonFraction unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_m6mpGMbdVU2n0bKhzjnGLA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr__JjyfxZhQEqLHlr3U3R68Q">2,467,500</ix:nonFraction> stock options, have not been included in the computation of diluted net loss per share for all periods as the result would be antidilutive. The effects of the corporate conversion on the Company&#8217;s weighted average shares of common stock outstanding and net loss per share have been reflected for all periods presented retroactively.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_A8HLpTb-YU-woTDsAthQaw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NOTE&#160;11&#160;&#8211; COMMITMENTS AND CONTINGENCIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">In conjunction with the Asset purchase in February&#160;2018, the Company is required to make certain milestone payments related to the ongoing development of ACX-362E totaling $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="As_Of_2_28_2018_srt_ProductOrServiceAxis_acxp_AcxThreeSixtyTwoEMember_b8X5m76NYkaaQE7rN9N3KQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherCommitment" scale="0" id="Narr_UFM7mYLHd0-ZvDfW0m1eRQ">700,000</ix:nonFraction> in the aggregate if certain milestones are achieved (which includes $<ix:nonFraction unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ" contextRef="Duration_2_1_2018_To_2_28_2018_srt_ProductOrServiceAxis_acxp_AcxThreeSixtyTwoEMember_Ney4atHhPEWi0zip1SpT4Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="0" id="Narr_n7fzBuEAY0ulpe69i3hQqQ">50,000</ix:nonFraction> already paid after the acquisition in February&#160;<span style="white-space:pre-wrap;">2018). There were no milestones reached during 2022 and 2021.  The Company is also obligated to make royalty payments equal to </span><ix:nonFraction unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q" contextRef="Duration_2_1_2018_To_2_28_2018_srt_ProductOrServiceAxis_acxp_AcxThreeSixtyTwoEMember_Ney4atHhPEWi0zip1SpT4Q" decimals="2" format="ixt:numdotdecimal" name="acxp:PercentageOfRoyaltyPaymentsOnNetSales" scale="-2" id="Narr_KgMD7erwGkmzM3wdDAAeEw">4</ix:nonFraction>% of net sales of ACX-362E for a period of time equal to the last to expire of any applicable patents, as defined in the purchase agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.6
<SEQUENCE>2
<FILENAME>acxp-20221231xex4d6.htm
<DESCRIPTION>EX-4.6
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/15/2023 09:18:51 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit 4.6</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REGISTERED PURSUANT TO SECTION 12 OF THE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Acurx Pharmaceuticals, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, par value $0.001 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Description of Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The following description of our common stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to our certificate of incorporation and our bylaws, each of which are incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4.2 is a part. We encourage you to read our certificate of incorporation and our bylaws for a description of the rights, restrictions and obligations relating to our capital stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Authorized Capital Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our authorized capital shares consist of 200,000,000 shares of common stock, $0.001 par value per share, and 10,000,000 shares of preferred stock, $0.001 par value per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Voting Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The holders of our common stock are entitled to one vote for each share held of record on all matters on which the holders are entitled to vote (or consent to).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Dividend Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The holders of our common stock are entitled to receive, ratably, dividends only if, when and as declared by our board of directors out of funds legally available therefor and after provision is made for each class of capital stock having preference over the common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Liquidation Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In the event of our liquidation, dissolution or winding-up, the holders of our common stock may be entitled to share, ratably, in all assets remaining available for distribution after payment or provision for payment of all debts and other liabilities and subject to the rights of each class or series of capital stock having preference over, or right to participate with, the common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Preemptive and Similar Rights.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The holders of our common stock have no preemptive or similar rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Listing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The common stock is traded on The Nasdaq Stock Market LLC under the trading symbol &#8220;ACXP.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Description of Preferred Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under our certificate of incorporation, our board of directors is authorized to direct us to issue shares of preferred stock in one or more series without stockholder approval. Our board of directors has the discretion to determine the powers, privileges, preferences and relative participating, optional and other special rights, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The purpose of authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could have the effect of making it more difficult for a third-party to acquire, or could discourage a third-party from seeking to acquire, a majority of our outstanding voting stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Description of Warrants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of December 31, 2022, there were 4,217,809 warrants to purchase an aggregate of 4,217,809 shares outstanding. Our series A warrants are exercisable for an aggregate of 1,289,980 shares of common stock (consisting of series A warrants to purchase up to 1,230,769 shares of common stock for the investor (the &#8220;Investor Series A Warrants&#8221;) and series A warrants to purchase up to 59,211 shares of common stock for the affiliate investors (the &#8220;Affiliate Series A Warrants&#8221;)) at an exercise price of $3.25 per share for the Investor Series A Warrants and $3.55 per share for the Affiliate Series A Warrants. Each series A warrant was exercisable commencing on January 27, 2023 and will expire on January 27, 2028. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our series B warrants are exercisable for an aggregate of 1,289,980 shares of common stock (consisting of series B warrants to purchase up to 1,230,769 shares of common stock for the investor (the &#8220;Investor Series B Warrants&#8221;) and Series B Warrants to purchase up to an aggregate of 59,211 shares of common stock for the affiliate investors (the &#8220;Affiliate Series B Warrants&#8221;)) at an exercise price of $3.25 per share for the Investor Series B Warrants and $3.55 per share for the Affiliate Series B Warrants. Each series B warrant was exercisable commencing on January 27, 2023 and will expire on January 27, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our underwriter warrants issued in connection with our initial public offering are exercisable for an aggregate amount of 150,000 shares of common stock at an exercise price of $7.50 per share. Each underwriter warrant was exercisable commencing on December 21, 2021 and will expire on June 24, 2026. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our placement agent warrants issued in connection with our registered direct offering are exercisable for an aggregate amount of 63,018 shares of common stock at an exercise price of $3.60 per share. Each placement agent warrant was exercisable commencing on January 27, 2023 and will expire on July 27, 2027. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><font style="white-space:pre-wrap;">Our purchase warrants are exercisable for an aggregate of 1,424,831 shares of common stock at a weighted average exercise price of $2.88 per share. Each purchase warrant was issued in connection with private placement financings prior to our initial public offering and will expire on the tenth anniversary of each respective issuance.  </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The exercise price and the number of warrant shares purchasable upon the exercise of the warrants are subject to adjustment upon the occurrence of certain events, including stock dividends, stock splits, combinations and reclassifications of our capital stock. The warrants also contain a &#8220;cashless exercise&#8221; provision. The warrants do not confer upon the holders thereof any voting, dividend or other rights as our stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Subject to limited exceptions, certain holders of warrants will not have the right to exercise any portion of its warrants if the holder (together with such holder&#8217;s affiliates, and any persons acting as a group together with such holder or any of such holder&#8217;s affiliates) would beneficially own a number of shares of common stock in excess of 4.99% (or, at the election of the purchaser, 9.99%) of the shares of our common stock then outstanding after giving effect to such exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Forum Selection</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our certificate of incorporation and our bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the DGCL, our certificate of incorporation or our bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. Notwithstanding the foregoing, the exclusive forum provision does not apply to suits brought to enforce any liability or duty created by the Exchange Act, the Securities Act or any other claim for which the federal courts have exclusive jurisdiction. Unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by applicable law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. The choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Anti-Takeover Provisions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our certificate of incorporation and bylaws contain provisions that may delay, defer or discourage another party from acquiring control of us. We expect that these provisions, which are summarized below, will discourage coercive takeover practices or inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors, which we believe may result in an improvement of the terms of any such acquisition in favor of our stockholders. However, they also give our board of directors the power to discourage acquisitions that some stockholders may favor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">Authorized but unissued shares</i>. The authorized but unissued shares of our common stock and our preferred stock are available for future issuance without stockholder approval, subject to the requirements of any national securities exchange on which our common stock is listed, should we so qualify for listing. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could make more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">Elimination of Stockholder Action by Written Consent</i>. Our certificate of incorporation will eliminate the right of stockholders to act by written consent without a meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">Special meetings of stockholders</i>. Our certificate of incorporation and bylaws provide that, except as otherwise required by law or provided by the resolution or resolutions adopted by our board of directors designating the rights, powers and preferences of any series of preferred stock, special meetings of our stockholders may be called only by (a)&#160;our board of directors pursuant to a resolution approved by a majority of the total number of our directors that we would have if there were no vacancies or (b)&#160;the chair of our board of directors, and any power of our stockholders to call a special meeting is specifically denied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">Advance notice requirements for stockholder proposals and director nominations</i>. Our bylaws provide for an advance notice procedure for stockholder proposals to be brought before an annual meeting of stockholders, including proposed nominations of candidates for election to our board of directors. In order for any matter to be &#8220;properly brought&#8221; before a meeting, a stockholder must comply with advance notice and duration of ownership requirements and provide us with certain information. Stockholders at an annual meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors or by a qualified stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has delivered timely written notice in proper form to our secretary of the stockholder&#8217;s intention to bring such business before the meeting. These provisions could have the effect of delaying stockholder actions that are favored by the holders of a majority of our outstanding voting securities until the next stockholder meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">Amendment of Certificate of Incorporation or Bylaw</i>s. The DGCL provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&#8217;s certificate of incorporation, unless a corporation&#8217;s certificate of incorporation requires a greater percentage. Our certificate of incorporation provides that certain provisions of our certificate of incorporation (namely, those provisions relating to (i)&#160;directors; (ii)&#160;limitation of director liability, indemnification and advancement of expenses and renunciation of corporate opportunities; (iii)&#160;meetings of stockholders; and (iv)&#160;certain amendments to our certificate of incorporation and bylaws) may not be altered, amended or repealed in any respect (including by merger, consolidation or otherwise), nor may any provision inconsistent therewith be adopted, unless such alteration, amendment, repeal or adoption is approved by the affirmative vote of the holders of at least sixty-six and two-thirds percent (662&#8725;3%) of the voting power of all of our then-outstanding shares then entitled to vote generally in an election of directors, voting together as a single class. Our certificate of incorporation and bylaws also provide that approval of stockholders holding sixty-six and two-thirds percent (662&#8725;3%) of the voting power of all of our then-outstanding shares entitled to vote generally in an election of directors, voting together as a single class, is required for stockholders to make, alter, amend, or repeal any provision of our bylaws. Our board of directors retains the right to alter, amend or repeal our bylaws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">Classified Board of Directors</i>. Our certificate of incorporation provides for a classified board of directors consisting of three classes of approximately equal size, each serving staggered three-year terms. Only the directors in one class will be subject to election by a plurality of the votes cast at each annual meeting of stockholders, with the directors in the other classes continuing for the remainder of their respective three-year terms. Stockholders do not have the ability to cumulate votes for the election of directors.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Limitations on Liability and Indemnification of Officers and Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our certificate of incorporation and bylaws provides indemnification for our directors and officers to the fullest extent permitted by the DGCL. We have entered into Indemnification Agreements with each of our directors that may be, in some cases, broader than the specific indemnification provisions contained under the DGCL. In addition, as permitted by the DGCL, our certificate of incorporation and bylaws includes provisions that eliminate the personal liability of our directors for monetary damages resulting from breaches of certain fiduciary duties as a director. The effect of this provision is to restrict our rights and the rights of our stockholders in derivative suits to recover monetary damages against a director for breach of fiduciary duties as a director. These provisions may be held not to be enforceable for violations of the federal securities laws of the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Section&#160;203 of the Delaware General Corporation Law</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We are subject to the provisions of Section&#160;203 of the DGCL. In general, Section&#160;203 prohibits a publicly-held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a three-year period following the time that such stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. A &#8220;business combination&#8221; includes, among other things, a merger, asset or stock sale or other transaction resulting in a financial benefit to the </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">interested stockholder. An &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or did own within three years prior to the determination of interested stockholder status, 15% or more of the corporation&#8217;s voting stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Under Section&#160;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8226;</p></td><td style="vertical-align:top;width:93.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">before the stockholder became interested, the board of directors approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8226;</p></td><td style="vertical-align:top;width:93.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances; or</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8226;</p></td><td style="vertical-align:top;width:93.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">at or after the time the stockholder became interested, the business combination was approved by the board of directors of the corporation and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock that is not owned by the interested stockholder.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">A Delaware corporation may &#8220;opt out&#8221; of these provisions with an express provision in its original certificate of incorporation or an express provision in its amended and restated certificate of incorporation or by-laws resulting from a stockholders&#8217; amendment approved by at least a majority of the outstanding voting shares. We have not opted out of these provisions. As a result, mergers or other takeover or change in control attempts of us may be discouraged or prevented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Listing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our common stock will be listed on The Nasdaq Capital Market under the symbol &#8220;ACXP.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Transfer Agent and Registrar</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The transfer agent and registrar of our common stock is VStock Transfer, LLC. They are located at 18 Lafayette Place, Woodmere, New York 11598. Their telephone number is (212) 828-8436.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>acxp-20221231xex21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/15/2023 09:18:50 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit 21.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">SUBSIDIARIES OF THE REGISTRANT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">None.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>acxp-20221231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/15/2023 09:18:50 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We consent to the incorporation by reference in the Registration Statements on Form S-1 (333-267412), Form S-3 (333-265956) and Form S-8 (333-258026 and 333-263609) of our report, which includes an explanatory paragraph relating to the Company&#8217;s ability to continue as a going concern, dated March 15, 2023, on our audits of the consolidated financial statements of Acurx Pharmaceuticals, Inc. as of December 31, 2022 and 2021 and for the years then ended, included in this Annual Report on Form 10-K of Acurx Pharmaceuticals, Inc. for the year ended December 31, 2022. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">/s/ CohnReznick LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Parsippany, New Jersey</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 15, 2023&#160;</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>acxp-20221231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/15/2023 09:18:51 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATIONS UNDER SECTION 302</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">I, David P. Luci, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font>I have reviewed this annual report on Form 10-K of Acurx Pharmaceuticals, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font>The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a)</font></font>designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">b)</font></font>designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">c)</font></font>evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">d)</font></font>disclosed in this report any change in the registrant&#39;s internal control over financial reporting that occurred during the registrant&#39;s most recent fiscal quarter (the registrant&#39;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#39;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font>The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a)</font></font>all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">b)</font></font>any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Date: March 15, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><font style="margin-left:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:46.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ David P. Luci</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">       David P. Luci</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">       President and Chief Executive Officer</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">       (Principal Executive Officer)</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>acxp-20221231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/15/2023 09:19:04 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATIONS UNDER SECTION 302</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">I, Robert G. Shawah, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font>I have reviewed this annual report on Form 10-K of Acurx Pharmaceuticals, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font>The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a)</font></font>designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">b)</font></font>designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">c)</font></font>evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">d)</font></font>disclosed in this report any change in the registrant&#39;s internal control over financial reporting that occurred during the registrant&#39;s most recent fiscal quarter (the registrant&#39;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#39;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font>The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a)</font></font>all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">b)</font></font>any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Date: March 15, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:50.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Robert G. Shawah</p></td></tr><tr><td style="vertical-align:bottom;width:50.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">       Robert G. Shawah</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">       Chief Financial Officer</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">      (Principal Financial Officer and Principal Accounting Officer)</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>acxp-20221231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/15/2023 09:19:09 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATIONS UNDER SECTION 906</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Acurx Pharmaceuticals, Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Annual Report for the year ended December 31, 2022 and 2021 (the &#8220;Form 10-K&#8221;) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Dated: March 15, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td style="vertical-align:bottom;width:46.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ David P. Luci</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">David P. Luci</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>acxp-20221231xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/15/2023 09:19:10 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATIONS UNDER SECTION 906</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Acurx Pharmaceuticals, Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Annual Report for the year ended December 31, 2022 and 2021 (the &#8220;Form 10-K&#8221;) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Dated: March 15, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:50.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:46.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Robert G. Shawah</p></td></tr><tr><td style="vertical-align:bottom;width:50.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Robert G. Shawah</p></td></tr><tr><td style="vertical-align:bottom;width:50.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:bottom;width:50.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial Officer and Principal Accounting Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>acxp-20221231x10k002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 acxp-20221231x10k002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $M J$# 2(  A$! Q$!_\0
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MF_Y[^'__  5G_P".5\N44?V3@/\ GS'[D'/+N?4?_#R+XS?\]_#_ /X*S_\
M'*/^'D7QF_Y[^'__  5G_P".5\N44?V3@/\ GS'[D'/+N?4?_#R+XS?\]_#_
M /X*S_\ '*U/"W_!1+XP:OXGT>QN)]!-O=7D,$FS3"#M:15.#YG!P37R16YX
M#_Y'GPY_V$K;_P!&K43RK J#:HQ^X:G+N?5_Q/\ ^"@/Q:\)?$/Q%HVGS:&+
M*QO9((1+II9MJGC)\P9-<O\ \/(OC-_SW\/_ /@K/_QRO%OCK_R6/QE_V$YO
MYUPM9T,JP,J4&Z,;V73R!SE?<^H_^'D7QF_Y[^'_ /P5G_XY1_P\B^,W_/?P
M_P#^"L__ !ROERBM_P"R<!_SYC]R%SR[GU'_ ,/(OC-_SW\/_P#@K/\ \<H_
MX>1?&;_GOX?_ /!6?_CE?+E%']DX#_GS'[D'/+N?4?\ P\B^,W_/?P__ ."L
M_P#QRC_AY%\9O^>_A_\ \%9_^.5\N44?V3@/^?,?N0<\NY]1_P##R+XS?\]_
M#_\ X*S_ /'*/^'D7QF_Y[^'_P#P5G_XY7RY11_9. _Y\Q^Y!SR[GU'_ ,/(
MOC-_SW\/_P#@K/\ \<H_X>1?&;_GOX?_ /!6?_CE?+E%']DX#_GS'[D'/+N?
M4?\ P\B^,W_/?P__ ."L_P#QRC_AY%\9O^>_A_\ \%9_^.5\N44?V3@/^?,?
MN0<\NY]1_P##R+XS?\]_#_\ X*S_ /'*/^'D7QF_Y[^'_P#P5G_XY7GW[,?[
M.=Y^T?XQO](BU/\ L2PL+3[3<Z@8/."DMM1 N1RWS'KT6N5^+'PJOOA-\4]5
M\%ZA-YTME=+"EUY>T31O@I(%SQE6!QGVKE6#RIUGAU3CSI7:MT*YIVO<]K_X
M>1?&;_GOX?\ _!6?_CE'_#R+XS?\]_#_ /X*S_\ '*YK]I_]D?5?V<K/1=37
M5#XAT34@8S>K;>3Y$X&X1L-QZKR#GG##M5N[_9:\/>'X?AS=^)?B+!X>TOQ=
MHTFJM>W5E\EHX6)EA^_\V[S#SQ]SWKGC2R>=.-6-.+4KVM&^VKTM<=ZE[7-K
M_AY%\9O^>_A__P %9_\ CE'_  \B^,W_ #W\/_\ @K/_ ,<KH+_]B#X?Z9X'
MT_QC=?'.P@\,:A+Y%KJCZ9B&9\L-JGS.OR/_ -\FO-_"G[,NF^-=%^+>KZ/X
MTCOM+\#IYMM=0V>Y-43RW<,/F^0?)CO40CDTTY*DK+1^XUK>UM5O=@_:+J=1
M_P /(OC-_P ]_#__ (*S_P#'*/\ AY%\9O\ GOX?_P#!6?\ XY4?A3]D/PI>
M_!SPKX_\5_%:U\&VNOH?)AO-/WJ) 6^0/O&>%ST%<M\9OV69?AK\/=,\>^'O
M&&E^._!UY.+5M1TU#&8922 &7<V1D$9SD'@CFJA3R>=3V2IJ][?"[772]K7^
M87J)7N=;_P /(OC-_P ]_#__ (*S_P#'*/\ AY%\9O\ GOX?_P#!6?\ XY7(
M_&7]E75/AM\0_!?@[0]0?Q5JWBBRCNK9%MQ!M=G*[#\Q&  26., $GI7H=Q^
MQ)X+\.ZE;>&O%/QRT+1O'$ZH!I*VX>..1A\J,[2 \YXSM)[#FE*&31C&?LXO
MFU5HMNRZV2NEZA>IW,K_ (>1?&;_ )[^'_\ P5G_ ..4?\/(OC-_SW\/_P#@
MK/\ \<KE7_9=@\$_%C4_!?Q/\9V/@.&"R^VV6LO"9K?4 9 JB/)4CC<2#R"A
M'O7I/B#]B+X?>%O#6B^(-6^.EA8:+K*[]/O9M,Q'<C;NRA\SGCFE..30<4Z:
M?-M:#=_1I,/WCZF!_P /(OC-_P ]_#__ (*S_P#'*/\ AY%\9O\ GOX?_P#!
M6?\ XY7$Z3^SE:ZY\(/B-X]L?%*W-GX4OWM((X[7*ZA&"H64-N^0,&!Q@UM?
M"_\ 9+@\0?#J#Q]\0/'&G_#GPG=N8[&:[C\VXNSDC<J$C@D''4D G '-:RHY
M1"+E*G'1V^'6]KV2M=NW85ZG<W/^'D7QF_Y[^'__  5G_P".4?\ #R+XS?\
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MDX#_ )\Q^Y!SR[GU'_P\B^,W_/?P_P#^"L__ !RC_AY%\9O^>_A__P %9_\
MCE?+E%']DX#_ )\Q^Y!SR[GU'_P\B^,W_/?P_P#^"L__ !RO7_V4OVT_B5\8
M/C5I/ACQ%+I#Z5<PS/(+2P,4F5 (PV\XZ^E?G[7T5^P#_P G.>'_ /KVN?\
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MUY#J7_!0[QG-;7LNE^$/".@ZY>QF.;6[*R;[2<CDY+=?]XFO'_"_QZ\0>%O
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MPM9X?^##T7Y#>X4445T""BBB@ HHHH **** "BBB@ HHH4@$;E#KGE2>H]*
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M)_8%^-6.OVQ/_08JM?MQ1O=_!WX$:EIN6\-KHWE+(AS&DQAAP">@.%D'X&O
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MZ?\ VKS_ ,8K_ /_ *]?_:)J/X1?\F"_%?\ Z_D_DM>'?$7X\ZW\2OA]X/\
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MX!0?_$T?VCX+_P"A+T[_ , H/_B:/]:5_P ^'_X$O\@]AYGXJ^?%_P ]8_\
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MX!0?_$T?VCX+_P"A+T[_ , H/_B:/]:5_P ^'_X$O\@]AYGXJ^?%_P ]8_\
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MU'CWCK_D:K[ZK_Z"*P:WO'7_ "-5]]5_]!%8->G#X42%%%%4(**** "BBB@
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MK8>,=#>\N'>!)Q;\Y,BJ1RZ@8'('-+FMT ^O<C&<\4JD,0 0<G%?/GC+P_\
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MXF7_ (SL/&>OZ=XO^$H^+_P^O-DFBOI-G:RW%CD8>":.4@GGG>#V_ ?1F*,
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MR"/IS2=16V&><3#]Z_\ O'^=,Q7H365AO;_B5V)Y/_+(_P"-)]BL/^@58_\
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M?K4RJ)IZ#.NHHHKB*.2UO_D)S?A_(51 R0!U/%7M;_Y"<WX?R%>#?MD_&(?
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M_P"NC_WA_.@9)>_\?<O^\:@J>]_X^Y?]XU!26P!1113$%%%% !1110 4444
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M90PX[<$4<D0.M_X3?_J&6_\ W]?_ !H_X3?_ *AEO_W]?_&N7!!HR/6CDCV
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M -0RW_[^O_C7+DXZTM')'L!T_P#PF_\ U#+?_OZ_^-'_  F__4,M_P#OZ_\
MC7,44<D>P'3_ /";_P#4,M_^_K_XT?\ ";_]0RW_ ._K_P"-<Q11R1[ =/\
M\)O_ -0RW_[^O_C1_P )O_U#+?\ [^O_ (US%%')'L!T_P#PF_\ U#+?_OZ_
M^-26OC3S+J%/[-@7<ZC(D?CFN4J>P_X_K;_KJO\ ,4G"/8#JM4\8_9]1N8O[
M.@?8Y7<9'R:J_P#";_\ 4,M_^_K_ .-8VN_\AF]_ZZM5&A0C;8#I_P#A-_\
MJ&6__?U_\:/^$W_ZAEO_ -_7_P :YBBGR1[ =/\ \)O_ -0RW_[^O_C1_P )
MO_U#+?\ [^O_ (US%%')'L!T_P#PF_\ U#+?_OZ_^-'_  F__4,M_P#OZ_\
MC7,44<D>P'3_ /";_P#4,M_^_K_XT?\ ";_]0RW_ ._K_P"-<Q11R1[ =/\
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M\*?$WAG2/$5OJ%K#K\_V6VU984:RBF[)*^\%">WRD4G"*W ]J_X3?_J&6_\
MW]?_ !H_X3?_ *AEO_W]?_&N)UW7+'PSHU]JVIW*6FGV4+3SSR'"HBC)-<[\
M*/BAI_Q@\'P>)M)T_4[#2KEV6V;5(%A>=%./,50S?(>Q.#[4<D=@/6/^$W_Z
MAEO_ -_7_P :/^$W_P"H9;_]_7_QKF*3(SC/-/DCV ZC_A-_^H9;_P#?U_\
M&C_A-_\ J&6__?U_\:YBBCDCV Z?_A-_^H9;_P#?U_\ &C_A-_\ J&6__?U_
M\:YBBCDCV Z?_A-_^H9;_P#?U_\ &C_A-_\ J&6__?U_\:YBBCDCV Z?_A-_
M^H9;_P#?U_\ &C_A-_\ J&6__?U_\:YBBCDCV Z?_A-_^H9;_P#?U_\ &C_A
M-_\ J&6__?U_\:YBBCDCV Z?_A-_^H9;_P#?U_\ &MCPGXH_M+6X8/L,,.X,
M=Z.Q(_.N KHO '_(SV_^ZW\JF4(\K ]>HHHKSRCQWQU_R-5]]5_]!%?&7[=^
MK76@ZK\#=1L=+N-:O+3QI%-#IUH0)KEU4$1H3QN8C SZU]F^.O\ D:K[ZK_Z
M"*^4?VQ_"_BG6+OX3ZSX7\+:AXMD\.>*(]5N['3BHD,2*#U;@9(QGFN__EVO
MD2>8_M/?'_QIXP^$.K^'-=^#7B7P7H6JM%;W_B/7$-S:Z;#YBEIBD*$EACCI
MBO</&+^+8_A?X"T[X6^(M+LM"E@MXKWQMJ#12I9V"0J%GCCD8*[O@8SP.AZY
M'#_$#XM?%WXE^"M;\*:%\ M=T:^UJTET_P#M#7M1MQ:6R2J4>1\ 9P&) ]<=
M:Y+XE? 'Q!X+\(_ O2+_ ,.W_P 4/ GA"&6/Q%X?T@[I+FX8%DF$)9?-1&9@
M%)Z#G&XT:ZL#2T/XN:[X _:"\"^%8/C78_%[1O$UQ)97]C)':?:M.D"Y257M
MR0%)['T/'<=3;>)?B'^T'\4_'&E^%?&\GP\\&>$+M=+-SIUA#<WNH7FTF0EI
M>$C4@C Z\>O'"W_A#Q!KWQ9^$6N^#_@E<> O N@:T)+E9+&VM;Z0R+@S/;Q,
M2D* =68DEN@Q79Z;%XL_9H^*7Q NX/ FN>.?!7BZ_76+:X\+Q1SW5E=%=LD4
ML3.IVL3D,/\ ' K]=@.%_:3TCXLS?LM^-++QSKD<$NAW\:Q:II]O %\169=
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MM'P[_P AZP_Z[+2>S&4)O]:_^\?YTVG3?ZU_]X_SIM,04444 %%%% !1110
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MX_PH_P"$;T;_ )XW?_?\?X4>T0'#8I:[C_A&]&_YXW?_ '_'^%'_  C>C?\
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MW_W_ !_A1[1 </17<?\ "-Z-_P \;O\ [_C_  H_X1O1O^>-W_W_ !_A1[1
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M_/&[_P"_X_PH_P"$;T;_ )XW?_?\?X4>T0'#T5W'_"-Z-_SQN_\ O^/\*/\
MA&]&_P">-W_W_'^%'M$!P]%=Q_PC>C?\\;O_ +_C_"C_ (1O1O\ GC=_]_Q_
MA1[1 </17<?\(WHW_/&[_P"_X_PH_P"$;T;_ )XW?_?\?X4>T0'#TF*[G_A&
M]&_YXW?_ '_'^%'_  C>C?\ /&[_ ._X_P */:(#AZ*[C_A&]&_YXW?_ '_'
M^%'_  C>C?\ /&[_ ._X_P */:(#AZ*[C_A&]&_YXW?_ '_'^%'_  C>C?\
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MM<$9^7@CZ\%PL?2%9/B+Q9HWA&VM[C6M4M-+AN;A+6!KJ4)YLSG"1H.K,3T
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MY:ZW9>!/#T'B6<7/B".QA2_E!!W3A1O.1P3GO70T450@HHHH **** "BBB@
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M?\)7I']R^_[Y3_&I+;Q1I+W$2JE[N+@#*IC.?K7#U/8?\?UM_P!=5_F*3IQ
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M?J,'O79?#^"9/VX?BM,8W6-M!TP+)M(4D*.AKP#]M3X8:]\'KC6+KPG9M<>
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MV>JW$#PKJ,S'+&-6 +*/6KN[[@?45%%%:B"BBB@ HHHH **** "BBB@ KHO
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M:[IOANP:^U;4+72[)65&N;V988PS'"@LQ R3P/6OSJ^.WA_QC:_MN_$7XB>
MIGD\0^!=(TS5'TI1QJ5FT06YA..OR#./8GJ!7KG[7GQ0T3XS?L,?\)?X?F\[
M3=3OM,D"MC?"_P!H >)QV96!4CVJ;CL?8RL&4,I!!&01WI:\,^*G[1%U\/\
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M+XMLOL>NZ/I^MV>=WV?4[2.YCSZ[9%(S^%3Z3HVGZ!816.EV%KIEC$,1VME
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ML7Z_X5TM%',PL<U_PC5S_P ]8OU_PH_X1JY_YZQ?K_A72T4<S"QS7_"-7/\
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M_P (U<_\]8OU_P *EM?#\\%S'(9(R%8$@9_PKH**7,PL<V?#=P23YD7)]_\
M"D_X1JY_YZQ?K_A72T4^9A8YK_A&KG_GK%^O^%'_  C5S_SUB_7_  KI:*.9
MA8YK_A&KG_GK%^O^%'_"-7/_ #UB_7_"NEHHYF%CFO\ A&KG_GK%^O\ A1_P
MC5S_ ,]8OU_PKI:*.9A8YK_A&KG_ )ZQ?K_A1_PC5S_SUB_7_"NEHHYF%CFO
M^$:N?^>L7Z_X4?\ "-7/_/6+]?\ "NEHHYF%CFO^$:N?^>L7Z_X4?\(U<_\
M/6+]?\*Z6BCF86.:_P"$:N?^>L7Z_P"%'_"-7/\ SUB_7_"NEHHYF%CFO^$:
MN?\ GK%^O^%'_"-7/_/6+]?\*Z6BCF86.:_X1JY_YZQ?K_A1_P (U<_\]8OU
M_P *Z6BCF86.:_X1JY_YZQ?K_A1_PC5S_P ]8OU_PKI:*.9A8YK_ (1JY_YZ
MQ?K_ (4?\(U<_P#/6+]?\*Z6BCF86.:_X1JY_P">L7Z_X4?\(U<_\]8OU_PK
LI:*.9A8YK_A&KG_GK%^O^%6M-T2:SNUE=XV4 \+G/\JVZ*7,PL%%%%2,_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>acxp-20221231x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 acxp-20221231x10k003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %L E8# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N,^*'Q''PWTW2
M)TTBYUN\U74HM+M;.U=49Y71V&2Q  Q&:[.O*?CS_P A#X6_]CI9_P#I/<T
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M;_XJO4<CUHR/6@#R[_A:GC/_ *)3K'_@PMO_ (JC_A:GC/\ Z)3K'_@PMO\
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MM3QG_P!$IUC_ ,&%M_\ %4?\+4\9_P#1*=8_\&%M_P#%5T7A_P"+GA#Q5?\
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M%G4__262L7PU^SI\+Y_#FE22> M >1[2)F9K%,DE!D]* /2/^$DTK_H(VO\
MW]7_ !H_X232O^@C:_\ ?U?\:XG_ (9O^%O_ $('A_\ \ (_\*/^&;_A;_T(
M'A__ , (_P#"@#MO^$DTK_H(VO\ W]7_ !H_X232O^@C:_\ ?U?\:XG_ (9O
M^%O_ $('A_\ \ (_\*/^&;_A;_T('A__ , (_P#"@#MO^$DTK_H(VO\ W]7_
M !H_X232O^@C:_\ ?U?\:XG_ (9O^%O_ $('A_\ \ (_\*/^&;_A;_T('A__
M , (_P#"@#MO^$DTK_H(VO\ W]7_ !H_X232O^@C:_\ ?U?\:XG_ (9O^%O_
M $('A_\ \ (_\*/^&;_A;_T('A__ , (_P#"@#MO^$DTK_H(VO\ W]7_ !H_
MX232O^@C:_\ ?U?\:XG_ (9O^%O_ $('A_\ \ (_\*/^&;_A;_T('A__ , (
M_P#"@#MO^$DTK_H(VO\ W]7_ !H_X232O^@C:_\ ?U?\:XG_ (9O^%O_ $('
MA_\ \ (_\*/^&;_A;_T('A__ , (_P#"@#MO^$DTK_H(VO\ W]7_ !H_X232
MO^@C:_\ ?U?\:XG_ (9O^%O_ $('A_\ \ (_\*/^&;_A;_T('A__ , (_P#"
M@#MO^$DTK_H(VO\ W]7_ !H_X232O^@C:_\ ?U?\:XG_ (9O^%O_ $('A_\
M\ (_\*/^&;_A;_T('A__ , (_P#"@#MO^$DTK_H(VO\ W]7_ !H_X232O^@C
M:_\ ?U?\:XG_ (9O^%O_ $('A_\ \ (_\*/^&;_A;_T('A__ , (_P#"@#MO
M^$DTK_H(VO\ W]7_ !H_X232O^@C:_\ ?U?\:XG_ (9O^%O_ $('A_\ \ (_
M\*/^&;_A;_T('A__ , (_P#"@#MO^$DTK_H(VO\ W]7_ !H_X232O^@C:_\
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M_%7PII>B:UJ/BKQ;?R:IX.UMM075)F:*VEMG5;9U&!Y;[1]X\MDGO7Z0B-
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M]%+11\!_^2*^!O\ L#6G_HI:* (OVA?^2!?$O_L6=3_])9*ZOPK_ ,BOH_\
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MOA@:LMQ)_P ([J4&JV1CEVGSX?N%^/F'J.]>7_&[]EW3_&GPX^*NG>'88_\
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M*PB61?L\XC&5<-_K"O&TC:<YK1^'7[67B::Q@T.#PK<>(O'NK>)=6LHM(O\
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M!_\ DBO@;_L#6G_HI:* (OVA?^2!?$O_ +%G4_\ TEDKJ_"O_(KZ/_UYP_\
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M$ ?[F_)^7/;/6JEQ\5/!UKH]MJTWB?28M,N8WE@NWNT$<J)C<RMG! R,^F:
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M &!K3_T4M% $7[0O_) OB7_V+.I_^DLE=7X5_P"17T?_ *\X?_0!7*?M"_\
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M;VQ7LE% !1110 5YG^TS_P F_?$#_L#7'_H!KTRO,_VF?^3?OB!_V!KC_P!
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M%%% !1110 4444 %%%% !1110 5B^-O^1,U__L'W'_HMJVJQ?&W_ ")FO_\
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MX4T'P_X9_MBRLO#^CWNOZOJNK 72->6JRKM BQ,P!RS?)DYP!71?&S]I37O
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2HD^F"?EZ5Z;10!XCK'['?PWUGRBUE?VDB7M]?&6TOGC=VO'+W*$C^!R>G;
MP:MM^R?\/UF\/26]K?60T316\/P);7C(LUB5"^3*/XP, C/<9KV.B@#R#1OV
M5_ ?ASQ#H>L:1!J.EW.DV5KIZQVE\\<5U#;($MQ.H_UFQ5 !/XYJY\4/V;?!
M?Q;U^+6=;AOH=0%J;">73[Q[?[7:EMQ@FV_?CR,X_P :]3HH X[PO\)/#'@S
MQ/=:]H^GBRO[BPMM,81L?+6W@&V)%7H-HXXKE+W]E_P5J_CZ#Q;JO]J:S>VU
MS)>6EGJ%^\UG:S2!@SQQ'A3AF'H,\8KURB@#PK3OV+?ACID>JQ16.HM!?6D]
MA'#)?R,EE;S.'ECMA_RR#$<X[<=*EM_V._A_!X$N/![/KEQH$GD%+6?597^S
M^2P:/RB?N8('3T%>X44 <MX5^'6F>$_"<WAV*XU#4M/F$BR-JEVUS*ROD,"[
M<XP>E>:^%OV+/A/X.NO"%QIGAYHIO"MQ/<Z8[W#,4>4DMNS]\ XP#TP,=*]S
MHH \?U']E7P#?M!+';7UA=P:_-XEBO+*\:*9+V4,)6##HK!V!7I@UH:=^S?X
M&TJ\TRZM].E6;3M?NO$UNQG8XOK@2B5SZ@^?)\O09%>H44 ><>,O@'X5\;^.
M[#QA=_VA9Z[:PK;//IUX]N+J%7#K%,%^^@8 X_I7&>!/V7M.T7XH_%_Q9K,-
ME<1>.ECM!:VRE?*M1"$D5B?XI&&XX[XKWJB@#PF?]C'X>3Z%H.F%M;0:-9/I
MEO=QZI(MPUDQR;1W'WH>% 7L%&,5L:C^ROX"U35="N9[6]-EH:1+I^CB\;[#
M T<7E1NL/0,J' ([\XSS7KU% 'D6D_LK?#S1;5+>TTN9(DT2?P\ ;EC_ *'-
M)YDB?4MSNZTD/[+G@JPUK2]4TLZKHES8V5II[#3;]HENX+9%2!9Q_'M50,\'
M'%>O44 <;X9^$V@>$M4NK^P2Y\ZYOIM2=9IVD47$HPSJ#TXR !P 379444 %
M%%% !1110 5B^-O^1,U__L'W'_HMJVJQ?&W_ ")FO_\ 8/N/_1;4 <]\!_\
MDBO@;_L#6G_HI:*/@/\ \D5\#?\ 8&M/_12T4 1?M"_\D"^)?_8LZG_Z2R5U
M?A7_ )%?1_\ KSA_] %<I^T+_P D"^)?_8LZG_Z2R5U?A7_D5]'_ .O.'_T
M4 :M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5YG^TS_P F_?$#_L#7'_H!KTRO,_VF?^3?OB!_V!KC
M_P! - '>Z!_R!+#_ *X)_(5?JAH'_($L/^N"?R%7Z "O*?CS_P A#X6_]CI9
M_P#I/<UZM7E/QY_Y"'PM_P"QTL__ $GN: /5J*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HI.E<9XJ^+7A_PJ[0/<F^O5ZVMGAW7I][G"]>_7M0
M!VE%> :S\>M?O)F_LRRM-.@R0!<@SN1V.05 /?'/UKC[WQIXEU*$1W'B'4&&
M<GRY!'D_\! H ^KLBC-?)']NZG_T$KP_]O#_ .-(VNZN&5H]8U"!E.<QW+C/
MUYYH ^N:*^8=,^*?BW2KGS4U=KU2I0PW\8D3KG<,;2#QCKC!/'0CTOP;\<[3
M5YH[36K9=*N6.U9Q)NA<]LD@;<^AS]: /4Z*16#*&!R#R"*6@ HHHH ****
M"BBB@ HHHH **** "L7QM_R)FO\ _8/N/_1;5M5B^-O^1,U__L'W'_HMJ .>
M^ __ "17P-_V!K3_ -%+11\!_P#DBO@;_L#6G_HI:* (OVA?^2!?$O\ [%G4
M_P#TEDKJ_"O_ "*^C_\ 7G#_ .@"N4_:%_Y(%\2_^Q9U/_TEDKJ_"O\ R*^C
M_P#7G#_Z * -6BBB@ HHHH **** "BBJ&MZ]IWAK39=0U6]@TZQB&9+BYD$<
M:#W8\"@"_15#1-=T_P 2:9!J6E7D&H:?<+NBN;:0/'(.F0PX/2K] !1110 4
M444 %%%% !1110 4444 8/C/QMI/@'13J>L3F& R)!&B+NDFE<X2-%'+,QX
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MFIZ\;_:$\23PPZ;H$#A([P-/<\\M&N %_%B#^% '.^/?B_?>)YVMM%GEL-(
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M1Z$<&MN@ HHHH *\S_:9_P"3?OB!_P!@:X_] ->F5YG^TS_R;]\0/^P-<?\
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M?_:FGW%I]HGM/.0IY]L^V1,CJIP<&N'_ .%/'/\ R._B_P#\&2__ !NO0Z*
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M7ZH:!_R!+#_K@G\A5^@ KRGX\_\ (0^%O_8Z6?\ Z3W->K5Y3\>?^0A\+?\
ML=+/_P!)[F@#U:BBB@ HHHH CN+>*Z@DAFC66*12KHXR&!Z@BO ?C#^S1\/K
M+PGXC\3Z+HI\,>(K2SFNHM3T*9K242*A8$[#@C/8BO>=2E:#3KJ1#ATB9@?0
M@&OR<UW]JKXHZYH.I6=[XNNWM)XC%+$+965D888,0!M&._KBO3P> J8U2E3:
M7+;?SV.>K6C2LFMS[@_8'\/6-G^S5X1U]8=^M>(+1-1U2_E.Z:ZG<99W8\FO
MHRORY_9:^-?C;PWXS\"^ ;77F3PU;S0VBV,31RQ^21D*'&<\$=Z_4:L\7@YX
M.48S:=U?0JE555.RV.1\=_"7P=\3;?R?%/ARPUM0NT-=0AG49S@-U'X&OF71
M_@CX3\,_MIZ-H%K9SS:#8>&Y-8LM+O+J2>WM;OST3S8T<D*=I(]J^AOB/K-]
M8:YIL%M>S6L+VTLCB)L9(9 "?S-?/GASQ;;^(/C?=ZTQN1J*63:=9ZLLSY>$
M.K,AXVX+8((]._;\SS+C'!Y;BJ^$G2G*5)*4G%1M9J^EY*[MK:VR?8]&&%E4
MBI)K4^Q  !@# ILL23Q/'(H>-P596&00>H-<I\-]2N]2TR\-W<27+17+(KR'
M)Q@''ZUOZ_/):Z'?S1,4EC@=E8=00IP:^OP.,IX_"T\72349Q4E?>S5]3FG%
MPDXOH>"_&G]F3X<:=X&\5^)M'\/)X>U^UT^>YAU#1IGM)$D5"5/R$#J!P1BM
M[]C;PII?AO\ 9L^']SI]JL-UK.BVFK:A.>9+FZGA2265V/)+,Q/Z= *^7_&G
MQE\9:AI::/<^(KN6WU97M9?.^:/84)8.!@@$ C.>I'K75? 3Q_KVGZQX(\-6
M6MS_ -@6DD6FQV2,#$L4<901CJ<#:!U[5YE/.Z%1Q2B_>=EMWMW/GEF])RBN
M5ZNW3O8^X:X[Q]\'O!?Q1B5/%7ANPUHJ,))<Q NGT8<C\Z[&ODW]M_XP^+OA
M?J/A6+PQK$NE)>0SM,(U4[RK(%ZCW->U7K1P]-U);(^VRG*ZV<XVG@<.TISO
M:^VBOY]C.^&OP3\+^%_VR]6T:""ZO=)T+P_#J&E66HW<ES%83RR;7:(.3MR!
MCV[5]AU^0=M\?OB'8_$*;Q0GB20:]>V*VMQ>",9>%&^5,=!@\YK]'/V4/&NL
M_$#X)Z3K6O7K:AJ<T]PCSN "P65E7IZ "N:AC:6(G[.%[VN>WFW"F/R7"+&8
MEQY7-PLF[W5[]-M'U/!OC3\"O%6B>+M:U:SL+C6M+O;F6]%Q:1EVB#L7*LHR
M1MR1GI@=NE>,QZNFCO;ZD94B6VDCG5WZ95@1GZXQ7Z7>(U+^'M44#)-K*!_W
MP:_,:YMKB73/)ADCAGV!0TB;U![Y&1G\Z_,N(\NHY?B*>(HMIS;;\FK/33_,
M_2>$,VKYKA:N$Q"35.*2[M--:Z^7D>ZG]N_4@L3&+1L2$A?O<X.#_%Z\5%<?
MMUW:R3QS0:%NB!,@<-QCK_%VS7S/X?\ @=J?B#7K2STBZ,VJ7;,@BBB( ^;S
M#Y8W_+T/))[UZ1JO[&_Q0UI]2%W9QRQ7$;10#RU#0 X[B3GIR<9/M730QV9X
ME<]"K*4>ZC_]J<F)RS)L&_9XFC"$^B<^G_@?<]%_X:AMO%DYEO/"6A:G&"OF
M[8FCD8=L/DX/'7!KU/0_#.A?%KPO/KO@AY--OX&V7.DW;&14?@[<]B1R"#CG
MIUKYKT;]G7QCX#;R=:73[,3E51IK@0@>YWRL3^ [=Z^@OA3KNE?!WP=J,.F[
MM=\2WTH,\H5HK92HVJ%=ERR*,G('S$G&,\?0Y-6S6>(E'%)NG;=JSOY:(^2X
M@P^1T\)">":5:^T6Y*WGJ[>6IS4<HD:1<%7BD>&1#U1U)5E/N""/PI]0VT!B
M,[N0TUQ/)<S,!@-)(Y=R!VRS$XJ:OLS\\"BBB@ HHJ.=G6(^6C22MA41!DLQ
MX  ^I% 'N'[.*RR^&-5NGA>&.:^98]X^\$ 4L/49!KUJN<^'GAQ_"G@S2],E
M?S+B*(-,V,9D;YGX_P!XFNCH **** "BBB@ K%\;?\B9K_\ V#[C_P!%M6U6
M+XV_Y$S7_P#L'W'_ *+:@#GO@/\ \D5\#?\ 8&M/_12T4? ?_DBO@;_L#6G_
M **6B@"+]H7_ )(%\2_^Q9U/_P!)9*ZOPK_R*^C_ /7G#_Z *Y3]H7_D@7Q+
M_P"Q9U/_ -)9*ZOPK_R*^C_]></_ * * -6BBB@ HHHH **** "O$OB[J=OH
M/[0'P<O]0F2TTXIK%H;F8[8Q/+% (D+'@%MKX'?%>VUA>,O V@_$+1)-(\1Z
M5;:QILC!FM[E-R[AR"/0CU% &VK!@"""/:G5GZ#H5CX9TBUTO38!;6-J@CAB
M#%MBCMDDFM"@ I",BEHH K_V?:YS]FB)_P!P4?V?:_\ /O%G_<%6** &1Q)"
MNU%"+Z 8I]%% 'B>M_%36OAG\5-<M_%>FZM>>#KZ&&;2=2TVPDN8K=P")891
M&I*G(5@3P=V.U75_:6\ 1A2R:M"@.0SZ'<J ?^_?6O76C5_O*&'H13/LL)_Y
M9)_WR* /*O\ AJ+P%M)6YU-L==NDW)Q_XY37_:A\$H"0-;D'^QHETW_LE>K?
M9(/^>,?_ 'R*46L(Z1)_WR* /')OVK?ALTL,.IWM[H\$K!1<ZSI<]K;@_P"U
M)(@4?B:W?%GQ_P#ASX%N(([_ ,1V!U"[19(K.S87%S*A^ZPC3+%??&*[W4=%
ML-5LYK6[M(;BWE4H\<D896!&""#7E_P#_9L\-? 32]5M-+B%Y)?7LES]JN$#
M2I$?]7#N.3M0<#ZT 1?\-8?#_P#Y[:Q_X)KK_P"(H_X:P^'_ /SWUC_P377_
M ,17KWV2#_GC'_WR*/LD'_/&/_OD4 >0#]K;X;YPVI7R-_=;3+@$?ALJEK_[
M5GAN71;G_A%+'6/$VN.A2RT^TTNXS-*?N@L4PJYZL>!7M1L+8_\ +O%_WP*5
M+2",@I$B$=U4"@#G?AA!XBMO &A)XMG2X\2?94-^\8 7SB,L!CL#Q^%=1110
M 5YG^TS_ ,F_?$#_ + UQ_Z :],KS/\ :9_Y-^^('_8&N/\ T T =[H'_($L
M/^N"?R%7ZH:!_P @2P_ZX)_(5?H *\I^//\ R$/A;_V.EG_Z3W->K5Y3\>?^
M0A\+?^QTL_\ TGN: /5J*** "BBB@"IJW.E7O_7%_P#T$U^),-S/I]VLT$CV
M]Q$V5="593TZU^WTNTQ/OQLP=V?3O7Y[?M7_  +\&^%/$>EZUHNB^*/[(UD&
M>YO=#TUKVRM<D$,<<@MGH":^GR3,*&"E.-?:5O/8\[&4)UDG#='A_P"SK++>
M_'SP=)([37$VIHS,QRSGDD^]?KY7QO\ L=?!'POX;TR'Q[K.CZWI&L&Z-K80
M^)+<6[KNP%D2/KEL\$GUK[(KFSG&TL;B%*C\*5C3"4948-3W9YC\40I\2Z2K
MXVM:3K@]_F3BN1MM#L+."V@@M(HHK8 0HBX" >E>Q>(AI%^$TS4&MY+F=&D@
MMI) LC[>I7OQD<CIFOG?P5K7BO6O&FF:;J_A*SMM#N+B6)Y8_$T$\L:)]TLJ
MQ@R9_NKM([DU_,W%_ F99SFWU[ U4HU+*2;:Y;*U_-6^>MMM3Z7#8N%*GR31
M[5\*&#Z5J)4AA]L89'J ,UT_B*)YM U&.-2\C6[JJCJ3M.!3M&ETU[0Q:6]N
MUO QB*VQ!5&'!7CH1Z59N[E+.UFGE.(XD+L?0 9-?M&68+^S\#1P?-S>SC&-
M]KV5KV/*J2YY.7<_/[XJ>&-5^%$?A1IE\+PW^H6S7,T_B?7EL8]/<8 "Q@AY
M#ABI(; )KI/@'X5U36Y?#?BX6^BPPP:X+>>VT+5$U"':8\^<)%SC+$Y1B2,@
MYKQ7X_\ [3D_Q/\ B)!JUAHVEQP:0\D6F75W9)-<",\$DOD#=UP!7IO[$O[1
MD6D^);?P%=>']-LK;6+EI8KK38! 3<%<DR*.#D*>0!VKZ&?"LJ.%C5]FK1][
M3==;_P"9\_&&"<E24=GOY^I^@%?)G[:?PC\4?%KQ7X-LO#>FO>&*VNFFG/RQ
M1?,F-S= 3V'4U]9US/C+Q3:Z)"+-[=KNZNHGV0@[5*]"6;L.17@9C5PU'"SJ
M8R:C36K;TL?:Y1F.(RK&PQF%2=2-[7UW37ZGYW)^R'XSU.SLTM/!^LZ?J_ER
M?:9]1EM_LYV\A5V.6&><=<]\5]F?L>^'=2\*_ O2M,U>RFT^_@NKL26]PA1E
M_?OC@UY_X%^#'A+X:>+;?Q/H7A^U@U* N8XQ)+M0/][9ES@GU.?I7TQX=UVW
M\1:6E[;*R(S,C(XP593AA^8-?+</9YDN=59RRR?O15FG=.U][/I_3L>YFV?Y
MMC\&L'F$N>/-SIV5T[.ZTZ:FD1D8/(KY0_:<\$^%O ^J6NOR^%?$5QIUZ[-J
M%]X?"RI [,,,T)!<EB?X!CDYKZNDD6*-G<[54%B3V%?$_P#P4%\/S>(=4\!Z
MEIFAZAJMW LC07N@:J(-3@#$?ZBW((FR.IP=H]*^QKX:CBH\E>"DO,^6PV,Q
M&"G[3#3<)=T['LO[-'@'1[/1/^$@'A;5=%OY6)@DUV2-YVB895E"<(".Q^;U
MKK?C1XDUW0],M(M(@E6&Y8K<7T0R80!P!Z9_O=L'OBO-/V(=(A\(_"6:*?2(
MM >>^RT0U;^T))'8?>E;^"0GJG&#FOI)E#C# $>A%71HTZ$%3I144NB(KXBM
MBJCJUYN4GU;NSXV9D>:2223S9Y&#2/(VYW; &23U. !^%:-CH.KZE<10V>C:
MA<^8"1)';/Y0QZOC:/;)Y[5Z'^U5^T';_ +PK9FRLH+SQ%JK,EE%,IV(JXWR
MMCJ!E1C(.7'H:^+=*_;F^*^G:I'=3:M:WL ?+6<MH@C(SR/E 8?G7T&#RC$X
MVFZM)*WF]SRZN)IT9<LGJ?4LOPT\8 CR?#\TH[[IHTQ^9J/_ (5KXV_Z%F3_
M ,"HO_BJ]I^!WQ5@^,WPWTSQ1!;_ &1KD-'+!NW!)$8JX!],@XKNYIDMX7ED
M8)&BEF9C@ #DFO(G"5.3A)6:.M-22:/EZ/X:>,.?.\/S1#MMFC?/Y-6/=:3J
M.GRR1WFF7MDZ-M/VB!D!]P2,,/<$BOJW0]>T[Q+ID.HZ5?0:C8S+NCN+:0.C
MCV(XI;[4["SN[.UNKB"*XO',5O%*P#2L%+%5!ZD*K'CL#4%6>Q\F06=S=N$M
M[6>Y<G 2",N3^ KU[X7_  ?FLKU-9\0PIYT9#6ED>3"W]]CG!;T';ZU[ L,:
M'*HH/L*Y[Q7XSA\-O';)"]S?S1F2.(<* #C+'L,FN3%XNA@*$L3B9J$([M[(
M<8RF^6.K.DHKR.V\8Z]97S7;78O(V.9+-U 3'HAZJ?KFO2O#VO6_B728K^U6
M18G++MD7#!E8JP_,&OGLBXHRSB+G6!G>4=TU9V[V[/\ X>QM6P]2A;G1I444
M5]8<X4444 %8OC;_ )$S7_\ L'W'_HMJVJQ?&W_(F:__ -@^X_\ 1;4 <]\!
M_P#DBO@;_L#6G_HI:*/@/_R17P-_V!K3_P!%+10!%^T+_P D"^)?_8LZG_Z2
MR5U?A7_D5]'_ .O.'_T 5RG[0O\ R0+XE_\ 8LZG_P"DLE=7X5_Y%?1_^O.'
M_P! % &K1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>:ZS\?O#&
M@>(K[2+X7T+V5Y;V%Q=&V8P1RS8\H%QT#9'/3FO2J^<?'_[*\/C3XA:UKUQK
M=G;3ZK?65Y WV1C=6WV;M$_F8R>Y*G&>E 'NS>,-$03E]6LU$#!)<SJ/+8]
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M_P! #Z1HHHH **** "O,_P!IG_DW[X@?]@:X_P#0#7IE>9_M,_\ )OWQ _[
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MQ''>+:S^>T?V5E+G![ESBOH:M,NAB8PG]:=Y-Z>FG8TP4:\82^L;W_ ^#_\
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MO'!!4CU!KT3]GCXJ>(/BW^U3X#US7[ZXNIY;BZV1S HL2_9)\*J?PBH/C?\
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M(8I&C5VW21QS,I948D]<D>M>Q>"?@WX*^'FDVFGZ#X;TZQ@MHEA1EMT+E5
MRV,D\=:[2B@!J1K&@5%"*.@48%>._&_]FS2_BUJ_AWQ'87S>&?&7AZY^U:;K
M-K"CE&((*R(1AU(/0U[)10!X#X9_9.TZ]^(=UXZ^)%_!\0/$SVBV-L]S8I%;
MVL().$BYR23R23[8KVG1O"FB^'8O*TO2K/3X\YVVT"H,_@*U:* *6KZ+8:_8
M366HV<-[:3*4DAGC#JP/4$&OG*V_9%U[PUH>M^$_"GQ$GT'P)JMQ+,VD_P!G
MQRRVRRL6DCBE/13D@9!Q7TU10!Y_\-/@-X&^$WA^QTGP]X=L;:.TA6$3O"K3
M28 ^9W(R2<9/O7?)&L:!44*HZ!1@4ZB@#RGXS_L^:3\6;C1M7M[Z?PUXLT2X
M^TZ=KFGHGFQ,5*LK!E(=2">#[5A>"_V5='LO&%]XO\<Z@WQ"\57,:P)>:I;1
M+';Q+T6.-5 'N3FO<Z* *=AHUAI:!;.QM[50, 0Q*G\A2:QHUEK^FW%AJ%M%
M=VEPACDBE0,K*1@C!J[10!\O#]CC6M,\(ZCX#T7XC75A\.KUV!TB6PBDN(87
M<L\23\84Y(R5) [U[+X#^!?@/X:Z9;V7A_POIMBD*!1(+=3(V!U+$9)KO**
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M8P^#-0N+U]2GU*X>$6T;31QQA(@Q8#"*H)R3SBNVHH **** "L7QM_R)FO\
M_8/N/_1;5M5B^-O^1,U__L'W'_HMJ .>^ __ "17P-_V!K3_ -%+11\!_P#D
MBO@;_L#6G_HI:* (OVA?^2!?$O\ [%G4_P#TEDKJ_"O_ "*^C_\ 7G#_ .@"
MN4_:%_Y(%\2_^Q9U/_TEDKJ_"O\ R*^C_P#7G#_Z * -6BBB@ HHHH ****
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M^BEHH^ __)%? W_8&M/_ $4M% $7[0O_ "0+XE_]BSJ?_I+)75^%?^17T?\
MZ\X?_0!7*?M"_P#) OB7_P!BSJ?_ *2R5U?A7_D5]'_Z\X?_ $ 4 :M%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5YG^TS_ ,F_?$#_ + UQ_Z :],KS/\ :9_Y-^^('_8&N/\ T T
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M:_\ ]@^X_P#1;4 <]\!_^2*^!O\ L#6G_HI:*/@/_P D5\#?]@:T_P#12T4
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MI5%0850H]A3JYAO&Z:253Q!:OHW S<NV^V[=91PO)Q\V*W_M]M]D-U]HC^S
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M7J=% 'D$7QL\.P3M-'X#\<)*SM(7'@Z]!+-C<W^JZG YJY_PT)I?_0G^/O\
MPD;[_P"-UZG10!Y9_P -":7_ -"?X^_\)&^_^-U"OQYT1)FF7P3X[65AAG'A
M"^!(]SY=>LT4 >1V7QRT#38REIX&\<VR$EBL7@Z^7))R3Q%5G_AH32_^A/\
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MJC!U$G@^^;##H1^[ZU,O[0>E(H \'>/@!T \(WW_ ,;KU2B@#RS_ (:$TO\
MZ$_Q]_X2-]_\;H_X:$TO_H3_ !]_X2-]_P#&Z]3HH \F/QWT,SB8^!_')F'2
M3_A#KW=^?E5-_P -":7_ -"?X^_\)&^_^-UZG10!Y6_[06E2*5;P;X]92,$'
MPC?8/_D.DC_: TF%%1/!OCU$48"KX0O@ /\ OW7JM% 'EG_#0FE_]"?X^_\
M"1OO_C=!_:$TLC'_  A_C[_PD;[_ .-UZG10!Y3#\?M'MXQ'%X+\>1H.BKX0
MO@!_Y#I__#0FE_\ 0G^/O_"1OO\ XW7J=% ;GEG_  T)I?\ T)_C[_PD;[_X
MW1_PT)I?_0G^/O\ PD;[_P"-UZG10!Y9_P -":7_ -"?X^_\)&^_^-UF^)OC
MM8ZGX;U:S@\&^/6GN+26&,'PE? %F0@<^7ZFO9:* .,^#&G76C_"3P=8WUO+
:9WEOI-M%-;S*5>-Q&H*L#R"#VHKLZ* /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>acxp-20221231x10k004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 acxp-20221231x10k004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #0 ?T# 2(  A$! Q$!_\0
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MTV?:E%97AW4CJFB:?=F1)3<6\<I>+[C%E!R/;FM6F2M0HHHH&%%)2T %%%%
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M MXMHP-H[8[4+8.I0UWP]8^(HH(K^$3QP3I<1J20 Z$,I]\$ U+K2#^Q+_\
MZ]Y/_037D?[3OB+Q5X>T70Y/#C316[W;?;9+:5XY-H0F-0R(Y&YP%^[@Y )
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MKO\ D'>-_P#KI!_)J^^:_*LX_P!^J?+\D=,=@HHHKQB@HHHH **** "BBB@
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MI)%)<O,[QG*LLSJ0?7@BOK[6/^"=_P 5M1U:[NDMK%4FE:0 W4><$D^M4_\
MAW#\5_\ GA8?^!2?XU^H_P!I9?."C.:L8<K/EHW$LF-\CMCIN8G%?IA_P3<T
MRT\0? W6;?4[2#4K?^UW/E7<8E7.Q,<-D5\Z?\.XOBN/^6%A_P"!2?XU]>?L
MB?"GQK^S[X!O]"U?03?SW%ZURLEK=P[0I51CENO%>/G..PM?"\E&:;NBHQ:>
MI])C2+(:9_9WV.W^P>7Y7V7RE\K9_=V8QCVQ2:5H]CH=M]FTZRM["WR6$-M$
ML:9/4X4 5A_\)+K_ /T*5U_X%P?_ !=5M3\;ZOH]A/>W7A6ZCMH$,DC_ &J
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MME)#*TMT(& C83;5!&_G* '\:T_B%9>(KSQ#%#I33)&\$91HFVA<2J7SDXY
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M !1110 4444 %%%% ";0>U&T>E+10 @ ':EHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
L3%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %)BEHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>acxp-20221231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 acxp-20221231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #H 5(# 2(  A$! Q$!_\0
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M*<9'F(=@QSCKD<5?L_@3?PWMF\UQI[Z>+_4)[K3(S-%#(EQ=_:(Y08RI,T>
MGS @CICN]+DJ]CUR_P!9T_2E5KV^MK16D2$&>54R['"KR>I/0=Z=::G#=H[
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M6954L,D[<<5<_P"$'^+G_15-&_\ "0'_ ,ET?\(/\7/^BJ:-_P"$@/\ Y+H
M[CP)JU_KGA/3[[5+*XTZ_E5O-MKI5$BD,0/N\$$ $' R""0I.!OUY1_P@_Q<
M_P"BJ:-_X2 _^2Z/^$'^+G_15-&_\) ?_)=#$>KT5Y1_P@_Q<_Z*IHW_ (2
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MSP#6APNFV'CO1]9NI+K3X;N8W5I9W6M6C)OO;)4F)G2$G$<H8QJZXQ]YER,
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M)$A6"=%Z;)G!<J>5&P8&6Q!]J^*+66JW$GEQZA"EFMO8)!&;:5S!&USMDR7
M\P2HK$';N!*L!4O_  CWQL_Z';P5_P"$O<__ "=1_P (]\;/^AV\%?\ A+W/
M_P G4 ;/BW5_&,-MH/\ 8^ES_:9!!+>C,,B1CS8A-&QR,MY;2D%<#*]>@*>
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M.?\ H8M!_P#!'-_\ET#3?'!Z>(]!/;_D"3?_ "70M'<#D?BAK/BGP_XS35=
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MDI=L_-@J0.GWCG.!7?T=$(*JZEJ=KI%G)=WLZ6UO'C=)(<#). /<DD  <DD
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MD=@=3?0H;2[;P_<")FFN+P+;>4DF1DIN:<+NX(#9/RBO?H2YAC,H DVC<%Z
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MDUHUB^#;35K#PS86^NSP7.J1H5FEMHQ&C<G;\HP =NW. !G. !BMJ@04444
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M=+NQNHVAF@D&5=",$&J^A:/IND_;&L K2W$WF74V_?)+*$5,NW4L%5%Y[ 4
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M9/\ !ZT;+3^OZL-*[-_4?@MX7UB]O=-DUF^-Q+%?2/:)/"7CCO+B.:8@&,D
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M<)Y^HV%S<6VI75S!?/<SH[0R07$<0*;2L;(9U7Y."$SU.*'H]/Z_JXEJE?\
MK^K%\_ ;PY>M)<I?ZCLGMC#']GEB2*-6>&0M&JQ[1EX$?T)+<8.*C/P5\,>(
M6OYH=8OK@R3W:3M!-"VR66[BN95XC.")($&#T&0?6LD?#'X@Q[I+;Q1%9W!1
MT#B\GD15^R01JHC*A1^^BD?(P0)"1SQ3=-^%?C;3+VWDM=5L+"U_M:?4[BW@
MO;EC*LC$F(L5^888\D9RH^@=[/0K9&^?@'X?^RK MWJ"HCW+(VZ(NJSQ2Q,A
M<QEF55GD*[B2"W4]*G_X4QH%E+;7CW^H1K8WD>I*[3HFR1(HHR=X0,%985W
M$ _,#P<5SFE_"_QAIL=J]_KUQ<PQ1P+=BVU2Z>6519217'EA@!O>8QR+TP4S
MD&I;;X=>.)=%@CN-?2]ENM&:&X%U<3PO;WQ5@LR;"P8$%%93P"FX9+$5.VH'
M2WGP;\+:SXQ7Q:\<[ZD\J7(>*X(B;$)C/RCC:Z^66]3%$?X16-HWP+\(7.G6
M?V2_NM0M+>RO=*65)HB9(I52&1'D1 S,@A5 V[<-IR34GA+P#XQT?Q=9:E?Z
MVDVGI)-Y]JE[-(K1-:V\<:JC*%&V6*5^W^L]R*YZ;X6^,]#LM0_LS6/LDUS,
M\UNMG<S2(ET^HO.LCQG:OE^5(4D /(!X/!IM*]A7>YV\WP\T*VT[0=#;5)K:
M]M;W^TK28- EQ<3(C*SLNS:_RN=WR^A]ZY?5OV<-*L= EL/#$TNG%IK9XEEE
M&;41M%N:WEV,\;LL2<Y*Y&=M0>)_A#XPU#4IY;#7876WAO(M,O+F\N$N;836
MJQ(O (RDBE_,!W'=VQS?U3X9>-I)YSI/BYM,19'EMI'FEG*H;81BU=6X9!+F
M7S<[^<8'6BXRO8_ [P\D$MO>Z_,E[9VR_;8;%H(8HP;.6T60QE#LS S#LI*;
ML#D5U_AWX>:/9^&M8M-/U"YNK#7X4WW"R1M\GV6.W5HV5<<QQH<D')YZ'%<G
M/\+?%$WB(ZQ%<V5C++%:0SP1:A<NK1HMR)8V+)\ZEIT(W#C8>G%4;;X0^.[/
MPM'IEOXJCM9[>P^SV\EO<S1HG^@K L. O"+*OG"4#?GC'4TNX[O0Z.#X3>#M
M"U6+6Y;UQ/HT5J\\T]P@"&V@:.*65@ 4Q$[9 *JPY(-/O_@=X;U\:A,]W?RV
M^JK>B=(YU,<D%YY;3Q#Y?N,8U8$'<.<, <5SGBKX0>+]7L?$.GV.LVRZ5J<3
MVXL[N\N&RKV0A+-)@O\ +*"X7)#!CG! KH_!/@'Q-HUGJL&KZV+AY;0VEF]M
M._EQKM^4^45 5D^Z&4G<!D@&J;W=R5LOZ]#:USPAHOB74],O9=2FB-G8W=I#
M%:W*HK12JJ2MG&[*[%PRL,&LS0_AIX7N?!LFE:/?F33)[^&_>XL)(2'FA>-Q
MC8NP9,*;@JC/S$\DFJL/P_U*>\\(W;6UDB:5H5WI=S!-*P9Y)%A4 %5/R9A.
M3G.&!QFG0?#K6[#P.VCV6I"VF?5(+M(TNY%2UMEEB:6V255#NI5) "P'^LP<
M 4NO]=_Z8NG]=CLO"7A>U\&Z%#I-G+--;Q22R*]P5+YDD:1ON@#&7...F*NR
MZM907\%E)=P1WD^?*MVD D? R<+U. "?H#7AFO>!?B/X?TB);'59[^6=HH)!
M%?W$H3$URQD8D;@HB>%,ID[HU)! )JY>?"?QAKEEH6II?6^EZW!=FZN5N[AY
M9#$MKY$=NTJ $EADNZE2#(Q7/2DAGN5%>,?#J#X@V_BO5;O4K.:2TGNVB1+Z
M^?RX+<7$A)";<-)L9=K+\I2- 0IR:]GHZ7#K8**** "O(?B'JGQ T_Q!J[^&
M+:35E^RL+* HT*VTH@)RVX>7.C'I\RLKX4@KFO7JYFQUS6I?&FJV$^E&/0X(
MT,&H,=H+; 6Z_>!+8XQC8<]10-'/:CJ=QI\,%QIE[K4UW)<6,8M]1B98Y-TN
MV10&0?-Y9=F X78IX[N\2ZAKL7Q"MAHLNHS+#:R>?836Q%E<,R_NPLNS:K*0
M79M_HF/FXO>!/BMI?Q#CO9K"PU"".SMH;HM=PJI990Y3: Q.2J!N<9#H1G-:
M_A_QK:>([M[>"TU"W=4\PM=6K1+C(&,GOSTI^0CSBUU+QY>_"_P9/(=0MO$K
M:PJ7[SV?S>2))06EB3&(RH0X!';FI]?\3>.KK2/!.MZ;IL]GJ4VF7-Q?Z2]M
M(\/VKR4:."09#)EPRAC]W/.:[#PYXSNK_P 9>(-"U*&"V-D();25-P%Q')O'
M4\$@QL."#U^4  GL*+Z!L>):OXO^(NO^5'%H<NB0KJRVTUK#%(]P\*K,6'G<
M(J.4BQ*I^7?@U;M/'WQ&NIM,C3PU%%'<%))9)K28&,?97E> @N-K+*JQ"0G:
M3(#C@Y]BHI#/,[#QQXQN? UOJT_AT1:A=7\$+6JQ2^98VSL@DDDC8!G:++Y"
M?>"@CO67:>/_ (A21ZC)=^'H[1;:TA\J.*PGF>>:2:6/</G "A4CD*_>42X)
MXY]@HH8CQ>Q\2>-KGP3XXU6;3-1BU9H+2>QTTQ2 I(UI"9HH>-V!*9!WP<U6
MU[QM\2+Z'5;2UTQM/5YYHK2\M],F>2../4(H58AFPQDMWDD!&,>62,]O<:*.
MMPZ6/(-"\>^-IKNUM+SPY-I5A+<R6JW,MK/=S6QC)"^<!C<)0 5E5BHR0>Q.
M?HGC/XB6]S;#4=*N+N25?*GN!821Q6@-[*F\Q _O"L0C;Y3DAL] :]OHI@>2
M:)X_^(%WK.D1ZCX7CLK.:2TBNT2WE9D$JS^9()-VU0ACA)!!($V"<C-7;KQ?
MX]B\;3:+'X=C;2FO#%'K8B8Q)$8TE1F3?E@%6>-F!'[SR@!AC7IU%(#Y^M-?
M^)M_'IFY+RQ_>:9*B2Z;(VP-#,;D3-D%U#A 5.TC*_CW\OC;Q&VF>$Y&T6>S
MGU.R-S>N+*6X6UG58V^SM&I#(7W2 .W *8/)%>A44 <1\./&>L>)(;I-=T>Z
MTNX^TR?92]E+"KP!(V#/NR%;,C+C/.P\<&N#U[5OB'&VMI9C4VM(]8U%8)DM
M09O+%FK6:H-OS1&XW#=@] "<$U[G10"T//KZV\9:1X!\0:E8[+SQ9/:"6TL&
MF,D,4PC&57<<9+%SC.WA1T&:P/&%SKRR^'/^$:N?$-Q)<:E9QWZWD$B1+ 4F
MWESY>4R=F[;P,+TSS[!13ZW!:*QY+HI\66^K>(M(U&;5I)#J>GR:=<JI:$VO
MDP>>!*%QCS%N,AL-R..16WJM]K$_C#6[74!J=EHD5K --?2HBS7,C[Q*[. <
M,A" *<  [CG/'?T47 \\^(OBS7=-\(Q?\(WI.HW]]=V=P8YS:.TD+I"2@:/Y
M2'=]H&<#J?0'R[Q-J7CNUTJ/0K2[G@N+5)(XY[MI_/NF2.VM[:4G<#\UQ-)*
M<8#>5SD;J^E*IOH]A)>"[:QMFNPP?SS$I?< 5!W8SD D?0FA,#Q^R\2>,]*\
M+ZQ:VNA7?VVUCFEA^TP74S7[O-+&NQR^8R L<C<_\M/E  S5WX>Z]XRF\67E
MA=:9>6VF2WLUV]YJ\<K9AWR11PP=DP(8Y#N//G<#G->OT47UN'2QXC>_%?QV
MFK?V5%H%M;:C.;]K&*YMIBMVL A:(*P8%0PD*L[@!6[,!S=N_B%\13+&MOX5
MC@\ZX$,GGV\LHL?]-6'+%6'G*8&:;<F NS!ZBO5YM,L[B^M[V6T@DO+=66&X
M>,&2(-C<%;&0#@9QUP*M4=@[GCS?$;XA"XN6/A)1;PZA]D,*PRM<-&LC*TR9
MQ&RLH1Q\_ 9AR0,[^L>)==M==\5V]M;RSSPP6D.DVR)A9#+N#3,V#PK\$GA0
MG^USZ%2;1NS@9Z9I=+!U/%K>^\:7_A?PDVHC6+37X=8ATC65MHR(I84:0/<C
M"XV2#RVWC &<#&#5Q;SQBFB:_P">-2_X2JSOKF/1K:-";2YB56%H9' VE77:
M9&8@A]PXP!7KU%']?E_7S XGPO=7;6<5T&UJ\U0Z8'EM-1C,$1GX."2H5'+9
M&%^4#MT-<7I6J^/;W1(GNH]1CUR#Q)+_ *,T(BCN+$7"Y4,%9-HC)"EB,@$@
MDX(]JHIWUN*QXQ?W7B6\L=?ETO4=;?%\LEE97UG-#))MC?=&)5C&Q)' ()!"
M@#)^;%6=4U;Q5IEQXEO5-TT;6PFM-Y<+;W2N@6T",NV0/DC>AP<'U%>O4C*&
MQD X.1FD45[&]6^B=UCEBV2-$1-&R$E3@D @9!QP1P1R*LT44""BBB@ HHHH
M *1E#J58!E(P0>AHHH KVFFVE@7-K:PVQ<*&,487<%&U0<#G   ] ,59HHH
MHQ:%IL&WR]/M8]LWVA=D"C$O/SCC[W)YZ\GUJ]110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
40 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>acxp-20221231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 acxp-20221231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "U 1@# 2(  A$! Q$!_\0
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M)_'S6V^SOU-[_AWS^SM_T2C0_P#R+_\ %T?\.^?V=O\ HE&A_P#D7_XNN?\
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MS&PG'^NV]>:Z>8]OZPNSWMTW^\X/_AWS^SM_T2C0_P#R+_\ %T?\.^?V=O\
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M=Q6L2>#]81GD; #&XM"!^(!/X5[/_P +'\,?]!RS_P"_E>3>+?\ D][X=?\
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M_P"*K?LYA<6L,JD%9$5P5;<#D9X/?ZU/4E(YG_A6WAO_ *!:?]_'_P#BJ/\
MA6WAO_H%I_W\?_XJNFHH&<S_ ,*V\-_] M/^_C__ !5'_"MO#?\ T"T_[^/_
M /%5TU% ',_\*V\-_P#0+3_OX_\ \51_PK;PW_T"T_[^/_\ %5TU% ',GX;>
M&_\ H%I_W\?_ .*K*U3X=^'+*^L+H:6FPR?9Y/WLG1_NG )SA@H[8W&NZKRK
M]ICQKJ?@+X47NK:2\27GVF"',R;UVLX!XR.?>LZDU3BYRV1Q8W$4\'AYXFK\
M,$V_EJ=>/AOX;/\ S#$_[^/_ /%4O_"M_#7_ $#$_P"_K_\ Q5?).C_M6?$"
M\\!^)M4ENK WMA/9)!(MD-BK*T@<$9Y)VC'T->L_LJ?&7Q-\6G\2#Q%/:S"Q
M^S^1]F@$6-^_=G!Y^Z*XZ>.I59QA&]W_ %^A\U@>*\OS#$4L-1YN:HFU=::7
MWU\F>N_\*V\-_P#0+3_OX_\ \569=?#SP[9ZO:O_ &6GDW(,#?O'X<?,I^]Z
M!A^(KN#7&_&'Q3+X(^'&MZ_!I=WK5QIT0N(K*Q&99&5AC'!X'4\'@'BNV<E&
M+D^A]UAZ<Z]6-&"NY-)>KT7XES_A6_AO'_(+3_OX_P#\57F/QU^ U_X[T*RT
MKPFNG:5&9O-O);N:7<X ^1% R,9.3GT%:L_QZNXO@0OQ$'@?6VN#:"Y_L/8/
M.!+[>3UV_P 6[;G;SBC6?CU=Z5\"H_B(/ ^M37#VD=S_ &)M F3<P7YCC(4?
M>)VYQSBN6I5HU(.,GHU?KL:XOAS%8^C+"58>[.?LG:45[W6-[_CMYGE&I_LL
M>.-2^'FD^&OM^B)-:3NTMX+FX)FBZQ1E2N/E);MT"^E+KO[+/CC6_ >A>'C?
M:)%+8._VB[^TW!-R@/[E2I7 V@L.G.%]*^E/A]XK?QSX*T7Q ^F7.COJ5JER
M;"\&)8-PSM;_ #TKHJA82E.-TW9I+?H?$UN%<'"=2E5<K\OLW[W2/3\-^NO<
M^2O$W[+7CGQ%X,\/Z']NT2&73PPNKG[3.QNR#B(D%2!M3(X')YI/%G[+/CGQ
M1X7\/:2=0T6!].B875Q]IN&-W)]U'(*D#" #CN6/>OK:BF\%3E>[>NF_8SJ<
M,8&KSJ;F^>*B_>>JC:WY?GW9\D^-/V6O'/B[1?#MC_:&BVLFG6Y6YF%S<,;J
M?./-.5./E"_B6]:7QW^RSXY\:6N@1#4-$LGT^S$<[K<W#&>XR=TW*G!("X].
M:^M:*'@J<KW;UM?7L.IPS@:WM.=S?.HJ7O/7EV^ZQ\D>/OV6/'/C2317BO\
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M/M=7N[*XUVQC\^5X(K*WDBA>W=V!8LPF'8CEC17JGBK_ )/V^'W_ &(>L_\
MI9945K"A&G?E;UU.W#Y-1PCFZ,YKG;D_>W;ZG0> [Y]=^+UYK,5EJME8W-I-
M"#<0211O,IA\R-U>5AF/@!U15),@!.TD^T5YA\/++QK/XNU#4O$@N[?3P)+6
MTM6ND9=JN"LDB* "Q!(#+CH<CD&L23X.>+3XH;4)?$L%_!+JHO@Y\V&2V7=
M2R)N=6;9"\.WY5VRD]20>D]XS/%O_)[OPZ_[$S6?_2FSKWVOG/Q_I]U>?MK?
M#Z.WU.?3W;P?K#++#'&Q4"XM 5 =2,'.>1GCBO9_^$9UG_H;]1_\!;3_ .-4
M =+574XS-IUU&K%&:)U#*Q4C(/((!(^N*Q/^$9UG_H;]1_\  6T_^-4C>&=9
MQ_R-^I?^ MI_\:HV$U=6-'PK<F\\-:5.6+L]K$Q<L[$G:,G+JK'ZLH)[@5JU
MY_X.\,ZVGAVTC?Q;JB-'OC(>TB!^5V&?WL9<].K'GJ."*V_^$9UG_H;]1_\
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MBLQJ0T__ (4M\8OMYA-P+;_A$_G,88*7QYO3) S[T ?2U%?-(_;ALSJ)T_\
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M1&W9.UR 15G6/@#X<UK5=6U&2YU2VN]2DL6E>UN_+"K:2>9!&H"XVAP#SD\
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M[%85DM[N"1AYY*1OP"F N).N2<H1BNZ@-M<1M-#Y4J3<M)'AA)VY(Z^E3\4
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MO31?%^EZG;:K</\ 98YA(;C,DUPCEL1,^['EJS;@-F00/FQD5Z#110 4444
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,B@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>acxp-20221231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 acxp-20221231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  S 1 # 2(  A$! Q$!_\0
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M W<G(K7T?XJ:9KWB,:0MK-NE"F$&-FDR&D5S)'M_=JC1 ;B<$NN*KJ(YJ_\
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MKFBM;F\T];PVCV4+,;=UV,&^;:<!(T903UC SQ5:P^+_ (!TVXD-IX>>QG:
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<@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>acxp-20221231x10k009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 acxp-20221231x10k009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %) :H# 2(  A$! Q$!_\0
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M?XT?\(M;_P#/U>?^!#?XT ;-%8O_  BUO_S]7O\ X$-_C2_\(O;_ //U>?\
M@0W^- &S16+_ ,(M;_\ /U>?^!#?XT?\(M;_ //U>?\ @0W^- &U16-_PB]O
M_P _-Y_X$-_C1_PBUO\ \_5Y_P"!#?XT ;-%8W_"+6__ #]7G_@0W^-'_"+6
M_P#S]7G_ ($-_C0!LT5C?\(O;_\ /S>?^!#?XT?\(O;_ //S>?\ @0W^- &S
M16-_PB]O_P _-Y_X$-_C1_PB]O\ \_-Y_P"!#?XT ;-%8W_"+V__ #\WG_@0
MW^-'_"+V_P#S\WG_ ($-_C0!LT5C?\(O;_\ /U>?^!#?XT?\(O;_ //U>?\
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M)8_]=)__ $<]=9<?\>\O^Z?Y5R?PE_Y$.P_ZZ3_^CGH ["F331V\3RRNL<:
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M8^G'-9&O?M ^.])36IM-OT>6.9&B74$!BAC:\2,YP >$8C.: /M"BOF7P_\
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MX17(O?AEX9N I42V$+X/;* UU] $=Q_J)/\ =/\ *N3^$O\ R(=A_P!=)_\
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M+6YM=/\ LS1^2K1C<0Q8Y&X,.E 'L5%%% "$ ]:6BB@ HHHH **** "BBB@
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MXJ?:5[*6MGH6Y4E)QY-E?;\#=_X5%X</_+.Z_P# I_\ &E_X5!X<'_+.Z_\
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M?"J]UP[+:YBM]S29R <<;?4L2 /<BN?DGIIOMYG3]92<E9Z?CZ?\$]2WBE#
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MW)4Y!HR<YH @_LY?^?BX_P"_IH_LY?\ GO<?]_35@-N!IID.\#M0!#_9R_\
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M_P#GV'_?1H U=Z_WA^=&]?[P_.LK_A%-+_Y]A_WT:/\ A%-+_P"?8?\ ?1H
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M>N<FT(X*)_>8GOQP*XSPGX>T?X;VU[IGBE]0AUR*4W*+:3.(;_+?*(U&,GD
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M #=Z9$>;*/\ A9#_ !$<ANF?PI8=;\5?$()XH\/WB6>D6I)LK&7K? 'YBY[
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M52BI1]3]'_,7NP'U-'FI_?7\ZS9-%L]0VO<P;I",GD\4W_A%-,_Y]A_WT:\
M],U/-3^^OYT>:G]]?SK+_P"$4TS_ )]A_P!]&C_A%-,_Y]A_WT: -3S4_OK^
M='FI_?7\ZR_^$4TS_GV'_?1H_P"$4TS_ )]A_P!]&@#4\U/[Z_G1YJ?WU_.L
MO_A%-,_Y]A_WT:/^$4TS_GV'_?1H U/-3^^OYT>:G]]?SK+_ .$4TS_GV'_?
M1H_X133/^?8?]]&@#4\U/[Z_G1YJ?WU_.LO_ (133/\ GV'_ 'T:/^$4TO\
MY]A_WT: -3S4_OK^='FI_?7\ZR_^$4TS_GV'_?1H_P"$4TS_ )]A_P!]&@#4
M\U/[Z_G1YJ?WU_.LO_A%-,_Y]A_WT:/^$4TS_GV'_?1H U/-3^^OYT>:G]]?
MSK+_ .$4TS_GV'_?1H_X133/^?8?]]&@#4\U/[Z_G1YJ?WU_.LO_ (133/\
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M8U')12U>J%SQLW?8]=HKSKXO_%RR^&?PTOO$\;17LBHJV<6_Y9Y6^XN1V/\
M*M+P'\3-,\:_#W3_ !5#/%%:W-I]ID4N/W1 ^=3[J<@_2I]G/EY[:7M\Q\\;
M\M]3LZ3->0_L^_'RT^-FCZO=[(K*>SO6C2$-RT#$F%SGNRCD>H-,TK]H33=5
M^/&I_#]/*\JUM0R7@?AKE3^]A^H#+^3>E4Z-12E%K5;B52+2=]SV'-%>/?$W
M]H?2?A[\2/"7A65HI7U:3_2I2^!:QGY4<_[SD#\ZW?C=\7+;X1?#^\U\QI>W
M2.L-M:>8%,TK'A1^ )^@-)4:C<5;XM@YXZZ['HM%<=H7Q,TC7OAU;^+XYUBT
MZ6Q%\V]AF-=NXAO0CI7+_L__ !RM_C/X3N]2DBCL+RWNWA>UWY(3),3?4I@G
MW!I>RG9RMHMQ\\;I7W/6:3->/?#C]HC2OB!\3_%7A.",0#2#B"X=Q_I.QMDQ
M ]%;:/?-)X\_:&TKP5\7O#7@J0++)J0S=39.+7=Q#G_>(/Y57L*G-RVUM?Y"
M]I&U[GL=5M2_Y!]S_P!<G_D:F$BGO4.I?\@^Y_ZY-_(UB:&!\,?^2?>'_P#K
MRB_]!%=17,?#'_DGWA__ *\HO_0173T 1W'^HD_W3_*N2^$O_(AV/_72?_T<
M]=;<?ZB3_=/\JY/X2_\ (AV'_72?_P!'/0!'X\^'G_";W^C2RW*0PZ?<I<[#
M$'8LK!AM)^[TQ^-:OC>QBO?"^H"9=P2!V')&#M-;]9'BW_D6=4_Z]W_D: ([
M3PMIIM83]G_@'\1]/K4C>%=-(_X]_P#QX_XUHV?_ !Z0_P"X/Y5(_P!TXZT
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M4K+3U_S#ZG3LUW/SX\1? #XO>*?!VB>&+[PS(^FZ>[S2'^TT+32\+&WWN-J
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M (TO_",:;_S[_P#CQ_QK4XS3\Q/[R_G1YB?WE_.LS_A&--_Y]_\ QX_XT?\
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M]_\ QX_XT?\ ",:;_P ^_P#X\?\ &@#3\Q/[R_G1YB?WE_.LS_A&--_Y]_\
MQX_XT?\ ",:;_P ^_P#X\?\ &@#3\Q/[R_G1YB?WE_.LS_A&--_Y]_\ QX_X
MT?\ ",:;_P ^_P#X\?\ &@#3\Q/[R_G1YB?WE_.LS_A&--_Y]_\ QX_XT?\
M",:;_P ^_P#X\?\ &@#3\Q/[R_G1YB?WE_.LS_A&--_Y]_\ QX_XT?\ ",:;
M_P ^_P#X\?\ &@#3\Q/[R_G1YB?WE_.LS_A&--_Y]_\ QX_XT?\ ",:;_P ^
M_P#X\?\ &@#3\Q/[R_G1YB?WE_.LS_A&--_Y]_\ QX_XT?\ ",:;_P ^_P#X
M\?\ &@#3\Q/[R_G1YB?WE_.LS_A&--_Y]_\ QX_XT?\ ",:;_P ^_P#X\?\
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M_P ?/^-:=% &9_PC>G_\\/\ Q\_XT?\ "-Z?_P \/_'S_C6G10!F?\(WI_\
MSP_\?/\ C1_PC>G_ //#_P ?/^-:=% &9_PC>G_\\/\ Q\_XT?\ "-Z?_P \
M/_'S_C6G10!F?\(WI_\ SP_\?/\ C1_PC>G_ //#_P ?/^-:=% &9_PC>G_\
M\/\ Q\_XT?\ "-Z?_P \/_'S_C6G10!F?\(WI_\ SP_\?/\ C1_PC>G_ //#
M_P ?/^-:=% &9_PC>G_\\/\ Q\_XT?\ "-Z?_P \/_'S_C6G10!F?\(WI_\
MSP_\?/\ C1_PC>G_ //#_P ?/^-:=% &9_PC>G_\\/\ Q\_XT?\ "-Z?_P \
M/_'S_C6G10!F?\(WI_\ SP_\?/\ C1_PC>G_ //#_P ?/^-:=% &9_PC>G_\
M\/\ Q\_XT?\ "-Z?_P \/_'S_C6G10!F?\(WI_\ SP_\?/\ C1_PC>G_ //#
M_P ?/^-:=% &9_PC>G_\\/\ Q\_XT?\ "-Z?_P \/_'S_C6G10!F?\(WI_\
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M59P@=_0;F _/TJ_XM<#PQJ9/>W?^1K-\2^!5\0ZK#>B]EM2J)%*B*I$J+()
M#D<<KCCL36UKFBP:YI<UG.,)(A7<.JY&,T 6;21?LD/(^X._M4PD4_Q#\ZS(
MO#6G)$J_9P=H SN/^-5],\)6%E;&%D:<^8[[W8Y^9RV.O09P/84 ;3RHJDE@
M .>M?'_Q._;4T3PU\3X(+'11J<>EM);RWAX?GAA&>PR.?7%?54GA?3Y'<^3P
MR;-NXX'7GK7P;\3OV)_&+^/;R30EAO-,O9S*DKO@Q[CDAJ\K,)8B,(_5U=W/
MT/@S#Y)B,556=3Y8\ONW=DV]'KWMLC[J\"^,]/\ 'GA73M=TZ0-:WD8D4$\K
MSR#]#6_YB_WA^=>;_"KX0VG@#X;Z;X>F8S7,,#++.K'[[$DD?3-=L/#FGA!F
MW!P.N37HTW)P3GO;4^'QD:,,34CAG>FI/E?=7T_ TO,7^\/SH\Q?[P_.LJV\
M,Z?#"$,.\@GYBQSUSZTL7AK3U:0^1D,<@%CQQCU]JT.0T_-7.,C\Z#*H/WA^
M=9#^%]/>[BE\L@(&!0,<-G'7GMC]:;?^$["\C150Q;9$D+(QR=K XZ]#C% &
MUYB_WA^='F+_ 'A^=9I\/Z=VMQ_WT?\ &H;/POI]K:QQ&,RE!@NS')]^M &Q
MYB_WA^=(9%'\0_.LM/#>GH\A\D,&;."QXX Q^E(?#>G><L@AX *[=QQ0!K>8
MO]X?G1YB_P!X?G63-X;TZ55 AV[6#<,>?;K1<>&M.G@DC$.PNI4,&.1[]: -
M42*?XA^=+YB_WA^=9-MX:T^""-&AWE0%W,QR:6+PWI\>[,(;))Y8_P"- &IY
MJ_WA^=!E0?Q#\ZQ5\*V"Z@]QL)1XU3R]QVC!)S]>?TI]QX7T^:2%UB*"-BQ
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MLX]ZUX[OQ,+>_>=K^)(=7M9+4V<,C+);GAT(==_ !+' &2,'K7M>*,4 >/\
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M@2KYC.#@L<'Y1$>@;)Y&/?@*,4 <U\.-0U74_!]A/K5E]@U+:4EB!.&VD@.
MQ) 8 -@G(S@\BMW4O^0?<_\ 7)_Y&K &*KZE_P @^Z_ZY-_(T 8/PQ_Y)]X?
M_P"O*+_T$5T]<O\ #'_DGWA__KRB_P#01744 1W/_'O+_NG^5>;^$O%VE>"?
MA;:ZGK-T+2Q2:56E*EL%IV X /<UZ1<?ZB3_ '3_ "KC?A=:0WG@"QCGB29#
M)-\LBAA_KG[&I=[:%P<%->T5UUMO;\2MK_QH\(^'HM1DO-4"&P$9G01.64R(
M'0# YRI!KE/AQ^U7X+^(T5X8)+C3Y+7S&:*ZB.62-2[.,9'"C..M>M7&A6%R
M)!)9P.),;]T2G=@8&>/2L_0? GA[PW'-'IFC6=DDK%G$40&XGK^=8.-;G34E
M;T_X)Z].KEBP\XU*4W4=K/F5EWTY>O\ 7GE)\6O#+.Z)J'F2+8?VEL6-\F#L
MPX_3K6;=_&_1-.3==V][;@ [PT62C["X3 )R2HR,9'(KN;C0]/NH9(I+.!HY
M(S"P\L#*$8*_2L"'X4>%(9(771XB\49B0L[MA3G.<GD\GD\\XK>/-;WCRJCI
MMKV2:7F[_HC"C^-NGO'=3-IMZEO;B(,YVEC))/Y*IMSG.[OTQSFI=%^,NF^(
M?$NDZ/9Q2"6^5Y?WO!$05BL@'HQ1P._RFNE/@'0#,9?[,BWG!)R><2"09&<'
M#C-,TKX>>'M$NC=6&F16USO=Q,I)92PP<9/ P3P..>E49$/B_P"(6G>#IK&.
M[CN)3=N%#01EP@+JNYCV +"N9\2_'O0-&T^UGLS)?//J"6&UE,(1BPWL2X'
M!_$X ZUV@\':4UC;VDUL+F*!-B&9BQQN#<GOR ?PJ2]\):-J-J+>XTRTEA#B
M38T*XW @ANG7(% %JYU:UL88I+B=(1*<(6. 3C/\JY_QC\1])\(^';K5II1/
M'"/EBBY9VR %'IR0,G@9KJ?(C*A2H('0$=*HZUX?L->TJYT^\MDFM;A#'(A'
M4'K2=[:&-55'"2IM)VTOW.7\$_%32/&>D->(_P!AECE,,]O.<&.0$#;GH>HY
M'K6IXL\91^'=&BOH83?&:XBMHT1PH+.X0$D]@3GU]*N>'?"6F>%M)@TW3[5(
M;6'[JD9)/7))Y)]ZN:IHMCK5B]G>VR7%L_6-QQ['V(]:%>WO;DT%55.*K-.7
M6W<\_A^,\-UH]W>VEC)?_9E4R"V#MM_?O"^5V[OD*,2,9X.,U6U'XYP6&H6T
M"67VR&[M/M%O<6[,4D8NB!5^7Y^7YVY(QR!D5TG_  I_PB(8HDTA8DBB:!1%
M/*GR,Q8YPPR2S,<G)R3S4W_"J?"H$H&CQ8DA^SD;W^5/1?F^7H.5P>.M,Z#D
M]7^.D6F68N8K1=0A:%)=UHS,4W2B+#IMW [MV!C)V&NPU/Q?+IBZ([V9DAU!
M]DD@;;Y/REA\I&X],8XK.7X(>"4^T;=#C47"+'*%GE 95^[P&Z@\YZYK8OOA
M_H6IPZ5%=632II;*]F#/(/+8=#D-\W3^+- '*Q_&>WM;*YNM1L)8D4VHA6U/
MG-+]H?9&, <'=P>PJE9_M'^&+^YT^UB2]6^OKG[-%:RQ>6_\/S?-CCYQ[]?2
MNUL?AUX=TVWDM[?2X8X9+A+IE)9LRJP96R3G@@$#H/2N=\3_  %\)^)Y8)FM
M7L)X0P66S?8_S;<G/)!^4<C!H PH_P!HS2K+6M2L=6C^S)';R7MH\66\VW1G
M0NQZ+\R'&2/O#WJ[>_'NQBTOPAJ-MIUQ/:^)KDV=H7=49)=V%W G[IPQW#/0
M>HKHKOX0>&+S2(+!]-C"P6Z6T<V,R+&N<+DYR.3D'@Y.:M67PST"UTNUL9;)
M+R.V1HXFG R@9MQ"XP%YQTQT% &0WQ8MM.LM5N-5MS"ME?1Z>C6Q,JSRR!=J
M*<=<N >P]:PA^T5HRZ-;74\,EO=3PB;R&^;9\X4J<<@C<#TQS[5V-A\*O"NF
MZ->:3!I*+IUW)YTT#22.&?.=P+,2#GG(Q4*?!WP;'(9$T"U#&-8C][E5Z#K[
M#GKP/2@#B;;]IG1YO J>(C93LT4:S7MK$"SP(2HR,#+'Y@0 .<''(Q6Q<_&2
M6RO!:SZ3LFE33_LY6<,KO=22(H)'0*8^3[UMZ5\'/"FCZE<WEOI<8:98$\HD
M^6@BW>7@>VX]<_H*<_P<\'R7$LS:,A>6!;9B9I?]6I)4 ;L#!)((Y&: .</Q
MYM'\.>'M2BTRX>;5KB*!H-PQ 'N! 69NX#$XQUQVJW:?'WPS=7-Q;[[A)X7$
M>P1[O,;(&$*Y#$!E) Z \UT]W\./#=ZFEK+I,#)I95K-!E5B((88 .#@@'G/
M(K.M?@WX2L+FPFM=)CM_L3S21(C,1OD0(S')SG: !SQ0!+<_$_2;7P='XC?S
M7LW98Q'"!))N9MJC"D]S4>E?%+2-?DCL[&1TU.2W-P+>ZB= H&<AGQM!&#WJ
M?2?A9X=T>&Z@@LBUM.\;F"21F12ARN 3V))SU)/-:\WA'1Y[":R?3X?L\T30
MR!5PS(V=PW#GG)[T 4?#7C"/6/!]MK]W']@@FB,Q5S]U,G!_$<_C5^3Q1IL9
M8-=QJ5E2$Y/1V&5'U-7XK*"&V6W2)1 J[1'CY0/3%)+8P2HRM$A#=?E'YU2M
MU)=^AQ'@_P"-OA;QKJ>LV&GZ@KS:9,\,F[@/L'S,OJH.1GVKK;#Q!8ZI,8K6
MX2601K,0O]QL[3^.#7,^"_@MX/\ A_J-U?Z%I"65U<KMED\QWW#.>C,179I;
MQ1G*1JAQC*J!Q5S]G?W+V\R8\]O>.#U_XTZ#X<MM1ENC.#8221W$>S#)L(YP
M2,ALY7^]@XZ53@^/?A^ZOOLD$-]-.\AC@40$?:""0VPG XVGK72ZU\,O#'B*
M6]DU'2(+I[QHVN&8L#(8P0F<$=-S?G3;OX7^%[V-$ET>$JA)3:64KEMQP0<C
M)YK(T.-U']I?PGI\MK$1>S279)MTB@+&5-KMO _NXB?KSQTY%6+G]HSPG86K
M2W;W=J_GO;+#+;L)'D1B'51WV\9/3YAZUTJ?"3PBET+D:';"82&4/S\K%2IQ
MSP,,PP..34EW\,/#=]>Q7,^F0N4^T'81E6:;;YC'W.T=* .?UKXY:-X;NIX=
M3AN8!!;I<S 1EC#&>K/CCC(Z9K2\1?$.70-;FL'L-T?V=9H)S, )&+JFTC'R
M@%AS]:T)OACX8N+9[>;2(98GMQ:N)&9BT0Z*23DT[5OAKX<US59M2OM.%Q>2
MVYM7D,T@S&<?+@-@=!R!GB@# F^,ME8:7!<75A=M<.\\;PVJ>9M\EU1VSZ99
M<?6J<?[07AVZFOH+=;B2:RM'NKE2 #%MP"A!.=V2!QP3WKMX/!>BV]G;6L>G
MQ+!;1-#$O)VJ2"1DG)R54Y//%<Q_PHSPL/$<VL):O%-,XDEB1L(Y!!Y[D9 .
M,XS0!STG[1VDZ!'>V_B&%K34[*^CTV6&W^9&N'1G50QX&1&YY/8=R >BU'XH
MO:^,[#P['IV;B_L3?V\LLX5-BX$@? .T@M'@'[VXD9VFI?%_P5\+>,[B"YO+
M$1W4-W]M\^'@O)L9<L#D'AVQD<'D8K4U'X:^'-8A,=_IL=TS1I&TKLPD955E
M4%@0>C-^9H X_P 6?':W\)?#2Z\4W&G27$T8N3#:0MD3K"6_>*V/N,%W!O1A
MP:35/CSHL%P;:*$37T3E&B//.QW&",X^XPYP>/I767'PI\*7?AFW\/SZ/%/H
M\!)CM99'8+D$$9+9Q@D8SBFV_P )?"-K=S746AVR7$TAF=_F.7(8$]>.&;IZ
MF@#B_%/QK\.R-#I;:9)JD.HW2:7(I&%%PXW"-SV  ;<>@. >31XC^/$'@Y]:
MCO-$:)](@N+N98Y0VZVA\K)! ^\1*I"^QYKMK+X7>';..[1M/CN/M5S<74AE
MY.^9P[XQC'(&.XQ4'_"G/!YN9KAM%CDFFF^T2-++(^Y^^<L>.GR].!QP* ,"
MW^/NC22W#M;SI9*L,L$Y(!FCD!(D SG' X^]STXK9TWXOZ#JUY96]M*[?:G\
MI9& 55?:K%"3_$-P!4<YSQP:L#X/^#Q,)?[#@\P2^<&W/PW/3G@<_=Z>W%1W
M/P>\,7FGR6<UAOC:ZGO RR,K++*Q9V&TCG)./3M0!)K7Q/TK0_$ZZ'.ETUQY
M0FDECA+1QH=V"S#UVG@<UG7GQ1L]6CTQ-'V7\&J/+"-P:.5%5&9Y-C ':, 9
M]6'K76MX6TM[P7;6<;W(18_-;))5<[0?ID_G4-YX:TNV,M_%8P17<5K+!'*B
M!2J-AF4 <<E5/X"@"G\,/^2?>'_^O*+_ -!%=17+_##_ ))]X?\ ^O*+_P!!
M%=10!'<?ZB3_ '3_ "KD_A+_ ,B'8?\ 72?_ -'/76RKOC9?48KP+3?$4&EZ
MSJ7AK2O$_B&-]-NS!+$FD[HHI)!YH7S#'C!#@YSWI7Z ?0%%>;:;HFOWMC;S
MR>,M0M'F3>()H;<.OJ#A<<>U6!X>UEAD>/;H\9.(H.GK]RBX'H-%< GAG7)6
M*IXZO'<#)40P$@?]\5E:2NI:SKNJZ/;^-]4^W:;L^T))91H!O&5*DQX8>XHN
M@/5**\H\2MJ/A:>T@N_&NK375T6\FUM+&.:5P!EB%6,G ]>E6-&L]5URR6Z@
M\<:E%&S,FRYM(HG# X(*L@(Y%%[@>GT5Y[_8&L;5;_A/;K:Q(#>5!@GT^Y6+
MX<FU3Q-J^MZ=!XSU.*XTFY%K*);:%=[&-),K\G(PXYHN!ZY17GUSX=UJU#^9
MXZO%95+D&&#(4=3]SI6!X/N-;\76<][%XKU2UL%?$%U-%;%+A.SJ0IP,\8.#
M[470'KX %+7GQ\.ZSOVCQY=[L[<>5!G/_?%1G1-7+LO_  G]SN49(\N#(_\
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M_P#^ \/_ ,10!VU%<3_PA7B+_H=;_P#\!X?_ (BC_A"O$?\ T.M__P!^(?\
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M>3K'INEWLNH7UU%>0L7DC$\*HKCY1\R%<_CUKZ/HJ7!/^OZ[%/4^=/"O[/\
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8B@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>acxp-20221231x10k011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 acxp-20221231x10k011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $5 9@# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4Z<&7RVV!I-J^X_L@:3K]KXA^-6JZ]HFH:(^M^+5U&W%]936JSQOI]J"\8D
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MQTOP_P#VV_A3\0+WQ3&OB&TT"S\/!))]3UK4+**TEA>>2!)/,2=_)W/'@17
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M9U#%25BG(R#@C_CVZ@@C\*T^IK_G[#[W_D9_6G_S[E]R_P SZFHKY;_X1?\
M:\_Z'#X<?]^;C_Y&JNNC_M8O?/9+XY^&37J()'MPLQD5"<!BOV?(!/>CZFO^
M?L/O?^0?6G_S[E]R_P SZLHKY87PY^UP\CQKXS^&S.F-RB.<E<],C[/Q3_\
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ME[N ZAI8@>5MTGEQ1V=L&?L&8VY<[0!\_KG/V)7S;_P4,&?V6?$?'_+U9?\
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M7_@4?\P^NT.[^Y_Y'U+17RU_PV'X[_Z-T\>?]^)/_C-'_#8?CO\ Z-T\>?\
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M,/KM#N_N?^1]245\M_\ #8?CO_HW3QY_WXD_^,T?\-A^._\ HW3QY_WXD_\
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MLQ?$""XF<%Y#<W\NV/[2MP\,:R6S+'&[H RH -O  P,=I_PVM\2O^C9_&_\
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M_D2O'/VL/VHO&'Q$^#E[X:UWX+^)/ ]KJ%U;I'JNJ^<L7F(_F",![= 68(<
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MOM#;4O[<+CSX\&;]V%V]/W?][^(\5WGPX^(]A\1]'FN((9M-U2RE-KJ>CW@
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M\>H_X85^!G_0AP_^#&\_^/5R,OAS]KB$*9/&?PVC#,%!:.<9). /^/?J:?\
M\(O^UY_T.'PX_P"_-Q_\C47Q/_04O_ I!:A_T#O_ ,!1U7_#"GP,/_,AQ?\
M@QO/_CU+_P ,*_ S_H0X?_!C>?\ QZN,FTC]K"WNDMI?'7PQBN'1I5A=9@Y1
M?O,!]GS@9&3VS26.D_M8:I"DUEXZ^&-W"ZAUD@$SJRDD @BWZ9!&?8T7Q/\
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M_;1_Y->^('_7BG_HZ.MG]EOC]G/X<?\ 8"M>V/\ EF*]-_[@O\?_ +:CS_\
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MKTZ0ICUB\CU>W2WL6N;N_D2\@966 KOD_>*1=,$;G;YF?EQD &5-X.^$W_"
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M%@IJ3P?^U_%X[MKR\TSX=^*+2RM?#6HZ[+'K'V:SO(KBSNYK:2PEMVE)24M
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M445YAZ 5\;>'?V<_C]\*?&OCJ_\ A_XG\%0Z3XDU:742-6%PTV"[LH($+!2
MY!PQ^M?9-%=5#$SH*2BDU+=-7V.>K0C6:;;36UG8^7?^$8_:[_Z&[X;_ /?J
MX_\ D>C_ (1C]KO_ *&[X;_]^KC_ .1Z^HJ*W^NO_GW#_P !1E]57\\OO9\@
M2?!S]I261I'N_A \C6@L&=M,D):VP!Y)/V7_ %> !LZ8 XXJ*^^"W[2VI0:5
M;W.H_">:STMB]G:-8R^1"2,96/[-M!ZXXXR<5]B44?77_P ^X_\ @*#ZJOYY
M?>SX[7X)?M'+O(E^#H+R><Y&E/\ ,^R1"Y_T7EBDTRY])7'1CF:+X/?M+027
MDD=Y\(8Y+QF>Y=-,D!G9A("SG[+\Q(FE&3G(D?/WCGZ^HH^NO_GW'_P%!]57
M\\OO9\A6WPB_:8L]7&JV]]\(K?5 \D@OHM-D6<,Y<N0XM=V6,DA)SR7;/4U)
MXN^&'[5OC?PMJ_A_5/%GPZ?3=5M);*Y6)+A6,<BE6P?L_!PW6OKFBFL=*+NJ
M<?\ P%">$BU9SE]YY_\  /X=7OPF^#WA?PCJ-S!>7^EVOE3S6N[RF<NS';N
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MF;<Q3Y?E)89)'4\U,G@#PO'H;Z*GAO2%T=Y!,VGK8Q"W9QC#&/;MSP.<9X%
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M!%OH?QW>U^&?P\^'-CX)U(HVK:X+.X6]:2Z,$]S=:=;A+B)I/(1H4D*FZ)A
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MUPL\B*8G;EU*H#NP,YS@9P/0Z** "BBB@ HHHH **** "BBB@ HHHH ****
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ML;1>%]'1U*.MG""K#!!V#C%:M%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% $-[>V^FV<]W=SQ6MI;QM+-/,X1(T499F8\   DD]
M,5-39(TFC9'4.C JRL,@@]013J>E@"BBBD 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>acxp-20221231x10k012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 acxp-20221231x10k012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #Q G$# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI*,T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA*W_ )U^5M?JE_P4A_Y-X;_L)6_\Z_*VOT_AS_<OF_T/,Q'QA7W+_P $R/\
MD/>(OHG\C7PU7W+_ ,$R/^0]XB^B?R-=&??[A/Y?FA4/C1^BU%%%?DYZA^(?
M[0'_ "6_QU_V&+G_ -&&N KO_P!H#_DM_CK_ +#%S_Z,-<!7[AA_X,/1?D>)
M+=EO2/\ D*6G_75?YU^Y7PU_Y$71?^O9/Y5^&ND?\A2S_P"NJ_S%?N5\-O\
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MX8BK"/)&5D<Z?!5@T<D9N;II&N/M/F>=\ZOC&0<>G%27?@_2[G24L1OM[<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO)9R'SK%]1$0?(Y25-PW+TX-5&$INT5<+I;F5!\?XI[;7GCTAY9-*C6=H5F
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MR@PP10V!G[P]: >AZK17FFA?%F74_B$OAN>PC@242>4_F,93MC1]Q4KC:=Q
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MORS_ /1ZU^2]?IG#?^Y/_$_R1YN(^,*^U_\ @FA_R.&N_P"Y'_[-7Q17VO\
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M5^,?[7?_ "<GX]_Z_P#_ -II7[.5^,?[7?\ R<GX]_Z__P#VFE>GPS_O,_\
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M1KHS[_<)_+\T30_B(_16BBBOR<]4_$/]H#_DM_CK_L,7/_HPUP%=_P#M ?\
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M 'A7[>? _P#Y)CH7_7LG\J^2XHVH_/\ 0ZL-U.\KYA_X*+?\FV7_ /U_VO\
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M,^9XP_Y$U7_MW_TI'A>.0*7'O28YS2U^Q'\Y"9YHXHQCK2T"$'I2XZ4@I<T
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M!(/AB7\'7_&OO^'\7AZ&%E&K-)\SW?DC@KQDYW2/"J^Q/^"<'_(_:I_NQ_\
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M&N KZH^,W['WQ2\0_%/Q3JUEX<DFL;_49[B"19$.Y&<D'@\<&N,_X8H^+?\
MT+$O_?:_XU^PT,PPBI03JQV75=CR)0FWL>*Z1_R%;3_KJO\ .OW*^&O_ "(V
MB_\ 7LG\J_*?3OV+?BS!?VTC^&90B2*Q.]>@/UK]6O L,VE^$]+M+B"1)HH%
M5EQT(%?(\18BCB'2]E-2M?9W['7AXN-[HZ2OCO\ ;"/_ !<S3?\ L%)_Z-DK
M["C?>N=I7V-> _M _ /Q/\4/%MEJVAWFDP0Q68MG34)94;(=FR-B,"/FKR,E
MKT\-C85:KM%7_(\/B;"5L=EE2AAX\TG;3YH^2.U+7L__  Q[\0_^@CX8_P#
MFX_^,T?\,>_$3_H(^&/_  )N/_C-?IG]N9=_S]7X_P"1^(?ZK9Q_SX?WK_,\
M8S1UKV?_ (8]^(G_ $$?#'_@3<?_ !F@?L>_$,?\Q'PS_P"!-Q_\9H_MS+O^
M?J_'_(/]5LX_Z!W]Z_S/%QZ48->T?\,>?$/_ *"/AG_P)N/_ (S1_P ,>_$/
M_H)>&?\ P)N/_C-']N9=_P _5^/^0?ZK9Q_T#O[U_F>+GM1U->T?\,>_$/\
MZ"/AC_P)N/\ XS2?\,>?$/\ Z"/AG_P)N/\ XS1_;F7?\_5^/^0?ZK9Q_P!
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %-;M110 ZFM110 HI:** "BBB@ HHHH *:.IHHH =2#J:** %
MHHHH **** "BBB@ HHHH *:>M%% #J1NE%%  O2EHHH **** &GJ*=110 UN
MM*.E%% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
C %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>acxp-20221231x10k013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 acxp-20221231x10k013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (+ WD# 2(  A$! Q$!_\0
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M_AL[XU_]%"U/_OF+_P"(KQ:BCZEA?^?4?N7^0<TNY[3_ ,-G?&O_ **%J?\
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M@XQ_=]Z\JE7RRM*,(TTN;:\+)V[-JQHU-*]SE?\ AL[XU_\ 10M3_P"^8O\
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M]%"U/_OF+_XBNSTK]DA?'4EIKUWXHT?P#;>+[Z:3POHE['))-<PL[&-0%^X
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M*[)WVT6JWL%I]SB/^&SOC7_T4+4_^^8O_B*/^&SOC7_T4+4_^^8O_B*]]O\
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M !%>+45Z/U+"_P#/J/W+_(CFEW/:?^&SOC7_ -%"U/\ [YB_^(H_X;.^-?\
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MR_\ DXN[_P"P#=?^C8:_5+%?G.>TX4L9RTXI*RVT.B#;CJ>%_MP?\FP^-?\
MK@G_ *,6OQMK]DOVX/\ DV'QK_UP3_T8M?C;7TG#7^ZS_P 7Z(SJ[H****^N
M,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KIOAC_ ,E&
M\,_]A&W_ /1@KF:Z;X8_\E&\,_\ 81M__1@K*K\$O1C6YH_'#_DLGCC_ +#5
MW_Z.:N(KM_CA_P ED\<?]AJ[_P#1S5Q%30_A1]%^0/<****W$%%%% !5K2O^
M0I9_]=D_]"%5:EM9S;7,4P&XQN'QZX.:3V _3G]JKPK\"]?F^'\_Q9\9:UX:
MU&+18Q9VVF6[R)-#P6+%;>7!SQU']:\T^(/[2'@7QSXP^!GPP^&L5U/X6\/>
M)--G^WW:.F\QL(HD0/\ .<+(^YF R<8]:^:_VBOVB;O]H2]\,W%UHL.BG1-/
M&GHL,YE\T9SN.5&#[5Y[X$\4OX&\;:!XBCMUNY-)OX+Y;=VVB0QN'"D\XSC&
M:^8PN52C0BZTFY13M&ZLF[]O\S9U-=#[R_;E^//BRS^,UC\*K&^BTWPGJT%H
MFI+%"AEN5FE*MF0C<H 7^$CO6C^U3^T9XN_9=\<>$/!/P\TVPL/#EM812?9C
M9+(+[DKLSU X_APV<\FOC#]H;X[7?Q^^)(\83Z7'H5R+6*V6"WG,@786(8,0
M#GYOTKVGPA_P44U[2_#ND6/B?P1HGC+4]) %GJU]A9HL# 891L-C^($9KG66
M3I4:%J2ERI\T;I7;6]]G;_ABN=-O4^N=5^#OA&7]LKPSXH;3((]4NO#=SJ,M
MEM 4W,3Q1I*5P,MME89/_/,'J*X;]FC]J7X@?%']IOQ+X1U^SM9-#M3=B!8;
M,1O8B-]JC>.3N'7<3D]*^+[_ /:W\?:A\<X/BB]W$NLVX\F&T52+=+;G]QMS
MRIW-DGG))]*]NM?^"FNH:=K;:G8_#+0+*XN!_ITL$NV:[./E+2",'CWS7)4R
MK%*ER2@JC<$D[_"[O:Y2J1OO8]*\+(S_ +/G[5X4%C_;6J< 9_Y8I7!?!FUF
M@_X)P_$F22-D26_G,;,,;@$A&1[5Y;\)OVW==^%GB;QM>CP]8ZSHWBF\DOKG
M1[J4A(Y'R#AMIR"I"D$<X%:_Q _;VU+QW\+M?\"KX(TC1=(U",0VR:=(8TLX
M^#A4" -SD]NM=7U+%QDX*%XN4)7NNB5U8GFCO<]S^._QA\0?LF?";X2Z7\-K
M6QT^ROK-+F[GDM5F%RVQ6:-L_P!XL<D'=TP14?P1_:%\8>-_VS-&M[WP7_PK
MJW\0Z:\>IV$L#>=J MX+B2&5GD12-K,<% N1@,6 &/#/AE^WMK?@[P-IOACQ
M+X/T?QW::65-A-JO^L@V_=ZJV2O9N#6#K/[;?C/7?CSH/Q-N;2T,NB1R6]EI
M"EO(CAD5ED7/7<P8Y;'9>.*F.657"=.=%.34O?ONWJM/6V^W0?.M'<R_VROB
M7XC\?_&[7K/7;X7=MH=W-96""!(_*AW9VY506^K9->%UZY^T;\?4_:!\26.L
M#PIIWA::"-UE6P;<;EV()D<[5RW&,G->1U]/@X.GAX0E'E:6W_#?>82=VV%%
M%%=A(4444 %%%% 'KOQ^_P"0;\-O^Q8M_P#T-Z\BKUWX_?\ (-^&W_8L6_\
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MR3@  ?@*SZ(Y3#E7-.7-:U]-K6MMM;ROYA[1]$?:NI?M%_#>?PU\;;6;5#J
M\1^);34+"R%E./MUJAC\P99 J9"L,.5KUJ']K3X10^*-7U./XGZC'H>IZ VF
MV7A:/0IX;+2Y=J;GE*)F61B,*P!V@N"Q!7'YH44IY-0FK.3_  [)=O[J\]^F
M@*HT?9_A+XU?#35?@_\ !JUUOQH^B^(? ^H-/<::VD7$PN$,KD$2HNU0%8>I
M.#Q6KXC_ &C_ (6_$/7/C!X,UK7KS2_"7B^ZBOK#Q1:V$LHAEC5,"2 J)"N8
MUX YR?N\&OANBM7E5%R<N9WU:VTO+FTT[][B]HS[F\(?M(_"[X::[\'?!&B^
M(+S5/!W@^YNK_4O%-WITL0N+B:.4_NH #(%#3.,%>,+RV"QXSP;\=?!.E6?[
M0B7>M&-_%9E_L<?99V^U9D)'1/DX(^_MKY,HIK*Z*N[N[M?;6TN:^W5_\ .=
MA1117L&84444 %%%% !1110 4444 ?6G_!,K_DXR[_[ -S_Z-AK]5*_*O_@F
M5_R<9=_]@&Z_]&PU^JE?E_$/^^_)'53^$\)_;@_Y-A\:_P#7!/\ T8M?C;7[
M)_MP#'[,/C7_ *X)_P"C%K\;*^BX:_W6?^+]$9U=T%%%%?7&(4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5TWPQ_Y*-X9_P"PC;_^C!7,
MUTWPQ_Y*-X9_["-O_P"C!657X)>C&MS1^.'_ "63QQ_V&KO_ -'-7$5V_P <
M/^2R>./^PU=_^CFKB*FA_"CZ+\@>X4445N(**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBK^@!#KNFB10\?VF/<I&01N&1BDW97
M ].^/W_(-^&W_8L6_P#Z&]>15^Q?Q\^,/PU^ V@>&+GQ+X)75X-0C\NUCL]/
MMI/)55!P0Y4 8/:O%O\ AO;X$?\ 1++S_P %%A_\<KY7!YCB:E%2I89R6NMU
MW.B4%?61^;M%?I%_PWM\"/\ HEEY_P""BP_^.4?\-[? C_HEEY_X*+#_ ..5
MV_7L;_T"2^]$<D?YC\W:*_2+_AO;X$?]$LO/_!18?_'*/^&]O@1_T2R\_P#!
M18?_ !RCZ]C?^@27WH.2/\Q^;M%?I%_PWM\"/^B67G_@HL/_ (Y1_P -[? C
M_HEEY_X*+#_XY1]>QO\ T"2^]!R1_F/S=HK](O\ AO;X$?\ 1++S_P %%A_\
M<H_X;V^!'_1++S_P46'_ ,<H^O8W_H$E]Z#DC_,?F[17Z1?\-[? C_HEEY_X
M*+#_ ..4?\-[? C_ *)9>?\ @HL/_CE'U[&_] DOO0<D?YC\W:*_2+_AO;X$
M?]$LO/\ P46'_P <H_X;V^!'_1++S_P46'_QRCZ]C?\ H$E]Z#DC_,?F[17Z
M1?\ #>WP(_Z)9>?^"BP_^.4?\-[? C_HEEY_X*+#_P".4?7L;_T"2^]!R1_F
M/S=HK]1](_;"^"VK>!]?\1P_#6>.PTF>VAG@;2K(/(TN_85 ?!QL;.2.O%<U
M_P -[? C_HEEY_X*+#_XY41S'&2;2PDM/-#Y(_S'YNT5^D7_  WM\"/^B67G
M_@HL/_CE'_#>WP(_Z)9>?^"BP_\ CE7]>QO_ $"2^]"Y(_S'YNT5^D7_  WM
M\"/^B67G_@HL/_CE'_#>WP(_Z)9>?^"BP_\ CE'U[&_] DOO0<D?YC\W:*_2
M+_AO;X$?]$LO/_!18?\ QRC_ (;V^!'_ $2R\_\ !18?_'*/KV-_Z!)?>@Y(
M_P Q^;M%?I%_PWM\"/\ HEEY_P""BP_^.4?\-[? C_HEEY_X*+#_ ..4?7L;
M_P! DOO0<D?YC\W:*_2+_AO;X$?]$LO/_!18?_'*/^&]O@1_T2R\_P#!18?_
M !RCZ]C?^@27WH.2/\Q^;M%?I%_PWM\"/^B67G_@HL/_ (Y1_P -[? C_HEE
MY_X*+#_XY1]>QO\ T"2^]!R1_F/S=HK](O\ AO;X$?\ 1++S_P %%A_\<H_X
M;V^!'_1++S_P46'_ ,<H^O8W_H$E]Z#DC_,?F[17Z1?\-[? C_HEEY_X*+#_
M ..4?\-[? C_ *)9>?\ @HL/_CE'U[&_] DOO0<D?YC\W:*_2+_AO;X$?]$L
MO/\ P46'_P <H_X;V^!'_1++S_P46'_QRCZ]C?\ H$E]Z#DC_,?F[17Z1?\
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M)+[T')'^8_-VBOTB_P"&]O@1_P!$LO/_  46'_QRC_AO;X$?]$LO/_!18?\
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M7UQ@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=-\,?\
MDHWAG_L(V_\ Z,%<S73?#'_DHWAG_L(V_P#Z,%95?@EZ,:W-'XX?\ED\<?\
M8:N__1S5Q%=O\</^2R>./^PU=_\ HYJXBIH?PH^B_('N%%%%;B"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J]H?_(;T_P#Z^(__
M $(51J]H?_(;T_\ Z^(__0A4O9@?H)_P4R_Y$GX:?1__ $4M? %??_\ P4R_
MY$GX:?1__12U\ 5YG#__ "+X>K_-FM7XV>X_#/\ 9^TKQGX-T?4=2UJZL-5U
M^ZNK32H+>%9(BT,88F5LY4$G''UKA_$OPYB\(_#_ $C5]2NY(];U:XD-MIZJ
M-HM4.WSF/7YG!"^PS78_L]>-?%DNH1^$['5HM.\-J9KZ_N9K>-VLX-F)WCD8
M;HRR#;\I!.17M_AB+P[\7M(L=<N/#>EWGAR>;4;76M0G57ET2R@@(L]KD@PG
MA2.A<D]:=;$U\+5?M'>-[Z=M;+Y_/5>8))K0^3_A7X.A^(7Q)\,^&;BY>T@U
M;4(;)YXU#-&'<*6 /!(S70I^S]XSUK5=73P[H=WJ^F66HW&GK>@HBLT3E>26
M !Z?G3OV;=J_M#?#W:?E&O6F#[>:M>E_&#5[O3_@;=PVMU+!'<>/]4\U8G*[
MPN2N<>AKJQ%>K#$*G3:U2W\V]>G8E)-79YCI?P7U5].\90:GIVIV7B+0Y;&W
MCLA"GE>9<3^4!,[,-@.1M(R"3S@<UUGQ"_9DNOAOKGB^PU%[^X@TG1XM1L[N
MUCC=)F*P^9Y@W91%:5ESC)P..:]<^,-PTGAWXYRF0F5M$\(,7SR3F+G/K6G\
M0M"OQXY^,NL7!,&AZ]X.LIM,U(N'AFB5;)'D0@X(5@<]*\Q8^M*2DVDGT^5-
MZ?\ @3^5_E?*OZ^9\N1?L_?$.;P^=:3PI>MIPM_M9D^3=Y.,[]F[?C'.<4GQ
M(^&=OX&\(?#_ %B&]EN9?$NEO?RQ2(%$#+,T>U2.HPN>:^W/AU\-AX<^*UA<
M2:/K.L1C36CB\;ZOX@!@U M;,!'!;J<.#T"Y8@+D@8%?+?[1O_)-_@J.XT"X
MX_[>Y*VPV8U,37C#2WEYJ6F[[>3[I"<$E<P/#'PAT.Q^']IXT\=ZS=:-I6I3
M/!IEIIT"RW-T4^^^&("H.F3WI?$WP3L]2?PS-\.-6?Q=%KWFQPZ?($BOH)8E
M+.LD>[@;02#T(!KM)_"%_P#'WX$^!+3P;&-5\0^$1<V5_HB2HMPT<LGF+.B$
M@NO\)QR*Z;X+_#+1O@C\8/A8/$NLI8^.;ZZNOMVEO<Q&#3XGMY(X%E8?=E=G
M V[N,CCD54\7*"G/G]].7N>23MIO;1.]^OF"C?0^9-(\&ZUKVD7NJ:?I\MU8
M64L,%Q.F-L;RL5B4Y/\ $00*ZC4OV?\ XAZ3JMAIEWX5O8M0OG>."V!1I&*C
M+9 8[0!W.!7N/A#X0>*/A1\"_&R^*]/&CWEWK^B+%9RRHTI5+D[G(5CA26 #
M=&P<=*ZKPWXEB'[4?QITV4V=[KVI6]Q;:/;:I,4AGE&TM '#H5+J,###-.IF
M4^:;HVE&-_.]N7K>VG,[^2!06ESY*\;?#+Q1\.7M!XCT:?3!=J6@D<JZ28X.
MUE)!([C.:YBOI3]H"7Q?HGP:T;0O$GA+PSX'M9M;:^MM(M;B=]3++"R-*4>2
M0+"=P'4$LJ\8YKYKKU,)6E7I<\K;O;;\W^;(DK,]8\#_ /)O/Q*_["&E?SGK
MR>O6/ __ ";S\2O^PAI7\YZ\GIT/CJ_XO_;8B?0*[3X-_#P?%7XDZ/X8>[-A
M#>>=)-<!=Q2**%YG('<[8VQ[XKBZU_"7BS5/ WB.PUW1;IK+5+*3S()U .TX
M(((/!!!((/!!(K>JIRIR5-VE9V]>@E:^IZP_[/\ IFI:OX6O=)UBZ_X0W6-,
MGU6>_O(56>SB@=DFW ?+G*@+SSD5XK>+ MW.MLSO;!V$32##%,\$CUQBOL?P
MCXI.J2^#_#?C'[!>:UXEL3>/8>6EM;0V:JSV-F$0*@$TG[QE&,@H#UKQ;]I+
MPY9^'M0\*EM&L_#OB.ZTI9M:TFRC6%+:?>P4&('"$H%../6O(PF*J.K[*KK?
M;[WKTOM:^VW<T<=+HL>&_@WX/TOX6^'O&OCSQ%JNF6OB&>YBTZ#1[$7!"P/Y
M;F5F("DMG ZD FL/QW\$IM*UMT\(7Z>+]%;31JZW=LR"2&W_ (A,F[Y&4]17
ML'P;T+XK67PRT6\^%FK6?CS1KMY&U;PQ=PV[?V7<!L%&BF<G#CG>FW(]*[E=
M T1/'^HZ!INGZ-H7CW7/!US%J6A:1<*;9+XME8D.=@=EY*ANM<<L;4I59>_S
M:O3LD^JLG&RZW:>_5%<J:/CS1_AKXH\06&EWFFZ+=7MMJEXUA9O" WG3J,L@
M&<Y .?2NS\/_ +-'C>]\;^&] U?1Y](BUFZ^SQW;-&\8QR_S!B,A<G;G/M7T
M/X(\%^,_A3\//A-8QG1]&\8GQ1?R16>OSA;="]J5$,Q0G:TB' '!RZ]#5ZXT
M&S\.-X,U75]#OOA1?)XMMF7P[=:S]IM+[/$EQ'&QS&%'&[[I!P"<TZF:5&W&
MG:VJ3W>[2>^VG1-=[(%!=3Y?U']G;QPOC+7M!TS0KC4&TJ8I),'C"!"Q$;,^
M[:"P&<9S4&G?!K5;'4O&&F>)M-U32M2T/0I-76WB@5^0\2J9"6P(B)#EESS@
M8ZU]&:7\%M76+X@OJNC^(/%-\WB)Y?\ A#]-U9;)!$Y9H[N5N2RE2,$< =2*
MZ'XFV*Z=K?B2!+>.TCC^"7E+#%=FZ2,K>QJ4$Q)\S;C;NSSBE_:<W)4TT]M5
M\O-]^UNS8<G4^48_V=_B/-I U1/"=\UB;9;Q9 4RT)0.'5=V2-I!X%4/"'P5
M\;^/=,.HZ#X=NM0LO,,0F4JBNXZJNXC<?89KZ036;V/]JCX/P)>3+;GPUI43
M1B0A"ALSE2.F#73$ZSXR\#> #X"\%:%XV33/-L[UKFYFAFTR[6=B7D"31A4(
M(8.1V//2KGF5>"C=+WDG?9*_-O=KMW0N1'R%X6^$7C'QI<:E!HWA^\O)--?R
M[P;1&('R1L8N0 V01MZUH_&OX7#X2>)M.T<SSS3SZ7;7TRW"!&BDD4EH\#^Z
M1BOHWXA1>)?CEX'\5:3X7&CZGXTM?&C7^L6GA2Z(MYXC:1Q+/"9"K.@=&!/.
M&);H<UY7^V997>F_$[0[/4)5FOK?PUIT4[I()!YBQD,-P)!P1C/M71A\;4KU
MXPDTM'>/7IJ_+731"<4D92?"#PGX+\*>']4^(7B#4-/O]?MA?V6EZ1;++*EJ
M3A992Q &[!P.O!K+\:_!-K34;>7P5J2>,-%NM-;54F@*K/;PKQ()X\_(RGMW
M[5Z?\3_ .O\ [2&@> O%/@&Q7Q#]DT*WT?4].M)D^T6%S"6!#QL0=C!@5;&,
M YQQG:^%OPTT?X?>,9_!UKK<6H>.M6\*7D.HV*W$;007KC,=K'(/E+[?O#<?
MFX!K%8R4(>T<[SUO'2RMWZJW=[_,?+TL?-_A_P"%WBKQ5::?=:3HMQ?6^H73
M6-J\97$LZKN*#)ZA>:UG^ 7Q CU^#1#X8NO[4FMVNEM@\998@<%V(;" 'CYB
M.:^N/@=\/=9^&NA?"#3?$5L-.U5_&5Q-)8NZ-)"IMF"[PI."1S@X/->7?LU:
M_=>(?"_Q>TN&SL?%7C/5#97-GI.KSNAOXXYI6N%1E=&+?.C;0W..G%#S*I+V
MDJ=G&-OQDXWO>UE:[_-!R+2Y\[^,? FO_#_4DL/$.ESZ7=2()428 AT/\2L"
M0P^AK!KZ!_:=U#Q+;^'O!>A>)M"\->&KBTBEEM])TF>:6\M8V;[MQO=P@)Y"
MAL^U?/U>QA:LJ])5)6N^VV_]=69R5G8*]9\$_P#)O'Q%_P"PAIO_ +5KR:O6
M?!/_ ";Q\1?^PAIO_M6EBO@7^*/_ *4@1Y-11178(*]S\'?L]:7XD\":#?3Z
MU=0>(_$-AJ.HZ;:I"IMO+M&9661LY#,4?&!C@>M>&5[Q^S]X^\2744F@76J1
MVW@C1K2YOM1D:W1IH;0D&6**3:9%$K;5VJ>2W2O/QKJQI<U*5K;_ '/R?6VG
M78J-KZGGGC/P!!X+\)^&KJ[NY/[>U>)KQ]/* +!;'B)B>NYN3CTQ5SX!_#6S
M^+WQ6T?PI?WTVG6E['=227-N@=T$5M+-P#QR8P/QKZ-GL]$^)O@*;Q5J'AW2
MI-&OM%U"ZU#6V53+I][&=MI:K*2#&  BA!C=D]:\C_8EE$'[2OA>0A6VV^I'
M#C*G_B7W/!%</UN<L)6EM."EVT>OY6Z^3ZE<JYD2^#/A#\./BI>WNB^%/$FO
MQ^(%LYKJVCU2RC$$OEH6*LR'*Y /-<#X6^!WCOQKIS7^B>&[O4+,2-$)D**'
M=>JIN(W$?[.:]Z^"_P 2(_BOX?\ %/@W1M)T'P-XZOK)SI>HZ)81VIOE R]J
M[!3M+#."I!/3FNTT>T\2:WX%^%8\&>!]!\63:-9I8ZA<WUU-%)I%['*2_G!)
MD"*#AMQ!SSUXKFGC:^&E*,NZ^)K31N]_=5GLM=T_0I13/D?PC\(?&7CN6_CT
M/P]=WK6#^5=$@1B%\XV,7( ;(^[UJMK/PT\4>';35+K4]%NK&#2[E+.\>90O
MDRN,JI&<\@9&.*^HO'EMXB^.OPYUG3O!R:5J'BNS\:W5YKEAX6F*PS[X51+N
M(R$.\6Y6&[GDD],&J=_\//$/BGX9^/O!.F:__P +"\8VNH:9<7,<4RF9%2%E
MD1=SG>L1(0LIQQ[5O',I7O/E6JNM;I72NWM;73;YBY.Q\[Z/\%_&WB"]M+33
MO#MU=W-WIJZO!&A7+VC2",3=?N[F Y]?2M&Y_9Y^(EI97-Y-X8N([2VW^;.9
M8O+7:%+#=OP2 P.!ZU]1ZOH]YX(74=+GGC74+'X'S02O;2AU5Q=1A@K*<''(
MR*\@U[7'LOV;OA*]S<R_8QX@O);E=Q.Y5:/.1WXS2IX^O6:<+6;ML^S??R!Q
M2/,9O@5X^@\,MX@D\+WJZ2L'VIIR%R(O^>A3.X+WSC%6='_9X^(WB#3+34=/
M\*7MS97<"W-O,I0":-@2"F6^;@'@<^U?8GBO4_%D'Q#U7QGX<\(>"I/";V#W
M$'C+5+VX%JUJT./+D"3$;\';Y83KCBO)_$.O7T?Q*_9DM([V2.T30-*G6&*0
MA [WLZLV/<(H^@%94\RQ%5:*/?O;1NSL]]/+T#D2/ O"/P;\:^.Q=MH?AV[O
MEM)/)G;"QJDG382Y W>W6I-$^"/CKQ#J6IV%CX:O9+K3)!#>+(%B$#GHK,Y
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M +"-O_Z,%<S73?#'_DHWAG_L(V__ *,%95?@EZ,:W-'XX?\ )9/''_8:N_\
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MDW$S_P!O^2.RE\)S7Q'\ Z)\3?!NH^&_$222:/>J%G6*4QL0"",,.1R*^?\
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MDA$R0!G'N0*/[1QO_/Z7WL.2/8\G_P"'>?P)_P"?+4?_  :R4?\ #O/X$_\
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MU:.::QLF)WSI"%,I7_=#KGZUL4?VCC?^?TOO8<D>QX?_ ,.\_@3_ ,^6H_\
M@UDH_P"'>?P)_P"?+4?_  :R5[A64/%.DGQ+_P (^+Z)M:%M]L-D#EQ#NV[S
MZ#)QSUH_M'&_\_I?>PY(]CR3_AWG\"?^?+4?_!K)1_P[S^!/_/EJ/_@UDKW"
MBC^T<;_S^E][#DCV/#_^'>?P)_Y\M1_\&LE'_#O/X$_\^6H_^#62NNO_ -H/
MX<:7XK/AJZ\8:9!K:RB!K5I?NR'HA;&T-[$YK;\=?$[PK\,M.@O_ !1KMIHU
MK</Y<+7#\RMZ(HR6_ 4O[1QO_/Z7WL.2/8\V_P"'>?P)_P"?+4?_  :R4?\
M#O/X$_\ /EJ/_@UDKT[PU\1/#/C#PN?$>C:Y9:AH0#,U_%*/+3;][<3]W'<'
M%8W@KXZ^ /B+JLFF>&_%6GZM?H"Q@@<AF X)7(&X#U7-/^T<;_S^E][#DCV.
M*_X=Y_ G_GRU'_P:R4?\.\_@3_SY:C_X-9*]<T+Q1I/B9M072[Z*\?3[I[*[
M2,_-!,N-R,#R#@@^X(-:E']HXW_G]+[V')'L>'_\.\_@3_SY:C_X-9*EMO\
M@GU\#+6XBGCLM0$D;AU)U23J#D5[712_M'&_\_I?>PY(]CS7]J/]FS3/V@M&
M\-V#^(Y-!3269HWBM!=&12H4 @NF,8Z\U\\?\.RM)_Z*3=_^"-?_ )(K[;O?
MNV__ %R']:JUMA\VQN%IJE1J6BO)?JA.G&3NT?%W_#LK2?\ HI-W_P""-?\
MY(H_X=E:3_T4F[_\$:__ "17VC173_;V9?\ /W\(_P"0O90['Q=_P[*TG_HI
M-W_X(U_^2*/^'96D_P#12;O_ ,$:_P#R17VC11_;V9?\_?PC_D'LH=CXN_X=
ME:3_ -%)N_\ P1K_ /)%'_#LK2?^BDW?_@C7_P"2*^T:X?QW\;_ GPRU"WL/
M%'B>QT>]N$\R.WF8F0I_>*J"0ON>*/[>S+_G[^$?\@]E#L?,W_#LK2?^BDW?
M_@C7_P"2*/\ AV5I/_12;O\ \$:__)%?65UX^\-V7A/_ (2B?6[&+P]Y0F&I
MM.OD%#T(;H:S_ 'Q>\&_%(7?_"*^(;/67M,>?' Q$D8/0E& 8 ^N,4?V]F7_
M #]_"/\ D'LH=CY=_P"'96D_]%)N_P#P1K_\D4?\.RM)_P"BDW?_ ((U_P#D
MBOM&BC^WLR_Y^_A'_(/90['Q=_P[*TG_ **3=_\ @C7_ .2*/^'96D_]%)N_
M_!&O_P D5]HT4?V]F7_/W\(_Y![*'8^+O^'96D_]%)N__!&O_P D4?\ #LK2
M?^BDW?\ X(U_^2*^T:*/[>S+_G[^$?\ (/90['R[H7[ &F:3\.?$WAM?'ES+
M'JUS:3M<G2%!B\GS, +YWS9W^HQCO7(?\.RM)_Z*3=_^"-?_ )(K[;A_X\+C
M_>7^M5:B.=YA%MJKOY1[6[![*'8^+O\ AV5I/_12;O\ \$:__)%'_#LK2?\
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M\QSBETKX'?$K5?C7X&\>^)]6\+Q6N@V]S9MH>APS1Q0QR*,-'(ZYD;<.00@
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M=Y\3?C-X+\"_#_XD:SXDTC5=*UJ^TZTU'PY#IB1+%%=,J>9'/G>7!;.#QST
M%?17_"XOA_<>)#X8_P"$X\.'Q$TIM3HXU>W^V"7H8_)W[]_^SC-<+XZ^!FL>
M*?@9X0\$VU]8Q:CHUUI4\T\K/Y+BUE1W"X4G)"'&0/?%=L?@C\/?^$E;Q(/
MOAJ/Q,TIN#K::1;B]$Q_Y:B?9OWYYW9S0!\Z_M4?#FX^'OP2USPSX(^'<=_X
M:OO,OM:U_P"TK+>60:4/+-'$Y#RN!E@=XQCI6C\/7T7XC?M/^&;R.[_M_0])
M^'=M<Z.]TNY6,\Y#3[3_ !E8U&>P.*V;_P"#?QQ/AK6? T'C[1-0\)ZE)-'_
M &]JR7$VM6]K*27BP<QR$*Q569A@=N!C1UC]FW6? NL>"/$'PGU#3-/U;PWH
MO_"-RV.O+(;6_L 0RJS1@LCJXW!@#UQTZ@'A_P 6_"VK-XF_:1\'^$=.N9;"
MXMM&UN73+ 8#$Y%RL:#^*2-,D#J13_C!\<?ASX@@^#,OPOMQ-J^F^*=,MI)K
M.R>'^S+>1O*EMYV*KAV#$;"<_(3C'->Z>%_V=_$B>&_B)J&M^+OL'Q'\;/'+
M<ZUX=$D$6GB%-EO%!DARBC.22"VXYI+#X.?$CQYXD\*W'Q/UWP_/HGABX6^M
MK'P_%,6U"[12L<UPTH^7;DMM3/S'K0!'?:DWP_\ VU])T^V81Z;\0/#4\EU;
M+T-]8.I6;V)AE*'UV+Z5]!U\_6&GM\3OVQ)O$, 5]"^'FB2:0MQC/F:I>,KS
M(I[^7 D8;T,N.QKZ!I@%%%% %J]^[;_]<A_6JM6KW[MO_P!<A_6JM" ****
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M %? ,OPL\=_"_P"'_P"SUX<66QTCQC-XPO;J)+P?:8--6>*9_+(1@'\J-B
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MHQ1B@ HHQ1B@ HHQ1B@ HHQ1B@ HHQ1B@ HHQ1B@ HHQ1B@"U#_QX7'^\O\
M6JM6H1_H%Q_O+_6JN* "BC%&* "BC%&* "BC%&* "BC%&* "BC%&* "BC%&*
M "BC%&* "BC%&* "BC%&* "BC%&* "K4/_'A<?[R_P!:JXJU"/\ 0+C_ 'E_
MK0!5HHQ1B@ HHQ1B@ HHQ1B@ HHQ1B@ HHQ1B@ HHQ1B@ HHQ1B@ HHQ1B@
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M651M' S]*J?\)?K'_/\ /_WRO^%5-;_Y#-]_UV?^9KYA_:&_:&NO"'Q5\'>
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M%_:BXFGW.%\B)&^7*]6/)]J7N]@/IC_A+]8_Y_G_ .^5_P */^$OUC_G^?\
M[Y7_  KYI^''C3Q_\7O WB*PL/$.F:1XD\/Z[+I,GB"VL1<VE^D84ETC8X!.
M[! )P16!X-\0_%V?]H&+PC+XXL/$FAZ3 +G7YHM%CMUB+ ^7 K@D[S]X^@'O
M1[O8#ZU_X2_6/^?Y_P#OE?\ "C_A+]8_Y_G_ .^5_P *\?\ AUX]U"[\>^,?
M!'B":.76='E2^LYT01_:M.GR8GVC^)&5XF]2@/\ %7I%5:+Z ;'_  E^L?\
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M!L?\)?K'_/\ /_WRO^%'_"7ZQ_S_ #_]\K_A6/11RKL!L?\ "7ZQ_P _S_\
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MF"<;B1@ 8[GXOV4_Q&^%OP?\(^#4DF^)@T&UOX-0M;CRGL;46BB7S'P>),[
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M(_PH]IY!8\OHKU#[?-_>'_?(_P */M\W]X?]\C_"CVGD%CR^BO4/M\W]X?\
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MWS?WA_WR/\*/M\W]X?\ ?(_PH]IY!8\OHKU#[?-_>'_?(_PH^WS?WA_WR/\
M"CVGD%CR^BO4/M\W]X?]\C_"C[?-_>'_ 'R/\*/:>06/+Z*]0^WS?WA_WR/\
M*/M\W]X?]\C_  H]IY!8\OHKU#[?-_>'_?(_PH^WS?WA_P!\C_"CVGD%CR^B
MO4/M\W]X?]\C_"C[?-_>'_?(_P */:>06/+Z*]0^WS?WA_WR/\*/M\W]X?\
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M&9+B))8G62-U#*ZG(8'H0:\B\-_&.37O&OC_ %*6]@LOA[X/SIT]T8MS37J
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M **** "BBB@"U#_QX7'^\O\ 6JM6H?\ CPN/]Y?ZU5H **** "BBB@ HHHH
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MREU)'X5\T?L_:A\:OCI\+[3Q@?BM!H[W=S=1+9IX>M9%C$<SQKR5R>%%=M\
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M=26__'Q'_O"@!UY_Q]S?[Y_G67K>A:;XETN?3=7T^UU73K@ 36=["LT,@!!
M9&!!P0#R.H%:EY_Q]S?[Y_G4- %#5/#^EZYI3Z9J6FVFH::ZA&L[J!9864=
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M=OIP4EY;UAM61^VU%)P/4FO0Z* "BBB@ HHHH M7OW;?_KD/ZU5JU>_=M_\
MKD/ZU5H0!1110 4444 %49M!TRXU>WU673K275+:-HH+YX%,\2-]Y5<C<H.!
MD \XJ]10!6U+3;/6+&:RO[6"^LYUV2V]S&)(Y%]&4@@CV-4O#?A'0O!EBUEX
M?T73M"LV8N;?3;6.WC+'J=J #/O6M10 4444 %%%% !1110!:A_X\+C_ 'E_
MK56K4/\ QX7'^\O]:JT %%%% !1110 4444 %%%% !5"^T#3-3U"PO[S3K2[
MOM/9GL[F>!7DMF8;6,;$90D<$C&15^B@#C=7^"WP]\0:E<:CJG@3PSJ6H7#;
MYKN\T>WEED.,99V0DG@=36[X;\):'X-T\V&@:-I^AV)8O]FTVU2WCW'J=J #
M/O6K10 4444 %%%% !1110 4444 %6H?^/"X_P!Y?ZU5JU#_ ,>%Q_O+_6@"
MK1110 4444 %%%% !1110 5SJ?#GPG'XA.OKX7T9==)R=4&GQ"Z)_P"NNW=^
MM=%10!C>)O!?A_QI;PV_B'0M,UZ"%M\<6IV<=PJ-ZJ'! /N*U+6T@L;:*WMH
M8[>WB4)'%$H5$4=  . *EHH **** "BBB@ HHHH **** -3PY_R$#_N'^E=/
M7,>'/^0@?]P_TKIZB6X%'6O^0;-]!_.N2KK=:_Y!LWT'\ZY*G'8#Y*^ ZO;?
M 3X[V5T1_:UKXB\1)?#&&\T@L"WKE&0@^F*POV:OV3M)\;?L^>!]0U'XA_$M
M;74-*C>?2+7Q9<PV&U@<QK"N J?[(KZ-TGX4'0?BUXD\36-Q;_V%XGL8TU?2
M)HMPDO(L(DZ]OFB)1P>NU#ZUWNGZ=:Z390V=C;0V5I"NR*WMXQ''&OHJC@#V
M%.P'S'\9OAMX:\$^)/V<_"NCZ1;VV@6'B=Q!9,#(H*6LKJQ+9+,& ;)R<C-7
MO'FMZ5X&_;)L/$>HRQV%E;?#V_FOKKI^YBNHF^;U R2/K7T9>:59:A/:S75G
M;W,UH_FV\DT2NT+XQN0D?*<$C(]:KZEX9T?699)=0TJQOI)(&M7>YMDD+0L<
MM&2P.4.!E>AIV ^,?#/Q<\&?M,^,=.\7?$#QMH6B>"=+NO/\/>"YM0C66ZE5
MODN[U=WW@1E(CTX)YK[:D=)+-GC(:-HR5*]",<8KE$^#'P^C8,O@7PTK Y!&
MD6X(/_?%=>J*B!%4*@& H' 'I0!\!_LU_LV7/Q+_ &6H]2T3XA^.?"_B"YN=
M0^S1:9XEN[>P5UN9 %-NCA0K8^;;@\DYS7/>)[JWUK]D27POH6@P^$=>\)^+
M+)O&VF1PR7I\M)29;ITD<R7$;'9)AFY (R*_1/2M'L-"LEL]-L;;3K1"66WM
M(EBC!)R2%4 <DDU%#X<TFWU"\OXM+LH[Z\4)<W*6Z"6=1T#MC+#GH:5@/BG5
M+J;QU\6?@U!)\9+'Q_=VNLKJ=G:>%/"T,+PVZ1-YOGS"[)B@=#L(P23CY3MX
MY'4O%DGPX\(>-;GP?XWT'4_#<&JW4E[\*_B'I$<ESYQF+/'$R$NX=OF3<".E
M??>A>"?#OA>>:;1M!TS2)I_];)86<<#2?[Q51G\:;=^!?#=_K"ZM<^'M*N-5
M4@K?2V433C'3#E=WZT6 ^7O 7CS2_!W[6'BS6_%\MMX-A\0^#]'N+.'4)!$G
M[M7$L:DX&4) Q7A5YKEGXF^%WQ)U;3Y#-87WQD@N+>4J5\R-I8"K 'G!!!'L
M17Z.:]X0T+Q2(!K6BZ=JX@;=$+^TCG\L^J[@<'Z4U_!V@2PRQ/H>FO%+.MU(
MC6D95YAC$A&.7&!ANO HL!\M:GJ'A]/C%^T5HNOK/=)J.AV['3+!E%[=0"V8
M2&!21N8#..V17GOACXD:QX)'PLMM/\:>%?C9X6N=6LK73-$U32(XM?TG<-BR
MQF,E1)"I8,[@-U&1DU]VR^&='GUJ+6)-*L9-7B79'?O;(9T7T$F-P'MFJNG>
M!?#6CZK)J=AX>TJQU*3.^\MK**.9L]<N%!/YT6 ^?_C9H4GB_P#:T^&VD66H
M7>F3-X=U=;N]TUE2XMX'"+E7*L%)/3(/(SVKUGX5?!]_A/9P:?:>,M>UC1K>
M PP:7J-OIR0QG(._=;VD4A?KRSG.XD@GFG>$/AA+I/Q+\4^-M7O(K_5=4$=G
M9"-"%L[*,9$8SU9G+,Q^GI7H-, HHHH **** "I+;_CXC_WA4=26_P#Q\1_[
MPH QM2\9);ZC<Q?V;&^R1EW&5AG!ZU6_X3A/^@7%_P!_7K"UO_D,WW_79_YF
MJ5;J"L3<ZK_A.$_Z!<7_ ']>C_A.$_Z!<7_?UZ\ZTC7;_4/$6N:?<:)<V%G8
M&$6VHRNICOMZDML Y&P@ Y]>*P?BC\5+7X7GPR+FPFOO[<U>#2(_*<+Y3R9P
MYSU QTI\L0N>Q_\ "<)_T"XO^_KT?\)PG_0+B_[^O7G7AG7;_6Y-96^T2YT9
M;'4)+2W:X=6%["JH5N$V]%8LP //R&MNCDB%SJO^$X3_ *!<7_?UZ/\ A.$_
MZ!<7_?UZ\"UWXXR^%;;PBVM>%K[3;KQ'XA&@16LLR%HMS.$G8C(*L$W #G#"
MO4Z.6(7.J_X3A/\ H%Q?]_7H_P"$X3_H%Q?]_7KE:*.2(7.J_P"$X3_H%Q?]
M_7H_X3A/^@7%_P!_7KE:XCX5_%*V^*=IK=Q;6,MB-+U.;3'$KAO,:,X+#'0'
MTHY8A<]A_P"$X3_H%Q?]_7H_X3A/^@7%_P!_7KE:H:]KEEX:T6^U;49UMK"R
MA>XGE;HJ*,D_I1R1"YW/_"<)_P! N+_OZ]'_  G"?] N+_OZ]><>!_$TGC+P
MIINMR:=-I0OHA,EK<,#(J'[N['0D8..V:W:.2(7.J_X3A/\ H%Q?]_7H_P"$
MX3_H%Q?]_7KE:\K\9_'&;1?'%SX2\-^$]1\8ZU8VL=YJ"6<B0QVD<F?+#._!
M9@K$*/2AQB@N>_?\)PG_ $"XO^_KT?\ "<)_T"XO^_KUX#:_M&^%[GX6OXW*
MW4=O'=-I[Z<8\W0O0^PVVW/+[N*C\(?'B75_'.G>$_$GA'4O!VJZK;2W6F"]
MECE2[6, R*"GW74$$J>U+EB&I]!?\)PG_0+B_P"_KT?\)PG_ $"XO^_KUY5\
M/?B#;>/K35-MK)IVI:5?2Z??Z?,P9X)4.1R.JLA5U/<,*ZNGRQ"YU7_"<)_T
M"XO^_KT?\)PG_0+B_P"_KURM%')$+G5?\)PG_0+B_P"_KT?\)PG_ $"XO^_K
MURM%')$+G<ZKXN2V2S/]GQOYD ?F1ACD\50_X3A/^@7%_P!_7K,U_P#U6F_]
M>J_S-9%)05@N=5_PG"?] N+_ +^O1_PG"?\ 0+B_[^O7*T4^2(7.J_X3A/\
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MZK_A.$_Z!<7_ ']>C_A.$_Z!<7_?UZY6BCDB%SJO^$X3_H%Q?]_7H_X3A/\
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M\/\ B^[DNCJ6APSPVD2R 0_O0 S,N,E@!QR/QKJZI+4 HHHIB"BBB@ HHHH
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MX?Z1X/T)[F32M,618&O) \I#R-(=S  'ESV'&*FSO<#K****L04444 %%%%
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M_P!!23_P&_\ LJ/^$)L_^@I)_P" W_V5/GB%CD**Z_\ X0FS_P"@I)_X#?\
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M?_PA-G_T%)/_  &_^RH_X0FS_P"@I)_X#?\ V5'/$+'(45U__"$V?_04D_\
M ;_[*C_A";/_ *"DG_@-_P#94<\0L<A177_\(39_]!23_P !O_LJ/^$)L_\
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M>A5@2#M.0>17T;118#YHU3]F;QUXFTVU\1ZOX_1_B=IVM_VYI5RL<DNE:?\
MN_*:SCA<[O)=,AB,,2<UJV7P1\?>._'VG>+_ (DZSH)GT.QNK;1]'\/)-]F6
M:>/8\\LDH#,0. H7 SU/?Z"HHL!\W:E^S)K][^RGX;^%RZIIJZSID]M++>$R
M?9V$=R93M^7=R#@9'6NQ^('P;U/Q3\<_@SXY@OK.#3? T>L"^@F+^;/]KM$A
M3R\*1\K*2=Q''3->P4$ @@C(/8T6 ^.?A[X.T/XF_MG^(?%GAG6(M9\%Z7%!
MJ=REN-]M_;1C:$,K=-XBY('0@9YKTG4_@Y\0_ GQ$\5^)/A?K'A];+Q5(MWJ
M.E^)(YMD%V$"&>)H@2VX 91L=!R*]OTC0=,\/6[P:7IUIIL#N9&BLX%B5F/5
MB% &3ZU>HL!\^^&?V=/$^B^-?AAKVJ^,)/%-UX;LM:35+[4Y)#/<SWWEE?)7
MD+$A0J%)&%"XK0\*_ 76=!_9S\3_  ]FU"QDU351J0BND+^0GVAW9-V5W<;A
MG ^F:]RHHL!SOP\\-3^$/ 6@:%=21S7&GV,-K))#G8S(@4D9 ...XKYY^''@
M6[LO#7QH^"7FPV=_/>7FI:/-."L<EE?$LIX!)$<A=&QD]/45]457.GVK7RWI
MMH3>+&8EN#&/,"$@E0W7&0#CVH \;\=? S5_%/P-\(^";>_LHM0T:ZTJ>:XE
M+^4XM9$=PN%SDA#C('OBO0-5^$O@C7[^6_U7P;X?U/4)L&6ZO-+@EED(  +.
MR$G@ <^E=910!Y=\0_@W-=^#$T_X;ZA;_#G5;:\COX)-+MA!;3NO6.XCBV[X
MV'!%<MH'P:\>^,?BKX7\;?%'5]!D'A1)SH^D>&XYO)^T3)Y<EQ*\H!)V9"J!
M@9SG/7WJB@#RKX>_"34O#/QM^)OCO5+RTNH_$GV"#3(82QDM;:"$JZ.2 ,M(
M2V 2*J?$7X??$=/B'#XP^'WBFS4R67V*\\.>(Y)VTY\'*S1>7DQR#.#A3GO[
M>P44 >%^ ? K_ +1?B1\2_'>N6VJ>*]?V:CK=]9Q&*VBBMHBEO;PH>2J*2 3
M\S%N:O\ [)?@2_\  _P?@FU>W^QZWXAO[KQ%?VV,&*:ZD,FP^X4J#[@UZ[?:
M?:ZI:O;7MM#=VSX+0SQAT;!R,@\<$ _A5B@ HHHH M7OW;?_ *Y#^M5:M7OW
M;?\ ZY#^M5:$ 4444 %%%% !7BWB[P'\6]+\?:[K7@3Q9I,VDZY%"LFF>*#<
M2IIDL:E/,M F1AA@M&0H+#.>:]IHH ^3OB5^RAXZNOA)H?@7P9XETJ6TFU"7
M4_%4FN//!_;4CL':,F!2RQELY4$< #->G_!_0OB_X<U"ST[Q5%\/[/PC:6IA
MAM/"Z722Q%0!&JK(H0(*]BHHL 4444 %%%% !1110!:A_P"/"X_WE_K56K4/
M_'A<?[R_UJK0 4444 %%%% !1110 4444 %>5? +X1ZC\*X_'5SK-Y:W^J^)
M_$]YKTDUJ6(6.7:L49+ 'Y40#'09.*]5HH X#X]_#R]^+'P?\4>$=-N;>TOM
M5M?(BGNBPB0[U;+;03CCL*['0K!]+T33[*1E>2VMXX69>A*J 2/RJ]10 444
M4 %%%% !1110 4444 %6H?\ CPN/]Y?ZU5JU#_QX7'^\O]: *M%%% !1110
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M;\37VN1-;!@(XYRI5&R!\PV\XXK0^/GPSO/BY\-[KPW87<%C<S7-O,)KD,4
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M]:^IOA-\-=-^$'P[T/PCI3R2V>EP"(32G+RMDEG;W+$G\:YKX4_"._\ A_\
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MT#>9/=3N^(X8]QP!P>3P #6IXSU/Q-^T+J?@W1+;P)X@\+V.GZK!JFK:AKL
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MX'\;:S8ZKX!U/Q'X:E2-]'OO#5H;ER=O[R.Y4O\ *=W1L!<=:;^R_P##_6/
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M\F3^XWY4>3)_<;\J &44_P F3^XWY4>3)_<;\J &44_R9/[C?E1Y,G]QORH
M913_ "9/[C?E1Y,G]QORH 913_)D_N-^5'DR?W&_*@!E%/\ )D_N-^5'DR?W
M&_*@!E%/\F3^XWY4>3)_<;\J &5);_\ 'Q'_ +PI/)D_N-^526\3^?'\C?>'
M:@#SW6_^0S??]=G_ )FJ5:>M65PVKWI$$I!F?!"'U-4_L-S_ ,^\O_?!KJ6Q
M!!14_P!AN?\ GWE_[X-'V&Y_Y]Y?^^#3 @HJ?[#<_P#/O+_WP:/L-S_S[R_]
M\&@""BI_L-S_ ,^\O_?!H^PW/_/O+_WP: (**G^PW/\ S[R_]\&C[#<_\^\O
M_?!H @HJ?[#<_P#/O+_WP:/L-S_S[R_]\&@""H;VR@U*SGM+J))[:>-HI8G&
M5=2,$$>A!J[]AN?^?>7_ +X-'V&Y_P"?>7_O@T <_P"#O"EEX'\-V.AZ<\[6
M%DGEP"XDWLJ9X7/H!P/8"MFI_L-S_P ^\O\ WP:/L-S_ ,^\O_?!H @HJ?[#
M<_\ /O+_ -\&C[#<_P#/O+_WP: (**G^PW/_ #[R_P#?!H^PW/\ S[R_]\&@
M""BI_L-S_P ^\O\ WP:/L-S_ ,^\O_?!H YCPAX'TOP3'J8TY96FU.^EU"\N
M+A]\LTTAY+-Z  *!V50*Z"I_L-S_ ,^\O_?!H^PW/_/O+_WP:0$%%3_8;G_G
MWE_[X-'V&Y_Y]Y?^^#3 T-?_ -5IO_7JO\S616YKUI.T>G;89#BV4'"'CDUE
M?8;G_GWE_P"^#4K89!14_P!AN?\ GWE_[X-'V&Y_Y]Y?^^#5"(**G^PW/_/O
M+_WP:/L-S_S[R_\ ?!H @HJ?[#<_\^\O_?!H^PW/_/O+_P!\&@""BI_L-S_S
M[R_]\&C[#<_\^\O_ 'P: (**G^PW/_/O+_WP:/L-S_S[R_\ ?!H @HJ?[#<_
M\^\O_?!H^PW/_/O+_P!\&@""BI_L-S_S[R_]\&C[#<_\^\O_ 'P: -"Q_P"1
M<U/_ *Z1?^S5D5NV-I./#VI*89 QDBP-AR?O5D_8;G_GWE_[X-2NH$%%3_8;
MG_GWE_[X-'V&Y_Y]Y?\ O@U0$%%3_8;G_GWE_P"^#1]AN?\ GWE_[X- $%%3
M_8;G_GWE_P"^#1]AN?\ GWE_[X- $%%3_8;G_GWE_P"^#1]AN?\ GWE_[X-
M$%%3_8;G_GWE_P"^#1]AN?\ GWE_[X- $%%3_8;G_GWE_P"^#1]AN?\ GWE_
M[X- $%%3_8;G_GWE_P"^#1]AN?\ GWE_[X- $%%3_8;G_GWE_P"^#1]AN?\
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MI_L-S_S[R_\ ?!H^PW/_ #[R_P#?!H @HJ?[#<_\^\O_ 'P:/L-S_P ^\O\
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M%_$BL[X%.2E&*LTKM)+5)Z?)FEL8U%Q<G=7T;;T=M?FCU;_A</CK_H<==_\
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M'7_0XZ[_ .#&7_XJN0HKI^JT/^?:^Y'/]9K_ ,[^]G7_ /"X?'7_ $..N_\
M@QE_^*K8\'_%KQM=>*]'AF\7:W+%)=Q*Z/J$I# L,@C=7G%;?@C_ )''1/\
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M+^M1JRHRFTU>^KZ'J_\ PN'QU_T..N_^#&7_ .*H_P"%P^.O^AQUW_P8R_\
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MO_H0K\YZ_1?]IO\ Y(EXE_ZY+_Z$*_.BOK>$O]SG_B_1'R_%'^]P_P /ZL\
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M[XS_ .ORR_\ :E<6+_AQ_P 4?_2D=>%^-_X9?^DL\^HHHKM.0**** "BBB@
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MS3VL,[-&8B9(PQ*'JO(Z'TK[:_X89\+?]##K'_?,7_Q-'_##/A;_ *&'6/\
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MF+_XFC_6;+?YG]S#_5W,/Y5]Z/BVBOM+_AAGPM_T,.L?]\Q?_$T?\,,^%O\
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M7<P_E7WH^+:*^TO^&&?"W_0PZQ_WS%_\31_PPSX6_P"AAUC_ +YB_P#B:/\
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M .KN8?RK[T?%M%?:7_##/A;_ *&'6/\ OF+_ .)H_P"&&?"W_0PZQ_WS%_\
M$T?ZS9;_ #/[F'^KN8?RK[T?%M%?:7_##/A;_H8=8_[YB_\ B:/^&&?"W_0P
MZQ_WS%_\31_K-EO\S^YA_J[F'\J^]'Q;17VE_P ,,^%O^AAUC_OF+_XFC_AA
MGPM_T,.L?]\Q?_$T?ZS9;_,_N8?ZNYA_*OO1\6T5]I?\,,^%O^AAUC_OF+_X
MFC_AAGPM_P!##K'_ 'S%_P#$T?ZS9;_,_N8?ZNYA_*OO1\6T5]I?\,,^%O\
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M^8O_ (FC_6;+?YG]S#_5W,/Y5]Z/BVBOM+_AAGPM_P!##K'_ 'S%_P#$T?\
M##/A;_H8=8_[YB_^)H_UFRW^9_<P_P!7<P_E7WH^+:*^TO\ AAGPM_T,.L?]
M\Q?_ !-'_##/A;_H8=8_[YB_^)H_UFRW^9_<P_U=S#^5?>CXMHK[2_X89\+?
M]##K'_?,7_Q-'_##/A;_ *&'6/\ OF+_ .)H_P!9LM_F?W,/]7<P_E7WH^+:
M*^TO^&&?"W_0PZQ_WS%_\31_PPSX6_Z&'6/^^8O_ (FC_6;+?YG]S#_5W,/Y
M5]Z/BVBOM+_AAGPM_P!##K'_ 'S%_P#$T?\ ##/A;_H8=8_[YB_^)H_UFRW^
M9_<P_P!7<P_E7WH\J_8H_P"2PW'_ &"I_P#T..ONO->._";]FG1/A'XGDUO3
M]6U"]G>V>V\NY";<,5.> #GY17K]?G>>XRCC\9[:@[QLEV/N\FPE7!87V596
M=VPHI-U&ZOGSW+BT4FZC=0%Q:*3=1NH"XM%)NHW4!<6BDW4;J N+12;J-U 7
M%HI-U&Z@+BT4FZC=0%Q:*3=1NH"XM%)NHW4!<6BDW4;J N+12;J-U 7%HI-U
M&Z@+BT4FZC=0%Q:*3=1NH"XM%)NHW4!<6BDW4;J N+12;J-U 7%HI-U&Z@+B
MT4FZC=0%Q:*3=1NH"XM%)NHW4!<6BDW4;J N+12;J-U 7%HI-U&Z@+BT4FZC
M=0%Q:*3=1NH"XM%)NHW4!<6BDW4;J N+12;J-U 7%HI-U&Z@+BT4FZC=0%Q:
M*3=1NH"XM%)NHW4!<6BDW4;J N+12;J-U 7%HI-U&Z@+BT4FZC=0%Q:*3=1N
MH"XM%)NHW4!<6BDW4;J N+12;J-U 7%HI-U&Z@+BT4FZC=0%Q:*3=1NH"XM%
M)NHW4!<6BDW4;J N+12;J-U 7%HI-U&Z@+BT4FZC=0%Q:*3=1NH"XM%)NHW4
M!<6BDW4;J N+12;J-U 7%HI-U&Z@+BT4FZC=0%QN11D4VBJL(=D49%-HHL [
M(HR*;118!V11D4VBBP#LBC(IM%%@'9%&13:*+ .R*,BFT46 =D49%-HHL [(
MHR*;118!V11D4VBBP#LBC(IM%%@'9%&13:*+ .R*,BFT46 =D49%-HHL [(H
MR*;118!V11D4VBBP#LBC(IM%%@'9%&13:*+ .R*,BFT46 =D49%-HHL [(HR
M*;118!V11D4VBBP#LBC(IM%%@'9%&13:*+ .R*,BFT46 =D49%-HHL [(HR*
M;118!V11D4VBBP#LBC(IM%%@'9%&13:*+ .R*,BFT46 =D49%-HHL [(HR*;
M118!V11D4VBBP#LBC(IM%%@'9%&13:*+ .R*,BFT46 =D49%-HHL [(HR*;1
M18!V11D4VBBP#LBC(IM%%@'9%&13:*+ .R*,BFT46 =D49%-HHL [(HR*;11
M8!V11D4VBBP#LBC(IM%%@'9%&13:*+ .R*,BFT46 =D49%-HHL [(HR*;118
M!V11D4VBBP#LBC(IM%%@'9%&13:*+ .R*,BFT46 =D49%-HHL 44W=1NIB'4
M4W=1NH =13=U&Z@!U%-W4;J '44W=1NH =13=U&Z@!U%-W4;J '44W=1NH =
M13=U&Z@!U%-W4;J '44W=1NH =13=U&Z@!U%-W4;J '44W=1NH =13=U&Z@!
MU%-W4;J '44W=1NH =13=U&Z@!U%-W4;J '44W=1NH =13=U&Z@!U%-W4;J
M'44W=1NH =13=U&Z@!U%-W4;J '44W=1NH =13=U&Z@!U%-W4;J '44W=1NH
M =13=U&Z@!U%-W4;J '44W=1NH =13=U&Z@!U%-W4;J '44W=1NH =13=U&Z
M@!U%-W4;J '44W=1NH =13=U&Z@!U%-W4;J '44W=1NH =13=U&Z@!U%-W4;
MJ '44W=1NH =13=U&Z@!U%-W4;J '44W=1NH =13=U&Z@!U%-W4;J '44W=1
MNH =13=U&Z@!U%-W4;J '44W=1NH =13=U&Z@!U%-W4;J '44W=1NH 2BBBJ
ML3<****+!<****+!<****+!<****+!<****+!<****+!<****+!<****+!<*
M***+!<****+!<****+!<****+!<****+!<****+!<****+!<****+!<****+
M!<****+!<****+!<****+!<****+!<****+!<****+!<****+!<****+!<**
M**+!<****+!<****+!<****+!<****+!<****+!<****+!<****+!<****+!
M<****+!<****+!<****+!<****+!<****+!<****+!<****+!<****+!<***
M*+!<****+!<****+!<****+!<****+!<****+!<****+!<****+!<****+!<
M****+!<****+!<****+!<****+!<;FC-%>8?#S0M8@^*GCW5-2O=4O+,M;VU
M@;[*Q!-N]UA0 +M#'&X9)[F@D]/S1FO,/A)X[U?QSXR^*374\9\/Z+KRZ-I<
M010R^3;0FY8L.3F9Y!STVXJM!^TCX=N-8MXDTK6SH%SJ1TB'Q2;>,:9)=ABA
MC5O,\PC>"F_R]A8$;N*+CU/6,T9KSFU^._AR]T7P_JD,5^UOKNM'0K%3$H>2
M<>9E\%O]6!"YSUP.E<QH/[2.D7VF03Z59>(_&=YJ+WE_%I]C:6JSVEC%<20"
M5R98X_*+Q-Y9+F1P<X.&VEPU/;<T9KE=.^)_AO4?ATGCE=16#PT;0WK7<Z,I
MCC7.X,N,[@05V@$Y&!DUYMXD_:KTS0/"WB6_NO"OB+2-1TWP_<>([*QU6"WC
M?4+.+ DEBVSD (7C+(Y23#C"D\47#4]SS1FN$\%>-]3'P>T;Q+XMTN^T_6?[
M-CGU#3UMUDN//V_.J1PLX.YN5 ).&&<'('GOC_\ :5>S^'_CE;#0]7\*^-=+
MTR*>QL=>@@+N]S)Y%K*HBED5AYS %6(.1R,47#4]]S1FJVF+.NG6HNI?.N1$
MHEDVA=[8&3@<#)[5\MZ9\<HO%OCOQO::E\>M%\ QZ=KCZ7INB/)I:SLB(@+,
MMPID)9V8#Z<4F[ KL^K<T9KQR3X\:3HNJZO:K/K7BC48=2AT&TT:QM+<RWEV
M(%FE: [D!4(V]WE9$780.2H;G? 7[2>H>*/$7CZY_P"$;\07^GZ;JMMH.G>'
M[6PB%\EVD/F7GF,9!&%4R(-[2;/DRC-O&2X69]"YHS7D%M^U)X,6UL;K5A?^
M'+:>6\MIY]5CC1+*YM5W2P3,DC /MRR[=RL%.#QBDB_:4TR]M=,&G^#_ !7J
M6L7MA_:S:'!:0+>6EB698[B<23JD8D*G8A?S&PWR?*VTN@U/8,T9KQ'4OVN?
M!MM'')ING:_XA1M&&O2-IEDI6"TW%6:1I'0(RE6RA.[Y2 ">*FC_ &I_"T^D
M:_J$^FZ_I.GZ;X>D\317E]9QQB\L5#$R0H9-P;*X"2K&22."*+H+,]HS1FO&
M'_:-T3PO:QVU[;>(->MM+^R6FN^)(K. 6VGW$J(V+G:Z_.%D1W6%'"!QG' J
M _M*Z#IVN_8(X/$7B*^U34[O3].TVQL(6;S+55\T*P=0(R6X>5@,@@D<9=PL
MSV[-&:XSP=\5-*\;_#M_&-A:WZ6,:7!DLYHE%RCP,Z2QE58J6#(R\,02.#CF
MN<U;]I;P=I&@^'=8=KZ>RUO1FU^)H(59K>R$2R&68%AM'SJO&?F8#WHN&IZM
MFC-<)\,?BS!\3X))8/#NNZ'&((KJ"75883#=0R E7BF@EEC;H<KN##C*C(KF
MK3XO2^'/BA\6M+\3W\4.B>'--T[7K%C&%,5G+#*DH) RV)K:0Y.<>8![ N&I
M[!FC->$^&?C=X@T+P;'J_B?PUXAUV^O()-:EM=(L($32+ DM$DKRR1!W$8#,
MJEGR3\N!5S7/VL/"NFSZG#INC^(/$SZ9HL'B&\.D6D92"QE61A(SRRQJ"HB)
M,9.]MP**X5RJN%F>U9HS7D>O?M,^&-(>22TTW6M?TZUM[>[U+4]+M4>WTR.=
M5>(S[Y$;)1@VV-795P6 R,E[^TQX9M-1<Q:;K5[X<AOXM,N?%5M;QG3+>XD9
M45&<R"0C>Z(72-D!898<X=T&IZYFC->'W?[77A*UOIHUT3Q-=:?%K\WAEM5M
M].#V[:A&[((4^?S)=[(55HT90?O%><;_ (;_ &A-!\0W%G:2:7K&D:A/K$FA
M265_#%YEM=+$)=LC1R.F"K#!5FZ]J5T&IZCFC->32_M(:%<:K/I6C:'KWB75
MUO+BUAL=+@A+W*0;1-<(\DJ((5=A'N=EW-D*&P37/:G^UEX+MK"S\2+?:R-'
MCT1-7GL8M/0NRS7 MXXW5CYBSK*LB^6O!*N,D@47069[UFC-<+\/_BY8?$#6
M];T=='U?0=4TH122VFL0QQO)%*I:.50DCX! ^Z^UQW45E?M'^-]8\!_"Z:Z\
M.7*VGB*_U+3](TZ5H1-MFNKR*#(1@0Q"R,V#_=IW#6]CT_-&:^:OBC\0?%OP
M$U;33>>.Y?%Z7EC?7$VFWNG6L,L$<,!=;A3#&A"A]BG=D'<!UKH/A=^TC#JG
MARSM_%&C^(++7(]!CUMI9M, .HQ$[2UO!$S2YWX4(\:,<C"\TKCL]SW7-&:\
M@O?VFO#_ (?LO$LOBC1-=\(W6@Z:FK3V.JQ6[2S6KNT:R1F&:1#\Z%2&92"0
M3@'-68_VA]*CT7[9?^&O$FEWTT\5O8:5<6L,D^I/*NZ/[,\4KPR J"2?- 4#
M+%>*=Q:GJV:,UR'PZ^)NG_$>#55@L;_1M4TB[-EJ.DZJB)<VDNQ74-Y;NC!D
M='#([ AASD$#RGXE^/\ QQX-\>6OE^)M*>ZO=4@MM)\!V<4<]Q?6.5$US(Q4
M2JP+.25Q&@1<DY-%P5SZ%S1FN%^)_P 7M*^%LF@VMW97VK:KKMV;/3M,TXPK
M-<.J%VP9Y(X^ .A?)R, \X\^US]I&]C^(G@;2;/PGKUIH]_I-]KNM27UG%#-
M900MY.QU>4,I25E+%0P8%#&7!8A7#4][S1FO,;G]H;PII^E^&=0O_MNGVFO:
M2^M0O<0J#;VRQK(3* Q(8AE "ALDXKR_QI^U\VA^,M%27PWXC\/Z)8:)J7BK
M6X=1L(#/<:9!$BQO#ME8#,DH)!97'EX*@,,ET"39]/9HS7,1?$'3;GX@-X0M
MH[B[U*+3QJ5Q/"JFWMHF?;&)&W9#.0Y4 '(1CQBN9_:-\;:SX$^%5_>>&IX[
M;Q->7-KIFERS1"5$N)YTB5F4\,%#,Q'HM,-3TW-&:^?+CX[ZWJ>A?""&R,-E
MXC\0Z[)I^N6I57^SK907$FHQC(XVR6_EYX/SC&#BN+^#_P <(?BGHNGZI>_M
M%Z)HVK:M>W#6_AJWDT<RQ1?:'6"':ZF0L8PG7GFE<=F?6^:,UYC\8/&^L>$[
M_P"'6C:+./[3\0>(H+&9WB5R;5(I)[DX/ RD6W(Z;QBO,O@/^TEJ?BJT^*VO
M^*KZW;0=)NY+W1DAA5"FG&YO+> $@9<N;,L">?FHN*SM<^F\T9KR+]F?QOXF
M^(G@G4]=\3744TLNJW$5K## L2V\*, (^/O%3E223RIKG/V@/B^_A+XK^!/"
M)^(FF?#;3-1T[4M3U'5M1:T3<(6MXX(HVN@4W,TTA( SB,]@<%]+AK>Q] 9H
MS7C.B?&/2O#VB:;%9^*[OXSZGJ\TIL!X=6PDDD2,#S,-&T4 1,C+.X.6 Y)
MKGO%'[337WB+X:1>$--U;5UUFXU ZCHUK:1&]"VR!'A;S'5(RLKJ2QD"_)@,
M=P!+A9GT/FC-<QX$\>Z?\3/ EAXG\/B1K6_A=X8KQ#%)'*K,CQ2KSM9)%9&
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M?CG&:P/@A\-Y_AEX#32=2EMKO59KZ\O[N>V!,;R3W#R?+N /"LHY':MCP/\
M$KPW\1[?4)?#VH_;AI]P+6[C>"2"2&0HL@#)(JL,HZL#C!!X->4Z7^U-IE_\
M2?&5A<W-EI?A+PPZ6=Q=W5K="ZN;MN"D0V;6P2!M&6.<@8YIZ"U,[3_V?_&?
MA'Q)H7C+1[K0M8\46NIZW=7MCJ5Q-;6L\6H2(^Y)DBD9)(_)A7!C(92PR,#.
M#+^R_P"-IX+.XUJ3PKXY>YUK5=6UG0-9EN(=(NY+B1?LLIB$4HD:"**-1'(I
M YPV0&/M<GQ]\ 0^&K;7Y?$EO#IEQ?'3(Y)8I4D-V%=O(\HJ'$A$;84KDX&
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MB0N HSD:7_#4VC:WXTU32-"OK :=8V=J7O\ 4(;A&6]N)S'%;-%M#ABJ.<$
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MUZTWKJ=]Y;,8D: 1+';G!"NZ2-N"G"KNP/9=.UFTU9[Q+61G:TG:WFW1,F'
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M7I@\6?#N71;O4O-TYM/@N$T2>4VIPLOR[;<C;G^->,8&?K67+5[K\3JYLO\
MY9_?'_(\HTSX>6^F^'OA+IFF>)M :;PI]OG!EE<I<:FUK)%%(!M.55II6);G
ME< FN-T?X&SZ3X(&F:-X[T>&]7PGI7AS3)HKV:#[1]D=Y;_S9$4/&EP[*"R9
M.T9QG@^F_%[X[_#[P9INJ6&F0:9KGBJ:YM-'ATQ[5_*NIY+F*%(3*$V,R&7<
M4#%@%/'!KOIO%WP\O-&L-8>;3I[#7[E;*WF^S%C=S(S*J!=N25*,.1QM/3%'
M+5[K\?\ /^OS?-E_\L_OC_E_5O/W?F/3?A!KWA:?Q9J_@"X^&'@#4_$>GVUC
M;V_A^:2V2SM(F8W#K.MJ"9F!^64Q\$YQD"N[A\*R6_A;X=2Z0/!7A[5_ E])
MJNEZ)#K,]QIU[9O:2VTIFN&MDDCEQ<2R!O+D^9.<[R5]Y"^&+W0+C7/L-L^G
MNIO999+386\L'YRK*#D;3C(KF/A'KMC\0/A)HGC37="TS17U2%=:FBV#RXC@
MLDK,PX8)@DGWI\M;NOQ%SY<_LS^^/^7]?/3QE_A&OBCQH_BGQ5XPT%+K4A<Z
MAJ4&FRR%+:,VCVUHD)909/+$DCEW"$LW" "K7P.^#WA_X?ZWH*WGAGX1V4NA
M6ZA=<T?3!+JU^[C9'*',4?V=R#\V&F+%B,KU/JVD_%GX4ZO#J%U;7]@D>G(V
MK3R7%C)!M3H;A?,C7>.1\Z9'(YYJ3P_\4OA5K)O9=.U/2531H?[4EGDMS D,
M3Y!N$=U4,IPPWH2,C&:%&K?=?C_F)RP%M(S^^/\ E_7RUE^)/@'Q!>>.O#?C
MKP?)I;Z_I%K<Z;-8:Q))#;WEI.T3.OFQH[1NKPHRL$8'Y@1SD<?XF^"WCKQD
MEOXDU77[%_%MEJMMJ=AH*W,YT6W6$,OD[MFXLP<DS^5G( V8'/>6'QZ\!ZEH
MFL:M%X@CCL](9%O1<V\T$T)<9C'E.@D)?^'"G<00,D5S/C[]J7PAX3\$0>(-
M.NGU?S]3ATI;9+6=94E=AN#Q^7O4A-S %06QQFNBR/*5SGF_9^\4^*?B1I'C
MCQ1>Z+'J1UVSOK_3[!I98;>RLK>[%I!#(Z*97^T7(E=V6/T ^49M:O\  35K
MC0?$L=S?Z>6UKQG'XDOW!D.;&+R@L2\<R>7 O' R3S7O$,RSPQR*<JZA@2".
M#['D5PGQ4^)LGP^OO!]I!;PW$VO:NFGL9V*B*':SRR#'=40G\*=D@NSPCX2_
M#3QW\2OAU+:ZK)H^G>$/$OB)_$5Y<J\RZG+"+KS1:M#LV ,8D!D\S(3(V<Y%
M>^_9"\4ZUKND7&J67@K4KZP\4KKEQXROVGNM<U&U2Z\R&VR\/^C*D0C38DK)
MB/"J@8X^E8_BCX5ELM%O%UF VVLK*]A+AL3K&I:0CC@  G)Q7+?![XZ:;\1/
MAS!XAU6:UTB_CTR'6-0L@S8LK6<2/;NQ8?Q1H3QW#5/*AW9PFO\ [+USJGPC
M\):#-;>'M?U?1=6EUF[T[7(VETO4YI99'E63,;$#]YPQC;&!P:CM?V<-8\/R
M>&O$GAKPS\.?"_B71-:EU)-$T*Q>PL)X)+62V,<US'%ODE59799?(4<[=G5J
M^A-&UFS\0:39ZG83>?8WD*SP2[67>C#*G! (R".HKQWXJ?&;QG\-X?$/B27P
MU81>"=!G@AD^USL+_4E=T5GM@ORC!DPJMRQ4@=13:2U$FWH=)\%?A[XB\'WG
MC?6O%U]I]]K_ (FUG^T&&E^9Y%M;K;PPPVX+@%M@C;+8&[.[ )('E&I_LK>*
MI;7Q$UAKVEVNH77B!;S3+DB7-E8-YGFJ/E_UV9I'7'RYQDXS74^+?VAM9TYO
M%FN:-I%C=>"_".H+INIW5U*ZW-U,I7SQ; ?+^Z+A26ZL& ^[6WK_ ,?&M?C)
MX5\!:5H%Y=?VI+.;O5;F,Q6\,<46]A'GEVRT8SC;R>2:+(-3CO&?[,VLWL7C
M#^P)M'BCOD\-Z?I=C<22PQIIVFW'GRV[ND;&,RM).,JKC&W(]-?6/@-XBUOP
MC\0;&;4M-CU/QAKL-[<2*7,<5B@A40@[,E\1-VQ\W:I_&?Q(^)GAWXE^'?"V
MG67A75I=:NGD6W0W*S6FG1LHENIF^Z-H=% _C=@!W(]CTG6K36[>2:SD:2..
M9X&+Q,GSHQ5AA@"1D'D<'L:+(+M%R"*.V@CAC&V.-0B@=@!@5)D4S(HR*JQ(
MVOFSQ[\$/%7BS]H6Y:.TBC^&NNV]E=Z[=>>@:::T8F.V\K.XASL9FQC$>.]?
M2.:X/PW\5AK_ (_U+PO+H5[IS6T9E@O)Y(V6X4-M)V*Q>/U&\#(Z4VNXDVMC
MY[^/_P -OBKXR?XG:;IWAKQ!JLVJ(+7P[>:1XBMM+TB*S^S*&6YC$Z333;S*
MNV6-T.4&Y$+$=%=_ ;Q*G@CXGVMIH\::KXEU6ST^U/VB+<-)MXX(U<ONXX69
MMI.[GI7HGBG]H[0_"NL>)=/GL;J5M#U;2-%DF5XU2:YORFU5)88\I)%D<G'R
M],XKT@>)M(.D_P!JC5;(Z9_S^_:4\GKC[^=O7WJ>5%7:/"O _@?Q)X2O_$GA
M#4_AS_PE&D:SX@:]D\0WFH6BV!LBRLF]"[7!EB5558_)VEE'[Q1\PY71OA/\
M0)?A;H/PNN?"3V1TS6/[5U7Q<]_:FVU(QWK70>V59#/YTYV[O.CC"%G^9MJE
MOIBZ\:^'[&SMKNYU[3+>UN03!/+>1JDH'7:Q;#?A2S^,M MM.M]0FUS38K"X
M)6&Z>[C6*4C.0K$X)X/0]C3Y1<S/!? _P*UNP3X0VVHZ'#;PZ1=ZAKNMNT\4
MFR^EW&,'!.]@9&^9<@8ZUP7CGP?XU\"^$?AA)I$$-K\4]5\<ZI-'9W%PLA1=
M0M[_ ,Z5MA(=8$>.=N<8@QG)%?7>H>*M&TB&.6^UBPLHI$$B/<7*1JRGHP)(
MR#ZUFZK'X-T+Q#!XEU)="T[7)[<V<.KW8ABN9(,AC$LS88IG!V@XS@XHY1\S
M/%=+^&.O_!3Q[++H'@F]\?Z'<^'+;1[26._M(6MIDED:X>[-Q(C8G:4.SQ+(
MQ*ME>F<:+]GWQ#JWCVVGO_"]EIWAY_%-K?36MM=1200V-G9LL"H."RM<,& V
M _+DJ*]YO?B=ING_ !"D\*7"/#)#I+:O<:A+(B6\$0D6,*Q)X)+$CMA34'B_
MXS>%/!VDZ5J%SK%I<V^J:A%IMJUM<1NLDKL%/S9QA1DL>P'N*.5!S,ROA'X*
MU;P_XL^*7B'6K3[-=^(O$7GVB>:C[K*"TM[: _*2%W>2[8/(W\@&O*=.^%'C
M7PY<>'/%]SX8EUZ]A\2ZIJ^I>'+*\MOM+";,5O*CS2I"S)&B'!D7 ;CD$5]'
MKXIT9]5?3%U>Q;4D!+68N4\Y1C<24SGISTZ<UC?#WXFZ'\3K75KG0KI;J#3K
M^73Y'5U(9TQEA@GY220#WP:.5"NSQ'P;\%?%>K?&+1_%_BC0H=/L;K5;_P 4
M7-E]KBG%A="V@L[*!@IP\OE&>1G0,BL,!C\I/I'QV\/:[XAN/ ?]E:)/KVGV
M/B&WO]3M[:>"-UBB5F1\3.BL!((\@'.,D XQ7/P_M+:G?^$]5\6:=\-M;U#P
MKIQNF?48KVT#210,PDD2$R;R,(Q QD]J['PA\<?#/C+Q%JVE6MY%;FR-HL4]
MS.B"[:>!9U6)2=Q*H\9(Q_&*22V&[[GB_B/X!^)]2^"UI$^C7$VNS^+/^$DU
MO1=.U-+6[O8_-?$<=R)%4.JF-QF10=F-PJ+4_A+XKM]$OM=\/>"_%&FW^KZK
M86VL6E]XLBU#7[O2(!/Q%)/.UO;2K+,&7R[@MY98AT?"CZ<D\3:1%JZ:4^K6
M2:H_W;)KE!,W&>$SN/ )Z41^)M(EU=M*35;)]47.ZR6Y0SC R<IG=TYZ4^5"
MYF?(_AKX+>/K3Q+>:S>^#]<>POO%VG7SV-_XAM]1OA86\+>6TDLUP0<2.Q9
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D%%4E83=PHHHIDW"BBB@+A1110%PHHHH"X4444!<**** N?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>acxp-20221231x10k014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 acxp-20221231x10k014.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #Q 8$# 2(  A$! Q$!_\0
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MF?VI9Z-%K5Y=V=OJRV-P)EM(6FF$KQ!&*[O*$1)&0">Q.*\+G78[['Z*R?\
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MPR$G[5&B'/E;FR3MP142E9*R/$P%;$5Z]7VDERQ;25OQN?=,G_!7/X0KHO\
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M@%26[]#6*ER-VTU9@?H9/_P4>^&T'WM!\6'Z6EM_\D54;_@IA\,%ZZ#XN_\
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MF3@,V/K2 ]#TK4(_- 5MV*[/3YDE ->+:3J36D@SG;G->@:-XDMT5?W@S[T
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M+=D@-M7U)JSJ)_$FK+-(T49^I%<C=NS_ "IQ[U+<7T0+9D#'VYK.>[DD;]V
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MK:&O)K(TVP2.,[$50HQU/TKE;O6+FYE+!S&I["K>I.9XF8_=&,>WM62L;2,
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M7YB>]9%&7*"5:+^]T^M3:3II<@D<YJ.6/?,,=<UU6E6>[8X'#?SH'86/2P4
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MS,S5]&MKV\>\NDB,LAR0% 'X <"J@T:S096!#_P&M-;=[I]S9-:=OIGRC*T
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MPUS\0=9_[!Q_]&+7R#X>N2H4E?E/>OK[]AE@WQ!UC'_0./\ Z,6@#[;HHHH
M_%'_ (*'KG]LSX@G_L'_ /INMJ^?F7$/I7T9_P % ;=9_P!LWX@;C@#^S_\
MTW6U?.U^RQ9 X% C&NWW-UJM4L[ N:C'6@!57FIXUYQ4:=:M(H&*!CXUQ]*L
M*HR*B QQ4RT 2HF:+F+S(&'?'%+&>:D- '-SRA2!Z5>L+]T "'%9E_ XU&2-
M>%SD?2M?3;+ 7C)H V;>XFD3YF.*EV%CR<U+;6OR#M4[6V* (K==K5U&A.%,
MC>BUSJ+LK9TMREI._P"%)[&53X;&W'<!U.X9S5W1M<G\.7/VBR(C/\2XX8>A
MKG8[K X-2-<94U$Z<*BY9JZ,Z^'I8F#IUHIIGJSMH7Q0M/*D*V6K!>".I/\
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M=/L)=;OQ^ZC;R[6$C_7R_P#Q*\$_@.]?6W_!1W7M M/VS_B%!?HC3K_9V_\
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M[B!YB\U^,A.:_0;_ ((O_P#)?O%W_8OG_P!'QUSV)O<_9*BBBD4?@;_P4_\
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M455 &  , 4)6*BK:O<CT+0[;P]91V]O&L:(, *,5H&ZP*K37>X=:S;G41'D
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MUAHH@X.$;H<T#+^I:Z(054_4USMUXC'."":SPDVK9;=LC]?6@Z5'"O4'W/-
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MURI0KU!%?0=C\1O /B!GAN-*_LZ2Y7R781A=P)'!*]N!5/7/@?HNMI._AW5
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MNB\/B)TWT9,ERNQ3K]!O^"+_ /R7[Q=_V+Y_]'QU^?-?H-_P1?\ ^2_>+O\
ML7S_ .CXZY&2?LE1114EGX>?\%19=1\0?M8^.+.UNEN+?3!8%[%!AT+6%NV_
M'\?#=>U?%>T[L8.?2OUY_:O_ ."9?C_X\_M(>*/B5X?\9:#HUIJAM&@M[L3^
M=&8;2& [MJ$<M$3UZ$5P]C_P1_\ ''VR+4+CQIX9M=17(D>TMY727CKM>/"-
M[@?A3N2?FQIO@_5-1"R"U:& \^;.1&"/;=C/X5Z9I&C1P6\<8Z(  >@_6ON"
MX_X)+_$A[Y98O&'A39GYIKDW4\Q'L6CPO_ 0*TX/^"47CR,@OXR\.L?I<?\
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MYBB)S]C-P6N''H0G"?\  B*O^&?B3:V7B1(?#7AZPTBW=L-<7 :YE5!U.7)
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M7<+<W!$(^[;PJ(XE^B+A1^5??O\ PY3^)7_0^^%/^^;G_P"-T?\ #E/XE?\
M0^^%/^^;G_XW4:"U/SZT74FTK4H;A?X3R/4=Z]-'AYO$&FWYLG#).J39)P,J
M<9/T#&OK@?\ !%3XE9_Y'WPI_P!\W/\ \;KLO G_  23^)?A5Y8KKQQX7NK)
MT*^4BW&03]8Z]S+L31C>AB?@?7L]A-.VA^?'BR[L-9\&6J:= 8H-$N?LPD;[
MTPE!;>WXQM],BN" K]1KS_@D!XP(UF.U\7>'([>_MMBQ,L^(Y@P*O]STW#_@
M5<8/^"*OQ*_Z'WPK_P!\W/\ \;KR*T5";C%IKNBK'YVT5^B7_#E7XE?]#[X4
M_P"^;G_XW1_PY5^)7_0^^%/^^;G_ .-UB4?G=N(QCJ.E=OH>J:CK,"7&FS2Q
MZY8)N81$[KB)1UQW*CKZCGM7VU_PY5^)7_0^^%?^^;G_ .-U>T/_ ((W?%;P
M[JUKJ5A\0_"T%W;.)(W5;G@C_MG5*<X/F@[,1\V:%K^G_$_2/[*UR%/M9C'E
M38P22N>#Z]?RKPOQ?X6N?".N7&GW(Y0Y1NS+V/Y5^FNO_P#!)/QS=:I'?Z3X
MP\-Z?*P6:2+;<!(Y\@MY>$^YDM@'H#CM4'Q#_P""2OQ&\=O;2MXQ\*P3PC;O
MVW/(_P"_?K7LSQ<,=A+XC2K';S7GYHNIRN5X*R/RVHK]$S_P13^)7_0^^%/^
M^;G_ .-T?\.4_B5_T/OA3_OFY_\ C=>-<RU/SLHK]$_^'*?Q*_Z'WPI_WS<_
M_&Z/^'*?Q*_Z'WPI_P!\W/\ \;HN&I^=E*A*L".HK]$O^'*?Q*_Z'WPI_P!\
MW/\ \;H_X<I_$O\ Z'WPI_WS<_\ QNBX:GRUHT47Q1^'C6!8-JFGJ F>IQT_
M3BO%[VTEL;F6"9#')&Q4J>Q%?I5X-_X) ?%3P=K4-];^/O"I53B2/;<X=>X_
MU=;/Q&_X) ^+O%]PE[8>+?#ME>GB7>L^Q_?A.M>UB*U+%X>-24K5(Z/S7<VE
M:2OU/RVK]!O^"+__ "7[Q=_V+Y_]'QU=_P"'*?Q*_P"A]\*?]\W/_P ;KZ:_
M8+_X)^>+?V3/B5K?B37_ !+HNLVU_IAL4ATT3!U;S%;)WJ!C"UXES+4^ZZ**
M*104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
/%%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>20
<FILENAME>acxp-20221231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/15/2023 9:19:02 PM-->
<!--Modified on: 3/15/2023 9:19:02 PM-->
<xsd:schema targetNamespace="http://www.acurxpharma.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:attributeFormDefault="unqualified" xmlns:srt="http://fasb.org/srt/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:acxp="http://www.acurxpharma.com/20221231" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.acurxpharma.com/role/StatementBalanceSheets" id="StatementBalanceSheets">
        <link:definition>00100 - Statement - BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/StatementStatementsOfOperations" id="StatementStatementsOfOperations">
        <link:definition>00200 - Statement - STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/StatementStatementsOfCashFlows" id="StatementStatementsOfCashFlows">
        <link:definition>00400 - Statement - STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails" id="DisclosureAccountsPayableAndAccruedExpensesDetails">
        <link:definition>40301 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetDetails" id="DisclosureIncomeTaxesDeferredTaxAssetDetails">
        <link:definition>40902 - Disclosure - INCOME TAXES - Deferred tax asset (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureIncomeTaxesTaxReconciliationDetails" id="DisclosureIncomeTaxesTaxReconciliationDetails">
        <link:definition>40903 - Disclosure - INCOME TAXES - Tax reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity" id="StatementStatementsOfChangesInMembersAndShareholdersEquity">
        <link:definition>00300 - Statement - STATEMENTS OF CHANGES IN MEMBERS' AND SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails" id="DisclosureNatureOfOperationsDetails">
        <link:definition>40101 - Disclosure - NATURE OF OPERATIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesConcentrationDetails">
        <link:definition>40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosurePaycheckProtectionProgramLoanDetails" id="DisclosurePaycheckProtectionProgramLoanDetails">
        <link:definition>40401 - Disclosure - PAYCHECK PROTECTION PROGRAM LOAN (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureExecutiveCompensationDetails" id="DisclosureExecutiveCompensationDetails">
        <link:definition>40501 - Disclosure - EXECUTIVE COMPENSATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails" id="DisclosureIssuanceOfEquityInterestsDetails">
        <link:definition>40601 - Disclosure - ISSUANCE OF EQUITY INTERESTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsFairValueDetails" id="DisclosureIssuanceOfEquityInterestsFairValueDetails">
        <link:definition>40602 - Disclosure - ISSUANCE OF EQUITY INTERESTS - Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsWarrantsDetails" id="DisclosureIssuanceOfEquityInterestsWarrantsDetails">
        <link:definition>40603 - Disclosure - ISSUANCE OF EQUITY INTERESTS - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails" id="DisclosureShareBasedCompensationDetails">
        <link:definition>40701 - Disclosure - SHARE-BASED COMPENSATION - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureShareBasedCompensationUnvestedDetails" id="DisclosureShareBasedCompensationUnvestedDetails">
        <link:definition>40702 - Disclosure - SHARE-BASED COMPENSATION - Unvested (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails" id="DisclosureShareBasedPaymentsToVendorsDetails">
        <link:definition>40801 - Disclosure - SHARE-BASED PAYMENTS TO VENDORS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureIncomeTaxesDetails" id="DisclosureIncomeTaxesDetails">
        <link:definition>40901 - Disclosure - INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureNetLossPerShareDetails" id="DisclosureNetLossPerShareDetails">
        <link:definition>41001 - Disclosure - NET LOSS PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>41101 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/StatementBalanceSheetsParenthetical" id="StatementBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquityParenthetical" id="StatementStatementsOfChangesInMembersAndShareholdersEquityParenthetical">
        <link:definition>00305 - Statement - STATEMENTS OF CHANGES IN MEMBERS' AND SHAREHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureNatureOfOperations" id="DisclosureNatureOfOperations">
        <link:definition>10101 - Disclosure - NATURE OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureAccountsPayableAndAccruedExpenses" id="DisclosureAccountsPayableAndAccruedExpenses">
        <link:definition>10301 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosurePaycheckProtectionProgramLoan" id="DisclosurePaycheckProtectionProgramLoan">
        <link:definition>10401 - Disclosure - PAYCHECK PROTECTION PROGRAM LOAN</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureExecutiveCompensation" id="DisclosureExecutiveCompensation">
        <link:definition>10501 - Disclosure - EXECUTIVE COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterests" id="DisclosureIssuanceOfEquityInterests">
        <link:definition>10601 - Disclosure - ISSUANCE OF EQUITY INTERESTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureShareBasedCompensation" id="DisclosureShareBasedCompensation">
        <link:definition>10701 - Disclosure - SHARE-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendors" id="DisclosureShareBasedPaymentsToVendors">
        <link:definition>10801 - Disclosure - SHARE-BASED PAYMENTS TO VENDORS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>10901 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>11001 - Disclosure - NET LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>11101 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureAccountsPayableAndAccruedExpensesTables" id="DisclosureAccountsPayableAndAccruedExpensesTables">
        <link:definition>30303 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsTables" id="DisclosureIssuanceOfEquityInterestsTables">
        <link:definition>30603 - Disclosure - ISSUANCE OF EQUITY INTERESTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureShareBasedCompensationTables" id="DisclosureShareBasedCompensationTables">
        <link:definition>30703 - Disclosure - SHARE-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>30903 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureShareBasedCompensationOptionPricingDetails" id="DisclosureShareBasedCompensationOptionPricingDetails">
        <link:definition>40703 - Disclosure - SHARE-BASED COMPENSATION - Option pricing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureShareBasedCompensationOptionActivityDetails" id="DisclosureShareBasedCompensationOptionActivityDetails">
        <link:definition>40704 - Disclosure - SHARE-BASED COMPENSATION - Option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="acxp-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="acxp-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="acxp-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="acxp-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.acurxpharma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:element name="CommonUnitClassMemberSCapitalMember" id="acxp_CommonUnitClassMemberSCapitalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommonUnitClassBMemberSCapitalMember" id="acxp_CommonUnitClassBMemberSCapitalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockUnitsIssuedDuringPeriodValueExecutiveCompensationSettled" id="acxp_StockUnitsIssuedDuringPeriodValueExecutiveCompensationSettled" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockUnitsIssuedDuringPeriodSharesExecutiveCompensationSettled" id="acxp_StockUnitsIssuedDuringPeriodSharesExecutiveCompensationSettled" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CancellationOfStockUnitsValue" id="acxp_CancellationOfStockUnitsValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="PaycheckProtectionProgramLoanAbstract" id="acxp_PaycheckProtectionProgramLoanAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PaycheckProtectionProgramLoanDisclosureTextBlock" id="acxp_PaycheckProtectionProgramLoanDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedPaymentsToVendorsPolicyTextBlock" id="acxp_ShareBasedPaymentsToVendorsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AcxThreeSixtyTwoEMember" id="acxp_AcxThreeSixtyTwoEMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PercentageOfRoyaltyPaymentsOnNetSales" id="acxp_PercentageOfRoyaltyPaymentsOnNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PaycheckProtectionProgramLoanMember" id="acxp_PaycheckProtectionProgramLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CancellationOfStockUnitsShares" id="acxp_CancellationOfStockUnitsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedPaymentToVendors" id="acxp_ShareBasedPaymentToVendors" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ClassOfWarrantOrRightExercisableTerm" id="acxp_ClassOfWarrantOrRightExercisableTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommonUnitClassAndClassBMemberSCapitalMember" id="acxp_CommonUnitClassAndClassBMemberSCapitalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedPaymentsToVendorsAbstract" id="acxp_ShareBasedPaymentsToVendorsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NonEmployeeMember" id="acxp_NonEmployeeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedPaymentsToVendorsDisclosureTextBlock" id="acxp_ShareBasedPaymentsToVendorsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedResearchAndDevelopmentCurrent" id="acxp_AccruedResearchAndDevelopmentCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="EquityIncentivePlan2021Member" id="acxp_EquityIncentivePlan2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodSharesCorporateConversionOfUnits" id="acxp_StockIssuedDuringPeriodSharesCorporateConversionOfUnits" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodValueCorporateConversionOfUnits" id="acxp_StockIssuedDuringPeriodValueCorporateConversionOfUnits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="StockholdersEquityPeriodIncreaseDecreaseThroughCashlessWarrantExercise" id="acxp_StockholdersEquityPeriodIncreaseDecreaseThroughCashlessWarrantExercise" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodSharesPeriodIncreaseDecreaseThroughCashlessWarrantExercise" id="acxp_StockIssuedDuringPeriodSharesPeriodIncreaseDecreaseThroughCashlessWarrantExercise" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NonCashFinancingActivitiesOfWarrantsIssuedInConnectionWithOfferings" id="acxp_NonCashFinancingActivitiesOfWarrantsIssuedInConnectionWithOfferings" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="RegisteredDirectOfferingMember" id="acxp_RegisteredDirectOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AffiliateInvestorsMember" id="acxp_AffiliateInvestorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ClassOfWarrantOrRightPurchasePrice" id="acxp_ClassOfWarrantOrRightPurchasePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PlacementAgentsMember" id="acxp_PlacementAgentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PercentageOfWeightedAveragePublicOfferingPriceOfAggregateNumberOfSharesOfCommonStockSold" id="acxp_PercentageOfWeightedAveragePublicOfferingPriceOfAggregateNumberOfSharesOfCommonStockSold" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SeriesWarrantsMember" id="acxp_SeriesWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SeriesBWarrantsMember" id="acxp_SeriesBWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="VendorOneMember" id="acxp_VendorOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="VendorTwoMember" id="acxp_VendorTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedPaymentArrangementGrantDateJune2021Member" id="acxp_ShareBasedPaymentArrangementGrantDateJune2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedPaymentArrangementGrantDateJuly2021Member" id="acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedPaymentArrangementGrantDateJanuary2022Member" id="acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedPaymentArrangementGrantDateApril2022Member" id="acxp_ShareBasedPaymentArrangementGrantDateApril2022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedPaymentArrangementGrantDatePreIpoMember" id="acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExecutivesIndependentDirectorsConsultantMember" id="acxp_ExecutivesIndependentDirectorsConsultantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IndependentDirectorsConsultantMember" id="acxp_IndependentDirectorsConsultantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedPaymentArrangementGrantDateOctober2019Member" id="acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedPaymentArrangementGrantDateMarch2022Member" id="acxp_ShareBasedPaymentArrangementGrantDateMarch2022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockIssuedDuringPeriodSharesBonus" id="acxp_StockIssuedDuringPeriodSharesBonus" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="WarrantExercisePreFunded" id="acxp_WarrantExercisePreFunded" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="WarrantExercisePreFundedShares" id="acxp_WarrantExercisePreFundedShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts" id="acxp_StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ClassOfWarrantOrRightIssued" id="acxp_ClassOfWarrantOrRightIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ClassOfWarrantOrRightExercised" id="acxp_ClassOfWarrantOrRightExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued" id="acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" id="acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedPaymentArrangementGrantDateSeptember2022Member" id="acxp_ShareBasedPaymentArrangementGrantDateSeptember2022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="UnderwriterMember" id="acxp_UnderwriterMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member" id="acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedPaymentArrangementGrantedInThirdQuarter2021Member" id="acxp_ShareBasedPaymentArrangementGrantedInThirdQuarter2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member" id="acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedPaymentArrangementGrantDateOctober2021Member" id="acxp_ShareBasedPaymentArrangementGrantDateOctober2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>21
<FILENAME>acxp-20221231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/15/2023 9:19:02 PM-->
<!--Modified on: 3/15/2023 9:19:02 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#StatementBalanceSheets" roleURI="http://www.acurxpharma.com/role/StatementBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#StatementStatementsOfOperations" roleURI="http://www.acurxpharma.com/role/StatementStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#StatementStatementsOfCashFlows" roleURI="http://www.acurxpharma.com/role/StatementStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureAccountsPayableAndAccruedExpensesDetails" roleURI="http://www.acurxpharma.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureIncomeTaxesDeferredTaxAssetDetails" roleURI="http://www.acurxpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureIncomeTaxesTaxReconciliationDetails" roleURI="http://www.acurxpharma.com/role/DisclosureIncomeTaxesTaxReconciliationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.acurxpharma.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638145119416276744" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_1" xlink:to="us-gaap_AssetsCurrent_638145119416276744" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash_638145119416276744" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638145119416276744" xlink:to="us-gaap_Cash_638145119416276744" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638145119416276744" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638145119416276744" xlink:to="us-gaap_PrepaidExpenseCurrent_638145119416276744" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638145119416276744" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638145119416276744" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MembersCapital" xlink:label="us-gaap_MembersCapital_638145119416276744" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638145119416276744" xlink:to="us-gaap_MembersCapital_638145119416276744" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638145119416276744" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638145119416276744" xlink:to="us-gaap_CommonStockValue_638145119416276744" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638145119416276744" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638145119416276744" xlink:to="us-gaap_AdditionalPaidInCapital_638145119416276744" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638145119416276744" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638145119416276744" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638145119416276744" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638145119416286714" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638145119416286714" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638145119416286714" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638145119416286714" xlink:to="us-gaap_LiabilitiesCurrent_638145119416286714" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638145119416286714" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638145119416286714" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638145119416286714" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638145119416286714" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_638145119416286714" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.acurxpharma.com/role/StatementStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638145119416286714" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="us-gaap_OperatingExpenses_638145119416286714" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638145119416286714" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638145119416286714" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638145119416286714" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638145119416286714" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638145119416286714" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638145119416286714" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638145119416286714" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638145119416286714" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.acurxpharma.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638145119416296712" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638145119416296712" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638145119416296712" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638145119416296712" xlink:to="us-gaap_ProfitLoss_638145119416296712" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638145119416296712" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638145119416296712" xlink:to="us-gaap_ShareBasedCompensation_638145119416296712" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentToVendors" xlink:label="acxp_ShareBasedPaymentToVendors_638145119416296712" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638145119416296712" xlink:to="acxp_ShareBasedPaymentToVendors_638145119416296712" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_638145119416296712" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638145119416296712" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_638145119416296712" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638145119416296712" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638145119416296712" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638145119416296712" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_638145119416296712" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638145119416296712" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_638145119416296712" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638145119416306757" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638145119416296712" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638145119416306757" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638145119416306757" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638145119416306757" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_638145119416306757" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638145119416306757" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_638145119416306757" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638145119416306757" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638145119416306757" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638145119416306757" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638145119416306757" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638145119416306757" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638145119416306757" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_638145119416306757" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638145119416306757" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_638145119416306757" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.acurxpharma.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="AccountsPayableAndAccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638145119416316724" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638145119416316724" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638145119416316724" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638145119416316724" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_638145119416316724" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_638145119416316724" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_AccruedResearchAndDevelopmentCurrent" xlink:label="acxp_AccruedResearchAndDevelopmentCurrent_638145119416316724" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="acxp_AccruedResearchAndDevelopmentCurrent_638145119416316724" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.acurxpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetDetails" xlink:type="extended" xlink:title="40902 - Disclosure - INCOME TAXES - Deferred tax asset (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638145119416316724" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638145119416316724" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638145119416316724" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross_638145119416316724" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638145119416316724" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638145119416316724" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638145119416316724" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638145119416316724" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638145119416316724" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638145119416316724" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638145119416316724" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638145119416316724" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638145119416316724" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638145119416326722" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638145119416316724" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638145119416326722" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.acurxpharma.com/role/DisclosureIncomeTaxesTaxReconciliationDetails" xlink:type="extended" xlink:title="40903 - Disclosure - INCOME TAXES - Tax reconciliation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638145119416326722" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638145119416326722" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638145119416326722" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638145119416326722" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638145119416326722" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638145119416326722" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_638145119416326722" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_638145119416326722" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638145119416326722" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638145119416326722" order="5" use="optional" weight="-1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>22
<FILENAME>acxp-20221231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/15/2023 9:19:02 PM-->
<!--Modified on: 3/15/2023 9:19:02 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#StatementBalanceSheets" roleURI="http://www.acurxpharma.com/role/StatementBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#StatementStatementsOfChangesInMembersAndShareholdersEquity" roleURI="http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureNatureOfOperationsDetails" roleURI="http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesConcentrationDetails" roleURI="http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosurePaycheckProtectionProgramLoanDetails" roleURI="http://www.acurxpharma.com/role/DisclosurePaycheckProtectionProgramLoanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureExecutiveCompensationDetails" roleURI="http://www.acurxpharma.com/role/DisclosureExecutiveCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureIssuanceOfEquityInterestsDetails" roleURI="http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureIssuanceOfEquityInterestsFairValueDetails" roleURI="http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsFairValueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureIssuanceOfEquityInterestsWarrantsDetails" roleURI="http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureShareBasedCompensationDetails" roleURI="http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureShareBasedCompensationUnvestedDetails" roleURI="http://www.acurxpharma.com/role/DisclosureShareBasedCompensationUnvestedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureShareBasedPaymentsToVendorsDetails" roleURI="http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureNetLossPerShareDetails" roleURI="http://www.acurxpharma.com/role/DisclosureNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.acurxpharma.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.acurxpharma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.acurxpharma.com/role/DisclosureStandardAndCustomAxisDomainDefaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="GranteeStatusAxis" xlink:title="GranteeStatusAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="GranteeStatusDomain" xlink:title="GranteeStatusDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="GranteeStatusAxis" xlink:to="GranteeStatusDomain" xlink:title="definition: GranteeStatusAxis to GranteeStatusDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="OptionIndexedToIssuersEquityTypeAxis" xlink:title="OptionIndexedToIssuersEquityTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="OptionIndexedToIssuersEquityTypeDomain" xlink:title="OptionIndexedToIssuersEquityTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="OptionIndexedToIssuersEquityTypeAxis" xlink:to="OptionIndexedToIssuersEquityTypeDomain" xlink:title="definition: OptionIndexedToIssuersEquityTypeAxis to OptionIndexedToIssuersEquityTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:title="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:title="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:title="definition: ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis to ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="ShortTermDebtTypeAxis" xlink:title="ShortTermDebtTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="ShortTermDebtTypeDomain" xlink:title="ShortTermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ShortTermDebtTypeAxis" xlink:to="ShortTermDebtTypeDomain" xlink:title="definition: ShortTermDebtTypeAxis to ShortTermDebtTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="VestingAxis" xlink:title="VestingAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="VestingDomain" xlink:title="VestingDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="VestingAxis" xlink:to="VestingDomain" xlink:title="definition: VestingAxis to VestingDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_1" xlink:title="us-gaap_TaxCreditCarryforwardAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_1" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxCreditCarryforwardAxis_1" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxCreditCarryforwardAxis_1 To us-gaap_TaxCreditCarryforwardNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:title="us-gaap_ConcentrationRiskByBenchmarkAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_1" xlink:title="us-gaap_ConcentrationRiskBenchmarkDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByBenchmarkAxis_1 To us-gaap_ConcentrationRiskBenchmarkDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:title="us-gaap_ConcentrationRiskByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_1" xlink:title="us-gaap_ConcentrationRiskTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:to="us-gaap_ConcentrationRiskTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByTypeAxis_1 To us-gaap_ConcentrationRiskTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis_1" xlink:title="us-gaap_AwardDateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_1" xlink:title="us-gaap_AwardDateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardDateAxis_1" xlink:to="us-gaap_AwardDateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardDateAxis_1 To us-gaap_AwardDateDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.acurxpharma.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_CommonUnitClassMemberSCapitalMember" xlink:label="acxp_CommonUnitClassMemberSCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acxp_CommonUnitClassMemberSCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_CommonUnitClassBMemberSCapitalMember" xlink:label="acxp_CommonUnitClassBMemberSCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acxp_CommonUnitClassBMemberSCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Cash" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MembersCapital" xlink:label="us-gaap_MembersCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_MembersCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - STATEMENTS OF CHANGES IN MEMBERS' AND SHAREHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MemberUnitsMember" xlink:label="us-gaap_MemberUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_MemberUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_CommonUnitClassMemberSCapitalMember" xlink:label="acxp_CommonUnitClassMemberSCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acxp_CommonUnitClassMemberSCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_CommonUnitClassBMemberSCapitalMember" xlink:label="acxp_CommonUnitClassBMemberSCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acxp_CommonUnitClassBMemberSCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonUnitOutstanding" xlink:label="us-gaap_CommonUnitOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonUnitOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_StockUnitsIssuedDuringPeriodValueExecutiveCompensationSettled" xlink:label="acxp_StockUnitsIssuedDuringPeriodValueExecutiveCompensationSettled" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="acxp_StockUnitsIssuedDuringPeriodValueExecutiveCompensationSettled" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_StockUnitsIssuedDuringPeriodSharesExecutiveCompensationSettled" xlink:label="acxp_StockUnitsIssuedDuringPeriodSharesExecutiveCompensationSettled" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="acxp_StockUnitsIssuedDuringPeriodValueExecutiveCompensationSettled" xlink:to="acxp_StockUnitsIssuedDuringPeriodSharesExecutiveCompensationSettled" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_CancellationOfStockUnitsValue" xlink:label="acxp_CancellationOfStockUnitsValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="acxp_CancellationOfStockUnitsValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_CancellationOfStockUnitsShares" xlink:label="acxp_CancellationOfStockUnitsShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="acxp_CancellationOfStockUnitsValue" xlink:to="acxp_CancellationOfStockUnitsShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_StockIssuedDuringPeriodValueCorporateConversionOfUnits" xlink:label="acxp_StockIssuedDuringPeriodValueCorporateConversionOfUnits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="acxp_StockIssuedDuringPeriodValueCorporateConversionOfUnits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_StockIssuedDuringPeriodSharesCorporateConversionOfUnits" xlink:label="acxp_StockIssuedDuringPeriodSharesCorporateConversionOfUnits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="acxp_StockIssuedDuringPeriodValueCorporateConversionOfUnits" xlink:to="acxp_StockIssuedDuringPeriodSharesCorporateConversionOfUnits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_StockholdersEquityPeriodIncreaseDecreaseThroughCashlessWarrantExercise" xlink:label="acxp_StockholdersEquityPeriodIncreaseDecreaseThroughCashlessWarrantExercise" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="acxp_StockholdersEquityPeriodIncreaseDecreaseThroughCashlessWarrantExercise" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_StockIssuedDuringPeriodSharesPeriodIncreaseDecreaseThroughCashlessWarrantExercise" xlink:label="acxp_StockIssuedDuringPeriodSharesPeriodIncreaseDecreaseThroughCashlessWarrantExercise" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="acxp_StockholdersEquityPeriodIncreaseDecreaseThroughCashlessWarrantExercise" xlink:to="acxp_StockIssuedDuringPeriodSharesPeriodIncreaseDecreaseThroughCashlessWarrantExercise" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_WarrantExercisePreFunded" xlink:label="acxp_WarrantExercisePreFunded" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="acxp_WarrantExercisePreFunded" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_WarrantExercisePreFundedShares" xlink:label="acxp_WarrantExercisePreFundedShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="acxp_WarrantExercisePreFunded" xlink:to="acxp_WarrantExercisePreFundedShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails" xlink:type="extended" xlink:title="40101 - Disclosure - NATURE OF OPERATIONS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_AcxThreeSixtyTwoEMember" xlink:label="acxp_AcxThreeSixtyTwoEMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="acxp_AcxThreeSixtyTwoEMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_CommonUnitClassBMemberSCapitalMember" xlink:label="acxp_CommonUnitClassBMemberSCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acxp_CommonUnitClassBMemberSCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_RegisteredDirectOfferingMember" xlink:label="acxp_RegisteredDirectOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acxp_RegisteredDirectOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_SeriesWarrantsMember" xlink:label="acxp_SeriesWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="acxp_SeriesWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_SeriesBWarrantsMember" xlink:label="acxp_SeriesBWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="acxp_SeriesBWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForOperatingActivities" xlink:label="us-gaap_PaymentsForOperatingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsForOperatingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherCommitment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RoyaltyExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_PercentageOfRoyaltyPaymentsOnNetSales" xlink:label="acxp_PercentageOfRoyaltyPaymentsOnNetSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="acxp_PercentageOfRoyaltyPaymentsOnNetSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts" xlink:label="acxp_StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="acxp_StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_WarrantExercisePreFundedShares" xlink:label="acxp_WarrantExercisePreFundedShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="acxp_WarrantExercisePreFundedShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Cash" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationDetails" xlink:type="extended" xlink:title="40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsTotalMember" xlink:label="us-gaap_CostOfGoodsTotalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_CostOfGoodsTotalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesTotalMember" xlink:label="us-gaap_LiabilitiesTotalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_LiabilitiesTotalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_SupplierConcentrationRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_VendorOneMember" xlink:label="acxp_VendorOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="acxp_VendorOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_VendorTwoMember" xlink:label="acxp_VendorTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="acxp_VendorTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.acurxpharma.com/role/DisclosurePaycheckProtectionProgramLoanDetails" xlink:type="extended" xlink:title="40401 - Disclosure - PAYCHECK PROTECTION PROGRAM LOAN (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_PaycheckProtectionProgramLoanMember" xlink:label="acxp_PaycheckProtectionProgramLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="acxp_PaycheckProtectionProgramLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTerm" xlink:label="us-gaap_LongTermDebtTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_LongTermDebtTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.acurxpharma.com/role/DisclosureExecutiveCompensationDetails" xlink:type="extended" xlink:title="40501 - Disclosure - EXECUTIVE COMPENSATION (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_CommonUnitClassMemberSCapitalMember" xlink:label="acxp_CommonUnitClassMemberSCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acxp_CommonUnitClassMemberSCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_CommonUnitClassBMemberSCapitalMember" xlink:label="acxp_CommonUnitClassBMemberSCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acxp_CommonUnitClassBMemberSCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_NonEmployeeMember" xlink:label="acxp_NonEmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="acxp_NonEmployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_StockIssuedDuringPeriodSharesBonus" xlink:label="acxp_StockIssuedDuringPeriodSharesBonus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="acxp_StockIssuedDuringPeriodSharesBonus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - ISSUANCE OF EQUITY INTERESTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_UnderwriterMember" xlink:label="acxp_UnderwriterMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acxp_UnderwriterMember" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_RegisteredDirectOfferingMember" xlink:label="acxp_RegisteredDirectOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acxp_RegisteredDirectOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_PlacementAgentsMember" xlink:label="acxp_PlacementAgentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acxp_PlacementAgentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_AffiliateInvestorsMember" xlink:label="acxp_AffiliateInvestorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="acxp_AffiliateInvestorsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_InvestorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_SeriesWarrantsMember" xlink:label="acxp_SeriesWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="acxp_SeriesWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_SeriesBWarrantsMember" xlink:label="acxp_SeriesBWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="acxp_SeriesBWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_CommonUnitClassAndClassBMemberSCapitalMember" xlink:label="acxp_CommonUnitClassAndClassBMemberSCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acxp_CommonUnitClassAndClassBMemberSCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ClassOfWarrantOrRightExercisableTerm" xlink:label="acxp_ClassOfWarrantOrRightExercisableTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="acxp_ClassOfWarrantOrRightExercisableTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_WarrantExercisePreFundedShares" xlink:label="acxp_WarrantExercisePreFundedShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="acxp_WarrantExercisePreFundedShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ClassOfWarrantOrRightPurchasePrice" xlink:label="acxp_ClassOfWarrantOrRightPurchasePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="acxp_ClassOfWarrantOrRightPurchasePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts" xlink:label="acxp_StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="acxp_StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_PercentageOfWeightedAveragePublicOfferingPriceOfAggregateNumberOfSharesOfCommonStockSold" xlink:label="acxp_PercentageOfWeightedAveragePublicOfferingPriceOfAggregateNumberOfSharesOfCommonStockSold" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="acxp_PercentageOfWeightedAveragePublicOfferingPriceOfAggregateNumberOfSharesOfCommonStockSold" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsFairValueDetails" xlink:type="extended" xlink:title="40602 - Disclosure - ISSUANCE OF EQUITY INTERESTS - Fair Value (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_UnderwriterMember" xlink:label="acxp_UnderwriterMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acxp_UnderwriterMember" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_PlacementAgentsMember" xlink:label="acxp_PlacementAgentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acxp_PlacementAgentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsWarrantsDetails" xlink:type="extended" xlink:title="40603 - Disclosure - ISSUANCE OF EQUITY INTERESTS - Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_WeightedAverageMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ClassOfWarrantOrRightIssued" xlink:label="acxp_ClassOfWarrantOrRightIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="acxp_ClassOfWarrantOrRightIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ClassOfWarrantOrRightExercised" xlink:label="acxp_ClassOfWarrantOrRightExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="acxp_ClassOfWarrantOrRightExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued" xlink:label="acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" xlink:label="acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ClassOfWarrantOrRightExercisableTerm" xlink:label="acxp_ClassOfWarrantOrRightExercisableTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="acxp_ClassOfWarrantOrRightExercisableTerm" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails" xlink:type="extended" xlink:title="40701 - Disclosure - SHARE-BASED COMPENSATION - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_EquityIncentivePlan2021Member" xlink:label="acxp_EquityIncentivePlan2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="acxp_EquityIncentivePlan2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardDateAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember" xlink:label="acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AwardDateDomain" xlink:to="acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDateJune2021Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateJune2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AwardDateDomain" xlink:to="acxp_ShareBasedPaymentArrangementGrantDateJune2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AwardDateDomain" xlink:to="acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AwardDateDomain" xlink:to="acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDateApril2022Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateApril2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AwardDateDomain" xlink:to="acxp_ShareBasedPaymentArrangementGrantDateApril2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ExecutivesIndependentDirectorsConsultantMember" xlink:label="acxp_ExecutivesIndependentDirectorsConsultantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="acxp_ExecutivesIndependentDirectorsConsultantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="acxp_ExecutivesIndependentDirectorsConsultantMember" xlink:to="srt_ExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_IndependentDirectorsConsultantMember" xlink:label="acxp_IndependentDirectorsConsultantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="acxp_ExecutivesIndependentDirectorsConsultantMember" xlink:to="acxp_IndependentDirectorsConsultantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.acurxpharma.com/role/DisclosureShareBasedCompensationUnvestedDetails" xlink:type="extended" xlink:title="40702 - Disclosure - SHARE-BASED COMPENSATION - Unvested (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_CommonUnitClassMemberSCapitalMember" xlink:label="acxp_CommonUnitClassMemberSCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acxp_CommonUnitClassMemberSCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - SHARE-BASED PAYMENTS TO VENDORS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardDateAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember" xlink:label="acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AwardDateDomain" xlink:to="acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AwardDateDomain" xlink:to="acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AwardDateDomain" xlink:to="acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AwardDateDomain" xlink:to="acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantedInThirdQuarter2021Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantedInThirdQuarter2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AwardDateDomain" xlink:to="acxp_ShareBasedPaymentArrangementGrantedInThirdQuarter2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDateOctober2021Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateOctober2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AwardDateDomain" xlink:to="acxp_ShareBasedPaymentArrangementGrantDateOctober2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AwardDateDomain" xlink:to="acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDateMarch2022Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateMarch2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_AwardDateDomain" xlink:to="acxp_ShareBasedPaymentArrangementGrantDateMarch2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDateSeptember2022Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateSeptember2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_AwardDateDomain" xlink:to="acxp_ShareBasedPaymentArrangementGrantDateSeptember2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_AwardDateDomain" xlink:to="acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_CommonUnitClassMemberSCapitalMember" xlink:label="acxp_CommonUnitClassMemberSCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acxp_CommonUnitClassMemberSCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentToVendors" xlink:label="acxp_ShareBasedPaymentToVendors" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="acxp_ShareBasedPaymentToVendors" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToSuppliers" xlink:label="us-gaap_PaymentsToSuppliers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PaymentsToSuppliers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_OtherCommitment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.acurxpharma.com/role/DisclosureNetLossPerShareDetails" xlink:type="extended" xlink:title="41001 - Disclosure - NET LOSS PER SHARE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_CommonUnitClassAndClassBMemberSCapitalMember" xlink:label="acxp_CommonUnitClassAndClassBMemberSCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acxp_CommonUnitClassAndClassBMemberSCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.acurxpharma.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="us-gaap_ProductLiabilityContingencyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ProductLiabilityContingencyTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_AcxThreeSixtyTwoEMember" xlink:label="acxp_AcxThreeSixtyTwoEMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="acxp_AcxThreeSixtyTwoEMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="us-gaap_ProductLiabilityContingencyLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ProductLiabilityContingencyLineItems" xlink:to="us-gaap_ProductLiabilityContingencyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ProductLiabilityContingencyLineItems" xlink:to="us-gaap_OtherCommitment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ProductLiabilityContingencyLineItems" xlink:to="us-gaap_RoyaltyExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_PercentageOfRoyaltyPaymentsOnNetSales" xlink:label="acxp_PercentageOfRoyaltyPaymentsOnNetSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ProductLiabilityContingencyLineItems" xlink:to="acxp_PercentageOfRoyaltyPaymentsOnNetSales" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>23
<FILENAME>acxp-20221231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/15/2023 9:19:02 PM-->
<!--Modified on: 3/15/2023 9:19:02 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address State Or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_CommonUnitClassMemberSCapitalMember" xlink:label="acxp_CommonUnitClassMemberSCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_CommonUnitClassMemberSCapitalMember" xlink:to="acxp_CommonUnitClassMemberSCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_CommonUnitClassMemberSCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Class A Membership Interests.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_CommonUnitClassMemberSCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Members' Equity, Class A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="acxp_CommonUnitClassMemberSCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Members' Equity, Class A</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_CommonUnitClassBMemberSCapitalMember" xlink:label="acxp_CommonUnitClassBMemberSCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_CommonUnitClassBMemberSCapitalMember" xlink:to="acxp_CommonUnitClassBMemberSCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_CommonUnitClassBMemberSCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Class B Membership Interests.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_CommonUnitClassBMemberSCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Members' Equity, Class B</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASSETS.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CURRENT ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TOTAL ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TOTAL ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIABILITIES AND MEMBERS' AND SHAREHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CURRENT LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TOTAL CURRENT LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TOTAL LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMITMENTS AND CONTINGENCIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">MEMBERS' AND SHAREHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MembersCapital" xlink:label="us-gaap_MembersCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MembersCapital" xlink:to="us-gaap_MembersCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MembersCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Members' Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MembersCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Members' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock; $.001 par value, 200,000,000 shares authorized, 11,627,609 and 10,215,792 shares issued and outstanding at December 31, 2022 and 2021, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-In Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TOTAL MEMBERS' AND SHAREHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TOTAL LIABILITIES AND MEMBERS' AND SHAREHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, Par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, Authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, Issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at ending, Common shares (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning, Common shares (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, Outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STATEMENTS OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OPERATING EXPENSES.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OPERATING EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TOTAL OPERATING EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain on Forgiveness of Paycheck Protection Program Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain on Forgiveness of Paycheck Protection Program Loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET LOSS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET LOSS PER SHARE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LOSS PER SHARE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic net loss per common share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted net loss per common share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares outstanding basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares outstanding diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STATEMENTS OF CHANGES IN MEMBERS' AND SHAREHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MemberUnitsMember" xlink:label="us-gaap_MemberUnitsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MemberUnitsMember" xlink:to="us-gaap_MemberUnitsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MemberUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Membership Interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-In Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonUnitOutstanding" xlink:label="us-gaap_CommonUnitOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonUnitOutstanding" xlink:to="us-gaap_CommonUnitOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonUnitOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Unit, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonUnitOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at ending, Member Units (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonUnitOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning, Member Units (in shares)</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_StockUnitsIssuedDuringPeriodValueExecutiveCompensationSettled" xlink:label="acxp_StockUnitsIssuedDuringPeriodValueExecutiveCompensationSettled" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_StockUnitsIssuedDuringPeriodValueExecutiveCompensationSettled" xlink:to="acxp_StockUnitsIssuedDuringPeriodValueExecutiveCompensationSettled_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_StockUnitsIssuedDuringPeriodValueExecutiveCompensationSettled_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity impact of the value of  stock  units issued during the period for executive compensation settlement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_StockUnitsIssuedDuringPeriodValueExecutiveCompensationSettled_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Units Issued During Period Value Executive Compensation Settled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="acxp_StockUnitsIssuedDuringPeriodValueExecutiveCompensationSettled_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Executive Compensation Settled with Membership Interests</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_StockUnitsIssuedDuringPeriodSharesExecutiveCompensationSettled" xlink:label="acxp_StockUnitsIssuedDuringPeriodSharesExecutiveCompensationSettled" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_StockUnitsIssuedDuringPeriodSharesExecutiveCompensationSettled" xlink:to="acxp_StockUnitsIssuedDuringPeriodSharesExecutiveCompensationSettled_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_StockUnitsIssuedDuringPeriodSharesExecutiveCompensationSettled_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of tock units issued during the period for executive compensation settlement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_StockUnitsIssuedDuringPeriodSharesExecutiveCompensationSettled_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Units Issued During Period Shares Executive Compensation Settled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="acxp_StockUnitsIssuedDuringPeriodSharesExecutiveCompensationSettled_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Executive Compensation Settled with Membership Interests (in shares)</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_CancellationOfStockUnitsValue" xlink:label="acxp_CancellationOfStockUnitsValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_CancellationOfStockUnitsValue" xlink:to="acxp_CancellationOfStockUnitsValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_CancellationOfStockUnitsValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity impact of the value of stock units cancelled during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_CancellationOfStockUnitsValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancellation Of Stock Units Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="acxp_CancellationOfStockUnitsValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancellation of Class B Issuance</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_CancellationOfStockUnitsShares" xlink:label="acxp_CancellationOfStockUnitsShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_CancellationOfStockUnitsShares" xlink:to="acxp_CancellationOfStockUnitsShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_CancellationOfStockUnitsShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity impact of the shares of stock units cancelled during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_CancellationOfStockUnitsShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancellation Of Stock Units Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="acxp_CancellationOfStockUnitsShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancellation of Class B Issuance (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payments to Vendors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payments to Vendors (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based vendor payments (in shares)</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_StockIssuedDuringPeriodValueCorporateConversionOfUnits" xlink:label="acxp_StockIssuedDuringPeriodValueCorporateConversionOfUnits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_StockIssuedDuringPeriodValueCorporateConversionOfUnits" xlink:to="acxp_StockIssuedDuringPeriodValueCorporateConversionOfUnits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_StockIssuedDuringPeriodValueCorporateConversionOfUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of stock issued during the period upon the corporate conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_StockIssuedDuringPeriodValueCorporateConversionOfUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Value Corporate Conversion Of Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="acxp_StockIssuedDuringPeriodValueCorporateConversionOfUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Conversion</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_StockIssuedDuringPeriodSharesCorporateConversionOfUnits" xlink:label="acxp_StockIssuedDuringPeriodSharesCorporateConversionOfUnits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_StockIssuedDuringPeriodSharesCorporateConversionOfUnits" xlink:to="acxp_StockIssuedDuringPeriodSharesCorporateConversionOfUnits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_StockIssuedDuringPeriodSharesCorporateConversionOfUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of shares issued during the period upon the corporate conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_StockIssuedDuringPeriodSharesCorporateConversionOfUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Shares Corporate Conversion Of Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="acxp_StockIssuedDuringPeriodSharesCorporateConversionOfUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Conversion (in shares)</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_StockholdersEquityPeriodIncreaseDecreaseThroughCashlessWarrantExercise" xlink:label="acxp_StockholdersEquityPeriodIncreaseDecreaseThroughCashlessWarrantExercise" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_StockholdersEquityPeriodIncreaseDecreaseThroughCashlessWarrantExercise" xlink:to="acxp_StockholdersEquityPeriodIncreaseDecreaseThroughCashlessWarrantExercise_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_StockholdersEquityPeriodIncreaseDecreaseThroughCashlessWarrantExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) in stockholders' equity through cashless warrant exercise during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_StockholdersEquityPeriodIncreaseDecreaseThroughCashlessWarrantExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity, Period Increase (Decrease) Through Cashless Warrant Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="acxp_StockholdersEquityPeriodIncreaseDecreaseThroughCashlessWarrantExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cashless Warrant Exercise</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_StockIssuedDuringPeriodSharesPeriodIncreaseDecreaseThroughCashlessWarrantExercise" xlink:label="acxp_StockIssuedDuringPeriodSharesPeriodIncreaseDecreaseThroughCashlessWarrantExercise" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_StockIssuedDuringPeriodSharesPeriodIncreaseDecreaseThroughCashlessWarrantExercise" xlink:to="acxp_StockIssuedDuringPeriodSharesPeriodIncreaseDecreaseThroughCashlessWarrantExercise_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_StockIssuedDuringPeriodSharesPeriodIncreaseDecreaseThroughCashlessWarrantExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) during the period in the number of shares issued through cashless warrant exercise.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_StockIssuedDuringPeriodSharesPeriodIncreaseDecreaseThroughCashlessWarrantExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Period Increase (Decrease) Through Cashless Warrant Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="acxp_StockIssuedDuringPeriodSharesPeriodIncreaseDecreaseThroughCashlessWarrantExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cashless Warrant Exercise (in shares)</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_WarrantExercisePreFunded" xlink:label="acxp_WarrantExercisePreFunded" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_WarrantExercisePreFunded" xlink:to="acxp_WarrantExercisePreFunded_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_WarrantExercisePreFunded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) in stockholders' equity through pre-funded warrant exercise during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_WarrantExercisePreFunded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Exercise, Pre Funded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="acxp_WarrantExercisePreFunded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-funded Warrant Exercise</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_WarrantExercisePreFundedShares" xlink:label="acxp_WarrantExercisePreFundedShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_WarrantExercisePreFundedShares" xlink:to="acxp_WarrantExercisePreFundedShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_WarrantExercisePreFundedShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) during the period in the number of shares issued through pre-funded warrant exercise.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_WarrantExercisePreFundedShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Exercise, Pre Funded, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="acxp_WarrantExercisePreFundedShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-funded Warrant Exercise (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Public Offering and underwriter warrants, net of cash issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Public Offering and underwriter warrants, net of cash issuance costs (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued during the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash issuance cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow from Operating Activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentToVendors" xlink:label="acxp_ShareBasedPaymentToVendors" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_ShareBasedPaymentToVendors" xlink:to="acxp_ShareBasedPaymentToVendors_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_ShareBasedPaymentToVendors_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of non cash expense for share based payment to vendors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_ShareBasedPaymentToVendors_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payments to Vendors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="acxp_ShareBasedPaymentToVendors_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payments to Vendors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="acxp_ShareBasedPaymentToVendors_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based vendor payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Stock and Warrants for Services or Claims</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Executive Compensation Settled with Membership Interests</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Increase) / Decrease in:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Used in Operating Activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow from Financing Activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Long-Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Paycheck Protection Program Loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Initial Public Offering, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Registered Direct Offering, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from stock issue, net of costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-funded Warrant Exercise</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by Financing Activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (Decrease) Increase in Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash at End of Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash at Beginning of Year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING ACTIVITIES</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_NonCashFinancingActivitiesOfWarrantsIssuedInConnectionWithOfferings" xlink:label="acxp_NonCashFinancingActivitiesOfWarrantsIssuedInConnectionWithOfferings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_NonCashFinancingActivitiesOfWarrantsIssuedInConnectionWithOfferings" xlink:to="acxp_NonCashFinancingActivitiesOfWarrantsIssuedInConnectionWithOfferings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_NonCashFinancingActivitiesOfWarrantsIssuedInConnectionWithOfferings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of offering costs issued in connection with warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_NonCashFinancingActivitiesOfWarrantsIssuedInConnectionWithOfferings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non Cash Financing Activities Of Warrants Issued In Connection With Offerings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="acxp_NonCashFinancingActivitiesOfWarrantsIssuedInConnectionWithOfferings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants issued in connection with offerings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NATURE OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NATURE OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_PaycheckProtectionProgramLoanAbstract" xlink:label="acxp_PaycheckProtectionProgramLoanAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_PaycheckProtectionProgramLoanAbstract" xlink:to="acxp_PaycheckProtectionProgramLoanAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_PaycheckProtectionProgramLoanAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the details pertaining to Paycheck Protection Program Loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_PaycheckProtectionProgramLoanAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PAYCHECK PROTECTION PROGRAM LOAN</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_PaycheckProtectionProgramLoanDisclosureTextBlock" xlink:label="acxp_PaycheckProtectionProgramLoanDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_PaycheckProtectionProgramLoanDisclosureTextBlock" xlink:to="acxp_PaycheckProtectionProgramLoanDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_PaycheckProtectionProgramLoanDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of paycheck protection program loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_PaycheckProtectionProgramLoanDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Paycheck Protection Program Loan Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="acxp_PaycheckProtectionProgramLoanDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PAYCHECK PROTECTION PROGRAM LOAN</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_CompensationRelatedCostsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">EXECUTIVE COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:label="us-gaap_CompensationRelatedCostsGeneralTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:to="us-gaap_CompensationRelatedCostsGeneralTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsGeneralTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation Related Costs, General [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsGeneralTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">EXECUTIVE COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ISSUANCE OF EQUITY INTERESTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ISSUANCE OF EQUITY INTERESTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHARE-BASED COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHARE-BASED COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentsToVendorsAbstract" xlink:label="acxp_ShareBasedPaymentsToVendorsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_ShareBasedPaymentsToVendorsAbstract" xlink:to="acxp_ShareBasedPaymentsToVendorsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_ShareBasedPaymentsToVendorsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ABSTRACT</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_ShareBasedPaymentsToVendorsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHARE-BASED PAYMENTS TO VENDORS</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentsToVendorsDisclosureTextBlock" xlink:label="acxp_ShareBasedPaymentsToVendorsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_ShareBasedPaymentsToVendorsDisclosureTextBlock" xlink:to="acxp_ShareBasedPaymentsToVendorsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_ShareBasedPaymentsToVendorsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the share based payments to vendors disclosure.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_ShareBasedPaymentsToVendorsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Payments To Vendors Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="acxp_ShareBasedPaymentsToVendorsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHARE-BASED PAYMENTS TO VENDORS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET LOSS PER SHARE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMITMENTS AND CONTINGENCIES.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMITMENTS AND CONTINGENCIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:label="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:to="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Guarantees, Indemnifications and Warranties Policies [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Guaranteed Payments to Members</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentsToVendorsPolicyTextBlock" xlink:label="acxp_ShareBasedPaymentsToVendorsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_ShareBasedPaymentsToVendorsPolicyTextBlock" xlink:to="acxp_ShareBasedPaymentsToVendorsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_ShareBasedPaymentsToVendorsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for share-based payments to vendors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_ShareBasedPaymentsToVendorsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payments to Vendors Policy Text block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="acxp_ShareBasedPaymentsToVendorsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payments to Vendors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Major Vendor</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of outstanding warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Nonvested Performance-based Units Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of unvested Class A membership interest converted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of fair value of options assumptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock option activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of net deferred income tax asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of reconciliation of income tax expense (benefit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_AcxThreeSixtyTwoEMember" xlink:label="acxp_AcxThreeSixtyTwoEMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_AcxThreeSixtyTwoEMember" xlink:to="acxp_AcxThreeSixtyTwoEMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_AcxThreeSixtyTwoEMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member is stands for ACX 362E.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_AcxThreeSixtyTwoEMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ACX362E</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_RegisteredDirectOfferingMember" xlink:label="acxp_RegisteredDirectOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_RegisteredDirectOfferingMember" xlink:to="acxp_RegisteredDirectOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_RegisteredDirectOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Registered direct offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_RegisteredDirectOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Registered direct offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_SeriesWarrantsMember" xlink:label="acxp_SeriesWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_SeriesWarrantsMember" xlink:to="acxp_SeriesWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_SeriesWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Series A warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_SeriesWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A warrants</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_SeriesBWarrantsMember" xlink:label="acxp_SeriesBWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_SeriesBWarrantsMember" xlink:to="acxp_SeriesBWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_SeriesBWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Series B warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_SeriesBWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForOperatingActivities" xlink:label="us-gaap_PaymentsForOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForOperatingActivities" xlink:to="us-gaap_PaymentsForOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Purchase of Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granting (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant exercise price (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant exercise price, outstanding (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCommitment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future commitment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty payments</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_PercentageOfRoyaltyPaymentsOnNetSales" xlink:label="acxp_PercentageOfRoyaltyPaymentsOnNetSales" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_PercentageOfRoyaltyPaymentsOnNetSales" xlink:to="acxp_PercentageOfRoyaltyPaymentsOnNetSales_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_PercentageOfRoyaltyPaymentsOnNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents for percentage of royalty payments on net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_PercentageOfRoyaltyPaymentsOnNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of royalty payments on net sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="acxp_PercentageOfRoyaltyPaymentsOnNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty payments on net sales (as a percent)</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts" xlink:label="acxp_StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts" xlink:to="acxp_StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from new stock issued during the period before offering costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues, Before Offering Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="acxp_StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock issue gross proceeds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Federal, State and Local, Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current federal or state income tax expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsTotalMember" xlink:label="us-gaap_CostOfGoodsTotalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsTotalMember" xlink:to="us-gaap_CostOfGoodsTotalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsTotalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenditures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesTotalMember" xlink:label="us-gaap_LiabilitiesTotalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesTotalMember" xlink:to="us-gaap_LiabilitiesTotalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesTotalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplier Concentration Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplier [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplier [Domain]</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_VendorOneMember" xlink:label="acxp_VendorOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_VendorOneMember" xlink:to="acxp_VendorOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_VendorOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information related to the first vendor.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_VendorOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vendor One</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_VendorTwoMember" xlink:label="acxp_VendorTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_VendorTwoMember" xlink:to="acxp_VendorTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_VendorTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information related to the second vendor.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_VendorTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vendor Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued compensation expenses</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_AccruedResearchAndDevelopmentCurrent" xlink:label="acxp_AccruedResearchAndDevelopmentCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_AccruedResearchAndDevelopmentCurrent" xlink:to="acxp_AccruedResearchAndDevelopmentCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_AccruedResearchAndDevelopmentCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount carrying value as of the balance sheet date of accrued research and development Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_AccruedResearchAndDevelopmentCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Research and Development Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="acxp_AccruedResearchAndDevelopmentCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued professional fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Short-term Debt [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Debt, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Debt, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_PaycheckProtectionProgramLoanMember" xlink:label="acxp_PaycheckProtectionProgramLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_PaycheckProtectionProgramLoanMember" xlink:to="acxp_PaycheckProtectionProgramLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_PaycheckProtectionProgramLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the details pertaining to Paycheck protection program loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_PaycheckProtectionProgramLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Paycheck Protection Program Loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Debt [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTerm" xlink:label="us-gaap_LongTermDebtTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTerm" xlink:to="us-gaap_LongTermDebtTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturity period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Directors</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_NonEmployeeMember" xlink:label="acxp_NonEmployeeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_NonEmployeeMember" xlink:to="acxp_NonEmployeeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_NonEmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the Non-Employee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_NonEmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-Employee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_StockIssuedDuringPeriodSharesBonus" xlink:label="acxp_StockIssuedDuringPeriodSharesBonus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_StockIssuedDuringPeriodSharesBonus" xlink:to="acxp_StockIssuedDuringPeriodSharesBonus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_StockIssuedDuringPeriodSharesBonus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares of stock issued attributable to bonus.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_StockIssuedDuringPeriodSharesBonus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Bonus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="acxp_StockIssuedDuringPeriodSharesBonus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued for bonus (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Table]</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_UnderwriterMember" xlink:label="acxp_UnderwriterMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_UnderwriterMember" xlink:to="acxp_UnderwriterMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_UnderwriterMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Relating to the IPO underwriter.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_UnderwriterMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriter</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_PlacementAgentsMember" xlink:label="acxp_PlacementAgentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_PlacementAgentsMember" xlink:to="acxp_PlacementAgentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_PlacementAgentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Placement Agents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_PlacementAgentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Placement Agents</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_AffiliateInvestorsMember" xlink:label="acxp_AffiliateInvestorsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_AffiliateInvestorsMember" xlink:to="acxp_AffiliateInvestorsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_AffiliateInvestorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to affiliate investors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_AffiliateInvestorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Affiliate Investors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investor</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_CommonUnitClassAndClassBMemberSCapitalMember" xlink:label="acxp_CommonUnitClassAndClassBMemberSCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_CommonUnitClassAndClassBMemberSCapitalMember" xlink:to="acxp_CommonUnitClassAndClassBMemberSCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_CommonUnitClassAndClassBMemberSCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the Class A and class B members capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_CommonUnitClassAndClassBMemberSCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Members' Equity, Class A and Class B</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range Axis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant date fair value ($ per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Shares Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Converted to shares of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Conversion of Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Converted shares of common stock</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ClassOfWarrantOrRightExercisableTerm" xlink:label="acxp_ClassOfWarrantOrRightExercisableTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_ClassOfWarrantOrRightExercisableTerm" xlink:to="acxp_ClassOfWarrantOrRightExercisableTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_ClassOfWarrantOrRightExercisableTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of warrant or right exercisable term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_ClassOfWarrantOrRightExercisableTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right Exercisable Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="acxp_ClassOfWarrantOrRightExercisableTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant exercisable term</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ClassOfWarrantOrRightPurchasePrice" xlink:label="acxp_ClassOfWarrantOrRightPurchasePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_ClassOfWarrantOrRightPurchasePrice" xlink:to="acxp_ClassOfWarrantOrRightPurchasePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_ClassOfWarrantOrRightPurchasePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase price per share or per unit of warrants or rights outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_ClassOfWarrantOrRightPurchasePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Purchase Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="acxp_ClassOfWarrantOrRightPurchasePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase price pre-funded warrant (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_PercentageOfWeightedAveragePublicOfferingPriceOfAggregateNumberOfSharesOfCommonStockSold" xlink:label="acxp_PercentageOfWeightedAveragePublicOfferingPriceOfAggregateNumberOfSharesOfCommonStockSold" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_PercentageOfWeightedAveragePublicOfferingPriceOfAggregateNumberOfSharesOfCommonStockSold" xlink:to="acxp_PercentageOfWeightedAveragePublicOfferingPriceOfAggregateNumberOfSharesOfCommonStockSold_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_PercentageOfWeightedAveragePublicOfferingPriceOfAggregateNumberOfSharesOfCommonStockSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of weighted average public offering price of the aggregate number of shares of common stock sold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_PercentageOfWeightedAveragePublicOfferingPriceOfAggregateNumberOfSharesOfCommonStockSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Weighted Average Public Offering Price Of The Aggregate Number Of Shares Of Common Stock Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="acxp_PercentageOfWeightedAveragePublicOfferingPriceOfAggregateNumberOfSharesOfCommonStockSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average aggregate offering price (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Expected Term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Risk Free Rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Share Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Settleable in Cash, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding, Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_WeightedAverageMember" xlink:to="srt_WeightedAverageMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_WeightedAverageMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants outstanding (in shares), ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants outstanding (in shares), beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ClassOfWarrantOrRightIssued" xlink:label="acxp_ClassOfWarrantOrRightIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_ClassOfWarrantOrRightIssued" xlink:to="acxp_ClassOfWarrantOrRightIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_ClassOfWarrantOrRightIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase in warrants outstanding during the period for the number of warrant issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_ClassOfWarrantOrRightIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="acxp_ClassOfWarrantOrRightIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ClassOfWarrantOrRightExercised" xlink:label="acxp_ClassOfWarrantOrRightExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_ClassOfWarrantOrRightExercised" xlink:to="acxp_ClassOfWarrantOrRightExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_ClassOfWarrantOrRightExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The decrease in warrants outstanding during the period for the number of warrant exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_ClassOfWarrantOrRightExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="acxp_ClassOfWarrantOrRightExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants exercised (in shares)</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued" xlink:label="acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued" xlink:to="acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price per share or per unit of warrants or rights issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant exercise price, issued (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" xlink:label="acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" xlink:to="acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price per share or per unit of warrants or rights exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant exercise price, exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_EquityIncentivePlan2021Member" xlink:label="acxp_EquityIncentivePlan2021Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_EquityIncentivePlan2021Member" xlink:to="acxp_EquityIncentivePlan2021Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_EquityIncentivePlan2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to 2021 Equity Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_EquityIncentivePlan2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 Equity Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Date [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Date [Domain]</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember" xlink:label="acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember" xlink:to="acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment arrangement granted pre-IPO.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre IPO</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDateJune2021Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateJune2021Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_ShareBasedPaymentArrangementGrantDateJune2021Member" xlink:to="acxp_ShareBasedPaymentArrangementGrantDateJune2021Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateJune2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment arrangement granted June 2021.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateJune2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">June 2021</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member" xlink:to="acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment arrangement granted July 2021.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 2021</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member" xlink:to="acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment arrangement granted January 2022.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">January 2022</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDateApril2022Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateApril2022Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_ShareBasedPaymentArrangementGrantDateApril2022Member" xlink:to="acxp_ShareBasedPaymentArrangementGrantDateApril2022Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateApril2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment arrangement granted April 2022.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateApril2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">April 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ExecutivesIndependentDirectorsConsultantMember" xlink:label="acxp_ExecutivesIndependentDirectorsConsultantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_ExecutivesIndependentDirectorsConsultantMember" xlink:to="acxp_ExecutivesIndependentDirectorsConsultantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_ExecutivesIndependentDirectorsConsultantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information related to executives pursuant to their respective employment agreements, the independent directors, and one consultant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_ExecutivesIndependentDirectorsConsultantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Executives, Independent Directors, Consultant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ExecutiveOfficerMember" xlink:to="srt_ExecutiveOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Executive officers</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_IndependentDirectorsConsultantMember" xlink:label="acxp_IndependentDirectorsConsultantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_IndependentDirectorsConsultantMember" xlink:to="acxp_IndependentDirectorsConsultantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_IndependentDirectorsConsultantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information related to the independent directors and one consultant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_IndependentDirectorsConsultantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Independent Directors, Consultant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche one</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock shares reserved</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional common stock shares reserved</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock shares available (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise price, granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant exercise price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting term of options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total compensation expense not yet recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average vesting period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise price, Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intrinsic value of stock option</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average contractual life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average grant date fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested at December 31, 2021</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested at December 31, 2020</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average grant date fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning of the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise price, End of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise price, Beginning of the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member" xlink:to="acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment arrangement granted October 2019.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">October 2019</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member" xlink:to="acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment arrangement granted second quarter 2021.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second Quarter 2021</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantedInThirdQuarter2021Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantedInThirdQuarter2021Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_ShareBasedPaymentArrangementGrantedInThirdQuarter2021Member" xlink:to="acxp_ShareBasedPaymentArrangementGrantedInThirdQuarter2021Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_ShareBasedPaymentArrangementGrantedInThirdQuarter2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share based payment arrangement 2021 third quarter</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_ShareBasedPaymentArrangementGrantedInThirdQuarter2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third Quarter 2021</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDateOctober2021Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateOctober2021Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_ShareBasedPaymentArrangementGrantDateOctober2021Member" xlink:to="acxp_ShareBasedPaymentArrangementGrantDateOctober2021Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateOctober2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment arrangement granted October 2021.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateOctober2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">October 2021</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDateMarch2022Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateMarch2022Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_ShareBasedPaymentArrangementGrantDateMarch2022Member" xlink:to="acxp_ShareBasedPaymentArrangementGrantDateMarch2022Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateMarch2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment arrangement granted March 2022.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateMarch2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2022</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDateSeptember2022Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateSeptember2022Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_ShareBasedPaymentArrangementGrantDateSeptember2022Member" xlink:to="acxp_ShareBasedPaymentArrangementGrantDateSeptember2022Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateSeptember2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment arrangement granted September 2022.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateSeptember2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">September 2022</label>
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member" xlink:to="acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share based payment arrangement 2022 fourth quarter</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fourth Quarter 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToSuppliers" xlink:label="us-gaap_PaymentsToSuppliers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToSuppliers" xlink:to="us-gaap_PaymentsToSuppliers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToSuppliers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Suppliers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToSuppliers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vendor payment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research tax credit carryforward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, in Process Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal income tax expense at statutory rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State income tax, net of federal benefit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Permanent differences</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development tax credit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potentially dilutive shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="us-gaap_ProductLiabilityContingencyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductLiabilityContingencyTable" xlink:to="us-gaap_ProductLiabilityContingencyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductLiabilityContingencyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Liability Contingency [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="us-gaap_ProductLiabilityContingencyLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductLiabilityContingencyLineItems" xlink:to="us-gaap_ProductLiabilityContingencyLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductLiabilityContingencyLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Liability Contingency [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductLiabilityContingencyLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingency</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>24
<FILENAME>acxp-20221231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/15/2023 9:19:02 PM-->
<!--Modified on: 3/15/2023 9:19:02 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#StatementBalanceSheets" roleURI="http://www.acurxpharma.com/role/StatementBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#StatementBalanceSheetsParenthetical" roleURI="http://www.acurxpharma.com/role/StatementBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#StatementStatementsOfOperations" roleURI="http://www.acurxpharma.com/role/StatementStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#StatementStatementsOfChangesInMembersAndShareholdersEquity" roleURI="http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#StatementStatementsOfChangesInMembersAndShareholdersEquityParenthetical" roleURI="http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquityParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#StatementStatementsOfCashFlows" roleURI="http://www.acurxpharma.com/role/StatementStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureNatureOfOperations" roleURI="http://www.acurxpharma.com/role/DisclosureNatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureAccountsPayableAndAccruedExpenses" roleURI="http://www.acurxpharma.com/role/DisclosureAccountsPayableAndAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosurePaycheckProtectionProgramLoan" roleURI="http://www.acurxpharma.com/role/DisclosurePaycheckProtectionProgramLoan" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureExecutiveCompensation" roleURI="http://www.acurxpharma.com/role/DisclosureExecutiveCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureIssuanceOfEquityInterests" roleURI="http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterests" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureShareBasedCompensation" roleURI="http://www.acurxpharma.com/role/DisclosureShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureShareBasedPaymentsToVendors" roleURI="http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendors" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureIncomeTaxes" roleURI="http://www.acurxpharma.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureNetLossPerShare" roleURI="http://www.acurxpharma.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.acurxpharma.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureAccountsPayableAndAccruedExpensesTables" roleURI="http://www.acurxpharma.com/role/DisclosureAccountsPayableAndAccruedExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureIssuanceOfEquityInterestsTables" roleURI="http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureShareBasedCompensationTables" roleURI="http://www.acurxpharma.com/role/DisclosureShareBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.acurxpharma.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureNatureOfOperationsDetails" roleURI="http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesConcentrationDetails" roleURI="http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureAccountsPayableAndAccruedExpensesDetails" roleURI="http://www.acurxpharma.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosurePaycheckProtectionProgramLoanDetails" roleURI="http://www.acurxpharma.com/role/DisclosurePaycheckProtectionProgramLoanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureExecutiveCompensationDetails" roleURI="http://www.acurxpharma.com/role/DisclosureExecutiveCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureIssuanceOfEquityInterestsDetails" roleURI="http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureIssuanceOfEquityInterestsFairValueDetails" roleURI="http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsFairValueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureIssuanceOfEquityInterestsWarrantsDetails" roleURI="http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureShareBasedCompensationDetails" roleURI="http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureShareBasedCompensationUnvestedDetails" roleURI="http://www.acurxpharma.com/role/DisclosureShareBasedCompensationUnvestedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureShareBasedCompensationOptionPricingDetails" roleURI="http://www.acurxpharma.com/role/DisclosureShareBasedCompensationOptionPricingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureShareBasedCompensationOptionActivityDetails" roleURI="http://www.acurxpharma.com/role/DisclosureShareBasedCompensationOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureShareBasedPaymentsToVendorsDetails" roleURI="http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureIncomeTaxesDetails" roleURI="http://www.acurxpharma.com/role/DisclosureIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureIncomeTaxesDeferredTaxAssetDetails" roleURI="http://www.acurxpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureIncomeTaxesTaxReconciliationDetails" roleURI="http://www.acurxpharma.com/role/DisclosureIncomeTaxesTaxReconciliationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureNetLossPerShareDetails" roleURI="http://www.acurxpharma.com/role/DisclosureNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="acxp-20221231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.acurxpharma.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638145119416922545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638145119416922545" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638145119416922545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentAnnualReport_638145119416922545" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638145119416926731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentTransitionReport_638145119416926731" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638145119416926731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638145119416926731" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638145119416926731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638145119416926731" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638145119416926731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638145119416926731" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638145119416926731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638145119416926731" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638145119416926731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638145119416926731" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638145119416926731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638145119416926731" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638145119416926731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638145119416926731" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638145119416926731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638145119416926731" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638145119416926731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638145119416926731" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638145119416926731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638145119416926731" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638145119416926731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638145119416926731" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638145119416926731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638145119416926731" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638145119416936731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638145119416936731" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638145119416936731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638145119416936731" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638145119416936731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_638145119416936731" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638145119416936731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_638145119416936731" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638145119416936731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638145119416936731" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638145119416936731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638145119416936731" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638145119416936731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFilerCategory_638145119416936731" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638145119416936731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntitySmallBusiness_638145119416936731" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638145119416936731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638145119416936731" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_638145119416936731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_638145119416936731" order="25" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638145119416946730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_638145119416946730" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638145119416946730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityShellCompany_638145119416946730" order="27" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638145119416946730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityPublicFloat_638145119416946730" order="28" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638145119416946730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638145119416946730" order="29" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638145119416956730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638145119416956730" order="30" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638145119416956730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638145119416956730" order="31" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638145119416956730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638145119416956730" order="32" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638145119416956730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638145119416956730" order="33" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638145119416956730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638145119416956730" order="34" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638145119416977427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorName_638145119416977427" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638145119416977427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorFirmId_638145119416977427" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638145119416977427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorLocation_638145119416977427" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638145119416977427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_638145119416977427" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638145119416986723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638145119416977427" xlink:to="us-gaap_StatementClassOfStockAxis_638145119416986723" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638145119416986723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638145119416986723" xlink:to="us-gaap_ClassOfStockDomain_638145119416986723" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_CommonUnitClassMemberSCapitalMember" xlink:label="acxp_CommonUnitClassMemberSCapitalMember_638145119416986723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638145119416986723" xlink:to="acxp_CommonUnitClassMemberSCapitalMember_638145119416986723" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_CommonUnitClassBMemberSCapitalMember" xlink:label="acxp_CommonUnitClassBMemberSCapitalMember_638145119416986723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638145119416986723" xlink:to="acxp_CommonUnitClassBMemberSCapitalMember_638145119416986723" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638145119416986723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638145119416977427" xlink:to="us-gaap_StatementLineItems_638145119416986723" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638145119416986723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638145119416986723" xlink:to="us-gaap_AssetsAbstract_638145119416986723" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638145119416986723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638145119416986723" xlink:to="us-gaap_AssetsCurrentAbstract_638145119416986723" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash_638145119416986723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638145119416986723" xlink:to="us-gaap_Cash_638145119416986723" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638145119416986723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638145119416986723" xlink:to="us-gaap_PrepaidExpenseCurrent_638145119416986723" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638145119416986723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638145119416986723" xlink:to="us-gaap_AssetsCurrent_638145119416986723" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638145119416996726" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638145119416986723" xlink:to="us-gaap_Assets_638145119416996726" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638145119416996726" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638145119416986723" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638145119416996726" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638145119416996726" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638145119416996726" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638145119416996726" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638145119416996726" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638145119416996726" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638145119416996726" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638145119416996726" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638145119416996726" xlink:to="us-gaap_LiabilitiesCurrent_638145119416996726" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638145119416996726" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638145119416996726" xlink:to="us-gaap_Liabilities_638145119416996726" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638145119416996726" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638145119416996726" xlink:to="us-gaap_CommitmentsAndContingencies_638145119416996726" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638145119416996726" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638145119416996726" xlink:to="us-gaap_StockholdersEquityAbstract_638145119416996726" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MembersCapital" xlink:label="us-gaap_MembersCapital_638145119416996726" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638145119416996726" xlink:to="us-gaap_MembersCapital_638145119416996726" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638145119416996726" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638145119416996726" xlink:to="us-gaap_CommonStockValue_638145119416996726" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638145119417006713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638145119416996726" xlink:to="us-gaap_AdditionalPaidInCapital_638145119417006713" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638145119417006713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638145119416996726" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638145119417006713" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638145119417006713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638145119416996726" xlink:to="us-gaap_StockholdersEquity_638145119417006713" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638145119417006713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638145119416996726" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638145119417006713" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/StatementBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638145119417006713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638145119417006713" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638145119417006713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638145119417006713" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638145119417006713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638145119417006713" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638145119417016714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638145119417016714" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/StatementStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638145119417016714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638145119417016714" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638145119417016714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638145119417016714" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638145119417016714" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638145119417016714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638145119417016714" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638145119417016714" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638145119417016714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638145119417016714" xlink:to="us-gaap_OperatingExpenses_638145119417016714" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638145119417016714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638145119417016714" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638145119417016714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_638145119417016714" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_638145119417016714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_638145119417016714" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638145119417016714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638145119417016714" xlink:to="us-gaap_EarningsPerShareBasic_638145119417016714" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638145119417016714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638145119417016714" xlink:to="us-gaap_EarningsPerShareDiluted_638145119417016714" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638145119417016714" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638145119417016714" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638145119417016714" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638145119417026770" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638145119417016714" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638145119417026770" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - STATEMENTS OF CHANGES IN MEMBERS' AND SHAREHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638145119417026770" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638145119417026770" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638145119417026770" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638145119417026770" xlink:to="us-gaap_StatementEquityComponentsAxis_638145119417026770" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MemberUnitsMember" xlink:label="us-gaap_MemberUnitsMember_638145119417026770" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638145119417026770" xlink:to="us-gaap_MemberUnitsMember_638145119417026770" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638145119417026770" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638145119417026770" xlink:to="us-gaap_CommonStockMember_638145119417026770" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638145119417026770" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638145119417026770" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638145119417026770" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638145119417026770" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638145119417026770" xlink:to="us-gaap_RetainedEarningsMember_638145119417026770" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638145119417026770" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638145119417026770" xlink:to="us-gaap_EquityComponentDomain_638145119417026770" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638145119417036742" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638145119417026770" xlink:to="us-gaap_StatementClassOfStockAxis_638145119417036742" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_CommonUnitClassMemberSCapitalMember" xlink:label="acxp_CommonUnitClassMemberSCapitalMember_638145119417036742" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638145119417036742" xlink:to="acxp_CommonUnitClassMemberSCapitalMember_638145119417036742" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_CommonUnitClassBMemberSCapitalMember" xlink:label="acxp_CommonUnitClassBMemberSCapitalMember_638145119417036742" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638145119417036742" xlink:to="acxp_CommonUnitClassBMemberSCapitalMember_638145119417036742" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638145119417036742" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638145119417036742" xlink:to="us-gaap_ClassOfStockDomain_638145119417036742" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638145119417036742" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638145119417026770" xlink:to="us-gaap_StatementLineItems_638145119417036742" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638145119417036742" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638145119417036742" xlink:to="us-gaap_StockholdersEquity_638145119417036742" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonUnitOutstanding" xlink:label="us-gaap_CommonUnitOutstanding_638145119417036742" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638145119417036742" xlink:to="us-gaap_CommonUnitOutstanding_638145119417036742" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638145119417036742" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638145119417036742" xlink:to="us-gaap_CommonStockSharesOutstanding_638145119417036742" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_StockUnitsIssuedDuringPeriodValueExecutiveCompensationSettled" xlink:label="acxp_StockUnitsIssuedDuringPeriodValueExecutiveCompensationSettled_638145119417036742" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638145119417036742" xlink:to="acxp_StockUnitsIssuedDuringPeriodValueExecutiveCompensationSettled_638145119417036742" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_StockUnitsIssuedDuringPeriodSharesExecutiveCompensationSettled" xlink:label="acxp_StockUnitsIssuedDuringPeriodSharesExecutiveCompensationSettled_638145119417046726" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acxp_StockUnitsIssuedDuringPeriodValueExecutiveCompensationSettled_638145119417036742" xlink:to="acxp_StockUnitsIssuedDuringPeriodSharesExecutiveCompensationSettled_638145119417046726" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_CancellationOfStockUnitsValue" xlink:label="acxp_CancellationOfStockUnitsValue_638145119417046726" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638145119417036742" xlink:to="acxp_CancellationOfStockUnitsValue_638145119417046726" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_CancellationOfStockUnitsShares" xlink:label="acxp_CancellationOfStockUnitsShares_638145119417046726" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acxp_CancellationOfStockUnitsValue_638145119417046726" xlink:to="acxp_CancellationOfStockUnitsShares_638145119417046726" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_638145119417046726" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638145119417036742" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_638145119417046726" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_638145119417046726" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_638145119417046726" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_638145119417046726" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_638145119417046726" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638145119417036742" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_638145119417046726" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_638145119417046726" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_638145119417046726" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_638145119417046726" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_StockIssuedDuringPeriodValueCorporateConversionOfUnits" xlink:label="acxp_StockIssuedDuringPeriodValueCorporateConversionOfUnits_638145119417046726" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638145119417036742" xlink:to="acxp_StockIssuedDuringPeriodValueCorporateConversionOfUnits_638145119417046726" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_StockIssuedDuringPeriodSharesCorporateConversionOfUnits" xlink:label="acxp_StockIssuedDuringPeriodSharesCorporateConversionOfUnits_638145119417056717" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acxp_StockIssuedDuringPeriodValueCorporateConversionOfUnits_638145119417046726" xlink:to="acxp_StockIssuedDuringPeriodSharesCorporateConversionOfUnits_638145119417056717" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_StockholdersEquityPeriodIncreaseDecreaseThroughCashlessWarrantExercise" xlink:label="acxp_StockholdersEquityPeriodIncreaseDecreaseThroughCashlessWarrantExercise_638145119417056717" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638145119417036742" xlink:to="acxp_StockholdersEquityPeriodIncreaseDecreaseThroughCashlessWarrantExercise_638145119417056717" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_StockIssuedDuringPeriodSharesPeriodIncreaseDecreaseThroughCashlessWarrantExercise" xlink:label="acxp_StockIssuedDuringPeriodSharesPeriodIncreaseDecreaseThroughCashlessWarrantExercise_638145119417056717" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acxp_StockholdersEquityPeriodIncreaseDecreaseThroughCashlessWarrantExercise_638145119417056717" xlink:to="acxp_StockIssuedDuringPeriodSharesPeriodIncreaseDecreaseThroughCashlessWarrantExercise_638145119417056717" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_WarrantExercisePreFunded" xlink:label="acxp_WarrantExercisePreFunded_638145119417056717" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638145119417036742" xlink:to="acxp_WarrantExercisePreFunded_638145119417056717" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_WarrantExercisePreFundedShares" xlink:label="acxp_WarrantExercisePreFundedShares_638145119417056717" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acxp_WarrantExercisePreFunded_638145119417056717" xlink:to="acxp_WarrantExercisePreFundedShares_638145119417056717" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638145119417056717" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638145119417036742" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638145119417056717" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638145119417056717" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_638145119417056717" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638145119417056717" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638145119417056717" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638145119417036742" xlink:to="us-gaap_NetIncomeLoss_638145119417056717" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638145119417066711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638145119417036742" xlink:to="us-gaap_StockholdersEquity_638145119417066711" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonUnitOutstanding" xlink:label="us-gaap_CommonUnitOutstanding_638145119417066711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638145119417036742" xlink:to="us-gaap_CommonUnitOutstanding_638145119417066711" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638145119417066711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638145119417036742" xlink:to="us-gaap_CommonStockSharesOutstanding_638145119417066711" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquityParenthetical" xlink:type="extended" xlink:title="00305 - Statement - STATEMENTS OF CHANGES IN MEMBERS' AND SHAREHOLDERS' EQUITY (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638145119417066711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract_1" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638145119417066711" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638145119417076743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638145119417076743" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638145119417076743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638145119417076743" xlink:to="us-gaap_ProfitLoss_638145119417076743" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638145119417076743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638145119417076743" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638145119417076743" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638145119417076743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638145119417076743" xlink:to="us-gaap_ShareBasedCompensation_638145119417076743" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentToVendors" xlink:label="acxp_ShareBasedPaymentToVendors_638145119417076743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638145119417076743" xlink:to="acxp_ShareBasedPaymentToVendors_638145119417076743" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_638145119417076743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638145119417076743" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_638145119417076743" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638145119417076743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638145119417076743" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638145119417076743" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638145119417076743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638145119417076743" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638145119417076743" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_638145119417076743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638145119417076743" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_638145119417076743" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638145119417076743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638145119417076743" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638145119417076743" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638145119417176746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638145119417076743" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638145119417176746" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638145119417176746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638145119417176746" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_638145119417176746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638145119417176746" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_638145119417176746" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638145119417186741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638145119417176746" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638145119417186741" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638145119417186741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638145119417176746" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638145119417186741" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_638145119417186741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638145119417176746" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_638145119417186741" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638145119417186741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638145119417176746" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638145119417186741" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638145119417186741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638145119417186741" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638145119417186741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638145119417186741" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381451194171867411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381451194171867411" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638145119417186741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638145119417186741" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_NonCashFinancingActivitiesOfWarrantsIssuedInConnectionWithOfferings" xlink:label="acxp_NonCashFinancingActivitiesOfWarrantsIssuedInConnectionWithOfferings_638145119417186741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638145119417186741" xlink:to="acxp_NonCashFinancingActivitiesOfWarrantsIssuedInConnectionWithOfferings_638145119417186741" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosureNatureOfOperations" xlink:type="extended" xlink:title="10101 - Disclosure - NATURE OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_638145119417196707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations_638145119417196707" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638145119417196707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638145119417196707" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosureAccountsPayableAndAccruedExpenses" xlink:type="extended" xlink:title="10301 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638145119417196707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638145119417196707" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosurePaycheckProtectionProgramLoan" xlink:type="extended" xlink:title="10401 - Disclosure - PAYCHECK PROTECTION PROGRAM LOAN" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_PaycheckProtectionProgramLoanAbstract" xlink:label="PaycheckProtectionProgramLoanAbstract" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_PaycheckProtectionProgramLoanDisclosureTextBlock" xlink:label="acxp_PaycheckProtectionProgramLoanDisclosureTextBlock_638145119417196707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaycheckProtectionProgramLoanAbstract" xlink:to="acxp_PaycheckProtectionProgramLoanDisclosureTextBlock_638145119417196707" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosureExecutiveCompensation" xlink:type="extended" xlink:title="10501 - Disclosure - EXECUTIVE COMPENSATION" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:label="us-gaap_CompensationRelatedCostsGeneralTextBlock_638145119417206704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract" xlink:to="us-gaap_CompensationRelatedCostsGeneralTextBlock_638145119417206704" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterests" xlink:type="extended" xlink:title="10601 - Disclosure - ISSUANCE OF EQUITY INTERESTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638145119417206704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638145119417206704" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosureShareBasedCompensation" xlink:type="extended" xlink:title="10701 - Disclosure - SHARE-BASED COMPENSATION" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638145119417206704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638145119417206704" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendors" xlink:type="extended" xlink:title="10801 - Disclosure - SHARE-BASED PAYMENTS TO VENDORS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentsToVendorsAbstract" xlink:label="ShareBasedPaymentsToVendorsAbstract" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentsToVendorsDisclosureTextBlock" xlink:label="acxp_ShareBasedPaymentsToVendorsDisclosureTextBlock_638145119417206704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsToVendorsAbstract" xlink:to="acxp_ShareBasedPaymentsToVendorsDisclosureTextBlock_638145119417206704" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="10901 - Disclosure - INCOME TAXES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638145119417206704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638145119417206704" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="11001 - Disclosure - NET LOSS PER SHARE" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638145119417216703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638145119417216703" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="11101 - Disclosure - COMMITMENTS AND CONTINGENCIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638145119417216703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638145119417216703" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638145119417216703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638145119417216703" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638145119417216703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638145119417216703" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638145119417216703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638145119417216703" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:label="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_638145119417216703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_638145119417216703" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638145119417216703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638145119417216703" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638145119417216703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638145119417216703" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentsToVendorsPolicyTextBlock" xlink:label="acxp_ShareBasedPaymentsToVendorsPolicyTextBlock_638145119417226708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="acxp_ShareBasedPaymentsToVendorsPolicyTextBlock_638145119417226708" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638145119417226708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638145119417226708" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosureAccountsPayableAndAccruedExpensesTables" xlink:type="extended" xlink:title="30303 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638145119417226708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638145119417226708" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsTables" xlink:type="extended" xlink:title="30603 - Disclosure - ISSUANCE OF EQUITY INTERESTS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638145119417226708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_3" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638145119417226708" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosureShareBasedCompensationTables" xlink:type="extended" xlink:title="30703 - Disclosure - SHARE-BASED COMPENSATION (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_638145119417226708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_638145119417226708" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638145119417226708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638145119417226708" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638145119417236707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638145119417236707" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="30903 - Disclosure - INCOME TAXES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638145119417236707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638145119417236707" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638145119417236707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638145119417236707" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails" xlink:type="extended" xlink:title="40101 - Disclosure - NATURE OF OPERATIONS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638145119417236707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1" xlink:to="us-gaap_StatementTable_638145119417236707" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638145119417236707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638145119417236707" xlink:to="srt_ProductOrServiceAxis_638145119417236707" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638145119417236707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638145119417236707" xlink:to="srt_ProductsAndServicesDomain_638145119417236707" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_AcxThreeSixtyTwoEMember" xlink:label="acxp_AcxThreeSixtyTwoEMember_638145119417236707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638145119417236707" xlink:to="acxp_AcxThreeSixtyTwoEMember_638145119417236707" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638145119417236707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638145119417236707" xlink:to="us-gaap_StatementClassOfStockAxis_638145119417236707" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638145119417236707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638145119417236707" xlink:to="us-gaap_ClassOfStockDomain_638145119417236707" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_CommonUnitClassBMemberSCapitalMember" xlink:label="acxp_CommonUnitClassBMemberSCapitalMember_638145119417236707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638145119417236707" xlink:to="acxp_CommonUnitClassBMemberSCapitalMember_638145119417236707" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638145119417246838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638145119417236707" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638145119417246838" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638145119417246838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638145119417246838" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638145119417246838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_RegisteredDirectOfferingMember" xlink:label="acxp_RegisteredDirectOfferingMember_638145119417246838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638145119417246838" xlink:to="acxp_RegisteredDirectOfferingMember_638145119417246838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_638145119417246838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638145119417246838" xlink:to="us-gaap_PrivatePlacementMember_638145119417246838" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638145119417246838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638145119417236707" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638145119417246838" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638145119417246838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638145119417246838" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638145119417246838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_SeriesWarrantsMember" xlink:label="acxp_SeriesWarrantsMember_638145119417246838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638145119417246838" xlink:to="acxp_SeriesWarrantsMember_638145119417246838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_SeriesBWarrantsMember" xlink:label="acxp_SeriesBWarrantsMember_638145119417246838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638145119417246838" xlink:to="acxp_SeriesBWarrantsMember_638145119417246838" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638145119417246838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638145119417236707" xlink:to="us-gaap_StatementLineItems_638145119417246838" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForOperatingActivities" xlink:label="us-gaap_PaymentsForOperatingActivities_638145119417246838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638145119417246838" xlink:to="us-gaap_PaymentsForOperatingActivities_638145119417246838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_638145119417246838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638145119417246838" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_638145119417246838" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638145119417246838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638145119417246838" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638145119417246838" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment_638145119417246838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638145119417246838" xlink:to="us-gaap_OtherCommitment_638145119417246838" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense_638145119417246838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638145119417246838" xlink:to="us-gaap_RoyaltyExpense_638145119417246838" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_PercentageOfRoyaltyPaymentsOnNetSales" xlink:label="acxp_PercentageOfRoyaltyPaymentsOnNetSales_638145119417246838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638145119417246838" xlink:to="acxp_PercentageOfRoyaltyPaymentsOnNetSales_638145119417246838" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638145119417246838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638145119417246838" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638145119417246838" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts" xlink:label="acxp_StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts_638145119417246838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638145119417246838" xlink:to="acxp_StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts_638145119417246838" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638145119417246838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638145119417246838" xlink:to="us-gaap_SharesIssuedPricePerShare_638145119417246838" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_WarrantExercisePreFundedShares" xlink:label="acxp_WarrantExercisePreFundedShares_638145119417246838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638145119417246838" xlink:to="acxp_WarrantExercisePreFundedShares_638145119417246838" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash_638145119417246838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638145119417246838" xlink:to="us-gaap_Cash_638145119417246838" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638145119417246838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638145119417246838" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638145119417246838" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638145119417246838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638145119417246838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_638145119417246838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_638145119417246838" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638145119417271963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638145119417271963" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash_638145119417271963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_Cash_638145119417271963" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638145119417271963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638145119417271963" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationDetails" xlink:type="extended" xlink:title="40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable_638145119417276729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ConcentrationRiskTable_638145119417276729" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_638145119417276729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638145119417276729" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_638145119417276729" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_638145119417276729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_638145119417276729" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_638145119417276729" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsTotalMember" xlink:label="us-gaap_CostOfGoodsTotalMember_638145119417276729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_638145119417276729" xlink:to="us-gaap_CostOfGoodsTotalMember_638145119417276729" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesTotalMember" xlink:label="us-gaap_LiabilitiesTotalMember_638145119417276729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_638145119417276729" xlink:to="us-gaap_LiabilitiesTotalMember_638145119417276729" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_638145119417276729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638145119417276729" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_638145119417276729" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_638145119417276729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_638145119417276729" xlink:to="us-gaap_ConcentrationRiskTypeDomain_638145119417276729" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember_638145119417276729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_638145119417276729" xlink:to="us-gaap_SupplierConcentrationRiskMember_638145119417276729" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_638145119417276729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638145119417276729" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_638145119417276729" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_638145119417276729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_638145119417276729" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_638145119417276729" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_VendorOneMember" xlink:label="acxp_VendorOneMember_638145119417276729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_638145119417276729" xlink:to="acxp_VendorOneMember_638145119417276729" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_VendorTwoMember" xlink:label="acxp_VendorTwoMember_638145119417276729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_638145119417276729" xlink:to="acxp_VendorTwoMember_638145119417276729" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems_638145119417286757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638145119417276729" xlink:to="us-gaap_ConcentrationRiskLineItems_638145119417286757" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1_638145119417286757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_638145119417286757" xlink:to="us-gaap_ConcentrationRiskPercentage1_638145119417286757" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638145119417286757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638145119417286757" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_AccruedResearchAndDevelopmentCurrent" xlink:label="acxp_AccruedResearchAndDevelopmentCurrent_638145119417286757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="acxp_AccruedResearchAndDevelopmentCurrent_638145119417286757" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638145119417286757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638145119417286757" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_638145119417286757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_638145119417286757" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638145119417286757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638145119417286757" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosurePaycheckProtectionProgramLoanDetails" xlink:type="extended" xlink:title="40401 - Disclosure - PAYCHECK PROTECTION PROGRAM LOAN (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_PaycheckProtectionProgramLoanAbstract" xlink:label="acxp_PaycheckProtectionProgramLoanAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_638145119417286757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acxp_PaycheckProtectionProgramLoanAbstract_1" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_638145119417286757" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_638145119417286757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable_638145119417286757" xlink:to="us-gaap_ShortTermDebtTypeAxis_638145119417286757" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_638145119417296768" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis_638145119417286757" xlink:to="us-gaap_ShortTermDebtTypeDomain_638145119417296768" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_PaycheckProtectionProgramLoanMember" xlink:label="acxp_PaycheckProtectionProgramLoanMember_638145119417296768" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain_638145119417296768" xlink:to="acxp_PaycheckProtectionProgramLoanMember_638145119417296768" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems_638145119417296768" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable_638145119417286757" xlink:to="us-gaap_ShortTermDebtLineItems_638145119417296768" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_638145119417296768" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_638145119417296768" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_638145119417296768" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_638145119417296768" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_638145119417296768" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_638145119417296768" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTerm" xlink:label="us-gaap_LongTermDebtTerm_638145119417296768" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_638145119417296768" xlink:to="us-gaap_LongTermDebtTerm_638145119417296768" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638145119417296768" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_638145119417296768" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638145119417296768" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosureExecutiveCompensationDetails" xlink:type="extended" xlink:title="40501 - Disclosure - EXECUTIVE COMPENSATION (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638145119417296768" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract_1" xlink:to="us-gaap_StatementTable_638145119417296768" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638145119417296768" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638145119417296768" xlink:to="us-gaap_StatementClassOfStockAxis_638145119417296768" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638145119417296768" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638145119417296768" xlink:to="us-gaap_ClassOfStockDomain_638145119417296768" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_CommonUnitClassMemberSCapitalMember" xlink:label="acxp_CommonUnitClassMemberSCapitalMember_638145119417296768" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638145119417296768" xlink:to="acxp_CommonUnitClassMemberSCapitalMember_638145119417296768" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_CommonUnitClassBMemberSCapitalMember" xlink:label="acxp_CommonUnitClassBMemberSCapitalMember_638145119417296768" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638145119417296768" xlink:to="acxp_CommonUnitClassBMemberSCapitalMember_638145119417296768" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638145119417306762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638145119417296768" xlink:to="srt_TitleOfIndividualAxis_638145119417306762" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638145119417306762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638145119417306762" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638145119417306762" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember_638145119417306762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638145119417306762" xlink:to="srt_DirectorMember_638145119417306762" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_NonEmployeeMember" xlink:label="acxp_NonEmployeeMember_638145119417306762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638145119417306762" xlink:to="acxp_NonEmployeeMember_638145119417306762" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638145119417306762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638145119417296768" xlink:to="us-gaap_StatementLineItems_638145119417306762" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_638145119417306762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638145119417306762" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_638145119417306762" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638145119417306762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638145119417306762" xlink:to="us-gaap_SharesIssuedPricePerShare_638145119417306762" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_StockIssuedDuringPeriodSharesBonus" xlink:label="acxp_StockIssuedDuringPeriodSharesBonus_638145119417306762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638145119417306762" xlink:to="acxp_StockIssuedDuringPeriodSharesBonus_638145119417306762" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638145119417306762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638145119417306762" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638145119417306762" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - ISSUANCE OF EQUITY INTERESTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_638145119417316731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_638145119417316731" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638145119417316731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638145119417316731" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638145119417316731" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638145119417316731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638145119417316731" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638145119417316731" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_UnderwriterMember" xlink:label="acxp_UnderwriterMember_638145119417316731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638145119417316731" xlink:to="acxp_UnderwriterMember_638145119417316731" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_RegisteredDirectOfferingMember" xlink:label="acxp_RegisteredDirectOfferingMember_638145119417316731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638145119417316731" xlink:to="acxp_RegisteredDirectOfferingMember_638145119417316731" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_PlacementAgentsMember" xlink:label="acxp_PlacementAgentsMember_638145119417316731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638145119417316731" xlink:to="acxp_PlacementAgentsMember_638145119417316731" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638145119417316731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638145119417316731" xlink:to="srt_TitleOfIndividualAxis_638145119417316731" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638145119417316731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638145119417316731" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638145119417316731" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_AffiliateInvestorsMember" xlink:label="acxp_AffiliateInvestorsMember_638145119417316731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638145119417316731" xlink:to="acxp_AffiliateInvestorsMember_638145119417316731" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember_638145119417316731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638145119417316731" xlink:to="us-gaap_InvestorMember_638145119417316731" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638145119417316731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638145119417316731" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638145119417316731" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638145119417316731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638145119417316731" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638145119417316731" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_SeriesWarrantsMember" xlink:label="acxp_SeriesWarrantsMember_638145119417316731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638145119417316731" xlink:to="acxp_SeriesWarrantsMember_638145119417316731" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_SeriesBWarrantsMember" xlink:label="acxp_SeriesBWarrantsMember_638145119417316731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638145119417316731" xlink:to="acxp_SeriesBWarrantsMember_638145119417316731" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638145119417326728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638145119417316731" xlink:to="us-gaap_StatementClassOfStockAxis_638145119417326728" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638145119417326728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638145119417326728" xlink:to="us-gaap_ClassOfStockDomain_638145119417326728" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_CommonUnitClassAndClassBMemberSCapitalMember" xlink:label="acxp_CommonUnitClassAndClassBMemberSCapitalMember_638145119417326728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638145119417326728" xlink:to="acxp_CommonUnitClassAndClassBMemberSCapitalMember_638145119417326728" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638145119417326728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638145119417316731" xlink:to="srt_RangeAxis_638145119417326728" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638145119417326728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638145119417326728" xlink:to="srt_RangeMember_638145119417326728" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638145119417326728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638145119417326728" xlink:to="srt_MaximumMember_638145119417326728" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_638145119417326728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638145119417316731" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_638145119417326728" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638145119417326728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638145119417326728" xlink:to="us-gaap_CommonStockSharesAuthorized_638145119417326728" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638145119417326728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638145119417326728" xlink:to="us-gaap_CommonStockSharesOutstanding_638145119417326728" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638145119417326728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638145119417326728" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638145119417326728" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638145119417336726" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638145119417326728" xlink:to="us-gaap_SharesIssuedPricePerShare_638145119417336726" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638145119417336726" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638145119417326728" xlink:to="us-gaap_SharePrice_638145119417336726" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638145119417336726" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638145119417326728" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638145119417336726" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638145119417336726" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638145119417326728" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638145119417336726" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1_638145119417336726" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638145119417326728" xlink:to="us-gaap_ConversionOfStockSharesConverted1_638145119417336726" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_638145119417336726" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638145119417326728" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_638145119417336726" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638145119417336726" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638145119417326728" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638145119417336726" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638145119417336726" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638145119417326728" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638145119417336726" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ClassOfWarrantOrRightExercisableTerm" xlink:label="acxp_ClassOfWarrantOrRightExercisableTerm_638145119417346728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638145119417326728" xlink:to="acxp_ClassOfWarrantOrRightExercisableTerm_638145119417346728" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638145119417346728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638145119417326728" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638145119417346728" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_WarrantExercisePreFundedShares" xlink:label="acxp_WarrantExercisePreFundedShares_638145119417346728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638145119417326728" xlink:to="acxp_WarrantExercisePreFundedShares_638145119417346728" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ClassOfWarrantOrRightPurchasePrice" xlink:label="acxp_ClassOfWarrantOrRightPurchasePrice_638145119417346728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638145119417326728" xlink:to="acxp_ClassOfWarrantOrRightPurchasePrice_638145119417346728" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts" xlink:label="acxp_StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts_638145119417346728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638145119417326728" xlink:to="acxp_StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts_638145119417346728" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638145119417346728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638145119417326728" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638145119417346728" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_PercentageOfWeightedAveragePublicOfferingPriceOfAggregateNumberOfSharesOfCommonStockSold" xlink:label="acxp_PercentageOfWeightedAveragePublicOfferingPriceOfAggregateNumberOfSharesOfCommonStockSold_638145119417346728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638145119417326728" xlink:to="acxp_PercentageOfWeightedAveragePublicOfferingPriceOfAggregateNumberOfSharesOfCommonStockSold_638145119417346728" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsFairValueDetails" xlink:type="extended" xlink:title="40602 - Disclosure - ISSUANCE OF EQUITY INTERESTS - Fair Value (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638145119417356743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_1" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638145119417356743" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638145119417356743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638145119417356743" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638145119417356743" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638145119417356743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638145119417356743" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638145119417356743" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_UnderwriterMember" xlink:label="acxp_UnderwriterMember_638145119417356743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638145119417356743" xlink:to="acxp_UnderwriterMember_638145119417356743" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_PlacementAgentsMember" xlink:label="acxp_PlacementAgentsMember_638145119417356743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638145119417356743" xlink:to="acxp_PlacementAgentsMember_638145119417356743" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638145119417356743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638145119417356743" xlink:to="us-gaap_MeasurementInputTypeAxis_638145119417356743" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638145119417356743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638145119417356743" xlink:to="us-gaap_MeasurementInputTypeDomain_638145119417356743" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_638145119417356743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638145119417356743" xlink:to="us-gaap_MeasurementInputExpectedTermMember_638145119417356743" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_638145119417356743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638145119417356743" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_638145119417356743" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_638145119417356743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638145119417356743" xlink:to="us-gaap_MeasurementInputSharePriceMember_638145119417356743" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_638145119417366719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638145119417356743" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_638145119417366719" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638145119417366719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638145119417356743" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638145119417366719" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_638145119417366719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638145119417366719" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_638145119417366719" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_638145119417366719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638145119417366719" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_638145119417366719" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsWarrantsDetails" xlink:type="extended" xlink:title="40603 - Disclosure - ISSUANCE OF EQUITY INTERESTS - Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_638145119417366719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_2" xlink:to="us-gaap_ClassOfWarrantOrRightTable_638145119417366719" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638145119417366719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638145119417366719" xlink:to="srt_RangeAxis_638145119417366719" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638145119417366719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638145119417366719" xlink:to="srt_RangeMember_638145119417366719" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember_638145119417366719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638145119417366719" xlink:to="srt_WeightedAverageMember_638145119417366719" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_638145119417366719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638145119417366719" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_638145119417366719" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638145119417366719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638145119417366719" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638145119417366719" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ClassOfWarrantOrRightIssued" xlink:label="acxp_ClassOfWarrantOrRightIssued_638145119417366719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638145119417366719" xlink:to="acxp_ClassOfWarrantOrRightIssued_638145119417366719" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ClassOfWarrantOrRightExercised" xlink:label="acxp_ClassOfWarrantOrRightExercised_638145119417376754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638145119417366719" xlink:to="acxp_ClassOfWarrantOrRightExercised_638145119417376754" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638145119417376754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638145119417366719" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638145119417376754" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638145119417376754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638145119417366719" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638145119417376754" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued" xlink:label="acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued_638145119417376754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638145119417366719" xlink:to="acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued_638145119417376754" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" xlink:label="acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised_638145119417376754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638145119417366719" xlink:to="acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised_638145119417376754" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ClassOfWarrantOrRightExercisableTerm" xlink:label="acxp_ClassOfWarrantOrRightExercisableTerm_638145119417376754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638145119417366719" xlink:to="acxp_ClassOfWarrantOrRightExercisableTerm_638145119417376754" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails" xlink:type="extended" xlink:title="40701 - Disclosure - SHARE-BASED COMPENSATION - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638145119417376754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638145119417376754" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638145119417386729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638145119417376754" xlink:to="us-gaap_AwardTypeAxis_638145119417386729" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638145119417386729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638145119417386729" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638145119417386729" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_EquityIncentivePlan2021Member" xlink:label="acxp_EquityIncentivePlan2021Member_638145119417386729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638145119417386729" xlink:to="acxp_EquityIncentivePlan2021Member_638145119417386729" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis_638145119417386729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638145119417376754" xlink:to="us-gaap_AwardDateAxis_638145119417386729" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_638145119417386729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis_638145119417386729" xlink:to="us-gaap_AwardDateDomain_638145119417386729" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember" xlink:label="acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember_638145119417386729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_638145119417386729" xlink:to="acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember_638145119417386729" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDateJune2021Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateJune2021Member_638145119417386729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_638145119417386729" xlink:to="acxp_ShareBasedPaymentArrangementGrantDateJune2021Member_638145119417386729" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_638145119417386729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_638145119417386729" xlink:to="acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_638145119417386729" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member_638145119417386729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_638145119417386729" xlink:to="acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member_638145119417386729" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDateApril2022Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateApril2022Member_638145119417386729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_638145119417386729" xlink:to="acxp_ShareBasedPaymentArrangementGrantDateApril2022Member_638145119417386729" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_638145119417386729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638145119417376754" xlink:to="us-gaap_GranteeStatusAxis_638145119417386729" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_638145119417386729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_638145119417386729" xlink:to="us-gaap_GranteeStatusDomain_638145119417386729" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_638145119417386729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_638145119417386729" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_638145119417386729" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638145119417396752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638145119417376754" xlink:to="srt_TitleOfIndividualAxis_638145119417396752" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638145119417396752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638145119417396752" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638145119417396752" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ExecutivesIndependentDirectorsConsultantMember" xlink:label="acxp_ExecutivesIndependentDirectorsConsultantMember_638145119417396752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638145119417396752" xlink:to="acxp_ExecutivesIndependentDirectorsConsultantMember_638145119417396752" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember_638145119417396752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acxp_ExecutivesIndependentDirectorsConsultantMember_638145119417396752" xlink:to="srt_ExecutiveOfficerMember_638145119417396752" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_IndependentDirectorsConsultantMember" xlink:label="acxp_IndependentDirectorsConsultantMember_638145119417396752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acxp_ExecutivesIndependentDirectorsConsultantMember_638145119417396752" xlink:to="acxp_IndependentDirectorsConsultantMember_638145119417396752" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638145119417396752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638145119417376754" xlink:to="us-gaap_VestingAxis_638145119417396752" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638145119417396752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638145119417396752" xlink:to="us-gaap_VestingDomain_638145119417396752" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638145119417396752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638145119417396752" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638145119417396752" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638145119417396752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638145119417396752" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638145119417396752" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638145119417396752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638145119417376754" xlink:to="srt_RangeAxis_638145119417396752" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638145119417406734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638145119417396752" xlink:to="srt_RangeMember_638145119417406734" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638145119417406734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638145119417406734" xlink:to="srt_MinimumMember_638145119417406734" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638145119417406734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638145119417406734" xlink:to="srt_MaximumMember_638145119417406734" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638145119417406734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638145119417376754" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638145119417406734" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638145119417406734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638145119417406734" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638145119417406734" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638145119417406734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638145119417406734" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638145119417406734" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638145119417406734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638145119417406734" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638145119417406734" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638145119417406734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638145119417406734" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638145119417406734" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638145119417416730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638145119417406734" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638145119417416730" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638145119417416730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638145119417406734" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638145119417416730" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638145119417416730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638145119417406734" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638145119417416730" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638145119417416730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638145119417406734" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638145119417416730" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638145119417416730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638145119417406734" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638145119417416730" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638145119417416730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638145119417406734" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638145119417416730" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638145119417416730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638145119417406734" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638145119417416730" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638145119417426754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638145119417406734" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638145119417426754" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638145119417426754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638145119417406734" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638145119417426754" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_638145119417426754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638145119417406734" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_638145119417426754" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638145119417426754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638145119417406734" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638145119417426754" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosureShareBasedCompensationUnvestedDetails" xlink:type="extended" xlink:title="40702 - Disclosure - SHARE-BASED COMPENSATION - Unvested (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638145119417426754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638145119417426754" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638145119417426754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638145119417426754" xlink:to="us-gaap_StatementClassOfStockAxis_638145119417426754" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638145119417436731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638145119417426754" xlink:to="us-gaap_ClassOfStockDomain_638145119417436731" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_CommonUnitClassMemberSCapitalMember" xlink:label="acxp_CommonUnitClassMemberSCapitalMember_638145119417436731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638145119417436731" xlink:to="acxp_CommonUnitClassMemberSCapitalMember_638145119417436731" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638145119417436731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638145119417426754" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638145119417436731" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638145119417436731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638145119417436731" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638145119417436731" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638145119417436731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638145119417436731" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638145119417436731" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6381451194174367311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638145119417436731" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6381451194174367311" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosureShareBasedCompensationOptionPricingDetails" xlink:type="extended" xlink:title="40703 - Disclosure - SHARE-BASED COMPENSATION - Option pricing (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638145119417436731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638145119417436731" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638145119417436731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638145119417436731" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638145119417436731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638145119417436731" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638145119417436731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638145119417436731" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosureShareBasedCompensationOptionActivityDetails" xlink:type="extended" xlink:title="40704 - Disclosure - SHARE-BASED COMPENSATION - Option activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638145119417446730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638145119417446730" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638145119417446730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638145119417446730" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638145119417446730" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638145119417446730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638145119417446730" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638145119417446730" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6381451194174467301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638145119417446730" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6381451194174467301" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638145119417446730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638145119417446730" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638145119417446730" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638145119417446730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638145119417446730" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638145119417446730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638145119417446730" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638145119417446730" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638145119417446730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638145119417446730" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638145119417446730" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638145119417446730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638145119417446730" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638145119417446730" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6381451194174467301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638145119417446730" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6381451194174467301" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638145119417446730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638145119417446730" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638145119417446730" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - SHARE-BASED PAYMENTS TO VENDORS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentsToVendorsAbstract" xlink:label="ShareBasedPaymentsToVendorsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638145119417456752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsToVendorsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638145119417456752" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis_638145119417456752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638145119417456752" xlink:to="us-gaap_AwardDateAxis_638145119417456752" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_638145119417456752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis_638145119417456752" xlink:to="us-gaap_AwardDateDomain_638145119417456752" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember" xlink:label="acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember_638145119417456752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_638145119417456752" xlink:to="acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember_638145119417456752" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member_638145119417456752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_638145119417456752" xlink:to="acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member_638145119417456752" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member_638145119417456752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_638145119417456752" xlink:to="acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member_638145119417456752" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_638145119417456752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_638145119417456752" xlink:to="acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_638145119417456752" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantedInThirdQuarter2021Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantedInThirdQuarter2021Member_638145119417456752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_638145119417456752" xlink:to="acxp_ShareBasedPaymentArrangementGrantedInThirdQuarter2021Member_638145119417456752" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDateOctober2021Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateOctober2021Member_638145119417456752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_638145119417456752" xlink:to="acxp_ShareBasedPaymentArrangementGrantDateOctober2021Member_638145119417456752" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member_638145119417456752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_638145119417456752" xlink:to="acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member_638145119417456752" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDateMarch2022Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateMarch2022Member_638145119417466733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_638145119417456752" xlink:to="acxp_ShareBasedPaymentArrangementGrantDateMarch2022Member_638145119417466733" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantDateSeptember2022Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantDateSeptember2022Member_638145119417466733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_638145119417456752" xlink:to="acxp_ShareBasedPaymentArrangementGrantDateSeptember2022Member_638145119417466733" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member" xlink:label="acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member_638145119417466733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_638145119417456752" xlink:to="acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member_638145119417466733" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638145119417466733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638145119417456752" xlink:to="us-gaap_IncomeStatementLocationAxis_638145119417466733" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638145119417466733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638145119417466733" xlink:to="us-gaap_IncomeStatementLocationDomain_638145119417466733" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638145119417466733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638145119417466733" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638145119417466733" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638145119417466733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638145119417466733" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638145119417466733" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638145119417466733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638145119417456752" xlink:to="us-gaap_StatementClassOfStockAxis_638145119417466733" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638145119417466733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638145119417466733" xlink:to="us-gaap_ClassOfStockDomain_638145119417466733" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_CommonUnitClassMemberSCapitalMember" xlink:label="acxp_CommonUnitClassMemberSCapitalMember_638145119417466733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638145119417466733" xlink:to="acxp_CommonUnitClassMemberSCapitalMember_638145119417466733" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638145119417466733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638145119417456752" xlink:to="srt_RangeAxis_638145119417466733" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638145119417476734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638145119417466733" xlink:to="srt_RangeMember_638145119417476734" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638145119417476734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638145119417476734" xlink:to="srt_MinimumMember_638145119417476734" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638145119417476734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638145119417476734" xlink:to="srt_MaximumMember_638145119417476734" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638145119417476734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638145119417456752" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638145119417476734" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_638145119417476734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638145119417476734" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_638145119417476734" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_ShareBasedPaymentToVendors" xlink:label="acxp_ShareBasedPaymentToVendors_638145119417476734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638145119417476734" xlink:to="acxp_ShareBasedPaymentToVendors_638145119417476734" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638145119417476734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638145119417476734" xlink:to="us-gaap_SharePrice_638145119417476734" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638145119417476734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638145119417476734" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638145119417476734" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToSuppliers" xlink:label="us-gaap_PaymentsToSuppliers_638145119417476734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638145119417476734" xlink:to="us-gaap_PaymentsToSuppliers_638145119417476734" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638145119417486751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638145119417476734" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638145119417486751" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638145119417486751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638145119417476734" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638145119417486751" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment_638145119417486751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638145119417476734" xlink:to="us-gaap_OtherCommitment_638145119417486751" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="40901 - Disclosure - INCOME TAXES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638145119417486751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_OperatingLossCarryforwards_638145119417486751" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_638145119417486751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_TaxCreditCarryforwardAmount_638145119417486751" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetDetails" xlink:type="extended" xlink:title="40902 - Disclosure - INCOME TAXES - Deferred tax asset (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638145119417496739" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638145119417496739" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638145119417496739" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638145119417496739" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638145119417496739" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638145119417496739" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638145119417496739" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638145119417496739" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638145119417496739" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638145119417496739" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638145119417496739" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638145119417496739" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638145119417496739" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638145119417496739" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638145119417496739" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638145119417496739" xlink:to="us-gaap_DeferredTaxAssetsGross_638145119417496739" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638145119417496739" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638145119417496739" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638145119417496739" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638145119417496739" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638145119417496739" xlink:to="us-gaap_DeferredTaxAssetsNet_638145119417496739" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired_638145119417496739" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638145119417496739" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired_638145119417496739" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosureIncomeTaxesTaxReconciliationDetails" xlink:type="extended" xlink:title="40903 - Disclosure - INCOME TAXES - Tax reconciliation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638145119417496739" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638145119417496739" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638145119417506760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638145119417506760" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638145119417506760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638145119417506760" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_638145119417506760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_638145119417506760" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638145119417506760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638145119417506760" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638145119417506760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638145119417506760" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638145119417506760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_UnrecognizedTaxBenefits_638145119417506760" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosureNetLossPerShareDetails" xlink:type="extended" xlink:title="41001 - Disclosure - NET LOSS PER SHARE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638145119417506760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_2" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638145119417506760" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638145119417506760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638145119417506760" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638145119417506760" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638145119417506760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638145119417506760" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638145119417506760" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638145119417506760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638145119417506760" xlink:to="us-gaap_WarrantMember_638145119417506760" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638145119417506760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638145119417506760" xlink:to="us-gaap_EmployeeStockOptionMember_638145119417506760" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638145119417516729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638145119417506760" xlink:to="us-gaap_StatementClassOfStockAxis_638145119417516729" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638145119417516729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638145119417516729" xlink:to="us-gaap_ClassOfStockDomain_638145119417516729" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_CommonUnitClassAndClassBMemberSCapitalMember" xlink:label="acxp_CommonUnitClassAndClassBMemberSCapitalMember_638145119417516729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638145119417516729" xlink:to="acxp_CommonUnitClassAndClassBMemberSCapitalMember_638145119417516729" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638145119417516729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638145119417506760" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638145119417516729" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1_638145119417516729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638145119417516729" xlink:to="us-gaap_ConversionOfStockSharesConverted1_638145119417516729" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_638145119417516729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638145119417516729" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_638145119417516729" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638145119417516729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638145119417516729" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638145119417516729" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.acurxpharma.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="us-gaap_ProductLiabilityContingencyTable_638145119417516729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" xlink:to="us-gaap_ProductLiabilityContingencyTable_638145119417516729" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638145119417516729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductLiabilityContingencyTable_638145119417516729" xlink:to="srt_ProductOrServiceAxis_638145119417516729" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638145119417516729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638145119417516729" xlink:to="srt_ProductsAndServicesDomain_638145119417516729" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_AcxThreeSixtyTwoEMember" xlink:label="acxp_AcxThreeSixtyTwoEMember_638145119417516729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638145119417516729" xlink:to="acxp_AcxThreeSixtyTwoEMember_638145119417516729" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="us-gaap_ProductLiabilityContingencyLineItems_638145119417526730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductLiabilityContingencyTable_638145119417516729" xlink:to="us-gaap_ProductLiabilityContingencyLineItems_638145119417526730" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment_638145119417526730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductLiabilityContingencyLineItems_638145119417526730" xlink:to="us-gaap_OtherCommitment_638145119417526730" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense_638145119417526730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductLiabilityContingencyLineItems_638145119417526730" xlink:to="us-gaap_RoyaltyExpense_638145119417526730" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="acxp-20221231.xsd#acxp_PercentageOfRoyaltyPaymentsOnNetSales" xlink:label="acxp_PercentageOfRoyaltyPaymentsOnNetSales_638145119417526730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductLiabilityContingencyLineItems_638145119417526730" xlink:to="acxp_PercentageOfRoyaltyPaymentsOnNetSales_638145119417526730" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202319657808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 15, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Acurx Pharmaceuticals,&#160;Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-3733567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">259 Liberty Ave.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Staten Island<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">533-1469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ACXP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,635,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001736243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">CohnReznick LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Parsippany, NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202318794240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 9,111,751<span></span>
</td>
<td class="nump">$ 12,958,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid Expenses</a></td>
<td class="nump">264,955<span></span>
</td>
<td class="nump">295,304<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">9,376,706<span></span>
</td>
<td class="nump">13,254,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="nump">2,061,685<span></span>
</td>
<td class="nump">843,909<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">2,061,685<span></span>
</td>
<td class="nump">843,909<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">2,061,685<span></span>
</td>
<td class="nump">843,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>MEMBERS' AND SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock; $.001 par value, 200,000,000 shares authorized, 11,627,609 and 10,215,792 shares issued and outstanding at December 31, 2022 and 2021, respectively</a></td>
<td class="nump">11,628<span></span>
</td>
<td class="nump">10,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional Paid-In Capital</a></td>
<td class="nump">45,944,478<span></span>
</td>
<td class="nump">38,948,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
<td class="num">(38,641,085)<span></span>
</td>
<td class="num">(26,548,309)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL MEMBERS' AND SHAREHOLDERS' EQUITY</a></td>
<td class="nump">7,315,021<span></span>
</td>
<td class="nump">12,410,241<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND MEMBERS' AND SHAREHOLDERS' EQUITY</a></td>
<td class="nump">9,376,706<span></span>
</td>
<td class="nump">13,254,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=acxp_CommonUnitClassMemberSCapitalMember', window );">Members' Equity, Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>MEMBERS' AND SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MembersCapital', window );">Members' Equity</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=acxp_CommonUnitClassBMemberSCapitalMember', window );">Members' Equity, Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>MEMBERS' AND SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MembersCapital', window );">Members' Equity</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MembersCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of member capital in limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MembersCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=acxp_CommonUnitClassMemberSCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=acxp_CommonUnitClassMemberSCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=acxp_CommonUnitClassBMemberSCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=acxp_CommonUnitClassBMemberSCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202323429728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, Par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, Authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, Issued (in shares)</a></td>
<td class="nump">11,627,609<span></span>
</td>
<td class="nump">10,215,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, Outstanding (in shares)</a></td>
<td class="nump">11,627,609<span></span>
</td>
<td class="nump">10,215,792<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202319561280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development</a></td>
<td class="nump">$ 4,754,271<span></span>
</td>
<td class="nump">$ 2,030,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and Administrative</a></td>
<td class="nump">7,338,505<span></span>
</td>
<td class="nump">10,784,023<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">TOTAL OPERATING EXPENSES</a></td>
<td class="nump">12,092,776<span></span>
</td>
<td class="nump">12,814,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on Forgiveness of Paycheck Protection Program Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,503<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (12,092,776)<span></span>
</td>
<td class="num">$ (12,747,697)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share</a></td>
<td class="num">$ (1.12)<span></span>
</td>
<td class="num">$ (1.49)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share</a></td>
<td class="num">$ (1.12)<span></span>
</td>
<td class="num">$ (1.49)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding basic</a></td>
<td class="nump">10,816,412<span></span>
</td>
<td class="nump">8,535,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding diluted</a></td>
<td class="nump">10,816,412<span></span>
</td>
<td class="nump">8,535,873<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202319304880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF CHANGES IN MEMBERS' AND SHAREHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th">
<div>Membership Interest </div>
<div>Members' Equity, Class A</div>
</th>
<th class="th">
<div>Membership Interest </div>
<div>Members' Equity, Class B</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning at Dec. 31, 2020</a></td>
<td class="nump">$ 16,402,198<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (13,800,612)<span></span>
</td>
<td class="nump">$ 2,701,586<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonUnitOutstanding', window );">Balance at beginning, Member Units (in shares) at Dec. 31, 2020</a></td>
<td class="nump">13,493,807<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_StockUnitsIssuedDuringPeriodValueExecutiveCompensationSettled', window );">Executive Compensation Settled with Membership Interests</a></td>
<td class="nump">$ 186,650<span></span>
</td>
<td class="nump">$ 730,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">916,765<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_StockUnitsIssuedDuringPeriodSharesExecutiveCompensationSettled', window );">Executive Compensation Settled with Membership Interests (in shares)</a></td>
<td class="nump">57,430<span></span>
</td>
<td class="nump">471,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_CancellationOfStockUnitsShares', window );">Cancellation of Class B Issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(471,042)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Share-Based Compensation</a></td>
<td class="nump">$ 755,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,399,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,154,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Share-Based Compensation (in shares)</a></td>
<td class="nump">400,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Share-Based Payments to Vendors</a></td>
<td class="nump">$ 172,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">1,414,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,587,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Share-Based Payments to Vendors (in shares)</a></td>
<td class="nump">30,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">299,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_StockIssuedDuringPeriodValueCorporateConversionOfUnits', window );">Corporate Conversion</a></td>
<td class="num">$ (17,517,375)<span></span>
</td>
<td class="num">$ (830,115)<span></span>
</td>
<td class="nump">$ 7,041<span></span>
</td>
<td class="nump">18,340,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_StockIssuedDuringPeriodSharesCorporateConversionOfUnits', window );">Corporate Conversion (in shares)</a></td>
<td class="num">(13,982,318)<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="nump">7,041,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Initial Public Offering and underwriter warrants, net of cash issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,875<span></span>
</td>
<td class="nump">14,794,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,797,132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Initial Public Offering and underwriter warrants, net of cash issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,747,697)<span></span>
</td>
<td class="num">(12,747,697)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at ending at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,216<span></span>
</td>
<td class="nump">38,948,334<span></span>
</td>
<td class="num">(26,548,309)<span></span>
</td>
<td class="nump">$ 12,410,241<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at ending, Common shares (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,215,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,215,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Share-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,871,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,871,681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Share-Based Payments to Vendors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">430,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Share-Based Payments to Vendors (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_StockholdersEquityPeriodIncreaseDecreaseThroughCashlessWarrantExercise', window );">Cashless Warrant Exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_StockIssuedDuringPeriodSharesPeriodIncreaseDecreaseThroughCashlessWarrantExercise', window );">Cashless Warrant Exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_WarrantExercisePreFunded', window );">Pre-funded Warrant Exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
<td class="num">(118)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_WarrantExercisePreFundedShares', window );">Pre-funded Warrant Exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Initial Public Offering and underwriter warrants, net of cash issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,159<span></span>
</td>
<td class="nump">3,694,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,695,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Initial Public Offering and underwriter warrants, net of cash issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,159,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,092,776)<span></span>
</td>
<td class="num">(12,092,776)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at ending at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,628<span></span>
</td>
<td class="nump">$ 45,944,478<span></span>
</td>
<td class="num">$ (38,641,085)<span></span>
</td>
<td class="nump">$ 7,315,021<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at ending, Common shares (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,627,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,627,609<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acxp_CancellationOfStockUnitsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the shares of stock units cancelled during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acxp_CancellationOfStockUnitsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acxp_StockIssuedDuringPeriodSharesCorporateConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the corporate conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acxp_StockIssuedDuringPeriodSharesCorporateConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acxp_StockIssuedDuringPeriodSharesPeriodIncreaseDecreaseThroughCashlessWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the number of shares issued through cashless warrant exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acxp_StockIssuedDuringPeriodSharesPeriodIncreaseDecreaseThroughCashlessWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acxp_StockIssuedDuringPeriodValueCorporateConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the corporate conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acxp_StockIssuedDuringPeriodValueCorporateConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acxp_StockUnitsIssuedDuringPeriodSharesExecutiveCompensationSettled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of tock units issued during the period for executive compensation settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acxp_StockUnitsIssuedDuringPeriodSharesExecutiveCompensationSettled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acxp_StockUnitsIssuedDuringPeriodValueExecutiveCompensationSettled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of  stock  units issued during the period for executive compensation settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acxp_StockUnitsIssuedDuringPeriodValueExecutiveCompensationSettled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acxp_StockholdersEquityPeriodIncreaseDecreaseThroughCashlessWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in stockholders' equity through cashless warrant exercise during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acxp_StockholdersEquityPeriodIncreaseDecreaseThroughCashlessWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acxp_WarrantExercisePreFunded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in stockholders' equity through pre-funded warrant exercise during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acxp_WarrantExercisePreFunded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acxp_WarrantExercisePreFundedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the number of shares issued through pre-funded warrant exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acxp_WarrantExercisePreFundedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonUnitOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common units of ownership outstanding of a limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonUnitOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 30<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=128088960&amp;loc=d3e3913-113898<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126965701&amp;loc=d3e15009-113911<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202324797824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CHANGES IN MEMBERS' AND SHAREHOLDERS' EQUITY (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>STATEMENTS OF CHANGES IN MEMBERS' AND SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Cash issuance cost</a></td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="nump">$ 529,805<span></span>
</td>
<td class="nump">$ 2,452,868<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202319602944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flow from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Loss</a></td>
<td class="num">$ (12,092,776)<span></span>
</td>
<td class="num">$ (12,747,697)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-Based Compensation</a></td>
<td class="nump">2,871,681<span></span>
</td>
<td class="nump">5,154,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_ShareBasedPaymentToVendors', window );">Share-Based Payments to Vendors</a></td>
<td class="nump">430,680<span></span>
</td>
<td class="nump">1,587,741<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Executive Compensation Settled with Membership Interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">916,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on Forgiveness of Paycheck Protection Program Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,503)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>(Increase) / Decrease in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid Expenses</a></td>
<td class="nump">30,349<span></span>
</td>
<td class="num">(246,695)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="nump">1,217,776<span></span>
</td>
<td class="nump">387,978<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used in Operating Activities</a></td>
<td class="num">(7,542,290)<span></span>
</td>
<td class="num">(5,013,697)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flow from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Initial Public Offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,797,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Registered Direct Offering, net of issuance costs</a></td>
<td class="nump">3,695,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Pre-funded Warrant Exercise</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided by Financing Activities</a></td>
<td class="nump">3,695,195<span></span>
</td>
<td class="nump">14,797,132<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (Decrease) Increase in Cash</a></td>
<td class="num">(3,847,095)<span></span>
</td>
<td class="nump">9,783,435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at Beginning of Year</a></td>
<td class="nump">12,958,846<span></span>
</td>
<td class="nump">3,175,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at End of Year</a></td>
<td class="nump">9,111,751<span></span>
</td>
<td class="nump">12,958,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_NonCashFinancingActivitiesOfWarrantsIssuedInConnectionWithOfferings', window );">Warrants issued in connection with offerings</a></td>
<td class="nump">$ 171,409<span></span>
</td>
<td class="nump">$ 618,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acxp_NonCashFinancingActivitiesOfWarrantsIssuedInConnectionWithOfferings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of offering costs issued in connection with warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acxp_NonCashFinancingActivitiesOfWarrantsIssuedInConnectionWithOfferings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acxp_ShareBasedPaymentToVendors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of non cash expense for share based payment to vendors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acxp_ShareBasedPaymentToVendors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202319528880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>NATURE OF OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">NATURE OF OPERATIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NOTE&#160;1&#160;&#8211; NATURE OF OPERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Business:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Acurx Pharmaceuticals,&#160;Inc., a Delaware corporation, formerly Acurx Pharmaceuticals, LLC (the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company formed in July&#160;2017, with operations commencing in February&#160;2018. The Company is focused on developing a novel class of antibiotics that address serious or life threatening bacterial infections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2020, the World Health Organization declared the outbreak of COVID-19, a novel strain of coronavirus, a global pandemic. This outbreak caused major disruptions to businesses and markets worldwide as the virus continued to spread. The COVID-19 pandemic has disrupted, and the Company expects it will continue to disrupt, its operations. The extent of the effect on the Company&#8217;s operational and financial performance will depend on future developments, including the duration, spread and intensity of the pandemic, and governmental, regulatory and private sector responses, direct and indirect economic effects as a result of inflation, supply chain disruptions and labor shortages all of which are uncertain and difficult to predict. Although the Company is unable to estimate the financial effect of the pandemic, at this time, if the pandemic continues over a long period of time, it could have a material adverse effect on the Company&#8217;s business, results of operations, financial condition, and cash flows. The financial statements do not reflect any adjustments as a result of the pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2018, the Company purchased the active pharmaceutical ingredient, the intellectual property and other rights to an antibiotic product candidate known as GLS362E (renamed ACX-362E and now approved for non-proprietary name, ibezapolstat) (the &#8220;Asset&#8221;) from GLSynthesis,&#160;Inc. The Company paid $110,174 in cash, along with granting 100,000 Class&#160;B Membership Interests, profits interests as defined in the operating agreement, with an exercise price of $0.10 per share. The Company was also required to make certain milestone payments totaling $700,000 in aggregate if certain milestones are achieved, $50,000 of which has already been paid by the Company and royalty payments equal to 4% of net sales for a period of time equal to the last to expire of any applicable patents, as defined in the asset purchase agreement. The purchase of the Asset has resulted in our lead antibiotic product candidate, ibezapolstat, which targets the treatment of C. difficile infections (&#8220;CDI&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s primary activities since inception aside from organizational activities have included performing research and development activities relating to the development of its two antibiotic candidates and raising funds through equity offerings including its initial public offering (&#8220;IPO&#8221;) consummated in June&#160;2021. The Company has not generated any revenues since inception.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. The Company has needed to raise capital from sales of its securities to sustain operations. On June&#160;29, 2021, the Company completed the IPO, issuing 2,875,000 shares of common stock at a price of $6.00 per share, with gross proceeds of approximately $17.3 million. On July 27, 2022, the Company completed a registered direct offering and a concurrent private placement, issuing 1,159,211 shares of common stock and 130,769 pre-funded warrants and series A warrants to purchase 1,289,980 shares of common stock and series B warrants to purchase 1,289,980 shares of common stock for gross proceeds of approximately $4.2<span style="white-space:pre-wrap;"> million.  As of December&#160;31, 2022, the Company had a cash balance of approximately </span>$9.1 million, which based on current estimates will not be sufficient to meet our anticipated cash requirements for at least 12&#160;months from the issuance of the financial statements for the&#160;year ended December&#160;<span style="white-space:pre-wrap;">31, 2022. Management believes that the Company will continue to incur losses for the foreseeable future and will need additional resources to sustain its operations until it can achieve profitability and positive cash flows, if ever. Management plans to seek additional equity financing and grant funding, but cannot assure that such financing and funding will be available at acceptable terms, or at all. These matters raise substantial doubt about the Company&#8217;s ability to continue as a going concern.  The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty. There can be no assurance that the Company&#8217;s research and development will be successfully completed or that any Company product candidate will be approved by </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">the Food and Drug Administration (&#8220;FDA&#8221;) or any other worldwide regulatory authority or become commercially viable. The Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with FDA and other governmental regulations and approval requirements</span>.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202321698960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NOTE&#160;2&#160;&#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;text-decoration-line:none;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results </span><span style="font-weight:normal;text-decoration-line:none;">could differ from those estimates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company estimates an annual effective tax rate of 0% as the Company incurred net losses for the&#160;year ended December&#160;31, 2022 resulting in an estimated net loss for both financial statement and tax purposes. Therefore, no current federal or state income tax expense has been recorded in the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Based on the Company&#8217;s history of generating operating losses and its anticipation of operating losses for the foreseeable future, the Company has determined that it is more likely than not that the tax benefits from those net operating losses would not be realized and a full valuation allowance against all deferred tax assets has been recorded. Should the Company&#8217;s assessment change, tax benefits associated with the historic net operating loss carryforwards could be limited due to future ownership changes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Prior to the Company&#8217;s corporate conversion in June&#160;2021, the Company was organized as a limited liability company. As such, the Company was not a tax paying entity for federal income tax purposes and, therefore, no income tax expense has been recorded in the financial statements. Income or losses of the Company was passed through to the members for inclusion in their respective income tax returns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Concentration of Credit Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company maintains its cash balance in one financial institution. The balance is insured up to the maximum allowable by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company has not experienced any losses in such accounts and does not believe it is exposed to any significant risk of loss on cash. At times, the cash balance may exceed the maximum insured limit of the FDIC. As of December&#160;31, 2022, the Company had cash of approximately $9.1 million in U.S. bank accounts which was not fully insured by the FDIC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Guaranteed Payments to Members</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Prior to the corporate conversion, guaranteed payments to members of the Company that were designated to represent reasonable compensation for services rendered were accounted for as Company expenses rather than an allocation of the Company&#8217;s net income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Research and Development</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company expenses research and development costs when incurred. At times, the Company may make cash advances for future research and development services. These amounts are deferred and expensed in the period the service is provided. The Company incurred research and development expenses in the amount of $4,754,271 and $2,030,177 for the&#160;years ended December&#160;31, 2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Costs for certain research and development activities, such as the provision of services for clinical trial activity, are estimated based on an evaluation of the progress to completion of specific tasks which may use data such as subject enrollment, clinical site activations or information provided to the Company by its vendors with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development expense, as the case may be. The estimates are adjusted to reflect the best information available at the time of the financial statement issuance. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company's estimate of the status and timing of services performed relative to the actual status and timing of services performed may vary. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Share-Based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for the cost of services performed by officers and directors received in exchange for an award of Company membership interests, common stock or stock options, based on the grant-date fair value of the award. The Company recognizes compensation expense based on the requisite service period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Compensation expense associated with stock option awards is recognized over the requisite service period based on the fair value of the option at the grant date determined based on the Black-Scholes option pricing model. Option valuation models require the input of highly subjective assumptions including the expected price volatility. The Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair value computation using the Black-Scholes option pricing model. Because there is no public market for the Company&#8217;s stock options and very little historical experience with the Company&#8217;s stock, similar public companies were used for the comparison of volatility and the dividend yield. The risk-free rate of return was derived from U.S. Treasury notes with comparable maturities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Share-Based Payments to Vendors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for the cost of services performed by vendors in exchange for an award of Company membership interests, common stock, or stock options, based on the grant-date fair value of the award or the fair value of the services rendered; whichever is more readily determinable. The Company recognizes the expense in the same period and in the same manner as if the Company had paid cash for the services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Major Vendor</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company had a major vendor that accounted for approximately 55% and 42% of the research and development expenditures for the&#160;years ended December&#160;31, 2022 and 2021, respectively. The same vendor also accounted for approximately 56% and 5% of the total accounts payable and accrued expenses as of December&#160;31, 2022 and 2021, respectively. The Company continues to maintain this vendor relationship and anticipates incurring significant expenses with this vendor over the next 12&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company had an additional major vendor that accounted for approximately 4% and 15% of the research and development expenditures for the&#160;years ended December&#160;31, 2022 and 2021. The same vendor did not account for any material portion of the total accounts payable and accrued expenses. The Company will continue to maintain this vendor relationship over the next 12&#160;months.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202321698960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NOTE&#160;3&#160;- ACCOUNTS PAYABLE AND ACCRUED EXPENSES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Accounts payable and accrued expenses as of December&#160;31, 2022 and 2021 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 542,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 508,343</p></td></tr><tr><td style="vertical-align:bottom;width:62.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,405,536</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 229,090</p></td></tr><tr><td style="vertical-align:bottom;width:62.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 83,715</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,102</p></td></tr><tr><td style="vertical-align:bottom;width:62.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,539</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63,374</p></td></tr><tr><td style="vertical-align:bottom;width:62.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,061,685</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 843,909</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202409317760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PAYCHECK PROTECTION PROGRAM LOAN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_PaycheckProtectionProgramLoanAbstract', window );"><strong>PAYCHECK PROTECTION PROGRAM LOAN</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_PaycheckProtectionProgramLoanDisclosureTextBlock', window );">PAYCHECK PROTECTION PROGRAM LOAN</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NOTE&#160;4&#160;&#8211; PAYCHECK PROTECTION PROGRAM LOAN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2020, the Company received a Paycheck Protection Program loan (&#8220;PPP Loan&#8221;) under the CARES Act, as administered by the U.S. Small Business Administration (&#8221;SBA&#8221;) in the amount of $66,503. <span style="color:#252525;">&#160;The Company did not provide any collateral or guarantees in connection with the PPP loan, nor did the Company pay any facility charge to obtain the&#160;PPP Loan. The note and agreement provided for customary events of default, including those relating to failure to make payment, bankruptcy, breaches of representations and material adverse effects. The Company was permitted to prepay the principal of the&#160;PPP Loan&#160;at any time without incurring any prepayment charges. </span>The PPP Loan carried an annual interest rate of 0.98% and a maturity date <span style="-sec-ix-hidden:Hidden_nx3AzEkhbUS8BxsxeUh0lg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> (2)&#160;years from issuance. The Company was not obligated to make any payments of principal or interest before the date on which the SBA remits the loan forgiveness amount to the lender or notifies the lender that no loan forgiveness is allowed. On April&#160;13, 2021, the SBA authorized the full forgiveness of the PPP Loan. Accordingly, the Company reduced the full amount of the liability and recorded a gain in the amount of $66,503 on the forgiveness of the PPP loan in the statements of operations for the&#160;year ended December&#160;31, 2021.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acxp_PaycheckProtectionProgramLoanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the details pertaining to Paycheck Protection Program Loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acxp_PaycheckProtectionProgramLoanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acxp_PaycheckProtectionProgramLoanDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of paycheck protection program loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acxp_PaycheckProtectionProgramLoanDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202321005888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EXECUTIVE COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>EXECUTIVE COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsGeneralTextBlock', window );">EXECUTIVE COMPENSATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NOTE&#160;5&#160;&#8211; EXECUTIVE COMPENSATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2021, the Company issued 57,430 Class&#160;A Membership Interests at $3.25 per unit, equal to the value of the most recent private placement, to two of its executives to settle unpaid&#160;year-end bonus award and deferred compensation, which was approved by the board of directors. The&#160;year-end bonus component was equal to 38,353 Class&#160;A Membership Interests, which was included as accrued compensation. In January&#160;2021, the Company also amended the employment agreements for the three executives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The board of directors also approved certain grants to members of management as a component of&#160;their 2020&#160;year-end compensation, authorizing the issuance of 1,540,000 Class&#160;B Membership Interests to its three executives, as well as 75,000 Class&#160;B Membership Interests which were granted to non-employee management team members. The Class&#160;B Membership Interests are profits interests with a defined exercise price of $3.25 per interest, the Company&#8217;s most recent financing offering price. In March&#160;2021, the Company along with its three executives and non-employee management team agreed voluntarily to cancel the aforementioned equity grants. The Company granted options to purchase 770,000 shares of the Company&#8217;s common stock in June&#160;2021 to the three-member management team in replacement of the cancelled&#160;year-end grants described above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company is currently managed by three executives, in each case pursuant to new employment agreements effective June&#160;29, 2021 and a controller hired in April 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsGeneralTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation costs, including compensated absences accruals, compensated absences liability, deferred compensation arrangements and income statement compensation items. Deferred compensation arrangements may include a description of an arrangement with an individual employee, which is generally an employment contract between the entity and a selected officer or key employee containing a promise by the employer to pay certain amounts at designated future dates, usually including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares (units) issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6409950&amp;loc=d3e20396-108366<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsGeneralTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202324635152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ISSUANCE OF EQUITY INTERESTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>ISSUANCE OF EQUITY INTERESTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">ISSUANCE OF EQUITY INTERESTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NOTE&#160;6&#160;&#8211; ISSUANCE OF EQUITY INTERESTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On June&#160;23, 2021, Acurx Pharmaceuticals, LLC was converted into a corporation and renamed Acurx Pharmaceuticals,&#160;Inc. The Company&#8217;s certificate of incorporation authorizes 200,000,000 shares of common stock of which 11,627,609 were outstanding as of December&#160;31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">On June&#160;29, 2021, the Company completed an IPO issuing 2,875,000 shares of common stock at a price of $6.00 per share, resulting in net cash proceeds of approximately $14.8 million, with cash issuance costs of approximately $2.4 million. The outstanding Class&#160;A and Class&#160;B Membership Interests were converted to shares of common stock pursuant to a conversion ratio of one-for-two of the Membership Interests outstanding, resulting in the conversion of 14,082,318 Class&#160;A and Class&#160;B Membership Interests into 7,041,208 shares of common stock. Warrants to purchase Class&#160;A </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Membership Interests were converted to warrants to purchase common stock at the same one-for two conversion ratio, resulting in 1,437,577 warrants to purchase common stock with a weighted average exercise price of $2.88.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In connection with the IPO, the Company issued 150,000 warrants to the underwriter. Each warrant is exercisable for 4.5 years from December&#160;21, 2021 at an exercise price of $7.50 per share. The Company used the Black-Scholes model to calculate the value of the warrants with an estimated fair value of $618,000. The inputs utilized in the calculation were as follows: <span style="-sec-ix-hidden:Hidden_RMD-11b8a0WEvsJ9XyenQg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four</span></span> and a half-year term, 0.79% risk-free rate, stock price at grant date of $6.26, and a 94% volatility utilizing comparable companies. This amount was recorded as both an increase to additional paid-in capital and as a non-cash issuance cost of the offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On July 25, 2022, the Company entered into securities purchase agreements (the &#8220;Purchase Agreements&#8221;) with two of the Company&#8217;s executives and a member of the Company&#8217;s board of directors (collectively, the &#8220;Affiliate Investors&#8221;), and a single U.S. institutional investor (the &#8220;Investor&#8221;) pursuant to which the Company issued and sold in a registered direct offering an aggregate of 1,159,211 shares of common stock, par value $0.001 per share and pre-funded warrants to purchase an aggregate of 130,769 shares of common stock. The Affiliate Investors purchased an aggregate of 59,211 shares of common stock at a purchase price of $3.80 per share. The Investor purchased an aggregate of 1,100,000 shares of common stock at a purchase price of $3.25 per share and an aggregate of 130,769 pre-funded warrants at a purchase price of $3.2499 per pre-funded warrant. The pre-funded warrants sold to the Investor have an exercise price of $0.0001<span style="white-space:pre-wrap;">, were immediately exercisable.  As of December 31, 2022, all of the pre-funded warrants were exercised.  The Company also issued to the Affiliate Investors and the Investor, series A warrants to purchase </span>1,289,980 shares of common stock and series B warrants to purchase 1,289,980 shares of common stock, all of which are deemed equity classified. These warrants included 59,211 series A warrants and an aggregate of 59,211 series B warrants to the Affiliate Investors with an exercise price per share of $3.55 and an aggregate of 1,230,769 series A warrants and an aggregate of 1,230,769 series B warrants to the Investor with an exercise price per share of $3.25. The series A warrants will be exercisable commencing on January 27, 2023 and will expire on January 27, 2028. The series B warrants will be exercisable commencing on January 27, 2023 and will expire on January 27, 2024. The registered direct offering closed on July 27, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The gross proceeds to the Company from the registered direct offering were $4.2 million and net proceeds after deducting the placement agents&#8217; fees and other offering expenses payable by the Company were approximately $3.7 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On July 25, 2022, the Company entered into a co-placement agent agreement (the &#8220;Placement Agent Agreement&#8221;), with two placement agents in connection with the registered direct offering pursuant to which the Company paid the Placement Agents a cash fee of $287,874 and issued to the Placement Agents an aggregate of 63,018<span style="white-space:pre-wrap;"> warrants to purchase shares of common stock.  The warrants have an exercise price of </span>$3.60 per share (representing 110%<span style="white-space:pre-wrap;"> of the weighted average public offering price of the aggregate number of shares of common stock sold in the registered direct offering to the Investor and Affiliate Investors) and expire on July 27, 2027.  The Company used the Black-Scholes model to calculate the value of the warrants with an estimated fair value of </span>$171,409<span style="white-space:pre-wrap;">.  The inputs utilized in the calculation were as follows: </span>five year term, 2.82% risk free rate, stock price at grant date of $3.70 and a 95%<span style="white-space:pre-wrap;"> volatility utilizing comparable companies.  This amount was recorded as both an increase to additional paid-in capital and as a non-cash issuance cost of the offering.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at December 31, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,588,477</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.32</p></td></tr><tr><td style="vertical-align:bottom;width:61.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">   Issued</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,776,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.12</p></td></tr><tr><td style="vertical-align:bottom;width:61.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">   Exercised</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (147,144)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.27</p></td></tr><tr><td style="vertical-align:bottom;width:61.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,217,809</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.29</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202324634320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED COMPENSATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;7&#160;&#8211; SHARE-BASED COMPENSATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">While the Company was a limited liability company in its pre-IPO phase of corporate development, the Company granted performance-based awards of restricted Class&#160;A Membership Interests to board members and corporate advisory council members in exchange for services. All of these awards of membership interests became fully vested upon consummation of the Company&#8217;s corporate conversion from Delaware limited liability company to a Delaware corporation immediately prior to the Company&#8217;s IPO, with the Company recognizing all previously unrecognized compensation expense. The fair value of the membership interests granted during 2020 and 2019 was equal to the per-membership interest value of the most recent private placement with a weighted average of $2.14 per membership interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Total share-based compensation associated with these awards has been recorded as general and administrative expenses in the amount of $0 and $755,556 for the&#160;years ended December&#160;31, 2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the unvested Class&#160;A Membership Interests converted to common stock pursuant to a conversion ratio of one-for-two, and associated activity for the 12&#160;months ended December&#160;31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:39.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Class A</p></td></tr><tr><td style="vertical-align:bottom;width:57.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Membership Interests</p></td></tr><tr><td style="vertical-align:bottom;width:57.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Converted to common stock at one-for-two ratio</p></td></tr><tr><td style="vertical-align:bottom;width:57.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 200,463</p></td></tr><tr><td style="vertical-align:bottom;width:57.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (200,463)</p></td></tr><tr><td style="vertical-align:bottom;width:57.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2021, the board of directors approved the creation of the 2021 Equity Incentive Plan (the &#8220;Plan&#8221;). The Plan became effective as of the completion of the corporate conversion. The Plan originally reserved an aggregate of 2,000,000 shares of common stock, subject to annual adjustments as provided in the Plan, which was 408,632 shares for 2022, of which 537,937 shares are currently still available for issuance as of December 31, 2022. The purpose of the Plan is to attract, retain and incentivize directors, officers, employees, and consultants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2021, the Company granted stock options to purchase a total of 807,500 shares of common stock to its three executives and three non-employee management team members to replace the Class&#160;B Membership Interests that were cancelled in March&#160;2021. The options were issued at an exercise price of $6.26, with the employee options vesting 40% upon issuance and the balance over 36 months, and the non-employee options vesting at grant date. The Company recorded general and administrative expense of $726,880 and $2,019,325 for the&#160;years ended December&#160;31, 2022 and 2021, respectively, related to compensation expense for these options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In July&#160;2021, the Company granted stock options to purchase a total of 1,550,000 shares of common stock to its three executives pursuant to their respective employment agreements, the independent directors, and one consultant, pursuant to the Plan. The options were issued at an exercise price of $6.18, the grant date fair value, with <span style="-sec-ix-hidden:Hidden_EzWf9zq7yU2COrvaqFHBLw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-quarter of the executive&#8217;s options vesting upon issuance and the balance over 36 months, and the options granted to the directors and consultants vesting over 36 months. The Company recorded general and administrative expenses of $1,963,667 and $2,379,833 for the&#160;years ended December&#160;31, 2022 and 2021, respectively, related to compensation expense for these options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In January 2022, the Company granted stock options to purchase a total of 80,000 shares of common stock to seven consultants pursuant to the Plan. The options were issued at an exercise price of $4.44, the grant date fair value, with <span style="-sec-ix-hidden:Hidden_GOeJkjeOiU-aNE91SNMVSA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-quarter of the options vesting upon issuance and the balance over 36 months. The Company recorded general and administrative expenses of $145,283 for the year ended December 31, 2022 related to compensation expense for these options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">In April 2022, the Company granted stock options to purchase a total of 30,000 shares of common stock to a new employee pursuant to the Plan. The options were issued at an exercise price of $3.79, the grant date fair value, with <span style="-sec-ix-hidden:Hidden__yx0SlixZk2t446zKw_EWA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">quarter of the options vesting upon issuance and the balance over 36 months. The Company recorded general and administrative expenses of $35,850 for the year ended December 31, 2022 related to compensation expense for these options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Compensation expense associated with these awards is recognized over the vesting period based on the fair value of the option at the grant date determined based on the Black-Scholes option pricing model. Option valuation models require the input of highly subjective assumptions including the expected price volatility. The Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair value computation using the Black-Scholes option pricing model. Because there is no public market for the Company&#8217;s stock options and very little historical experience with the Company&#8217;s stock, similar public companies were used for the comparison of volatility and the dividend yield. The risk-free rate of return was derived from U.S. Treasury notes with comparable maturities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company determined the fair value of the option awards using the Black-Scholes option pricing model using the following weighted average assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Year Ended </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average grant date fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">A summary of the Company&#8217;s stock option activity is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Year Ended </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Weighted&#160;Average</p></td></tr><tr><td style="vertical-align:bottom;width:55.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Exercise&#160;Price</p></td></tr><tr><td style="vertical-align:bottom;width:55.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at the beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,357,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.21</p></td></tr><tr><td style="vertical-align:bottom;width:55.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 110,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.26</p></td></tr><tr><td style="vertical-align:bottom;width:55.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:55.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:55.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at the end of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,467,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.12</p></td></tr><tr><td style="vertical-align:bottom;width:55.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,552,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.15</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The total compensation expense not yet recognized as of December&#160;31, 2022 was $4,243,927. The weighted average vesting period for the unvested options is 1.54 years. The intrinsic value of the stock options as of December&#160;31, 2022 was $5,700, with a remaining weighted average contractual life of 8.53 years. The weighted average grant date fair value of all options granted is $4.67 as of December&#160;31, 2022. The Company records the impact of any forfeitures of options as they occur.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202324623088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED PAYMENTS TO VENDORS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_ShareBasedPaymentsToVendorsAbstract', window );"><strong>SHARE-BASED PAYMENTS TO VENDORS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_ShareBasedPaymentsToVendorsDisclosureTextBlock', window );">SHARE-BASED PAYMENTS TO VENDORS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NOTE&#160;8&#160;&#8211; SHARE-BASED PAYMENTS TO VENDORS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">While the Company was a limited liability company in its pre-IPO phase of corporate development, the Company granted Class&#160;A Membership Interests to certain vendors in the ordinary course of business in exchange for consulting services relating to research and development activities and investor relations. The Company granted 30,145 Class&#160;A Membership Interests for the&#160;year ended December&#160;31, 2021. The fair value of the Class&#160;A Membership Interests granted was equal to the value of the most recent private placement. The Company recognized the expense in the same period and in the same manner as if the Company had paid cash for the services. The Company recorded general and administrative expenses and research and development expenses for vendor equity grants in the amounts of $0 for the year ended December 31, 2022 and $201,375 and $21,596 for the&#160;year ended December&#160;31, 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2019, the Company granted a total of 150,000 restricted Class&#160;A Membership Interests to three consultants for investor relations consulting services performed in 2019 through October&#160;2021. These Class&#160;A Membership Interests vested on the second anniversary of the grant date, and were subject to accelerated vesting provisions upon a change of control of the Company. The fair value of the Class&#160;A Membership Interests granted was equal to the value of the most recent private placement, $2.00 per Class&#160;A Membership Interest. The Company recognized the expense on a straight-line basis over the vesting period. The Company recorded general and administrative expenses of $0 and $125,000 for the&#160;years ended December&#160;31, 2022 and 2021, respectively. The conversion adjusted shares of common stock were issued in October&#160;2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In the second quarter of 2021, the Company entered into a number of agreements with vendors pursuant to which the Company made grants of a total of 175,000 shares of common stock with a grant date fair value of $6.26, cash payments in the amount of $343,500, and 100,000 options which were included as a part of the July&#160;2021 grant. These contracts have terms which range from six months to three years. The common stock was valued based on the grant date fair value and the options valued utilizing Black-Scholes option pricing model. The cash payments were expensed over the service period and the equity component expensed consistent with the contractual vesting. These shares and options were granted in the third quarter of 2021 pursuant to the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In the third quarter of 2021, the Company granted vendors a total of 35,695 shares of common stock, which fully vested in 2021, pursuant to the Plan. The Company recorded general and administrative expense of $208,270, based on the respective grant date fair values, for the&#160;year ended December&#160;31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2021, the Company entered into an agreement with a consultant to provide financial advisory services for a six-month term. Pursuant to the agreement, the Company granted $150,000 of common stock over the term of service. The Company granted total of 27,778 shares of common stock at grant date fair value and recorded general and administrative expenses of $75,000 for each of the&#160;years ended December&#160;31, 2022, and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In March 2022, the Company entered into an agreement with a consultant to provide investor relation services for a six-month term. Pursuant to the agreement, the Company granted 30,000 shares of common stock with a grant date fair value of $3.77 and paid $25,000 of cash compensation The cash component was expensed over the service period and the equity component was expensed consistent with the contractual vesting. The Company recorded general and administrative expenses of $113,100 for the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In September 2022, the Company entered into an agreement with a company to provide consulting services for a <span style="-sec-ix-hidden:Hidden_pe6sq_5jwkGHEr32NVYkWA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">six-month</span></span><span style="white-space:pre-wrap;"> term.  Pursuant to the agreement, the Company granted </span>36,000 shares of common stock with a grant date fair value of $3.53<span style="white-space:pre-wrap;">, which was expensed consistent with the contractual vesting.  The Company recorded general and administrative expenses of </span>$127,080<span style="white-space:pre-wrap;"> for the year ended December 31, 2022.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In the fourth quarter of 2022, the Company entered into a number of agreements with vendors pursuant to which the Company will make grants of a total of 43,186 share of common stock with a grant date fair values ranging from $3.30 to $3.67, up to 10,096<span style="white-space:pre-wrap;"> of warrants, and cash payments.  These contracts have </span><span style="-sec-ix-hidden:Hidden_xpnuvER5pkCZfclL6LaL-Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">six-months</span></span><span style="white-space:pre-wrap;"> terms with various contractual vesting periods.  The cash payments will be expensed over the service period and the equity component will be expensed consistent with the various contractual vesting periods.  The Company recorded general and administrative expenses of </span>$115,500 for the year ended December 31, 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acxp_ShareBasedPaymentsToVendorsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ABSTRACT</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acxp_ShareBasedPaymentsToVendorsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acxp_ShareBasedPaymentsToVendorsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the share based payments to vendors disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acxp_ShareBasedPaymentsToVendorsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202405934192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NOTE&#160;9&#160;&#8211; INCOME TAXES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company has $10.7 million of net operating loss carryforwards and $0.1 million of research tax credit carryforwards as of December&#160;31, 2022. The net operating loss carryforwards are indefinite lived and research tax credit carryforwards will expire in 2042. Net operating loss and tax credit carryforwards may become subject to annual limitations in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined by Sections 382 and 383 of the Internal Revenue Code as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The components of the net deferred income tax asset at December&#160;31, 2022 and 2021 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Net operating loss carry forwards</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,359,183</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,594,650</p></td></tr><tr><td style="vertical-align:bottom;width:66.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Share-based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,262,381</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,149,720</p></td></tr><tr><td style="vertical-align:bottom;width:66.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Research and development credit carryforwards</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 141,671</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105,881</p></td></tr><tr><td style="vertical-align:bottom;width:66.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Capitalized research and development </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,347,028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Gross deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,110,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,850,251</p></td></tr><tr><td style="vertical-align:bottom;width:66.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,110,263)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,850,251)</p></td></tr><tr><td style="vertical-align:bottom;width:66.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">    Net deferred tax asset</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Tax Cuts and Jobs Act of 2017 (TCJA) amended IRC Section 174 to require capitalization of all research and developmental (R&amp;D) costs incurred in tax years beginning after December 31, 2021. These costs are required to be amortized over five years if the R&amp;D activities are performed in the U.S., or over 15 years if the activities were performed outside the U.S. The Company capitalized approximately $4.3 million of R&amp;D expenses incurred as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In assessing the realizability of deferred tax assets, the Company considers whether it is more-likely-than-not that some portion or all the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the temporary differences representing net future deductible amounts become deductible. After consideration of all the evidence, both positive and negative, the Company has recorded a full valuation allowance against their net deferred tax assets at December&#160;31, 2022 because the Company has concluded that it is more-likely-than-not that these assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">A reconciliation of income tax expense (benefit) at the statutory Federal income tax rate and income taxes as reflected in the financial statements for both&#160;years ended December&#160;31, 2022 and 2021 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:49.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:81.59%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:16.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:17.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Federal income tax expense at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State income tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.4</p></td><td style="vertical-align:bottom;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.5)</p></td><td style="vertical-align:bottom;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development tax credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.3</p></td><td style="vertical-align:bottom;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (35.2)</p></td><td style="vertical-align:bottom;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (27.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company files income tax returns in the U.S. and the State of New York. The tax&#160;years 2022 and 2021 are open and potentially subject to examination by the federal and state taxing authorities. The Company is currently not under examination by the Internal Revenue Service (&#8220;IRS&#8221;) or any other jurisdictions for any tax&#160;years and has no knowledge of any pending examinations by the IRS or any other jurisdictions. To the extent the Company utilizes any tax attributes from a tax period that may otherwise be closed due to statute expiration, the IRS, state tax authorities, or other governing parties may still adjust the tax attributes upon their examination of the future period in which the attribute was utilized. There are no uncertain tax positions recorded for any federal or state positions. The Company&#8217;s policy is to record interest and penalties related to tax matters in income tax expense.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202324577312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NOTE&#160;10&#160;&#8211; NET LOSS PER SHARE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On June&#160;23, 2021, the Company completed a corporate conversion from a limited liability company to a corporation. Accordingly, the outstanding Class&#160;A and Class&#160;B Membership Interests were converted to shares of common stock using a conversion ratio of one-half of one share of common stock for each Class&#160;A membership interest or Class&#160;B membership interest, resulting in the conversion of 14,082,318 Class&#160;A and Class&#160;B Membership Interests into 7,041,208 shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Basic and diluted net loss per share of common stock for the year ended December&#160;31, 2022 was determined by dividing net loss by the weighted average shares of common stock outstanding during the period. The Company&#8217;s potentially dilutive shares, consisting of 4,217,809 warrants, and 2,467,500 stock options, have not been included in the computation of diluted net loss per share for all periods as the result would be antidilutive. The effects of the corporate conversion on the Company&#8217;s weighted average shares of common stock outstanding and net loss per share have been reflected for all periods presented retroactively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202405832016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NOTE&#160;11&#160;&#8211; COMMITMENTS AND CONTINGENCIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">In conjunction with the Asset purchase in February&#160;2018, the Company is required to make certain milestone payments related to the ongoing development of ACX-362E totaling $700,000 in the aggregate if certain milestones are achieved (which includes $50,000 already paid after the acquisition in February&#160;<span style="white-space:pre-wrap;">2018). There were no milestones reached during 2022 and 2021.  The Company is also obligated to make royalty payments equal to </span>4% of net sales of ACX-362E for a period of time equal to the last to expire of any applicable patents, as defined in the purchase agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202323462336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;text-decoration-line:none;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results </span><span style="font-weight:normal;text-decoration-line:none;">could differ from those estimates.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company estimates an annual effective tax rate of 0% as the Company incurred net losses for the&#160;year ended December&#160;31, 2022 resulting in an estimated net loss for both financial statement and tax purposes. Therefore, no current federal or state income tax expense has been recorded in the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Based on the Company&#8217;s history of generating operating losses and its anticipation of operating losses for the foreseeable future, the Company has determined that it is more likely than not that the tax benefits from those net operating losses would not be realized and a full valuation allowance against all deferred tax assets has been recorded. Should the Company&#8217;s assessment change, tax benefits associated with the historic net operating loss carryforwards could be limited due to future ownership changes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Prior to the Company&#8217;s corporate conversion in June&#160;2021, the Company was organized as a limited liability company. As such, the Company was not a tax paying entity for federal income tax purposes and, therefore, no income tax expense has been recorded in the financial statements. Income or losses of the Company was passed through to the members for inclusion in their respective income tax returns.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Concentration of Credit Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company maintains its cash balance in one financial institution. The balance is insured up to the maximum allowable by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company has not experienced any losses in such accounts and does not believe it is exposed to any significant risk of loss on cash. At times, the cash balance may exceed the maximum insured limit of the FDIC. As of December&#160;31, 2022, the Company had cash of approximately $9.1 million in U.S. bank accounts which was not fully insured by the FDIC.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies', window );">Guaranteed Payments to Members</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Guaranteed Payments to Members</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Prior to the corporate conversion, guaranteed payments to members of the Company that were designated to represent reasonable compensation for services rendered were accounted for as Company expenses rather than an allocation of the Company&#8217;s net income.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Research and Development</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company expenses research and development costs when incurred. At times, the Company may make cash advances for future research and development services. These amounts are deferred and expensed in the period the service is provided. The Company incurred research and development expenses in the amount of $4,754,271 and $2,030,177 for the&#160;years ended December&#160;31, 2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Costs for certain research and development activities, such as the provision of services for clinical trial activity, are estimated based on an evaluation of the progress to completion of specific tasks which may use data such as subject enrollment, clinical site activations or information provided to the Company by its vendors with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development expense, as the case may be. The estimates are adjusted to reflect the best information available at the time of the financial statement issuance. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company's estimate of the status and timing of services performed relative to the actual status and timing of services performed may vary. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Share-Based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for the cost of services performed by officers and directors received in exchange for an award of Company membership interests, common stock or stock options, based on the grant-date fair value of the award. The Company recognizes compensation expense based on the requisite service period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Compensation expense associated with stock option awards is recognized over the requisite service period based on the fair value of the option at the grant date determined based on the Black-Scholes option pricing model. Option valuation models require the input of highly subjective assumptions including the expected price volatility. The Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair value computation using the Black-Scholes option pricing model. Because there is no public market for the Company&#8217;s stock options and very little historical experience with the Company&#8217;s stock, similar public companies were used for the comparison of volatility and the dividend yield. The risk-free rate of return was derived from U.S. Treasury notes with comparable maturities.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_ShareBasedPaymentsToVendorsPolicyTextBlock', window );">Share-Based Payments to Vendors</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Share-Based Payments to Vendors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for the cost of services performed by vendors in exchange for an award of Company membership interests, common stock, or stock options, based on the grant-date fair value of the award or the fair value of the services rendered; whichever is more readily determinable. The Company recognizes the expense in the same period and in the same manner as if the Company had paid cash for the services.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Major Vendor</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Major Vendor</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company had a major vendor that accounted for approximately 55% and 42% of the research and development expenditures for the&#160;years ended December&#160;31, 2022 and 2021, respectively. The same vendor also accounted for approximately 56% and 5% of the total accounts payable and accrued expenses as of December&#160;31, 2022 and 2021, respectively. The Company continues to maintain this vendor relationship and anticipates incurring significant expenses with this vendor over the next 12&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company had an additional major vendor that accounted for approximately 4% and 15% of the research and development expenditures for the&#160;years ended December&#160;31, 2022 and 2021. The same vendor did not account for any material portion of the total accounts payable and accrued expenses. The Company will continue to maintain this vendor relationship over the next 12&#160;months.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acxp_ShareBasedPaymentsToVendorsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for share-based payments to vendors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acxp_ShareBasedPaymentsToVendorsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for guarantees, indemnifications and product warranties, and methodologies used in determining the amount of such liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202405766576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of accounts payable and accrued expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 542,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 508,343</p></td></tr><tr><td style="vertical-align:bottom;width:62.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,405,536</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 229,090</p></td></tr><tr><td style="vertical-align:bottom;width:62.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 83,715</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,102</p></td></tr><tr><td style="vertical-align:bottom;width:62.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,539</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63,374</p></td></tr><tr><td style="vertical-align:bottom;width:62.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,061,685</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 843,909</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202321353184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ISSUANCE OF EQUITY INTERESTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>ISSUANCE OF EQUITY INTERESTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of outstanding warrants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,588,477</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.32</p></td></tr><tr><td style="vertical-align:bottom;width:61.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">   Issued</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,776,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.12</p></td></tr><tr><td style="vertical-align:bottom;width:61.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">   Exercised</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (147,144)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.27</p></td></tr><tr><td style="vertical-align:bottom;width:61.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,217,809</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.29</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202319710064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock', window );">Schedule of unvested Class A membership interest converted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:39.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Class A</p></td></tr><tr><td style="vertical-align:bottom;width:57.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Membership Interests</p></td></tr><tr><td style="vertical-align:bottom;width:57.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Converted to common stock at one-for-two ratio</p></td></tr><tr><td style="vertical-align:bottom;width:57.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 200,463</p></td></tr><tr><td style="vertical-align:bottom;width:57.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (200,463)</p></td></tr><tr><td style="vertical-align:bottom;width:57.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of fair value of options assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Year Ended </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average grant date fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Year Ended </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Weighted&#160;Average</p></td></tr><tr><td style="vertical-align:bottom;width:55.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Exercise&#160;Price</p></td></tr><tr><td style="vertical-align:bottom;width:55.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at the beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,357,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.21</p></td></tr><tr><td style="vertical-align:bottom;width:55.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 110,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.26</p></td></tr><tr><td style="vertical-align:bottom;width:55.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:55.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:55.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at the end of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,467,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.12</p></td></tr><tr><td style="vertical-align:bottom;width:55.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,552,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.15</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested performance-based units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202321527600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of components of net deferred income tax asset</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Net operating loss carry forwards</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,359,183</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,594,650</p></td></tr><tr><td style="vertical-align:bottom;width:66.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Share-based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,262,381</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,149,720</p></td></tr><tr><td style="vertical-align:bottom;width:66.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Research and development credit carryforwards</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 141,671</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105,881</p></td></tr><tr><td style="vertical-align:bottom;width:66.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Capitalized research and development </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,347,028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Gross deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,110,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,850,251</p></td></tr><tr><td style="vertical-align:bottom;width:66.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,110,263)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,850,251)</p></td></tr><tr><td style="vertical-align:bottom;width:66.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">    Net deferred tax asset</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of reconciliation of income tax expense (benefit)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:49.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:81.59%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:16.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:17.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Federal income tax expense at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State income tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.4</p></td><td style="vertical-align:bottom;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.5)</p></td><td style="vertical-align:bottom;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development tax credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.3</p></td><td style="vertical-align:bottom;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (35.2)</p></td><td style="vertical-align:bottom;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (27.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202318243504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Jul. 25, 2022</div></th>
<th class="th"><div>Jun. 29, 2021</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,159,211<span></span>
</td>
<td class="nump">2,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts', window );">Stock issue gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="nump">$ 17,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,111,751<span></span>
</td>
<td class="nump">$ 12,958,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,437,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=acxp_SeriesWarrantsMember', window );">Series A warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,289,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=acxp_SeriesBWarrantsMember', window );">Series B warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,289,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=acxp_RegisteredDirectOfferingMember', window );">Registered direct offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during the period</a></td>
<td class="nump">1,159,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts', window );">Stock issue gross proceeds</a></td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_WarrantExercisePreFundedShares', window );">Pre-funded Warrant Exercise (in shares)</a></td>
<td class="nump">130,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Series A warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants</a></td>
<td class="nump">1,289,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Series B warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants</a></td>
<td class="nump">1,289,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=acxp_CommonUnitClassBMemberSCapitalMember', window );">Members' Equity, Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=acxp_AcxThreeSixtyTwoEMember', window );">ACX362E</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForOperatingActivities', window );">Cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Future commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_PercentageOfRoyaltyPaymentsOnNetSales', window );">Royalty payments on net sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=acxp_AcxThreeSixtyTwoEMember', window );">ACX362E | Members' Equity, Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Granting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acxp_PercentageOfRoyaltyPaymentsOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents for percentage of royalty payments on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acxp_PercentageOfRoyaltyPaymentsOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acxp_StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from new stock issued during the period before offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acxp_StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acxp_WarrantExercisePreFundedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the number of shares issued through pre-funded warrant exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acxp_WarrantExercisePreFundedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of cash paid for operating activities during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (d)-(g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=acxp_SeriesWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=acxp_SeriesWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=acxp_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=acxp_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=acxp_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=acxp_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=acxp_CommonUnitClassBMemberSCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=acxp_CommonUnitClassBMemberSCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=acxp_AcxThreeSixtyTwoEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=acxp_AcxThreeSixtyTwoEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202318728704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit', window );">Current federal or state income tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">9,111,751<span></span>
</td>
<td class="nump">$ 12,958,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 4,754,271<span></span>
</td>
<td class="nump">$ 2,030,177<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202318784928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration (Details) - Supplier Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsTotalMember', window );">Research and development expenditures | Vendor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk (as a percent)</a></td>
<td class="nump">55.00%<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsTotalMember', window );">Research and development expenditures | Vendor Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk (as a percent)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_LiabilitiesTotalMember', window );">Accounts payable and accrued expense | Vendor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk (as a percent)</a></td>
<td class="nump">56.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=acxp_VendorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=acxp_VendorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=acxp_VendorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=acxp_VendorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_LiabilitiesTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_LiabilitiesTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202314358304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation expenses</a></td>
<td class="nump">$ 542,895<span></span>
</td>
<td class="nump">$ 508,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_AccruedResearchAndDevelopmentCurrent', window );">Accrued research and development</a></td>
<td class="nump">1,405,536<span></span>
</td>
<td class="nump">229,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">83,715<span></span>
</td>
<td class="nump">43,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Other accounts payable and accrued expenses</a></td>
<td class="nump">29,539<span></span>
</td>
<td class="nump">63,374<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 2,061,685<span></span>
</td>
<td class="nump">$ 843,909<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acxp_AccruedResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount carrying value as of the balance sheet date of accrued research and development Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acxp_AccruedResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202318075040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PAYCHECK PROTECTION PROGRAM LOAN (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on Forgiveness of Paycheck Protection Program Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,503<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=acxp_PaycheckProtectionProgramLoanMember', window );">Paycheck Protection Program Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from Paycheck Protection Program Loan</a></td>
<td class="nump">$ 66,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Annual interest rate</a></td>
<td class="nump">0.98%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTerm', window );">Maturity period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on Forgiveness of Paycheck Protection Program Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,503<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=acxp_PaycheckProtectionProgramLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=acxp_PaycheckProtectionProgramLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202318218176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EXECUTIVE COMPENSATION (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 29, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="nump">770,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=acxp_CommonUnitClassMemberSCapitalMember', window );">Members' Equity, Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_StockIssuedDuringPeriodSharesBonus', window );">Shares issued for bonus (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=acxp_CommonUnitClassBMemberSCapitalMember', window );">Members' Equity, Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=acxp_CommonUnitClassBMemberSCapitalMember', window );">Members' Equity, Class B | Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=acxp_CommonUnitClassBMemberSCapitalMember', window );">Members' Equity, Class B | Non-Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acxp_StockIssuedDuringPeriodSharesBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to bonus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acxp_StockIssuedDuringPeriodSharesBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=acxp_CommonUnitClassMemberSCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=acxp_CommonUnitClassMemberSCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=acxp_CommonUnitClassBMemberSCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=acxp_CommonUnitClassBMemberSCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=acxp_NonEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=acxp_NonEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202314561760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ISSUANCE OF EQUITY INTERESTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Jul. 25, 2022</div></th>
<th class="th"><div>Jun. 29, 2021</div></th>
<th class="th"><div>Jun. 23, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,627,609<span></span>
</td>
<td class="nump">10,215,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,159,211<span></span>
</td>
<td class="nump">2,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Initial Public Offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,797,132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Cash issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 529,805<span></span>
</td>
<td class="nump">$ 2,452,868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Converted shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,041,208<span></span>
</td>
<td class="nump">7,041,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,437,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts', window );">Stock issue gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="nump">$ 17,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from stock issue, net of costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,695,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=acxp_CommonUnitClassAndClassBMemberSCapitalMember', window );">Members' Equity, Class A and Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted to shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,082,318<span></span>
</td>
<td class="nump">14,082,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=acxp_SeriesWarrantsMember', window );">Series A warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,289,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=acxp_SeriesBWarrantsMember', window );">Series B warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,289,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=acxp_AffiliateInvestorsMember', window );">Affiliate Investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_WarrantExercisePreFundedShares', window );">Pre-funded Warrant Exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=acxp_AffiliateInvestorsMember', window );">Affiliate Investors | Series A warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=acxp_AffiliateInvestorsMember', window );">Affiliate Investors | Series B warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=us-gaap_InvestorMember', window );">Investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_WarrantExercisePreFundedShares', window );">Pre-funded Warrant Exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_ClassOfWarrantOrRightPurchasePrice', window );">Purchase price pre-funded warrant (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.2499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=us-gaap_InvestorMember', window );">Investor | Series A warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,230,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=us-gaap_InvestorMember', window );">Investor | Series B warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,230,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=acxp_UnderwriterMember', window );">Underwriter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_ClassOfWarrantOrRightExercisableTerm', window );">Warrant exercisable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=acxp_RegisteredDirectOfferingMember', window );">Registered direct offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during the period</a></td>
<td class="nump">1,159,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_WarrantExercisePreFundedShares', window );">Pre-funded Warrant Exercise (in shares)</a></td>
<td class="nump">130,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts', window );">Stock issue gross proceeds</a></td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=acxp_PlacementAgentsMember', window );">Placement Agents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Cash issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 287,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_PercentageOfWeightedAveragePublicOfferingPriceOfAggregateNumberOfSharesOfCommonStockSold', window );">Weighted average aggregate offering price (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acxp_ClassOfWarrantOrRightExercisableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right exercisable term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acxp_ClassOfWarrantOrRightExercisableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acxp_ClassOfWarrantOrRightPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acxp_ClassOfWarrantOrRightPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acxp_PercentageOfWeightedAveragePublicOfferingPriceOfAggregateNumberOfSharesOfCommonStockSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of weighted average public offering price of the aggregate number of shares of common stock sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acxp_PercentageOfWeightedAveragePublicOfferingPriceOfAggregateNumberOfSharesOfCommonStockSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acxp_StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from new stock issued during the period before offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acxp_StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acxp_WarrantExercisePreFundedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the number of shares issued through pre-funded warrant exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acxp_WarrantExercisePreFundedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=acxp_CommonUnitClassAndClassBMemberSCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=acxp_CommonUnitClassAndClassBMemberSCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=acxp_SeriesWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=acxp_SeriesWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=acxp_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=acxp_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=acxp_AffiliateInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=acxp_AffiliateInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=acxp_UnderwriterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=acxp_UnderwriterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=acxp_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=acxp_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=acxp_PlacementAgentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=acxp_PlacementAgentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202314403760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ISSUANCE OF EQUITY INTERESTS - Fair Value (Details)<br></strong></div></th>
<th class="th">
<div>Jul. 25, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>Y</div>
</th>
<th class="th">
<div>Jun. 29, 2021 </div>
<div>USD ($) </div>
<div>Y </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=acxp_UnderwriterMember', window );">Underwriter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Warrants fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Fair value of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 618,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=acxp_UnderwriterMember', window );">Underwriter | Measurement Input, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Warrants fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement Input, Warrants | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=acxp_UnderwriterMember', window );">Underwriter | Measurement Input, Risk Free Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Warrants fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement Input, Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=acxp_UnderwriterMember', window );">Underwriter | Measurement Input, Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Warrants fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement Input, Warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=acxp_UnderwriterMember', window );">Underwriter | Measurement Input, Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Warrants fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement Input, Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=acxp_PlacementAgentsMember', window );">Placement Agents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Warrants fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Fair value of Warrants</a></td>
<td class="nump">$ 171,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=acxp_PlacementAgentsMember', window );">Placement Agents | Measurement Input, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Warrants fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement Input, Warrants | Y</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=acxp_PlacementAgentsMember', window );">Placement Agents | Measurement Input, Risk Free Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Warrants fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement Input, Warrants</a></td>
<td class="nump">2.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=acxp_PlacementAgentsMember', window );">Placement Agents | Measurement Input, Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Warrants fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement Input, Warrants | $ / shares</a></td>
<td class="nump">3.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=acxp_PlacementAgentsMember', window );">Placement Agents | Measurement Input, Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Warrants fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement Input, Warrants</a></td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=acxp_UnderwriterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=acxp_UnderwriterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=acxp_PlacementAgentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=acxp_PlacementAgentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202319183312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ISSUANCE OF EQUITY INTERESTS - Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 29, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares), beginning balance</a></td>
<td class="nump">1,588,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_ClassOfWarrantOrRightIssued', window );">Warrants issued (in shares)</a></td>
<td class="nump">2,776,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_ClassOfWarrantOrRightExercised', window );">Warrants exercised (in shares)</a></td>
<td class="num">(147,144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares), ending balance</a></td>
<td class="nump">4,217,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price, outstanding (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price, outstanding (in dollars per share)</a></td>
<td class="nump">$ 3.29<span></span>
</td>
<td class="nump">$ 3.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued', window );">Warrant exercise price, issued (in dollars per share)</a></td>
<td class="nump">3.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised', window );">Warrant exercise price, exercised (in dollars per share)</a></td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acxp_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in warrants outstanding during the period for the number of warrant exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acxp_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acxp_ClassOfWarrantOrRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in warrants outstanding during the period for the number of warrant issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acxp_ClassOfWarrantOrRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202313990096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 755,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">770,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Grant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total compensation expense not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,243,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value of stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 6 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember', window );">Pre IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Grant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateJune2021Member', window );">June 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 726,880<span></span>
</td>
<td class="nump">2,019,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">807,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Grant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateJune2021Member', window );">June 2021 | Employee | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateJune2021Member', window );">June 2021 | Employee | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting term of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member', window );">July 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,963,667<span></span>
</td>
<td class="nump">$ 2,379,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Grant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member', window );">July 2021 | Executive officers | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member', window );">July 2021 | Executive officers | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting term of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member', window );">July 2021 | Independent Directors, Consultant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting term of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member', window );">January 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member', window );">January 2022 | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member', window );">January 2022 | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting term of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateApril2022Member', window );">April 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateApril2022Member', window );">April 2022 | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateApril2022Member', window );">April 2022 | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting term of options</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=acxp_EquityIncentivePlan2021Member', window );">2021 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional common stock shares reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">408,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock shares available (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">537,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">537,937<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateJune2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateJune2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=acxp_IndependentDirectorsConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=acxp_IndependentDirectorsConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateApril2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateApril2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=acxp_EquityIncentivePlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=acxp_EquityIncentivePlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202321527600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Unvested (Details) - Members' Equity, Class A<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at December 31, 2020</a></td>
<td class="nump">200,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="num">(200,463)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=acxp_CommonUnitClassMemberSCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=acxp_CommonUnitClassMemberSCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202318819856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Option pricing (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">90.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.01%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="nump">$ 3.54<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202318194048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Option activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,357,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">770,000<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,467,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,552,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise price, Beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise price, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise price, End of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202312510048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED PAYMENTS TO VENDORS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_ShareBasedPaymentToVendors', window );">Share-based vendor payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 430,680<span></span>
</td>
<td class="nump">$ 1,587,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">770,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,217,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,217,809<span></span>
</td>
<td class="nump">1,588,477<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember', window );">Pre IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_ShareBasedPaymentToVendors', window );">Share-based vendor payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember', window );">Pre IPO | Members' Equity, Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Share-based vendor payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember', window );">Pre IPO | General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_ShareBasedPaymentToVendors', window );">Share-based vendor payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 201,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember', window );">Pre IPO | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_ShareBasedPaymentToVendors', window );">Share-based vendor payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,596<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member', window );">October 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_ShareBasedPaymentToVendors', window );">Share-based vendor payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member', window );">October 2019 | Members' Equity, Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Share-based vendor payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Grant date fair value ($ per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member', window );">Second Quarter 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Share-based vendor payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Grant date fair value ($ per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToSuppliers', window );">Vendor payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 343,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member', window );">Second Quarter 2021 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member', window );">Second Quarter 2021 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member', window );">July 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantedInThirdQuarter2021Member', window );">Third Quarter 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Share-based vendor payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_ShareBasedPaymentToVendors', window );">Share-based vendor payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateOctober2021Member', window );">October 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Share-based vendor payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_ShareBasedPaymentToVendors', window );">Share-based vendor payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member', window );">January 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateMarch2022Member', window );">March 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Share-based vendor payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_ShareBasedPaymentToVendors', window );">Share-based vendor payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Grant date fair value ($ per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToSuppliers', window );">Vendor payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateSeptember2022Member', window );">September 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Share-based vendor payments (in shares)</a></td>
<td class="nump">36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_ShareBasedPaymentToVendors', window );">Share-based vendor payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Grant date fair value ($ per share)</a></td>
<td class="nump">$ 3.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contract term</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member', window );">Fourth Quarter 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Share-based vendor payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_ShareBasedPaymentToVendors', window );">Share-based vendor payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member', window );">Fourth Quarter 2022 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Grant date fair value ($ per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member', window );">Fourth Quarter 2022 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Grant date fair value ($ per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acxp_ShareBasedPaymentToVendors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of non cash expense for share based payment to vendors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acxp_ShareBasedPaymentToVendors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of cash to suppliers for goods and services during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=acxp_CommonUnitClassMemberSCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=acxp_CommonUnitClassMemberSCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantedInThirdQuarter2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantedInThirdQuarter2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateOctober2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateOctober2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateMarch2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateMarch2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateSeptember2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantDateSeptember2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202323551888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 10.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research tax credit carryforward</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202318420848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Deferred tax asset (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 3,359,183<span></span>
</td>
<td class="nump">$ 1,594,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">2,262,381<span></span>
</td>
<td class="nump">1,149,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">141,671<span></span>
</td>
<td class="nump">105,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">1,347,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">7,110,263<span></span>
</td>
<td class="nump">2,850,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(7,110,263)<span></span>
</td>
<td class="num">$ (2,850,251)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired', window );">Capitalized research and development</a></td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of capitalized costs of a research and development nature that were acquired during the period in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202319235744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Tax reconciliation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax expense at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal benefit</a></td>
<td class="nump">14.40%<span></span>
</td>
<td class="nump">5.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Permanent differences</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research and development tax credit</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(35.20%)<span></span>
</td>
<td class="num">(27.10%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202319225024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Details) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2021</div></th>
<th class="th"><div>Jun. 23, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Converted shares of common stock</a></td>
<td class="nump">7,041,208<span></span>
</td>
<td class="nump">7,041,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=acxp_CommonUnitClassAndClassBMemberSCapitalMember', window );">Members' Equity, Class A and Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted to shares of common stock</a></td>
<td class="nump">14,082,318<span></span>
</td>
<td class="nump">14,082,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,217,809<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,467,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=acxp_CommonUnitClassAndClassBMemberSCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=acxp_CommonUnitClassAndClassBMemberSCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140202324790016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - ACX362E<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Feb. 28, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Contingency</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Future commitment</a></td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty payments</a></td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acxp_PercentageOfRoyaltyPaymentsOnNetSales', window );">Royalty payments on net sales (as a percent)</a></td>
<td class="nump">4.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acxp_PercentageOfRoyaltyPaymentsOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents for percentage of royalty payments on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acxp_PercentageOfRoyaltyPaymentsOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acxp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductLiabilityContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductLiabilityContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=acxp_AcxThreeSixtyTwoEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=acxp_AcxThreeSixtyTwoEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>acxp-20221231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:acxp="http://www.acurxpharma.com/20221231"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="acxp-20221231.xsd" xlink:type="simple"/>
    <context id="As_Of_7_25_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_SubsidiarySaleOfStockAxis_acxp_PlacementAgentsMember_DLWS4dqct0WPZhuICr1W5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acxp:PlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="As_Of_7_25_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_acxp_PlacementAgentsMember_24jUSFL8IkuQJWmQuEKwcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acxp:PlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="As_Of_7_25_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_SubsidiarySaleOfStockAxis_acxp_PlacementAgentsMember_3LCeKF0DIEaVdX-Uh1jhPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acxp:PlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="As_Of_7_25_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_SubsidiarySaleOfStockAxis_acxp_PlacementAgentsMember_BIzTc_rBT0-1HSfagb5b0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acxp:PlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="As_Of_6_29_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_SubsidiarySaleOfStockAxis_acxp_UnderwriterMember_v5jYpz8bRUyI--9gq4owJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acxp:UnderwriterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-29</instant>
        </period>
    </context>
    <context id="As_Of_6_29_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_acxp_UnderwriterMember_u8q_TpmED0-Ky05QbeiMpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acxp:UnderwriterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-29</instant>
        </period>
    </context>
    <context id="As_Of_6_29_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_SubsidiarySaleOfStockAxis_acxp_UnderwriterMember_sGehJTCm7kCXCyDe_BzraA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acxp:UnderwriterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-29</instant>
        </period>
    </context>
    <context id="As_Of_6_29_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_SubsidiarySaleOfStockAxis_acxp_UnderwriterMember_72h-4I7Sxki4jJ07k-e5bQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acxp:UnderwriterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-29</instant>
        </period>
    </context>
    <context id="Duration_2_1_2018_To_2_28_2018_srt_ProductOrServiceAxis_acxp_AcxThreeSixtyTwoEMember_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_J2BW4s8qOUKn-acaK_Oxcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acxp:AcxThreeSixtyTwoEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassBMemberSCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_1_31_2021_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_JtClA5RErEGfEeffjvyvtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassBMemberSCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantedInThirdQuarter2021Member_I8bs4d9ViU-viuLd-_7bTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantedInThirdQuarter2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_MYOlceR8bEyBXaE8PmDn2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDatePreIpoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassMemberSCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_10_31_2019_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_Gf1McXFwrk6xhgFzNeubnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateOctober2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassMemberSCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="Duration_6_23_2021_To_6_23_2021_TsxTykL9E0-yFWUKq9d3cQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
        </entity>
        <period>
            <startDate>2021-06-23</startDate>
            <endDate>2021-06-23</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_uxop3ZMQk0-ZXskL-V_mVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OYU0ijkQlkuzhtPcTOLIow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_GWozgFjldEK0a6rNLQuu1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XcVxdLM7g0aTslPVvSHW0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_XyHsu6ymoke-MXFBVwUwUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_25_2022_srt_TitleOfIndividualAxis_acxp_AffiliateInvestorsMember_0RaPP3HInkGg-_0ekTA3OQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">acxp:AffiliateInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_Ol44zQexSUa7wj9xwWiDsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassMemberSCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_boZANUamJEaYYgHn5Q9v8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassBMemberSCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member_7kblQvMdtEmqcKGRTUh1qw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member_YIfVK7k8V069cOaEAb-EWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateSeptember2022Member_lQ0vComUSUesFn-c_7_IYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateSeptember2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateMarch2022Member_XlEHT5yyoES9L354AxvHSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateMarch2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member_mxmMtGXpS0GIYfMeHwojow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2019_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_619kTaw0GEyZLXk7eliAdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateOctober2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassMemberSCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_4_30_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateApril2022Member_Jnl-Bb2R2EiM_K13OPkf4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateApril2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member_BaBBng1QkES6yfdBQj_5SA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateJanuary2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_7_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_D82Hstg3QkSYlPP9MHSV6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateJuly2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJune2021Member_iWpvZWkOx02nS35b2LJKJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateJune2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2021_To_6_30_2021_aPFoy3uQQkGd9asBZ1avUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_g7TcRnVZ-EeKEa9jZmWMBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateJuly2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_1_31_2021_srt_TitleOfIndividualAxis_acxp_NonEmployeeMember_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_UquoWzH2YUOrWpEKLgXNoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">acxp:NonEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassBMemberSCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_acxp_EquityIncentivePlan2021Member_W5IQ42UzGEy4rC9lIUrHjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">acxp:EquityIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_acxp_EquityIncentivePlan2021Member_TIyqWUA_-EClFlY5kpwukQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">acxp:EquityIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member_90xI89oKiEeLdXH5k-9FsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2022_To_9_30_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateSeptember2022Member_8MlpVu0cokmsSI5c6YJyTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateSeptember2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member_wrQ7Eh3v4EOO3IZeFBTejw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member_F_YLDKPV7UizWtFPSMLXBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_F5y4v9FsWES_CUZktDE-_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassMemberSCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_PvS7_eCOf02Kg60XmKqo1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassMemberSCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_4_30_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateApril2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_qohyZAg_4kexsYHlr-DRIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateApril2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Py4eXl-AxUWLsBuY7wnXUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateJanuary2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_7_31_2021_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_8YmAD-SQN0Gy2_-YJBttqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateJuly2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJune2021Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_xCQTnSxqU0yUl6NgiOZEdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateJune2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_4_30_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateApril2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_yPD_ZJI8H06PJt30JeyqDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateApril2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_4BRIuZGIFUyVO7Kq0DGlew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateJanuary2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_7_31_2021_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_owyoKTuxS0ybPw8J5ZH77A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateJuly2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_7_31_2021_srt_TitleOfIndividualAxis_acxp_IndependentDirectorsConsultantMember_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_Cgh2BZaRvECW2Z1yqwQ8tA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">acxp:IndependentDirectorsConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateJuly2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJune2021Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_p0UPlSeFgEOxcBPz5o_OfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateJune2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2022_To_3_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateMarch2022Member_-nNTg44K_E6nnbx1CwtZmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateMarch2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member_w1T2TY_SNkCVkeO9pZPLhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_2_28_2018_srt_ProductOrServiceAxis_acxp_AcxThreeSixtyTwoEMember_b8X5m76NYkaaQE7rN9N3KQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acxp:AcxThreeSixtyTwoEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-28</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Go-pCQ7LGkWyi1cgoF9ZQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__BvIcav9hkGe2hyzvEmB2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_FhifAapFH0uKzJs-MjO_1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassMemberSCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember__wGs7OIFT0CPK-kkN4m2Tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassBMemberSCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_svnDIsmsoEWsEvfBIapN1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassMemberSCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_TKQ1abvx9UijoSdLGqZqww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassBMemberSCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2020_us-gaap_ShortTermDebtTypeAxis_acxp_PaycheckProtectionProgramLoanMember_sS6eiAQzIkmyBpb68LMOBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">acxp:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ShortTermDebtTypeAxis_acxp_PaycheckProtectionProgramLoanMember_ITpBNU5NNkaQ1aNsqLkRmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">acxp:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2020_To_5_31_2020_us-gaap_ShortTermDebtTypeAxis_acxp_PaycheckProtectionProgramLoanMember_6co5NWgV9EOO1mbFZkcoFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">acxp:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="Duration_6_29_2021_To_6_29_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassAndClassBMemberSCapitalMember_sGnNM7X_Y0a52s50X0s31g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassAndClassBMemberSCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-29</startDate>
            <endDate>2021-06-29</endDate>
        </period>
    </context>
    <context id="Duration_6_23_2021_To_6_23_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassAndClassBMemberSCapitalMember_9R3-6dGcWEaNHCoKMihkrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassAndClassBMemberSCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-23</startDate>
            <endDate>2021-06-23</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_LiabilitiesTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_acxp_VendorOneMember_r8R9a4Obr0Ot0gf8VEQ9Gw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">acxp:VendorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_acxp_VendorTwoMember_yFuWsT6s0UCyH_YTEghzqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">acxp:VendorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_acxp_VendorOneMember_4oZxhIVJI0KIX3uwgXpLww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">acxp:VendorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_LiabilitiesTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_acxp_VendorOneMember_FamfXN_U9ECbf8TAjQXRNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">acxp:VendorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_acxp_VendorTwoMember__H92yBaZYkKfxsX2SKyheA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">acxp:VendorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_acxp_VendorOneMember_8CM4InADYkOReoekH1g7Zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">acxp:VendorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_27b4PKohgEW2UtRdiEuquw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassMemberSCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_vRcsmNgV3Eq09f5ms-XUQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassBMemberSCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2gVXSaZ170Wf8nqxjc_rMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_scb5hQt9d0-OCtp3xVkWXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_25_2022_YegiBECCekyLQBPmihkK7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="As_Of_4_30_2021_us-gaap_AwardTypeAxis_acxp_EquityIncentivePlan2021Member_HrihoDSDdE2dXqf1m4_VhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">acxp:EquityIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member_UmPpwgUbXEq7CaPHpNFPOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_27_2022_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Igcj6YgXu0uL014Kv8JyFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acxp:SeriesWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-27</instant>
        </period>
    </context>
    <context id="As_Of_7_27_2022_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_BaulSGACgEqCM8yVww4XkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acxp:SeriesBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-27</instant>
        </period>
    </context>
    <context id="As_Of_7_25_2022_srt_TitleOfIndividualAxis_us-gaap_InvestorMember_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesWarrantsMember_NWDnHTpMZUCylxU3oQXj-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acxp:SeriesWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="As_Of_7_25_2022_srt_TitleOfIndividualAxis_acxp_AffiliateInvestorsMember_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesBWarrantsMember_0trLt8KDDU2-A92s7AKaAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">acxp:AffiliateInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acxp:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="As_Of_7_25_2022_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesWarrantsMember_HHLsVDf1Skma7FwgAwWjhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acxp:SeriesWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="As_Of_7_25_2022_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesBWarrantsMember_WAQhRe6t0EmrCSaWui2e9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acxp:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_WeightedAverageMember__LDIrfLVM0-4X8uUinUNww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_25_2022_srt_TitleOfIndividualAxis_us-gaap_InvestorMember_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesBWarrantsMember_EZQw2mZf6Euo9EwTGvaY4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acxp:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="As_Of_7_25_2022_srt_TitleOfIndividualAxis_acxp_AffiliateInvestorsMember_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesWarrantsMember_6hXj30MhOU2VHM0OprvNzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">acxp:AffiliateInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acxp:SeriesWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="As_Of_7_25_2022_srt_TitleOfIndividualAxis_us-gaap_InvestorMember_Ri0JCPeSzE6DD189Cr4yVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="As_Of_7_25_2022_us-gaap_SubsidiarySaleOfStockAxis_acxp_PlacementAgentsMember_xZ4u8T8GOEmEbz0QrR2l2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acxp:PlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RangeAxis_srt_WeightedAverageMember_e70u-YktPE-UR-XzQ15xzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_acxp_UnderwriterMember_UBZF9KBTGk6x1d7NF_WJMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acxp:UnderwriterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-29</instant>
        </period>
    </context>
    <context id="As_Of_6_29_2021_jxXdY4PAdk6_gydSF_zR1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
        </entity>
        <period>
            <instant>2021-06-29</instant>
        </period>
    </context>
    <context id="As_Of_2_28_2018_srt_ProductOrServiceAxis_acxp_AcxThreeSixtyTwoEMember_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_gOS8l29JHkSEb-8_CljtJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acxp:AcxThreeSixtyTwoEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassBMemberSCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-28</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_GjIfeLZ3Ck689XNTpPYicQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_HEBRdNbrGUqT6x6-UyBm6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_m6mpGMbdVU2n0bKhzjnGLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJune2021Member_QNhUB26_yk2TvwRPRCTv5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateJune2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_dQo-EEliWUuFEj9-VZ9N3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateJuly2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member_eIYvcQou2k6kRaWtqOy8qQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateJanuary2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateApril2022Member_vR_7z-bGCUubmqFX9FxQYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateApril2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJune2021Member_vb95mGglMUy4oh0WaAepFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateJune2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_qx3OtHXhPUaPRIR812d3Ww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateJuly2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2022_arPPEgMHzESpDcWdrf7Z0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_15_2023_EMUzP5iUwESxrsXBZFLNEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
        </entity>
        <period>
            <instant>2023-03-15</instant>
        </period>
    </context>
    <context id="Duration_7_25_2022_To_7_25_2022_srt_TitleOfIndividualAxis_acxp_AffiliateInvestorsMember_p7F3gkO8pE2NTMNCZ9i1nQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">acxp:AffiliateInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-25</startDate>
            <endDate>2022-07-25</endDate>
        </period>
    </context>
    <context id="Duration_7_27_2022_To_7_27_2022_us-gaap_SubsidiarySaleOfStockAxis_acxp_RegisteredDirectOfferingMember_95IFFOAcVEe4mj_2dDLvKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acxp:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-27</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="Duration_7_25_2022_To_7_25_2022_sWcLqEbyWkeHbC8OdzC6_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
        </entity>
        <period>
            <startDate>2022-07-25</startDate>
            <endDate>2022-07-25</endDate>
        </period>
    </context>
    <context id="Duration_6_29_2021_To_6_29_2021_ZftWEESwJUi8qhJm8t8FPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
        </entity>
        <period>
            <startDate>2021-06-29</startDate>
            <endDate>2021-06-29</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bAx1kdchGkS4wq4G6E6-eA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_NHdyZ3imJk-CuOuyJfGKCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassMemberSCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_po048zYXXkK5B_bKRi3sOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_1_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_8oqL0Hgh60e7ICqaSonkbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassMemberSCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jVrdnRA-J0qI3Y9UjDQQ5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zlsc7iOms0m26BVpMKK4ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member_dxrWwDmqfUKvdyQbLpmhnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateSeptember2022Member_FgQUZhXKi0mL6FXLRm0gIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateSeptember2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember_EdWadodcnUyBlBRFeYfBqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDatePreIpoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateOctober2021Member_WyWUGX-ss020568gQjYm8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateOctober2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member_glK66UkK8kaOPtF_EMotIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateOctober2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateMarch2022Member_laHCYr4uL0S16Yf2nc-A4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateMarch2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_10_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateOctober2021Member_6LGtqepcjEOliJ4jOXHUIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateOctober2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_m2h7V2EdPEine3-RW3GKcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDatePreIpoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_At7Vvf6ODEu2VV8vZNhcWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDatePreIpoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantedInThirdQuarter2021Member_Tlp76MoUFEqKyMnI6aK_eQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantedInThirdQuarter2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateOctober2021Member_5i2X2rTyx0SYX8Xybc8Psw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateOctober2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member_TsKzRMZrzEyys7D-3GS8aw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">acxp:ShareBasedPaymentArrangementGrantDateOctober2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_25_2022_To_7_25_2022_us-gaap_SubsidiarySaleOfStockAxis_acxp_PlacementAgentsMember_E-IOxhM4rk2gkD8cStTzjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acxp:PlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-25</startDate>
            <endDate>2022-07-25</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2018_To_2_28_2018_srt_ProductOrServiceAxis_acxp_AcxThreeSixtyTwoEMember_Ney4atHhPEWi0zip1SpT4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acxp:AcxThreeSixtyTwoEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_25_2022_To_7_25_2022_srt_TitleOfIndividualAxis_us-gaap_InvestorMember__XKurX6OPUKTdaHa_IwqkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-25</startDate>
            <endDate>2022-07-25</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_WeightedAverageMember_XhK5Z9PZ80SoOyza28-Ohw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_29_2021_To_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_acxp_UnderwriterMember_-kSXTBxSPkq5OVNeYmsV1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acxp:UnderwriterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-29</startDate>
            <endDate>2021-06-29</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_YaTMIktqsk6w51g7L20gNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acxp:CommonUnitClassBMemberSCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001736243</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <unit id="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_Y_m6Q1ZS4FGUy3pAlacn4HHg">
        <measure>acxp:Y</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      id="Hidden_0To5aG5ayEeWsfoYnrjh9Q"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw"
      id="Hidden_qMXX6Qpp-kG_R1RF2J6ZpQ"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ"
      xsi:nil="true"/>
    <us-gaap:MembersCapital
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_FhifAapFH0uKzJs-MjO_1g"
      id="Hidden_CjhtDG9o-0eHLcphgHG_2Q"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ"
      xsi:nil="true"/>
    <us-gaap:MembersCapital
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_svnDIsmsoEWsEvfBIapN1g"
      id="Hidden_z-cA2B_zx0afjyItvPH4_Q"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ"
      xsi:nil="true"/>
    <us-gaap:MembersCapital
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember__wGs7OIFT0CPK-kkN4m2Tg"
      id="Hidden_1vP5TIDe006NnCGIW5-y5Q"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ"
      xsi:nil="true"/>
    <us-gaap:MembersCapital
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_TKQ1abvx9UijoSdLGqZqww"
      id="Hidden_clbq5dV84UWgpftBSE5TLw"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="INF"
      id="Hidden_7GDmEFwfuUmQonB5fSquiQ"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">11627609</us-gaap:CommonStockSharesOutstanding>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tc_kldvYc0vIEOE4zQkO47BrQ_2_1">0001736243</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tc_KlsDt4Op7U-g671RsWGygw_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tc_SWKvYl5oUUuif026bGP6qQ_4_1">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tc_P9aZrxWbuUygEOfkkSfCNA_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tc_1VWpinzz8EyW7JA6HZ9xNg_6_1">false</dei:AmendmentFlag>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_7_1_2021_To_7_31_2021_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_8YmAD-SQN0Gy2_-YJBttqQ"
      decimals="2"
      id="Hidden_EzWf9zq7yU2COrvaqFHBLw"
      unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="2"
      id="Tc_wPXw0E442UG5-WFLunMfqw_4_3"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">-1.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="2"
      id="Tc_9GKmzq3TF0eyMwIQXoFW1g_4_6"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">-1.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="0"
      id="Tc_uzdYWJ9yIEaikKMAvF16OA_5_3"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">10816412</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="0"
      id="Tc_GflXhuF6m0iVMW-L9rqovw_5_6"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">8535873</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="2"
      id="Tc_lRZ12Qay6EOceUx3t_RE_A_6_3"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">-1.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="2"
      id="Tc_oFmrqxhv8Eakqm6xQzfRNA_6_6"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">-1.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="0"
      id="Tc_PsnNGrFzPE-DAFx-f8ov6A_7_3"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">10816412</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="0"
      id="Tc_FLTpBblsfk2jyRBqdq8fOg_7_6"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">8535873</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_4_1_2022_To_4_30_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateApril2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_qohyZAg_4kexsYHlr-DRIg"
      decimals="2"
      id="Hidden__yx0SlixZk2t446zKw_EWA"
      unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2022_To_1_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Py4eXl-AxUWLsBuY7wnXUg"
      decimals="2"
      id="Hidden_GOeJkjeOiU-aNE91SNMVSA"
      unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_6_29_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_SubsidiarySaleOfStockAxis_acxp_UnderwriterMember_72h-4I7Sxki4jJ07k-e5bQ"
      decimals="1"
      id="Hidden_RMD-11b8a0WEvsJ9XyenQg"
      unitRef="Unit_Standard_Y_m6Q1ZS4FGUy3pAlacn4HHg">4.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_9_1_2022_To_9_30_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateSeptember2022Member_8MlpVu0cokmsSI5c6YJyTg"
      id="Hidden_pe6sq_5jwkGHEr32NVYkWA">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_10_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member_90xI89oKiEeLdXH5k-9FsA"
      id="Hidden_xpnuvER5pkCZfclL6LaL-Q">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw"
      decimals="INF"
      id="Hidden_hn7L1KzQWEKv4ikJD9PDqA"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">10215792</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:LongTermDebtTerm
      contextRef="As_Of_5_31_2020_us-gaap_ShortTermDebtTypeAxis_acxp_PaycheckProtectionProgramLoanMember_sS6eiAQzIkmyBpb68LMOBA"
      id="Hidden_nx3AzEkhbUS8BxsxeUh0lg">P2Y</us-gaap:LongTermDebtTerm>
    <dei:DocumentType
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Narr_0eWHmz9UQk213bwRlX2Xig">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Narr_-u4OKbxiHkSlwQaoOudcGw">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Narr_fEIwqM72LU6UbBl6K16k9Q">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Narr_VbxtM2UHxkG3nkBA4UK07A">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Narr_9np30a0ZYEuVZeiuaGhj_Q">001-40536</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Narr_vpDq0cSp4UqEAt_KYPHpuA">Acurx Pharmaceuticals,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Narr_LPTf94vezE-Us40hmVmxRA">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Narr_pPf78jDtzEGSJYATv4ssEg">259 Liberty Ave.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Narr_7loCAQU7WkiO6AnJW6sVQg">Staten Island</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Narr_j39j5HnWLUmN0wezIkiQ-g">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Narr_fBNA0NIHB0ezEHebFNkpaw">82-3733567</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Narr_TjxX2nqpFE6lJbAvcM2RBQ">10305</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Narr_88K_QOKa70ewqo17aMQQpw">917</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Narr_vSif5ez_J0y0YPTtyEzUFQ">533-1469</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tc_FxjgwsKAoEi92VCYW6RJ2A_1_0">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tc_cELoj8nc1EiTUfh68spBQw_1_2">ACXP</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Narr_ZSV2V4SbSkGg0GdfnJGWnw">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Narr_FOod1RMQlk6E_JLNtG88HA">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Narr_b_NYlwUpXkOUZdVTIIJ--Q">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Narr_d2PWDfAr3UKBk9kM4Hot8A">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Narr_GbOdqsYvWUSFOBFqv3Y9Cw">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tc_uC96wqgKkEKZFGBB52lr7g_3_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tc_SEanpHGeFEKDtqGLeK7pxA_3_6">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tc_FuRFhv4FwEuUlaV-xBBlIg_5_2">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Narr_HKZ_VKWUfEOAMl2hK6K_Yg">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Narr_ASQMpyv4nkyylnB3-8pkvQ">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Narr_1lYe_JrvFE-bJQGEm2I_LA">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2022_arPPEgMHzESpDcWdrf7Z0Q"
      decimals="-5"
      id="Narr_K2R2_7yAmE6rqi10wUYp9w"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">29800000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_15_2023_EMUzP5iUwESxrsXBZFLNEA"
      decimals="INF"
      id="Narr_qZJzBoLOIUqOVO2HtdaSsQ"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">11635795</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Narr_BUaWsW5urEaJGKLzKyMy9g">CohnReznick LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Narr_EzlDQ8ovhUO9dQAOOF4LvQ">Parsippany, NJ</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Narr_mZNmeUMECkGb41wxQMl0cQ">596</dei:AuditorFirmId>
    <us-gaap:Cash
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="0"
      id="Tc_BB-AxLiX3UGFMk3oi7heUw_7_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">9111751</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw"
      decimals="0"
      id="Tc_iNX1tgjQvkyjRYrGfYTaJA_7_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">12958846</us-gaap:Cash>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="0"
      id="Tc_RatL04oMgUq3Uorcwa1UGg_8_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">264955</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw"
      decimals="0"
      id="Tc_qvJhMPbDS0G9rAnv5D7y9g_8_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">295304</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="0"
      id="Tc_Fy2UC94FzU6mOVlAro9ZLw_9_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">9376706</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw"
      decimals="0"
      id="Tc_d705WBIW5U2OlPmO84SU7Q_9_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">13254150</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="0"
      id="Tc_Cac6AhHj5UqYB5qW7b7Rfg_14_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">2061685</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw"
      decimals="0"
      id="Tc_31v1ostg2kakB5CDlpNiTA_14_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">843909</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="0"
      id="Tc_9F1-2VCpu0Son5Oyn6DSdg_15_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">2061685</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw"
      decimals="0"
      id="Tc_4-Ik8Fjmf06AUEZYuZsj1w_15_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">843909</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="0"
      id="Tc_fH7ZbJ0mCEWMtNu3KFLZPQ_17_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">2061685</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw"
      decimals="0"
      id="Tc_bNK6xiwPXEGqBezEg5K37A_17_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">843909</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw"
      decimals="INF"
      id="Narr_Lbar9G-8OUeEkkO7ooRzig"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="INF"
      id="Narr_DHKGlpxTwEWv_VDKTPvsAQ"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw"
      decimals="INF"
      id="Narr_9FoVDLHZu0KkBv6lGujtwQ"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="INF"
      id="Narr_CcDq2ynyMk2Srd5qOXgh-w"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="INF"
      id="Narr_VkWQZ7Z5kkOhDKErdCwcBg"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">11627609</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw"
      decimals="INF"
      id="Narr_KCbMvC9HoUa-fFFGh_aaGA"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">10215792</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="0"
      id="Tc_IMJ4_tzQLUS1HlLCnsrNyQ_24_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">11628</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw"
      decimals="0"
      id="Tc_9Dk58kYJ4UeiP11bhfiCKg_24_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">10216</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="0"
      id="Tc_CMGooX_pbEanj-QcHFNhvA_25_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">45944478</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw"
      decimals="0"
      id="Tc_v3HzWjxLZUy5h7UiqJNB-w_25_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">38948334</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="0"
      id="Tc_JUoBhOQ1V0iQC9EQLNqcZw_26_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">-38641085</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw"
      decimals="0"
      id="Tc_upPBgoH-NEm7t6XmLm71mQ_26_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">-26548309</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="0"
      id="Tc_uZZ2jFZM406kMO4sJnEdEA_28_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">7315021</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw"
      decimals="0"
      id="Tc_YI03XrFWlUKYo7iCUbk3Zg_28_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">12410241</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="0"
      id="Tc_t4VXjwdHzEilbXAnd03UyQ_30_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">9376706</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw"
      decimals="0"
      id="Tc_vCfb6syQ9EW8g7yGQnPEVw_30_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">13254150</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="0"
      id="Tc_lv6uEQlXBkmPy39ISUAEhg_6_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">4754271</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="0"
      id="Tc_x_0jrJhPfkOvIMz_wtwqog_6_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">2030177</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="0"
      id="Tc_rVV5Kx1tPEmIkIcdqz1ebg_7_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">7338505</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="0"
      id="Tc_LYcX-h6FvEiCQ5CQ7DyeLA_7_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">10784023</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="0"
      id="Tc_LHG8VslPjEaSrVr3jTuBRA_9_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">12092776</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="0"
      id="Tc_fhmxJk3OKEaoCu1Jo1-mXQ_9_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">12814200</us-gaap:OperatingExpenses>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="0"
      id="Tc_q1Gz_IIEZUuQmyJHwt3ixQ_11_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">66503</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="0"
      id="Tc_SfbKLyKDo0uDa8m1Q8wrvA_13_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">-12092776</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="0"
      id="Tc_ADgPtfHI1U6Q8IP4fNTCDw_13_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">-12747697</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="2"
      id="Tc_PG7F54kU10yovPamns1wnw_16_3"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">-1.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="2"
      id="Tc_D38B5ESFNEGXh7dm8wTgCw_16_6"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">-1.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="0"
      id="Tc_E9Rkq9WeSEa4GPoqyPvQ0Q_18_3"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">10816412</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="0"
      id="Tc__HFK1niRfUu0Ta8xQws2hg_18_6"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">8535873</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonUnitOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_27b4PKohgEW2UtRdiEuquw"
      decimals="INF"
      id="Tc_9NORdN3MTk26klxefcrxWQ_6_2"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">13493807</us-gaap:CommonUnitOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_27b4PKohgEW2UtRdiEuquw"
      decimals="0"
      id="Tc_uENOgUswtEaNLyTtbnFILg_6_5"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">16402198</us-gaap:StockholdersEquity>
    <us-gaap:CommonUnitOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_vRcsmNgV3Eq09f5ms-XUQQ"
      decimals="INF"
      id="Tc_s0ffuAGVDEyk5xqZ6Uxv2A_6_7"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">100000</us-gaap:CommonUnitOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_vRcsmNgV3Eq09f5ms-XUQQ"
      decimals="0"
      id="Tc_Xa3WsUseqEC6VqNfb5S6NA_6_10"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_XyHsu6ymoke-MXFBVwUwUQ"
      decimals="0"
      id="Tc_NVLDynPPvE2Uzx0Jl-pJ-g_6_21"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">-13800612</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_GjIfeLZ3Ck689XNTpPYicQ"
      decimals="0"
      id="Tc_x5nM851HGEKNwmbqAEFkig_6_24"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">2701586</us-gaap:StockholdersEquity>
    <acxp:StockUnitsIssuedDuringPeriodSharesExecutiveCompensationSettled
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_NHdyZ3imJk-CuOuyJfGKCQ"
      decimals="INF"
      id="Tc_Qj9kun2T4UezZ3wGzwwBdA_7_2"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">57430</acxp:StockUnitsIssuedDuringPeriodSharesExecutiveCompensationSettled>
    <acxp:StockUnitsIssuedDuringPeriodValueExecutiveCompensationSettled
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_NHdyZ3imJk-CuOuyJfGKCQ"
      decimals="0"
      id="Tc_MUSdJNdQGUuMi5aEvMjvdA_7_5"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">186650</acxp:StockUnitsIssuedDuringPeriodValueExecutiveCompensationSettled>
    <acxp:StockUnitsIssuedDuringPeriodSharesExecutiveCompensationSettled
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_YaTMIktqsk6w51g7L20gNQ"
      decimals="INF"
      id="Tc_I0BaRZHZ1UKgUAdFyFvoAQ_7_7"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">471042</acxp:StockUnitsIssuedDuringPeriodSharesExecutiveCompensationSettled>
    <acxp:StockUnitsIssuedDuringPeriodValueExecutiveCompensationSettled
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_YaTMIktqsk6w51g7L20gNQ"
      decimals="0"
      id="Tc_LjfGSfxy_0i0fEq9aCZuWQ_7_10"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">730115</acxp:StockUnitsIssuedDuringPeriodValueExecutiveCompensationSettled>
    <acxp:StockUnitsIssuedDuringPeriodValueExecutiveCompensationSettled
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="0"
      id="Tc_Tp4VT1Lc-0GqqE1rWyid6A_7_24"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">916765</acxp:StockUnitsIssuedDuringPeriodValueExecutiveCompensationSettled>
    <acxp:CancellationOfStockUnitsShares
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_YaTMIktqsk6w51g7L20gNQ"
      decimals="INF"
      id="Tc_Tb40Krhi1EerIOBJjGnCLw_8_7"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">471042</acxp:CancellationOfStockUnitsShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_NHdyZ3imJk-CuOuyJfGKCQ"
      decimals="INF"
      id="Tc_B-eSILxrwk2w1Ec5dFYhfQ_9_2"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">400936</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_NHdyZ3imJk-CuOuyJfGKCQ"
      decimals="0"
      id="Tc_Jx-NAzkC4kubiczxMtT9xA_9_5"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">755556</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bAx1kdchGkS4wq4G6E6-eA"
      decimals="0"
      id="Tc_4mjRzJbXXUGEExwCJ41-VA_9_18"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">4399158</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="0"
      id="Tc_30OubhT270OwKxHPRqmvnQ_9_24"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">5154714</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_NHdyZ3imJk-CuOuyJfGKCQ"
      decimals="INF"
      id="Tc_WprY4jdsl06SgWZMa2ilTw_10_2"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">30145</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_NHdyZ3imJk-CuOuyJfGKCQ"
      decimals="0"
      id="Tc_56f-bi4A_0Gx2JjtOeCtyg_10_5"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">172971</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_po048zYXXkK5B_bKRi3sOQ"
      decimals="INF"
      id="Tc_0iJBznJCakOn_VTpK2loKA_10_12"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">299584</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_po048zYXXkK5B_bKRi3sOQ"
      decimals="0"
      id="Tc_7noU_ySMO06-3HWzhWDhbQ_10_15"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">300</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bAx1kdchGkS4wq4G6E6-eA"
      decimals="0"
      id="Tc_NcIeBl0i-UW1roEcFo968Q_10_18"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">1414470</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="0"
      id="Tc_X0H2kdDJAE-zQe_jv0cZzA_10_24"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">1587741</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <acxp:StockIssuedDuringPeriodSharesCorporateConversionOfUnits
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_NHdyZ3imJk-CuOuyJfGKCQ"
      decimals="INF"
      id="Tc_EPfJgw76qEK8NF8gsYZ_qA_11_2"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">13982318</acxp:StockIssuedDuringPeriodSharesCorporateConversionOfUnits>
    <acxp:StockIssuedDuringPeriodValueCorporateConversionOfUnits
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_NHdyZ3imJk-CuOuyJfGKCQ"
      decimals="0"
      id="Tc_yQbwaG7yTUqUiEL3ZQe1Xw_11_5"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">17517375</acxp:StockIssuedDuringPeriodValueCorporateConversionOfUnits>
    <acxp:StockIssuedDuringPeriodSharesCorporateConversionOfUnits
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_YaTMIktqsk6w51g7L20gNQ"
      decimals="INF"
      id="Tc_5XMCypNU4kK7812ItZ3xGw_11_7"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">100000</acxp:StockIssuedDuringPeriodSharesCorporateConversionOfUnits>
    <acxp:StockIssuedDuringPeriodValueCorporateConversionOfUnits
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_YaTMIktqsk6w51g7L20gNQ"
      decimals="0"
      id="Tc_R5uFpR6btkixBnloQuSeKg_11_10"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">830115</acxp:StockIssuedDuringPeriodValueCorporateConversionOfUnits>
    <acxp:StockIssuedDuringPeriodSharesCorporateConversionOfUnits
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_po048zYXXkK5B_bKRi3sOQ"
      decimals="INF"
      id="Tc_P23a0S_oxkGxB75y2nUw6w_11_12"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">-7041208</acxp:StockIssuedDuringPeriodSharesCorporateConversionOfUnits>
    <acxp:StockIssuedDuringPeriodValueCorporateConversionOfUnits
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_po048zYXXkK5B_bKRi3sOQ"
      decimals="0"
      id="Tc_RPgUujhNEU-8DRLqrboEYA_11_15"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">-7041</acxp:StockIssuedDuringPeriodValueCorporateConversionOfUnits>
    <acxp:StockIssuedDuringPeriodValueCorporateConversionOfUnits
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bAx1kdchGkS4wq4G6E6-eA"
      decimals="0"
      id="Tc_2Xi2JYuKIEeHbu_7Fq8rwA_11_18"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">-18340449</acxp:StockIssuedDuringPeriodValueCorporateConversionOfUnits>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="0"
      id="Narr_RcqqmYHA802oLgTmUHZSvA"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">2452868</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_po048zYXXkK5B_bKRi3sOQ"
      decimals="INF"
      id="Tc_uInYiQ9_UUWjCovGxBWfLA_12_12"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">2875000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_po048zYXXkK5B_bKRi3sOQ"
      decimals="0"
      id="Tc_zf-g3i4WWUK4KqYw_l3-wg_12_15"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">2875</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bAx1kdchGkS4wq4G6E6-eA"
      decimals="0"
      id="Tc_bG26gHP8E0qiyKNJe9i9nw_12_18"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">14794257</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="0"
      id="Tc_tdSo8AyHIUWEzWnDwI5_IA_12_24"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">14797132</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__BvIcav9hkGe2hyzvEmB2Q"
      decimals="0"
      id="Tc_FahQ9Eigwk6vYF6SkTt-xQ_13_21"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">-12747697</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="0"
      id="Tc_8LW4rR2W9UanRhqqtgvGSw_13_24"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">-12747697</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_scb5hQt9d0-OCtp3xVkWXA"
      decimals="INF"
      id="Tc_JJUASPVojku_hxoDMYW0Tg_14_12"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">10215792</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_scb5hQt9d0-OCtp3xVkWXA"
      decimals="0"
      id="Tc_W4lGOSH1MUOkEvBf40N4kg_14_15"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">10216</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XcVxdLM7g0aTslPVvSHW0A"
      decimals="0"
      id="Tc_yIXw5FoB00mzdrkT7nsrQA_14_18"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">38948334</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_GWozgFjldEK0a6rNLQuu1g"
      decimals="0"
      id="Tc_KZDRuPzhY0O7beWT7Fzdjw_14_21"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">-26548309</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw"
      decimals="0"
      id="Tc_HWBxvqgdh0KbVsyu7bnFnA_14_24"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">12410241</us-gaap:StockholdersEquity>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zlsc7iOms0m26BVpMKK4ag"
      decimals="0"
      id="Tc_CqjCfLvA50mytZ27C9fvTA_15_18"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">2871681</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="0"
      id="Tc_5ddCgEWxdkeFf4KWrEWXcQ_15_24"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">2871681</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jVrdnRA-J0qI3Y9UjDQQ5w"
      decimals="INF"
      id="Tc_69QpntfeNE-eL5_AxYluWQ_16_12"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">114889</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jVrdnRA-J0qI3Y9UjDQQ5w"
      decimals="0"
      id="Tc_GVzjxGnu7EakYgsPFngWhQ_16_15"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">115</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zlsc7iOms0m26BVpMKK4ag"
      decimals="0"
      id="Tc_eSx2z5zEBUKmtFJITulM7g_16_18"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">430565</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="0"
      id="Tc_DgSaLHVhFEiss5yNKgBzcA_16_24"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">430680</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="0"
      id="Narr_OlD0KfZIwE63c44Pvngbdw"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">529805</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jVrdnRA-J0qI3Y9UjDQQ5w"
      decimals="INF"
      id="Tc_ukUb81aKVkOSV8MBeQGf2A_17_12"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">1159211</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jVrdnRA-J0qI3Y9UjDQQ5w"
      decimals="0"
      id="Tc_nJyvY3gwQkeDcUSLZGOhdQ_17_15"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">1159</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zlsc7iOms0m26BVpMKK4ag"
      decimals="0"
      id="Tc_xYCXKJcDvkijwTDeJ52yRA_17_18"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">3694023</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="0"
      id="Tc_c6yTxgvBF0uCc2dZEeC1Og_17_24"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">3695182</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <acxp:StockIssuedDuringPeriodSharesPeriodIncreaseDecreaseThroughCashlessWarrantExercise
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jVrdnRA-J0qI3Y9UjDQQ5w"
      decimals="INF"
      id="Tc_rViCsKrNPEueyb4sVWhbgg_18_12"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">6948</acxp:StockIssuedDuringPeriodSharesPeriodIncreaseDecreaseThroughCashlessWarrantExercise>
    <acxp:StockholdersEquityPeriodIncreaseDecreaseThroughCashlessWarrantExercise
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jVrdnRA-J0qI3Y9UjDQQ5w"
      decimals="0"
      id="Tc_mVLN4C07AEuNXH1K17qALw_18_15"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">7</acxp:StockholdersEquityPeriodIncreaseDecreaseThroughCashlessWarrantExercise>
    <acxp:StockholdersEquityPeriodIncreaseDecreaseThroughCashlessWarrantExercise
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zlsc7iOms0m26BVpMKK4ag"
      decimals="0"
      id="Tc_a28poIEfwkCV1nPUZNeyIA_18_18"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">-7</acxp:StockholdersEquityPeriodIncreaseDecreaseThroughCashlessWarrantExercise>
    <acxp:WarrantExercisePreFundedShares
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jVrdnRA-J0qI3Y9UjDQQ5w"
      decimals="INF"
      id="Tc_v3jcy3Yve06gRn_aGnd5lg_19_12"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">130769</acxp:WarrantExercisePreFundedShares>
    <acxp:WarrantExercisePreFunded
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jVrdnRA-J0qI3Y9UjDQQ5w"
      decimals="0"
      id="Tc_E3mKIQlMckahnBKxAoxuOw_19_15"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">131</acxp:WarrantExercisePreFunded>
    <acxp:WarrantExercisePreFunded
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zlsc7iOms0m26BVpMKK4ag"
      decimals="0"
      id="Tc_osK9cxORBEupwZSgfmREYQ_19_18"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">-118</acxp:WarrantExercisePreFunded>
    <acxp:WarrantExercisePreFunded
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="0"
      id="Tc_wziH2OnPxkWmlJqeJ4GYag_19_24"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">13</acxp:WarrantExercisePreFunded>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Go-pCQ7LGkWyi1cgoF9ZQw"
      decimals="0"
      id="Tc_pDtQD7mIv0aQsECQxPae8Q_20_21"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">-12092776</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="0"
      id="Tc_4OGuDyw8fUqfkmTLUEbXTA_20_24"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">-12092776</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2gVXSaZ170Wf8nqxjc_rMg"
      decimals="INF"
      id="Tc_lrdfo9-qBkOl3earhFxvBg_21_12"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">11627609</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2gVXSaZ170Wf8nqxjc_rMg"
      decimals="0"
      id="Tc_GGIzovSkBUiXFavSU3-85A_21_15"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">11628</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OYU0ijkQlkuzhtPcTOLIow"
      decimals="0"
      id="Tc_-DzhqsKt4E6k1bSnOCx-OA_21_18"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">45944478</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_uxop3ZMQk0-ZXskL-V_mVw"
      decimals="0"
      id="Tc_hUMQXte0bUiGPxBTOPqu6Q_21_21"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">-38641085</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="0"
      id="Tc_NnPeug4Y4kKxyeDiK95FBQ_21_24"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">7315021</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="0"
      id="Tc_9rf1BzhKB0qFTluH1OFGRw_6_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">-12092776</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="0"
      id="Tc_5Z07wuO2PEC2EJQNr8kUaQ_6_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">-12747697</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="0"
      id="Tc_fIehG5k7HkusCenzac4tVA_8_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">2871681</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="0"
      id="Tc_JxHZU1z9rUWhCyBZGqnhEA_8_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">5154714</us-gaap:ShareBasedCompensation>
    <acxp:ShareBasedPaymentToVendors
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="0"
      id="Tc_K9BoXO6kEEaLBeXMazlb_A_9_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">430680</acxp:ShareBasedPaymentToVendors>
    <acxp:ShareBasedPaymentToVendors
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="0"
      id="Tc_v2C2jNgD4Uae_ojnsbz5rw_9_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">1587741</acxp:ShareBasedPaymentToVendors>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="0"
      id="Tc_sSqU4WY5lE2A5fvnDo2bbg_10_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">916765</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="0"
      id="Tc_r5SKqYlQP0SLMNFHOIZTpA_11_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">66503</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="0"
      id="Tc_HPlVF-o9PkeuLDako4pU2w_13_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">-30349</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="0"
      id="Tc_Mzhp957UbUK6duYSS0Xv6A_13_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">246695</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="0"
      id="Tc_R-_lGN2kCkOmeZ_ufeSObg_14_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">1217776</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="0"
      id="Tc_Txh7q3wRFE2uJLwHYTYtzw_14_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">387978</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="0"
      id="Tc_vKzZ1A2LOEyEYN9XaZvoLw_15_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">-7542290</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="0"
      id="Tc_mIoZ1djtjEuF6TEwS2NOyw_15_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">-5013697</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="0"
      id="Tc_4zUtID1sQU-9gKjJsVH4eA_18_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">14797132</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="0"
      id="Tc_rqId2cdBrkqaQak7Xwhcyw_19_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">3695182</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="0"
      id="Tc_ZJJTUTStSUyM2uKGG0Y2rA_20_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">13</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="0"
      id="Tc_17n4_8RfPUKYEJnkbDX5_w_21_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">3695195</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="0"
      id="Tc_I9BNdBr9MUiNZD-qK0e4fg_21_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">14797132</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="0"
      id="Tc_67QXhmETK0CHV9wyJf5IsQ_22_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">-3847095</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="0"
      id="Tc_3DC5rkd0G0-bC4lOqIOeYA_22_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">9783435</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw"
      decimals="0"
      id="Tc_dy3CxiV6OEm8nfyXezTlxQ_23_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">12958846</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_GjIfeLZ3Ck689XNTpPYicQ"
      decimals="0"
      id="Tc_VCkNTtfsaUCRgh8lNnBqcA_23_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">3175411</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="0"
      id="Tc_G5XQo-B9aUalAUItpyxdZg_24_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">9111751</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw"
      decimals="0"
      id="Tc_rWAqqqlSaky2j8vRToOE1w_24_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">12958846</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <acxp:NonCashFinancingActivitiesOfWarrantsIssuedInConnectionWithOfferings
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="0"
      id="Tc_HKSFB5gLcEy1B2wtpVe4iQ_26_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">171409</acxp:NonCashFinancingActivitiesOfWarrantsIssuedInConnectionWithOfferings>
    <acxp:NonCashFinancingActivitiesOfWarrantsIssuedInConnectionWithOfferings
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="0"
      id="Tc_ZhkclRfj_EaOAALu7HMT3g_26_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">618000</acxp:NonCashFinancingActivitiesOfWarrantsIssuedInConnectionWithOfferings>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tb_nnSLHEIprki9xdHgMVXqiw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;NOTE&#160;1&#160;&#x2013; NATURE OF OPERATIONS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;"&gt;Business:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Acurx Pharmaceuticals,&#160;Inc., a Delaware corporation, formerly Acurx Pharmaceuticals, LLC (the &#x201c;Company&#x201d;) is a clinical stage biopharmaceutical company formed in July&#160;2017, with operations commencing in February&#160;2018. The Company is focused on developing a novel class of antibiotics that address serious or life threatening bacterial infections.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;In March&#160;2020, the World Health Organization declared the outbreak of COVID-19, a novel strain of coronavirus, a global pandemic. This outbreak caused major disruptions to businesses and markets worldwide as the virus continued to spread. The COVID-19 pandemic has disrupted, and the Company expects it will continue to disrupt, its operations. The extent of the effect on the Company&#x2019;s operational and financial performance will depend on future developments, including the duration, spread and intensity of the pandemic, and governmental, regulatory and private sector responses, direct and indirect economic effects as a result of inflation, supply chain disruptions and labor shortages all of which are uncertain and difficult to predict. Although the Company is unable to estimate the financial effect of the pandemic, at this time, if the pandemic continues over a long period of time, it could have a material adverse effect on the Company&#x2019;s business, results of operations, financial condition, and cash flows. The financial statements do not reflect any adjustments as a result of the pandemic.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;In February&#160;2018, the Company purchased the active pharmaceutical ingredient, the intellectual property and other rights to an antibiotic product candidate known as GLS362E (renamed ACX-362E and now approved for non-proprietary name, ibezapolstat) (the &#x201c;Asset&#x201d;) from GLSynthesis,&#160;Inc. The Company paid $110,174 in cash, along with granting 100,000 Class&#160;B Membership Interests, profits interests as defined in the operating agreement, with an exercise price of $0.10 per share. The Company was also required to make certain milestone payments totaling $700,000 in aggregate if certain milestones are achieved, $50,000 of which has already been paid by the Company and royalty payments equal to 4% of net sales for a period of time equal to the last to expire of any applicable patents, as defined in the asset purchase agreement. The purchase of the Asset has resulted in our lead antibiotic product candidate, ibezapolstat, which targets the treatment of C. difficile infections (&#x201c;CDI&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s primary activities since inception aside from organizational activities have included performing research and development activities relating to the development of its two antibiotic candidates and raising funds through equity offerings including its initial public offering (&#x201c;IPO&#x201d;) consummated in June&#160;2021. The Company has not generated any revenues since inception.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. The Company has needed to raise capital from sales of its securities to sustain operations. On June&#160;29, 2021, the Company completed the IPO, issuing 2,875,000 shares of common stock at a price of $6.00 per share, with gross proceeds of approximately $17.3 million. On July 27, 2022, the Company completed a registered direct offering and a concurrent private placement, issuing 1,159,211 shares of common stock and 130,769 pre-funded warrants and series A warrants to purchase 1,289,980 shares of common stock and series B warrants to purchase 1,289,980 shares of common stock for gross proceeds of approximately $4.2&lt;span style="white-space:pre-wrap;"&gt; million.  As of December&#160;31, 2022, the Company had a cash balance of approximately &lt;/span&gt;$9.1 million, which based on current estimates will not be sufficient to meet our anticipated cash requirements for at least 12&#160;months from the issuance of the financial statements for the&#160;year ended December&#160;&lt;span style="white-space:pre-wrap;"&gt;31, 2022. Management believes that the Company will continue to incur losses for the foreseeable future and will need additional resources to sustain its operations until it can achieve profitability and positive cash flows, if ever. Management plans to seek additional equity financing and grant funding, but cannot assure that such financing and funding will be available at acceptable terms, or at all. These matters raise substantial doubt about the Company&#x2019;s ability to continue as a going concern.  The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty. There can be no assurance that the Company&#x2019;s research and development will be successfully completed or that any Company product candidate will be approved by &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;the Food and Drug Administration (&#x201c;FDA&#x201d;) or any other worldwide regulatory authority or become commercially viable. The Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with FDA and other governmental regulations and approval requirements&lt;/span&gt;.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:PaymentsForOperatingActivities
      contextRef="Duration_2_1_2018_To_2_28_2018_srt_ProductOrServiceAxis_acxp_AcxThreeSixtyTwoEMember_Ney4atHhPEWi0zip1SpT4Q"
      decimals="0"
      id="Narr_pH4O5_HNp06BuVlggbimdQ"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">110174</us-gaap:PaymentsForOperatingActivities>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="Duration_2_1_2018_To_2_28_2018_srt_ProductOrServiceAxis_acxp_AcxThreeSixtyTwoEMember_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_J2BW4s8qOUKn-acaK_Oxcg"
      decimals="INF"
      id="Narr_lhTw_SMa10-vIknrb3Em9g"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">100000</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_2_28_2018_srt_ProductOrServiceAxis_acxp_AcxThreeSixtyTwoEMember_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_gOS8l29JHkSEb-8_CljtJw"
      decimals="2"
      id="Narr_6NMEccEozkCeYvUrt8vaMg"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:OtherCommitment
      contextRef="As_Of_2_28_2018_srt_ProductOrServiceAxis_acxp_AcxThreeSixtyTwoEMember_b8X5m76NYkaaQE7rN9N3KQ"
      decimals="0"
      id="Narr_wlWOQ7uA8ECgmwhwqZJkxw"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">700000</us-gaap:OtherCommitment>
    <us-gaap:RoyaltyExpense
      contextRef="Duration_2_1_2018_To_2_28_2018_srt_ProductOrServiceAxis_acxp_AcxThreeSixtyTwoEMember_Ney4atHhPEWi0zip1SpT4Q"
      decimals="0"
      id="Narr_B5uDqXeZNEOhi08eDaVwMQ"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">50000</us-gaap:RoyaltyExpense>
    <acxp:PercentageOfRoyaltyPaymentsOnNetSales
      contextRef="Duration_2_1_2018_To_2_28_2018_srt_ProductOrServiceAxis_acxp_AcxThreeSixtyTwoEMember_Ney4atHhPEWi0zip1SpT4Q"
      decimals="2"
      id="Narr_yPEfpvA5bU6v633v7OQueQ"
      unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q">0.04</acxp:PercentageOfRoyaltyPaymentsOnNetSales>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_6_29_2021_To_6_29_2021_ZftWEESwJUi8qhJm8t8FPQ"
      decimals="INF"
      id="Narr_prJ-kPpSHUmHsz_f8--H-Q"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">2875000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_6_29_2021_jxXdY4PAdk6_gydSF_zR1g"
      decimals="2"
      id="Narr_QytYRAzjSEK_kZK6UoP7Lg"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">6.00</us-gaap:SharesIssuedPricePerShare>
    <acxp:StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts
      contextRef="Duration_6_29_2021_To_6_29_2021_ZftWEESwJUi8qhJm8t8FPQ"
      decimals="-5"
      id="Narr_OPkOVSEC8ESJwCzuL7LxaA"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">17300000</acxp:StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_27_2022_To_7_27_2022_us-gaap_SubsidiarySaleOfStockAxis_acxp_RegisteredDirectOfferingMember_95IFFOAcVEe4mj_2dDLvKQ"
      decimals="INF"
      id="Narr_uDrpny78CU2uvJEI5PifRg"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">1159211</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <acxp:WarrantExercisePreFundedShares
      contextRef="Duration_7_27_2022_To_7_27_2022_us-gaap_SubsidiarySaleOfStockAxis_acxp_RegisteredDirectOfferingMember_95IFFOAcVEe4mj_2dDLvKQ"
      decimals="INF"
      id="Narr_oLzNYzVMOEW8dheq4EWGGw"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">130769</acxp:WarrantExercisePreFundedShares>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_7_27_2022_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Igcj6YgXu0uL014Kv8JyFA"
      decimals="INF"
      id="Narr_N0a65ViJ3EuIfz_n-Xw-lQ"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">1289980</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_7_27_2022_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_BaulSGACgEqCM8yVww4XkA"
      decimals="INF"
      id="Narr_uDF-7XKbUUuhJJXHXD_A0g"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">1289980</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <acxp:StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts
      contextRef="Duration_7_27_2022_To_7_27_2022_us-gaap_SubsidiarySaleOfStockAxis_acxp_RegisteredDirectOfferingMember_95IFFOAcVEe4mj_2dDLvKQ"
      decimals="-5"
      id="Narr_bE0G22TkKEOVIE2uyfvDCA"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">4200000</acxp:StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts>
    <us-gaap:Cash
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="-5"
      id="Narr_0x0xgIgyVU-ui5xdJ5iVaA"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">9100000</us-gaap:Cash>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tb_VZl6lUJN4kq0YsmTWs9bgw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;NOTE&#160;2&#160;&#x2013; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;"&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;text-decoration-line:none;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results &lt;/span&gt;&lt;span style="font-weight:normal;text-decoration-line:none;"&gt;could differ from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;"&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company estimates an annual effective tax rate of 0% as the Company incurred net losses for the&#160;year ended December&#160;31, 2022 resulting in an estimated net loss for both financial statement and tax purposes. Therefore, no current federal or state income tax expense has been recorded in the financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Based on the Company&#x2019;s history of generating operating losses and its anticipation of operating losses for the foreseeable future, the Company has determined that it is more likely than not that the tax benefits from those net operating losses would not be realized and a full valuation allowance against all deferred tax assets has been recorded. Should the Company&#x2019;s assessment change, tax benefits associated with the historic net operating loss carryforwards could be limited due to future ownership changes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Prior to the Company&#x2019;s corporate conversion in June&#160;2021, the Company was organized as a limited liability company. As such, the Company was not a tax paying entity for federal income tax purposes and, therefore, no income tax expense has been recorded in the financial statements. Income or losses of the Company was passed through to the members for inclusion in their respective income tax returns.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;"&gt;Concentration of Credit Risk&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company maintains its cash balance in one financial institution. The balance is insured up to the maximum allowable by the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). The Company has not experienced any losses in such accounts and does not believe it is exposed to any significant risk of loss on cash. At times, the cash balance may exceed the maximum insured limit of the FDIC. As of December&#160;31, 2022, the Company had cash of approximately $9.1 million in U.S. bank accounts which was not fully insured by the FDIC.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;"&gt;Guaranteed Payments to Members&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Prior to the corporate conversion, guaranteed payments to members of the Company that were designated to represent reasonable compensation for services rendered were accounted for as Company expenses rather than an allocation of the Company&#x2019;s net income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;"&gt;Research and Development&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company expenses research and development costs when incurred. At times, the Company may make cash advances for future research and development services. These amounts are deferred and expensed in the period the service is provided. The Company incurred research and development expenses in the amount of $4,754,271 and $2,030,177 for the&#160;years ended December&#160;31, 2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Costs for certain research and development activities, such as the provision of services for clinical trial activity, are estimated based on an evaluation of the progress to completion of specific tasks which may use data such as subject enrollment, clinical site activations or information provided to the Company by its vendors with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development expense, as the case may be. The estimates are adjusted to reflect the best information available at the time of the financial statement issuance. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company's estimate of the status and timing of services performed relative to the actual status and timing of services performed may vary. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;"&gt;Share-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for the cost of services performed by officers and directors received in exchange for an award of Company membership interests, common stock or stock options, based on the grant-date fair value of the award. The Company recognizes compensation expense based on the requisite service period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Compensation expense associated with stock option awards is recognized over the requisite service period based on the fair value of the option at the grant date determined based on the Black-Scholes option pricing model. Option valuation models require the input of highly subjective assumptions including the expected price volatility. The Company&#x2019;s employee stock options have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair value computation using the Black-Scholes option pricing model. Because there is no public market for the Company&#x2019;s stock options and very little historical experience with the Company&#x2019;s stock, similar public companies were used for the comparison of volatility and the dividend yield. The risk-free rate of return was derived from U.S. Treasury notes with comparable maturities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;"&gt;Share-Based Payments to Vendors&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for the cost of services performed by vendors in exchange for an award of Company membership interests, common stock, or stock options, based on the grant-date fair value of the award or the fair value of the services rendered; whichever is more readily determinable. The Company recognizes the expense in the same period and in the same manner as if the Company had paid cash for the services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;"&gt;Major Vendor&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company had a major vendor that accounted for approximately 55% and 42% of the research and development expenditures for the&#160;years ended December&#160;31, 2022 and 2021, respectively. The same vendor also accounted for approximately 56% and 5% of the total accounts payable and accrued expenses as of December&#160;31, 2022 and 2021, respectively. The Company continues to maintain this vendor relationship and anticipates incurring significant expenses with this vendor over the next 12&#160;months.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company had an additional major vendor that accounted for approximately 4% and 15% of the research and development expenditures for the&#160;years ended December&#160;31, 2022 and 2021. The same vendor did not account for any material portion of the total accounts payable and accrued expenses. The Company will continue to maintain this vendor relationship over the next 12&#160;months.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tb_qLxEFSOFZU2dWK0adujUeg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;"&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;text-decoration-line:none;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results &lt;/span&gt;&lt;span style="font-weight:normal;text-decoration-line:none;"&gt;could differ from those estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tb_fqxuU3WMQUCKiuDfnLB3WA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;"&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company estimates an annual effective tax rate of 0% as the Company incurred net losses for the&#160;year ended December&#160;31, 2022 resulting in an estimated net loss for both financial statement and tax purposes. Therefore, no current federal or state income tax expense has been recorded in the financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Based on the Company&#x2019;s history of generating operating losses and its anticipation of operating losses for the foreseeable future, the Company has determined that it is more likely than not that the tax benefits from those net operating losses would not be realized and a full valuation allowance against all deferred tax assets has been recorded. Should the Company&#x2019;s assessment change, tax benefits associated with the historic net operating loss carryforwards could be limited due to future ownership changes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Prior to the Company&#x2019;s corporate conversion in June&#160;2021, the Company was organized as a limited liability company. As such, the Company was not a tax paying entity for federal income tax purposes and, therefore, no income tax expense has been recorded in the financial statements. Income or losses of the Company was passed through to the members for inclusion in their respective income tax returns.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="2"
      id="Narr_Ei66PiOkaE-ml1Wc9FWI9w"
      unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="0"
      id="Narr_5TQ1x2iUwEqNxOS2WpfKIg"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">0</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="0"
      id="Narr_kcsEUeXlQEKmy7IfJLvSug"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tb_IhFkXCtPDEmSLf6cRtV6Dg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;"&gt;Concentration of Credit Risk&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company maintains its cash balance in one financial institution. The balance is insured up to the maximum allowable by the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). The Company has not experienced any losses in such accounts and does not believe it is exposed to any significant risk of loss on cash. At times, the cash balance may exceed the maximum insured limit of the FDIC. As of December&#160;31, 2022, the Company had cash of approximately $9.1 million in U.S. bank accounts which was not fully insured by the FDIC.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:Cash
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="-5"
      id="Narr_NVJeOp1odUKVAfssY2aItA"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">9100000</us-gaap:Cash>
    <us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tb_I2sQOofwPEWWgXK-XE7lgw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;"&gt;Guaranteed Payments to Members&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Prior to the corporate conversion, guaranteed payments to members of the Company that were designated to represent reasonable compensation for services rendered were accounted for as Company expenses rather than an allocation of the Company&#x2019;s net income.&lt;/p&gt;</us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tb_QMBzVb4h9EuqVENkEL8i9A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;"&gt;Research and Development&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company expenses research and development costs when incurred. At times, the Company may make cash advances for future research and development services. These amounts are deferred and expensed in the period the service is provided. The Company incurred research and development expenses in the amount of $4,754,271 and $2,030,177 for the&#160;years ended December&#160;31, 2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Costs for certain research and development activities, such as the provision of services for clinical trial activity, are estimated based on an evaluation of the progress to completion of specific tasks which may use data such as subject enrollment, clinical site activations or information provided to the Company by its vendors with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development expense, as the case may be. The estimates are adjusted to reflect the best information available at the time of the financial statement issuance. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company's estimate of the status and timing of services performed relative to the actual status and timing of services performed may vary. &lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="0"
      id="Narr_CKF-frw0tEGy7sYflBoozQ"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">4754271</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="0"
      id="Narr_KCnFwwT9skKJoE1uss6-eA"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">2030177</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tb_SuRhtDQE3UaT-c2RmLE9ug">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;"&gt;Share-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for the cost of services performed by officers and directors received in exchange for an award of Company membership interests, common stock or stock options, based on the grant-date fair value of the award. The Company recognizes compensation expense based on the requisite service period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Compensation expense associated with stock option awards is recognized over the requisite service period based on the fair value of the option at the grant date determined based on the Black-Scholes option pricing model. Option valuation models require the input of highly subjective assumptions including the expected price volatility. The Company&#x2019;s employee stock options have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair value computation using the Black-Scholes option pricing model. Because there is no public market for the Company&#x2019;s stock options and very little historical experience with the Company&#x2019;s stock, similar public companies were used for the comparison of volatility and the dividend yield. The risk-free rate of return was derived from U.S. Treasury notes with comparable maturities.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <acxp:ShareBasedPaymentsToVendorsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tb_KGSGebMGEESMzzf2_7qKwQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;"&gt;Share-Based Payments to Vendors&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for the cost of services performed by vendors in exchange for an award of Company membership interests, common stock, or stock options, based on the grant-date fair value of the award or the fair value of the services rendered; whichever is more readily determinable. The Company recognizes the expense in the same period and in the same manner as if the Company had paid cash for the services.&lt;/p&gt;</acxp:ShareBasedPaymentsToVendorsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tb_QElX4vnjkEGb8fFZMjf9OQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;"&gt;Major Vendor&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company had a major vendor that accounted for approximately 55% and 42% of the research and development expenditures for the&#160;years ended December&#160;31, 2022 and 2021, respectively. The same vendor also accounted for approximately 56% and 5% of the total accounts payable and accrued expenses as of December&#160;31, 2022 and 2021, respectively. The Company continues to maintain this vendor relationship and anticipates incurring significant expenses with this vendor over the next 12&#160;months.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company had an additional major vendor that accounted for approximately 4% and 15% of the research and development expenditures for the&#160;years ended December&#160;31, 2022 and 2021. The same vendor did not account for any material portion of the total accounts payable and accrued expenses. The Company will continue to maintain this vendor relationship over the next 12&#160;months.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_acxp_VendorOneMember_4oZxhIVJI0KIX3uwgXpLww"
      decimals="2"
      id="Narr_55yiZv9kDkO8ccvAlOBLkg"
      unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q">0.55</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_acxp_VendorOneMember_8CM4InADYkOReoekH1g7Zg"
      decimals="2"
      id="Narr_sG1ugIlmPEeG2U8LynEDbw"
      unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q">0.42</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_LiabilitiesTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_acxp_VendorOneMember_r8R9a4Obr0Ot0gf8VEQ9Gw"
      decimals="2"
      id="Narr_d207u5vZ8ESCHw5-PPLy2w"
      unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q">0.56</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_LiabilitiesTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_acxp_VendorOneMember_FamfXN_U9ECbf8TAjQXRNg"
      decimals="2"
      id="Narr_JWJ2GshvXE6PgMA0ziYQWQ"
      unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q">0.05</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_acxp_VendorTwoMember_yFuWsT6s0UCyH_YTEghzqA"
      decimals="2"
      id="Narr_VL374KonTU6ND-guUv4DwQ"
      unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q">0.04</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_acxp_VendorTwoMember__H92yBaZYkKfxsX2SKyheA"
      decimals="2"
      id="Narr_L-ugyJaYXUeIgM1O4rWk-w"
      unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tb_YVCN2V8LFEemjsrJ64spNQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;NOTE&#160;3&#160;- ACCOUNTS PAYABLE AND ACCRUED EXPENSES&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Accounts payable and accrued expenses as of December&#160;31, 2022 and 2021 were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued compensation expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 542,895&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 508,343&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,405,536&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 229,090&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 83,715&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,102&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other accounts payable and accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,539&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 63,374&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,061,685&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 843,909&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tb_G-4w8GXIzE-XplryH1XPvg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued compensation expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 542,895&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 508,343&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,405,536&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 229,090&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 83,715&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,102&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other accounts payable and accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,539&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 63,374&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,061,685&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 843,909&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="0"
      id="Tc_JzpOAwDvH0Kd2_E40vcYsQ_2_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">542895</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw"
      decimals="0"
      id="Tc_b_qMHHBFp06ob3xZwpisDg_2_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">508343</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <acxp:AccruedResearchAndDevelopmentCurrent
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="0"
      id="Tc_k3Kwp_pGn0WCADfhmcH7Rg_3_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">1405536</acxp:AccruedResearchAndDevelopmentCurrent>
    <acxp:AccruedResearchAndDevelopmentCurrent
      contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw"
      decimals="0"
      id="Tc_MKvC-lOSV02gniVihdHu2A_3_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">229090</acxp:AccruedResearchAndDevelopmentCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="0"
      id="Tc_u2C6_POBUEO2uEBI6U40xQ_4_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">83715</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw"
      decimals="0"
      id="Tc_VxJiQWfceUipMEa9I3u5Vg_4_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">43102</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="0"
      id="Tc_aNcnNK-8A0SRz5OIBPkMOQ_5_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">29539</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw"
      decimals="0"
      id="Tc_5RBQTPuVGEO1N5V7Hmj3mA_5_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">63374</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="0"
      id="Tc_B6JrSmNcj020zSteUwwsKQ_6_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">2061685</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw"
      decimals="0"
      id="Tc_Xun4CoBDykeRrlalUMEzSA_6_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">843909</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <acxp:PaycheckProtectionProgramLoanDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tb_Hxl_2VREOEadXP0F6zFFTw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;NOTE&#160;4&#160;&#x2013; PAYCHECK PROTECTION PROGRAM LOAN&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;In May&#160;2020, the Company received a Paycheck Protection Program loan (&#x201c;PPP Loan&#x201d;) under the CARES Act, as administered by the U.S. Small Business Administration (&#x201d;SBA&#x201d;) in the amount of $66,503. &lt;span style="color:#252525;"&gt;&#160;The Company did not provide any collateral or guarantees in connection with the PPP loan, nor did the Company pay any facility charge to obtain the&#160;PPP Loan. The note and agreement provided for customary events of default, including those relating to failure to make payment, bankruptcy, breaches of representations and material adverse effects. The Company was permitted to prepay the principal of the&#160;PPP Loan&#160;at any time without incurring any prepayment charges. &lt;/span&gt;The PPP Loan carried an annual interest rate of 0.98% and a maturity date &lt;span style="-sec-ix-hidden:Hidden_nx3AzEkhbUS8BxsxeUh0lg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two&lt;/span&gt;&lt;/span&gt; (2)&#160;years from issuance. The Company was not obligated to make any payments of principal or interest before the date on which the SBA remits the loan forgiveness amount to the lender or notifies the lender that no loan forgiveness is allowed. On April&#160;13, 2021, the SBA authorized the full forgiveness of the PPP Loan. Accordingly, the Company reduced the full amount of the liability and recorded a gain in the amount of $66,503 on the forgiveness of the PPP loan in the statements of operations for the&#160;year ended December&#160;31, 2021.&lt;/p&gt;</acxp:PaycheckProtectionProgramLoanDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="Duration_5_1_2020_To_5_31_2020_us-gaap_ShortTermDebtTypeAxis_acxp_PaycheckProtectionProgramLoanMember_6co5NWgV9EOO1mbFZkcoFA"
      decimals="0"
      id="Narr_Ddgc-knUWUyy9vjuY4eVQQ"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">66503</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="Duration_5_1_2020_To_5_31_2020_us-gaap_ShortTermDebtTypeAxis_acxp_PaycheckProtectionProgramLoanMember_6co5NWgV9EOO1mbFZkcoFA"
      decimals="4"
      id="Narr_fT7pTVsfBUit_cVp4WOsnw"
      unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q">0.0098</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShortTermDebtTypeAxis_acxp_PaycheckProtectionProgramLoanMember_ITpBNU5NNkaQ1aNsqLkRmg"
      decimals="0"
      id="Narr_9eDEDcgh60CCTAsfcvGThw"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">66503</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:CompensationRelatedCostsGeneralTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tb_4DQe3rLfMUG0ibFKmlWl-A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;NOTE&#160;5&#160;&#x2013; EXECUTIVE COMPENSATION&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;In January&#160;2021, the Company issued 57,430 Class&#160;A Membership Interests at $3.25 per unit, equal to the value of the most recent private placement, to two of its executives to settle unpaid&#160;year-end bonus award and deferred compensation, which was approved by the board of directors. The&#160;year-end bonus component was equal to 38,353 Class&#160;A Membership Interests, which was included as accrued compensation. In January&#160;2021, the Company also amended the employment agreements for the three executives.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The board of directors also approved certain grants to members of management as a component of&#160;their 2020&#160;year-end compensation, authorizing the issuance of 1,540,000 Class&#160;B Membership Interests to its three executives, as well as 75,000 Class&#160;B Membership Interests which were granted to non-employee management team members. The Class&#160;B Membership Interests are profits interests with a defined exercise price of $3.25 per interest, the Company&#x2019;s most recent financing offering price. In March&#160;2021, the Company along with its three executives and non-employee management team agreed voluntarily to cancel the aforementioned equity grants. The Company granted options to purchase 770,000 shares of the Company&#x2019;s common stock in June&#160;2021 to the three-member management team in replacement of the cancelled&#160;year-end grants described above.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is currently managed by three executives, in each case pursuant to new employment agreements effective June&#160;29, 2021 and a controller hired in April 2022.&lt;/p&gt;</us-gaap:CompensationRelatedCostsGeneralTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_8oqL0Hgh60e7ICqaSonkbQ"
      decimals="INF"
      id="Narr_rlxgW674P0KGGc3zWDu2lw"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">57430</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_1_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_Ol44zQexSUa7wj9xwWiDsQ"
      decimals="2"
      id="Narr_Hh6-XgJzekejawdjLD3l5Q"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">3.25</us-gaap:SharesIssuedPricePerShare>
    <acxp:StockIssuedDuringPeriodSharesBonus
      contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_8oqL0Hgh60e7ICqaSonkbQ"
      decimals="INF"
      id="Narr_jq5DMKQzTkSMOtgwZl5YVg"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">38353</acxp:StockIssuedDuringPeriodSharesBonus>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="Duration_1_1_2021_To_1_31_2021_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_JtClA5RErEGfEeffjvyvtg"
      decimals="INF"
      id="Narr_wDh9Ia6dWU6k3i4ty9Obfw"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">1540000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_1_31_2021_srt_TitleOfIndividualAxis_acxp_NonEmployeeMember_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_UquoWzH2YUOrWpEKLgXNoA"
      decimals="INF"
      id="Narr_ffYGDTj5N0amJn0I8Ms8Xg"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_1_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassBMemberSCapitalMember_boZANUamJEaYYgHn5Q9v8g"
      decimals="2"
      id="Narr_O7NRB83-n0eIY7xax--_Gg"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">3.25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_6_1_2021_To_6_30_2021_aPFoy3uQQkGd9asBZ1avUg"
      decimals="INF"
      id="Narr_Tte_DVmJ8ketLPB-zi8iKw"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">770000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tb__aSFRGZej06UQah44a0NcQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;NOTE&#160;6&#160;&#x2013; ISSUANCE OF EQUITY INTERESTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;On June&#160;23, 2021, Acurx Pharmaceuticals, LLC was converted into a corporation and renamed Acurx Pharmaceuticals,&#160;Inc. The Company&#x2019;s certificate of incorporation authorizes 200,000,000 shares of common stock of which 11,627,609 were outstanding as of December&#160;31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;On June&#160;29, 2021, the Company completed an IPO issuing 2,875,000 shares of common stock at a price of $6.00 per share, resulting in net cash proceeds of approximately $14.8 million, with cash issuance costs of approximately $2.4 million. The outstanding Class&#160;A and Class&#160;B Membership Interests were converted to shares of common stock pursuant to a conversion ratio of one-for-two of the Membership Interests outstanding, resulting in the conversion of 14,082,318 Class&#160;A and Class&#160;B Membership Interests into 7,041,208 shares of common stock. Warrants to purchase Class&#160;A &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Membership Interests were converted to warrants to purchase common stock at the same one-for two conversion ratio, resulting in 1,437,577 warrants to purchase common stock with a weighted average exercise price of $2.88.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the IPO, the Company issued 150,000 warrants to the underwriter. Each warrant is exercisable for 4.5 years from December&#160;21, 2021 at an exercise price of $7.50 per share. The Company used the Black-Scholes model to calculate the value of the warrants with an estimated fair value of $618,000. The inputs utilized in the calculation were as follows: &lt;span style="-sec-ix-hidden:Hidden_RMD-11b8a0WEvsJ9XyenQg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;four&lt;/span&gt;&lt;/span&gt; and a half-year term, 0.79% risk-free rate, stock price at grant date of $6.26, and a 94% volatility utilizing comparable companies. This amount was recorded as both an increase to additional paid-in capital and as a non-cash issuance cost of the offering.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;On July 25, 2022, the Company entered into securities purchase agreements (the &#x201c;Purchase Agreements&#x201d;) with two of the Company&#x2019;s executives and a member of the Company&#x2019;s board of directors (collectively, the &#x201c;Affiliate Investors&#x201d;), and a single U.S. institutional investor (the &#x201c;Investor&#x201d;) pursuant to which the Company issued and sold in a registered direct offering an aggregate of 1,159,211 shares of common stock, par value $0.001 per share and pre-funded warrants to purchase an aggregate of 130,769 shares of common stock. The Affiliate Investors purchased an aggregate of 59,211 shares of common stock at a purchase price of $3.80 per share. The Investor purchased an aggregate of 1,100,000 shares of common stock at a purchase price of $3.25 per share and an aggregate of 130,769 pre-funded warrants at a purchase price of $3.2499 per pre-funded warrant. The pre-funded warrants sold to the Investor have an exercise price of $0.0001&lt;span style="white-space:pre-wrap;"&gt;, were immediately exercisable.  As of December 31, 2022, all of the pre-funded warrants were exercised.  The Company also issued to the Affiliate Investors and the Investor, series A warrants to purchase &lt;/span&gt;1,289,980 shares of common stock and series B warrants to purchase 1,289,980 shares of common stock, all of which are deemed equity classified. These warrants included 59,211 series A warrants and an aggregate of 59,211 series B warrants to the Affiliate Investors with an exercise price per share of $3.55 and an aggregate of 1,230,769 series A warrants and an aggregate of 1,230,769 series B warrants to the Investor with an exercise price per share of $3.25. The series A warrants will be exercisable commencing on January 27, 2023 and will expire on January 27, 2028. The series B warrants will be exercisable commencing on January 27, 2023 and will expire on January 27, 2024. The registered direct offering closed on July 27, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The gross proceeds to the Company from the registered direct offering were $4.2 million and net proceeds after deducting the placement agents&#x2019; fees and other offering expenses payable by the Company were approximately $3.7 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;On July 25, 2022, the Company entered into a co-placement agent agreement (the &#x201c;Placement Agent Agreement&#x201d;), with two placement agents in connection with the registered direct offering pursuant to which the Company paid the Placement Agents a cash fee of $287,874 and issued to the Placement Agents an aggregate of 63,018&lt;span style="white-space:pre-wrap;"&gt; warrants to purchase shares of common stock.  The warrants have an exercise price of &lt;/span&gt;$3.60 per share (representing 110%&lt;span style="white-space:pre-wrap;"&gt; of the weighted average public offering price of the aggregate number of shares of common stock sold in the registered direct offering to the Investor and Affiliate Investors) and expire on July 27, 2027.  The Company used the Black-Scholes model to calculate the value of the warrants with an estimated fair value of &lt;/span&gt;$171,409&lt;span style="white-space:pre-wrap;"&gt;.  The inputs utilized in the calculation were as follows: &lt;/span&gt;five year term, 2.82% risk free rate, stock price at grant date of $3.70 and a 95%&lt;span style="white-space:pre-wrap;"&gt; volatility utilizing comparable companies.  This amount was recorded as both an increase to additional paid-in capital and as a non-cash issuance cost of the offering.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at December 31, 2022:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,588,477&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.32&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,776,476&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.12&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (147,144)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.27&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,217,809&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.29&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="INF"
      id="Narr_ccPjeDPXiE20L5XP6nulGA"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="INF"
      id="Narr_DjNmT8p6hE2nhm9i2NmCzg"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">11627609</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_6_29_2021_To_6_29_2021_ZftWEESwJUi8qhJm8t8FPQ"
      decimals="INF"
      id="Narr_YCojkCXLAEmiscJQp4cYbA"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">2875000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_6_29_2021_jxXdY4PAdk6_gydSF_zR1g"
      decimals="2"
      id="Narr_I4Rz196mOEmcXG8_M2JuZA"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">6.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_6_29_2021_To_6_29_2021_ZftWEESwJUi8qhJm8t8FPQ"
      decimals="-5"
      id="Narr_evKRhJAiEUqldZ5g161f8w"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">14800000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_6_29_2021_To_6_29_2021_ZftWEESwJUi8qhJm8t8FPQ"
      decimals="-5"
      id="Narr_dJGbpgwQAk6-LUnKcsvi-A"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">2400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_6_29_2021_To_6_29_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassAndClassBMemberSCapitalMember_sGnNM7X_Y0a52s50X0s31g"
      decimals="INF"
      id="Narr_7AsQ3rJQWES7BzZJvLJc8w"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">14082318</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="Duration_6_29_2021_To_6_29_2021_ZftWEESwJUi8qhJm8t8FPQ"
      decimals="INF"
      id="Narr_D4pLN02qbUGhYdRGjfoeCw"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">7041208</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_6_29_2021_jxXdY4PAdk6_gydSF_zR1g"
      decimals="INF"
      id="Narr_5Z64-H5WXkOuXJYmW7xrIg"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">1437577</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_6_29_2021_jxXdY4PAdk6_gydSF_zR1g"
      decimals="2"
      id="Narr_GSHa1kaCqEGCOAQ4A_ka5A"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">2.88</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_acxp_UnderwriterMember_UBZF9KBTGk6x1d7NF_WJMw"
      decimals="INF"
      id="Narr_HyWA3-clSUi1-DjN99dWew"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">150000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <acxp:ClassOfWarrantOrRightExercisableTerm
      contextRef="Duration_6_29_2021_To_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_acxp_UnderwriterMember_-kSXTBxSPkq5OVNeYmsV1w"
      id="Narr_Lyc7B_Ao-k659mm9SrRseg">P4Y6M</acxp:ClassOfWarrantOrRightExercisableTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_acxp_UnderwriterMember_UBZF9KBTGk6x1d7NF_WJMw"
      decimals="2"
      id="Narr_vxaEIxfTjE-f1G_5rQjm6w"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">7.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_acxp_UnderwriterMember_UBZF9KBTGk6x1d7NF_WJMw"
      decimals="0"
      id="Narr_sO7NlsbNZkm540Y99trG0Q"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">618000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_6_29_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_acxp_UnderwriterMember_u8q_TpmED0-Ky05QbeiMpw"
      decimals="2"
      id="Narr_Isrhz25eREiIulKMV7qZ6A"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">0.79</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_6_29_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_SubsidiarySaleOfStockAxis_acxp_UnderwriterMember_v5jYpz8bRUyI--9gq4owJw"
      decimals="2"
      id="Narr_oi7znlsjxESatoUS4FCbSw"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">6.26</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_6_29_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_SubsidiarySaleOfStockAxis_acxp_UnderwriterMember_sGehJTCm7kCXCyDe_BzraA"
      decimals="0"
      id="Narr_1bCmI0pqoUCioXEK0kBsUw"
      unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q">94</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_25_2022_To_7_25_2022_sWcLqEbyWkeHbC8OdzC6_A"
      decimals="INF"
      id="Narr_e8fbb_VDwU2R_d92v6pikA"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">1159211</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_7_25_2022_YegiBECCekyLQBPmihkK7Q"
      decimals="INF"
      id="Narr_secrVBmJ8kWU8-AaaqvvKA"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <acxp:WarrantExercisePreFundedShares
      contextRef="Duration_7_25_2022_To_7_25_2022_srt_TitleOfIndividualAxis_acxp_AffiliateInvestorsMember_p7F3gkO8pE2NTMNCZ9i1nQ"
      decimals="INF"
      id="Narr_R9WpSmedpUexT0Y9z8sNZg"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">130769</acxp:WarrantExercisePreFundedShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_25_2022_To_7_25_2022_srt_TitleOfIndividualAxis_acxp_AffiliateInvestorsMember_p7F3gkO8pE2NTMNCZ9i1nQ"
      decimals="INF"
      id="Narr_wiYwzFPgd0KNtqswsKVxeQ"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">59211</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_7_25_2022_srt_TitleOfIndividualAxis_acxp_AffiliateInvestorsMember_0RaPP3HInkGg-_0ekTA3OQ"
      decimals="2"
      id="Narr_LujeHguQPE-hSbflk_rZbg"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">3.80</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_25_2022_To_7_25_2022_srt_TitleOfIndividualAxis_us-gaap_InvestorMember__XKurX6OPUKTdaHa_IwqkA"
      decimals="INF"
      id="Narr_35xhorLLaES2FaeZZm-mbg"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">1100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_7_25_2022_srt_TitleOfIndividualAxis_us-gaap_InvestorMember_Ri0JCPeSzE6DD189Cr4yVQ"
      decimals="2"
      id="Narr_nTeRY4U9C06NGgGo3LDmYw"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">3.25</us-gaap:SharesIssuedPricePerShare>
    <acxp:WarrantExercisePreFundedShares
      contextRef="Duration_7_25_2022_To_7_25_2022_srt_TitleOfIndividualAxis_us-gaap_InvestorMember__XKurX6OPUKTdaHa_IwqkA"
      decimals="INF"
      id="Narr_zacjdO0ZO0idS9u3t0z0pA"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">130769</acxp:WarrantExercisePreFundedShares>
    <acxp:ClassOfWarrantOrRightPurchasePrice
      contextRef="Duration_7_25_2022_To_7_25_2022_srt_TitleOfIndividualAxis_us-gaap_InvestorMember__XKurX6OPUKTdaHa_IwqkA"
      decimals="4"
      id="Narr_KgYXMvIbmE-i3N38dWa9Jw"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">3.2499</acxp:ClassOfWarrantOrRightPurchasePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_7_25_2022_srt_TitleOfIndividualAxis_us-gaap_InvestorMember_Ri0JCPeSzE6DD189Cr4yVQ"
      decimals="4"
      id="Narr_h1Cf2CzL5UOG1Vw8vxusOA"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_7_25_2022_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesWarrantsMember_HHLsVDf1Skma7FwgAwWjhA"
      decimals="INF"
      id="Narr_Qa3YnWPPrUWITTeUfLaT1A"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">1289980</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_7_25_2022_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesBWarrantsMember_WAQhRe6t0EmrCSaWui2e9A"
      decimals="INF"
      id="Narr_HTxJJeNBmECZKfCva8aElA"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">1289980</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_7_25_2022_srt_TitleOfIndividualAxis_acxp_AffiliateInvestorsMember_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesWarrantsMember_6hXj30MhOU2VHM0OprvNzQ"
      decimals="INF"
      id="Narr_-grvrhBhK0WdsC4pb3rQpA"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">59211</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_7_25_2022_srt_TitleOfIndividualAxis_acxp_AffiliateInvestorsMember_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesBWarrantsMember_0trLt8KDDU2-A92s7AKaAg"
      decimals="INF"
      id="Narr_rsu5JiNP00qe3sXO6O-Vog"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">59211</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_7_25_2022_srt_TitleOfIndividualAxis_acxp_AffiliateInvestorsMember_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesWarrantsMember_6hXj30MhOU2VHM0OprvNzQ"
      decimals="2"
      id="Narr_F4hwmusrR0a_Vspymoj2jA"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">3.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_7_25_2022_srt_TitleOfIndividualAxis_us-gaap_InvestorMember_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesWarrantsMember_NWDnHTpMZUCylxU3oQXj-Q"
      decimals="INF"
      id="Narr_cjVEJb6N0E6qw6go3emz-w"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">1230769</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_7_25_2022_srt_TitleOfIndividualAxis_us-gaap_InvestorMember_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesBWarrantsMember_EZQw2mZf6Euo9EwTGvaY4g"
      decimals="INF"
      id="Narr_eOCCYBTF_U2jbgb5U37Nww"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">1230769</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_7_25_2022_srt_TitleOfIndividualAxis_us-gaap_InvestorMember_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesBWarrantsMember_EZQw2mZf6Euo9EwTGvaY4g"
      decimals="2"
      id="Narr_uhWSwVkrhEWUlP-xULU94g"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">3.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <acxp:StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts
      contextRef="Duration_7_25_2022_To_7_25_2022_sWcLqEbyWkeHbC8OdzC6_A"
      decimals="-5"
      id="Narr_oDwPZEgd00Sr1FZAnkD-MA"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">4200000</acxp:StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_7_25_2022_To_7_25_2022_sWcLqEbyWkeHbC8OdzC6_A"
      decimals="-5"
      id="Narr_1o4oVSOO80Gj_aFnl_PF1g"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">3700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_7_25_2022_To_7_25_2022_us-gaap_SubsidiarySaleOfStockAxis_acxp_PlacementAgentsMember_E-IOxhM4rk2gkD8cStTzjA"
      decimals="0"
      id="Narr_gPLZWWlBwECF-VMJleqk_A"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">287874</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_7_25_2022_us-gaap_SubsidiarySaleOfStockAxis_acxp_PlacementAgentsMember_xZ4u8T8GOEmEbz0QrR2l2w"
      decimals="INF"
      id="Narr_8E4cALhA_UumkUG5sr3lfg"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">63018</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_7_25_2022_us-gaap_SubsidiarySaleOfStockAxis_acxp_PlacementAgentsMember_xZ4u8T8GOEmEbz0QrR2l2w"
      decimals="2"
      id="Narr_lcWq8bcdw0yxjXIh4yM7bQ"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">3.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <acxp:PercentageOfWeightedAveragePublicOfferingPriceOfAggregateNumberOfSharesOfCommonStockSold
      contextRef="Duration_7_25_2022_To_7_25_2022_us-gaap_SubsidiarySaleOfStockAxis_acxp_PlacementAgentsMember_E-IOxhM4rk2gkD8cStTzjA"
      decimals="2"
      id="Narr_W-xEbZ4zPkuVAxqe_dmJeA"
      unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q">1.10</acxp:PercentageOfWeightedAveragePublicOfferingPriceOfAggregateNumberOfSharesOfCommonStockSold>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_7_25_2022_us-gaap_SubsidiarySaleOfStockAxis_acxp_PlacementAgentsMember_xZ4u8T8GOEmEbz0QrR2l2w"
      decimals="0"
      id="Narr_BaIAMzl_eUO_pxsnewY5bg"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">171409</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_25_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_SubsidiarySaleOfStockAxis_acxp_PlacementAgentsMember_BIzTc_rBT0-1HSfagb5b0g"
      decimals="0"
      id="Narr_zohC2CNbM0iZDgw59QiIxQ"
      unitRef="Unit_Standard_Y_m6Q1ZS4FGUy3pAlacn4HHg">5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_25_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_SubsidiarySaleOfStockAxis_acxp_PlacementAgentsMember_24jUSFL8IkuQJWmQuEKwcA"
      decimals="2"
      id="Narr_yLnrLfSr_06DZbfdKZgAeA"
      unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q">2.82</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_25_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_SubsidiarySaleOfStockAxis_acxp_PlacementAgentsMember_DLWS4dqct0WPZhuICr1W5Q"
      decimals="2"
      id="Narr_7ZzqtuTifU6G2NTh717WHA"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">3.70</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_7_25_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_SubsidiarySaleOfStockAxis_acxp_PlacementAgentsMember_3LCeKF0DIEaVdX-Uh1jhPg"
      decimals="0"
      id="Narr_i6yAkiw5f0yYVHa6UYNx7w"
      unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q">95</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tb_No94wPldJUiiK2iIX7jGOg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,588,477&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.32&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,776,476&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.12&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (147,144)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.27&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,217,809&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.29&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw"
      decimals="INF"
      id="Tc_oyEGPQE0802Nzzjw5qiZDQ_3_3"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">1588477</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_WeightedAverageMember_e70u-YktPE-UR-XzQ15xzQ"
      decimals="2"
      id="Tc_dOuOjsPmDUGFT29awMEF_A_3_6"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">3.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <acxp:ClassOfWarrantOrRightIssued
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="INF"
      id="Tc_t7XKoKBKgUyKFdgkfJSNSw_4_3"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">2776476</acxp:ClassOfWarrantOrRightIssued>
    <acxp:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_WeightedAverageMember_XhK5Z9PZ80SoOyza28-Ohw"
      decimals="2"
      id="Tc_pZe3zY5ELUqa1YZRPSgA_Q_4_6"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">3.12</acxp:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued>
    <acxp:ClassOfWarrantOrRightExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="INF"
      id="Tc_5pFAeU1EjUGHXtDvHpmaag_5_3"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">-147144</acxp:ClassOfWarrantOrRightExercised>
    <acxp:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_WeightedAverageMember_XhK5Z9PZ80SoOyza28-Ohw"
      decimals="2"
      id="Tc_TzIwOwFZbEezhtH5VRRH8Q_5_6"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">0.27</acxp:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="INF"
      id="Tc_o96rWBJKakWVLgOPYfN_aA_6_3"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">4217809</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_WeightedAverageMember__LDIrfLVM0-4X8uUinUNww"
      decimals="2"
      id="Tc_WPmaeoxGYEOSXgO1__cavw_6_6"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">3.29</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tb_KAl1sVPhSkm75fQV9SKf9A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;7&#160;&#x2013; SHARE-BASED COMPENSATION&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;While the Company was a limited liability company in its pre-IPO phase of corporate development, the Company granted performance-based awards of restricted Class&#160;A Membership Interests to board members and corporate advisory council members in exchange for services. All of these awards of membership interests became fully vested upon consummation of the Company&#x2019;s corporate conversion from Delaware limited liability company to a Delaware corporation immediately prior to the Company&#x2019;s IPO, with the Company recognizing all previously unrecognized compensation expense. The fair value of the membership interests granted during 2020 and 2019 was equal to the per-membership interest value of the most recent private placement with a weighted average of $2.14 per membership interest.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Total share-based compensation associated with these awards has been recorded as general and administrative expenses in the amount of $0 and $755,556 for the&#160;years ended December&#160;31, 2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the unvested Class&#160;A Membership Interests converted to common stock pursuant to a conversion ratio of one-for-two, and associated activity for the 12&#160;months ended December&#160;31, 2021:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Class A&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Membership Interests&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Converted to common stock at one-for-two ratio&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 200,463&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (200,463)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;In April&#160;2021, the board of directors approved the creation of the 2021 Equity Incentive Plan (the &#x201c;Plan&#x201d;). The Plan became effective as of the completion of the corporate conversion. The Plan originally reserved an aggregate of 2,000,000 shares of common stock, subject to annual adjustments as provided in the Plan, which was 408,632 shares for 2022, of which 537,937 shares are currently still available for issuance as of December 31, 2022. The purpose of the Plan is to attract, retain and incentivize directors, officers, employees, and consultants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;In June&#160;2021, the Company granted stock options to purchase a total of 807,500 shares of common stock to its three executives and three non-employee management team members to replace the Class&#160;B Membership Interests that were cancelled in March&#160;2021. The options were issued at an exercise price of $6.26, with the employee options vesting 40% upon issuance and the balance over 36 months, and the non-employee options vesting at grant date. The Company recorded general and administrative expense of $726,880 and $2,019,325 for the&#160;years ended December&#160;31, 2022 and 2021, respectively, related to compensation expense for these options.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;In July&#160;2021, the Company granted stock options to purchase a total of 1,550,000 shares of common stock to its three executives pursuant to their respective employment agreements, the independent directors, and one consultant, pursuant to the Plan. The options were issued at an exercise price of $6.18, the grant date fair value, with &lt;span style="-sec-ix-hidden:Hidden_EzWf9zq7yU2COrvaqFHBLw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt;-quarter of the executive&#x2019;s options vesting upon issuance and the balance over 36 months, and the options granted to the directors and consultants vesting over 36 months. The Company recorded general and administrative expenses of $1,963,667 and $2,379,833 for the&#160;years ended December&#160;31, 2022 and 2021, respectively, related to compensation expense for these options.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;In January 2022, the Company granted stock options to purchase a total of 80,000 shares of common stock to seven consultants pursuant to the Plan. The options were issued at an exercise price of $4.44, the grant date fair value, with &lt;span style="-sec-ix-hidden:Hidden_GOeJkjeOiU-aNE91SNMVSA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt;-quarter of the options vesting upon issuance and the balance over 36 months. The Company recorded general and administrative expenses of $145,283 for the year ended December 31, 2022 related to compensation expense for these options.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;In April 2022, the Company granted stock options to purchase a total of 30,000 shares of common stock to a new employee pursuant to the Plan. The options were issued at an exercise price of $3.79, the grant date fair value, with &lt;span style="-sec-ix-hidden:Hidden__yx0SlixZk2t446zKw_EWA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt;-&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;quarter of the options vesting upon issuance and the balance over 36 months. The Company recorded general and administrative expenses of $35,850 for the year ended December 31, 2022 related to compensation expense for these options.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Compensation expense associated with these awards is recognized over the vesting period based on the fair value of the option at the grant date determined based on the Black-Scholes option pricing model. Option valuation models require the input of highly subjective assumptions including the expected price volatility. The Company&#x2019;s employee stock options have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair value computation using the Black-Scholes option pricing model. Because there is no public market for the Company&#x2019;s stock options and very little historical experience with the Company&#x2019;s stock, similar public companies were used for the comparison of volatility and the dividend yield. The risk-free rate of return was derived from U.S. Treasury notes with comparable maturities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company determined the fair value of the option awards using the Black-Scholes option pricing model using the following weighted average assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Year Ended &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average grant date fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.54&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;A summary of the Company&#x2019;s stock option activity is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Year Ended &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Weighted&#160;Average&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Exercise&#160;Price&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at the beginning of the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,357,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.21&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 110,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.26&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at the end of the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,467,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.12&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,552,333&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The total compensation expense not yet recognized as of December&#160;31, 2022 was $4,243,927. The weighted average vesting period for the unvested options is 1.54 years. The intrinsic value of the stock options as of December&#160;31, 2022 was $5,700, with a remaining weighted average contractual life of 8.53 years. The weighted average grant date fair value of all options granted is $4.67 as of December&#160;31, 2022. The Company records the impact of any forfeitures of options as they occur.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember_EdWadodcnUyBlBRFeYfBqg"
      decimals="2"
      id="Narr_TwfHtwJtRUCI6kgLbzSGVA"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">2.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="0"
      id="Narr_fOm5Yu9uyEi4lsBq5eB1Xg"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="0"
      id="Narr_LTu4SGsc0U2gtD32yot-xg"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">755556</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tb_8SXmwpUFY02Ss1Hc8lpNJg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Class A&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Membership Interests&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Converted to common stock at one-for-two ratio&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 200,463&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (200,463)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_PvS7_eCOf02Kg60XmKqo1Q"
      decimals="INF"
      id="Tc__Dxa_G-PH0m1OFr2e_u2EQ_5_2"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">200463</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_F5y4v9FsWES_CUZktDE-_A"
      decimals="INF"
      id="Tc_McXaynkWpUyvXdjgLT2PrQ_6_2"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">200463</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_4_30_2021_us-gaap_AwardTypeAxis_acxp_EquityIncentivePlan2021Member_HrihoDSDdE2dXqf1m4_VhQ"
      decimals="INF"
      id="Narr_83QvOJ326kWdHv_8tPdjUQ"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">2000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_acxp_EquityIncentivePlan2021Member_TIyqWUA_-EClFlY5kpwukQ"
      decimals="INF"
      id="Narr_Zibw4BWffEeB-wFAWJ_ipg"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">408632</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_4_30_2021_us-gaap_AwardTypeAxis_acxp_EquityIncentivePlan2021Member_HrihoDSDdE2dXqf1m4_VhQ"
      decimals="INF"
      id="Narr_z14BdFycrkmHPyemfV0WUA"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">537937</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_acxp_EquityIncentivePlan2021Member_W5IQ42UzGEy4rC9lIUrHjA"
      decimals="INF"
      id="Narr_1caikmbvYUeRXLpu8Fg-8g"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">537937</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJune2021Member_iWpvZWkOx02nS35b2LJKJg"
      decimals="INF"
      id="Narr_Mp8bx6frH0-UC_Bu6ib8TQ"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">807500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJune2021Member_iWpvZWkOx02nS35b2LJKJg"
      decimals="2"
      id="Narr_Sw5oThlBcEWABwapRirCEA"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">6.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJune2021Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_xCQTnSxqU0yUl6NgiOZEdg"
      decimals="2"
      id="Narr_zpcpxRdrgUeBIHDMh58TLw"
      unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q">0.40</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJune2021Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_p0UPlSeFgEOxcBPz5o_OfQ"
      id="Narr_18ytK9Aipke4iiSA0Xl37w">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJune2021Member_QNhUB26_yk2TvwRPRCTv5Q"
      decimals="0"
      id="Narr_ExRgtshJnUaokdC9I9MTkg"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">726880</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJune2021Member_vb95mGglMUy4oh0WaAepFQ"
      decimals="0"
      id="Narr_1OKeUnLYlEOLBhsgYT3y-w"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">2019325</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_7_1_2021_To_7_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_D82Hstg3QkSYlPP9MHSV6Q"
      decimals="INF"
      id="Narr_pi499Hp30EWGztdAxnY4HQ"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">1550000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_7_1_2021_To_7_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_D82Hstg3QkSYlPP9MHSV6Q"
      decimals="2"
      id="Narr_S2dy3DITDUulCcSb2z1beQ"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">6.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2021_To_7_31_2021_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_owyoKTuxS0ybPw8J5ZH77A"
      id="Narr_fGfkw6aVVEC47ZPXu_HZLQ">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2021_To_7_31_2021_srt_TitleOfIndividualAxis_acxp_IndependentDirectorsConsultantMember_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_Cgh2BZaRvECW2Z1yqwQ8tA"
      id="Narr__RLxQlpS1EejvCtfIpQGvA">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_dQo-EEliWUuFEj9-VZ9N3g"
      decimals="0"
      id="Narr_4jvNcZ2FDkGU8yRdXtFqfg"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">1963667</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_qx3OtHXhPUaPRIR812d3Ww"
      decimals="0"
      id="Narr_ir-iWhy5mkWb5uj6K-Lssw"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">2379833</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_1_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member_BaBBng1QkES6yfdBQj_5SA"
      decimals="INF"
      id="Narr_RxGPKUzSPkW0jfsp4MeFmw"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">80000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_1_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member_BaBBng1QkES6yfdBQj_5SA"
      decimals="2"
      id="Narr_ARe_7KHztkqArYWd9xcqOg"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">4.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2022_To_1_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_4BRIuZGIFUyVO7Kq0DGlew"
      id="Narr_vHfauoGEjkSFunVnvIX5WA">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member_eIYvcQou2k6kRaWtqOy8qQ"
      decimals="0"
      id="Narr_dNoIvAEZ4UaY7XUq7QuZew"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">145283</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_4_1_2022_To_4_30_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateApril2022Member_Jnl-Bb2R2EiM_K13OPkf4Q"
      decimals="0"
      id="Narr_ytKUc3KMNU-dRjV4UiDjjA"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_4_1_2022_To_4_30_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateApril2022Member_Jnl-Bb2R2EiM_K13OPkf4Q"
      decimals="2"
      id="Narr_wJjwDQ3OHEGlpZ0NodlHmw"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">3.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_4_1_2022_To_4_30_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateApril2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_yPD_ZJI8H06PJt30JeyqDw"
      id="Narr_OZTyuHkGi0yOYZP1fZldTQ">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateApril2022Member_vR_7z-bGCUubmqFX9FxQYw"
      decimals="0"
      id="Narr_X3WGKkZAfkimQX_eJquqVA"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">35850</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tb_mB96oKJ6H0On2LZZn37JPg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Year Ended &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average grant date fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.54&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tc_whipuyNts06X85_eUQTrFg_3_3">P9Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="2"
      id="Tc_2UeuKEl9kUirhHZoL1bMhw_4_3"
      unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="4"
      id="Tc_19NBSmomSkuWJKRA90C1kw_6_3"
      unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q">0.0201</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="2"
      id="Tc_ELIKiQA-eUaDFvsflNrdXQ_7_3"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">3.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tb_9Ssx-cDm00aYMCFJfKutBA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Year Ended &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Weighted&#160;Average&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Exercise&#160;Price&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at the beginning of the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,357,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.21&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 110,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.26&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at the end of the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,467,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.12&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,552,333&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw"
      decimals="INF"
      id="Tc_22xARAZ8J0yW9Y5eMwOkHQ_3_2"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">2357500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw"
      decimals="2"
      id="Tc_ZUDI2GxGF0SJ8R3i_PaTWg_3_5"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">6.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="INF"
      id="Tc_tCGLWipbNEmpOPh88OpKCg_4_2"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">110000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="2"
      id="Tc_k4kwJmoezEC8ptKCOnekLA_4_5"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">4.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="INF"
      id="Tc_SvX9vRiIbE-2lmIJe1C-UA_7_2"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">2467500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="2"
      id="Tc_RbZPZlJ5y02y6Bpl4b7xLw_7_5"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">6.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="INF"
      id="Tc_UwpnhEdBQ0u87OerPfn9Sg_8_2"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">1552333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="2"
      id="Tc_PgoMw-4vUUuOcUufyo2R3g_8_5"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">6.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="0"
      id="Narr_ZFSqaN5WA0iwHLE7nsisGw"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">4243927</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Narr_yACK6Z0UQU2hN9UsU9RGwg">P1Y6M14D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="0"
      id="Narr_-J6AKAvIPEiqPhiXlbD0OA"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">5700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Narr_q2lrwi_5W0iDponQ7Iz-Nw">P8Y6M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="2"
      id="Narr_VA94clAlIEWWNDgrRZOSLg"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">4.67</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <acxp:ShareBasedPaymentsToVendorsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tb_HyXS-TPqwEuXJ6UvE6ypuw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;NOTE&#160;8&#160;&#x2013; SHARE-BASED PAYMENTS TO VENDORS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;While the Company was a limited liability company in its pre-IPO phase of corporate development, the Company granted Class&#160;A Membership Interests to certain vendors in the ordinary course of business in exchange for consulting services relating to research and development activities and investor relations. The Company granted 30,145 Class&#160;A Membership Interests for the&#160;year ended December&#160;31, 2021. The fair value of the Class&#160;A Membership Interests granted was equal to the value of the most recent private placement. The Company recognized the expense in the same period and in the same manner as if the Company had paid cash for the services. The Company recorded general and administrative expenses and research and development expenses for vendor equity grants in the amounts of $0 for the year ended December 31, 2022 and $201,375 and $21,596 for the&#160;year ended December&#160;31, 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;In October&#160;2019, the Company granted a total of 150,000 restricted Class&#160;A Membership Interests to three consultants for investor relations consulting services performed in 2019 through October&#160;2021. These Class&#160;A Membership Interests vested on the second anniversary of the grant date, and were subject to accelerated vesting provisions upon a change of control of the Company. The fair value of the Class&#160;A Membership Interests granted was equal to the value of the most recent private placement, $2.00 per Class&#160;A Membership Interest. The Company recognized the expense on a straight-line basis over the vesting period. The Company recorded general and administrative expenses of $0 and $125,000 for the&#160;years ended December&#160;31, 2022 and 2021, respectively. The conversion adjusted shares of common stock were issued in October&#160;2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;In the second quarter of 2021, the Company entered into a number of agreements with vendors pursuant to which the Company made grants of a total of 175,000 shares of common stock with a grant date fair value of $6.26, cash payments in the amount of $343,500, and 100,000 options which were included as a part of the July&#160;2021 grant. These contracts have terms which range from six months to three years. The common stock was valued based on the grant date fair value and the options valued utilizing Black-Scholes option pricing model. The cash payments were expensed over the service period and the equity component expensed consistent with the contractual vesting. These shares and options were granted in the third quarter of 2021 pursuant to the Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;In the third quarter of 2021, the Company granted vendors a total of 35,695 shares of common stock, which fully vested in 2021, pursuant to the Plan. The Company recorded general and administrative expense of $208,270, based on the respective grant date fair values, for the&#160;year ended December&#160;31, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;In October&#160;2021, the Company entered into an agreement with a consultant to provide financial advisory services for a six-month term. Pursuant to the agreement, the Company granted $150,000 of common stock over the term of service. The Company granted total of 27,778 shares of common stock at grant date fair value and recorded general and administrative expenses of $75,000 for each of the&#160;years ended December&#160;31, 2022, and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;In March 2022, the Company entered into an agreement with a consultant to provide investor relation services for a six-month term. Pursuant to the agreement, the Company granted 30,000 shares of common stock with a grant date fair value of $3.77 and paid $25,000 of cash compensation The cash component was expensed over the service period and the equity component was expensed consistent with the contractual vesting. The Company recorded general and administrative expenses of $113,100 for the year ended December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;In September 2022, the Company entered into an agreement with a company to provide consulting services for a &lt;span style="-sec-ix-hidden:Hidden_pe6sq_5jwkGHEr32NVYkWA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;six-month&lt;/span&gt;&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt; term.  Pursuant to the agreement, the Company granted &lt;/span&gt;36,000 shares of common stock with a grant date fair value of $3.53&lt;span style="white-space:pre-wrap;"&gt;, which was expensed consistent with the contractual vesting.  The Company recorded general and administrative expenses of &lt;/span&gt;$127,080&lt;span style="white-space:pre-wrap;"&gt; for the year ended December 31, 2022.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;In the fourth quarter of 2022, the Company entered into a number of agreements with vendors pursuant to which the Company will make grants of a total of 43,186 share of common stock with a grant date fair values ranging from $3.30 to $3.67, up to 10,096&lt;span style="white-space:pre-wrap;"&gt; of warrants, and cash payments.  These contracts have &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_xpnuvER5pkCZfclL6LaL-Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;six-months&lt;/span&gt;&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt; terms with various contractual vesting periods.  The cash payments will be expensed over the service period and the equity component will be expensed consistent with the various contractual vesting periods.  The Company recorded general and administrative expenses of &lt;/span&gt;$115,500 for the year ended December 31, 2022.&lt;/p&gt;</acxp:ShareBasedPaymentsToVendorsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_MYOlceR8bEyBXaE8PmDn2g"
      decimals="INF"
      id="Narr_8jd9D4xdDUyWlAM2B7T3gw"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">30145</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <acxp:ShareBasedPaymentToVendors
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember_EdWadodcnUyBlBRFeYfBqg"
      decimals="0"
      id="Narr_zIPLWyJmjEK3Obw0vrwAPQ"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">0</acxp:ShareBasedPaymentToVendors>
    <acxp:ShareBasedPaymentToVendors
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_At7Vvf6ODEu2VV8vZNhcWQ"
      decimals="0"
      id="Narr_4uwicf0r7kiLmSq4WJS72Q"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">201375</acxp:ShareBasedPaymentToVendors>
    <acxp:ShareBasedPaymentToVendors
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_m2h7V2EdPEine3-RW3GKcg"
      decimals="0"
      id="Narr_ezxfJ67vuE63njPgRZZC5g"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">21596</acxp:ShareBasedPaymentToVendors>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_Gf1McXFwrk6xhgFzNeubnw"
      decimals="INF"
      id="Narr_RF90H45TJUyYyYbqzupRrw"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">150000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:SharePrice
      contextRef="As_Of_10_31_2019_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_619kTaw0GEyZLXk7eliAdQ"
      decimals="2"
      id="Narr_HdFtSLq260K2psD0cq_hcg"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">2.00</us-gaap:SharePrice>
    <acxp:ShareBasedPaymentToVendors
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member_glK66UkK8kaOPtF_EMotIg"
      decimals="0"
      id="Narr_Y4IZxP4-902ut8ix_aF54g"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">0</acxp:ShareBasedPaymentToVendors>
    <acxp:ShareBasedPaymentToVendors
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member_TsKzRMZrzEyys7D-3GS8aw"
      decimals="0"
      id="Narr_CeEuvLSoo0iAo-HBBJKEWg"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">125000</acxp:ShareBasedPaymentToVendors>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member_w1T2TY_SNkCVkeO9pZPLhA"
      decimals="INF"
      id="Narr_cjNzVSC8KUWROyhE6621PQ"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">175000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:SharePrice
      contextRef="As_Of_6_30_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member_mxmMtGXpS0GIYfMeHwojow"
      decimals="2"
      id="Narr_s2B43oT9pUy_Ep4GfjCnrg"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">6.26</us-gaap:SharePrice>
    <us-gaap:PaymentsToSuppliers
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member_w1T2TY_SNkCVkeO9pZPLhA"
      decimals="0"
      id="Narr_my8DozThaU6QQ6_igzG2nw"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">343500</us-gaap:PaymentsToSuppliers>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member_g7TcRnVZ-EeKEa9jZmWMBw"
      decimals="INF"
      id="Narr_M_Lndmh2IUeCkgKR-KfA-Q"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_4_1_2021_To_6_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member_wrQ7Eh3v4EOO3IZeFBTejw"
      id="Narr_F3KarQywwkeXl4bTA4L0yA">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_4_1_2021_To_6_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member_F_YLDKPV7UizWtFPSMLXBw"
      id="Narr__w8xjg0sykq42t0uomWRFw">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantedInThirdQuarter2021Member_I8bs4d9ViU-viuLd-_7bTQ"
      decimals="INF"
      id="Narr_3KOgGrEya0m8Gc7JuBWFgw"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">35695</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <acxp:ShareBasedPaymentToVendors
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantedInThirdQuarter2021Member_Tlp76MoUFEqKyMnI6aK_eQ"
      decimals="0"
      id="Narr_5qEXVxl9EkuMSJbADTTeIg"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">208270</acxp:ShareBasedPaymentToVendors>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_10_1_2021_To_10_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateOctober2021Member_6LGtqepcjEOliJ4jOXHUIA"
      id="Narr_SoDJEbMebkqNIWsB2vIX_g">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <acxp:ShareBasedPaymentToVendors
      contextRef="Duration_10_1_2021_To_10_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateOctober2021Member_6LGtqepcjEOliJ4jOXHUIA"
      decimals="0"
      id="Narr_Xcly0RZrxkydyMuUE0yL4g"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">150000</acxp:ShareBasedPaymentToVendors>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_10_1_2021_To_10_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateOctober2021Member_6LGtqepcjEOliJ4jOXHUIA"
      decimals="0"
      id="Narr_EDKL85QzfkyPxIujxgRINw"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">27778</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <acxp:ShareBasedPaymentToVendors
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateOctober2021Member_5i2X2rTyx0SYX8Xybc8Psw"
      decimals="0"
      id="Narr_vQSClH2f2UuLsJdn1NxRvg"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">75000</acxp:ShareBasedPaymentToVendors>
    <acxp:ShareBasedPaymentToVendors
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateOctober2021Member_WyWUGX-ss020568gQjYm8g"
      decimals="0"
      id="Narr_748ZcNeJPEKvWtRcCY_CPA"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">75000</acxp:ShareBasedPaymentToVendors>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateMarch2022Member_-nNTg44K_E6nnbx1CwtZmQ"
      id="Narr_SvvdNK_ilEKEkiKG5yvkGA">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateMarch2022Member_-nNTg44K_E6nnbx1CwtZmQ"
      decimals="INF"
      id="Narr_SqUd0tSvX0Cd_Ci4_x_0rA"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">30000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:SharePrice
      contextRef="As_Of_3_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateMarch2022Member_XlEHT5yyoES9L354AxvHSw"
      decimals="2"
      id="Narr_5kFzUrTBO0GCiGBKADbEjw"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">3.77</us-gaap:SharePrice>
    <us-gaap:PaymentsToSuppliers
      contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateMarch2022Member_-nNTg44K_E6nnbx1CwtZmQ"
      decimals="0"
      id="Narr_V09Ufb5Tg0amKOnRN7Fcig"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">25000</us-gaap:PaymentsToSuppliers>
    <acxp:ShareBasedPaymentToVendors
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateMarch2022Member_laHCYr4uL0S16Yf2nc-A4A"
      decimals="0"
      id="Narr_QHwyyo7FKUmCOTL0UEXQNw"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">113100</acxp:ShareBasedPaymentToVendors>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_9_1_2022_To_9_30_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateSeptember2022Member_8MlpVu0cokmsSI5c6YJyTg"
      decimals="INF"
      id="Narr_Miw8gIrQfUacUT7EiMcB4g"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">36000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:SharePrice
      contextRef="As_Of_9_30_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateSeptember2022Member_lQ0vComUSUesFn-c_7_IYg"
      decimals="2"
      id="Narr_GJsWzWAQVUWqvrwomu0h3A"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">3.53</us-gaap:SharePrice>
    <acxp:ShareBasedPaymentToVendors
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDateSeptember2022Member_FgQUZhXKi0mL6FXLRm0gIQ"
      decimals="0"
      id="Narr_DJhcDkm1hE2PdoQbROcpLw"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">127080</acxp:ShareBasedPaymentToVendors>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_10_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member_90xI89oKiEeLdXH5k-9FsA"
      decimals="INF"
      id="Narr_ZUDCIKCF80qE8eRF3dMyQQ"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">43186</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member_7kblQvMdtEmqcKGRTUh1qw"
      decimals="2"
      id="Narr_PDIx5PA9YEinBnPyJAN_IA"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">3.30</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member_YIfVK7k8V069cOaEAb-EWA"
      decimals="2"
      id="Narr_LfXzLV_XcU2RSwUzJ4putA"
      unitRef="Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng">3.67</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member_UmPpwgUbXEq7CaPHpNFPOg"
      decimals="INF"
      id="Narr_vEjU-cha60eYBPxxscAuhQ"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">10096</us-gaap:ClassOfWarrantOrRightOutstanding>
    <acxp:ShareBasedPaymentToVendors
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member_dxrWwDmqfUKvdyQbLpmhnA"
      decimals="0"
      id="Narr_icmzTVpj9kai_BI4GjBUCA"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">115500</acxp:ShareBasedPaymentToVendors>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tb_k3ELON3oh02k_nxMhqx_5g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;NOTE&#160;9&#160;&#x2013; INCOME TAXES&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has $10.7 million of net operating loss carryforwards and $0.1 million of research tax credit carryforwards as of December&#160;31, 2022. The net operating loss carryforwards are indefinite lived and research tax credit carryforwards will expire in 2042. Net operating loss and tax credit carryforwards may become subject to annual limitations in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined by Sections 382 and 383 of the Internal Revenue Code as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The components of the net deferred income tax asset at December&#160;31, 2022 and 2021 are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Net operating loss carry forwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,359,183&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,594,650&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,262,381&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,149,720&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Research and development credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 141,671&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 105,881&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Capitalized research and development &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,347,028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,110,263&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,850,251&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,110,263)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,850,251)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Net deferred tax asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Tax Cuts and Jobs Act of 2017 (TCJA) amended IRC Section 174 to require capitalization of all research and developmental (R&amp;amp;D) costs incurred in tax years beginning after December 31, 2021. These costs are required to be amortized over five years if the R&amp;amp;D activities are performed in the U.S., or over 15 years if the activities were performed outside the U.S. The Company capitalized approximately $4.3 million of R&amp;amp;D expenses incurred as of December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;In assessing the realizability of deferred tax assets, the Company considers whether it is more-likely-than-not that some portion or all the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the temporary differences representing net future deductible amounts become deductible. After consideration of all the evidence, both positive and negative, the Company has recorded a full valuation allowance against their net deferred tax assets at December&#160;31, 2022 because the Company has concluded that it is more-likely-than-not that these assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;A reconciliation of income tax expense (benefit) at the statutory Federal income tax rate and income taxes as reflected in the financial statements for both&#160;years ended December&#160;31, 2022 and 2021 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:49.5pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:81.59%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:16.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:17.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Federal income tax expense at statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State income tax, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development tax credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (35.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (27.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company files income tax returns in the U.S. and the State of New York. The tax&#160;years 2022 and 2021 are open and potentially subject to examination by the federal and state taxing authorities. The Company is currently not under examination by the Internal Revenue Service (&#x201c;IRS&#x201d;) or any other jurisdictions for any tax&#160;years and has no knowledge of any pending examinations by the IRS or any other jurisdictions. To the extent the Company utilizes any tax attributes from a tax period that may otherwise be closed due to statute expiration, the IRS, state tax authorities, or other governing parties may still adjust the tax attributes upon their examination of the future period in which the attribute was utilized. There are no uncertain tax positions recorded for any federal or state positions. The Company&#x2019;s policy is to record interest and penalties related to tax matters in income tax expense.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="-5"
      id="Narr_RhsfWXp1O0eZpgL50bp_dw"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">10700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="-5"
      id="Narr_JhOvv4-Snk2R560WdGXkrQ"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tb_vEW6edb1O0ibfvaDgKeEeg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Net operating loss carry forwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,359,183&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,594,650&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,262,381&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,149,720&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Research and development credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 141,671&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 105,881&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Capitalized research and development &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,347,028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,110,263&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,850,251&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,110,263)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,850,251)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Net deferred tax asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="0"
      id="Tc_e-w-RJ4ViECjmRS4_kGcRg_3_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">3359183</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw"
      decimals="0"
      id="Tc_VnW-BUeaskatMKM9FAu1Fg_3_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">1594650</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="0"
      id="Tc_TMr7T_eQlkyUhzT5Ztwzaw_4_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">2262381</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw"
      decimals="0"
      id="Tc_Q3AhFMZIH0WrIlOxzdzz-g_4_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">1149720</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="0"
      id="Tc_vJjB2CjL1UGClyiiUxJoPQ_5_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">141671</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw"
      decimals="0"
      id="Tc_lsTYdC86zEy8CxMAv8f_Ow_5_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">105881</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="0"
      id="Tc_zPuJizMTAEi2EDEtcQ2mPw_6_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">1347028</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="0"
      id="Tc_uiviOngoWkGfgWJ7htH7wQ_7_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">7110263</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw"
      decimals="0"
      id="Tc_-ZjacOLyi0ewUprjMdn0kw_7_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">2850251</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="0"
      id="Tc_zi9XNSdG8UOixp972tt5FA_8_3"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">7110263</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw"
      decimals="0"
      id="Tc_Bg22lZQpokCyMemWdegZaA_8_6"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">2850251</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="-5"
      id="Narr_Q2tg3l4r0Uuw5K2jFttucg"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">4300000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tb_V-Mz0xg_Q0-xS7XTH_Siig">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:49.5pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:81.59%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:16.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:17.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Federal income tax expense at statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State income tax, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development tax credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (35.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (27.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="3"
      id="Tc_huLn2AfGpEaUipyFeXvg1Q_2_1"
      unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="3"
      id="Tc_xBCgzGu63kiszIwvAXjE-A_2_4"
      unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="3"
      id="Tc_id0cXTHYUUKl1yGcyrJ0UA_3_1"
      unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q">0.144</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="3"
      id="Tc_5-6EvSL9dE-vdFVAJEMeBQ_3_4"
      unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q">0.051</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="3"
      id="Tc_n-XvKW6mZ0mpFcef08oGbQ_4_1"
      unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="3"
      id="Tc_5fMXiAbxa0irRyfPflh4VA_5_1"
      unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="3"
      id="Tc_qu0Qo0uJiEmtsjhnRI9-Dw_5_4"
      unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      decimals="3"
      id="Tc_Iln44orXs0acuIuorPe-xA_6_1"
      unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q">-0.352</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg"
      decimals="3"
      id="Tc_KJemDoaeJki7isOLpGWJKg_6_4"
      unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q">-0.271</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA"
      decimals="0"
      id="Narr_r-zZ8cyhsEuNoebgw9uYQg"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tb_-OrNgNCjEESdrFC4hKrcLw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;NOTE&#160;10&#160;&#x2013; NET LOSS PER SHARE&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;On June&#160;23, 2021, the Company completed a corporate conversion from a limited liability company to a corporation. Accordingly, the outstanding Class&#160;A and Class&#160;B Membership Interests were converted to shares of common stock using a conversion ratio of one-half of one share of common stock for each Class&#160;A membership interest or Class&#160;B membership interest, resulting in the conversion of 14,082,318 Class&#160;A and Class&#160;B Membership Interests into 7,041,208 shares of common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic and diluted net loss per share of common stock for the year ended December&#160;31, 2022 was determined by dividing net loss by the weighted average shares of common stock outstanding during the period. The Company&#x2019;s potentially dilutive shares, consisting of 4,217,809 warrants, and 2,467,500 stock options, have not been included in the computation of diluted net loss per share for all periods as the result would be antidilutive. The effects of the corporate conversion on the Company&#x2019;s weighted average shares of common stock outstanding and net loss per share have been reflected for all periods presented retroactively.&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_6_23_2021_To_6_23_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassAndClassBMemberSCapitalMember_9R3-6dGcWEaNHCoKMihkrA"
      decimals="INF"
      id="Narr_6e_PeRloPEuHfm4ML_uooQ"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">14082318</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="Duration_6_23_2021_To_6_23_2021_TsxTykL9E0-yFWUKq9d3cQ"
      decimals="INF"
      id="Narr_fbc3b-o1KkayBfqoqB8wPA"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">7041208</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_HEBRdNbrGUqT6x6-UyBm6w"
      decimals="INF"
      id="Narr_NucdiJBPNEG7ScwsEXhctg"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">4217809</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_m6mpGMbdVU2n0bKhzjnGLA"
      decimals="INF"
      id="Narr__JjyfxZhQEqLHlr3U3R68Q"
      unitRef="Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ">2467500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ"
      id="Tb_A8HLpTb-YU-woTDsAthQaw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;NOTE&#160;11&#160;&#x2013; COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;In conjunction with the Asset purchase in February&#160;2018, the Company is required to make certain milestone payments related to the ongoing development of ACX-362E totaling $700,000 in the aggregate if certain milestones are achieved (which includes $50,000 already paid after the acquisition in February&#160;&lt;span style="white-space:pre-wrap;"&gt;2018). There were no milestones reached during 2022 and 2021.  The Company is also obligated to make royalty payments equal to &lt;/span&gt;4% of net sales of ACX-362E for a period of time equal to the last to expire of any applicable patents, as defined in the purchase agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OtherCommitment
      contextRef="As_Of_2_28_2018_srt_ProductOrServiceAxis_acxp_AcxThreeSixtyTwoEMember_b8X5m76NYkaaQE7rN9N3KQ"
      decimals="0"
      id="Narr_UFM7mYLHd0-ZvDfW0m1eRQ"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">700000</us-gaap:OtherCommitment>
    <us-gaap:RoyaltyExpense
      contextRef="Duration_2_1_2018_To_2_28_2018_srt_ProductOrServiceAxis_acxp_AcxThreeSixtyTwoEMember_Ney4atHhPEWi0zip1SpT4Q"
      decimals="0"
      id="Narr_n7fzBuEAY0ulpe69i3hQqQ"
      unitRef="Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ">50000</us-gaap:RoyaltyExpense>
    <acxp:PercentageOfRoyaltyPaymentsOnNetSales
      contextRef="Duration_2_1_2018_To_2_28_2018_srt_ProductOrServiceAxis_acxp_AcxThreeSixtyTwoEMember_Ney4atHhPEWi0zip1SpT4Q"
      decimals="2"
      id="Narr_KgMD7erwGkmzM3wdDAAeEw"
      unitRef="Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q">0.04</acxp:PercentageOfRoyaltyPaymentsOnNetSales>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>68
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( !V+;U8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  =BV]6O\:E7>\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M3L,P#(9?!>7>NDD'AZCK96BG(2$Q"<0M2KPMHDFCQ*C=VY.6K1."!^ 8^\_G
MSY(;':3N(S['/F DB^EN=)U/4H<U.Q$%"9#T"9U*94[XW#STT2G*SWB$H/2'
M.B*(JGH AZ2,(@43L @+D;6-T5)'5-3'"][H!1\^8S?#C ;LT*&G!+SDP-II
M8CB/70,WP 0CC"Y]%] LQ+GZ)W;N +LDQV27U# ,Y5#/N;P#A[>GW<N\;F%]
M(N4UYE_)2CH'7+/KY-=Z\[C?LE94HBZJNN#W>\&E6,E5_3ZY_O"[";O>V(/]
MQ\97P;:!7W?1?@%02P,$%     @ '8MO5IE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M%Z_ZV&HBV:YL!1^9A,:R'&ZA]Z=<&<#[-8,:7D_4!YI_$\/_ 5!+ P04
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M %,)\GQ-J3AL5('FT^7]!5!+ P04    "  =BV]6=0_YR9\%  "'%0  &
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M1Q;R+(P3AK:X]5?]G"?R6;((Q=G;T]@Y9QK/Y.P@3EX5)Z\QC=,E%:Q]174
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MQ=/\<<EHQ(0V@-_G',XTY8N>H+I[[?\/4$L#!!0    ( !V+;U9-'1?(/PH
M (<8   8    >&PO=V]R:W-H965T<R]S:&5E=#@N>&ULI5EM<]LV$OXK&#77
M26<869*=V$YLS\@ON?HFJ3U)VMY7B(1$Q"#! J!E]=??LPN0HNPXN;G[TE@D
M=K$OSSZ[RYZLK;OSI5)!/%2F]J>C,H3F[=Z>STM523^VC:KQ9FE=)0-^NM6>
M;YR2!0M59F\VF;S9JZ2N1V<G_.S6G9W8-AA=JULG?%M5TFW.E;'KT]%TU#WX
MI%=EH =[9R>-7*G/*OS>W#K\VNNU%+I2M=>V%DXM3T?SZ=OS SK/!_[0:NT'
M?POR9&'M'?VX+DY'$S)(&94'TB#QS[VZ4,:0(ICQ5](YZJ\DP>'?G?;W[#M\
M64BO+JSY4Q>A/!T=C42AEK(UX9-=_ZJ2/Z])7VZ-Y_^*=3P[PXUYZX.MDC!^
M5[J._\J'%(>!P-'D&8%9$IBQW?$BMO)2!GEVXNQ:.#H-;?0'N\K2,$[7E)3/
MP>&MAEPX^VW^Y?=/5^+FO;BYO?HT_W)]\]OGD[T S?1^+T]:SJ.6V3-:IC/Q
MT=:A].*J+E2QJV /)O5VS3J[SF??U7BI\K'8GV9B-IG-OJ-OO_=SG_7M_Y]^
M1BT'W]9"%?+6-S)7IR.4@%?N7HW.?OYI^F;R[CLV'O0V'GQ/^W]MXP^TW'RY
M$E/Q\T]'L^GTG?B64G'>>DAY_U;,\]8]B-M2 N&Y:H/.I?&9N*[S<2:DN%1&
MKJ53(K>NL4Y2)66"N$ YLWE.^L.'"_$RE(J-F$W>7=BJD?6&?TW?_2*TA^H<
MAM-YX0.J7RRT;7;TX$J6BK<50M?B7RWNG$VFAQFJ))0"U!1-\G085)'K>D4'
MWZN%:\$Q=/AH++[ E&0#W;VT*"QH!"D4ZAZ\U)"8%+7%#]@EO1=V*60=-*R"
M,5Z$4@8ABP))]P)YU[;%&2>,7BJ\!!T&59.6!6@&KV&^KI>1>?P8X10?I<M+
M0O,D$Q2:/ZTSA?A520-';MQ*UOIO]@4VP00'^^@8>'0![7=DT,7-']>7KZ;'
M66^K#PZ\2^^0'UO+>^U:3Z]7QBY@ SPN5*5S"@$<[Y7ED@-0R:_PH=#>M4T,
M8[!BD;"AD*2:SK@[%3R1JRG 34I(SY;Q7;@74:I;LM:*V!=2O).QO0VBA&"Z
M2Q49*P^#Q*B'!O'R0@<DUYA>,RE.8AE>^D'6XTWJ ;$/% 12IY84=LKM0#D7
MP^&[@2R"0P8L=2V!&@J5<MSBZES%^PN%QL<@6;:A10DDK !F 3'6=6[:@E).
M]Q1M5QLQ!JQ<UX&Z5]ATMG6AB,ZOD$)7DSII,C2X56MDL  MO6R<O@>F@+4<
MS_#6-W!8X>)".W(P7I!^* 3+4HRC]YYR)$D(O8DN!Q9-9U_;-*BBO"3@#%-/
M"HU<X#)?6D<UB6>( \37I09VB09:A ?O($K'"[U<ZISN0([@=Z'S,!9S(-JV
MJW(GNT!?6\N%X70J'W1%WM&);0JZU#T)%O03?"&D$/C=USU.D%S$$VX;BZ0T
M5*,%ZXI2 0=;5%PI[P%A0==SF<H"4OY'N.F*(DM!98+8 C$;> %["AUC33'*
MI2_%$K-/0NOV('@O*$:3*"P*.M"08V)N 8+B*[I_?/THFT/WF5MVZ"[;B7O3
M@G:D3VP29R#QB&@!8LH=KHJRA%M#AK14%X[<#!&5%J\!1IITF"MD/6!).EJT
M,#_'45U0?N]JNZ[)_']^^+S_9G8E7CI52V+S^<6_7_$34HM30C80O\<;5"$>
MU*_H8J=5(+](!CE<J+]E@X$'@?MEI\',05>A;R]+9RNZ<8.)1'F=VME.%VBD
M+L2+Z72230\/J&-0FI PQ@[WEI4CS_!K.IEDD\E$7'!?.!<?5;4 8DK=0"U
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M\=Z4_'$)6E*6%N#YW(#QXQ<ZH'T3??8_4$L#!!0    ( !V+;U9TFCP,RP(
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M=%/*&[;]B+M^.IHO8:4PO[!M<T.5G&R$9-4.K!141=V.]''W'0X L?\*@.P
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MJ5F&BX".AD%]Q&#Y_MWD.KJ[P'<V\)U=0O]/?"\C/A$.S.#]NYMX,KF#?RL
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M5F$;J$,JA?L +ZXR&G\[GL6IR&"O<Y&P#,T$L(JK#+$(B9YI5K$F-5MO;/A
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MS(F]O%N1VRO0SU0N8'0E&9L#J^=&PQZ1]EK1+K0HS54>E($6N7E,&85C$Q+
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ME;-"+%>8_T6.COK3XV]S%$,R9A'=-(5-<O@>OOEA[C#>YDEP- G7R&(G5_P
M)UQM6[=W]$9O[!Q8G*]D6!,:C/M2)<P/],KW^N=G%Z^?,K61C40@[(B&V!!Q
MB4;T>' ?IRJCP/CME%G2F:M$9'UVZ^^2(N^/NT_F8L[2HN:2LG)S?XKS"LT-
M?F[Q,Q0F]3K1:/-9E;@9/O4)<8=F7TH+A3"[@^-:;MLC8%NVZUA(<31B@ +-
M% @2PA4;9B0"B=F!NRDFD9CH:*+Q)U:;-H.)YI3Q6E(]6;AC=GNBZ3CB?>RZ
M _'H\Z35S7G<S8V;J:&2J:R/7&4:W[\E\)<81ROC NQ0B,X*R#YD,H96_2AL
M6[Z;H5J/$+F%>GK"R=Q:#'$I@H3Q- 9,* 5:"H+7YN%Z71A&41SO,Z"DML"?
M[:6H.:*BHFK,<<^0"C\LK_+:0CJ1-+3BXDF*+/'IQOK'@QGU-EV/QY@/*UVX
M,3:!E31!N_Q]Z-]C"R9_4\&I0EDR@JSW>MV@BK3@J&ZEV""*#A#V0\BC\GL2
MUEF\.JL^.\!WZN?[CX";?_]+M.5>8+:WGM/7=0,S\KQ==UP/2!]7V6D?A>PE
M>[V6HC7-=&9[R=ZU^6K?;[C$-2NC?CC$LD^; =C:(]I=+]BH/QD_<_2B>0^_
MZ_U4M^)7IW'ISD@^&[\@W%O"WKIW4;NW+P]UY[QS='=;68-Y(ZFG8M?I!(Z,
M!=VHO:Q9/PI&$W\V><$POP_9W_54,!SZCK^*WACC?:LI>7;$WDSC7TK/A'MK
MM_EDUXXM9E.5K!O<UD P/O2&KRS$$-C&PD&U>40#,#P=C=873]I+PK&?=;:V
M81 !:MIVV^B.$ZJCE!?C(!J/@N-HZAGB&5(W6F]#;NV+IH9>461#JEF')R\+
MB-"R,*#)-6[9H.5]QDV":1@&S6M +>B+U58^P>#JCM/T;B"3,Z?KJ#\9=<UY
MMFD[!K&37J(V]C6CIZ18]0^G^\_[ZY.8?R<G<2MV8P$]F?E:J^K9M!,&K 6P
MX[C2_6T?) :=#T:YT'/W6<RXM^36?SMJ[[9?WB[\!Z?5<O_9#D=G0,RP3,RP
M->Q/)STT'O<IS%]85;K/3P_*6I6[GZG E*!I 9[/%-I-?4$*VN^1Y_\'4$L#
M!!0    ( !V+;U9:UM$B!0<  $,7   9    >&PO=V]R:W-H965T<R]S:&5E
M=#$U+GAM;,58VU+;2!#]E2DOE2=A2S*V20)4<=L*6T6@,)O4/HZEL35!TB@S
M(QOR]=O=(\EVD!T'J-T7T*6GK^=TMW6T4/K!)$)8]IBEN3GN)-86'WH]$R4B
MXZ:K"I'#FZG2&;=PJV<]4VC!8SJ4I;W0]X>]C,N\<W)$SV[UR9$J;2IS<:N9
M*;.,ZZ<SD:K%<2?HU _NY"RQ^*!W<E3PF1@+^W=QJ^&NUVB)929R(U7.M)@>
M=TZ##V<'*$\"7Z18F)5KAI%,E'K FZOXN..C0R(5D44-'/[-Q;E(4U0$;GRO
M='8:DWAP];K6_B?%#K%,N!'G*OTJ8YL<=PX[+!937J;V3BT^B2J> >J+5&KH
M+ULXV7[885%IK,JJP^!!)G/WGS]6>5@Y<.AO.!!6!T+RVQDB+R^XY2='6BV8
M1FG0AA<4*IT&YV2.11E;#6\EG+,GXT^G=Y?[9Z?CRPMV>_K/]>7G^S&[OV%?
M+C]?W-R-CWH6C*!H+ZH4GCF%X0:%0<BN56X3PR[S6,3K"GK@7>-B6+MX%F[5
M>"&B+NL''@O],-RBK]^$W"=]_;<+V2D\:%>(O/E@"AZ)XPX0PP@]%YV3=W\$
M0__C%G</&G</MFE_B;M;%;:[^_GF_I(=LG=_'(9!\)']PBC[FLA4,)L(=JZR
M@N=/;,$-XRR5F;0BAO]\(E-IGUA4O9<YD]8PL+A_=7O#B@2HQ-04WNM":6X%
M<&D./:( QEMO3?5,\QR5GJ?<&';*KD4V$=HDLF!7\ )B ,56L4AH"VV(S44>
M*VW0)*I1.I8Y-!PP56IG=%(:2(HA$?$8)3R?"08=#D1R WR6^8QA8F0D#+2>
ME-,3,('YXCI*&,_C58===Y%6@CR^DOD<O *%[C!H[;+[EI#ZOA<<#+9'AGYA
M'$]@F0DD%0-*D&1-B\!IGW*IV9RG)05)*=RFN'8"2R>^ESS%"/'4FHI,&0MA
M1!AEH>4<2U6D !^,>STJD%*S7/X G7A2/,+H@(17=3 \@Y-"2Q57.5H^SGB>
M0SC@B)RNU3[A,2NXC%G$3=*DHJ[-<_,:TS,3H S"02L\AJXIC06(0?NO?7)5
MVEC-1@H-.CAAAA#/E+0&6SQ3)=Y"KO;\72H5DJV]T ^\_FA0W03>X/UPISI[
MZ',A:)2E3UTH)KN)K$(14/F^G3<<ZFHA'>!D,/ ]W_=1B]4RVH55-M%"U,2@
MV-'1YP!OY0Z4&Q<'0=5&#U&=*F?)BML5>LTOT(KV0(^J4 .UQNKF.61"&Z1W
MA5>*FL4 4X_2NX#SL'-,OD'6,!X>1; 38,>)22?Z6V@UEX:B* O<%5C5$ZA!
MY5:KM&&42^[_13@/X-*% D)BM]G:B9<4*#(#-Y=]'!.XX$A ,Z34^57GAUC[
M"K8Y?A#:@W! $%R%N]G*EC;@HR=0&:P]+7?QMY+@81*NG3T8/!F\ 9!&#PX$
MTIC2(7$=?%=KD(*Z:$@BJG"&5RDE*+^H Y'$\I*\!5$^ Y9@@0PL<#9I9E !
M(Z=$0(+\(I'0:U;593P6=4=!)2M$';DL;8H';? 5K/\$Q;UA-QQZKFD6_,DY
MMM:S2*I_T/<&ON^($OBN-ZC"\=FYZS*71VF)!:(A7T"":K#^5:9/E"?G2\UD
M(@W,1 ,-''  2<MJA=H-6ZTR9N0CH)V6Q:;1$!SJ^JY&#*8IO)BV\*81M*<
MXZ'97\52G2PM+"4_$-%G0*B'_7&4J!332V+(M@A?9BH6:>7#6@8I&16HXR5-
MJG:W.MR(9VYBX :D\I6Q$E.K!);@,ZJD398IP[90\:[.9@4"U-L4!SVI^TE5
M6)M(_0R_:PA$J=N4YPWF6X^T3Y$:T2L@[0^\X?O!!HQZ5;VG90H0J;HW30&T
MT.[5"_L+83GT#[UP!%A>@\>R:[0CQ7@[[E=7ZUUC6UO(E]V@)NIR?&+ -&Z
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M]%HI3 [:4XUV$YJP(UJM]EVG&G:'/G_9M;<7\^Y/PHVP&ZD=*%R3:SHZ.XG
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MM.#$F\'KIN!I0:ZIJ#,Z/+EHN9AP.K>A['@&;&U1M]PIU6.X;\J?Q;_IP+)
M(F_<CU2',8F,-#6#K-8N9?>@@<G,+6+O=M@T)HP"M1(\W_7#MTZK#1-V\ZMA
MU%LFW+&[TZC[[*,+#_2A1)U[%31TN;6TK53L=_=".VKUY1>\5>D9TSF7!@2N
MR37J7%T$H%OE:PVK*J\V*V5)N_RRH":B=@ Z7RME=X8+L/_[&?X$4$L#!!0
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M*KZX[#F(=_K6&9*U1E.63"J%,M-"/0G =8!:SQF3.T,7L(],\@=02P,$%
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M;8TARSPKY""49S/.YT63+4966UNV,&?/@KZ<?!Y9X![O9SN]AAT]9.]\)"Q
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M.I>1^BZ\NC"JB62EZ;E+)E4'-\-4W;' -4"]7S,FGR>ZC3>W=OP74$L#!!0
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M"$<=^N",WE$ 3#'69L#.\X!GCI+XN<@N@&M] ([EV!T=FI^1(RFW3\H#M3S
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M:R A\*R#>KYD3#[?9 &JKR_>?U!+ P04    "  =BV]6P>T?N-X,   GM@
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M>]_]\]\79V4U9SWR;-KXUR]^<,#WO9^R57E?>&(U,[..\=(]/CPV7AV9/W
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M]R?5L\]/65EFR_7%>Y/.3%Y?H?K_VRPKOWY13_"<Y7^M;\[E_P%02P,$%
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M!=4T'$BQ)M+,1C;S87-CT>B&<;.,4RUQE"%.AU=?1]^NQ^3V[.=X2CZ16_J
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M@0;-6W,MLIH*5:!%X3IQ);3I:[?,S"!%:1/,^5H(?0RL0#V:XU]02P,$%
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MFKH1P-P.H@A#X&[$$<P!>,"0*#+OP9WW4;!Z3P7K_^ ._P)02P,$%     @
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MZ]5?_TMHU[A697/T9]T/F_DG4$L! A0#%     @ '8MO5@=!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M"  =BV]6O\:E7>\    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    "  =BV]6F5R<(Q &  "<)P  $P
M    @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( !V+;U8Q
M*2&]CP<   ,R   8              " @0X(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    "  =BV]6!D[:#J8$  #:%   &
M    @('3#P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @
M'8MO5F7+?Z]N @  $P<  !@              ("!KQ0  'AL+W=O<FMS:&5E
M=',O<VAE970S+GAM;%!+ 0(4 Q0    ( !V+;U:2]V<#K@,  %D,   8
M          " @5,7  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M    "  =BV]63(RIIP8(   '.P  &               @($W&P  >&PO=V]R
M:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ '8MO5BO0"WF, @  Q@8
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M965T,3 N>&UL4$L! A0#%     @ '8MO5DUMX ]Y P  CP<  !D
M     ("!JT0  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !V+;U99OU3?/P@  'L5   9              "
M@?AE  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ '8MO
M5D.UF?J_ P  "0D  !D              ("!;FX  'AL+W=O<FMS:&5E=',O
M<VAE970Q-RYX;6Q02P$"% ,4    "  =BV]62Q_\A?@"  "*!@  &0
M        @(%D<@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0
M   ( !V+;U;4OR8N;@L  #8B   9              " @9-U  !X;"]W;W)K
M<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ '8MO5F?661NZ @  < 8
M !D              ("!.($  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q0
M2P$"% ,4    "  =BV]6O39%,)4"   X!@  &0              @($IA
M>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( !V+;U9GECEZ
MI ,  / )   9              " @?6&  !X;"]W;W)K<VAE971S+W-H965T
M,C(N>&UL4$L! A0#%     @ '8MO5D2K%%&R P  # H  !D
M ("!T(H  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  =
MBV]6"AT[%BX'  !T2   &0              @(&YC@  >&PO=V]R:W-H965T
M<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( !V+;U:YZ:M8Y@(  ,@(   9
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M970R.2YX;6Q02P$"% ,4    "  =BV]6YR&EU,$+  "\B@  &0
M    @($!IP  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (
M !V+;U9/6E#@DP0  +0?   9              " @?FR  !X;"]W;W)K<VAE
M971S+W-H965T,S$N>&UL4$L! A0#%     @ '8MO5CG1(1&H P  B1$  !D
M             ("!P[<  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"
M% ,4    "  =BV]6P>T?N-X,   GM@  &0              @(&BNP  >&PO
M=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( !V+;U8B7KS<=@(
M &\%   9              " @;?(  !X;"]W;W)K<VAE971S+W-H965T,S0N
M>&UL4$L! A0#%     @ '8MO5MO03W&* @  .P8  !D              ("!
M9,L  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  =BV]6
M"K>YU$D#  # #   &0              @($ES@  >&PO=V]R:W-H965T<R]S
M:&5E=#,V+GAM;%!+ 0(4 Q0    ( !V+;U9<!V3E^Q   ,0K 0 9
M      " @:71  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%
M  @ '8MO5NS&(0P8 @  DP0  !D              ("!U^(  'AL+W=O<FMS
M:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  =BV]6H1>173P#   1"@
M&0              @($FY0  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+
M 0(4 Q0    ( !V+;U:P%Y&50@,  &4*   9              " @9GH  !X
M;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ '8MO5LU>]P2?
M P  5Q(  !D              ("!$NP  'AL+W=O<FMS:&5E=',O<VAE970T
M,2YX;6Q02P$"% ,4    "  =BV]66CV:K&X"  "F!0  &0
M@('H[P  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( !V+
M;U9.H;005@,  ,X5   -              "  8WR  !X;"]S='EL97,N>&UL
M4$L! A0#%     @ '8MO5I>*NQS     $P(   L              ( !#O8
M %]R96QS+RYR96QS4$L! A0#%     @ '8MO5O,Y# KY P  =!P   \
M         ( !]_8  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( !V+;U:^
MRS-!F0$  '49   :              "  1W[  !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( !V+;U8CU6X-J $  +@9   3
M      "  >[\  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     R #( E0T
' ,?^      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>137</ContextCount>
  <ElementCount>197</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>53</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/StatementBalanceSheets</Role>
      <ShortName>BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/StatementBalanceSheetsParenthetical</Role>
      <ShortName>BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/StatementStatementsOfOperations</Role>
      <ShortName>STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - STATEMENTS OF CHANGES IN MEMBERS' AND SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity</Role>
      <ShortName>STATEMENTS OF CHANGES IN MEMBERS' AND SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - STATEMENTS OF CHANGES IN MEMBERS' AND SHAREHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquityParenthetical</Role>
      <ShortName>STATEMENTS OF CHANGES IN MEMBERS' AND SHAREHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/StatementStatementsOfCashFlows</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - NATURE OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosureNatureOfOperations</Role>
      <ShortName>NATURE OF OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosureAccountsPayableAndAccruedExpenses</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - PAYCHECK PROTECTION PROGRAM LOAN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosurePaycheckProtectionProgramLoan</Role>
      <ShortName>PAYCHECK PROTECTION PROGRAM LOAN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - EXECUTIVE COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosureExecutiveCompensation</Role>
      <ShortName>EXECUTIVE COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - ISSUANCE OF EQUITY INTERESTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterests</Role>
      <ShortName>ISSUANCE OF EQUITY INTERESTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - SHARE-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosureShareBasedCompensation</Role>
      <ShortName>SHARE-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - SHARE-BASED PAYMENTS TO VENDORS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendors</Role>
      <ShortName>SHARE-BASED PAYMENTS TO VENDORS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11001 - Disclosure - NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11101 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>30303 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosureAccountsPayableAndAccruedExpensesTables</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acurxpharma.com/role/DisclosureAccountsPayableAndAccruedExpenses</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>30603 - Disclosure - ISSUANCE OF EQUITY INTERESTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsTables</Role>
      <ShortName>ISSUANCE OF EQUITY INTERESTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterests</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30703 - Disclosure - SHARE-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosureShareBasedCompensationTables</Role>
      <ShortName>SHARE-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acurxpharma.com/role/DisclosureShareBasedCompensation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30903 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acurxpharma.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>40101 - Disclosure - NATURE OF OPERATIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails</Role>
      <ShortName>NATURE OF OPERATIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acurxpharma.com/role/DisclosureNatureOfOperations</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40301 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acurxpharma.com/role/DisclosureAccountsPayableAndAccruedExpensesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40401 - Disclosure - PAYCHECK PROTECTION PROGRAM LOAN (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosurePaycheckProtectionProgramLoanDetails</Role>
      <ShortName>PAYCHECK PROTECTION PROGRAM LOAN (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acurxpharma.com/role/DisclosurePaycheckProtectionProgramLoan</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40501 - Disclosure - EXECUTIVE COMPENSATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosureExecutiveCompensationDetails</Role>
      <ShortName>EXECUTIVE COMPENSATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acurxpharma.com/role/DisclosureExecutiveCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40601 - Disclosure - ISSUANCE OF EQUITY INTERESTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails</Role>
      <ShortName>ISSUANCE OF EQUITY INTERESTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40602 - Disclosure - ISSUANCE OF EQUITY INTERESTS - Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsFairValueDetails</Role>
      <ShortName>ISSUANCE OF EQUITY INTERESTS - Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40603 - Disclosure - ISSUANCE OF EQUITY INTERESTS - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsWarrantsDetails</Role>
      <ShortName>ISSUANCE OF EQUITY INTERESTS - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40701 - Disclosure - SHARE-BASED COMPENSATION - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acurxpharma.com/role/DisclosureShareBasedCompensationTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40702 - Disclosure - SHARE-BASED COMPENSATION - Unvested (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosureShareBasedCompensationUnvestedDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Unvested (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40703 - Disclosure - SHARE-BASED COMPENSATION - Option pricing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosureShareBasedCompensationOptionPricingDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Option pricing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40704 - Disclosure - SHARE-BASED COMPENSATION - Option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosureShareBasedCompensationOptionActivityDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40801 - Disclosure - SHARE-BASED PAYMENTS TO VENDORS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails</Role>
      <ShortName>SHARE-BASED PAYMENTS TO VENDORS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendors</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40901 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosureIncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acurxpharma.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40902 - Disclosure - INCOME TAXES - Deferred tax asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetDetails</Role>
      <ShortName>INCOME TAXES - Deferred tax asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40903 - Disclosure - INCOME TAXES - Tax reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosureIncomeTaxesTaxReconciliationDetails</Role>
      <ShortName>INCOME TAXES - Tax reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>41001 - Disclosure - NET LOSS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosureNetLossPerShareDetails</Role>
      <ShortName>NET LOSS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acurxpharma.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="acxp-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>41101 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acurxpharma.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acurxpharma.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>42</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 18 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, us-gaap:CommonStockSharesOutstanding, us-gaap:EarningsPerShareBasic, us-gaap:EarningsPerShareDiluted, us-gaap:LongTermDebtTerm, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod, us-gaap:WarrantsAndRightsOutstandingMeasurementInput, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding, us-gaap:WeightedAverageNumberOfSharesOutstandingBasic -  acxp-20221231x10k.htm 9</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 2 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies -  acxp-20221231x10k.htm 9</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="acxp-20221231x10k.htm">acxp-20221231x10k.htm</File>
    <File>acxp-20221231.xsd</File>
    <File>acxp-20221231_cal.xml</File>
    <File>acxp-20221231_def.xml</File>
    <File>acxp-20221231_lab.xml</File>
    <File>acxp-20221231_pre.xml</File>
    <File>acxp-20221231xex21d1.htm</File>
    <File>acxp-20221231xex23d1.htm</File>
    <File>acxp-20221231xex31d1.htm</File>
    <File>acxp-20221231xex31d2.htm</File>
    <File>acxp-20221231xex32d1.htm</File>
    <File>acxp-20221231xex32d2.htm</File>
    <File>acxp-20221231xex4d6.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>acxp-20221231x10k002.jpg</File>
    <File>acxp-20221231x10k003.jpg</File>
    <File>acxp-20221231x10k004.jpg</File>
    <File>acxp-20221231x10k006.jpg</File>
    <File>acxp-20221231x10k007.jpg</File>
    <File>acxp-20221231x10k008.jpg</File>
    <File>acxp-20221231x10k009.jpg</File>
    <File>acxp-20221231x10k011.jpg</File>
    <File>acxp-20221231x10k012.jpg</File>
    <File>acxp-20221231x10k013.jpg</File>
    <File>acxp-20221231x10k014.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="338">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>74
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "acxp-20221231x10k.htm": {
   "axisCustom": 0,
   "axisStandard": 18,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 338,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 137,
   "dts": {
    "calculationLink": {
     "local": [
      "acxp-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "acxp-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "acxp-20221231x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "acxp-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "acxp-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "acxp-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 336,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 23,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 28
   },
   "keyCustom": 25,
   "keyStandard": 172,
   "memberCustom": 28,
   "memberStandard": 25,
   "nsprefix": "acxp",
   "nsuri": "http://www.acurxpharma.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.acurxpharma.com/role/DisclosureAccountsPayableAndAccruedExpenses",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acxp:PaycheckProtectionProgramLoanDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - PAYCHECK PROTECTION PROGRAM LOAN",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.acurxpharma.com/role/DisclosurePaycheckProtectionProgramLoan",
     "shortName": "PAYCHECK PROTECTION PROGRAM LOAN",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acxp:PaycheckProtectionProgramLoanDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationRelatedCostsGeneralTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - EXECUTIVE COMPENSATION",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.acurxpharma.com/role/DisclosureExecutiveCompensation",
     "shortName": "EXECUTIVE COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationRelatedCostsGeneralTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - ISSUANCE OF EQUITY INTERESTS",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterests",
     "shortName": "ISSUANCE OF EQUITY INTERESTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - SHARE-BASED COMPENSATION",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.acurxpharma.com/role/DisclosureShareBasedCompensation",
     "shortName": "SHARE-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acxp:ShareBasedPaymentsToVendorsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - SHARE-BASED PAYMENTS TO VENDORS",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendors",
     "shortName": "SHARE-BASED PAYMENTS TO VENDORS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acxp:ShareBasedPaymentsToVendorsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - INCOME TAXES",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.acurxpharma.com/role/DisclosureIncomeTaxes",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - NET LOSS PER SHARE",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.acurxpharma.com/role/DisclosureNetLossPerShare",
     "shortName": "NET LOSS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.acurxpharma.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "19",
     "role": "http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.acurxpharma.com/role/StatementBalanceSheets",
     "shortName": "BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.acurxpharma.com/role/DisclosureAccountsPayableAndAccruedExpensesTables",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - ISSUANCE OF EQUITY INTERESTS (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsTables",
     "shortName": "ISSUANCE OF EQUITY INTERESTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - SHARE-BASED COMPENSATION (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationTables",
     "shortName": "SHARE-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - INCOME TAXES (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.acurxpharma.com/role/DisclosureIncomeTaxesTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "As_Of_6_29_2021_jxXdY4PAdk6_gydSF_zR1g",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - NATURE OF OPERATIONS (Details)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails",
     "shortName": "NATURE OF OPERATIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "As_Of_7_27_2022_us-gaap_ClassOfWarrantOrRightAxis_acxp_SeriesWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Igcj6YgXu0uL014Kv8JyFA",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unitRef": "Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_acxp_VendorOneMember_4oZxhIVJI0KIX3uwgXpLww",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_acxp_VendorOneMember_4oZxhIVJI0KIX3uwgXpLww",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.acurxpharma.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_vVawK8LOn0KO72C5Zlb_Wg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - PAYCHECK PROTECTION PROGRAM LOAN (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.acurxpharma.com/role/DisclosurePaycheckProtectionProgramLoanDetails",
     "shortName": "PAYCHECK PROTECTION PROGRAM LOAN (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "acxp:PaycheckProtectionProgramLoanDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_5_1_2020_To_5_31_2020_us-gaap_ShortTermDebtTypeAxis_acxp_PaycheckProtectionProgramLoanMember_6co5NWgV9EOO1mbFZkcoFA",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "As_Of_6_29_2021_jxXdY4PAdk6_gydSF_zR1g",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssuedPricePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - EXECUTIVE COMPENSATION (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.acurxpharma.com/role/DisclosureExecutiveCompensationDetails",
     "shortName": "EXECUTIVE COMPENSATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CompensationRelatedCostsGeneralTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_1_31_2021_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_8oqL0Hgh60e7ICqaSonkbQ",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_E87IzmnY70qruzdZuQN9Ng",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.acurxpharma.com/role/StatementBalanceSheetsParenthetical",
     "shortName": "BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - ISSUANCE OF EQUITY INTERESTS (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
     "shortName": "ISSUANCE OF EQUITY INTERESTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_6_29_2021_To_6_29_2021_ZftWEESwJUi8qhJm8t8FPQ",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "As_Of_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_acxp_UnderwriterMember_UBZF9KBTGk6x1d7NF_WJMw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:WarrantsNotSettleableInCashFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40602 - Disclosure - ISSUANCE OF EQUITY INTERESTS - Fair Value (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsFairValueDetails",
     "shortName": "ISSUANCE OF EQUITY INTERESTS - Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "As_Of_6_29_2021_us-gaap_SubsidiarySaleOfStockAxis_acxp_UnderwriterMember_UBZF9KBTGk6x1d7NF_WJMw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:WarrantsNotSettleableInCashFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40603 - Disclosure - ISSUANCE OF EQUITY INTERESTS - Warrants (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsWarrantsDetails",
     "shortName": "ISSUANCE OF EQUITY INTERESTS - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": "INF",
      "lang": null,
      "name": "acxp:ClassOfWarrantOrRightIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - SHARE-BASED COMPENSATION - (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails",
     "shortName": "SHARE-BASED COMPENSATION - (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_PvS7_eCOf02Kg60XmKqo1Q",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - SHARE-BASED COMPENSATION - Unvested (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationUnvestedDetails",
     "shortName": "SHARE-BASED COMPENSATION - Unvested (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_PvS7_eCOf02Kg60XmKqo1Q",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40703 - Disclosure - SHARE-BASED COMPENSATION - Option pricing (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationOptionPricingDetails",
     "shortName": "SHARE-BASED COMPENSATION - Option pricing (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40704 - Disclosure - SHARE-BASED COMPENSATION - Option activity (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationOptionActivityDetails",
     "shortName": "SHARE-BASED COMPENSATION - Option activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_63sojJ4UvUWzyi3D718SXw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "acxp:ShareBasedPaymentToVendors",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - SHARE-BASED PAYMENTS TO VENDORS (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails",
     "shortName": "SHARE-BASED PAYMENTS TO VENDORS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "acxp:ShareBasedPaymentsToVendorsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_AwardDateAxis_acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember_EdWadodcnUyBlBRFeYfBqg",
      "decimals": "0",
      "lang": null,
      "name": "acxp:ShareBasedPaymentToVendors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - INCOME TAXES (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.acurxpharma.com/role/DisclosureIncomeTaxesDetails",
     "shortName": "INCOME TAXES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - INCOME TAXES - Deferred tax asset (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.acurxpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetDetails",
     "shortName": "INCOME TAXES - Deferred tax asset (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_Z7KgzplvzUqiWaYZSFWqQA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - STATEMENTS OF OPERATIONS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.acurxpharma.com/role/StatementStatementsOfOperations",
     "shortName": "STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40903 - Disclosure - INCOME TAXES - Tax reconciliation (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.acurxpharma.com/role/DisclosureIncomeTaxesTaxReconciliationDetails",
     "shortName": "INCOME TAXES - Tax reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_Jhm0ZEzxzEWN0MWyPO-Q-Q",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_6_29_2021_To_6_29_2021_ZftWEESwJUi8qhJm8t8FPQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - NET LOSS PER SHARE (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.acurxpharma.com/role/DisclosureNetLossPerShareDetails",
     "shortName": "NET LOSS PER SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_HEBRdNbrGUqT6x6-UyBm6w",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_yPp0RWcsVku4YHsEpJBGrQ",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "As_Of_2_28_2018_srt_ProductOrServiceAxis_acxp_AcxThreeSixtyTwoEMember_b8X5m76NYkaaQE7rN9N3KQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherCommitment",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.acurxpharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_27b4PKohgEW2UtRdiEuquw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - STATEMENTS OF CHANGES IN MEMBERS' AND SHAREHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity",
     "shortName": "STATEMENTS OF CHANGES IN MEMBERS' AND SHAREHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_acxp_CommonUnitClassMemberSCapitalMember_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_27b4PKohgEW2UtRdiEuquw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_6_29_2021_To_6_29_2021_ZftWEESwJUi8qhJm8t8FPQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00305 - Statement - STATEMENTS OF CHANGES IN MEMBERS' AND SHAREHOLDERS' EQUITY (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquityParenthetical",
     "shortName": "STATEMENTS OF CHANGES IN MEMBERS' AND SHAREHOLDERS' EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows",
     "shortName": "STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_fHF5RljLj02_H8XmIYdeOQ",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - NATURE OF OPERATIONS",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.acurxpharma.com/role/DisclosureNatureOfOperations",
     "shortName": "NATURE OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acxp-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_3lyrzvdF30W4l8RW7OT5wQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 53,
   "tag": {
    "acxp_AccruedResearchAndDevelopmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.acurxpharma.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount carrying value as of the balance sheet date of accrued research and development Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Research and Development Current",
        "terseLabel": "Accrued research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCurrent",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acxp_AcxThreeSixtyTwoEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member is stands for ACX 362E.",
        "label": "ACX362E"
       }
      }
     },
     "localname": "AcxThreeSixtyTwoEMember",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acxp_AffiliateInvestorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to affiliate investors.",
        "label": "Affiliate Investors"
       }
      }
     },
     "localname": "AffiliateInvestorsMember",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acxp_CancellationOfStockUnitsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the shares of stock units cancelled during the period.",
        "label": "Cancellation Of Stock Units Shares",
        "negatedLabel": "Cancellation of Class B Issuance (in shares)"
       }
      }
     },
     "localname": "CancellationOfStockUnitsShares",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "acxp_CancellationOfStockUnitsValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock units cancelled during the period.",
        "label": "Cancellation Of Stock Units Value",
        "negatedLabel": "Cancellation of Class B Issuance"
       }
      }
     },
     "localname": "CancellationOfStockUnitsValue",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acxp_ClassOfWarrantOrRightExercisableTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right exercisable term.",
        "label": "Class Of Warrant Or Right Exercisable Term",
        "terseLabel": "Warrant exercisable term"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisableTerm",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights exercised.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights, Exercised",
        "terseLabel": "Warrant exercise price, exercised (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "acxp_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights issued.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights, Issued",
        "terseLabel": "Warrant exercise price, issued (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "acxp_ClassOfWarrantOrRightExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The decrease in warrants outstanding during the period for the number of warrant exercised.",
        "label": "Class of Warrant or Right, Exercised",
        "terseLabel": "Warrants exercised (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercised",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "acxp_ClassOfWarrantOrRightIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase in warrants outstanding during the period for the number of warrant issued.",
        "label": "Class of Warrant or Right, Issued",
        "terseLabel": "Warrants issued (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssued",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "acxp_ClassOfWarrantOrRightPurchasePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Purchase Price",
        "terseLabel": "Purchase price pre-funded warrant (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightPurchasePrice",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "acxp_CommonUnitClassAndClassBMemberSCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Class A and class B members capital.",
        "label": "Members' Equity, Class A and Class B"
       }
      }
     },
     "localname": "CommonUnitClassAndClassBMemberSCapitalMember",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acxp_CommonUnitClassBMemberSCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Class B Membership Interests.",
        "label": "Members' Equity, Class B"
       }
      }
     },
     "localname": "CommonUnitClassBMemberSCapitalMember",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureExecutiveCompensationDetails",
      "http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails",
      "http://www.acurxpharma.com/role/StatementBalanceSheets",
      "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "acxp_CommonUnitClassMemberSCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Class A Membership Interests.",
        "label": "Members' Equity, Class A",
        "terseLabel": "Members' Equity, Class A"
       }
      }
     },
     "localname": "CommonUnitClassMemberSCapitalMember",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureExecutiveCompensationDetails",
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationUnvestedDetails",
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails",
      "http://www.acurxpharma.com/role/StatementBalanceSheets",
      "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "acxp_EquityIncentivePlan2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 2021 Equity Incentive Plan.",
        "label": "2021 Equity Incentive Plan"
       }
      }
     },
     "localname": "EquityIncentivePlan2021Member",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acxp_ExecutivesIndependentDirectorsConsultantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to executives pursuant to their respective employment agreements, the independent directors, and one consultant.",
        "label": "Executives, Independent Directors, Consultant"
       }
      }
     },
     "localname": "ExecutivesIndependentDirectorsConsultantMember",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acxp_IndependentDirectorsConsultantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to the independent directors and one consultant.",
        "label": "Independent Directors, Consultant"
       }
      }
     },
     "localname": "IndependentDirectorsConsultantMember",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acxp_NonCashFinancingActivitiesOfWarrantsIssuedInConnectionWithOfferings": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of offering costs issued in connection with warrants.",
        "label": "Non Cash Financing Activities Of Warrants Issued In Connection With Offerings",
        "terseLabel": "Warrants issued in connection with offerings"
       }
      }
     },
     "localname": "NonCashFinancingActivitiesOfWarrantsIssuedInConnectionWithOfferings",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acxp_NonEmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Non-Employee.",
        "label": "Non-Employee"
       }
      }
     },
     "localname": "NonEmployeeMember",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureExecutiveCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acxp_PaycheckProtectionProgramLoanAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the details pertaining to Paycheck Protection Program Loan.",
        "label": "PAYCHECK PROTECTION PROGRAM LOAN"
       }
      }
     },
     "localname": "PaycheckProtectionProgramLoanAbstract",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "acxp_PaycheckProtectionProgramLoanDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of paycheck protection program loan.",
        "label": "Paycheck Protection Program Loan Disclosure [Text Block]",
        "terseLabel": "PAYCHECK PROTECTION PROGRAM LOAN"
       }
      }
     },
     "localname": "PaycheckProtectionProgramLoanDisclosureTextBlock",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosurePaycheckProtectionProgramLoan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "acxp_PaycheckProtectionProgramLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the details pertaining to Paycheck protection program loan.",
        "label": "Paycheck Protection Program Loan"
       }
      }
     },
     "localname": "PaycheckProtectionProgramLoanMember",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosurePaycheckProtectionProgramLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acxp_PercentageOfRoyaltyPaymentsOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents for percentage of royalty payments on net sales.",
        "label": "Percentage of royalty payments on net sales",
        "terseLabel": "Royalty payments on net sales (as a percent)"
       }
      }
     },
     "localname": "PercentageOfRoyaltyPaymentsOnNetSales",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "acxp_PercentageOfWeightedAveragePublicOfferingPriceOfAggregateNumberOfSharesOfCommonStockSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of weighted average public offering price of the aggregate number of shares of common stock sold.",
        "label": "Percentage Of Weighted Average Public Offering Price Of The Aggregate Number Of Shares Of Common Stock Sold",
        "terseLabel": "Weighted average aggregate offering price (as a percent)"
       }
      }
     },
     "localname": "PercentageOfWeightedAveragePublicOfferingPriceOfAggregateNumberOfSharesOfCommonStockSold",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "acxp_PlacementAgentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Placement Agents.",
        "label": "Placement Agents"
       }
      }
     },
     "localname": "PlacementAgentsMember",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acxp_RegisteredDirectOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Registered direct offering.",
        "label": "Registered direct offering"
       }
      }
     },
     "localname": "RegisteredDirectOfferingMember",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acxp_SeriesBWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Series B warrants.",
        "label": "Series B warrants"
       }
      }
     },
     "localname": "SeriesBWarrantsMember",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acxp_SeriesWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Series A warrants.",
        "label": "Series A warrants"
       }
      }
     },
     "localname": "SeriesWarrantsMember",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acxp_ShareBasedPaymentArrangementGrantDateApril2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granted April 2022.",
        "label": "April 2022"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementGrantDateApril2022Member",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acxp_ShareBasedPaymentArrangementGrantDateJanuary2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granted January 2022.",
        "label": "January 2022"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementGrantDateJanuary2022Member",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acxp_ShareBasedPaymentArrangementGrantDateJuly2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granted July 2021.",
        "label": "July 2021"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementGrantDateJuly2021Member",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acxp_ShareBasedPaymentArrangementGrantDateJune2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granted June 2021.",
        "label": "June 2021"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementGrantDateJune2021Member",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acxp_ShareBasedPaymentArrangementGrantDateMarch2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granted March 2022.",
        "label": "March 2022"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementGrantDateMarch2022Member",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acxp_ShareBasedPaymentArrangementGrantDateOctober2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granted October 2019.",
        "label": "October 2019"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementGrantDateOctober2019Member",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acxp_ShareBasedPaymentArrangementGrantDateOctober2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granted October 2021.",
        "label": "October 2021"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementGrantDateOctober2021Member",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acxp_ShareBasedPaymentArrangementGrantDatePreIpoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granted pre-IPO.",
        "label": "Pre IPO"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementGrantDatePreIpoMember",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acxp_ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granted second quarter 2021.",
        "label": "Second Quarter 2021"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementGrantDateSecondQuarter2021Member",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acxp_ShareBasedPaymentArrangementGrantDateSeptember2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granted September 2022.",
        "label": "September 2022"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementGrantDateSeptember2022Member",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acxp_ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based payment arrangement 2022 fourth quarter",
        "label": "Fourth Quarter 2022"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementGrantedInFourthQuarter2022Member",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acxp_ShareBasedPaymentArrangementGrantedInThirdQuarter2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based payment arrangement 2021 third quarter",
        "label": "Third Quarter 2021"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementGrantedInThirdQuarter2021Member",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acxp_ShareBasedPaymentToVendors": {
     "auth_ref": [],
     "calculation": {
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of non cash expense for share based payment to vendors.",
        "label": "Share-Based Payments to Vendors.",
        "terseLabel": "Share-Based Payments to Vendors",
        "verboseLabel": "Share-based vendor payments"
       }
      }
     },
     "localname": "ShareBasedPaymentToVendors",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails",
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acxp_ShareBasedPaymentsToVendorsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ABSTRACT",
        "label": "SHARE-BASED PAYMENTS TO VENDORS"
       }
      }
     },
     "localname": "ShareBasedPaymentsToVendorsAbstract",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "acxp_ShareBasedPaymentsToVendorsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the share based payments to vendors disclosure.",
        "label": "Share Based Payments To Vendors Disclosure [Text Block]",
        "terseLabel": "SHARE-BASED PAYMENTS TO VENDORS"
       }
      }
     },
     "localname": "ShareBasedPaymentsToVendorsDisclosureTextBlock",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendors"
     ],
     "xbrltype": "textBlockItemType"
    },
    "acxp_ShareBasedPaymentsToVendorsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for share-based payments to vendors.",
        "label": "Share-Based Payments to Vendors Policy Text block",
        "terseLabel": "Share-Based Payments to Vendors"
       }
      }
     },
     "localname": "ShareBasedPaymentsToVendorsPolicyTextBlock",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "acxp_StockIssuedDuringPeriodSharesBonus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to bonus.",
        "label": "Stock Issued During Period, Shares, Bonus",
        "terseLabel": "Shares issued for bonus (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesBonus",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureExecutiveCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "acxp_StockIssuedDuringPeriodSharesCorporateConversionOfUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued during the period upon the corporate conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Stock Issued During Period Shares Corporate Conversion Of Units",
        "negatedLabel": "Corporate Conversion (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCorporateConversionOfUnits",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "acxp_StockIssuedDuringPeriodSharesPeriodIncreaseDecreaseThroughCashlessWarrantExercise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the number of shares issued through cashless warrant exercise.",
        "label": "Stock Issued During Period, Shares, Period Increase (Decrease) Through Cashless Warrant Exercise",
        "terseLabel": "Cashless Warrant Exercise (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesPeriodIncreaseDecreaseThroughCashlessWarrantExercise",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "acxp_StockIssuedDuringPeriodValueCorporateConversionOfUnits": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued during the period upon the corporate conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Stock Issued During Period Value Corporate Conversion Of Units",
        "negatedLabel": "Corporate Conversion"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCorporateConversionOfUnits",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acxp_StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from new stock issued during the period before offering costs.",
        "label": "Stock Issued During Period, Value, New Issues, Before Offering Costs",
        "terseLabel": "Stock issue gross proceeds"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssuesBeforeOfferingCosts",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acxp_StockUnitsIssuedDuringPeriodSharesExecutiveCompensationSettled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of tock units issued during the period for executive compensation settlement.",
        "label": "Stock Units Issued During Period Shares Executive Compensation Settled",
        "terseLabel": "Executive Compensation Settled with Membership Interests (in shares)"
       }
      }
     },
     "localname": "StockUnitsIssuedDuringPeriodSharesExecutiveCompensationSettled",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "acxp_StockUnitsIssuedDuringPeriodValueExecutiveCompensationSettled": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of  stock  units issued during the period for executive compensation settlement.",
        "label": "Stock Units Issued During Period Value Executive Compensation Settled",
        "terseLabel": "Executive Compensation Settled with Membership Interests"
       }
      }
     },
     "localname": "StockUnitsIssuedDuringPeriodValueExecutiveCompensationSettled",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acxp_StockholdersEquityPeriodIncreaseDecreaseThroughCashlessWarrantExercise": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in stockholders' equity through cashless warrant exercise during the period.",
        "label": "Stockholders' Equity, Period Increase (Decrease) Through Cashless Warrant Exercise",
        "terseLabel": "Cashless Warrant Exercise"
       }
      }
     },
     "localname": "StockholdersEquityPeriodIncreaseDecreaseThroughCashlessWarrantExercise",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acxp_UnderwriterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Relating to the IPO underwriter.",
        "label": "Underwriter"
       }
      }
     },
     "localname": "UnderwriterMember",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acxp_VendorOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to the first vendor.",
        "label": "Vendor One"
       }
      }
     },
     "localname": "VendorOneMember",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acxp_VendorTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to the second vendor.",
        "label": "Vendor Two"
       }
      }
     },
     "localname": "VendorTwoMember",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acxp_WarrantExercisePreFunded": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in stockholders' equity through pre-funded warrant exercise during the period.",
        "label": "Warrant Exercise, Pre Funded",
        "terseLabel": "Pre-funded Warrant Exercise"
       }
      }
     },
     "localname": "WarrantExercisePreFunded",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acxp_WarrantExercisePreFundedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the number of shares issued through pre-funded warrant exercise.",
        "label": "Warrant Exercise, Pre Funded, Shares",
        "terseLabel": "Pre-funded Warrant Exercise (in shares)"
       }
      }
     },
     "localname": "WarrantExercisePreFundedShares",
     "nsuri": "http://www.acurxpharma.com/20221231",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails",
      "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r327",
      "r328",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r327",
      "r328",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r327",
      "r328",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r327",
      "r328",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r327",
      "r328",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Directors"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureExecutiveCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ExecutiveOfficerMember": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive officers"
       }
      }
     },
     "localname": "ExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r171",
      "r201",
      "r290",
      "r296",
      "r307",
      "r308",
      "r314",
      "r316",
      "r323",
      "r356",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r171",
      "r201",
      "r290",
      "r296",
      "r307",
      "r308",
      "r314",
      "r316",
      "r323",
      "r356",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r158",
      "r291",
      "r315",
      "r322",
      "r351",
      "r352",
      "r357",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r158",
      "r291",
      "r315",
      "r322",
      "r351",
      "r352",
      "r357",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r171",
      "r200",
      "r201",
      "r230",
      "r231",
      "r232",
      "r289",
      "r290",
      "r296",
      "r307",
      "r308",
      "r314",
      "r316",
      "r323",
      "r348",
      "r356",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range Axis"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsWarrantsDetails",
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r171",
      "r200",
      "r201",
      "r230",
      "r231",
      "r232",
      "r289",
      "r290",
      "r296",
      "r307",
      "r308",
      "r314",
      "r316",
      "r323",
      "r348",
      "r356",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsWarrantsDetails",
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r346",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureExecutiveCompensationDetails",
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureExecutiveCompensationDetails",
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r307",
      "r308",
      "r399",
      "r401",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.acurxpharma.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts Payable and Accrued Expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails",
      "http://www.acurxpharma.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureAccountsPayableAndAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.acurxpharma.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Other accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r2",
      "r321"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r341",
      "r342",
      "r343",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r80",
      "r85",
      "r95",
      "r112",
      "r152",
      "r154",
      "r156",
      "r160",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r269",
      "r273",
      "r281",
      "r321",
      "r354",
      "r355",
      "r397"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS."
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r93",
      "r100",
      "r112",
      "r160",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r269",
      "r273",
      "r281",
      "r321",
      "r354",
      "r355",
      "r397"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Domain]"
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r303",
      "r304",
      "r321",
      "r335"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails",
      "http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.acurxpharma.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r25",
      "r31",
      "r36"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash at End of Year",
        "periodStartLabel": "Cash at Beginning of Year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r25",
      "r78"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
        "totalLabel": "Net (Decrease) Increase in Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r112",
      "r130",
      "r131",
      "r133",
      "r135",
      "r142",
      "r143",
      "r160",
      "r172",
      "r174",
      "r175",
      "r176",
      "r179",
      "r180",
      "r182",
      "r183",
      "r185",
      "r189",
      "r195",
      "r281",
      "r309",
      "r334",
      "r339",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureExecutiveCompensationDetails",
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails",
      "http://www.acurxpharma.com/role/DisclosureNetLossPerShareDetails",
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationUnvestedDetails",
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails",
      "http://www.acurxpharma.com/role/StatementBalanceSheets",
      "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r56",
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrant exercise price (in dollars per share)",
        "verboseLabel": "Warrant exercise price, outstanding (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsWarrantsDetails",
      "http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Warrants outstanding (in shares), ending balance",
        "periodStartLabel": "Warrants outstanding (in shares), beginning balance",
        "terseLabel": "Warrants outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsWarrantsDetails",
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r56",
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r15",
      "r82",
      "r88"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES."
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r49",
      "r166",
      "r167",
      "r306",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock shares reserved"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r341",
      "r342",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, Par value",
        "verboseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, Authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, Issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r1",
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance at ending, Common shares (in shares)",
        "periodStartLabel": "Balance at beginning, Common shares (in shares)",
        "terseLabel": "Common stock, Outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/StatementBalanceSheetsParenthetical",
      "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r1",
      "r321"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common Stock; $.001 par value, 200,000,000 shares authorized, 11,627,609 and 10,215,792 shares issued and outstanding at December 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonUnitOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common units of ownership outstanding of a limited liability company (LLC).",
        "label": "Common Unit, Outstanding",
        "periodEndLabel": "Balance at ending, Member Units (in shares)",
        "periodStartLabel": "Balance at beginning, Member Units (in shares)"
       }
      }
     },
     "localname": "CommonUnitOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CompensationRelatedCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EXECUTIVE COMPENSATION"
       }
      }
     },
     "localname": "CompensationRelatedCostsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsGeneralTextBlock": {
     "auth_ref": [
      "r198",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for compensation costs, including compensated absences accruals, compensated absences liability, deferred compensation arrangements and income statement compensation items. Deferred compensation arrangements may include a description of an arrangement with an individual employee, which is generally an employment contract between the entity and a selected officer or key employee containing a promise by the employer to pay certain amounts at designated future dates, usually including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares (units) issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability.",
        "label": "Compensation Related Costs, General [Text Block]",
        "terseLabel": "EXECUTIVE COMPENSATION"
       }
      }
     },
     "localname": "CompensationRelatedCostsGeneralTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureExecutiveCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r41",
      "r42",
      "r75",
      "r76",
      "r159",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r41",
      "r42",
      "r75",
      "r76",
      "r159",
      "r302",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r41",
      "r42",
      "r75",
      "r76",
      "r159",
      "r305",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r84",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Major Vendor"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r41",
      "r42",
      "r75",
      "r76",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration Risk (as a percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r39",
      "r41",
      "r42",
      "r43",
      "r75",
      "r77",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r41",
      "r42",
      "r75",
      "r76",
      "r159",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r33",
      "r34",
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Converted to shares of common stock"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CostOfGoodsTotalMember": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of product sold and service rendered, when it serves as benchmark in concentration of risk calculation.",
        "label": "Research and development expenditures"
       }
      }
     },
     "localname": "CostOfGoodsTotalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r388"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal, State and Local, Tax Expense (Benefit)",
        "terseLabel": "Current federal or state income tax expense"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r14",
      "r79",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Annual interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosurePaycheckProtectionProgramLoanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r253"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r72",
      "r387"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "verboseLabel": "Capitalized research and development"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r386"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r72",
      "r387"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r71",
      "r72",
      "r387"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r72",
      "r387"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r254"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r204",
      "r235",
      "r236",
      "r238",
      "r243",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "SHARE-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHARE-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NET LOSS PER SHARE",
        "terseLabel": "LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r107",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r128",
      "r130",
      "r133",
      "r134",
      "r135",
      "r139",
      "r277",
      "r278",
      "r292",
      "r294",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per common share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r107",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r130",
      "r133",
      "r134",
      "r135",
      "r139",
      "r277",
      "r278",
      "r292",
      "r294",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per common share"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r248"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxesTaxReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxesTaxReconciliationDetails",
      "http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r113",
      "r248",
      "r262"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxesTaxReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal income tax expense at statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxesTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r385",
      "r389"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxesTaxReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxesTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r385",
      "r389"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxesTaxReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "terseLabel": "Research and development tax credit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxesTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxesTaxReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxesTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r385",
      "r389"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxesTaxReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income tax, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxesTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average vesting period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r384"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total compensation expense not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ISSUANCE OF EQUITY INTERESTS"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r53",
      "r91",
      "r104",
      "r105",
      "r106",
      "r115",
      "r116",
      "r117",
      "r119",
      "r125",
      "r127",
      "r141",
      "r161",
      "r197",
      "r239",
      "r240",
      "r241",
      "r258",
      "r259",
      "r276",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r297",
      "r298",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Warrants fair value"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r29",
      "r51",
      "r52"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.acurxpharma.com/role/StatementStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Gain on Forgiveness of Paycheck Protection Program Loan",
        "terseLabel": "Gain on Forgiveness of Paycheck Protection Program Loan"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosurePaycheckProtectionProgramLoanDetails",
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows",
      "http://www.acurxpharma.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/StatementStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense.",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for guarantees, indemnifications and product warranties, and methodologies used in determining the amount of such liabilities.",
        "label": "Guarantees, Indemnifications and Warranties Policies [Policy Text Block]",
        "terseLabel": "Guaranteed Payments to Members"
       }
      }
     },
     "localname": "GuaranteesIndemnificationsAndWarrantiesPolicies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENTS OF OPERATIONS"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r164",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r113",
      "r249",
      "r251",
      "r256",
      "r260",
      "r263",
      "r265",
      "r266",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r114",
      "r126",
      "r127",
      "r151",
      "r247",
      "r261",
      "r264",
      "r295"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r103",
      "r245",
      "r246",
      "r251",
      "r252",
      "r255",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "(Increase) / Decrease in:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid Expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestorMember": {
     "auth_ref": [
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.",
        "label": "Investor"
       }
      }
     },
     "localname": "InvestorMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "terseLabel": "Executive Compensation Settled with Membership Interests"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r11",
      "r112",
      "r160",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r270",
      "r273",
      "r274",
      "r281",
      "r312",
      "r354",
      "r397",
      "r398"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r6",
      "r81",
      "r87",
      "r321",
      "r340",
      "r347",
      "r393"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND MEMBERS' AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND MEMBERS' AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r94",
      "r112",
      "r160",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r270",
      "r273",
      "r274",
      "r281",
      "r321",
      "r354",
      "r397",
      "r398"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "TOTAL CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesTotalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of total liabilities, when it serves as a benchmark in a concentration of risk calculation. Sum of all reported liabilities as of the balance sheet date.",
        "label": "Accounts payable and accrued expense"
       }
      }
     },
     "localname": "LiabilitiesTotalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtTerm": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Long-Term Debt, Term",
        "terseLabel": "Maturity period"
       }
      }
     },
     "localname": "LongTermDebtTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosurePaycheckProtectionProgramLoanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using share price of saleable stock.",
        "label": "Measurement Input, Share Price"
       }
      }
     },
     "localname": "MeasurementInputSharePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MemberUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest in limited liability company (LLC).",
        "label": "Membership Interest"
       }
      }
     },
     "localname": "MemberUnitsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MembersCapital": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of member capital in limited liability company (LLC).",
        "label": "Members' Capital",
        "terseLabel": "Members' Equity"
       }
      }
     },
     "localname": "MembersCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r144",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "NATURE OF OPERATIONS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureNatureOfOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net Cash Provided by Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow from Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r25",
      "r27",
      "r30"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net Cash Used in Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow from Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r18",
      "r30",
      "r83",
      "r89",
      "r92",
      "r101",
      "r102",
      "r106",
      "r112",
      "r118",
      "r120",
      "r121",
      "r122",
      "r123",
      "r126",
      "r127",
      "r132",
      "r152",
      "r153",
      "r155",
      "r157",
      "r160",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r278",
      "r281",
      "r313",
      "r354"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/StatementStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net Loss",
        "totalLabel": "NET LOSS"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity",
      "http://www.acurxpharma.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.acurxpharma.com/role/StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "TOTAL OPERATING EXPENSES"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING EXPENSES.",
        "terseLabel": "OPERATING EXPENSES"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforward"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NATURE OF OPERATIONS"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.",
        "label": "Other Commitment",
        "terseLabel": "Future commitment"
       }
      }
     },
     "localname": "OtherCommitment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails",
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForOperatingActivities": {
     "auth_ref": [
      "r26"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total amount of cash paid for operating activities during the current period.",
        "label": "Payments for Operating Activities",
        "terseLabel": "Cash paid"
       }
      }
     },
     "localname": "PaymentsForOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r24"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Cash issuance cost"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToSuppliers": {
     "auth_ref": [
      "r337",
      "r338"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of cash to suppliers for goods and services during the current period.",
        "label": "Payments to Suppliers",
        "terseLabel": "Vendor payment"
       }
      }
     },
     "localname": "PaymentsToSuppliers",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r99",
      "r162",
      "r163",
      "r310"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid Expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "verboseLabel": "Proceeds from Initial Public Offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from Registered Direct Offering, net of issuance costs",
        "verboseLabel": "Proceeds from stock issue, net of costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from Paycheck Protection Program Loan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosurePaycheckProtectionProgramLoanDetails",
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Pre-funded Warrant Exercise"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductLiabilityContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Product Liability Contingency [Line Items]",
        "terseLabel": "Contingency"
       }
      }
     },
     "localname": "ProductLiabilityContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProductLiabilityContingencyTable": {
     "auth_ref": [
      "r170",
      "r349",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information and financial data about the reasonably possible loss or the recognized and additional reasonably possible loss from product liability related to an individual product.",
        "label": "Product Liability Contingency [Table]"
       }
      }
     },
     "localname": "ProductLiabilityContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r92",
      "r101",
      "r102",
      "r108",
      "r112",
      "r118",
      "r126",
      "r127",
      "r152",
      "r153",
      "r155",
      "r157",
      "r160",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r268",
      "r271",
      "r272",
      "r278",
      "r281",
      "r293",
      "r313",
      "r319",
      "r320",
      "r336",
      "r354"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net Loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of capitalized costs of a research and development nature that were acquired during the period in a transaction other than a business combination.",
        "label": "Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired",
        "terseLabel": "Capitalized research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r68",
      "r90",
      "r405"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense.",
        "terseLabel": "Research and Development",
        "verboseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.acurxpharma.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r3",
      "r55",
      "r86",
      "r300",
      "r301",
      "r321"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r91",
      "r115",
      "r116",
      "r117",
      "r119",
      "r125",
      "r127",
      "r161",
      "r239",
      "r240",
      "r241",
      "r258",
      "r259",
      "r276",
      "r297",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r20"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty payments"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsFairValueDetails",
      "http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of accounts payable and accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureAccountsPayableAndAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of components of net deferred income tax asset"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Summary of reconciliation of income tax expense (benefit)"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.",
        "label": "Schedule of Nonvested Performance-based Units Activity [Table Text Block]",
        "terseLabel": "Schedule of unvested Class A membership interest converted"
       }
      }
     },
     "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationUnvestedDetails",
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r60",
      "r62",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of fair value of options assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosurePaycheckProtectionProgramLoanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r56",
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Summary of outstanding warrants"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting term of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r217",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested at December 31, 2021",
        "periodStartLabel": "Unvested at December 31, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationUnvestedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationUnvestedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationOptionPricingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationOptionPricingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationUnvestedDetails",
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional common stock shares reserved"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Common stock shares available (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Share-Based Compensation (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted",
        "verboseLabel": "Stock options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureExecutiveCompensationDetails",
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationOptionActivityDetails",
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationOptionPricingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Intrinsic value of stock option"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r209",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at the end of the period",
        "periodStartLabel": "Outstanding at the beginning of the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r209",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise price, End of the period",
        "periodStartLabel": "Weighted Average Exercise price, Beginning of the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price (in dollars per share)",
        "verboseLabel": "Weighted Average Exercise price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise price, granted",
        "verboseLabel": "Grant exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Tranche one"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Tranche two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r208",
      "r227",
      "r228",
      "r229",
      "r230",
      "r233",
      "r242",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by supplier.",
        "label": "Supplier [Axis]"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received.",
        "label": "Supplier [Domain]"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r203",
      "r205",
      "r206",
      "r207",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Employee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "verboseLabel": "Grant date fair value ($ per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Contract term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationOptionPricingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Share price (in dollars per share)",
        "verboseLabel": "Purchase price (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureExecutiveCompensationDetails",
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosurePaycheckProtectionProgramLoanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosurePaycheckProtectionProgramLoanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosurePaycheckProtectionProgramLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r37",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r112",
      "r130",
      "r131",
      "r133",
      "r135",
      "r142",
      "r143",
      "r160",
      "r172",
      "r174",
      "r175",
      "r176",
      "r179",
      "r180",
      "r182",
      "r183",
      "r185",
      "r189",
      "r195",
      "r281",
      "r309",
      "r334",
      "r339",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureExecutiveCompensationDetails",
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails",
      "http://www.acurxpharma.com/role/DisclosureNetLossPerShareDetails",
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationUnvestedDetails",
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails",
      "http://www.acurxpharma.com/role/StatementBalanceSheets",
      "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r17",
      "r53",
      "r91",
      "r104",
      "r105",
      "r106",
      "r115",
      "r116",
      "r117",
      "r119",
      "r125",
      "r127",
      "r141",
      "r161",
      "r197",
      "r239",
      "r240",
      "r241",
      "r258",
      "r259",
      "r276",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r297",
      "r298",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "verboseLabel": "Disclosure"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureExecutiveCompensationDetails",
      "http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails",
      "http://www.acurxpharma.com/role/StatementBalanceSheets",
      "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENTS OF CHANGES IN MEMBERS' AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r141",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureExecutiveCompensationDetails",
      "http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails",
      "http://www.acurxpharma.com/role/StatementBalanceSheets",
      "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": {
     "auth_ref": [
      "r58",
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "auth_ref": [
      "r0",
      "r1",
      "r53",
      "r54",
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Stock Issued During Period, Shares, Conversion of Units",
        "verboseLabel": "Converted shares of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Share-Based Payments to Vendors (in shares)",
        "verboseLabel": "Share-based vendor payments (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedPaymentsToVendorsDetails",
      "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r0",
      "r1",
      "r53",
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Initial Public Offering and underwriter warrants, net of cash issuance costs (in shares)",
        "verboseLabel": "Shares issued during the period"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails",
      "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureExecutiveCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Stock Issued During Period, Shares, Purchase of Assets",
        "terseLabel": "Granting (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Share-Based Payments to Vendors"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r0",
      "r1",
      "r53",
      "r55"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Initial Public Offering and underwriter warrants, net of cash issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r1",
      "r4",
      "r5",
      "r47",
      "r321",
      "r340",
      "r347",
      "r393"
     ],
     "calculation": {
      "http://www.acurxpharma.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at ending",
        "periodStartLabel": "Balance at beginning",
        "totalLabel": "TOTAL MEMBERS' AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementBalanceSheets",
      "http://www.acurxpharma.com/role/StatementStatementsOfChangesInMembersAndShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "MEMBERS' AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r57",
      "r111",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r197",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "ISSUANCE OF EQUITY INTERESTS"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterests"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsDetails",
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsFairValueDetails",
      "http://www.acurxpharma.com/role/DisclosureNatureOfOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.",
        "label": "Supplier Concentration Risk"
       }
      }
     },
     "localname": "SupplierConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Research tax credit carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r244",
      "r250"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIncomeTaxesTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r44",
      "r45",
      "r46",
      "r145",
      "r146",
      "r148",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Measurement Input, Warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsFairValueDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": {
     "auth_ref": [
      "r73"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of warrants not settleable in cash classified as equity.",
        "label": "Warrants Not Settleable in Cash, Fair Value Disclosure",
        "terseLabel": "Fair value of Warrants"
       }
      }
     },
     "localname": "WarrantsNotSettleableInCashFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/DisclosureIssuanceOfEquityInterestsFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r129",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r128",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.acurxpharma.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409950&loc=d3e20396-108366",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)-(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r324": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r325": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r326": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r327": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r328": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r329": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r331": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r332": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r333": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128088960&loc=d3e3913-113898",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126965701&loc=d3e15009-113911",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>75
<FILENAME>0001558370-23-003929-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-23-003929-xbrl.zip
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M3%$HX-6$(U+!Y"T"4@ ,>4; RXU)^#\D/FZPWH@_1 )Y0'R?8!2(D&.+O8#
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MJS1+.($MUSG-+DHQK]8P^_2TKDDR!'QG8X0_?0U_LO?S?P%02P,$%     @
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M$+:MS#O+X_JC2<I!V+S*'X$J[%LS](/9K4H9SRD'8;^JS7@._2"WIU(A*.I
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MP."+-5K$*LI5V B8$5]6GS5D+@3=SE9(@&B$R183JLHC[+X@XH4V2VBN"+=
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M92 I#^$T_1AY2"#UOEH-NB0WM2CV#EO?N</6T+7"_V^.]-Q2U(>P[I1WX5*
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M<"7L-#&\JM=A$,"Z @A8PYA!$L)79E=KMZZ/5^1CXS*MV!!H+#<K)UR89:T
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MYZ.7%G1O06J"\-[60$WXWD1GH@#?6BWE=U0(:/M9XF!RAOS?.-\5YP?_G6J
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MUU1"Y/K?" =A]&LJ9^5MSW$@;WHFIR*QD8-\9M9.# QHDB,N021;-\D: \?
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M'PE[5. /9<8PBJUJC6(4?-IG[D@LVHD <)#I;@RUC"[ 8**@1)\$DHZ'R<.
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M!<"PH*C(D'<)RCC"^!J; XQKG1Q$]"&([#A+M"I8ON#0=B.:M"<HKM.E'U
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M9[N#&ZPW=H.=,@]N.AF"ER?8>D"\]SG6QMYCY^3AI/S"E25_*SR2/19>5UQ
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M2:R']7_#_F2Q_DUL)!FNC?M&-YO,6O7J;6Y(&1A(VW-_XP-IQY]AH"VMW^E
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MY)+$;@ID@,>WJF&*0=^5!F D4%9%-5I2AHCB!&<Y0VS<VZ&,+<KX&B\*9LY
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MVN29LJ^HK[\N< (T-U[Q1/F'/7Q"VV?DI'AD)85((R<?J7U$(@#A5=DR'?'
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MV;$%=?Z0N&) =#)1Y4K'C[W$HT]L<@'@/@U6])K\Q*G:<GUS<0NV+<@-32,
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M&U#+=#U^R!V3)9^D-%5/?TA7VN+X6A#O[P=76JR>FB:#KV@%))AQPM5>V4_
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MM.J&X&FMHV\IZKXI<%)9DME@P<+*F!.( Q/1=84$AS0YPOQ>X*3"C-L+9)<
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M8Y#)4F<C@>&S.XXD-^-'*-D8(D%>(IE;S( 4&J ;TU_T2B=:A;*Z?^EB<\>
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M(%7%6[GZ;,4M#[1+7]*&+"*FN6A2#C! SRTF+0._9S@T)FM2!Q44-S1$DZP
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M!G^?ELHPJ,L(&\NK:U#<E=L.LA!'7"*6)5ZTI5#RPB.[8R-4# &R]JWGRA=
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M\4F5*U^7&!28"V#>W'<T5RP3U9,20_3(0:.,.VFQTMEVN[_#S,\"YIUX::M
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MI#2J#;GHWJE<C&_Q^ 4O-#1ABVB9W1#>N#L=<V*<5=ZH-)V8N+D [AA'PX$
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M'GB-G7T7HK%6^L>6P!XADSK&R:S,N)#,R$BXSM&5QC6Y:-U2]%>M^-O[WRB
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M@ILU69OZV_2F-+.NC5&__GYN8<Z.F\KNZ%3VP=IDDZ?@8U.P8J6[RT=\:MK
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M3Q9NRAYR7/4NUJ[20AWK%S7%L5UR4]/?^12^/8!W?IS/5'!1QD69P7^!DFJ
MW&,NR,+E\*SP9:S0W396T"'X@83@LS 9J]7T7]X/B[V65FA\]1;L<SA!9-LP
M#@KIVIR$>9!/TNLD*"9A$41]]6<X2^.\P'_DP00.(9X'LQ0[+X-PC%F'(C@]
M@953!@(;8C.%"BD8Q%&"9(>OI2!2%?WMEAA3JQI:"B)<A@I^;UVV;OYF@SY^
M'163(*2FU,,VOJX;<&LJ=J;"'X;RQU/ZXX'SQT9@]BWOY O;5W%ZW0HN(Z!%
MF.FMZ<."A_2.#H*799;.%#S:[!2?I(9!A$2@,\ VV:LP+E7^#?2^W@S6Y!LM
M-M69Y!M@MI$N)ZW3$T^7[:.+OR_;21=_7[:3+OZ^;"==_'W93KKX^[*==('[
MXK%[MJE1_&M@_S[@$$YF2["TOE*U_R/GP)]6(R<KN-WIXUQKRZ_GE!WFE'<?
M_Y]G%,\HMQ_7/\]_]8SR2(RR>1B;-1[7JQ?__E+D@">!E(WY&,K8/5O;G7CJ
M]2RWR,)MIVB[M;QJ93W0 9[ 6T#@%75):ZQ+\V3> C*OJ#X[\A2^FS&R_11N
M]X*5-SDX^5+C8[MV2[4HZ[,R=H51;TQ);&N%['JQ SPY-TW.->,,>8)NFJ!K
M[9#;)7(^U7%[ZX"#>BH!B=,UF@D[;.(^!2?F3MQ]L&YAY8GNB>Z)[HG^I(G^
M%"(8#_05'WG>8I5*]656N\.H\>B.Q2I?ORVIW\_4511B[5/^+'CW\?_]-'6Q
MK<^"?Y[_^M-5F S2Z5Q%R5GPZL6_?QK!7S^GTV@0):W-K/OC1&'WT%4$:PW"
M01%=88-8.JIV45V'.34087]0$OR]3!1?GVZ[<QKTJ:$,Y^9A?]$T2J)I.87/
M38!019K17Y%!,SJ<8 _,QGW3CJ3;L3KM@_LV6BTT:S7@I8.XQ)L6%),T5]Q<
M%4UQ%F"8%$$6 2O-9RIO!:_LR3<"(0O]C!U7%<H%URI309GC4, <]C*=A;"3
M-(.'_&NBDNI!A8-)I*[@H]B.!7QYTCX\.SUMG?X0] DQ(H+E?HKB.-B+6JK5
M"'K-.!T'F:+32ZF1RWXPH:$+^3[LJ\ UT4,O]*[?AOV4%C(/+F%WPS ;YL$;
M.,NH* N% PY/NMWVV<7;RS?T8^=L/QAD$3T[&*69?M$ ]AE;TH-H&$RP;2X$
M,39#B@-]7[TX;P4?)_#;3(&\R'%V9! &L5W"5(4Y]I4"Y\!)1W83U'8WF ?]
ML@B&*;!QDL)&LC#)D69 TDP-BG@..R_28%(">P<*J1P.]%JP=S5-X"-]%0#7
M@"B*\@ESHF&! M^5;^@.?5!Y&<.!P*=A,051/V1JW7BC<NG0@XW3%^ S^!V'
MQ0*%#7CXR(8T"@9)F&7I=6"2P6N^0; &/O7_Z[5_8-:'7^'7X$?W"DEK8@HK
MS@+SV2+]'(T5/+0%K!B$TJO9" XJ'96X2S6+A@KN7\!=F,Z#V]UC>GC[^"2
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M$+*N2W.PNX7;VA3;=IIW'A,C9#-,_Y4*\T^>0A?=ZME%:T*/\"3>/(F74_C
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M56E4'\D^NN*6:EV&RJV)7#C7_=QI4QW@CUAQ*1V%NF5Z& RS<DS%<&XAX5E
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M&.7VPAG)0Y[C$]J )_AD8]<'PI NW+$H%M=*$N!_#Y.*F7I*SP$MCW7<*LG
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M6FBBI]3W&O0(6O:5;6?2(;CJO<$*2Q*S"JO(DM!\Q,*)Z)):L.W4C(&$@ +
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MCBP>+:V7=<56J$771":]TS!,I]^0< \BPDDQ@<#E<XK$YK.LZ;C5MKJ%M.
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M>=6P-HX68$L@3;5[;J]!#2',]UEZCK0<*;!R-0PZ*_ 42MN!JDSV<#XTJ%:
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M=YTF1.H*031U4;3)V\V)Q-$GQ2 !?3=V!+^ZBL@G)/[$(DQ."+MR@F0"V;/
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M:["39UQH!9X\:*:\8KPRI+BS'5+DV*L(R9TFB>*;86IL%W<O8$G$YP(3 6>
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MO+-BU<I;<X_X^AA&KEPAG6H+@+]TFHQA/K!>?A"XV@I%^I F:62J-FEE 2_
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MQU_>SCT_2]QS<!^;1KW'15F3+98R3>>\<2VH><G'H0M 5R%_MU1_/%KG 9U
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MF7QQ6EAC$WC#3?[_^&*I&RH=ZSZP(H>&Q1^>/OCR\"*A^<J#KW7_2R_4[9=
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M$@JN;BP+EK+E13R\Q!*8W7*5 NH8RD=UQ0K3!52-6:_V-#N/^L>'KHA8BS[
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MN)\),OFPC\$EK\ 4VNADO%?E5EH3=%"<9N>F:&;@E[ NOOVK_$"LY29@&Q4
MN1THX=,HZ+_";8E'$C'<R[*34AKH4U8HCG#A"NE^NR&'T/%K:D4GW/OT=3,L
M:;,MFZ$?FTAX@="&U[& ANL6]1W%#A__X"Q-B,.48:*BCJN5(S(&JWE/"AR&
M,[+D@"^;"*4S"\9#SL0.6:HBHY2!OG+ M">S91<\FM!K1+T.K#6^YL0 KXNJ
MN=&(CR]_:QZ-(RCQ<)A 2D&VGS<&?XZGJ<&N&!?.]P#;D><G;3RPMHF85B@Q
M:ONPA?]J18@OOE7PTY)12,O18)87L:^MK\T7A*6MJ07)VA<IDWS615>"DS>L
MA]$P[=QW^"TP_CXNH^OIL]"D[T[W(\*823O6 I^)%^)L6/]U$)=F81*J^HI
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M]A=L'F-:)/KQ1<5$#LNBOV'$_ALN(>3XFC^]H]NOBQ&&9;1$BK'07"T\GL-
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M$!Y9\+S1%49G.1Z"6*)5%/\2 QV*!,;Q$BO%#K$9T'Y%W5*N@E=S,6YE6*-
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M@BG.F.4F^$K20YHS3LJ+E=*4=NH)PUX6RFNJ 7[!YV;-K!S ?$7HPA2'(#]
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M"&2T(0J;^-)<J$KQ1G TQPL4,8+#I :S;?*K1,S&+%TFOA@4E(1J;8'JYF7
MP',N+A7VW-+34344VXI#0#M#MJ)X!M/"+M< 'H>.S:KZK$4VJ=].,C. 1Q*+
MT%4])*8,>Z>/,M<OX-9+X1D<:M1JM\QE9$^OZ>Z$@'" ET8(]NWVL(3%AP<=
MPRBS>AX]/D/ZS)]DEL/!JA:=VW^>KLZOT6EV;KFQS"DJ5?-QC<,))<-CPH><
MCVSCC,+GUMQ^/#>WY^;VW>J5_$.SXN0_;<J:1QS;8SE]RIT;A-RU1I@2'JMT
M'!=4-&'<4K"@4&8*FUA[+!0IKHN$][[LA-B:AQ2-P$$B-AV5G18/5S=M*82F
M%18S&\]K* 0;E\0=A:<_2BC'(U%\%!N_(LL$.,5LT6D,^GP;,C^$C1IYH%);
MU+(N>YFRCD9@W?G"B9YG%R7/ D4EK:/]*OUSE$CV"B.!C4/]>&3NB$-K'_S3
M\#X#E^QJZ,B_PU8" EXCA<#BP*0^U@@)\W$RCAFNNLJWO!_VI3LB\S;/F-0H
MRK#)*M]\E+)P;\+K-(CZ"9M8+\PC%DOU38]C3\02X_HELI3'!3,\L8F?F -)
M+Y_[[JV(9L9"LX+.4H*H))#R'JM1U!KV(1#1%D;0Q."_"*SXW:[K"TY*_WQ5
M5H7+IHQ9/8R96IC@&=2;I+T3M=_"]*QM<;P[NBZ+Z!CI@2>V=R3M]A"A)IS?
M<-;*//>BY.$2*%>7=B+->Z7(CPI89%1V]4ZF+TZS*%:-9)FB99ZB=4*9*JJK
M3 210S7(X:HTI*P>2[ZP6M%*5-I]*39*#/4J[^F&D[H5W>/(=<15&.WE9/T^
ME'6FM!7"T5T',OXHB*2TW>E4[)TKB!\MTQXXY/S(K@H0VYX93QC'GOCX](.R
MB4_997-Z(O;4D#&Q*WD^OR,Y6X4H+;Y3?E4QU5P$O0LOY&H.47Q_<B9$':8?
M7KZ"(JAJ&:H'C<T//3+R-@A:@)F M<.JJJ@OS=^9*B9MJDME1PC2]J'X'QFL
MSZNN66A&+2SE-WF[#A(=SD8]5[FY=]J<UA:@B/JFE^I <NCYYTLM-]03VW$C
MKKZHAD(EK8,"U&C+V",$D@KNG(C"+?^_]WJ)QJ4Z67>E>,PF9XN=\%9D6<B)
M"W5Z:V6IOH<LN;8!V^*OQ9B9)(V*/AE2HE=!V3PIK6I\$,[\*5L46C\Y-:S%
MR#XTMB*Y1W3RKER]XWR+N4KR00+ ?&EZ'+YB([+STOQ-SHO4:(KWT+^3U#TT
MT$(K<:+OEU3X\@V9-8JJVZ&W,A/.'YA1N3&DA<1#"K^0]2BD,WI7+O2'N$RJ
M*L;1F./"/?:6MJ"29TO=@!Z,U=Q+BSK@@UF"V@0 DH!%9_O_@:'^5S$\/4#&
MEMXQXLI@?+SKDK>^;)M\7>V\K?UDXXK$ZE ,!PTV)J"L*4J/&&.1Y.[#41$V
M3W_5@F\GK,F-1CJ\)(M(O!;!@>G1G)TS-<A(&$,2#.91X[!8&7T\&\TZI%/F
M4,G%%72GU3AC""Z323]PI)ID(*VJA9N+&&N&UO_^.UI,1.8?6NJMQ$H:(TV]
MLJU*'IL(EA0G,XN00I0:7[RVE*+FT(]:1HM?.Y/>_^:QDM^KK3H7>LZGTW_J
MZ02]^Z'7FCKM1V@L<$#AM%][UAEACPL8E38*&30I<9@9J,#<NH8LM)1*/PAV
MK>9?B)@=NM_LQ 48LAGJ(LJQ1$W/J/"))'F5=U?*GOB.?K50$=!AI4$,AVX+
M_8.V((<+9<E P:@Y)GQ#T'=;TPVM!T$Q!2B2Q5S\@W6A84UR3 A.DB/A!HY"
M?<O"'0HF>Q:DTM:%TJSEP7M<)8<:Q/DL8)S,?R5I4P?+[B"Z[1%M%A_Y(3X4
M!,K^[S1"4ZP/!P8<"$:9;XO\@DX<7JLQ<DZ$3E<3A[2'4$FW>AY9F!U4.KFH
MVR%$<QPL7)R$S6HN"0Z"]V%3DX-@YU/S5N%+D MKWV5_Y'*%;C]S8SY&A-.2
MR[(]ASW6M$Y,4D]AIU\KM4I%"0FZ!RFR9KD66"AV2+;"S16JS85[*,!,A5/1
M"C+AET&KM]QPO@K9(BP\JB_\X1NN+-)6DTD,UK=4M#7M78U=8WRV(%<#6$Z.
MZ&1 %24M?[&4KH2XN4#GYFTY;\NP+6U+7E <3;EPE9>;3N+:)$B8CA'BL6HB
MA0J,3F,&SK/X=X@26N@*:W2\+.R77(W5;P>?J1ZJN-)^S+Z(ATU2=_2%L( :
M"635\HR<ZG!0/E38/_&@=1E8>!);!*A;KYH 9."\0N3FKB&GW;A,COU)["A8
M[HYL;YRT1\R$)57R)W1#75\52RF\T!W_;2BSGB5]+?^7]HQ]>D2VJ L9EI8#
MI>NRB379CXD6%ZG?C2L?@X"3M"@>[PN&I(AJTXYE?,(_T8CYD[D+/W?AYQ'S
M^;S]^#!8/&_V(M3@7[,PNS:-P!>]@MZZ_>A<H)=G3Y]^N0A@]A]>O#X_CVAV
M.<IDQJ2;.GT8/R:7 _#Q/08R1+YS=55LA"6_L++5SJ=ZRZ(N>!S!Z\O3D=J$
MIJ$]6/C:_4#B8"F!#^?R8H<@@?LM]+5:08!".O][V'I9[@OT_S@9?B>G\LXW
M6^6L1\5.ZIB"3*ZU9Q$PF3HM+5@ %W<T[<23\]G&;6E7"9#'0T\&C=5XS(6W
M&X93LQ^+U55-I\"E+/YW=$,-,P/S2CPSU)U^[IP'"K"Z]C*;9:68T>2,)>-<
M2Z3O6P"*&<9S*LDX9@#S"\H,<F5_D3[:=;[:+60ZT R/+E-WF[+K-%Z(@9[C
M)(#O"@W \)1S>C&[N[WTPF7\ Q>2ZA02ZW0)SI^=FQ?3O^C&_,9QPM ZHNM"
M!7Z6)6^O<J7"+=H1#D-C:(PR@IA1'V+-BF/XX8>W"V_%L3W>F%/PW6ULD N]
M&]:EAM^,%8C%?E_&=;.PQ1AESKOPJND %M*?Q_Q?0OR@]6OE@(XN6L'+C)IB
MA[_1BH-ENU]V,.V'_\_>F_>VC65YP_^_P/L=B.Z:00+0:N]+U<P#N)RD.OUT
M58RXJGOFKX 2KRQV*%+-Q8[JTS]GO0M%*4[B1$J* TQ7;).7=SGW[.=WB)F[
MB /JK MUD'8;2@TNA.&.]X<>7I38Q.$9W$JFYJNRGAM8-XLSNM;]K@1.QZ2Z
M%_)<8:Z;WY+#NK5CS^/7P6U'7X%S?P<@ IRU,)WN$;9/I)$X]S'2!?P.\1;U
MA)+W!G"2@>I#JN=@,.5-"(H *+L12BP0!XK1H)5$7(Z)( (J$-E3HD&@((F$
M!^WZX_RBOD0;FDCNFQ\16@G>RQ@@2<J<@G)^LM.*-FM]:"1ABK+8"Y+ ^D+D
M3A75K#!-!XLUS13- );F]%A?Z%_$<Z=TIOLLA@'ADBZM&QT6U7*_3P^0!'L;
M&:HRLV$Q$.<&^W=V']/<IWF;WY*\%^U=SZF3$>W.0*MKB$FLP N(EO%X"L7[
M)'Q  ]1!,LTHK3?V4A<ZU%K+ZCJV@*3.B3E@<RN"Q6"')@8NP8K9K)JT<T%R
MP?PQO[(?FP>9BIDS7P=:! [@I9BBDXN7.&U,8:MU%XBYNY!C\:^.R[=#\Q==
ME&TM1SOA_%3OG%W3LJ\*\>>YR]FE^D2)VX=@!N_I^BC!XUX0C?<ELM"[S#:,
M0O6P3QO3]$?12X+<!MN4ZRAI<NLR1FT4FY)4>A;B@M4NS<<#\I'LR])F6'&T
MBW/< GP?[!E&K-@QO T95#W.[-[-L!A ?@D9AA30LRN1C*Z3W76RK&50[:G4
M"5Q014A/KI9E\VUMH6#"/$3_"I%[)PY=/DE*F7Z-UBUX,"&:(JB@(G.X_759
M<%#1O(-S(N.?[JW'!*<M^3A6$QH\:;8AI8&R:5M,D,HUWYY*<5K;Z*J[S;3S
ME)GG>&'?J06LT,9O7(CVWF\(E);^%?*.44K<N?%F@&_E$1&+8RKZ7ST2W7]-
MT:2*@N 4O"Q.)SKMCM<?L.6/GF'[L'S:U]BZ)WKMY-E+,$WSW+#GZ9JP*YOE
MKF3_NEY+PLLH'(9GV&8V^M\8=B9*K(H3%A/R^6\I#_;*:RR.\\?VED HX=2B
M7U%C:J53,C^@]ZHMA/_^CI7#TDU-F_39<B8=OM,=;9KE)AS1;1BAF(&R/3;2
MJCJ[D^)C6/L>@6X@(D@'(@SK]8IP2 *C,RD9=8C+!7R!,2M L;!"HG!E=[QH
M%#IX34%)0JZ2H?-(CDW+H!'?3)[2#W+(F!6W*7)^Y)X@Y(DC:;4::K5T^R1
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M/3</<=7!V=:;-T/QH7*P8V\"M2)TK?D8^6W=:'&T12-ZSV?H6O(!PGFCQUY
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MDQE="+;)9>[LVO%G;YWJ:Y]8G:J\06N..U?($0-U LQJ*EQ;2".1L( L#B"
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MUW71TQ1)!0]7W5(0AJ5;DMWGP$^GQVF[,.E'N"X<FT+MY67YEBM +"5PMJQ
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M(ON=*?&)K.6??WWE-LB6J5R16<2S %V.DBFOI!8;*?^:@;3]@:Z>7=D-459
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MAS"F"AA=.:=^V4\.L&'&P=.8FGZC/BF>@CA*RQ;V8F\,? 3[=!,O0!:"6D+
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MWLUW%Z,#+4+8;AW4,^?&VU).^$-LSA]]199L2OQQ#-]&;S4)%9N7I)'0=>(
M@VKLIBNBOR5%B[S&5N-&5^J I&2ZQ%/HT-"92]@1+8>75FYRI0IN#H?4%XYI
M/7GYR[.G?#E?/+ND<#@*=4%0A3&X6)). E?Q<UE@2(TBN5@CTC3&P"#/?KYZ
MZJ6Q4(9+-@_%ZBA"S'-/,8?GX9N\+!R!JS.]3)A0*I-9YTO(:71TNJ("K-E5
M";G+YKEJ6N(KJDX<GCQ\.!K/S5H+6#4^((:G1I/UPWY+NSEF,-&U _6.NX9H
M8T-A?9*:)I'6T)0RFZ87/1'U7K^+-SW%V+]EPVOLZJ=26<,=H%NK:7L;+VO7
MH=EM+TE,J+EY&H(8Q_ D:0ZD]MO3EO:B=21=59AD^/@[WT#PT?DX%Y.8WK;0
M]:@7".P7VZ6'1Z*J(_?G1K$P7/3X+I95F?U![ WK8YD/+&L$,"TP)?46Q N1
MT*]TCC>8M/;\'4R\WAK"PTM,H\V73FSD25N0]9D@=&=1"L+R*J709<\U#+>0
MU:GFOV$'K$& /K<%ID#\WCN^E$^]CZ-V'574PZ+CHF(5O3#W5&(OEB!FF:\_
M)DF;)?.LP.+XO&.K<-8NFMV3DK)+^-=:SQ9.$A/W:C;LN9TW,7*GH/3,Q%E1
MKZ\](PI6)!BM@4QO[F&DY=X4SVJ./DG$XF@W3H>ZRQ#H-:@)$IWUHS(&=F$6
MICRYM$UL&^IF?TUNHAE<C3VTP3 CERHDW5I$?R:VR'%:3D)-HVZ>6Y E@+8&
MMVB0Q"5<*!S+'@P 1\NNBR\7>EM))+(KC/QU$V=TC!(3GZ1.D"X5-TO9L\YE
M!E^+_8W&'14FZ$IE83_^U5*>2 L,T;@V"<Y\PU H&>:]]*=Y41X2(FWNT3Y5
MU/KBT>XWR)4]+.>6O8ZCNKV]Q6N@'ILDZ"M48%<&XM72AU-SN?VP+':N<I@6
M9&DA^4M_"38XOLKPVL407AO":[L:7F.N;9E'+X?(IJ$'%G,^L^F2%6Q6QQ!T
M:S(SMII#);\MI79,B)L3DD_09U=]']8^BQH\D/1)XR';D"K.;DE/VQ2+8KQD
MS9%\Q*QLAH;9.EU_:VX7SXFY21&)/1])XK%7:=;&82&4^B97^!G:*%/,N+/B
M3#S<&%EQRI7/CN>"-8J*2<4->+N_)X,-$03 Y@7&35FM;K TJZMV(6"EFLM'
M%DHW'WA;SA(+Z4#0^UV=5XE-L 3L'O=2*NT/H25QA9<?15U13IU?0$)HHK^L
MD<^EZ'$1\9Y1M#OVC$5]>480$%M&27F(U^:5GO*)YQ0C"4[Q&>Q,XDH*'?B'
M0RWR \8*9Q!=VK\'*GGT++G+TNAZ%/V]G62L2U]C_EVJT9BK66:F8.W!-^FZ
MOF+TC!@V!ZBMB?XVBIX9>'F"_D9\W3UZ-4LR$$)%'%TE51[]8Q3=P!W$=Y-H
M;BQ#Z,>*>C)!]\=$VTYX:[I44 U7<N15QU":/J:OYU*YH7:3(C=)59:_2SJ.
MW1J_')39V'T_'$SDX0KQW%UE:5*$.O!!?'!R$1]B%<1:")@8KRFFA[4F^FY_
MM+]_X/!9V!$,A() ("BEDHH0+T,0F.Y'04<^.[W8A(!',K)G4^V@Z<JH*^L(
M8% $=49FY.!FCD;G'MP,?]=6R:W_&.S;_OX&I)T-WT/?6;!]Z[:G;ULW#'M\
M<4$#K[[&J^H;CFA&S"^[:AN^>(=)F<%G\/3W*=$/2W:](+<\*]&N5'OJZA I
M31Q4$H(F!]&7Y9Q ZIX815'HAH^<!]ZK<.Q;!>=AV(&VFB*$.PUF25T[4!O/
M9&4E:^WMI(5\=SPZ=+!&L)<!0DX7YXCV!"M"V8UTJ]P4\9BF)D A7\4F6B1+
M.K$QN@_ZP"N!KLYL=(.H* "IHP#XE):B2HKX(7UFE10>R%4],_E4]D#<7747
M22NZV3MR(%H1X6>=GER<G#[UPV'LUU_%[L$F!)9P$,F0>>7#,+?PY<\ J_:!
MS9\I5B?55 MJS.8=<NSQ?;FZ?8Q2*P7U-S'E%V!4KY])'\2'YQ?QQ?E&,#!.
MJZ!A?OSX8>R%YJ/A B6J'38,;D1YZ^2\"3'/^AG^RK+ZF&KX<#CY=5NH*5(=
M1NBX-W/>DY-1%"K%]VOG#-NCPN]!TUYY?G7FEF\_<+J')WJ35R;@V"BQ!4FW
M$!AB&V$[8\Q;!Q,*_ 0K1E>?.0^^].-G_-(Q?VFCYI-NO%81MBK@T"2KNF=;
M90/OU[B12^QU6+]3N4.-VSYU><O_*T\Y'96(YW+TT^AZ])=+X/=D[_Z4EV,$
M<^3*#^=$O_PI+)'Y.0&)$?U4E>V"2[JU8@=_+T\R,PYA5V"<0(ONS-.9!1DA
MC!1^ZN)[1&FOMLS0>^C Z'R(6O75,Y28=$L.S\_B\[-C+I4*6.WJFYT;>WH4
M[Q^<]S/'-;KB$T%EK"-L13OM>*H]+_ :57.-"JX&P7MVJLM&<+C#T4?-Q%<G
M>QBJY <[O0VO] 9M\VATZNGFT1.;E$:XAP1\R%-DPQO9K;0 7PLO^3$+^K@M
M[%M_O,+XQC!H01F;7:87]W(]CS.=[4QGXJV"OJX@ZU^$U4A>>CYANV;%>NNY
M#S]U57GQ87RXO:@C7M$G?714(;NLZL-'50#6%9S4-7K3AV&G*J(#YG1R(NUG
M1E+M6AAJ>?;">U*9*C?\Q@J43!"M8'N^QGC5Z?X0KQKB5;L:KU)&N#$7ZB'9
M'S%<5.^FVG%1 >D%_H!!-8^4> 2\KN]CM%KA_14VR&@F4M!$6%)264W%A ]"
MU!>0(6(VP#ZQSQBCNXE,5@2'."QQ+KH1_5H<),T,&Z\0%@[5WW.:QKB\PX)U
M$,^(UT;@[+%%_O>_'4>SC$T-Q\P9K+DP.?#N"1BW?/3$=;% NS&360'<X#9C
M>&=)!Q9 K$6R9(,?%!_W3P^W#G01,U]HUSUXRD+Z3V%F6:UA*&E)X'<(B*,2
MI,BM@("5G5X&HGR4U5M&^Z<_!:UD%"F=NGN#UD6(>I25X:"@M.V!:TP^<:EP
MY5K0*(5-]'P]<.2VA?H5.@>8@"[%95_/LH4%"V-1Y#WU8_]3Y+YRD\<81K\2
M&/BRY W"LZ,)DZ NS-XLR:?R;V=N!^,@N5.*T/M6@,?QOOGSG[Q]B47.2R"-
M@XR%UZ/PX#C>/S^,C\ X>:PMI&,\B_>/#^+#_?,U^\?Y8IM;'.%L^UL<E7U=
MDW9&\WU.CL2:)4,%-_XNJQ"Q0F.U3W'^N/P?!8%R>T[I#P(LH[S<VX)*@VW<
MF8+FHGS.>!Q%8UK:7(%"DZBIW* J/%^-Y-7OTQGNL[L+A[QE+X.&M?$-O\42
MNV.ER+7[+ VBV%7)6U-H2BY6E-B9LXW9:80N$6H9$6O%RCD7CCDD6$9<!#7V
M'\ED@@=(E]B.:W-_&64E$00V\=$P0%F1<>.T1#,S6-:0%DUNL8240K9C\8SB
M:-QRV14<L HLS3JXXWG I]B88$&1EZ"F8;YS /+ .2IW.O/5MC@,Q>4@3$?1
M90OB3]S[@A-2RF1H;M(M &7^G,MXYR:A!I_^OF,[ DYW8'W#H73A3W1%@H+?
MQK87:N@.<"(@ZA$,XD7<#;@%(F>,%>05.1 8/M((2/J,<CU>L0<W3=(I%?H5
MQ3,F/V-J74'*!0BW/918>S-$M&23'K2Q&F5]_;;3A0C#%K#!<-_8Y1:1ZLTS
MX1T.4G=K#$#7BZS1NCHXE[+"@3R:K$D[(*Q!1@>9MXWT88;-1/4 MR6A[[,C
M2AKR**P/-?0UD@S2<4'CZ_?)';-C^U&$/@1VI>-*.B%WO&4?!T:F;3@&$P]!
M7CEE2PPZ[9CKC4P3](;V#UC<)8P[)#_P?8,;;(2%)B%R;E9,<]$',"\';BUH
M-D!;+CV&-S\'_0SM7=A=L)A0!T,*Y=PIHA(A<2#!%*CEL=O ?@ 3OLDTA0AV
MN&KT.O3 _+%219PE94@VS X*4DH#M &JGEJOTV_$60LQ;C R@PKV[<Q/2:J(
M=Z5&$WNP@!C3FA/*D_5A'[R&412KUMJ^C9G3KX@I)3BXS;U0P&8<$+@DU7P6
MI703\6FKW(34YJ$9D?WRUBRC.[@PV(LYK'V5>MV5PZ![B;G8N7@8&R9_)#<I
M]_5VU?]V5DA5M*8XBZ 1R4FN)TV :G,&99#>TX0:#68(*4*A# ZQ!ZC:4).E
M.^G?;#Q1:K@M+C!<ZZ(QD+4(E0+IZ?"@QTL+#%:96YAN@U@0XS*EK54HT"U"
M!8BHM,[^_L,D;RKJR!+>5C[F49RJT2NMZ];!RW/<("_O:VF71^##MEN?J\F3
M#&]LE(/TM'1R%[X)2F^*V1!8)Z'1*BYI17[8T"DC_^+"\HPEI8) W[L&[?:^
M$-!>MV\ZK[<.!HFC6Y!ZQ:HN!/M5P[+2\EZTC)(((/<S%&&/Y!V?2=>*S@'7
M?,R0"?42Q-S<1:4%5*T?1MWU//+B^SU\,CRWWKZ"_>#_^$6$:6UF7MM BV/M
M0:23>KFB-WK['G 0.8=[;/2F7AX/"5!H(J'N?&@J6 5)[IL$<I";:EDAY?LR
MF#N\7+ )2KV>V#>EJZ(<4M"LRL*F"/C**<4V,0N5BQ+77 ^>F6&(^X -RUB$
M')Q[&AB#/BC>_O8R)GY.E@X.AU;/O0JI/N,Z64YF!LS.ZZIL)(2HE4EYF3@#
MZ/KZ.OH[_,):0:ZY@F_=768I=43.S)05L^=Z7Z2OPI(:,%CTHLO7SV^BRZM?
MO83 .K05)&I J8$W<[QC:B^N0W6^^?'2#XY26&N.)@7' 4[CD_TC@06212'F
M4I5)2D)1M)1W*/X&M2[V1Q?G_R'Y6^Q.:^[+Z,GA4]>)4)SX*+X(7A?1X"X7
M59:+M6:QX"BMYL?+*&&3XG>1G10N >(FIF-J6\RDTQQ%ORVXH'/=$W*\:3N1
M(9U[22M*JY0._I94#]M6==V JD\%BF_9Z93RM44C#H9HQ!"-V&XTX@/\:)@V
M"+)20('P,O8V+=H5M]]K%,NMV7*?;%#W.'I"F0\%(NO0M##3?&*DP1!B"*BJ
M*AVJV4@CDT1>#]ZV0=HZ82K3H(0*F@(K&%F9X8(B:D&R,S[9U[XUZ(%B8'4X
M!:6W9*4H6,5&B]6FYM(1*S(4HUIE^=+#D;?8WX'Y#NJC!T9.\"Z>X\__JV<;
MZV>TD1(8M],RS\I1]/J]\TPJXSN+L<19>YTR1LR2C1]J0K[PXT>DH2UH#;=E
MF4IGJ.HNF[ W<6PX,8 -Z34&/H9P$F<G<V8YF3(K0\I,22O<DJ;Z_NV40.?W
M-#\&_U")3>(5I76>+&KSO?[CAT>04ZJZ>+]!D4FKPSGLY<FR;)OOI]D[D_KR
M4F4^2[:F@O]/;2D1/W;.?_M+D_I__*1)8\0.:5B4(3H F.\/?O%245+IDC<)
M42!DLO_YYXO3LXL?NO,*'UH5SH_ T39)=G1C5 4[8]Y/*7S-V$CQ:JW(9$:+
MK4+GAAVI]&(^-35WNWK]2ES+".D'XE83%@5P1*.PRC- J2_?9:@OWB[7<!7A
M.3]8C02W]R](&'\A2AJ(^H]'U.2B9X\A>8D&^ACHPZ</:KCN*R%!KDT/1)[O
M_Z<:)VVIWLRR*MU#G_K2&T3C=%5R[URB0HG50(H#*7JL"C1%]&C:RCDK/3&Y
M'B;V _YVH)B!8I1B@,6@[S%#KI1B?0+&+=3@9OT(<0(GC+TNRINF-HJV[P?(
M5Q\64!_TZA-,M"DT\NA_&]NI(9@(&)B8N.!2'1VV!0K>T7K:[7>;H?7B7'9?
M'DVW"P!<2_58XD>A*09-_B/<EO?KSIR)P'LO0ZY$G)PD455:H\:8=$<H4QVX
M)@(/*=<%NYV]'0O,+R?*B\*/Z2IDC%/&!9C1K)QG'JRD [A?P4[3_%4W:3%[
M47HB6GS%#1QK#/%2K:^&U0PC(ZR;]K;ZA/^3*O,HWN5M,2'.<1;" ]TH-O96
MXK.&0;+\.)R+DLU,U[7"YL\*0"\7P9JWY(S!>@C"5',SH-R;U?=&T3,.QE$*
M08&HZI0_$>2F2)M==KMYSAH_9]F;)0?ZL)5PXP%KL@$H\50.+6&@'[,EM)\B
M%NQPA#1MM?E7)7<!.0MO45^SICX/DW,2!NN]\J?OO^?O,\:@<T[)XOK^<JSA
M',X_FF@?RS#(Y8_!\\:&E6NZ7/MY*72'D9X(=\:%;BDY8)Z\-78G-5I<N[R"
M->00M >4%#"I\ZE;1D28E:!]MDZ38.JIQ!-+><$K@TM*.$4J2:18 ,=Q4A,4
MJ O"6J^:"WC+LY32R >ZSCW8.>C8S_((<A@T-]N.C9EUM?RM7K\2"]#O>GTY
MV"0"3]2D>9^D\=9.$N!8:S=?<"8$'P^_KZ2+RM:XM.D;]S-3"&_%ZL-;ZRN!
M0Q\+K 'FX5E_MM:KPIL)7B[TK_0-0%D#G!G +=5\4K"Q<LVN][,*M]B:M'N_
M5R\3;NP=UB.&R5ZV#XGM7<_B:G!8_C'5WP6<L,+->BK:8%0/-&)I),2!$U4B
MZ)/J21O"G[F#]P8*&BBHGX($79/MM[#OUL!X!K()R<;5V=C"?T<M'#_F8!<<
MQ4 [ ^WXM).;XK:AGB\$6V=%EBO) ,OU-D/2T+S\@88&&EHCMFSI!CD<'/*M
M&2380$$/HJ 481&4?(28)*-IH)J!:@*J2:MRL4?M4BMV4I.;FSV]7 GFL:2!
M>@;J<2X=U[[3 Z5*IJ:Q]4/H^45MR-32?=0WX!$/8'.*S]=62W$XU%(,M10?
M6TLQ,- _&@,E\6NCJE;*^LTNRB)4^CE&IUVB!W$\4%- 30L%]>HD*$C / R*
M#BEJ P6M4)#%!:+D%5;F@'(00W\M(>U$KIBWQ@\O!?M)P 4)C]<KI+XS6RX&
M\R>6A!.SJ4M8DX'96J[X"V,?29Y4FK5AYHN\7!JSI[G3%'OULZ,);FV/@_:8
M(P<C2]H/AMTL.*%60!MMDZ-H"L9/8PSG.6V+B>33,(!+F(_'\'"<8B=YBLON
M/'-SBVV=3 >V$7,<J<T.UJACTU]326VW XF<)PUBZ\9$Q(8@:'4H0DZ8D-_?
MPWU7:#Q7#D8Y@)(TR3/JS0S"?;E]P'%1)HG-3M.FNYQG05ELU%Q,,'T5W.<!
MR#4Q0VO:M!E%;8,WM)U;7V*,^(4$P8PV0B*K<=0SF/T<[P'BRG@;X7IZV>5Z
MZ?H)T%HCIQED#E$"#:C(^JS;^TZV)>6UPO\3V"0BBC+\//W-O&/0GR@7/$L<
M%?MUA !=VJ1)<8BQ'Y1WOK"'\ZR=Z[$+3C=3'>9X]6>!.G -'_M.0"RWUNU]
MAPNC_Y<0(IX3#KWV\1'8/^FJPO#R^X<'V\,*8CV;F WK0NT<&>SOZ!/CI-(>
MR!A))/6!,,Q#EOG!B5&\+#2OQ;1&(W/"QJGJ463+)VU3ZB_8D*??!/;^OE-1
MY)E5ATI3Z<3D@P>B>%G]I:,:L5XGHYR>C(X._\/'8^]H.YZJX(V/.;,(FO3]
M+$OAW.S/U'#N>_:.W,,^O=<KX2F9]M%D7)=Y"YKP%_!&[(_V3_I;Z7GOH7J9
MU1FGM>J245T\/]P_^L'O5^4YF;I:Y)I36*>>'H[V3X=SV;US.1@='@WGLGOG
M<CXZ.!C.9??.Y6!T<3&<RRZ>R^'Q<"Z[=R[ QP9]; ?/9=#'=O-<X+X,Q[)[
MQW(P.AO8V.<[%_+FAZ&53[+RO_ F/'39GY5C?X$UCX-/^#XX7"\ZG%;_][_^
M,@Y7/RESW)+__M/)GSYV)_;?<QL_>2O.%QMR<CY\;] /*6[(E>WX6HEA_7E_
M\N+>(P,?/>6*7)';6NS[),N7.DFWE*^<&8>W^(_"FM?OP H_^L M>31^+8$&
MT64.%N^PRVF61IJ?^/7P\Y4@RQI1-U#3(UVPSRT1'ID^KDV%0R2WYI%(8OM"
MXG.1Q"!L=HX]](2L/Z<9</BQ8N6"\L2_':F"@?I'XQ>;HQ1_)!HY^\9HY.!K
M43.^#(U\@D+Q[9#%%>6D?2W*QB,01KA442(Z'MC]-1(YX"P'^Y:U=)8YJ">[
MR5:^"5OXZV$M3[*"KQPVXJR3(JV??BT":.?ORNXY.K>](UN7/8_C#'4UN-__
M>3(Q9CK=*IV_NG[^^O+7E[_\%#W_G^OGO]P\O_G^T>[OCBWU$?WRF!BY8ZO[
M\E%'SD/<PC9\='SFT<SG'3O[QZ3LXYU;W58H>SN<>IN4_6WS;+;J_U@GRAK3
MCIWH1]_FK\G>EOKB=0T>OST+Z0M9 )L+4C[_FK][-+5IFWSG:.-1^A/'@EZ:
M^I_^3W0<GYT</^9A?N8XQ&X2\,9*A*^&@+\ 8WU\ CZ,]X_VOR5OYK>35?=Q
M!WIP]*C\:-MY%/_QS;B61/U9#VKRK9HKV]*)>K9ABQ',+\JX^LVZ;:_^\9G=
M67QT_(C2:R?]6-O2R':0@+[4]>D7&]M>_6?0%?;CL_-'5!=V4OQ\=F_9+M/%
M9FZRCBZ>'!T^?6PE<L>HXI/URBTID0R=^.NK7R__'JV&*;\)"VYK^N(?1+IM
M-Y/O<XFRPWC_8O#$/8;>]P>Y!MNML/I\U^#\X-$UNF_ER'?[Q#]25SM]=%7M
MJ];+=DS/_"E!<-X" 2AOLSM38#?L<AI=)\O)S$S>1M=5V1A"XL5_4JOHOY=)
M\:T:8X,O</ %?B;11SW*#Q^5<@9OX. -_.-X T_/!D_@X GL:)<'^_N#*W G
M78'\B5], PIC77\3MMYN>/Z.X-ZF98N0[[L@RAXOO6[KR_P<_(G\?H_*H@;'
MW[=["U:<?M_,+3@[/GO$6[!]6? Y_7[?QJ&??-../^U5]O@]9L*9=+>;_V)U
M>$S:>R /_N+=</XK"[Y(_]:N/^OK+&SOM%'T7W_)PL?\'E:N-9:I3/3=\>B<
MKR0L*\_8HQFVU-G842>F\;\#OO()HQS@**Y+5SG% <\C'<NU6DM;PZW(7#\O
MKXE8T,=,9Q!=4Y?&PW$TR;,"KPXW]WS,/E&/=K8/Z(S'I_N03G5\OF>CHT<X
MWX/]3R*3@U'TD!FG1AN:C9?<&.T=G'QCX.2_.QJ=K">([PY&1_:O.@I2QTH?
MNAA)J__9>I8 &U[MRJ=]\<KIM :K#*;VW?[HP [A$V.W<]TNTIA:EDQ(^%,.
M/T7W20W;>#@Z^#1JH2YL%7>@P^'./I$MN!-"KK _.@W&BU=) :\\OH#=P>J&
M^$$R+N_,EOK"_3W[=YNEF71*O$H6> X1,.>RK2;;ZG/Y$#WD)D,RQO]9<&O*
M>Q/-$KBMW'41][4H8:?O3 $;/ZW*N=^7#1>K+\ 8;84D,6GG+<.Z$\D9BIAU
MK_GYZ-1>K82>4-J(E,JH&2(-/6V)>K _G/=Q1Q,T+6Q("/N?U76+5Y-[*4HC
M1EB$P0:-]0Q9Q<28M&]20,<7=E+^F-R.$V1/#=*E),9EFGMCBNAGDKV'^P?G
MM!>O)DV)2X#I[X^B5T7TM[8 H72A='YON,.B:60Y+Z]?2<L[E&S 6G">FZ9X
M[ E,:F /-P>[3^+KN$O5?971;[.:FG#2(, WC]U;W*(1B(OZ/=9-[W<<YQM%
MO!#X]>&9WO]@(0FVG00^;_#TN16D^X)T "7:**B?ZATVM5SD0(BDJ'S(\H]&
M9VM7[T9,;K$K)37:S$@H"%,Y>L\>P".'=M6K /[KNM#["N<1WKS/T:%@+<31
MX;&JX_;>GQYUVP[\__]?T%[!.G"Q#6)9?:]6E+<L 14[)%OB%N0E=6^@/?\^
MR>^392W+/+L861?<]]80.R)6M(^0E9'W;]R/E<W$%HO>E@4M%.6UL(NB_O(]
M723D9+ W,F@FV-,1U)$]6=@QF$PGG^FL.ASYR)W,?R71K#+3__[3GW]]==4+
M/T1"?%,_Z5^IF250ZU5)72EK2ZC)0X@UW.J^'?SB8NI'4L7:1<EMD.$:O\7U
MJ<Q!M7&";$8U??@O&#V&]H%;_++V.C:3I&4-HFCG!@B\CJJL?LMBJ@694&&;
MVR;KZ8'+Z@2;4G'8"QC>E4;"JYU[L4LI3'FU S!Q2%"0X+,T3]!83-T0'^,/
MZF26].ED;GFUZ_8[$2VB;)L<[ALS+=L3E[1IT#A@8CVM<]O*ZR"<=FRB>D/#
MXRWILI?]*H"H(["JLGI+O%KW9$HF3V051.G738+ ;]G]W86GP\//I .0K>/+
M _@#Z$2+)',]E@-#X# <1!I<@PJ2+.EXR=J93*K6:]+\Z)IHH.!_@&YZPSHH
M3MRJJ5OJ_UM&>#N<DBE]SOM4NP)I-\_Q?L!-OIVM:@ZTHJ[6%]-] K6*><(F
MU>3S'M#Z7;C*X;JR?7,9_4P$7\^R1?3":IG;.9VO1-OFG>NJW/K;PWTT!RMB
M!,0*N=TXTPM]!>EC4NY-2U*78>*7>:Z,?'4&Y%TAY]-\SE9F@[W(JPRLIBHI
M;O$[-"RHS/O[$>Q7M.Y\7Z+:!G.)GG36\92LZ*/1X<D#WT=EW%MP[S8\A1-)
M*I@BG 0VX@(ECHQ_;$.?X?F"M@WW*QJW#2U]#EKP'AX@O&#7STWD9_AF9ZB,
MA34(S'P)A(^_\G8-=P8E-F[,(:B *Z_#@D_V5W\?X[@F 9,*J ?Y!)Y@@OL/
M?Z_%)P0[#^>$PHS= $B#1OZ@KV_[CC\H0?2+W_"7>(4\RB%&;"]M$EU?7]/L
MV)*DS;VZ?/W\)KJ\^C5&,UT]>L1.QZR[W/QXB=ONU!@2NZ>G\<G^$7$%4(FB
MHFR4\H"FEA%U76_(4PA:W6V;(!D86#>[>@O9,JN;Z<QB&*FB$6'F('UIL&DR
M(?=^-)G!THFXRC%J5\&KH^A7[R<@L*K*<-5H#19(3IG>+W1[X"+V1Q?G_\$^
M#EA[#0>:MCG[O( 7H$;8W)?1D\.G?E]ZHGEEB^0#N 32S/F1@R/U!.C.)6TS
M*RLX3+YGTQ:N9"?9.%S$;XO5=.1PA^A,01^5(?,LX>@'K01.&TTU/.U;R6T6
MG7K=@'JXY&4C;1&9I14,V[IA+PO05^'4KMLQ/!B]D@N_M8N%GAY[L[JN'M%)
MZ 2(7:7TSQH4-R+ VUM04Y#J#N/SLY,8;'%V4]-AH-E1HIE83M["N+-L@E)M
MDK=XC$<KCR-;]E_1#R[:"HFR4;;I>8MJ2KX]^P&.E:X=/ %/3RBB@I9WPXYU
M_D8L(I#WW7I1F/_2U5=!2,_'9+?U*@0/]&;A#\Z=Q?XD]>R(503KJ3H.G6W1
MY6NG;SYC?7.[I/D0)_!+]>]]A&\OV>C=BXGZ\-F#^.#D(CX\.%A#V338P=%^
M?'9Z@<;8GJBAHB+P0>-NP*N7[K<^J1[$A^<7\<7YNLOC#_'C1PZ!Q'Q;821E
M@VI[[/D1H^AK]B0>#Y[$P9.X74_B)_D^KE#FO,C+^RW9U+^2;I7#!) '4DX,
M<"!.6R#3ANS*:JE*EY63V#=9W7++U7AJO3$^2XP.U1#&/9?/RI7E5"I2P!>U
M^5[_X2\2*5RH&\]YPO2A#(JN$^BMI?Z"[Q+])KAR7B*2/+/*TU;:F!PP>3\L
M@_OL:'2^,=US:%2]G0;BAZ.CC;"FP[ELJ['[\?EP+KMW+A?O05$=SF7@8\.Y
M#'QLU\\%^-C&1/3A7#[I7#ZPP/&]ZO&WWW/L?0Q\U_K/?7BSV(_OS7<T.OO\
M+5$?<6]>2 *0EU#<VQASN![#]7BTZ_'M=,U=\15MZ"T[7*'A"GUZ._(#[O[Z
M[5RA1^Q9/Y#-1K+YQJCFX-$Z>)\]9@/O@7U__GNX.>CZH7NR0EY?OJ7WUV8V
MO+>E]\==FAV#0?I%(X=/VIJR.Y^Z5,_Q\G$:(!_M7HO@1VPLB1[%'5O=E\>2
MN=A6M]SMMHD=*/N/0-E?;0/DKT^M>V4+U5QMV5>CK>T6X;XOUO5UH'>]+\*]
MLSA-9_')\6/VTQE(^"LFX2TWB?U($CZ)]P^.5DGXF[![7KA:M<<7-#NVUFU=
MW!W$2OXBFO-:8VC;JW]\]/"C^/3BY+&%W'!]_NC7YX\"OG]P')]=K +P?WUV
M&[H1GR@8V]/H+R$(8U+/!@WX4SC!MG%LOXR5M_5E?HZ>JO'Y(T,T#Y?@V[T$
MNPY4_G%2[J*WW_0?&N^9?\2!/J(ZT3E)+T/;]8O7*=KHH00//: Q9U8S>.R9
MA] [7<W([,'P<M!!2=-4V;AM%!--2QX)FI80 3RD+1^!:RUH+X-(7[AW_"<7
MR9*!?^!3=S"]LE*<QQ .LXM*[<,,(TS.EX;[^CP'=S+:[Q[<@P%Z/^P(SS[X
M"$]<Q?S#CO# QX]E.+<+'Z+-'\.\,Y.6\&C][^X,/MM+0JC:*2[@90X(@%:7
MH! 6JR@5\N1CZY-WY@R<%W$GSV#:X^3D2^TCXCZ,&S. #+Z\[BI;9 N+E_9E
M0/0^WRX%0#,?S_L\[/'5?1(XY]TAZ;9 G3)ZC:!V%2,F;@U8<&SRS  #;F8)
MP\V9=X+62:=X#T=#&&%C$]7M=)I-,L-(17-CFE4X4WRG\M9%9PHCYR#"\=."
M'@\SGGE4K*A<BI(D](+(1HIM57\@$OXH^FMY#PNK8AZQA,N!4Q X!Y#%69G2
M3["9%LJ2KV XA4JQXGDSQHB\A#!W#9%<W2X69=5T01DSN,3XT?ND2O?RLB2,
M5 ?41;L-_+O,@86OP\(5H,Q)T_(LVIRPL]L\C>X0F0)!;1 U-E_& CMEL141
MM*I*+0[?' P&6OK5JW^\?+9W<!$)I&\(/PL;6I5YCC-T$.\LJ9L9K,@"Y1(T
M?-W.%[Q86LT\6=*=IUV!3;JORN(V5B!ZGG9J"+R(/RV L6Y[ZQ+$%IXQ:'WW
M"B^\)3;V"DE P(7M1#VR)E* Y1@$N2I@\8QVUX 6Y!W&!Z-\?)KAK,:6]QM$
MQJ&EXQSV\F19MLWWT^R=2?VJ2X7V82LN=(O*8^<+E\OL_OA)D^X8[W0Z,-\-
M7HKS%8O\/_]\<7IV\4-W7AVS?25K]Q'X_B8 '[QT<%4RO  +!)<TM=QFO<;"
MZ."*E(K7M<B3HNB!A%X+9>V,YA5C?R"Y/QK)D206.$F"P2Q:Y$?(P#RY;6D+
MQ1;C</?3EL67Y1X,".-GRNE <0/%68I#Y,=6L!Y5Z<#V,B6H)MCH8X)*/BLB
M!+$%Q)2:&C9!.X\0R2DN9@\.OB6_6)@I0TJVS:2<&VY$8#]8F;L,%CCPRH%R
M'R:>D;"8RIBT@'+6-I-P1JNO:"N1.59+\AY.]JUIZ)]UD@LG3;'9&EKTY$8C
MFZC8Q'WQ"7$'6!QH-S*C6M[!6@:J'JBZ2]6,>XKD1>"[/=2%AK29S(HR+V_9
M9\@8Q&8#/7UM^*@G SZJ&?!1>XGU_?BH _/\HS'/COED:MS^3#H2S=$AAYC\
MU#'5W&:3:)%43<'M/T IR#-@2#6I$96P7<*POA5OD6JSSJD(/&1.C+INL47P
M;67XT4&B#T092'1IM@:*)PGUV'4%(>^Y4U9%VQ39_PDZ)5+K0(4#%:[JE:&Y
M1'W9V.:9 N-4+V95UA341PLI::B'W6(!#)(#([%EIOJ"*8 P*3:(/!A;O>2Y
MX9@'C+6 ;07K'F>DS?&FAL-G2.:]C^_9/N1YDLWKT7IB[M>4*%?):FE?//3P
M6]%D.<L%C$W1S>= 5D*J.EQIVP,8'AN#J"JHX8K>>6$9=3<\U1?(B%VD!1^7
MMF_R.(B_@L*H&A[#EA+S,3RCZ2'::Z2R#2:D49=&H6OLV3CV&E?5,;<8@EOJ
MM2IV C20FU::ZM0E5#2*?N7(%NRJ#:<A5TNRL#&*OJ<+H'8Y"2N/.M-*NE@U
M&7(VFBU2<"4&/[Y2WHNL=ZV(Q':GWA.S,L>&938^2$-BO&N,/980XC*-K0Y@
M)3_\4!OO4Q1!D_8QL"'8#U#VN;*F'!!_9;"K&R\Y2;'[%G:V2&"_\0A18O!E
MZ6DX(_,<1<^"(^%KV&FPQ@+G+LERO"JQ3(X"EIZZHH%,GC0V"RNH<T<.7*(1
M?0BWJ\JX=4Q'S6J2M[ #0'S9%*@HF0B+8)VHEL;5-$-WI'A .)V@ZV30<Q/[
M4!FX^Q7WI\$LA"*%5;^<.AK!'B:.KD.*C-V.U[ .&"BD2NE]E54IJ8&9-!7%
M'<+K@@L##I05L*-P@T"DMB0SY5RP!]::SJ3B@-+^JK!M)IG7LH?4 96C2?)+
M_""%:&'(6^K6QM<(MZ 0.K.A68GA3Y,[6*:DE;1T^?XB0W%K*B(AG+/IHR#=
MQ+"!ZLJU"W?77;0.*Z#&91@?GIF"M@[OB>SDV"B?H@U-@:4O8Z:K6*=*?HQJ
MCOS(!)OJ=U MJ_6./3/%;@^TF;R![HQD"-'_44E:YZO#T\++ A._IUM/I'./
M6\(7=LUP1.5]WID6K_3=9^A3^K#TE-?<:O"2<ROQ#EU795%B:L(64U6P7\<+
M:SYYD[L!\9<F%=#;CR7F/,R0<7!C+<FET#11<=IZ2^DTN._DPK%489Y.(0=#
M3!;59K0%0?("@5)S)4HFJ7^(9IIR K20EG+GO/P:<?HVLY*((Y@*TP[=9PR2
M($<$BK2L7?I^.@O26]3<)'5;.9F)D9F\K(D98H]>H$>\4(9R9GD144KN:LD\
MH\R:I.$':<4TC\2?B<TB*8AOL*R1Y!D:/MRB+1'O%<K224@AUV6>43 *+]^-
MMZ*_M>FM,]"?2W;+8Q+X)^6)_<9)SY]C7A]X\5C5MUI?;WH6]X<$?CI'9D\R
M\J?+RVOEXJC>%,FMI#]A@!I$OR84\0&LI!3Y2HU!-1;;GKF&W/"\:51_9*U"
M3]G= .X31H1 MLB:=_@KJ?27#'TUWB)5B>N;CN:;Z]5RSQ'C(1XQPBS6U72N
M-$-U6?/AD#G8G=F9K,77JH+@'CQS G9[5'E5 D<"CFHWOO*GZ.L ;+Z2FL$Z
MI<&3:(A]B8JO@Z'N0;3)_<C3.VJB3,X3JYZM^0HLZBYCZX14>Z4-5);0;,7/
MLJ[-$TZU@:<D(Y)QPF-@_J FT(ZB[6SQ%6T:+ESEZ-J5^P%25=YI8;B$6A/_
M97MXR##Q4/MIQ;192ORI)!]2)0'H6:A)*P^2X2FU"OF)-$;4;ZE-T2286LEN
M+SS:MJ9;GMAI@AC_%S(9E_H8>UDR&? #FIO8JB5Z*)#'\3QLCK,D6BH187(^
M[)V614AV1*U6-CR:59K8R;3IR/):ZRHDW[4V?M(T;H_=E*XY":.0N8/#^A9+
M[&U R&JP56\#0Q3,)OV92/8I$?PT9PU$Z+6?-=8L)K(4=TF+<-:2C-R!6$D%
MVTJ+XL_]@#W94*%Q\:^V;M2XHOG0:V.TQ?TCL29KH**LY^E>1^#+''$HQ4N@
M1YF6, -4Y,1)@N?JIL:IKBX15[:76G7C#EL60&>=+[W=]3[RGW\^NOC!3Z^=
MVKZ^;=?K9F\1, U<->TQ1ZZ4"H6P'OHZ;CKF$PN?^=H"O:=#H'<(]'[%C3!O
MJ![N1^+I5UX5W/;U*EM=J>5+E#/5ST1 XAD0P.72H Y08L(I>D19%\>Z))2#
M-G2%9NB[R0P%E"1#10E62O!1BR)&)GG@="7?L=?RMZST'PMQW 6BD5PZ>Z33
M3Q,0N-:K14P2O\>21K^('=C!./S=U&$9I(BJ<' R:T@_4)5--/S=;29]U;<H
M,(A*D(@H6DE-\3>4-XF*6>S>P ;<F6KC%H0;M;KU.GCC3HDMK]2P.\]TAO@Q
M!R:^=S.9E13A7(CNE9'S>EZF)A]%K_BW3D>DW]=J?HIZM&B)@&=P,4$8B^Z'
MHM.W/5V*'X<8%JS\<!_UNQ*Y!SJP ^*1/NVUO04A9;(_!2B^ N$,FP22?E)W
M_#P=U8'M0-RR*D$5T](X9<_2W:E5(?,6PFOTEX/Q(D]#\8QJ[VB0X-N&=ZZM
M=>T/V?@?S21!K9I2Q)%4BE+#0N+H5/;1W:IPAW!90%E+L,N;!KC^##:IK$@-
MQR.H,HQ[J.]]S6"Q==C+#";TE*V+I5)LQ\WF&+^LV6)PYVJ-? T=1,O,Y,(K
ML%1K;UH9C",TDH0,5F%!U8R@%;C(_&^C&WBE(M<<N=^-& +\79)L<"P2_*%Z
M*_*\L;."ZQF3(LF7OYN0#GG;NM3(CG0<@%5E\A9N/#^?1M 1C_%_^!LL:Q1%
ME\ /.T2&)71<K1(.ZXU#GD1QA>-^8R9-+D9/B_/\W1"OS]'D8)UU;H#0^5"0
M$KE,SJ<+X@^L^+]7PL3B3UF4J"TPO:O;4H-U?87NEAD6[&7UJW1L3=]HQS J
M?,7AVBO&_P=;G;LKASY!QU"+^G$4B/C3-8A(IOW_V'O3YK9U95WX^ZDZ_X&5
M==:IY%Y)(:DY67M5:;(M3Y(UV([?>DL%D9!$BR)E#I;E7W_1 #AHL&,GMC4$
MN_;.EB40!!K=C:<'-%9_#B?@P#%58O)]9U8X! A 34YL:EHCG9Y?YCL?: 6J
M"I#IVM19\7,5'))NZCM3OF=P4S+0XXNCBVO<&?43>$3_2)5(W%=UQ_-"_G+9
M#MX-N4C\U4&TA@=&^1('HAP3WQ=):5Q(D63H__G44_O9C)8?*+V"DI5[F5QV
MT"OVU4(/Y755*ZJZ5B@HGYA-P9ZH>WB2+UWXD%?AT:F05Y(_3?Y7E7N7^4,?
M'N2 \;%85;Z4DN+CI+2)C52JQD)!I;Y-H,$9VY1;9"/;$%:]8O%CLIRVR]:=
M P5V#IIO-S8<&X)CSAH-B ;1Z#Z@$^R&3E;V3%0)(,A%"!,UZ#Y-6]&#%Q@.
M(%$?C*7-(R42M:(D-*R!R;8&^EU*:E)D"V@$3EO3&#7/"=4QM2Q=7H^&"+H!
MVU7D:C(L(HR>'V!+>"=F%5D&F"@&[A:")=)9?)N! =YOE(I#'GVBTR#])8@U
M4K )&%=BPY'N*$<PC$!_#!Q:#%7I-# 9C_5!S1B61L#\I(&6IKOM8F!SMK*:
MT)EO^2[U;K(! !7)$W.;0RMFX2_\NFR(Q#(;^\BBV1[,<B<SAJS;K0F,''"F
MJ@1,50N8"F1L,R)6(CB0"TP(FD*]&2M3 "O'A $L$-/64,S-V[4H)[<]&H<*
M"@(DN'E"AIKT["1+4</6$ W9DX!?P<H)T2[[DY8'"M)J8MLXBH21_4:/_]/7
M X#6(3/'H?E>L U3T6/LC72);)C&A-D'+-8'&6RF#^[/4-J>%WDW<#]3+W%@
MOF)O!L'R,"+(8N-DLW)YBA*E&WFYQ_@U-!BX2<!+(['$'0T;4R_^+=G[6?J>
MR0[@NB-(T--]MB8I&KFF1R:YIHD)&A<]'IP/C+K%^2_/UWEC1?];LE*CQB=5
M?O5 Q6Y&0L+7QQ8#\='Y+BNO1 N/!6EK 3"EB6+!6?ZGPHV,YUE$A6GS1:49
M[2^0K@*\'%].9J'S$AUK44X\QLRS3R#ZXH*WG+N@./@IZ/TB4HIZ+X]EW,O@
M@MPC<$?KD:_E0K]8T#6]N )^"F&F33L,\)!)MN'0./V+[,N;!S^%5"PCJ+T8
MI%\8JE1%'MH0V.D\ETH0)"JOBTNYQ%30?1.["WEPD,)GF)@%YDS#C:GK.AG/
M [1YDBA,:Q'M,H541_9D1$XE"SS61(['_JY?,E.&Z"NRQ06-Y.1):B?C1'D1
M)Q)QHE^-$W%EBO)%+/?[Z5Y!Z^N]3$$GRC1;+/:47#J?+A!]JJ7E%65:Y(8U
M2*5.[+$H>QH $LM3V[PR+:;B#@":XQ,?*@-S/*F.6NUD>XKEV,$#D=Z)K,Y-
M5:&S+;RP#>(^4M(#+=\KHGR_EU'3^5Y?+0YZ&81U19-5K,KIU94K 3\YM@F;
M7Q-JRNE@2/=RQ6PVF]^"-2/6?S!"N@+1&+<&\46L\-10-^:$"$UX""*H\O=8
MTJ 6'^HT'&J"ME2^2]39/Z"1*O)\"[9IOC^F45+)?L9?V)_PN)+5XU_YX VD
M&W8[.OH1FHPE5A)%*:8S-#4&36B1NT3@9XPW3/ L22<HK,*]Y!:S!=C)C"@S
M9@E&\-E&^('E*D;>!, 9U$'J]R?$2(_&O3!8'AMTZ" II5P7/KK^!#PRC]P\
M"A,F08_P%\9L+C?(V(J&TZY5PN".$Q$8.H,YP2F6GZY7X U*T->"]XLZ6! K
MP_'40QLE)M(T?^*;H5T);A ?LM&\R$4:9=+&ZY&PXPGD;V-*;<*@M"Z;7?!]
M!#6#$ KE+;(,+M@5W-M.PS \E#;PK>!@SF*8B/IZ3-.>T96D7FS-8/6 HK(_
M(:$BZ4I)C85)Q /O89K\4Q((X<4)S5F#;'M"6EJ'CR\8]7!0(PE8$ *?/$./
M[%8F!/@1F21+#G/)2(*2DT@;$:N,VU.&(]E!-#7RF<1&:V'@<5YS&8XV I^1
MI;[EV>34Q\?CT-Q$ SLPV2=VY@"\73$O%O4+V*Y+CYX],>4-;:&EF.%!K.%7
MZ3@> EE45J_G7,ZAX2(\P\6)H* 4Y8)XKB@*LR-IK<:%\I]P8(W/+[1S)#!Q
MPD>"XPP6=]DN5;$*+?+ V_;S/21%##7>17CV+N*6E_6Q3,SMDB#:FT-CK'0$
M,7E*2>4HOD;&&:U3XD5<\ P'P-NHLM>EL);MSRG)0EC1P1X4'#=8,T\37#R_
MQD\;DN&MW"'[D(6]O$]N=HM\(8N]V0:X,<A+SXX;-  48VQ^2)2['V<8C4'=
M1:%@&DNCQZD#@888=KQ"<G#*)5XN&G)GO 5(QPY0L.U_@ R3NZR-"7?5+19;
MB9^V>^G[6<R8N4SI/NPX/,[P9%EI.OGEYQ ]M1RXXIZK2DT9D"9 ^33[ N:U
M4!X[&IS=-XUAF$NR'>;962@G(=@N619$[EJ8%0ZPR'[%R5^)DS^R]EO!##=7
MJCFV%5*#Q)T2(E-0!<D'836?8,-=J$$1%/->SV7+M<#Y5!/L[ C4:,!$QQLK
M]N "5!JL0J7!ER<TW 8+7L>HN("FX-"<ZP:B0+>^E;,X*TCI=8IC\2!N>"G"
M8CJ.1JQET%&2R[(*/1H4Y];["I=2AB:V.OPP9/[N X?8TS/;&4N?5;AX-S#G
M>08*W;9I;A+9@#Q,D4T;.,FFP9:&,T06/SH>@@#(\--G:,Z>HN50-[2",61E
MN+$U6P&+:X#2*S0\6:D87%J_;%NCWDID&5V>UAHH-+9NK>CBC";+%8UY,P\,
M9_(QBT@C1,8:I;L8<HF.(07Y+2"6L<DYX>38GA-.CB?"QDZ+#\CD@@LSP%1Z
MP"RQ*U*3D2@<-\IM"KM C7)!(TP$HQ]*0\>>!?FLD&/+I2DEE<)*$!#"9OS%
M:N4#^^UD]*@@HD<B>K394T9/:[F?BWL<E\<-,WM*,$N0:?#R3<"G):IXYA<Q
M)4R;@!>:A;M>.<RW9D.(Q;A6 $-CJV#M2S*I2S3KX]ZP?9<Z9YB//;'6,Z2'
M)3["#&F:0[7>[&,)C;^'WI24!*DO,3L0K;Z.UGGB3E%VH!9)D'E,O4H!-'<)
M@,/#$&_&N3MP3K]#=OY;I[W#R>4)UIGG@!Y'>FJ"NL_.TB\!M\_&ES#3#DFT
M E42*E#-6?0$03X(.R#-BN%#UA)+[EM92WXNV*;\,8$@4^#6)-8XW.+#K%OP
M%3#L3=U"Y+V63Y<8<LRCTQB?#3*R$54J*'B#R0H?+4YY[3P9_(9#ZC;+^J0I
MJ:S[P*%>FCI$XX17U)$7DC>&C@/Z7D))POV..5^;3D.=3T& 2HJ7+:-G#R:4
MGX%L[A,53@*N(R:)R6I"P$!N"9$M>G.2Y]!C/(OI>['%XZE?E-LAZ2LD#,L=
M7!6,(#D(/"0_X10XNKU![B?F*Y["H3-ZS(FL1=^&/%%V(HQ?2+A0E6_QI,'+
M]<SGU;CK6CM[3?SARY(_BKS+PE1U1&?*%JU::MVOC(V93!H[Q1]/PQN0J9!^
M.!<&2-R$.\<&A@O'V.B=9?1Y6/^5(WD\RDO]%]S[#(?AQN!8I#GR2^T3KR/>
M0CJ$GD8XKQ=0+UV$) B<2??Z:5GM9>1T1E%UI:CH:](AR@U8TGKDY.T5%455
MMB$3HIR2Z."DV.BV)?>DD%84+:L3.JN#8B\ST'"OKZ%<+ZUH:F& \WFEGUV3
M-10Y[UN!,YFGFA\3KG-U0]L"NE<6PO#A0*4@*3X8:NR@0I/6-_3(2M&"*&_M
M#GW52H7%:>'<U1L.XNEKL5]ZG?N.V<=%81\+^_@WLRO3FI97T@KJ99!"]&1Z
MH/2* _)G>E! @RPJ8%SH+^C)9JG5J=?K/267+^3E]]6&3TK#&KT"X^(YU/5Z
M;"< O:G(U>"T<BV(/S9X)@X!E!5(SMZ\7B?\+E6C4]7A2*5&_-QU)<@DEPX!
M==#2T1M2Y>TP(D!PMCVCC@EZT Q-L!LE9P252&B:0WPJ&,&]KP.> !3%@ 'I
M36.%JKG1XX3)4,'F$7-ZK@^#!SD!0.2P4K01>.)YA)08.&E(C7R81[G[[$"B
MNYBY#]":/-,'JY_7A-Z&RB,O\,U\^K>*[@U=:J:D4U\S6)A&_0ZPP*40G;'6
MR,"#5;Y+A%RY]>;^F<,G:+C\_%!R8-.07^(G<XUG(X"E "?)P:IRP\E+K@%Q
M^P/<=WPXWZ+*2H&8GN$K8TZAZ&$8! WW CX+>Z*'^18ZXMZ]8]_"W(O3#+M+
M1.^8\9-S+UHWZAXRIOC!\"=2<X2(=&C8IY5:7>GS.7)U=/=-JC9;UU^(8$G3
MA1:!$Y$(N.:']0 ] J-L\KND._XP?OPJL3HGF<\)O%JT_#NQIYJG#WPD!(EJ
MJ6@4S=/KYA>6! #.3,Q/SNN0&_0_N6)*#N\KC_DEE'Q*.EAZK5R$]QPC*QQ&
MC'S1NB!>J2"(3/5M7L@@4E?DCY*FT4MD9]2H'O$* 5$OE1$RR%S">&S)AY.U
M42B3+<YBFX6"0+&F+DL*XZP'[,(.:A(EZ)O\;G#"[K1>O WY+X$-C#16$8A;
MT&=(<^S*"$\X;4('(:%-7@K*@R]0[%<IQ%+* TY<?'?3,6R'%<=#WMH71/QZ
M"555PHX2G)\CIW"HAP[9J4%"-M]R(2UL83]L8\W!].@9&4K9L+'%ZF F.*^1
M\<2^!9ZW DN>[R&$N7\B!?Z4A\47>#]VH0M/C5HL>0Y;H048?!A>$A.F=RU5
M(D]%I.H3P\Z"DCSD9P>3E: ^DYICN9[TOV@R_2Y=C0S+PG/I]+0I?;;(#AS[
M\0>AT1!^H6(%&OD'Q.#IRD)M4>:460Q=P"ETB-1S[H-Y'F%D>B,8 %DA.(E+
MENJ0\- T17Z2P%D&.S?[ :8>+(:)9B"[3>2;TA&BE]N[=)RQP82"10NO\L[)
MK@HTAX1VR/,B YX&IU>#P;*$,7KS!5,6_*1=) BTDD4P%'Z_1H)=BN#S2R/=
MA7YXN?SX>6.6G4=%T,&, 0*BC"*BD+W+)[W.8^LV=)#NLR.&((!E7QM;(-I=
MRX";(\)*S8@P$9SU86M2)F"(<!25M[;&"B^1UY5YZ04"=>#D-;T,*_2?4?4
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MDP7.KU <(,C(@F1\ EKY*/H8Z+S4;[AYD0?@4/FFBGM0'Y85W%BJ!P%=..H
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MQ<\VDG<D!S5V_Z#Y+EBN.['Z[>1K-S4P9[9L$N^YI NVR4XLJ9S]JN:_JKL
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MC\I$=UWL24U^Z?0J&#[ ?<='#O?+4+>,4O@U,'QX2N"P-\*NX4:_""0LD+!
MPMLR88&$!1+>UZ432/C#)J4JJ5U@1H&#WQ('(^UAFE1E5574M/* 'U1%_S 4
MV_;[KJ$;R#'P:G:]X,'M1937 B/N&D9\9R- X,D]4CH"9.[VC'<?B:8%$A5(
M-/UQ2+1B6RY4\*#'/4=6"S]:AC8.(O]-X>\4Z'0G-+] IP*="G2Z9^LIT.EV
MS3PM_*0"G:8_T$]: <H/".WIQ7D$H\*5T$W'L#1CBDRI]H UGUX(W1B05MB1
MIK[C^HC@6<^6VEB#QQB63<MJ\'P;.7UD83?9>##Q7"II%/VJLJP*M"O0[D[L
M) +M"K0KT.Z>K:= N]LU<X)VU1W@6(%VWQGMJEN"=@\,"Y&/Y)- NP+M"K0K
MT.Z?-&&!=O=K/07:W:Z9 [K; 8X5:/==T:ZZ0=_N<W[=9@SI*@6IFVJG*JE%
MS*NDLW)"0JY4TNTI' 5K/H6.BW).H&.!CK=K!@(="W0LT/%6Z52!C@4ZCM"Q
M\ 4+=+Q!7_!S?F"!CK=%+@0ZWK*=1Z!C@8X%.MZS]13H>+MF#C>IU<_;.\"T
M?Q9 CL\ONI+QVU\#^I_O<%V,:5A8NBZW3J6ZY7H$5V*I:FL^E-1B<#!)D: 1
M_*CS'\D',C#+]B0TG6+DD!:T81VX@\!P<-Y6D8?H[0!2'VO(=TDWGLM>YJ&A
M*R$'2WC2QSI<+0TW(85]1*,*WK<[>E%@38$U!=846',_E8[ FKL]X[W FNW*
MT0XPK<":3V+-#GJP+7LREVH/'K9<<''"[7@3%(+/W=%- N\)O"?PGL![^ZET
M!-[;[1GO!=ZKE$YW@&D%WGL-WJL@4_--%MX^-:QQ'\KY"_0GT-^N:%:!_@3Z
M$^AOS]93H+_MFCF@OVKM8 >85J"_UZ"_*AX8EB' GP!_NZE8!?@3X$^ OSU;
M3P'^MFOF /Y.2^4=8%H!_EX#_DY1'YNN 'X"^.V>4A7 3P _ ?SV;#T%\-NN
MF0/P:[9J.\"T OB]!O@U'0R7#8F@KX!_.ZI:!?P3\$_ OSU;3P'_MFOFBIS9
M 885T&\!^E7L>ZA$@X:8G1M>?Q#X<^V%YWTE9.F286FF#XU)PQHKZ_-E=S2:
M0(D")0J4*%#B?BH=@1)W>\84)7[U4-_$Y/]UX_[??\@_04^:B9'SK6][(_ZZ
M)/GLV9-O:7AML.W(?W_ /-5,0%CV/_+*?);-@XZ:_OO?_Q4??010DIIMVLZW
MOV3ZG^^Q:8U8P3V5KN,0)_L.1N,D&I W?T/F#,U=/LU\,4445]]V=/*+'(P*
MZ""1C3>=_5N*?09ZK!!S@AZ2,9)QMDF:>.!]XX\%WSET4,&7MDM3Y+XY& Y*
MW&/H?:%?NC*$1;^I2BH'TD_^Y!/+*$1 WVFM(@ZDBY*.5N8?Q&LG_M5I5):X
MDW4"GY^M?-@!EF3WD1,VL#QWI=3@L\RZ2.H5"L8H1 2:2VJLKU^G2RJB3" L
M\N*2*"FEB"=K!K6X1B]AY*!'X-Z5[H AY%2.O(JKZFQ*#CG8LBT<+J"$?,^6
M9$F.^);]2_5". KZ)(S 1%,7?PL^1$+QZ6<&)P@W5:4CP\-)LIX:,,',0:%V
M+2PJU+=FUF!)%#7ZBM*)ONJO=3O!QD8#M3\1,7DTVQH81(M[4.MS:CNPRBZK
MS6FX@4'$K*T9=HC,3 P/2GOVY]($(]:4=#XFDY!<7QM%?8#Q)?6)>3;&GBM]
MACU"E;__?__G__R?_Y]^5KY_"6LVT?)/=!0#@W2^?E"?C2]L(%#3":I"31!1
MI- $[+C/1O#SS/9-,D!,NIE,L6< OYIS:82<R< W)6,@3?V^:6CD.]UP-=-V
ML9YZ8M/Z71YEC,>VZZ6U_@DF^"DWJ[EUO7X<!_W?K>+G*B8<07HE_9&=EEKW
M=/DMET6"IB;9)&P'6(N6\'UJP1'AP_]\ZJ&TEL_G!OU>&NMR+Y/5]!X:H$Q/
MS67Z^>P@V^^GE4]LNV!/U#T\47('9(-1Y).V/R$#G/<R<BZ3S?-V;T.+^';6
MMTU]>9\$ZO!]$H;$"_/F4A(,C?\E)T\D/D1&AC=$5X8%<LM4[=-#.V<UW8@0
M M7?<A"_#5S#81#=0)AFSC:SUXT)7$W!AOS\H*+1PX\OQ=8[AJ1S DD+)/U+
M2'I[7!9\7RCTT]F!FAOTTNETOI?1BJA7'.CI7E[+9E64S6=1.OV^^OXY6WU9
MS;;KA^>E3K=5:V]&S<?KOP/$<_"=;SAT=Z; <:EZ/.S/2O:SSG%<4" >:[Y#
M^ (#'-5&R!KBH$J\4DQG:,%Y1+K4L9[@;QD:+MGDR7M'Y#?=)T"/PDR=@5H'
M Z2$,1&,Z!)"DA\(0H"ZH7T\0N8 P"UT1#02=E@#VK.#?8L\13LD1LW(=@A1
M]'_Z"V2-K]6G?\G6UF<,]#(D&:,U: BN'4!.-"9?WVD_2;(QV;[W#4RK)9WQ
MPJ!<5G[2S91-!3J<?GKC38-SSO-"N0;QO=+31B@*7_[GD_II]VA1JG1;UU+S
MJ-0Z*U5JW4Z]4CIM)Z3Z>649MN[J:E>)Z?9-.D,.L1B5;$)2937]*D]I-O5T
M3'DS4RK/O[U@!HRE^20RF91:#-!*R.W3!\FU34.7 ART5=/\ZGZ5JNB>#*^9
MDDY]S=@3CGQC_;-[_/LA!'B&_0$8;SGO"[X7?/]V?+]55("T:>IRI<[4RLC
M@]4K4I_PF6V)B;9UYLTO6"^1>0*F2Q]C*[!0^MBT9X%E,B#V@CT#G_N46"C4
M8V\%Q@M_<2NR@G@*E(:F2&-#@36VV;<Z K<IF3#< Q8XPM_*6%EPGL08G7M.
M5KU3SVK10(B>\HBG,ZEL^M?@5$K]T(#Z<R9CFSR%/-_!H>GX"M6BII3<TQ0
M=B!T<V!I-D\%9N6O_ON*.3_%"43#9@L[SPD=PS,%%_PZ%RBY5#:[\UP IO(B
M$_P<;[Y.4[X<>7\P65;\T7'*O#TN8V*S9?-^TVF^3%\*?OC3^6%1<^X_/[S&
M@M\>E/E2O]P.@H8/R[CEFF_SS!P:X(FGK&]JM56)@:EYMK.UNNPC5NXG:FOS
MBTD#&SRLN1+=^'5ELS%%_!(OZ)OQX<Z)[C_&FJ0)PR,/:.37S]&MZBLB_>6?
MK\9[P))WEJ%?9>/=5S_[JU.W3*2>2$7B4B76<K?WQP\Y=[[%0+UE]\FHI<.4
MU!ZA&1H)K+Y3VHD!] /#0F1C)_OZ2GA,Z)SMTSE[C<G?1J'L%RS__#PNCV!Y
M2=-LW_(@G!HWM:,&:R3=^/>+P.V[HZ+V5^]NE\R)E=NC'5.@=+JI'J>D*C[U
M-;(!")R^4]HH\K=51LAP2(^2T#C;K''^!(S^V^IDOU"Z0 Q[)+\?B1AV?TWW
MEU&%BMG5E1,J9LN-D@IR3.DR);618?ZJRUD8)!MB7I&]LPLJ9J^MD+?0'\("
M$;*[I;(K+!#!J$+%[/+*"16SY1;(L>WBZ4BJ$ RAV3IRQ$F#W5)&P@C9!2VS
MUT;(&ZD088<(\=U2\15VB&!4H6)V>>6$BMER.Z0S(L^YTA%R',.U+6&%[)0J
M$E;(+NB8O;9"WD2!"!M$".^6"J^P002C"A6SRRLG5,R6VR#'2!M+1Y#1C80!
MLEMZ2!@@NZ!@]MH ^7WM(:P/(;E;*KG"^A",*E3,+J^<4#%;;WU !U7;LD<^
M%N;'3BDB87[L@H;9<_/CM]6'L#^$Z&ZIZ/X>.'C;NZU>?@%9[,&PW:]<1[8[
M%Z>%(]W A>OTKU^Y-&"W;F#_)5$0U[4/Q77MK[ZN/;@G/8.+J*"K/555M%XF
MG>_W^H5\NM=/Z[F!FLMI_6+FT[_;<D]Z_;Q:NY8Z#>F@?EXZK]1+IU*[4^K4
MSFKGG?:;7HC'N8IR)[V\FW_!6)-^L\#!L?TS=F?>;]T!O@!)"K]X2]H;[>-K
M[E>D2\.Z?^Y6K!^$*UVI!O<F2E6LX4D?.U):H1!=I>4[R0?EA9>G15!43:E/
MWD_Z#C/^V2R?OASM1?-:6.IB*J]L?+%_YR*T)ME)?O4BM&5F?\UEP^^FVF.L
M'FKV5JW9:'4:!Z"2FC7RSWFG53NLMSNU5JW:[)9/ZY52I=+H_IKZ;[&[18G^
MKQ/)F6**[/A5H=@AHM3T^Z:AQ2OB'AC.)+9)2)^;E5*C+-6KWZ1L,?>2(K@?
M*%T?[JE?$*K-,%5,I.@.L3C_@Z3Z6_*R!2)1+IV23;G6/JK5.NU>5DVGL^E?
M8_\R,I&E8:D]PG@-]/G#N7C3C/HJS]HV,FJ$&1L'C6:M5>K4&^?M7D;)9XOJ
MKW%LVT->=*%T8XH=!)!;\.Z6\6YFGWBW<E0Z/ZRUZ^=GM;-RK=4NG5?;1Z56
M[:AQ6GT+-J[0:]#ATG'IC )W%UA R7^GN+T]0@X>$<@7^[YVYQ.6$4R_74R?
MW2NF+[6/#DX;5^V>*F<R^<R;,#IR1]*!:<^$OMXRULWM.NN>-SJU=J?1.:J%
M/JN(FWO9;%I6B[_&PN>V1P;KV9(WPK&;3R+.%KR\7;R<_[#0E;+JO1*QJVU@
MV=T*1QTD%1%B$B&FWPTQZ;DTUK5!3\_(Q5Y&*Z)>H5 L]M*#W !G"C+.Z44>
M8F)/O,*UNJ&X%'AHZ2"EQH$4&Z84C5-B Y7H2,\[]?-#Z:#>.GLGO?D3A;]I
MQ;FC0UW1^1T&MLHV<G20G" WT&4&L6=K8VX0?]2(2IKO/$A-8HI/D(9]BH#<
MA%2WM-3[#R&WFL#P7%RH,34LHB,D\M^G(6O_ Q9S==Q76!JA>RPA7S<\K-/Q
M(4VS)X2[YA!=Z7./M$L]TK#VSU!>^@S/ XNJ\O<*ZX3^I7S_(B'Z]-.AT 3]
M!!U078H!X,9M53OT+28D+7+03%8=-.X:!PVF#AKZLP9&[P",7FE@._2-<QJL
M)9\L"4).^NI8+&IT?(9(.N%\HNC-.?EM@!T(2A%;!-''@[D/PB6.YA 0(D5(
M)=F^0R9$V2)!'USWA#1UL OQKP$R''.>@.DBTY0FI($#3<G/4S(:=[F+8%<"
MLL$O?"E^N@2Q6;N^R<ANP/^%I*<MX*L7$9&,5[,M\OL$:#\SO!%E+AZXF[+K
M*TU"UR&VR!M,0E/R.YX"P0TF+%V+\B65%,9^$S)W#6V?E'<B0O_O7^GB=U<J
M,>4-[ %0P[!\#$N I$,;YD^^T[!C;4KT%W:?>+8DX;HDS9=D<UI0!VO9E&J0
M/B;K3AZ%E'R=3-/U)_" -T+> @_.#,+!V@(YAI0<&B-'2I)*KJ0;KN:[+N,#
M,/@E);#XUPTAL?"*$0+-0-04C(1L5.0#O,"T28>$71U[$N=HUP#]!O],J<P
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M'C4NE$O9N*@4:Q>GYW?:#=%L.8 71+/E,DI"7E-DZ8O0 T(/"#VP16CF]_2
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M>=8U'MLR8_W;I,^!:<\"+1/\G03[[AN#13-"IY_"$:Z\Z(N#IJA/%++OX8^
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MT:";&M9S_07O"G,MD\I10F7EK/#0L.NYI1J;GE4:S JFY2PHB3-I'A]YAFE
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MCXAP(P&,')AHLA:A?B3W'YV0?=UR[Z&^L'0A*?XV;CV6Y)EJ0>-)^?$_L@S
M9/+9BSM92D;2)4,&A.009<EP)6M+4#&")FGJPP3Z:U=X"S+N8_N7<_Z(+!9*
M4SX^U* ?:?9PMH&BT__1-G#:1MZ29%0M1KB&YK3 Y+\/**(U:CN2H4B6,K*Q
MPSO:-A9DJR?;W9G+#(JVL"AG"E;S@9#A#.!K\1=Y>U2?C"AZE*!&4,3(D6O'
M54E:H(<Y8 XYA2^JJ4]P+TA^H]DC2=XL1EZ;2/1:_'>O7J+M6UW>;^%'>>H)
MO[HP#?BKC1\7C/*^A$-S_O=I;LPT*N94%7JTZ+0437"7[OJ!4("LS27=_N]#
MJ99_(":F-9><_SYH&^>'X<X5T_$'/!"&-(?\\=_PXS#GNNO8B%B0FP^$#:4$
MCB(?"$WY[T-''J5K]9922SQU9G1RIF_ 1+8VO>8H.:(??E*)&)-.Q%(D]Y]_
MG3+CX[:;"^//!R><7E2GSD'-_T9P<0H78CLWFA3S;$M_KCZ3]*B8ZL]+ P74
M[PHKR-] "KP _S#<F\@9F'"%6ET5[;4C2+7JMN.,C7RIJD*88"%,)&,,2<>H
M="J"B7>>'-V'+GW]UIOY%'U:M61[7E.["6%)IB?LW([WQ6;S\_=>FYQ,7+[0
MS0G;&;M9#I/B9D7S4*DXJ%0D&8.>1J11WWCCO2NP^.*-]U)(\>$[;U]*]&S1
M!DLAF^PN:Y,QVT[6$$A09(02OQO,OW)5PKF(],?EE-X+]RZUFJ_!>#H2S$@P
MKTXP(\2,!/-*!?/JPE%($O_YY7;PF[9K"SB29@!%D"P#4B(P8/O;HNTFMW-S
M!N)/_7RFNQ;7XL<:L)! _WV(G[%D:]UJ;FLT&BN!%G<;LJS'%^4XBB'1%(XU
MIZ QFZ3HD#'[?S>J#[=P%'3'..&?Y%X33ES >RX\ER:@.DQD9\E4NE_K+!H#
M3?Y<CW7#&D\IEBH6A$IM/1\O>2$_T[">,P\_Z1A'4C$VE7S#9[VZ"JS3?7I?
M@)7$CQ<V0'8=;04(!,7 L"7,R#9P'!THQ%ISIH3?8FVJ+8BC2PBO/V/C,QWR
MKZU2O4C4.^=:6!A&U BK(S7JF ?EI*[I3*E65+;#A#8OS^)9M^YNRY-")?L'
M,7 T80\F\--+MNT"!=(!LK8!660J7H+Z7FF.=<97F3.0TGQ.SUR#[C BV T3
MZ\)NO<XH_(A#I]0L%V,2GQ@"NTGU^IK^1U=ERMPNHKQW<[\K.'F/V?%+,.E*
MN@M^$TN>Q+92KBG-@N@^::PDK)Z>5QA+T%%V*AE+LA&87+;]W1WMU9]S##60
M.D^EF;.T9\DU2ZE<E2;5VM5LUB4R([6&Q2$E5E215_+;_,KDFU#!N(>?#$?%
M2";LXW]O!?N&N_7M8LIE=^M+ <K%MNOJ\Z30GFRV(U(C)\(R+66';@^A"3K_
MYA)DC*+8"$XNVHWL N<T-\F7F^Z3\C?'VY$H1J)X<5&,4#$2Q:L1Q:L+5=V0
M*-[.N>HW)\)7=WZ\/A]OU976E52U;I"5.D=GV:$^'O74J_"K.@NFVZ&J<IPL
M+)<"9?6VFI+$1RK,P\\TE8QQR;?\JMNK-GYQ;)M%=<>Z[AW6FA,">]=$AD#4
M17^ZX>2*SSRQO?9\BB@A\'K*9*[5\(ID^#9E^ KKH7XG\S,ZC/JUE7.\*_O+
MP>_R#J+.F3%CAJQ84XT2@%6J9\K/!2-;78]2;QTVW6I":;0[?$E;WVO"E[O;
M'6[!;XU*7VX9RRXFU5<EPU%=823#MR[#$0Y',GS[,AQ%'"(9OFT9OHU*NI ,
MWU89&8YPQ#.2#9230K);.(R,RL2N,-IWU65B^X)21"4L],<RSUN69*AX?IGM
M84A#VJ*/^#6D;WV!!MH%.-"Q2X9W#GHF/IB)@W:INK'6,WI-"3*KY ?327.4
M1I5C#$G&THFW*E&_H\I]PV3TVT69J'3L/17K&"7.I$Q@:!F_1)\S*%+>Q&O\
M;I9E9NY8DW>;)Z>3WO 01=B'GQS+QE@V0I&KK^^XH12W"-WON]0H$L4H(?MJ
M^?(-$[*C,I5(%*]$%*\0%2_MB[SI0/"0.NAIDMZ0-*5DG#HC8WY#S11Y6IBU
MF?62*22%9!SPEW4FF/ES:U<>]_MB01 VZVR9H>)=Y$Q0J8>?3"R13L<H]A/O
M4HB0X%:0X.JB$M&F]#U%,:KD^9A*GH_=2!)DW1U/.S1'UM>53;'16LY7!HYM
M,P\_6;B),#&.8NZYB.?XT,P_'; )QR2ZP%!,Z^-:+-[+>?9M9"-$)VP?><*&
MEO!:9R?O\[QIM8&UTN2S&?:]A35@GA5;)Y-MM3=\DFA-[ZQ'%(F.T%#_%>83
M^Z_<B^)%"?9W!S_1T=N?(0^V<=X#/&QR$A]K##\B"QNZ_.S40=;9J@AX4*=&
MCHZE.2I"GJBHY9ZY%^T;D0S?N@S?1AK_%3@=;^[6WOZ/]U1_MUZ8))/:#?K]
M687-C,:5EI:PZY?T%$BMG-D9Y:PTJQNC;F=1H76SPJ,-FX*N IU.Q]C46^&(
M2%^BI/,;*V"[M*_PX9#QE08^9YCB:-M^JI/)>*+8VTU[N>FXB?&"1:&%Z%[3
MJUS-]6'%75D8W^08_2]PHR:70$8GM;C8HRQ3D/-F.IGR<"/U\).*,1038[@(
M/:YR-=>('K<0E8R\R^M9S?7)\&V4:-[^F?U?[%I]LDC/E%R9%^*[)A@]KTAY
MN,/>,3JN1W<B<C&.>2NB?5L%K5G36IB00>A>1 /.TXZ*62^<T/7O6VI6=]6'
MZX>.O*_%R_;2?Q#^^@1/Y0PT"(U)65USR:502=7R*=4>#$=+" T4.F*G$K%T
MBHXEJ'!*Z,<ULKM)??J&M4RW!"'1 ?D?H <V)WX+/+;-\5HJ<-N.N!0UH9H8
M-@'57R/PP,?D,1;^+\&%<W2^.7A<NBKPIC;C&^@<^W&[,=M_RFX7-9&95;@4
M19><86)3P K%084BR1AY)C+]S;7I&V[%MP0@T9V%7[,7MU@WOV@EQ\Y,VV0,
MW6RZ;5!1$72@VPI3K]Q6^,VQXW8K'N\P&>0O]U)(W_\^Q,]H1H-.2&1[9&YF
MA4V&8[>T(:Z3>%-%N2%<C&2H&$U&58_?OM3L"DOQ+[W)7B3)X^\VQE=QH-50
M1?=Y6A/$>"K7JBZML2D,<*@+Y7Q@'(@PX+MCP.U:!/>;O/%)>$#W-;H\<"LE
M 13'[HC++U/6VL,#E,N1BB48,L8PZ0@4(E"(VB%$HG@5HGB%[1 ^J/OU%=7V
ME^#6H4DZT7#'NB83]<D$H!V'@#LMW'T58*TMR!Z+6$L6;@(<(PS@H)L\__>F
MTTR"-@9^4"VXCC1KVN&(4PTN?=22E\OYH,BG2-JLJIVY6!RV5_S#3SK&L'0L
ME0S[U(0LV5-"\Y\,UPH??:.96-^]54*4%1C5348R?)\R'%6]WC+W(@2*9/C6
M9?BNZJKN\+#N797;D.KX3^?.J]V2,=":Z9$H]IZSYJJPR?0F51XM%5=LQU(<
M>S;;)=*4*UC-5:)]5+-]G<=Y[ZEB>0LI=I.XFM"87D^L,)7E8#W2$_&UBI&"
M]9$B0HEK7,WUH<1=617W>^#WMX@Q+M!)M=A(">12VU9J99#6TL8:(P8ZV6-B
M7)J)T2P7P<8UKN8:82,*9GT_KD=4B,J[+U[>_=8VYRAM,\5OBR6Q)^QZ1FY=
M8D<E[$+CLFZTS7$Q*D'?35UW#3A$U;0_[L3P)O=D?S<R+058<6_P#VJQ(6Q3
MUQ3B?TC\SW6I9Y2M<@C+7XYOU[>Y1*)\FZ+LGZU$?+LQOD40%(GRG8BR'\J+
M^'9C?/.]Z@B"0F=7D2A'HGSKHARA<B3*=R/*U^V;_OL:FG"\>538 HZD&4 1
M),N A FZ9XPRJY(LK=+360'0T^UN)<PS]!]G%=2 4S)D<PY08/"M<K^\-&VF
M!4U=SY*K03[9GG6<^*8YHA(CFGKX2=$QCN%BR73X4/ F>F1<G_Y\PR7[9R41
M9'S:4<F[M3U5[3%6B^ZE1<EH39=+1UT5VFNL[<Q[M?WVZMC@(S.2CDNK)(?(
M 1DCKF<E)*B8]P-BRXT>CT8U5[=\Q'^'%0]'[).A_0.LZ]J0(JF^9:F.*EAN
MF7L1)D52?7]2?5<9U+]1E\7;H_KD(VLK;'G,3IM.6B'C]:RS2&RZLUZ?__-"
MK*,W>,57==>QT4(A)\[X1^6RR+<;7?-YYHZF&S/W-.B1'75$,;C\BB)C-,7&
MN/1;N6.11EPV3?3Z<?[[561= "9^.]-T:NH*L&QO(F>@H<?HA7J[2#V)]9FP
MRDP8LL;,/&A@?6A(1K!PC:NY!5BX*P/BBV#A[9JKOMS=*-4G3B6ECJTWNJMV
ML4=^+D1L2_TUFS<S)#G?*=:LPQFVU>0Q1*0>?B92L323BB42T8W;5[F:VX")
MJXM<?<;IR5\"PRLGK(6>N5/SS[HB5$@I:=6J3=>E_JX\Y24BO'KP4AGF6FYC
M-QV0=6X,>ATNOU.>UP@:T#$KG8RQ"!K(<%?5CSMFC;#AOK'A6Y:DA9 BF;#-
MYS(CKL3>;JLE<AR5:O?7G[KM%WN9S6JI*E.R,N[:6Y<;&WD#;_O^H2J#O(,/
MNDCT->Y?N 8-!U?B&<D&"H%0&1@V/O^^A8R)^[U?]+;S^JXOD^4;7JH5B?!]
M\?/2EZ1%_(P@*1+A2(2O^W*9&^)G=(_$?=]U%HGB]Q3%*T3%3\Z1IT]RY.D/
M/0W:Z;;,:?6Y3<[I9*:[>*I4&.GO8K\%=,G)F=Y$.!0R1I&0XT#(F;A1=OF<
MG517/$O.M\Z0YK+IR:K#CR@6'Q>A#IY4+)F*;M^+H"#RP2-1O Y1O,*+MKYX
M5TKH6VNW4O()LL?HJ5:/JW?8]=]U?_[KG815E*PJ]#;*#.0G3*5G";V^W$0[
M"3J!>,].\F$'$%=T7]GQF41PB1?AF$07&(II11=LW4!RP=VEH%\?HD?7XD2R
M_UVY'A7=?$>N1X@7R7Z4-G:7F>=_<:78WT4?PR4JSUU+,5I\O$PN2XE!6GS.
M-9OL^I.N%/,^SYM6&U@K33[;%SV9;BX,9P)J0AQ4V1&_&>AN#SJ)2:^VC6)B
MJ50X__1&->\.TT^O"C6^91G;Y2'CH^Y/> ]>%+J[YTW!<#E!F@U4NY$WU-[4
MPPM4\$9%UXM=Y6JN#RONRL+X)H>;?X$;H+VA=^Q.R(B5N9,OESJN_L2I&#=2
M#S^9!!ECDQ%V7.5JKA$[HKA<),.W+</?LC#K L>H?[%GY=2V5"UVIWE!LVUV
M6ZNHF9W,HST+':"B/2N9>NO2[=NZ, Q1!'?#-">$%S%!/\G8'X$OAJ0D(+>)
MA07B$RBO0"'6DH7.J&U",P@+J)KM  M^K&@6D!WXY0E 1(\1!D"_$?][T\(4
MG!77)WNQ0M3*FK83DIT:),RHKN?(RF186@O)A,PPC96ACI7UPT^63L=29-C6
M(63)GA):P 49/?@6TE&B0KGKY,OU;7G?L"HE$N'[XF=4971?_/R&D!2)\'WQ
M\W9+0K[KN>Q;]U2[,W&<HJ1*=U9O=U-/&= L3&CH<W+>>6R,8M,QFKK-\H_K
MTYUON.0K+&:\ZD.62Q[(O@441GF[&B34=7,&<K+8K@X+]:G2Q$#!^D 1@42T
MY.]F4WSOD]BW &,SR/8K93FWFFG/ZTX.E%EZV_(L"]2'-)9,,S&23MPD:$35
M?%',ZDKX&8EB5%AZM8=8?[IWR,EM9Z.N,GG2S<JT,A1 EJJK:.] )Z%H[V!C
M5.JM"S#NL90T*]E3'=@VT?,.0@EA RQ9L\&-)DE$1:2WG+!S?>@=E51%LO]=
MN1X5TGU'KD>(%\G^=^7Z715TW.'1I"1O?G$NZ?U<,F0+2#;( >^_G2EDISH-
MG!W?UPE<G3/.HM75LG;%JC4$%VS'C-WM3<<J=!93^ @SB>X[NI="C^O3PH@*
M42'J59]['F#HY :5#\*>>;=:8[(DQPMNK5^D*A2WY*MKC#WLPT\NPIT(=[Z9
M#?3O3[B)[?8.3S\6=;37+G23Z-3"+ F3]2S;I8R&.*R!;8G'\),Z!S_1/6[7
ML)IKQ)$H9AC)\&W+\&T4N,;OZ+J]QJ$T\]-.)&]2(:.,EON"EF]8M1.)\'WQ
M,ZK"NB]^?D-(BD3XOOAYNTG_]WI:]R+R!.W[/#;OO>.Z,_&G5>)9WB8&*T F
MU98QD@J&PNKJB$I[U8,),L8EH[*@J"PHJAV\_3.TU\#A#"P(B7FEU-2?Y)DT
M-3*5#6]NW/H:PP*J%4Q$Y<01)-RHT1 =;[T'$%X]L#+M2EK>U%L9P5VLAVUU
M,F\)@R9&AA1JYQS.U/FX(ZN;#"5^2Q6/0D^1*%Z%*$;U@!]3#_B[!N1ZIQ7I
MNM'8S'ISO;P$9:8PD+!?B>K_J+>*QO^L">H55?G5@$-433NZ&?+=20ICTU*
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M'X]Z?]S\Y7T*R Y);NW6Z8:0I85RLV:E9J+4A J8Q K(,5PLF>8^L-7M%7B
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MS7)M]&=5-\=P\9#4"IAK,J(]I/C^8;*$*3^7GB'Q%,VVW(7'1&@0CWW=@/1
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MM,OK[,ZM<M6-Q*-DPL=PDVYDJ^L(>#U$@'2D.0P&]&M@@"*4^TM__+CT?K-
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M6R!9!,"[^:E$O$>H JEY))XD0U+Q\^$"=10P]_.@CL4IE#&C(4L[B%:\'DS
M^XU'0(!L>,6+1<!5P9&0<O)II. T_08*HJ/I.+4"G<=[T7S_*$[RLMJ]7!:<
MY'L2*,%I''"T=;(^Z QX81 XR=GQ9/P0U61_B0C.G\&WD2%["5\K.G;Q/) @
M0,!':\-4LETH/:=?]+_BK1L*C;22-!T3!3G>,HK5>)DJP)K#F7K2 ;<'''F!
M.S 4._@GVX^VV! E'21@<)ZHS 8.'9NN<S:-)*#*<:0')W>H)IH0\H^ A8"D
M,WU1K_!6VH@?3PREC>#US]$N%B2/[*493A ^W!=FG)OCG]$X6[Q*E'0(>0J)
M8Y@>.;'LOY2[_<)>#5\&-(9L@+)D3UQ=/W8:L6!*7L;+/CLBE,VQ9U20JC'>
M@Z.7<'Z2A7R#Y1)<5"X1E4O\:;D$%'X?3+S\T3?3X_VT]T^BW''J]CLV.80D
M>=/TLB5SEJL2O )9KJ&T5KR4X(PAG^/W9PP(CB%*>!EAAZS4X_Q)UYF:%C[3
ML"!L8*##V<D6 E"(/RL-\224D R1_!E%K5 @7;-G=F"I8[1&HY!7YI^NA3.F
M-4.!R M?OS\^\?8DA-"Z-M=PP-R,^7FE )L2J(1?QTF7WDD"]CV\S1!E>A[A
MZ(O#6[@PM!>C:0%'@ZNVO:/%-=RTY*D!04+U)V68JR!'\?3-,[!%L50;52;J
M.(/&\7L)P"<=Y\#MG[CU,QH1>FM^HJPS)2!SCG+TCK-: Z;L\TL] ,=_.-A?
MOCX\[J'\6)H_O\*D#3%:@T8CW,)YN..Z.%.L8>K(C+0[\%T9'=]T[*M5=Z@G
M=;%<8V9+<F#/.ST[/5;/5)V<'Q=5G?@G2Z=5)VWQZ8EO#5#92;M4J)7RI2Q?
MZQ!\-EL7:QW4'*E1KY:RN#627[#QV6(AHBPV(7 R]NQ?5C="OEW/#T5:Z55(
M27&?1:#>%$-_BV6BER*P)\0%:X%">^_I3GMVF5!$@'^J"_>=A>3O*W!%9PUJ
MKZ<*/I-WMAZZ%7B^$<"5#4W_O;,29)(='%&,<-!6G@?%%-BR]?+*$7C#"9@6
M/BJ9(YCQ(CTX3])+OM<\]T#S'Z5HM@P=.-=+_/#P1<4I :]\QWL+MIC?<E*#
MPHMSTP%>.I*-"AJ"V@9OG+9/JG]$5SBZGHN(4^$#@^8O&.3EYJ.\$+B%^%Z*
M:1\1]_$M>_^SL:!D(!NB(VWPMK -;PJ3Y<85$[VGIIBM:&YN8E0SB1Y_OZC@
M$82 %/EP1/BC/)T3)83_;[C[<A)D5CG2AK!\M?BTQ+8_;C3S.P?K0K"FO4BB
M^SZRGNT!5?2X3/9<KIJ@)9,-K3Z3A/A<IWIR.M\KI=<//\,!ZW\$=5Y[ ]D[
MNSU)@WE?O"N(9?F X5<(HJ1KGVN'9^(G(L_G''1YR 5Y"9D#/2%@^Z$*%-:*
M77L#H;@-9,1;Z+$H-C!"05,OK)D'4 $E'2=V\X92-2$/(9/]+-$,,,!$.Y^D
MRW::U(;6Q+6PK&WJ;;JWF%1*ZL-/PPS'5H,8ZL1[&_(F,)$1CY%>(QK[.P%.
M,,(YI!8" ^607_C933/>#P29(#9\+C(UA=XD<@JAZONI9O@"F'TMP%%"EX8W
M1S]2[)L)H8&OQU)?!OA11B8*(>*D3&P+: YR,^?PFW#CGJ$0/_S8P![B/K*&
M:#_V^&P?[X1(0T*36>-MTX]]6T#2(?44/]D"A=H(Z&OY40'H^)IK[+1)JJ09
M-HYHHIQ1@)4:O=:W*T(<?R3:4_RBLR%--!$;JZ=W 5'L= GP[R:4$J3DV)Y"
MS_!X K?J\*((&0KS%A)W#975]FOVQF#O02M>>-N/7IMKPZ\%\=Y](0%L0+/(
M"K(R7Q(H*-[&J7ZHUA#':%XF1YX*#ZI;\)-($3]1A#@@0&#Q;8,2[4=TZH2B
MW.%'X%BXAY@2CB+#I> X.IQMH/M'*A_ *A(@_+#[@-;]5OD.%)W)MB""OMX4
M*O,M5YJ4JZNV^PJ*_C58$KX99>X/:GRS_9B'"Z1@RCY9UQ>RN5<%A3F)XTV!
M5,$_:EZYL&_[',W2 E!I@CKXK[:A_:[1+R\U>\6@+DWSLW[6:>2$>;LZ2<HM
MIYO,W;&;G44G/X9S<$^SJ##6(5J:/;L* WN.SH;0ON'%'8_/K5$&L7$LXFAW
MT1P7YVWC&.M^)/*PD4.K$.YB+\K21IN[<W^#0MNI'^OT;2%H3.*P-]26X!@J
M>^B'<10B+F7W=0-G,\V/4[G1Y[[.P>GC,T+)"_[YOK<);']?Q4>N_M8-'V':
M7JHU>H)]"!WBB#%B'-[$3*\(%4*S@ZLZ; ^;3\@VEU#/ Y3R<4*&@$ 8[P-
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MPOM//.BLTB8:_(#/5 6"K^70ARU1R!%"OR'4VL)'W_O[.Y?C?IC1YN>W(RA
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MM]M(7ZZ1+^PC246,N3[&1$!VG7R)@.Q*^1(!V:<RYE^.A8SF#S.0+T:$U+D
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M0'4_(5'(J_[--V\_ ^"*@C?Q;$RKU#!B.6;RTP'?RL\FJI"!>9(P%L/#!!9
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M$2XG'H"M#]&\ V3C3@-@5 @%B,3$M6P'F@+LF<I)"(394[V]F9E"S$%!4 Y
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M(5)LU$/:E'4&+@.*:*KN#*1>";*J08D+']S:LW(9F34,MU,WY(PV-Z:2%O(
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MX&='ZX>O#/$9%#4T!_HB"[R(B 8OA6@9<!6^MS)VK]5JO_(TL%C5 :K8F.A
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MIJN;NHH@IP79OE=B P8GDHDP3F%@@IXM"@H'1"LK&3 #: 5E.RBR4-$ZX\B
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M]+FH&%=2^J6LO*Z>T-#8]+6YI;NGMZ]_X/O@$)$T,3GU<WIF=HZRLKJV3MT
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M/F\6/=A+.FNP]T#</L5VK*%</7RP[T/B10; Y67CK'BH)WO]4@L#B(A'WF<
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M)?1*V4YZI?'XL@#2LAI4>C?;.9P*6?"*5YBK[5%6&;F8Z>/Z7/;,8J^8U7B
M.0DCX!#(2?Z9B77R?G;G_6RG6EM?:\AY=^S5( [8&<TVD[=.26FRG<6+-K5#
MQN+;#Y;>>IOEVGIROP_]>DHZ<M-R8D_\!+/&'Z=T4N"Q#]=O+9CY1SE[UW\0
M-G&%B^Q-!HXU'+54FEI];N,W_9$\&D61KH=^'@@GDM%1AWH]6^<M12^7DCS8
M3!^4*+/Y?W,*^KRW9O/<ZNI^HQJ!3=QW2$8H:V>HU0B>KU)'F*"%8I4\ Q6
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MK!I'"2,-R)B(AW0IVN[$&C_9F+Q!QU)3JUH[)Y3O5'.P!"^A22']U:O4B#/
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M3(; .Y=P;1JW^BQO5:D+>95+OAOYMK(XLJ=N_LV:2+,<SKOQQ)1)@C^&)LL
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MFFS.N$QK@LL3(%P>N[=$62B/O95I(\$?E'$Q12DG)[Z>=;N#.Y\TE].IW!)
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MH<!5&8MGNK!8#O2A>[*YSU&AK"376:]ZTE#)H6C^HD30V:#9[28W$6R-@BC
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MTB;.1=S]RJ*P> [[<:(M(%&:_-]%DG-HY4B,.'DPC.T$8-+;SB(%Z?N'59$
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MNKN?3)<SA[=6G>P:'ZGJ[]3?CEW:0!A']KDD1&W2VVQYVB!?R) %R@CX6!.
MMZ/B^4*1!H&==2*@CYO/:A7K9!],C=64VO]8L/784UC$)/FLMFKK<?CC(BPT
MQZGXK!I,-?E\$Z)8W0589F4:]E@VQSYUOS8++@C)U!XHH]MA-+H!\ &&(0_^
M=P+8=?]/T/]?R?^2:N=_(.7;]F[)W=)@:%_]A/K7[B['UE9PJ&-QQ!M9QXL(
M$RH/;3!E$WK7"9;?TR15I[!U0Y/S\MAZR"T*377T^%S[^0H/.,\L3M<?P7\[
M(0#RB3P,A&*2(-O92Y9W$H'Z[$"/66 @#(H (/7@!_7<MNHN)C$O-^66VL?G
MB]S)=@LD?_'+(XI3@FJ*%15#NLPJZ)312:SUH73>E]'I[;UJ0<)3.%[TV+15
M@:JAYT)03:ZJI;_8ECWFZV7O\;?C<]'J1LG:#[]Q\<5^$<K]CVL>@^@V7%(!
M ;B(/0 =VUG._OO'_LF*L(S$\%I]7L%0-A,71 /MO\ZWK2=C>?&?YXK/KKJ7
M4/?\J_7LD_'_L)970F_[[VQZS[/<50GV,LPSF?5].%W[B#L+\>LVG[OZ#Y0$
MZ06[UMWY("(2]'CA:6NQSI-0[-=9^JGUA5H 0S[=3?5K%P";J?8_R4/L^!#<
M.#K(O'J7]=7#&R+,I3+;8CEC+ JF(_(" +M5WPJSPCB[)SPAF\?>>@=SB:_I
MA^/PQK?&[I";W+?,6Z*%4Y^I6A7C?_" %KL!;/&#9Q[2P<:,_1=ME?;::9,.
M=L_0K=27?_^84_[,+W9NB6U!BP]T[*-G%+W"O)N?T^AN#-)W]'U<LQ)9;Z[5
M%SGF5S&AFE#X!_/8?T&;QW&O3P<8S\GLH5N473?^Z:SP!%7$/U"E*O=_&/4E
MI/]T#%AQ9W8#) !=OX)JPP\;@"[$/Y4P6M9S(G7R$$Y,8)I3752-"$]]J>7\
M?A:?=//3J#"59WK<G_G6YX.UQ1I*IAO7G4C5Y!&'"5&\OC2['])LYZ9.RAIG
M'KZ@X*BEE7C\1$I),+M:77+>O;2Z,ROG6;)$^?6_O_FF2I88NCJQCD\YSFU)
M!K!T/S:&\H(BF"\F#BV"ZG^WQ713[Y#,.'!<FF>5 F<=BS6A4D6NI)PNBQ?6
M-=ML?)@">G-T%MS4TKORIOF*-S=K>$I(-(%P\\1[__87Y8_IJ-7II=E(]@@
M"<1-J22OF[^KW>9Q8YIH,SD_7O=G[ZU-^J%(N9,&IX;\*,8=9FN(T?2<RT;*
MZS#GM*3/;G^L9>=IAE$-[ZK^PW?WU#KQ0K_D-Q#[5(.8:K1;O"UETWK6[\\3
MA[D@D=N6PJ-O'?XM59JB!/%Z#3$]>_0>Q!MR_WI$ZW]8I)9\^2^@(C#[CQ8U
ML&)GRZRQG43BU^=+O\LQ BU;^EJ]8N"F+*<O"I-[E2*K [?/+#K9ST$6LR1
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M5ZYL&^3LG*ZFKS2YD=T$NDE6U'*LE%CBL<PS+7U\(?.-EE:"2<1/,\;B01!
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M8YE5J"F'=N0U.:'Q2)9)V-3AR(.S#K!H:VWCI//RQ!%^77/<H2)G-TE@<1M
MZ5]^YAV_P5T6*16>#XP2C^ )80I$OAQ? B3[JKGYR9Y$FE%XWD\5;+A:]5]Q
MG]PUDU AQSF]SD1 <IV3YH<9>HB?5RMW?KN^7[*_X8]O-M7*[<X.3?@TXZ:J
MJ!K\?8.UZ/00LS_=RHTZ$]4-Z_G4;IO$[%\YKA9^E;SQD^F-'&.OTIN)NG0B
MMRF375B\N7&B7,JRW'[VS[)O_^JR[^_G87W9WZBS'/WYWY)Z?X<2 *4KA5O
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M8^2OE**]+.O*>OH+%1<F?.VBWFA< ;RD2*/11@[:X1I%/A.2(S#GF2?*IOF
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M_3 ]#G+/KXG_JS1A>T-]N4B,D.IQI;0(Q7#S,HMUY8O2EGBFM7DM33O<^JE
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M)K/9\FIO<V#0 F8/E=BN<TO#>BV$>=%N?%</=DZE+-4XO=78%#>4,L[PZ1V
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MS+&W@)Y/^-HM2HG<4J)45,]SK\I97U69^[UO65)1^C7]8:NNI39T;5F7$S5
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MAA^!7\@2),VPOHHO)_W/(IWFS"'A^8?GQ/T/1?]4EN%$2/P[FJGOJ<6$%E;
M7@$!NAK_H&N?3'*<39<K>7N=9WI(ESA#U4[\+K%9V0OB1-EY7+40BL>=$)D7
MKX/*L$: U4&[YUZM-G[*WTU/_CI7N%KP%G#_7VOF6S?J2J4A6H7J"\:;EC@2
M\@@""-R0#/P?:9$NZQ_-D.E_TEQMT.GK=;'%\#:C$1(\]&EQ8VT*=2<R&7GO
MQWWZBX"BMI1(P#J0T!YF)-NEA6^P8CQDZ^U2L* DTCJHN^Y*^Z6<A#EX/O(
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M<4VY6[Q(F54*L+A<A,8P,V6,NX$,P[ <[Y:_-Q+22 V S*KM80&=LY,?UV?
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M'=U_([V'5A%?#LUE/5MD53]2?ZIJY6Q:4M7/RRY>!I2LNXP$\&??KB]7, M
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MNY\$_IS9SH&V6+:V$JUD9A=QUI?+8- [=L4%LY+<K/O48_6C96%$=5&@/1+
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MQ^[D SS\BITDTB6-08?%81QJJ5EG2KL9_9/BHZ3S^S/UQ^M:Z8[Y3]FME <
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M"Q#(%]]]SKU[O^?[[C[W^W%_W9FL'YESS#&>9\PQUQ@S:V%^8I8!"F5Y)7D
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M925Y8Y_C1H!92\0R;ES4=QIS]73E6SJJ=N.#S%YAFM^6UT29'AWOKJ,_AG9
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MT.AJ=;I[D^B4Q%P[FK0?@\[-"^S1"939(*Y[GX#E1(Z($?PB=49K6,:#9L2
MJ-YT\7[L@=W;3Q/G?(HZ)/)3#&L;7(0E<@5>1>U)S2*35<22#=Y2*N8.^(,G
MC<Z9PF)Y?&P"/UN'NEIZV4<L7M."R!ZE@U=I<]>>BPJ6+.GE!R<EG=G<^O'F
M>Q;9,G.-XA8]7O"=2$19>\ =Y&GY&K]$:XG[E3$>K"G]K4L<3_D;9:HJ$=_
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M123^T(E: %"!KJ-=6_ \-Y9BE'I>NS$*)/("DIXQJ<'MLPN?[+U@:-YA258
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MYB1NM0R542OEF9KG\UKI"-Q4D! CMUQZ<P4!6,,WU&:_BORUK,B\A/;S<^7
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M=H"4R)R9YS-SJ5TSW<G34Q@LJ7.NC^V-$EO@; ^B545I(?0[;F\[>,?E.8*
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M]R_@YJ15/%[N&&\ PU3'U!+G/;.,FZ:.)OS$#KO&/#2EL^!1$6U8=6^A4]8
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MA1DR\T91TDI>TN 71.V8IB#,&PDL$-*7?D(D#%WX4S7QJWRX+EG$ BFG<E@
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M$I4P%UGTWE/(@S4I7:?*4HD;)+8;2@\^U&(@F([70$5\]GPRC?-PR(_B!1;
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M9IM6X<^>!\CFH,^;J3ZXI;']_%UYF+FIBYT3:;ZJOOYEDX@G%SP=V[<?)BC
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MR&YZ%V2[:%D'^G<3BG^S]_Y71/_(O_V_@I0?1FN@IX.R5*^JNN%V>;PV>(1
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MT35W<1BBG&SF4,O:9:NOY'=MGGT<L9YCZ@V-[L3T8 'F HP(ZM&V6B3OAJ#
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MGL%H=H=P+8Z;?E&=?.O>3&$(0%?,) R\+4/.>4=XA>+<\NL?^9[2WT<J-FY
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M55.'(JV7-F#D+_&N/2/-. GBDO+]*H;XGMA,JD_GWT4F1%;9U5&*]E9N[S&
MH,JVN4_\(A>H<S.HW^Y/9VJKJ'LA <&[GV<?<#RM[C2?KPV?6+^((WURYZFL
MT&T1NL+KHR@1*$KTZU5U1'G==RZ3(TZ.?VMY?@X4#"X-EC;E)XM3D!*C]N[1
ML=;W$Z9M\18"7;MG:Z#1_NO#,#D!!X=QLCR+@CQ8(,\*XDN2DH1E+'13]'<*
MRC#<#I%E;\&Z:_(_'/B"C6(<+5UI4F8>80=;1M[.B:9?QQV2E(,C7G^Y\5>
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M?!F[ J!\==2.7T YY>\YVKP.1&>O +,?O$Z" 5NY1:R7]XH)O 8V4+S>NU<
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MASP/N<6K"'%?-+6KC)"'M^B/"':1V5Z/IQ]YZ-7?\%D;@[.46B+W:#$_N__
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M-;A$A2_6&O%3+<?[O2UUGUV+8T'5V.3;S-G8V@T$=B;V18BM.#"5-[;+3RQ
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MF LHFY2<]8=1FX::8/(),_W&?NWZL>ZZ#7+;*RA9D*GQ/5[!R_#]K YOD_N
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M2CED!!O\HE3$C+5/PFG4>2 V'3BVZPO3>)A^P^B7YF_\@P(:3#T5TZM"8J(
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M3>]7*T /%:].4[M[YHM/Z3[5XFQ\A^'KL>Y)\6GM^UYKGBJN5&,^.\A(25/
MS7M5H"$_O-SNCJFUK +REDISM)]U[&)U/[+O=#;ZQ(/ 1=\+^^.5HT8$D$PP
M;"9HY>MY(!'0V5H=/L.*$@&.2B)0A^5)(Y#S'=T\W:,[V(>MA>AK0QN( &WD
M*O)4V8@7MA0%P@_Q8:9#58E OA]V\P*?0@1B1R[@'W:1&#$BD!X2$!EX##I4
M+\QKLR8"$5W8I0NNX@30 0I^[IR ?P'B(0(C+9 CPOD#(M#C2AA&!8#QS+ ?
MZJV:K6?P$SZ3$; TK.L9_H 0-]8+/T8;$6[IGBOQQ1.!WPMJ040@5(@(K"K
M7-"JLN?70!M\=KD+%\/G":6NU:G(_PRG8L\!AYV WI#)%HTF4..;NC@]UT>M
MI?>_T+A]KWVIW).;11(_OQ:N,&D7]5JLN@VT0<^EX;YTR8!_S"56K;!_3:SZ
MDPS(2_]"OSM'>.1<'!/9K2[[[GY;<B?ZV(!\ZO4M&3TMSV\2J"NO=(L?;N5'
MEG] UEDTGA:>I)M5&\9]6[SDDN9VRS]-TW_&_9\MTP+Z=\/+_;OA'VA#F_X[
MAK]LCVS^.X;_5POTW["\6+74Q6?"72O"+P(E LN2D^"?FW57QTXI6+6);E!
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M5IF=^7LE5?[J/FEGD?;A?+FG=QI'[RL5)LG#,- <]2H/HG&(,L'_-M/BC*=
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M+%MMGU5#9W:9/Z5O_NQ.=AN)*^O4$'^^/#ZN0Q^B%)@:'/^S:E*F7R!#R.C
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M54:$F^%=T44C_B!]SPH+X08+V9Y"$/7VV75EFY/56#"?6%/IB[\#-XM5RGK
M(6B-# "0^.S/;A'5L7":3>4[]@X; 2UF!S:[^Q_[:_B:PH09)WHI[JY+#(KE
M-8@JFWJ]G-WT[Q!G,4GL$<N+C?@_SH:S_U>\M:KU/[6_*XW(@ :9"Z&[4WQ
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M/N,I*:FTYS04*N?3#D-P[Y  F0MBN 6D&_KY<H,@<J0]MEP;-F?D7C2CYYR
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MQK/W27%>1K[9D"M+;<(*&10R)=GRSW/14V.ZN[H;J&XD/1G45/D!@2E [)]
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MD$<FB65/H %9U[R,F-IAV,7L8589OH_O"7&"B7Z2P*E:XI7\'0%Y?R(@XB<
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M(G2P\;Z\!]C:6EY_('C?1H<@UL]-D4$17;^-QH+CM]'LS +P!X%.D:Z2LFW
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M1[K51?@J<A+XP[$]3E/3>YV91M!H;GEPA+VM)ZRV<1BI==CCB&M YPO _RP
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MFNS]*%+O0_+)P+0"$L>-_-,%GME!R"#1@(D,:&<=R&]?6$QV'T/^^7G@/U_
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MI%!$3Q_+%NDA;75BVCJ2<Z=AWP7\N(>>MKRX,N$9$TM^XOQ&,H:MF0R<P+M
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MB)#Q(0./&7OQ_6VS;!L7,4:"">B;?;6.,(R54G"BK##\S$ <7N@T\BN+KWA
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M3%ML6!,YV\G?LID@EV"'V6+5) .CGWV>A58F=(T]3'C+_.'KBJ5<PK$\GC2
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MN\5'N#ZL1*429NL)SUJF<&%W=8^FK^BLXQFJUX%?;U4*K/H^0^SXN>*G<PD
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M[UE<ZTWA@69T-P.O'2S0C;R#VJ,A594P5::^1JH&X]KA9V,IV5YZG@\) U4
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M[RK<S.32XZ0E^U&&\(TO+ ^=/@=<>9[D[\F[A2'+XYZ5/&94')#J3'^.&O_
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M)<QTQ=6MJJ_BYPP%S^SK]B+2]3)7P;W;BZETW!O!G\-.^/[E*H5:0$]E_XJ
M!MXEF_ZD2<'K':0<$^&G*_#N/^=KUXLN@%A1CU,IOQG[_B'2RU$[4?BI]YNU
MQG_$3);JOI@[_&!,_"RG[O:MJN=_ ??;^]6='O]:BJ=H<E7\=XC5%MHF&_B7
M_&[^V^AKVW]#<2!1C+"UUJG&YT@=A+Z<23IOTY'//0'S@GHFY0NGWP8?64'P
MQL(3"7SHNU*81Z^K\0F]K*0)FMC?.DU3WK]DOB5E1#\)4VU_=.5O2)^V_8O9
M0@43EO$5'Z!%9OI2H'%E9G22T#3'76,B2BGCO0Y(K)?E;$SLCF_DL%?H2 'C
M'D*4(#*NK%UN*5"R7:=/FJ_#>_NA#],OAQ&L[%S/SU'7^2D2Y%\JVH%W!?^W
M@?-O[/B_B".W:7RN288&(K-Z=C"%S:QS26'$?4789H"H.:=';-4^<Y.O[A3_
MBVF9_$^P8[S"_P/$_*\I\WCE'. Z9]M[H;K%T4G7M%L:L)E]?7-5WRM"R+,/
MOQ3:OK:C^>5I3#?RX[!X J2FDO_7TUT%)JLR*6N6P6Q&"<!"_)(FEB;>U6>+
M([F\2H,Z;?E[F@:;Y!U QBK/YRM!\&XPG$$P-G^IE^?..,'=ZXDN^+U;4VT7
M:W9RI-V-EKT<D1KPI8USP/]F>?<_!V#:7YV*Q,+RK22:X2$]8/IP0SB2[P?H
M'2@+]K>8EZ1SP%8D7*;&M+/:/4=/_65CS3'9\&_@]Q:A+;\_LJ^V*8YK#L7.
M :D%.U?. 4X&%[,8]3](<RL2O["0P2E)BE;SLOG9"*KZ1CGWF8=**,VY H_5
M5GV#1<%>.A*"&@[T L&$[W@PN@TS\9?A-M!"5EI"6;#O0?F\4?1/KLS2E;A!
MJ0Z=3V73EEK: ZO@W2886\[[H@?!0]#V%PYQ)NZ:E(Z91F_V@\;95^996_"1
M6#HTC.<*#M(%AO#@>;N'J_BGVKG]F'8"O=2O%->E"N\*^?1*D+\QFV]^CQ?O
M[[A,9,3SH2OD"#?F12?>UC7&+6=9W/C8[)RSP?;UV[$15;\&S]4!-N:J=S .
M/&YQCH..VM662?JVLIQ'Q#SJR'C,4E^+3:V3G:;V%?73-%2K:K1JO4!-=P$#
M5*'R -CD:L,Z*E99Q9MG4"!P,(&QRBV[J_*4 O!\OJ<$X&-;/_R&Y\Y9L8H\
M--8B1N$@B=.X>?3Y[]<!,GFOHN0?CU"RQRG8-&Z#;"D(,N< J@0#?"Q7Q@;Q
M9HI^]D/H3HDY!A&6NH#0;_&)<GJD);40OZSL@E7J];=EW"6$8)=ZS7+(FLO5
MLDZJ8LH\G.L^7SWBBKZ1.? PN3'; <LW$%06OT?PPQ2PFKOSR#2.>3U?H)V9
MGFFW]'KUZS;-;6,]G=Z=+W>C ; .''P@E +?L01)XKD^T>Y=Y-JZ%A.EJ!KE
M6>-'&J-QMSC_>=V'=+IAR:C!TR[OG+T.-R"[ZSF@(7:[&6OR^).Z7RD^I3^'
MN9%PJ7:H?D"1RX=.Y&Z]K3J!^2RG_3:V&1T:CLX]8]5!^BG)JX[[*56PK017
MQ B4I-:7VU-)] ?;M]<9_!RRK/]([!Y7UBB;P=N,#QRJ2(Y[Y+#.@:D?V5AY
M)ZLX*Y ^N_61B^X%P:B"((J_BBM;%$\2*VGM&+UP;ZVA(/,6/D5$RO(GS9'
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M;&SE1C:4&S @#QWA2?P0#+(#EUB8SUG/65ET07S]OQY=TV2L^-;I>660W1X
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MX\\!OL#$WYQZJLS5*9R6X""L"=@/TM*L379XBYLV /:A]]H7]LJ4:2'4-,P
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M("![=*?+\&B>_\.MGDW]:3M1>.I&^ZOI1S,Q&F(J1GL[?UIG0:KY_HGPQ']
MZ ^ EOV_9RW_9UN!?YX#!MO*X4B=<T!5@.J_]V#&V_[R/T"H\3? !?V7@"M"
M!?Y+VKE;]B_A_?^)9FLJ?]8!2F_G=&5PH*=:W5##N\+O*F_N[K+<VK+=I\E=
M5\WS,9WZ(_M8VR[_"G9@B5 W2_"<4/8N1_V$!G>%WLQ^%+&N]EC=O;9?Z^QM
MEM*;7_$[,*53+8(LSB4!U*-HD% )D2FG$C';Y#;SZ8!J\MW2E2#V<!QS]GX
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M/3I8/P=$H57765G/SH*PH@'_@[WW#FMJZ_:%HZ" " C2JP+2B])[1 4$1)J
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M-S0P56^6)FG=NO:)9H'_@G=H_%^(5(W[UJK!O]"[;N]_?)89;3>95=@Q)!(
M-EUOI94K/SFYIR*+?R[!O%)?\+_#OO[7YM\W+=#20:C'3J0);_M'G] <N/U9
MU23'6;HJTOJ3U?KOFVI".F8'H#\E.]#DN"0LBCP(D=2F!AN=G=$:1=KE!:RR
MT:EY6880U5\Q9&@#1G@AF/&,M@&2%>5I6M7CAD::QK/B^;T62G>7$H+Q$J?J
M(L_H_"^0^K_W;7^IZ%R(:$=Q,9@"4*'IQOETOD*</2<FH'IN\B7NE^))Q"^U
MDX9E]A$C0[8YI; >*><LO&>OD>FO_^K%M%_@>UOXSQ7K7WY^W3)!QZ;N3 !P
M4!, 37Q$SR8(@"_B_@2 >>9AZJ$^:C7(H84S8$J):DC2IRSS#HS,W,QLJMT%
MH^9>L^Q5DG:W+U1@:D\99+ )VV5J.5VN#>+Z76HS+WZ/W D_@L5R^V673JTG
MK.MR]B@DDO>PA9M9U=Q<!89XF*S30*M1)S =K#5P^XPS\F-:Y+5*=O911QZ:
MRNHWVD2J5GIN;@QO,I9XRJ#66#ID9A@5.L5PZ.L.5V-*9ZJ'-R=X_1K#UF<E
M]^+$9&*;*U3-(-7:MMB+L_89TDU--8FZ($8U8I.\TM'S(<E\TQ*D &*7;H4,
MUY&Z%P@K[5/YV]HR>*?N1'CJ9UFH^.2U%]JW>'B%BL<S%]TWRI*OF (XT;YY
MR,ZU%/EQ%<N!.>X9$W%T8D"]=&EWI0U6N#*8'_MROTN;?6\M@ OKFH^CPPZB
MRS8_U#+LAYDC,N^/&X)[GS(4?TE9X%FYTH)\<SR9OP&L' S9 U) *F^G.MXQ
MAJ18@*CGDU[?+AUIHCS+]H;'<6GQ><"! F84"T>NI"RQP=J9FX]GA2?#G.;W
M/]U"/FB\>KOIDMMUOR>9?!RLZ[4TLUCRQ8_]7'T$ +J&ER4]DI4\+8H2;-J9
M7 .B:3+'L.\N?,C@PQ9)9N0HYLHU@'B2\FWQ#QZQ0(Q7STU+730>5GH"(2DZ
MHIS9=T;GE<4CFV5YQEH&LS9W4/*W;,R[UM-GP^1E[_7,7F1_,TZ>^1G\H6*3
M>7F\IA2E):HU\=6J:<Q#$6A@Z^#$ ]N+T:'H>[AWH97CGJM^7RL&066?07EJ
M0=; \Q $RO-E"\_$XQHPF]+,H%=#RYL>0QE]NW-3;RXN%4AFNJ/;'YYDX(GL
M&RHL6@)1")9-9O\D7$U"?>R=ZE27C >R Q>XWHN.5=J\AULTG,0H<.[CZ4(_
M6F"4XC(8C8WNT4L/BR:NW'CB,GQ]5KQ*2CQ&W-P@I96-_[N6LRJ&ZH6"RI(Y
MEU$M_;?/D-!=V9R;+"Y6GYGI'MV\6AEWDXM8?_F1CW9'9IB<T=:W=Y#+'>RD
M&?BNHU63VE%G1XLC]13]4/VP;W13H8\/:CU133$'G29?X]'?=(:J9'9RE;BP
MB:X%YCQI'LFUEV\G])^]MU7,HOZL,9(27_W+$>E/$118[PYFBW*?8DA8QX&<
MZOW7[(@BEE<E]V^\FK0]+&]].NLZ7P"LA 7QH$-KD8V%(CL>)T9ZCN;3QA@)
M!I5:LJN>%W2*UM2XYF,,22*PY&H8CO:=: N*6!4T!0'0WD^E_VW;4Y/"M)->
M^L8"W[V2^%NUE-N<4F1\9&VR<+63\CVR[1;:]9H;H6!_TPZ3IVD>#$TT9B*X
M8Y=S'BUD)YD>'"20=U0TLQL-.Q'5,P^9IP<..HP6[/QDI@";ERYD>S^R?O_P
M0+(<DXE<Q.:@EXR&:'2=_03(2@J NWTK8NP\!$#+,QQ9@<W39[L+TRSMX2A@
MY *1PO7)VF0Y\Y/Y8HJ1J8&AJO?=3ZQV/_(3"_H\OB]_V0R?CA061R*Z8.P0
M4>WR\6J.<Q8014EU!6E+P7XN[?U8X:9G Z1/S2Z>E:7;8B8)FD0!L-Y+5#0/
M%^S8>= C9@I>]]H,GJ82.4MA@NH<N8N(O12^ET6(AJ6: 6EL, W-W?N?IA^-
M&&O&\O;2^#P+Z?)VVLE(+ZS545(^#2^:2.\3%G@7%>X<#'\/7JQ@;(\7&_5T
M)/E@(1+4KG2M]N&YK?WXV^[>ME&Y716J'5NS]6U.K@DMU;.3K["K^P%#"G:H
M7@7M\T5E6! H8\Y1!(Y3]-^W:0QWK[8^9VSJ=)]23!%"N^WX#'OT?=/0XAR:
M  @JM0FZ-P8%8BX:;S#C2*UB=NV4'WO<"0E[I>E&=D5*47"-O%'+>7&P.S-T
MV@0"?XAQ2D2MME3554U:F[YVM(J@DM F>D1+0BP6FT*R;I%(LG6R^$*)16OQ
M<1[#T&K<K(;%4VF:^Z;>&=8#.]+>\I6I8:V9  D.(FPZ5(6GJ R29A(Z.VTR
M#WE^O*UE0W;<>VDZVSTP\;EVJ4;D3;< QOI$]9,J!9L\4R[AY *D()OA*H?'
M[+6.N**CEWB#';HO! "IPM7"CTO:+-";DP[+HWML7LL.6PX%C D+VK5]W75>
M8E*'I%M,X F!H7.TNO=^($F>;T'@B[4( +@!_FF%( A$ !CDGR:,I\%=W)@V
M^4=$>O5+<563Z'[.N+-D&N@"5'KTFJU3DTUAI'R1I8QMB8YSG7.GZ@*6SB_/
MS;>[78O+'!N.W&&:4_QH/TW7W%G]!GSE4LB;,UQB2]?>YY HZ/EF9T@?:]B^
ME\7JHU?;AU7>VDM/9WB46JX0:1Q+F$9R/B>.,A*L>N-]91QXWO9HL-UYNF]D
MIO-H$L<K!X^ *@KY.M5>:YC1*NATV-B=>95X$&":8D0)D ^E])VLQ:ECS;-P
M#T:NE$^@TBTF'KO;^%G?>+XRHCMR-Y>UZ(3*]2$>@&7*AI!T>%MP'@? 44#J
M02>A 3C<PC\?LCC7V'=/X)V(CXQNXD3^=.!:U7^BLHRH#V9?U03[/(@B?3^W
MG[E5Y%IEM;T$P\LW-,EWFH#" Q@#!HZH.LE![!L-+=F6C@6S@SES<E+QWA=C
M:5[1SXJ, 8!]'[]94:JOM+0U50;I5&5,K'!G3$.F^9_$69LS/BIB:R..P,P)
M[FNCG5+\"HA@\ 5;.<>>Q@KT^-?<D?7D7:*7@M1,5[4%2CJH-$+3IJPYIOW,
M6R8DM"] 2#3M')V;' .2]=_W0(0!"[(RZ[O1]=NI^]'D=RK0$]'6>79#UZJC
MWP@2W[C2:J#[3)#<% O.W<0#3^='Y-<O#7+)81?1TW<JSE#MW+SXJ:[W$0EK
M;%=#0VXUX)_UAK_N#/DM1P5S5F_!OIB/(39S81.)1)P1?+]'FP#)8!&M)B2!
M 4I0 2VJ>T':TK4-2>,?NY1\\B 'XN+LZKT[(#6C&RBJL 90.-04N4!MWOQA
M84U+T*3D/K%53Z,II(TWYA5GHA'3(@==@ #6VQ0[VR =E6)4CDX)UC"_#68/
M\_-F+RV,?QE7=;WAT(6HE=MZP)>OE K+6Q#Q?<YYWQ+=DFC'O>V?RST\5Y)<
MT15A59\^:5D1DAB31WYF:!$#TF@(4]4?BC+B1Q<@,^+1WDA\_.()V5>KD:K.
M^$?@7J*^VSTC;)\ )"F*88Q%E<VMFZ<2*/_Y.3F;<[OH(>,,OD[ZF\F>_6YF
M*&CW1NV)B_-*]<9XKSZ*G_:W8S0V]W2B'_-Y\=5]"4Q=:4K3/CQ,Q)_ ]C:>
MD!:KF.PZ E=7M(_W3J=I3F\5 9#Y&K@S20!8%%J;"$PFVA$ 0#'8 AS?S*Y5
M@,/U$@ !B*/O/ZK2ODS#!C]E'FR>3G:UGYH!#-Z6^DAE?OO&>W)$ &P._]3L
M1P&9Q4^]_-1LZ-S_9XC]E@Q+_]1&B=3QSC *V3LKL_NCU<K1 B[4&;%9>>K8
M'A37CD'9[%P+S?JF7[X8Y+JAZ_S&ZNCKJ<]#!W\F (;TM''G"8"M8D^9J336
M$+I3V7ZX;$, **L#T2P$0$4._E(:\.B".@'P;.$D20D2$G,KXI0!)-EIWUFY
MF=C32/]9]]05:V6>G.,F %J=\7TQ_[?1?W^C*/^?B^K\WT$T)I:%VNUI>%-(
ME2.A7]P'Y]]Q_$[A1?Q=;99Q;QL( .PM!P)@C9\73P3;?P#[G?8+!B^5]^B:
MPW!7I6#?:4_7Y&<0QP+ WP_E?UZ3V#\$M,899S*3[MSYFY)D%WK6-$\R\\5G
MO)M/91S,,XA_G@!;E#Y=**C?O_K_4W']]S4Q;([%13:DG'C$'DUT_ZXQPA$I
M^/![6IUJ]E5C)C)8Y?<N/Z?<U4OEK<-_V:O^ZHN'7_C*$+]S8K^?!X7_M\F_
M;/*[&(Y28$$V^O,:V:&:_4)OB&W9>GFSKKJ6S=>_DUC.<M"=0'QAD1Z"R7TI
M+IFX[_&Y)7.B7DYWRK8=O1K]793!8M,P5:F XF0@$N(@28H:<"P#7+1TB*F[
M@MDT34)_C5\JM4%F!B+ \,M87\AV=:ETY\%EDX]"8,[B0QU*@T 2N.]W15 7
M 4"/9\2F(2=*4:(T=K[X<%2SAK#2L4J0UET&;;'\Y>M]E ?3D,-O&4T>[^H&
M<YK44,+2'TPHLTO!#*Y3=H:7%/O'Q^H_T]J+?7*=.F.A:W/\%$>+R"#-QH;G
M.;T*B4*\BNCX?OCZY@GX]A_K![6#%ZAPTBCGS\=M]'(9(07SIN98^S8>8\>X
M'0HPNYOK9$;5F8WD6IT%4Q571S$ST[[LI62>BV4%<<JLU'J3JV%!0#O!G< %
MDE(H!QB^?J0+8]JPX!C=.[%E<OS^D=&L9H7IL"^H6M5W#ZZ*!1_?M[?@P29)
MMYOSHC+",30[%L.B(AXP:KN:&^TBK_UH:&@@2=#:6Y3+,OBSI+)Y+DJ];UL,
M.*HRPW'*QT#(!7]A9!4V#<5F J0T4^$66+!ICM!+B;*\4M@:O<#8.BL8@:':
M]E9JQ!!U3AOA1+0I<"+EZ+WAT5+A/38E^;1HC0>Z+7;>_AW"<6<?'0^[*+5/
M-CEF0RP-AR7Z]?5"^P@ D_32JC7N@<W7!MYT9I19%[^=:K "ZLS!!@<^!3&8
M<5//\T9XLLB//M6\N=M&_&+DCO8U5L"2HK1EM2]O:--C3,J2=I@D <"&->UD
M!H54F8*+"SW\+_CS.P5\9KWXL<'G8:CYLC99E-\I[;RW+2HU)UDMG#C06,"E
M:0C[CC9Z$U*I,<8[P5U?8YI4[F=WU0C2MOSBVO"#."67NS*=HE$!LJ<+(TU+
M#.B#[TJ1#1P2JXRNQ7$?,;S@++]+/.R3H:\FP<5?#V)]=H8D3SYPKY\.LQJN
MQ(ES01MFHUO4<<;9&WK8$WSW2:9(0M'Y%*Y;UVARBA9XQ@?[NHF/+B#<CV]#
MVA=!D2T"$%BW;W]M-!=Z->0)QC#=CR["^&Y;KFUT4Z"2GG1(NZ4,KT09R<1+
MHU8O6$TS 1#F,4B%3?VVQ!'<!/+T<W5JB'WN<4P77CIB>":9+&Q@D/VK-PTE
MA>_7:!0\$L00< VJ,0R57=*DNK#F>VY+=VI6*9YN[*M5K1KU^P"ILV[:\_(O
M>CH9B-9.0!W,3H'[P&V6*8?HY3X3T_ W_,DV,G= AKS5MD:M 3*8@I@6.:@L
ME@PEF.[%00$&H=/+$KWITE^ZWQ%]7)]*5V]^N.ACM75<X/J=[B C[5QG33J8
M8FYP1B0GG,8T.E!A$G#>/R<P,3&PM?^ZT ]4DP?_? &<4R1, "RA@ <A +EO
M>*45 @!* ,B%YC>=9JCUB 7@0!.H@X/:DP @P8]:,*$'\MQB%Q?H[1C(\X,N
MA ;IURA9O3"[&(=.:+T\3LE'-%4(3Z+JCN4 LY-@@Y:T3B.S2N4_\.^.KN$K
MT#/3=OLZUR-0AW.OH4,C) )YX8<WSU8H4>%'CF)RCF^N99!&HD(3,2"5\2V;
MI!TAB:IJ*?'NH$#N1]P1R@IN:C^*9#^\;1%&+W0,_H"JR]C[ 577K5ZEQ;HA
MUO869MFQ6=AIYRIP/?66LJHS_TN':0#@30*X+G%)+1I_ [+0SDZ)ELJS09(Y
M*8C:H=(M'Z2..RV'B-#ZN'2RX)H2W+H5^>HXM'1!(I @5&T7\+RI+?O9,4>/
M(J@W"GA),W<-?\TV9:OR83=UJNEDK:J\N0[U<L(9+H4+S>X8$I1T&RQ<CBH$
M9XG2!#*M6_!6-!V??]?@X>5-[QUWQXJT+\PR)VHIZCE0;-%?4 4JL<""E[%#
MG#JHL(#K6BA']A7!XKI'I\F*8U75P[(G/E'*\X^_Y:QFI@ L\WR!.%X0K1('
MSA--$@151\U079K"*8]ZWK;;]Q>0?SI2MBT\ <TF/GQQ>XDJ<?=XI(Y#6Q?$
M.X4?"1#\@=EV+?4\MI*^;IXZ7F_.*_VF=F4_M>4Y: 5'8-33ZBHX(U0?^W$)
MSK@6<!GC'Q9<-7CN4ZI*__&ZZ[Q6H?W9:S[D@HO<C]XC;_(JJL@'?J?,7F)C
MT,!()2)GFF_Q29::R*Z45SCLI%^]8"W8I:2SF5GJ,-GO"^I8>&'W X M?(E-
MH/W6A.0/ +8G(^<B7$9F2._HM?/UWG&9V0_"W9360$K$AH-8F]30VAV9EX5Q
MEKG&W5FSH%<>EKFJF_X430-4:3S*MQX\<NB^?WCJ(@=+LE&EW-A76 CHSO10
MS?'C"K.4A]Z.\WYG$F-\QYU_ *DA?@"I84A9="HBMM^27-7,>@(T.80C85'5
M+)G!F2Q*HJ:?@CJD4S-RV**^!N(B314ZG=DG&!>+;["1N=^C*BF$Q\$#KN&>
MHHT"3P5^=P*JG;LQ;5'M7V!BK\02IGDW@:_LM?ZG&.B."+D-25#&LPOSV-(E
M?TTM;&#QC/*Q+D2TU94K?X%RP^L(;&;\5%+>[.,5Z)NOAV&J;(5U'&J0L Y?
M4' 5N-34&!%T;]0Q!3II)$)]R2_1;#(0+XGE0&F I$.;-*V+6;B_B7"]J.AE
M]IS5?>;8@NUT83^#CDG$P%MA5ACG#BV6)>&\_ *V6>]IT7A:ZEZ.3_%UM6ZE
M00,LNW")$4ES0]$94#L#NQ0Z%T8U\NU.\PA.+EDL[Y-<^UGN>)NDZW3QM&+9
M]U=7UDA)BM2/P5#J4"D?I:OKA1%BQCFO $J-@D48FVT*]&KKM%+XN\T6P8K1
MJA-[<9%TB<">^GM$]3?U7)_+1>P"8X[8TS#.2QPA 11V^U(31X^"\#0<ES\Z
M7\CQ#^=PN&Y%J?#Y/%7%\7ALQ,)%I:L;L"JJ$$]G$HA[^PC6^0X:-W%]%KS[
M=(3)O)N<V,;ONH&.TAJ1PGXN23'6>S\0ZX<:)+>?YQZ!ZMKY9*\+%?G[%E_1
M=)OJVBJ4684K6P2R1@K9K[4-/[.VEB5F#V9&(Y[C%9TC2%# ]E@&B*7F$$X?
M61OZT:1J!._'4NB4;?/<MO=,3</Y0]/X6%_O+3"J$7X)QYZBT5P';LR\L"D]
MSR1-J6Y'/Z'W0ETQ0"M(::SU0./O*Z_:(:M+8<_PS*?J]@YOTK;,79@5P6[G
M/1FAPV,,B ._N@C6PV.K=IBPTHO=VVP8-U"$*\QF#IL 5J]B4\4/KX8>]3M^
M8($P"E)L("LYB+^P>F11Y>\APEMH3^,1)T8J#T5.KG56)U]8>>4\O[3_7*X_
MRO^\U@,L#!/4EDF+GU(01+$H/M44.]=Q/:%")2,D_MDCJK(;((F 7B5:]$X'
M@FA^ 9*BD3IY#PV+E"3O9Q_43<J)Z6?A/2B\/T+W,*Y$2?N)8 [66+&V*W8Z
M=14%"JK:JT!3!KT=1!( VSU+U/D(KU%!Z9<D1SV/IV\F9C^YV3- UWJ4_-.3
ML'.%OP+4E]XF -C_ 7U2]?/6T5^VCV:B."[9X6F'13W]3=:%JF9D/DTR4)(]
M'/+D!:3N\IQ4!Y#FSQ$ E[YWS+8I6[TZJ][*FN?W8$C-_;**$%C(Z7K/XB6U
M.LG=E69DL^C2SK:J@E"#9P6$"_E6N7 COO/LNX7-RV<GT.5$*W=SSO4,SC\B
MS:+*55!&-7-]:.'(-!O?(_78YB'MJ)@;F-%]\)WW&UW>3^#N=V/DQ.+C8 *'
M-OL[6%W1"#PMMJ"C(?:%)U'NVK2;IG66:6V2\WZ\ /[HEJQ[T+."0) Z%HA7
M$;Z,;SIUV,/@F\S?_U>WH5IN!(@.>YB[:P[#J_F$J[5TZBJJO$Z^'*N:VN[3
ME8,XL&'(.RWD)R5X1DB0 88^&V7N;=0X5JOM-?.DII9Z188SRN5=5HQO8F\6
ME1=F<OL:>A29^8)["*>-FM'B,HBF5ZU^S2U$%_H ]TZ-LSJ &6J+UN[B\V2"
M,J%8S ,494?D*QT8?81:DTA<6.,*=LML]E,Q7]/1*4BE6E3FEI^Y*>@Q6VBB
MX[6&G@/IT>L1<[),7'YGU0X>C"]\GEGLK&WC"-WW5;9NF"R;6@";O"#R7-[*
ME"CSKZ6A]0+HD!3\T01^7\I$ /RSEJGQW;6ZUVI_!O8E$,>UXFBT;X8Y704^
M:U&T57^W'GD::DT2]4:_6/)\]+!^<2[ER\#.7&9C? _\#K84G:*'V2YHQY;L
M"#O.M#<TE^6XV @?=X3?M;Y'U+O]YD+?.,)A(4B.!UYHYYTA4QN!_X#<=GIL
M*I^RFW<[5,^04XQT"UPZVJ*  X[C+LU?K\!H12^$3A@$[B"%-A+$SSVP)G)+
MN+L8.)$1) 0%HQ5/LY!@B^OH]&"TR?RFB7EGE+A9XG).3XBRPUD7LBT*2&T8
MGN,TL]%^+@$G[42)AC%KA21G4KYJ2"]MWCK0[69]<GVCC(Y\T29#?+KE3?3$
M R/]I$>D2F^;EGX4NH6U:Y^'Y&M3;BJ)OB^?X+12SW+<>B_N/RSX[F74FQC6
M", WO\'/9Z#RZ(,V*27RR9#8*.A5?YXBNU)[G<-P/W<^H*WTA5R:"IORGJ6B
ME4:J,#PQ-MT=PPBI15%%.-!/3W26E. DD>&\IN=M'IF@8.+GU0&,.D87J%CW
M]M:>QOQ2T_S$\V),F$#K+JEBIX_-"X0]* 1/B^')R[*WX*.V/W)X+MCXL,3I
MZ?5RIC,1=]IE9#=OLL*"" #KQMB+IUP/=I",;7]!EY1*91?8OF"4;,F1X_:^
M3!U=9QU[Y<N;\ER.<W@>J#C&.6)'B6$S@X69*MQI1B=-&\,M_O5]_2.B)N%+
M\F-+\BRL!_ '6$],8AN,7@_3Q(LB-W^\-27\B8]9-ILW'SLK*(H2K,RB2E_8
MM\>P -MJ$1AH!F\C.J#(O<C^*+E2*%H1DRJM5T[U2N#YE $W(,N A2H01(=G
ML\-?1<.?*>@C>Z LQ6:S9J;J):;W)J>-,M3CGY#M:IQY8N1JYMWO+ZQ"3X3:
MH8<*3@;0XRRP9$C1L.G.$N:RQ.Q-%B?)5\:++5P]8D)ME,N4Z@YE+C<7OY?-
M&)^\PH&6FJE03\M1<\YJ:=UXH6'@>^'S&17YZ07&Q<X/VQZ9][K7OX);!-%]
MIXH0]1"EL*O-X)_HK*ZNB;11')M^.>SD9^IY:_?](_(SU6XW-V/V0!JG?J#9
M44%NPJ2SB@! QWV./.$GNG3@A3?I7>&,HYPK*8B[$:_1ZH.(#2"QQPN-M5#,
MSH",;V60-9FF#?-#!]XN]'5 ] =\#LL[K2$[^X^=7Q  C#AG%,63_5F(94<+
MN39Y&D33_QW_G6W15+%&%S'2+V]BDG;V^C<YJ'$WLL!>J:K99<8F&T9Z33=F
MFH*N3M"G!\5WP!H,89E,1%&C1!W?=X)!K*)5I40?4@=COX.I+JZ+M:V F<^:
M*1<OM%%*=1T><LT"* UB?%#-5$CO#_VW6S.4L-%E<^8SLR;8%-V(W0F9UU'Q
MG!_BXWENK@IH$T]J^6" '[R8.VN2@"\<:(Z0YCFQ \2/=>2='N_"^Y0/7_1P
M,96]9K-2\7C4UWXUL(?SF9(I1\5@E 0BV()Q6*+4\LYI)IW3WB*6V6D(]UYE
MD:TU[Q>[LVP$.;0&Q%%Q8> %$H,U;%*3QS=OB>+RCF_6<'>N/'*:NDOBY!X5
MA2H9_H=W_G6?BH#</RN0=(C@P*6O/[#,X.PG^2V4&PN,>([I::SE@Z!;F.38
M(M.-:9YB][IK39@:%E<=4[#J"#_ /3YUG^7?3@G98 8<=G<C*H*GP]J 8>P4
MZ&9\^KF%YR+"SL+(\44[!TFR)WJL9IR[!I]?'W&\6J5M +4NA,O!N^!$V(-.
MYL%0KIHAQZ\.,W>&KZ3*9,>H,-K.38K,A%T)!GCTPG-LW[9"C (#SH"5Z$Z2
M/6&A#,PA40V=7YB;U+VI895%C75UR6)NC767^10\29A*7(\5L(-MWO@+&+7
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M<!R.)^;%#M< #X^J"8#6X%-A?#/A/P;>^*O[?/L!C]U':G[K7G6* %C=F"0
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MQT6;J$NPC5H8\PZ&&I.R$%N1O)MQ+_JK^J[K\'/P']<IO%G)O\V I&HOAL6
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M#V,$ZR>@EF^Q,.WG^P2 ;BBY'>9+BR:3^ZBM63+NG)Q^JV%8541T\K'=YI1
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M4\%ALP9XHE9V?/W9[N0 @.++-0\<G^N*OSWL&/>M-KE0&L?O/EUN65%W6UP
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MHGT#H+J>(RMO.=P"A=X [/]C3:?@_V;-?[B\B8(QB2L&-7+=PMN"S/,Z_<.
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M8<G!=RVVHT(6'R*AN:C (P="SP3UKRI39/)J=)$^7I:3;G?P_0=L3#.>QRO
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MV3Z2][5M1VT[9C9TQA[)?AY: A7?!,<I.<,!.TEB$TKDS0Y:!5@AE'&$HEH
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MKH[L9 F&Z2>@\X\G*C<&MLF."1M@15U@DH-;BWAX2C\C=,5U*%^HO4U]4$(
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M=A]U->2.4"Q.MO7X</YG4F &/[HAK/@!X!1O-'R0?W%W]>7<?_MLW]W*/\_
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MRUZ0I)V<-"1_+*3OJ[7I"-5D1N0F*BTG>EI2H.J1PB5;-9^[:%&DJ0@2BXZ
M$K/^DC$[OU)S-1NFP4<C[Q<A+[49=@<7!3WC'&1OG\<(<G-NU<1?Y?&@!Q9C
M7/-?SAT'ZOLB!92D!3[*])V]IQVV>!YZ=_?\I<*C:A,"<YH;CPX%T@J29^=
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MR1M.37"?"SX?:C?P^'?^$AO_ !?_ ,)]8:K)K6LK'X6CB,5W%*S2;M1:,>;
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M5S9V+=-]]YU4**,<YU'V 30EAF?#"(1GUC>D%RP?+/ERUM5\BAV-/Q,8B4[
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MY\B9_-.:S2=STP0*5$?I#5!F/V@,>G-IU1]%)'#)897&.]96TF=ID[X3M[6
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MC?((]I8N3Z#X8 !&QQ%G<35\HT@VMZ7?1FYFY"] Z !U6MY^HD$0LTXM:[7
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M/G1J#Q"-@ PI_?!4?73)=.,N(M@=!4IMK\VVTBRPYA7%,N.4!"K*(U52E[A
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MJKN9MC B(*+7&/1:+C9&G&0YKYGIHY<IBP]9R'(X,HS#RN9\C)"]8)E49^-
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M^D."EN\X<6C,9:V2R\FZ,H1<#'GJ"DQC:-1C_JJU)8BX^5,QQR'>:)U'I^!
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MJ1,K2CXX),-Q)2(/$O&\2?)PZ/9/#^#6K/GV!43SEL*^]IC^ 5!+ P04
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M@]-4&TKH^R'TJSII5U30)T= 1 ;]Y,@P=)*":.@/S$XK,7AP$EFQ9GM!,!K
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MSIN-Q!0$JJFZBE5AHWRW=4$5P3.$- 59XH-Z7[7QLH/<P+84&ZMB'J0Q%;.
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M,7V;P"0+BHQ7Z&C9PS%KHC7EJI)#/Y01-Q>SPO:U@E.5V K_)>"OXEI\TSC
MJ3MJF\M*=KTPZ@\1@;P[ZU#8&+W"Y%]FFR#4%1)K<U#;-@@'J3,@3)E+/$+1
MW:'N[G#/P1*0OMNNT#57 OOPEP5M1#XED]>&<7!>ETIR#DNBG;A:TQ/@Z4:8
M<Z14!:8F(WC.S-DBDA%<W7$@?Y^NP_7Z=VK[8JR;?AY(_#'[X\#%7PU& QD$
MSA2ML%;>Z))PHM?WW33Y*TSJA":&['"%$ZWL1"XL<HHH88,4B?TWL2GGMH/0
M+KKL<NR6&Q#XA&$.)+()2$J2.FEW,$8A'[SB6]>3)D@.(SH3_ 9(D>1%=>T9
M"_;([/FSX,0:]UYN-&TYMVA;"V/DNRQ#'G4=)8>%,<2ZU$J<TG'"A_(1;_<6
M6L/LB0Q7S3; AL6M'B=RZ'),D#>)RU:TQNX5P/FJ:=/B_*QKX,ER .H8RRGL
M]SZ<6BJI'W\AM1^TSP7UZ5IR\_IX 8N)Z31#EW5T&M/VN5$&%F16J^3;4+7C
MY)+,( 0_F$]H&7.TGJ$+ )L/7A1XV]Q\:)D/KSH$#12SHW>NN->>C3*%26T[
M$_JGXM.S+J\UQ8-(;/SX4*K;PPY"A#4@'@ND-B"4SXID"380*UZISS?9&MZF
ME W%&6H^TN<2H'P6SA)I"S\XGS*H:DRTJ_LXVAW-4:?G<EF7%>>(UK8EL\TM
M8GIMO*W*5QFL=*&+]JXQE##;:YN<<546C3G!I>0LW'FH'5S4[C 5X8- @[IY
MVOO2WGBG0%PXI5H@$XW]EVZ+3'<;\3GW[91RDS9#S2P/CESWG5HS#$/-R>F0
MF:U3BPS>]%LBJZ8/QF_$:H%MMIL'%RTYCD8JW\*C"SI7EV*U%A\&Y4P;VVT7
MS@F(@F5EZ80*_&&C*MFDW/LR=)@TSIPH<HZ.XN-I74(P5Y8][.M)!FSMAZ4<
MB"^..O<^#J)@ZA7"F+>Q?4%][G;=K8WC7\-:4I8) *JVR']+7LTQ7MO@,B G
M;<?EK%N'>('XB7!J8PVL8#BU+L4<@A%#MLH7=;"J2*I]:<_R;NQ44.W;$'3R
MECR<Z;)QA] '0,(Q3=R0Z&7U^M,Q-2?Z/_Y5-S]76[%483!]A:E1"'YNX?MY
M5A&#'/X%ZN$BYNL&>9A)5&U,,^5MY0KO$GBHK:/BL>D(/G,?4BK>8[8WFKXB
M@Y8J4<O,MQRP*\/0[Z0%DXT0$;@>A:S.L'7?CMG$M'F!I? Z([TC(AP5VSSI
M(QKQH;ZTSSE&22>KY:VOG&"+_XB,!E:FIHIK-AC-VQM+V&TNE$S93J#(V0X7
MH,$;;(I;,1ZE$T%T/5!3GW,.^Z,(9C$T&_E]S8GDS/:>TFES]"_)!"(Y[*5[
ML>2D(])HQ=6O.K)DDDE*^(P3G>D*'.!M2M=%RTJD2H)E+_55M08HN>)VF54^
MH+,$I9-K\7!O;P+*\73RY&BWJ<];//5^+;JP5G:Q/C\(L==J-]7M-U2\P0Q.
MR8;UM<"1MO/YY@9J>,""5&KOM/FXP(MRLZT*M$LD;83!^#>MXHLQZK/Q*&I!
M:,>Y)97"!$_$PF?E+FJTHR/1S@<BCFX]Z8=^A<[*=I],.$$P?C#<-V%Z3VQ3
M%VS&"\>YEXYSM\PF>(O"2<6X&;)G,]KM[]7"*"L9-K9'';C2@!SH.6)U)Q6X
MTLB?7+QD!TW.Y^QCX@B#M9*&ZR9 ;Y:N U^9#IUFP<U3E'V:MAKIO#23WURD
M$$ND@6^ &@"4(U:!FA(A-P59A*P;1%"#GFL4H"5CUE%G-1T&\^5QO$W NNKP
M@39AL^/F>EO1BFV5\\YM4-..ZV6=X@;R<MQTO9K\+16)7WD_A&YN>>4[0A!D
MSSHN"##I35A<#W3EFRPI>]WO^FJS;L\#5UT<[V[17N+:DZBHS%TS&3>P0QB8
M;^S,\1RO4E#<'@G*YSJF>I)MG/RC6SRHK F:C6T7$(-+[BR1K*K-&<_.7*U@
MDFKJ_N*ZANJSS-=@Z'*ZWL7=HO<JX#9[@JK<J."WD^E<S@9X"KJ;NHR8T1GZ
MC$/N1"[EG*[AP\HT@1%6^;GMS+986O^WU8!&MY&@B7?CVO*/CZCI\K/6G3AT
M4X_M2*)S"<W9W/9%)AMI2I@\Z*KC-AB^]X<J_QN+<2TR#76TZ"V]=/U+:<<V
M-FE,ES\ARG)RR[:3^9KAI<[3)I<6MF(%H3]M9U\KUA_,[?A$S+77.S)-D]&N
M8X5OK_R)_4UQ$BC"*XS[_S0H"Z#6:><GU6W%X5O9Y #&NN71YI,P$%TY2)<-
MTF&+=#T@R?4\#D&&]%UE<SFGO'_0K>]S:\&1 )>XY61LYAZEGDZ%9>IN]@X?
M=H?*O?\",*7S)+A1DFHEP%+;<8)!:)@3FX*F+RG4%_TS^?@5!^JCNQ6ITB(+
M0T>ZIPHKRQDP<RB.;[-RA\080>3H ))7!W"7S4LZYF[#=+HA2K@P1Y00X#<M
M?T&%/8!>HLN>GY&I+Z]; ?FK&^8/VPW34O]^"0;INZ4V\2VB9.@Q\QYU#ETT
M1RGL=7?V3@ML#EUA/P?U3"1TI@)?H. $8S'4S.#,%H4P]C(-[P'W4X9!657#
MT.,GW_L;>BQ@]64Y/]=M#_<)ZN_#RXL]&",@],+15%4KA3<2BJ[#MQ7C!#M4
MA.WD=!+@ 3Z4\'(YHQ)QYOG>8"OXJ>R+EH=?@->H:N0:_.,!:BI>/4_^D4,J
MUG@ HU06I3IT/X3#[\&8%H]01:D])ZO: , 0$ZH_?A)H,TYLX$_B[QM"3SN6
MJ75< *CLX[O#W=WOP_78<9TWLU,E=S+.9^$[0,*>[9.\)9D']T!G4)SKF'6Y
M5(&X\_F%GMR1-]U*6W.[Q<SG_N(W;U_)I6 CVY1B-[P+KF5N4;V PSLH53LD
MT\X._Z50?RG4%Z:33L)B0A4[Z<,SC7<L^%%S8FO3'F&S1=(4<_;1^+?J#NSY
M;CH"[0.45>C]MU=@+P! 8* C18G+EKHKKKAVSTZ*BR/:DS<S1;XQ>&5/H[GF
M?^Q?D$9U,E94IG%IJZC=^<J#4]]KDTS"G /=!X;'Y/Y"C+\0XVM"#,GG%>FT
M<DO?;F.0^RPMW@O1K?WVM21M:C\I5],:WFJSRLU&*^)F5U!Y7:W9XU%0);5#
M;+MQSA]5Q=2>1X?MR#>\1^7^$K',<7^F").@-D+-"\SA^C8^YF\[9>HR1.H*
M,RVM7##_:QZP_3 E'H^]X?SQ=8.X+@IN L$X% \4W##@=#V@+&PGZ=UJ/2QM
MM-HT0+1;?9V4;?83]4D9&9ZFG$%R1MW1]I[Y+O>&XKCD/F,@T!U%"(Z,^E-O
M>",C'R$)CCK80Q"E/?-@D]?-08F$.[GI:I _7%/O)]?Z/L=]UO=>K N/SKCR
M-I\7ZMR2[?[Y%'M/=E.R^B)W8W^]<D'_Z!Z>?#VFJZ@01][1A5E&FC^1L%PX
MSQJ7*OU2C5MJ[VDYL(C_Y-O5'9<BO&"=ZF-K\IC3/";$!3@<[XM7<B;7"L!'
MO,7KH"+Q:YX#=.+UK[B.?^?F@QB/GQSLTP@:^QA252PP:V6/2,",#R?CR2.Q
M/]D?[#_>W1M^T:SW?YOBOLQU<E.&>X?_T47Z5QR?_S]02P$"% ,4    "  =
MBV]6&;UNO-<-  #(D0  $0              @ $     86-X<"TR,#(R,3(S
M,2YX<V102P$"% ,4    "  =BV]6[0D"ZM0(  #I:0  %0
M@ $&#@  86-X<"TR,#(R,3(S,5]C86PN>&UL4$L! A0#%     @ '8MO5N+.
MGT^7(@  &DP" !4              ( !#1<  &%C>' M,C R,C$R,S%?9&5F
M+GAM;%!+ 0(4 Q0    ( !V+;U9=8/V[$DT  !,0!0 5              "
M =<Y  !A8WAP+3(P,C(Q,C,Q7VQA8BYX;6Q02P$"% ,4    "  =BV]6JQW2
MXJ8X   6*P0 %0              @ $<AP  86-X<"TR,#(R,3(S,5]P<F4N
M>&UL4$L! A0#%     @ '8MO5HL9$CL<S@( .W<8 !4              ( !
M];\  &%C>' M,C R,C$R,S%X,3!K+FAT;5!+ 0(4 Q0    ( !V+;U8@^)65
MMGD  %JD   8              "  42. P!A8WAP+3(P,C(Q,C,Q>#$P:S P
M,BYJ<&=02P$"% ,4    "  =BV]65'XY*FN"  ! G0  &
M@ $P" 0 86-X<"TR,#(R,3(S,7@Q,&LP,#,N:G!G4$L! A0#%     @ '8MO
M5B79D].#.@  .3X  !@              ( !T8H$ &%C>' M,C R,C$R,S%X
M,3!K,# T+FIP9U!+ 0(4 Q0    ( !V+;U8;GSVLQE0  &!9   8
M      "  8K%! !A8WAP+3(P,C(Q,C,Q>#$P:S P-BYJ<&=02P$"% ,4
M"  =BV]644(JF;L]   R0P  &               @ &&&@4 86-X<"TR,#(R
M,3(S,7@Q,&LP,#<N:G!G4$L! A0#%     @ '8MO5L7<'U/S&P  PQP  !@
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M,RYJ<&=02P$"% ,4    "  =BV]6#_[YSY!8   \6@  &
M@ $$[ < 86-X<"TR,#(R,3(S,7@Q,&LP,30N:G!G4$L! A0#%     @ '8MO
M5I=0L.)! @  Q@0  !@              ( !RD0( &%C>' M,C R,C$R,S%X
M97@R,60Q+FAT;5!+ 0(4 Q0    ( !V+;U9'RRL'G0,  /L(   8
M      "  4%'" !A8WAP+3(P,C(Q,C,Q>&5X,C-D,2YH=&U02P$"% ,4
M"  =BV]6DQ6RZHT(  !?*0  &               @ $42P@ 86-X<"TR,#(R
M,3(S,7AE>#,Q9#$N:'1M4$L! A0#%     @ '8MO5BC#5&N""   'BD  !@
M             ( !UU,( &%C>' M,C R,C$R,S%X97@S,60R+FAT;5!+ 0(4
M Q0    ( !V+;U8G]U\+]@0  ,H1   8              "  8]<" !A8WAP
M+3(P,C(Q,C,Q>&5X,S)D,2YH=&U02P$"% ,4    "  =BV]6;]#R-P %  #W
M$0  &               @ &[80@ 86-X<"TR,#(R,3(S,7AE>#,R9#(N:'1M
M4$L! A0#%     @ '8MO5B).$#Q3&0  F7(  !<              ( !\68(
M &%C>' M,C R,C$R,S%X97@T9#8N:'1M4$L%!@     8 !@ >08  'F "
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
